<SEC-DOCUMENT>0001485003-23-000090.txt : 20230228
<SEC-HEADER>0001485003-23-000090.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228080139
ACCESSION NUMBER:		0001485003-23-000090
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sesen Bio, Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		23678466

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-444-8550

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sesn-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:cb59ddaf-3c33-4c46-89b9-ef07748101c9,g:f5662b05-afda-41c0-b68c-8f02735bc2a0,d:6d755c213f784994a9d98b9e4ebda9e0--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:sesn="http://www.sesenbio.com/20221231" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sesn-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF80L2ZyYWc6OWZmOWM3OGY3NzYyNDliY2E4ODM2Nzk1MTdkNWZlYjQvdGFibGU6MmQ4MzdkMjYwYzk0NGE2ZDk3YWNjN2Q5M2RlZDUzZDMvdGFibGVyYW5nZToyZDgzN2QyNjBjOTQ0YTZkOTdhY2M3ZDkzZGVkNTNkM181LTEtMS0xLTkyMzc1_d72eeab9-7c4e-4a92-8b5d-8282876ec8a1">0001485003</ix:nonNumeric><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF80L2ZyYWc6OWZmOWM3OGY3NzYyNDliY2E4ODM2Nzk1MTdkNWZlYjQvdGFibGU6MmQ4MzdkMjYwYzk0NGE2ZDk3YWNjN2Q5M2RlZDUzZDMvdGFibGVyYW5nZToyZDgzN2QyNjBjOTQ0YTZkOTdhY2M3ZDkzZGVkNTNkM183LTEtMS0xLTkyMzc1_99adb8a8-c224-4071-8a4e-bdee5b5aa779">2022</ix:nonNumeric><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF80L2ZyYWc6OWZmOWM3OGY3NzYyNDliY2E4ODM2Nzk1MTdkNWZlYjQvdGFibGU6MmQ4MzdkMjYwYzk0NGE2ZDk3YWNjN2Q5M2RlZDUzZDMvdGFibGVyYW5nZToyZDgzN2QyNjBjOTQ0YTZkOTdhY2M3ZDkzZGVkNTNkM184LTEtMS0xLTkyMzc1_b4412a16-d909-4837-9700-2bf552fc9384">FY</ix:nonNumeric><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF80L2ZyYWc6OWZmOWM3OGY3NzYyNDliY2E4ODM2Nzk1MTdkNWZlYjQvdGFibGU6MmQ4MzdkMjYwYzk0NGE2ZDk3YWNjN2Q5M2RlZDUzZDMvdGFibGVyYW5nZToyZDgzN2QyNjBjOTQ0YTZkOTdhY2M3ZDkzZGVkNTNkM185LTEtMS0xLTkyMzc1_a8cf9118-2623-43d7-b967-a4fdfacf6709">false</ix:nonNumeric><ix:nonNumeric contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0wLTEtMS05MjM3NQ_5772ccbb-05be-4692-8ecd-73c875653a3d">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0wLTEtMS05MjM3NQ_c3c9da0a-6e9f-449c-aa05-5f9295a51172">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0wLTEtMS05MjM3NQ_dbe520d3-9099-41ec-b93b-68530628d03e">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzA1L2ZyYWc6MjU5Y2NiODAzZGVmNDI2ZGE4NzFjNjg1ZTJiM2FlM2QvdGV4dHJlZ2lvbjoyNTljY2I4MDNkZWY0MjZkYTg3MWM2ODVlMmIzYWUzZF81NDk3NTU4MTM5MzI_a7289bd8-890c-4d0e-ad9f-c448aa6961f8">immaterial</ix:nonFraction><ix:nonNumeric contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzU_722ba763-9575-481e-82ea-4900d469c804">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzU_e7bf87fd-276f-41e8-a126-4410ad3340e7">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzODc_0f5642b4-7404-4c0d-8695-7cd3f0d7638d">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzODc_e3383e46-0bd5-473a-9c94-1fb2c501553a">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i9b7c25990186472f9eefe41ce144971d_D20230302-20230302" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjM3L2ZyYWc6ZDVhOTQ4MmFkZTlkNDkwZDg5MDJhMzY0NTBjNWE5ZTEvdGV4dHJlZ2lvbjpkNWE5NDgyYWRlOWQ0OTBkODkwMmEzNjQ1MGM1YTllMV81NDk3NTU4MTM5ODk_a7ff2e96-6e77-482e-90d6-984cd826cc2f">.05</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sesn-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb401e67dfc467b98d93144d057b5fc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2e57ab72df0c4d23813023acb9286a55_I20230221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a787f6e1c15471ebea82677593dbf11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d35c30040aa4486b9b15a04bdee6aa2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9289325bda434664a6a39b85b67bfae9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89feec3c1c304077906365e7fa3071f1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09358b4a0bcc4a3385a7f499156e77ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i405074fedfc34261a6aa9a70d2ea0ce6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73c47e791149483dac9b339dd293b4ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id683680be9e042e0acf2733abe0d9cdb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97dd7567e83c47af9d549f491e6200b0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i887ce3b59fe94c8084e3c22ab03fb7ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f82fd2d2e7407a97261cd8548780c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib748ce8528614265bc45eb9a76e9bfb0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3799557388394b24b27d06e94128d950_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i295ca9347a54466f93585f285c63b26b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9e5a066bf5f4ca5a26ac3aa00160ed3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib968e3f687d845e2a83107904373ff5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87c1ee91ad034903b0d19285c24c8b19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d57c119960482d81011d8c04ff8399_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3da3a125129480eb2e8ebb6f49f42bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ddcc8cd57e7497282b01d86668e8ae3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83051d731ef64fbab70f1bd36b04864c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib200f78d81c84f1caf083a586963ba04_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib82c4185c6fb4d92896edaac365482ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7947774ff61e417ca66c44d164ba6650_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4462842a9194410a79f71e762585fbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbabad301b294437b56c5d188d25d543_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if21d4b6455c5495b8488303a238975a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d4fa9f625b54b30b2dff2dc6a1a867b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12d3333974e14f89a7ec3f471522f303_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b86eb7007d470aa9e0586557f94125_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822d046be15341d59a14431cd169a913_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i521bc055cda840c99e95281f5864c7ad_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3abd01beb2944a8aabb8c310e92e38a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40b12428f67b4fb289c73df6c14dd797_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e556b75c0e543168782ac584ea02832_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c1925aa09c546e6bb1bbc2f922a757c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8207bee1099a4945acebe2cd3e4d4b1c_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae93f5204e234406aa4669d7fa75acb3_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia2f5bb9a1d474d50a682361408fd22f0_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cdc0620bb5249d1b453c6ee1ee52d9f_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifec4efcaaaba4d86ae2f9115d511c3ad_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d5d00287d2b402c81fe18e1a760ee21_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1276d33828844073b58b8708d329e283_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife760fe6115044c2ba0cfc773be36b66_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f4a4968e654e81812812835738bfba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bd951ea3e6843248bca81db2ab27548_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff61ad1254204984b2cd73c3460b9b29_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied811451007444bf9c9766b4e6b6f65e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>sesn:unit</xbrli:measure></xbrli:unit><xbrli:context id="i6bb37825c3464e0e96f96656c460f0b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8733b9f5af3744478388e7790ab97043_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i438fa29ca3bb484a8da013a3e14bb5aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b69c2d148fb4538a3850c0e09af5f52_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideb2c67211a74687ab81a95f14fff15e_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60b94d2194694dd39ade84abefa3fbd2_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ea235079af435bad2ec47753289b96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i494cedbff9d444cdaac1c2802663fc2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88aacf670d6d4b4d880e4b578f023b29_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b14fcd0c3d7431fa4d0dfee8ba33375_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7077879bdc245db95b0560b33dc1e1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6b0b19859b4275a8ba10b9aa85008e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65e64d741e894999bf76a1e7cf64b004_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89820af99a774c6da12e89d3f3b664cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f8f5e0d0c4144a4959bc06d609ca157_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib898a55a349649d690d06fb7f3e654d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id74fe8f2daef45e18f8d67cb5c61198b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2efef4133dd04188a2f6d5ffc3064dcd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6f81f8bf0246f39eed469355ba430e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f40cef73b6f464299f697a3de9e26bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i074825a299f84fcd81b16f4255ea2ad7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i917a1b8a73ae45318b8d10a7f14926dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica10e8f91cd84acdbe3c5774e4168b74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a8370652ea34632aa61254cc191c0a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4b6eb53935e4e5f9644289109556c1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c307f87ede64e08ba34df00d1e3be8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd6d796c44ea43198dc7c3fb8d6ae129_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c2a1c5a91084f178b29a4fe51e14ea2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39409440477849f689c25e277356952c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i426ddaf2851e41c3b2b8a1b26933b3da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8260e3eaa13f41a3a609d11ef48a8540_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3cd4cc1171943f0abebe901bfe21fec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93938c1286d6418fb704e36349eb0d31_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9871161ad5a44399978150d031c7b8ce_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71d9693f005d44b68ed0b5546044f4d8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if34f56efef5946f89e9010b83ecc7d97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i611e9ad1d7694553bcda04f42fc4e80b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df7ab1adf0148c78a21e7ce97a4d22f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id44669cb53d947d4ad326771aa7b9afe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4f414a7418a405588fb22be6f30e0c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i655ddc8bcc5848c5b1d7a3ff27a40ba1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ab420bf8ef045078703d770aad32427_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6e3f81d8d1b4f3f97c34c9b3d9b0f02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife751660f97f4281991e4b6aa712c73d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25d39b728d0147189730e15e9fd156c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94c243529fbd4ad2a365269cda0a0347_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bf382fe4d8647e58e6ad3d32e4f377c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id21ae50c8649402492cc8890f61aece0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6fca7ca9a1e4c2bb4c5439eaa2b6d6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50aaf5a9d1c54113a3349e45d1378020_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica22b69fbf7d46f5a9b967bc6cee46d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6a7b597081d4512984c70d7af968aac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sesn:InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>sesn:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="ic2c8425e295a4831bc9d718ca118ecff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sesn:FederalDerivativeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1c302f137734bc69da3529bc113e959_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sesn:FederalDerivativeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebe3ee0020554764957e449756650c1d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i0673287f84aa4bb4988c54a1565f24ce_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i973f2496cf69482fb40920ac6f30b991_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf5b39852dc407e946c46788b3a04b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f88572fbcae4d3b843b90b31979aadf_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2761fdbe240c456bb83255f46df5df11_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f7e4670d4c7461595be03c9af5334ba_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cda9cd3a8574fc2a6b9461f91c4497c_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f4d91941044efabca8fc31db5686f0_D20210601-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4e17d327564862bc9c9d71d1aabc8f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cdc8306a15942548c12172f72054f94_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84030fd2a4514267a4a2169a1b8e2e55_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i653d509451834b36b0c7c25dd6f1e8ea_I20210502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26100f264698454388e652d4dcede710_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34e59a9de0bb4644baea5c1090868f0b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd6743eae8e4cfdbb03b06c8b121eee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2979721cc12044649222cc680229209d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fff5776971a48a586881cd89287df3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i106b662daae24333b435aacc7c1a07b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72d9266aa5eb429b9daf124e3bbc9a6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8327d77c1755491d93d7990856f3cc52_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i019d2729b50e475f80b2f52267d77679_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica9046a3714e4afebe942291c8bb1be6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9f2bff1e4304c31873755098104fc76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>sesn:vote</xbrli:measure></xbrli:unit><xbrli:context id="i800abfbe2a3a4ff98ee18c6daa3452eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7529f34d71c8489d8eddf8fd724fd5ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc78166d67464d8dbbf2a4acfe7206bd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d3704f824a24ee3ab53e3e9b975ae7f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e4124d7d374ca0bc952081d6c500f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82a243d92e624ce19e709802a563543c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie68ccfa087a542998d3e397047b34a57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdcb7e9d6aeb45f3b64cf0988fbf00e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed2728c8f6640a5b89ab51323c10e96_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib00557f6793a464ebb3158651e79e729_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3c6905ce21c40b18f3059d5f6e237f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeddaa2b96474d13a379ff7566291039_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b7cb6c58024d5b9f676827326355bb_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa5fc09e9b4244549466aede24ab208e_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48ca0d5ad9bd4085818dc426b3589eb2_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6e50ab15b3f4156bd82e204e7b093e6_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a1490314240433882cb0da9a6d1b2de_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d82589e0dd040a795545a962a2cb1a0_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i015d83f362d9409aaffa4d0d06f715d7_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id958531e2fb946e3920b1cee8b9b3c37_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5725754243984358952852405d13672b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56bec24a6f664962bb4939227b4c9cda_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05fdf323c4eb41f591b33f27de2e40b4_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f9fd02125934e03bde7e6db929d631b_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dcf8ba7b1154c71807f93d29f6d1cc8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia76e658e62f94a39b6fa63c38baf1887_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id51afed260f64269a2103be0fab8e386_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacca46a3fbcd45eab8928c23a788895e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69316b9d7f84c72bf9062ad8a344515_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4cad1b5e12a475d81796c7dfd472fba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea92dc95dce94ad983cf2eaf1ef27507_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sesn:RestrictedStockUnitsPerformanceBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i645aef5340be4c348f095065f63145e6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sesn:RestrictedStockUnitsPerformanceBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33fae254eac8482dab713b9f73f69e41_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sesn:RestrictedStockUnitsPerformanceBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ca9f2083e648768635ed14bf7c4dd2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1333cc72fc424e2a8f8774a8f0d872fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa2ee52082f4e3e8053f82bebfa0168_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad3615d1132f4e6db8c87630585bb158_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f6527bbe7574825a65695e1c732589c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic025f71331f24e12b56e608440ce56ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i486533c551a2452c99626829ee478c51_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i236b00a74d3948dcae1d6b9ffcfa4fcf_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16c46bb406f14eaa81b7c198dcc44d8a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic44a95cc271a49b0aa716f7ebe2e6879_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a361b7208b64753a71edeaa3c23d956_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61d80b79fadf491ba762bf6b77e43e6a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf581044871b4e4a95de21bdefb73475_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9a728dfe3c4454cbc533710495f8f5b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifadff6a5daba493cb2a7db4117d654bf_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbcb93bc03d34a29ba0472e96a5c17db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramCashManagementMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee027c64b36746299c057f499c9540ad_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7750d93e565f4062abf14eab356f22e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idedbd5e4782a4a07988637e4ee0dffc0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac240dff34d54c259fa7dcc1af037866_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie548983137d0429b97bbb1a0cea18f7f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e7114012079469c8021b30d065673e7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f1e396274dc4a98b5466fd643278d94_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe3f29a701248b9893e3e02d72f5095_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1249ce1aca94aa89687426119ea9780_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cd59fe7a7ec49b7be31865888e57cd0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e820c7440e2402791def7b12470f1f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0c3c6cf2a04d4383911137e51d3b5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f2e215c48c94cc88ad545b140478fd4_I20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50afeb8b2fbe4a90bd225677491dd878_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9ccb359bb07464c8b5a4bf7acd0ee69_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81090f1cef414033a4de39f36d28f951_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieddcde47d6134b21a63f741b8434c23a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i284162f0c4ac4a84a203966f8ee455b8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice90a69ceeff49f0b8f1ce82d2bb4ded_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i921a13a0674c431a99d0b747823d5a59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib11ddd9e85084edeb9ff837ed2550dcc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7b74c8246e3465ebe694e85ae1cf30f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1992bb56f84f4d954e523e989b4498_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2917e2d690494115aa405efdcd442035_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="sesn:NetOperatingLossCarryforwardAxis">sesn:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaedc518daaca46d48e4045cf67580747_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id942c56598a7425a8f604363c0ccee90_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ce909ec953045fcb9590f2a8585912f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3541e5363f343a3a43242a6a366098b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7959f49c234c9eaa2618a72fb438f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sesn:NonCapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd3a316709d6476199e3824ccf11239c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea773b2e97a1449f9f95fa34f634aee4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7c86274f4d47eaa8553199408d4b91_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15671c3d0d094adaac0c1229062ca074_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22d0546a2e584012b01ef15556862322_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced9f5bd4c3647f9a7e60cc7a6ea99ed_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i211e8012b6af40e08411ca15f526f29f_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5589d69bf52247d28185c2f78a22516f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672eb9cc12ef4dfabefe71540f49d9d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eaf6421a30f4d65931441ab3517bbd0_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icabd5c54fc0449559aeac9215c25207e_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie66655811a134f9b8b6e989ecb525174_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a4679b42de470d95370417666d7ba5_D20200730-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-30</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4383d15b8e8f48599512b909df5f7d25_D20200730-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-30</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9cd9290db5c494b8aac997b30e9f530_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i068115fbd385473eaf14a517d80898f9_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdcdf96fee1148569a372008cbcbc48f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40dde77c20a24756b6c9849cf8a19522_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3078e30e83804e5189a02bd018d21ad5_D20220720-20220720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-20</xbrli:startDate><xbrli:endDate>2022-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a1663e77ac1498184a0073f406681d3_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa658292b071478aa327ee12757b1aec_D20210805-20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1294558bb964edc87c70925cf5cde03_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia82aa374295f472f94fa22a817803cf0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sesn:A2022RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib391d9ecf3114b2c994998943181cc31_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sesn:A2022RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i712c5f7e1c9a4489a1932903418a4389_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sesn:A2022RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2ad0b07f8ff40c5a4c7df314a525778_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sesn:A2022RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5532051f20ab4b50a0fedc0c29b03429_D20210830-20210830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sesn:A2021RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>sesn:position</xbrli:measure></xbrli:unit><xbrli:context id="i9b7c25990186472f9eefe41ce144971d_D20230302-20230302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-02</xbrli:startDate><xbrli:endDate>2023-03-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjM1_3f4fb906-c666-4164-809a-1ec4f90e3e50">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6YmViMzliN2JhODU1NGIwZDkzMzU3M2FjNzVkZDkyOWIvdGFibGVyYW5nZTpiZWIzOWI3YmE4NTU0YjBkOTMzNTczYWM3NWRkOTI5Yl8wLTAtMS0xLTkyMzc1_011d32f0-9df7-43bf-8981-61c156d61546">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8xMzE_1ef4c990-cb7a-4e76-941f-8d3a0bdfe99f"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8xMzE_7b8c1d35-de5d-47f7-aed6-5e1f2dfaa72a">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6ZmNjNzA5YTNiMjk0NGU3OWFkNjRlODAzZjVmZWNhMDMvdGFibGVyYW5nZTpmY2M3MDlhM2IyOTQ0ZTc5YWQ2NGU4MDNmNWZlY2EwM18wLTAtMS0xLTkyMzc1_3693dc61-a884-4420-902f-25dfbe5f53e2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from _____ to _____</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQz_89a32ee1-a440-4003-9335-15570c93eabc">001-36296</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjM5_813ae05c-e153-485b-8ff8-58fcc4bda765">Sesen Bio, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6NmIwZjZiNWE0YTY1NDllZDgzMjkyNmM0YmE1ZjNhZWQvdGFibGVyYW5nZTo2YjBmNmI1YTRhNjU0OWVkODMyOTI2YzRiYTVmM2FlZF8wLTAtMS0xLTkyMzc1_f3ef3c52-1e10-478e-960a-bee2557cd38e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6NmIwZjZiNWE0YTY1NDllZDgzMjkyNmM0YmE1ZjNhZWQvdGFibGVyYW5nZTo2YjBmNmI1YTRhNjU0OWVkODMyOTI2YzRiYTVmM2FlZF8wLTEtMS0xLTkyMzc1_93667a39-a824-47c2-b299-26eaf3950d76">26-2025616</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MTUwZDA3NTg2M2M0NDk5NmJhNWExOThiNWFkYTgxZjcvdGFibGVyYW5nZToxNTBkMDc1ODYzYzQ0OTk2YmE1YTE5OGI1YWRhODFmN18wLTAtMS0xLTkyMzc1L3RleHRyZWdpb246ODFlYTI4MGMxYWY0NDliNzg1YWI5ZTBiNjc4OTQzZjZfNA_393c3a8b-37b6-4ba7-8c29-87e9293ed744">245 First Street</ix:nonNumeric>, <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MTUwZDA3NTg2M2M0NDk5NmJhNWExOThiNWFkYTgxZjcvdGFibGVyYW5nZToxNTBkMDc1ODYzYzQ0OTk2YmE1YTE5OGI1YWRhODFmN18wLTAtMS0xLTkyMzc1L3RleHRyZWdpb246ODFlYTI4MGMxYWY0NDliNzg1YWI5ZTBiNjc4OTQzZjZfOA_5b8eebd3-3b36-47a0-9fc5-69f59ef92632">Suite 1800</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MTUwZDA3NTg2M2M0NDk5NmJhNWExOThiNWFkYTgxZjcvdGFibGVyYW5nZToxNTBkMDc1ODYzYzQ0OTk2YmE1YTE5OGI1YWRhODFmN18wLTAtMS0xLTkyMzc1L3RleHRyZWdpb246ODFlYTI4MGMxYWY0NDliNzg1YWI5ZTBiNjc4OTQzZjZfMTE_e2dfef00-959e-4281-b87f-88697db8c07d">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MTUwZDA3NTg2M2M0NDk5NmJhNWExOThiNWFkYTgxZjcvdGFibGVyYW5nZToxNTBkMDc1ODYzYzQ0OTk2YmE1YTE5OGI1YWRhODFmN18wLTAtMS0xLTkyMzc1L3RleHRyZWdpb246ODFlYTI4MGMxYWY0NDliNzg1YWI5ZTBiNjc4OTQzZjZfMTU_bd413e8e-5c1b-4dbc-a463-4fd1cdcb37e8">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MTUwZDA3NTg2M2M0NDk5NmJhNWExOThiNWFkYTgxZjcvdGFibGVyYW5nZToxNTBkMDc1ODYzYzQ0OTk2YmE1YTE5OGI1YWRhODFmN18wLTEtMS0xLTkyMzc1_1d4922c9-bdd1-4991-949c-f52fcc66eef7">02142</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zNTE_5ba6486e-5d7c-425e-aadc-471c403b9d02">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjM2_8f111dea-5b4c-4cb4-a621-26e6c80e5f3a">444-8550</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.472%"><tr><td style="width:1.0%"></td><td style="width:43.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6NWM1NDlmYmY4MGM4NDExZjliMGUzODY2NzUyMjdlMTgvdGFibGVyYW5nZTo1YzU0OWZiZjgwYzg0MTFmOWIwZTM4NjY3NTIyN2UxOF8xLTAtMS0xLTkyMzc1_bef0faf5-d4a2-4e6f-beba-6dbebe6eb061">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6NWM1NDlmYmY4MGM4NDExZjliMGUzODY2NzUyMjdlMTgvdGFibGVyYW5nZTo1YzU0OWZiZjgwYzg0MTFmOWIwZTM4NjY3NTIyN2UxOF8xLTEtMS0xLTkyMzc1_48b43de9-6a22-4795-bd3e-111ae52f7f3b">SESN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6NWM1NDlmYmY4MGM4NDExZjliMGUzODY2NzUyMjdlMTgvdGFibGVyYW5nZTo1YzU0OWZiZjgwYzg0MTFmOWIwZTM4NjY3NTIyN2UxOF8xLTItMS0xLTkyMzc1_61825b7e-ffa6-46e3-bdf0-843333432273">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQw_e749678a-5010-40f8-a91a-b1137861039b">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQx_d2f2d9a1-692f-44e5-9d84-0c32419fe923">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQ2_3c8bf5b5-e8af-4438-b94d-d8a3682d9119">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQ3_94837c8e-3a82-4eb7-bdbf-e35e0fd10f87">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer," &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.166%"><tr><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MjA5NGQzZTNkNWVhNGQwMWE3MmFlYjk4Yjc3ZTJiNTcvdGFibGVyYW5nZToyMDk0ZDNlM2Q1ZWE0ZDAxYTcyYWViOThiNzdlMmI1N18wLTMtMS0xLTkyMzc1_da5a3ddc-19ab-4413-8107-f88fa5205980">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MjA5NGQzZTNkNWVhNGQwMWE3MmFlYjk4Yjc3ZTJiNTcvdGFibGVyYW5nZToyMDk0ZDNlM2Q1ZWE0ZDAxYTcyYWViOThiNzdlMmI1N18xLTMtMS0xLTkyMzc1_c7298eea-5edb-4570-ab8a-7862ff9237b6">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MjA5NGQzZTNkNWVhNGQwMWE3MmFlYjk4Yjc3ZTJiNTcvdGFibGVyYW5nZToyMDk0ZDNlM2Q1ZWE0ZDAxYTcyYWViOThiNzdlMmI1N18yLTAtMS0xLTEwNzE3MA_ccdffb92-a8de-46ef-ae55-a0c0e22b1604">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8xMDk5NTExNjMxNDcz_230604dc-d9bd-4e6d-b6dc-59d16762796e">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). &#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjM4_622a80f8-69ee-4c7d-9724-ce5c8d3afe73">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates of the registrant, computed by reference to the closing price of the common stock on the Nasdaq Capital Market on June 30, 2022, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl83Njk2NTgxMzk3NzI4_8e594aa7-93c8-4533-abb6-0fd27817d9bd">161.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="i2e57ab72df0c4d23813023acb9286a55_I20230221" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8yNzQ4Nzc5MDc1NDcw_9d8c4146-5475-4143-986a-685bc3ea75c4">203,492,202</ix:nonFraction> shares of the registrant's common stock outstanding as of</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;21, 2023</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Documents Incorporated by Reference</span></div><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQ0_1c83c024-8873-40e1-b185-156c757d0596" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders ("2023 Proxy Statement") or an amendment to this Annual Report on Form 10-K are incorporated by reference into Part III of this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant will file the 2023 Proxy Statement or an amendment to this Annual Report on Form 10-K with the Securities and Exchange Commission within 120 days of December&#160;31, 2022.</span></ix:nonNumeric></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:17pt;margin-top:12pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Report on Form 10-K for the Fiscal Year Ended December&#160;31, 2022</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward-looking Statements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_10">i</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk Factors Summary </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_10">iii</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_19">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unresolved Staff Comments.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_22">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Properties.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_22">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_22">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_22">25</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_28">26</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[Reserved.]</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_28">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_31">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_34">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements and Supplementary Data.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_34">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_34">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_37">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_40">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_40">45</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;III</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors, Executive Officers and Corporate Governance.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_43">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Compensation.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_43">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_43">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain Relationships and Related Transactions, and Director Independence.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_43">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Accountant Fees and Services.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_43">46</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;IV</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits and Financial Statement Schedules.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_49">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K Summary.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_52">51</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_55">SIGNATURES</a></span></div></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Annual Report on Form 10-K to "Sesen," the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; include Sesen Bio, Inc. and its subsidiaries. We refer to the surviving corporation following the merger (as discussed below) as the &#8220;combined company&#8221;.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_1185"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_10"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, the proposed merger with CARISMA Therapeutics Inc. (&#8220;Carisma&#8221;), the impact of the COVID-19 pandemic, business strategy, current and prospective products, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;goals,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; "contemplate," &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete, on a timely basis or at all, the proposed merger with Carisma announced on September 21, 2022, pursuant to the terms and conditions of the Merger Agreement (as defined below);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the receipt of any potential future payments to our stockholders under the CVR Agreement (as defined below);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strategy or future operations of the combined company following the closing of the proposed merger with Carisma, </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advancement of the combined company&#8217;s product candidates and product pipeline, clinical development of the combined company&#8217;s product candidates, including expectations regarding timing of initiation and results of clinical trials of the combined company;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to seek a partner for the further development of Vicineum, and the potential challenges involved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected timing of implementing and completing our 2022 Restructuring Plan (as defined below) following the decision to voluntarily pause further development of Vicineum in the United States;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected timing for incurring costs associated with the 2022 Restructuring Plan;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to preserve capital during the pendency of the proposed merger with Carisma and while we seek a potential partner for the further development of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of the COVID-19 pandemic on our ability to consummate the proposed merger with Carisma and seek a partner for the further development of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected financial position;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain intellectual property protection for our product candidates and our proprietary technology;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding key advantages of our targeted fusion protein therapeutics platform; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the amount of future milestone payments pursuant to our Asset Purchase Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, among others, the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that the conditions to the closing of the proposed merger with Carisma are not satisfied, including the failure to obtain stockholder approval of matters related to the proposed merger in a timely manner or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties as to the timing of the consummation of the proposed merger with Carisma and the ability of each of us and Carisma to consummate the proposed merger, including Carisma&#8217;s completion of the Carisma Pre-Closing Financing (as defined below);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ability to correctly estimate our expected net cash at the closing of the proposed merger and our ability to correctly estimate and manage our respective operating expenses and expenses associated with the proposed merger;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our continued listing on The Nasdaq Stock Market LLC;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that as a result of adjustments to the Exchange Ratio (as defined below) our stockholders could own less of the combined company than is currently anticipated;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that the conditions to payment under the CVR Agreement will not be met and may never deliver any value to our stockholders;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the possible failure to realize certain anticipated benefits of the proposed merger, including with respect to future financial and operating results;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties regarding the impact any delay in the closing of the proposed merger would have on the anticipated cash resources of the combined company upon closing of the proposed merger and other events and unanticipated spending and costs that could reduce the combined company&#8217;s cash resources;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of uncertainties related to the actions of activist stockholders, which could make it more difficult to obtain the approval of our stockholders with respect to the proposed merger related proposals and result in us incurring significant fees and other expenses, including for third-party advisors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of the announcement, pendency or completion of the proposed merger on our or Carisma&#8217;s business relationships, operating results and business generally;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to the proposed merger;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any legal proceedings that have been and may be instituted against us or any of our directors or officers related to the Merger Agreement or the transactions contemplated thereby;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of us or Carisma to protect our and their intellectual property rights, as applicable;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive responses to the proposed merger and changes in expected or existing competition;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legislative, regulatory, political and economic developments, among other risks and uncertainties;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that we may not be successful in identifying a partner for the further development of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that we may not be able to implement the 2022 Restructuring Plan as currently anticipated or within the timing currently anticipated;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that we may incur unanticipated charges as a result of the 2022 Restructuring Plan; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that we may be unable to defend and enforce patent claims and other intellectual property rights; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that we may be unable to defend against pending or threatened litigation, which may be costly and time-consuming; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such other factors described in &#8220;Item 1A. Risk Factors&#8221; and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risks and uncertainties. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Annual Report on Form 10-K to the &#8220;Company,&#8221; &#8220;Sesen,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; include Sesen Bio, Inc. and its subsidiaries.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors Summary</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following summarizes the principal factors that make an investment in us speculative or risky, all of which are more fully described in &#8220;Item 1A. Risk Factors&#8221; below. This summary should be read in conjunction with &#8220;Item 1A. Risk Factors&#8221; and should not be relied upon as an exhaustive summary of the material risks facing our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Merger with CARISMA Therapeutics Inc.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Exchange Ratio will not change or otherwise be adjusted based on the market price of our common stock as the exchange ratio depends on our net cash at the closing of the Merger and not the market price of our common stock, so the merger consideration at the closing of the Merger may have a greater or lesser value than at the time the Merger Agreement was signed.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stockholders and Carisma&#8217;s stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger and the Carisma Pre-Closing Financing and the conversion of the Carisma convertible note. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to complete the Merger may result in either us or Carisma paying a termination fee to the other party and could significantly harm the market price of our common stock and negatively affect the future business and operations of each company.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The issuance of our common stock to Carisma&#8217;s stockholders pursuant to the Merger Agreement and the resulting change in control from the Merger must be approved by our stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by Carisma's stockholders. Failure to obtain these approvals would prevent the closing of the Merger.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Some of our executive officers and directors have interests in the Merger that are different from our stockholders and that may influence them to support or approve the Merger without regard to the interests of our stockholders.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stockholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the closing of the Merger as compared to their current ownership and voting interest in our company.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the pendency of the Merger, we may not be able to enter into a business combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect our business prospects.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Certain provisions of the Merger Agreement may discourage third parties from submitting alternative takeover proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because the lack of a public market for Carisma common stock makes it difficult to evaluate the value of Carisma common stock, the Carisma stockholders may receive shares of our common stock in the Merger that have a value that is less than, or greater than, the fair market value of Carisma common stock.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the conditions to the Merger are not satisfied or waived, the Merger will not occur.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lawsuits have been filed, and additional lawsuits may be filed in the future, against us and the members of our board of directors arising out of the proposed Merger, which may delay or prevent the proposed Merger.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the Merger is not completed, our board of directors may decide to pursue a dissolution of our company. In a dissolution, there can be no assurances as to the amount or timing of available cash, if any, to distribute to our stockholders after paying our debts and other obligations and setting aside funds for reserves.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stockholders may not receive any payment on the CVRs (as defined below) from the proceeds related to either the Roche Asset Purchase Agreement (as defined below) or any sale of our non-cash assets and therefore the CVR may expire valueless or result in lower returns than anticipated or none at all. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The United States federal income tax treatment of the CVRs is unclear and there can be no assurance that the Internal Revenue Service would not assert, or that a court would not sustain, a position that could result in adverse United States federal income tax consequences to holders of the CVRs.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have never paid and, other than in connection with the Merger with Carisma, do not intend to pay any cash dividends in the foreseeable future.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on our remaining employees to facilitate the consummation of the Merger.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we cannot meet the requirements under our license agreements with Zurich, Micromet and XOMA, we could lose important rights to Vicineum, which could have material adverse effect on our ability to sell Vicineum.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business and Operations</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our restructuring plans and the associated headcount reductions may not result in anticipated savings, could result in total costs and expenses that are greater than expected.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to enter into a transaction with a suitable acquiror or licensee for Vicineum or any transaction entered into may not be on terms that are favorable to us.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In connection with our strategic decision to voluntarily pause further development of Vicineum in the United States, we may become involved in disagreements or disputes with our licensees, licensors and other counterparties relating to the development and/or commercialization of Vicineum, which may be time consuming, costly and could divert our efforts and attention from consummating the proposed Merger with Carisma and harm our efforts to seek a partner to continue development of Vicineum. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and certain of our officers have been, and may in the future be, named as defendants in lawsuits. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. Any other lawsuits to which we are subject may be costly to defend and are uncertain in their outcome.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to regain compliance with the listing requirements of the Nasdaq Capital Market, our common stock may be delisted from the Nasdaq Capital Market which could have a material adverse effect on our business and could make it more difficult for you to sell your shares of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_16"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. &#160;&#160;&#160;&#160;Business.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical company that previously focused on advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidate, Vicineum, also known as VB4-845, is a locally administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of non-muscle invasive bladder cancer ("NMIBC").  </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the United States Food and Drug Administration ("FDA"), which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial, which the FDA previously confirmed would be required for a potential resubmission of a biologics license application ("BLA") for Vicineum for the treatment of NMIBC. As a result of this decision, we turned our primary focus to consummating a strategic transaction with the goal of maximizing stockholder value.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on September 20, 2022, we, Seahawk Merger Sub, Inc., a Delaware corporation and our wholly-owned subsidiary (&#8220;Merger Sub&#8221;), and CARISMA Therapeutics Inc. (&#8220;Carisma&#8221;), entered into the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (the &#8220;Merger Agreement&#8221;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma continuing as our wholly-owned subsidiary and the surviving corporation of the merger (the &#8220;Merger&#8221;). Our board of directors unanimously approved the Merger Agreement and resolved to recommend that our stockholders approve the proposals described in the Merger Agreement. If the Merger is completed, the business of Carisma will continue as the business of the combined company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, we are seeking a partner that can execute further development to realize the full potential of Vicineum. As a result of such decision and our subsequent decision to enter into the proposed Merger with Carisma, we no longer plan to pursue regulatory approval of Vicineum for NMIBC in the European Union (the &#8220;E.U.&#8221;) and have started to wind down certain of our manufacturing operations and business development partnerships. Additionally, we are seeking a partner for the further development of Vicineum and have initiated a formal process and engaged a financial advisor for the potential sale of Vicineum. If the proposed Merger is consummated, the combined company does not expect to pursue further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current Strategy</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anticipated Merger with CARISMA Therapeutics Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger is expected to be completed during the first quarter of 2023.</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, we are seeking the approval of our stockholders to, among other things, (a) issue the shares of our common stock issuable in connection with the Merger pursuant to the rules of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), and (b) amend our amended and restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of our common stock at a ratio of 1-for-20 (clauses (a) and (b), collectively, the &#8220;Sesen Bio Voting Proposals&#8221;). The special meeting of stockholders in which our stockholders will be asked to vote on the Sesen Bio Voting Proposals (the &#8220;Special Meeting&#8221;) will be held on March 2, 2023 at 10:00 a.m. Eastern Time. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consummation of the Merger is subject to certain closing conditions, including, among other things, (a) approval by our stockholders of the Sesen Bio Voting Proposals as described in the Merger Agreement, (b) approval by Carisma&#8217;s stockholders of, among other things, the adoption of the Merger Agreement, (c) Nasdaq&#8217;s approval of the listing of the shares of our common stock to be issued in connection with the Merger, (d) the effectiveness of a registration statement on Form S-4 to register the shares of our common stock to be issued in connection with the Merger, and (e) our having net cash as of closing of the Merger greater than or equal to $70.0&#160;million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger Agreement contains certain termination rights of each of us and Carisma. Upon termination of the Merger Agreement under specified circumstances, we may be required to pay Carisma a termination fee of $7.6&#160;million and/or reimburse Carisma&#8217;s expenses up to a maximum of $1.75&#160;million, and Carisma may be required to pay us a termination fee of $5.49&#160;million and/or reimburse our expenses up to a maximum of $1.75 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Merger Agreement, at the completion of the Merger, (a) each then outstanding share of Carisma common stock and Carisma preferred stock (including shares of Carisma&#8217;s common stock issued in connection with the pre-closing financing described below) will be converted into the right to receive a number of the shares of our common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), and (b) each then outstanding Carisma stock option to purchase Carisma&#8217;s common stock will be assumed by us, subject to adjustment as set forth in the Merger Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution and delivery of the Merger Agreement, Carisma entered into a subscription agreement with certain investors named therein, pursuant to which such investors have agreed, subject to the terms and conditions of such subscription agreement, to purchase prior to the consummation of the Merger shares of Carisma&#8217;s common stock for an aggregate purchase price of approximately $30.6 million (the &#8220;Carisma Pre-Closing Financing&#8221;). The consummation of the Carisma Pre-Closing Financing is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement. Shares of Carisma&#8217;s common stock issued pursuant to the Carisma Pre-Closing Financing will be converted into shares of our common stock in the Merger in accordance with the Exchange Ratio.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At or prior to the effective time of the Merger, we will enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with a rights agent (the &#8220;Rights Agent&#8221;) pursuant to which we intend to declare a dividend payable to our stockholders of record as of a date agreed to by us and Carisma prior to the effective time of the Merger with respect to the receipt of one contingent value right (each, a &#8220;CVR&#8221;), for each outstanding share of our common stock held by such stockholders on such date. Each CVR will represent the contractual right to receive (i) contingent cash payments upon the receipt by us of certain proceeds payable by Roche, if any, pursuant to the asset purchase agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) (the &#8220;Roche Asset Purchase Agreement&#8221;), upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement as well as (ii) proceeds from any sale of our legacy assets, including Vicineum, subject to certain customary deductions, including for expenses and taxes, in the event any sale occurs prior to March 31, 2027. The contingent payments under the CVR Agreement, if they become due, will be payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance that any cash payment will be made or that any holders of CVRs will receive any amounts with respect thereto.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in connection with the Merger, we intend to declare a one-time $75.0 million cash dividend payable to our stockholders of record as of a date prior to the effective time of the Merger, subject to the terms and condition set forth in the Merger Agreement.   </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2023, a group of our significant stockholders (the &#8220;Investor Group&#8221;) entered into a voting and support agreement with us and Carisma (the &#8220;Support Agreement&#8221;) pursuant to which the Investor Group agreed to vote, at the Special Meeting, any and all of their shares of our common stock in favor of the Merger and related matters, subject to the terms and conditions set forth in the Support Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that we do not complete the Merger with Carisma, we may decide to pursue a dissolution under Delaware law. In a dissolution, there can be no assurances as to the amount or timing of available cash, if any, to distribute to our stockholders after paying our debts and other obligations and setting aside funds for reserves.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Recent Events</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Restructuring Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following the decision to voluntarily pause further development of Vicineum in the United States (the &#8220;2022 Restructuring Plan&#8221;). Execution of the 2022 Restructuring Plan is expected to be substantially completed in connection with the closing of the Merger, which is expected to occur in the first quarter of 2023. The 2022 Restructuring Plan includes an incremental reduction in our workforce as well as additional cost-saving initiatives intended to preserve capital during the pendency of the Merger and while we seek a potential partner for the further development of Vicineum. We also incurred one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Retention Program</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2022, our board of directors and the compensation committee of the board of directors approved a retention program for certain employees pursuant to which we will provide a cash incentive designed to retain such employees (the &#8220;2022 Retention Program&#8221;). Pursuant to the 2022 Retention Program, certain of our employees, including certain executive officers other than our Chief Executive Officer, were to have received a cash bonus award, vesting in full upon the earlier of (a) the completion of a strategic transaction and (b) the termination of such employee without cause, subject to the employee&#8217;s continued employment through that time. On February 7, 2023, the compensation committee of the board of directors approved a modification to the 2022 Retention Program, such that the vesting of the retention bonus awards for employees, other than </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">executive officers, will occur upon the earlier of (a) 5:00 pm Eastern Time on the second business day following the date of the Special Meeting regardless of the results of the Special Meeting and (b) the termination of the Merger Agreement in accordance with its terms. The terms of the 2022 Retention Program for those executive officers participating in the 2022 Retention Program were not modified.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nasdaq Delisting Notice </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2023, we were notified by the Listing Qualifications Department (the &#8220;Staff&#8221;) of Nasdaq that, based upon our non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price Rule&#8221;), our common stock will be delisted from Nasdaq unless we timely request a hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We requested a hearing before the Panel, which stayed any delisting action by the Staff and ensured our common stock remains listed and eligible for trading on Nasdaq pending a determination by the Panel. The hearing had been scheduled for March 16, 2023. On February 24, 2023, we received a determination from the Nasdaq Office of General Counsel that the Panel granted us an exception from our non-compliance with the Bid Price Rule to complete the Merger by March 10, 2023. Pursuant to Nasdaq Listing Rule 5110(a), we must demonstrate compliance with all initial listing requirements of Nasdaq upon the closing of the Merger. We are seeking approval for the Merger and the implementation of a reverse stock split of our common stock at the Special Meeting. In the event we fail to establish compliance with the initial listing standards by March 10, 2023, our common stock will be delisted from Nasdaq, unless granted an additional exception by the Panel.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 24, 2022, we received written notice from the Staff indicating that, based upon the closing bid price for our common stock for the previous 30 consecutive business days, we no longer satisfied the Bid Price Rule and, in accordance with the Nasdaq Listing Rules, were afforded an initial grace period of 180 calendar days, through July 25, 2022, and a second 180-calendar day period, through January 23, 2023, to regain compliance with the Bid Price Rule. We did not regain compliance with the Bid Price Rule by January 23, 2023, which resulted in the Staff&#8217;s January 25, 2023, determination.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of EBI-031 Legacy Technology to Roche</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into a license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which we granted Roche an exclusive, worldwide license, including the right to sublicense, to our patent rights and know-how related to our monoclonal antibody EBI-031 and all other IL-6 anti-IL antagonist monoclonal antibody technology owned by us (collectively, the &#8220;Roche Licensed Intellectual Property&#8221;). Under the Roche License Agreement, Roche was required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody and pursue ongoing patent prosecution, at its cost. At the time of entering into the Roche License Agreement, EBI-031, which was derived using our previous AMP-Rx platform, was in pre-clinical development as an intravitreal injection for diabetic macular edema and uveitis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we entered into the Roche Asset Purchase Agreement pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by us for up to $70.0&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40.0&#160;million payment to us upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30.0&#160;million payment to us upon Roche&#8217;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with the Merger, each CVR will represent the contractual right to receive contingent cash payments upon the receipt by us of certain proceeds payable by Roche, if any, pursuant to the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement as well as proceeds from any sale of our legacy assets, including Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Historical TFPT Platform </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our historical product candidates are based on our proprietary TFPT platform and are focused on addressing areas of unmet medical need in cancer. Our novel TFPTs have been designed to overcome the efficacy and safety challenges of existing antibody drug conjugates and were being developed for both local and systemic administration. Our TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through our proprietary recombinant one-step, microbial manufacturing process. Our TFPT platform uses antibody fragments, which include Fabs, single chain variable domains ("scFvs"), and non-covalent scFv dimers, derived from the domains of antibodies that confer antigen recognition. We selected antibody fragments for our historical product candidates depending upon the target therapeutic indication. We targeted tumor cell surface antigens showing limited expression on normal cells and once bound, is rapidly internalized into the targeted cancer cell. For local administrations, we utilized an immunogenic cytotoxic protein payload designed to both target cancer cells and promote a heightened local immune response against the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tumor. Our most advanced locally administered TFPT product candidate was Vicineum, in development for the treatment of non-muscle invasive carcinoma in situ (&#8220;CIS&#8221;) of the bladder in patients previously treated with adequate or less than adequate bacillus Calmette-Gu&#233;rin (&#8220;BCG&#8221;). For systemic administrations, we used deBouganin, a plant-derived, protein payload of reduced immunogenic potential that we believe can be repeatedly administered via infusion without the generation of an efficacy-limiting immune response against the payload.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vicineum for the treatment of NMIBC</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the follow-up stage of our single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the &#8220;VISTA Trial&#8221;) in May 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. In December 2020, we submitted our completed BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target Prescription Drug User Fee Act date for a decision on the BLA of August 18, 2021. On August 13, 2021, we received a Complete Response Letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing, and controls (&#8220;CMC&#8221;) issues pertaining to a pre-approval inspection and product quality. On August 20, 2021, we withdrew our marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (the &#8220;EMA&#8221;) for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the E.U. until there was more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name conditionally approved by the EMA for oportuzumab monatox in the E.U. In October 2021, the EMA issued its Withdrawal Assessment Report relating to its MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The EMA Withdrawal Assessment Report reflected the initial assessment and corresponding questions from the EMA and identified major objections in the areas of quality, good clinical practice, efficacy, and safety. As a result of our decision on July 15, 2022 to pause further development of Vicineum in the United States, we no longer plan to pursue regulatory approval of Vysyneum for NMIBC in the E.U.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 and December 2021, we participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed would be required for a potential resubmission of a BLA. In March 2022, we participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. On July 11, 2022, we participated in a Type B meeting with the FDA to discuss outstanding items related to our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. As discussed above, on July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the United States. If the Merger is consummated, the combined company does not expect to pursue further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Clinical Trial &#8211; VISTA Trial</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2015, in the United States and Canada, through our subsidiary Viventia Bio, Inc., we commenced the VISTA Trial in patients with BCG-unresponsive NMIBC who had received adequate BCG and whose disease was-then BCG-unresponsive, and for whom the then-current standard of care was radical cystectomy. In November 2016, the FDA issued draft guidance regarding appropriate clinical trial design for new drugs and biologics for BCG-unresponsive NMIBC, including the use of single-arm trials. The FDA finalized this guidance in February 2018 and retained many of the recommendations from the 2016 draft guidance regarding clinical trial design, including the use of single-arm trials. We believe that our VISTA Trial design was consistent with these aspects of the FDA&#8217;s guidance. In May 2022, we completed the follow up phase of the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary and secondary endpoints for the VISTA Trial were as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:26.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dose</span></div></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 mg of Vicineum (in 50 mL of saline)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total enrollment</span></div></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 patients, including 93 CIS patients whose disease is BCG-unresponsive</span></div></td></tr><tr style="height:26pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Primary endpoints</span></div></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complete response rate ("CRR") at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive</span></td></tr><tr style="height:36pt"><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kaplan-Meier estimate of duration of response ("DoR") for BCG-unresponsive CIS patients who experience a complete response ("CR") at 3 months (post-induction)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with CIS were considered to have a CR if at the time of any disease status evaluation (per protocol every 13 weeks or any unscheduled evaluation) there was no evidence of high-grade disease (CIS, high-grade Ta or any grade T1 disease) or disease progression (e.g., to muscle invasive disease). Low-grade disease was not considered a treatment failure in these patients, and they could remain on study treatment following TURBT.</span></div><div style="margin-bottom:7pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:26.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.921%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="7" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Secondary endpoints</span></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Event-free survival in all patients</span></td></tr><tr style="height:26pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRR at 6, 9, 12, 15, 18, 21 and 24 months in patients with CIS whose disease is BCG-unresponsive</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time to cystectomy in all patients</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time to disease recurrence in papillary patients</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Progression free survival (PFS) in all patients</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overall survival (OS) in all patients</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safety and tolerability of Vicineum therapy in all patients</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exploratory endpoint</span></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To evaluate biomarkers that may be associated with response or disease progression or treatment failure, which may include, for example, EpCAM status, tumor subtype morphology, furin levels in tumor cell endosomes, presence of a glycosaminoglycan coat and presence of receptors that could impede a host anti-tumor immune response, such as PD-L1.</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VISTA Trial completed enrollment in April 2018 with a total of 133 patients across three cohorts based on histology and time to disease recurrence after adequate BCG treatment (under 2018 FDA guidance on treatment of NMIBC, adequate BCG is defined as at least one of the following (i) at least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy or (ii) at least five of six doses of an initial induction course plus at least two of six doses of a second induction course):</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 (n=86): Patients with CIS with or without papillary disease that were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined to be r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efractory or recurred within six months of their last course of adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 2 (n=7): Patients with CIS with or without papillary disease that recurred after six months, but less than 11 months, after their last course of adequate BCG; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 3 (n=40): Patients with high-risk (Ta or T1) papillary disease without CIS that recurred within six months of their last course of adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, preliminary primary and secondary endpoint data for each of the trial cohorts were as follows: </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 1 (n=86) Evaluable Population (n=82) Complete Response Rate, for CIS:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39% (28%-50%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26% (17%-36%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20% (12%-30%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-27%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 2 (n=7) Evaluable Population (n=7) Complete Response Rate, for CIS:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">43% (10%-82%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14% (0%-58%)</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pooled Cohorts 1 and 2 (n=93) Evaluable Population (n=89) Complete Response Rate, for CIS:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase 3 Pooled Complete Response Rate vs. Phase 2 Pooled Complete Response Rate:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.245%"><tr><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 3 Pooled CRR (95% Confidence Interval)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 2 Pooled CRR (95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (26%-56%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27% (15%-42%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18% (8%-32%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16% (7%-30%)</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 3 (n=40) Evaluable Population (n=38) Recurrence-Free Rate&#8224;:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recurrence-Free Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">71% (54%-85%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58% (41%-74%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45% (29%-62%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42% (26%-59%)</span></div></td></tr></table></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8224;Recurrence-free rate is defined as the percentage of patients that are recurrence-free at the given assessment time point.</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duration of Response:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median DoR for patients in Cohort 1 and Cohort 2 combined (n=93) was 287 days (95% CI, 154-NE), using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis of pooled data for all patients with CIS (Cohorts 1 and 2, n=93) showed that among patients who achieved a complete response at 3 months, 52% remained disease-free for a total of 12 months or longer after starting treatment, using the Kaplan-Meier method. DoR is defined as the time from first occurrence of complete response to documentation of treatment failure or death.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have conducted additional analyses for secondary endpoints. These additional data include the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Cystectomy:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all 133 patients treated with Vicineum in the VISTA Trial, greater than 75% of all patients are estimated to remain cystectomy-free at 3 years, using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis showed that approximately 88% of responders are estimated to remain cystectomy-free at 3 years. Time to cystectomy is defined as the time from the date of first dose of study treatment to surgical bladder removal. The first 2018 FDA guidance on treatment of BCG-unresponsive NMIBC patients states that the goal of therapy in such patients is to avoid cystectomy. Therefore, time to cystectomy is a key secondary endpoint in the VISTA Trial. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Disease Recurrence:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> High-grade papillary (Ta or T1) NMIBC is associated with high rates of progression and recurrence. The median time to disease recurrence for patients in Cohort 3 (n=40) was 402 days (95% CI, 170-NE), using the Kaplan-Meier method. Time to disease recurrence is defined as the time from the date of the first dose of study treatment to the first occurrence of treatment failure or death on or prior to treatment discontinuation. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Progression-Free Survival ("PFS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain progression-free for 2 years or greater, using the Kaplan-Meier method. PFS is defined as the time from the date of first dose of study treatment to the first occurrence of disease progression (e.g., T2 or more advanced disease) or death on or prior to treatment discontinuation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Event-Free Survival:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain event-free at 12 months, using the Kaplan-Meier method. Event-free survival is defined as the time from the date of first dose of study treatment to the first occurrence of disease recurrence, progression or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Overall Survival ("OS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to have an overall survival of 2 years or greater, using the Kaplan-Meier method. OS is defined as the time from the date of first dose of study treatment to death from any cause.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data is as of the May 29, 2019 data cut from the Phase III VISTA Trial. The clinical data shown are based on the data submitted in the BLA on December 18, 2020. Final numbers</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are pending. On August 13, 2021, the FDA issued a CRL for the BLA that included requests for additional clinical and statistical data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Safety Results</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%), all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outside of United States ("OUS") Business Development Partnering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our decision to voluntarily pause further development of Vicineum, we commenced the process to wind down our OUS business development partnerships in the Middle East and North Africa region (&#8220;MENA&#8221;) and Turkey by providing notice of termination for our exclusive license agreements in these respective regions on July 20, 2022. In connection with the termination of the exclusive license agreement with our partner in MENA, we refunded the $3.0 million upfront payment previously paid to us.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Greater China</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we and our wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical, Co., Ltd. ("Qilu") (the &#8220;Qilu License Agreement&#8221;) pursuant to which we granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture, and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum for the treatment of BCG-unresponsive NMIBC and other types of cancer in China, Hong Kong, Macau and Taiwan (collectively, &#8220;Greater China&#8221;). We also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by us to develop, manufacture and commercialize Vicineum in Greater China. We retained (i) development and commercialization rights in the rest of the world excluding Greater China, MENA, and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding Greater China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2022, we terminated the Qilu License Agreement. In connection with the termination of the Qilu License Agreement, we agreed to make an aggregate payment to Qilu of $1.4 million, which consists of a $1.2 million termination fee payable upon the termination of the Qilu License Agreement, which was paid in the fourth quarter of 2022, and a $200,000 payment payable upon our receipt of certain clinical data and chemistry, manufacturing, and controls data from Qilu, which such payment was not made as of December 31, 2022. As a result of the termination of the Qilu License Agreement, all rights to Vicineum in Greater China have reverted to us. We currently retain all global rights to Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">MENA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, we and our wholly owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Hikma Pharmaceuticals LLC (&#8220;Hikma&#8221;) (the &#8220;Hikma License Agreement&#8221;), to develop and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in the MENA region (20 countries in the Middle East and North Africa). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration for the rights granted by us, Hikma agreed to pay to us an upfront payment, sales related milestones payments, and royalties on net sales in the MENA region for the term of the Hikma License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2022, we provided notice of termination of the Hikma License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with such termination and as required under the Hikma License Agreement, we refunded to Hikma the $3.0 million upfront payment previously paid to us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Turkey</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, we entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which we granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement&#8221;). On July 20, 2022, we provided notice of termination of the EIP License Agreement as a result of our strategic decision to voluntarily pause further development of Vicineum in the United States. The EIP License Agreement was terminated on October 20, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Intellectual Property </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently own or exclusively license approximately 13 families of patents and applications, which generally relate to our TFPT-based historical product candidates and our platform of targeting agents, cytotoxins (such as deBouganin) and linker technologies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclusively license two families under a license agreement with the University of Zurich ("Zurich") (the "Zurich License Agreement") which, among other things, include composition of matter claims directed to EpCAM antibody chimeras, EpCAM antibody chimera-cytotoxin conjugates, and their potential use in treating bladder and head and neck cancer. These families claim all or portions of Vicineum, as well as methods of treating bladder and head and neck cancer consist of issued patents in the United States, Europe, Canada, China, Israel, and Japan and also include pending applications in the United States. The expiry dates of the patents in this family are April 2024 and June 2025, subject to any applicable patent term adjustment or extension that may be available on a jurisdictional basis. See "Our Vicineum License Agreements" below for additional information.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Zurich portfolio, we own two issued United States patents related to Vicineum. The expiry date of these patents is February 2029, subject to any applicable patent term extension that may be available on a jurisdictional basis. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have patent families relating to treatment regimens using Vicineum that include issued patents in the United States, Australia and Japan and patent applications in Canada, Europe, and Hong Kong. These patents will expire in 2036. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a license agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants us non-exclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the "Micromet License Agreement"). These patents cover some key aspects of Vicineum. See "Our Vicineum License Agreements" below for additional information.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a license agreement with XOMA Ireland Limited ("XOMA") which grants us non-exclusive rights, with certain sublicense rights, to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the "XOMA License Agreement"). These patents and related know-how cover some key aspects of Vicineum. See "Our Vicineum License Agreements" below for additional information.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Vicineum License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview and Exclusivity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with the University of Zurich ("Zurich") which grants us exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to our targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. Upon receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, we became obligated to pay a $0.5&#160;million milestone payment to Zurich pursuant to the Zurich License Agreement. We are also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by us to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. For the year ended December 31, 2020, we recorded an expense of $0.3&#160;million for the achievement of the development milestone related to the submission of the BLA for Vicineum with the FDA. For the year ended December 31, 2021, we recorded an expense of $0.5&#160;million for the regulatory milestone related to receipt of the CRL from the FDA in August 2021. For the year ended December 31, 2022, no related expense was recorded.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Rights</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for the patent filing, prosecution and maintenance activities pertaining to the patent rights, at our sole expense, while Zurich is afforded reasonable opportunities to review and comment on such activities. If appropriate, we shall apply for an extension of the term of any licensed patent where available, for example, in at least the United States, Europe and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Japan. In the event of any substantial infringement of the patent rights, we may request Zurich to take action to enforce the licensed patents against third parties. If the infringing activity is not abated within 90 days and Zurich has elected not to take legal action, we may bring suit in our own name (and in Zurich&#8217;s name, if necessary). Such action will be at our own expense and Zurich will have the opportunity to join at its own expense. Recoveries from any action shall generally belong to the party bringing the suit, but (a) in the event that we bring the action and an acceptable settlement or monetary damages are awarded, then Zurich will be reimbursed for any amount that would have been due to Zurich if the products sold by the infringer actually had been sold by us, or (b) in the event a joint legal action is brought, then the parties shall share the expense and recoveries shall be shared in proportion to the share of expense paid by the respective party. Each party is required to cooperate with the other in litigation proceedings at the expense of the party bringing the action.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term and Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Zurich License Agreement expires as of the expiration date of the last patent to expire within the Zurich patent rights. We are currently projecting an expiration date for the United States licensed patents in June 2025, subject to any applicable patent term extension that may be available on a jurisdictional basis. Zurich has the right to terminate the Zurich License Agreement if we breach any obligation of the agreement and fail to cure such breach within the applicable cure periods. We have the right to terminate the Zurich License Agreement at any time and for any reason by giving 90 days written notice to Zurich.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Micromet License Agreement grants us nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. These patents (which are now expired) cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of December 31, 2021, even though the patents have expired, we may be obligated to pay up to &#8364;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.6&#160;million at exchange rates in effect on December&#160;31, 2022). We are also required to pay up to a 3.5% royalty on the net sales for products covered by the Micromet License Agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, we are required to pay to Micromet an annual license maintenance fee of &#8364;50,000, which can be credited towards any royalty payment we owe to Micromet. We recorded an expense of &#8364;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. We recorded an expense of &#8364;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, we recorded an expense of &#8364;50,000 ($51,770) related to the annual license maintenance fee.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Rights</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Micromet, at its sole expense, is responsible for the patent filing, prosecution and maintenance activities pertaining to the patent rights. In any patent enforcement action initiated by Micromet, we may be required, upon the request of Micromet and at Micromet&#8217;s expense, to provide reasonable assistance to Micromet with respect to such enforcement action.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term and Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Micromet License Agreement expires as of the expiration of any royalty obligations under covered by the Micromet License Agreement. Either party has the right to terminate the Micromet License Agreement if the other party fails to comply with any of its material obligations under the Micromet License Agreement and fails to cure such non-compliance within the applicable cure periods.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XOMA License Agreement grants us non-exclusive rights, with certain sublicense rights, to certain XOMA patent rights (which are now expired) and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, even though the patents have expired, we are required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. We are also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. We have the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Rights</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XOMA, at its sole expense, is responsible for the patent filing, prosecution and maintenance activities pertaining to the patent rights. In any patent enforcement action initiated by XOMA, we may be required, upon the request of XOMA and at XOMA&#8217;s expense, to provide reasonable assistance to XOMA with respect to such enforcement action.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term and Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the XOMA License Agreement expires as of the expiration of any royalty obligations under the XOMA License Agreement. Either party has the right to terminate the XOMA License Agreement if the other party fails to comply with any of its material obligations under the XOMA License Agreement and fails to cure such non-compliance within the applicable cure periods.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Manufacturing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, we entered into a Lease Termination Agreement (the &#8220;Lease Termination Agreement&#8221;) pursuant to which we terminated the operating lease agreement for our 31,100 square foot facility in Winnipeg, Manitoba which consisted of manufacturing, laboratory, warehouse, and office space and agreed to end the lease by September&#160;30, 2022. As part of the execution of the Lease Termination Agreement, we paid the landlord the all-inclusive sum of CAD $1.2 million (USD $0.9 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fujifilm and Baxter </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a Master Bioprocessing Services Agreement with FUJIFILM DIOSYNTH Biotechnologies U.S.A., Inc.("Fujifilm") (the &#8220;Fujifilm MSA&#8221;) for the manufacturing process and technology transfer of Vicineum drug substance production.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a Commercial Manufacturing and Supply Agreement with Baxter Oncology GmbH ("Baxter") (the &#8220;Baxter CMSA&#8221;) for the manufacturing process and technology transfer of Vicineum drug product production. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we completed manufacturing of the drug substance process performance qualification (&#8220;PPQ&#8221;) batches at Fujifilm and in September 2020, we successfully completed the drug product PPQ batches at Baxter. All of the completed drug substance PPQ batches and drug product PPQ batches met all quality acceptance criteria. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we received and analyzed all of the analytical comparability test results from the drug substance and drug product PPQ batches. For analytical comparability, we conducted testing across four categories: release testing, biophysical characterization, forced degradation studies, and stability studies. This approach was in alignment with requirements of the FDA, the EMA and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The test results for Vicineum produced by Fujifilm and Baxter were found to be highly comparable to our supply of Vicineum produced at our Winnipeg facility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, at the CMC Type A Meeting, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials and confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, and that any of these future trials can proceed while addressing CMC issues raised in the CRL.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we signed a Scope of Work with Fujifilm under the Fujifilm MSA for the manufacturing of commercial batches of Vicineum in 2022 and 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, in connection with our decision to voluntarily pause further development of Vicineum, we terminated the Fujifilm MSA and Baxter CMSA and requested that Fujifilm and Baxter cease all work under the respective agreements and refrain from incurring any additional costs or expenses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the termination, and in accordance with the terms of the Fujifilm MSA and Baxter CMSA, we paid Fujifilm and Baxter for certain non-manufacturing stage services and current Good Manufacturing Practice batches of drug substance of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qilu</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for, if approved, global commercial supply of Vicineum drug substance and drug product (the &#8220;Qilu Global Supply Agreement&#8221;). On December 23, 2022, we terminated the Qilu Global Supply Agreement in connection with the termination of the Qilu License Agreement. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate History and Acquisition of Viventia</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware in 2008. We were formerly known as &#8220;Denovo Therapeutics, Inc.&#8221; and &#8220;Newco LS14, Inc.&#8221; before changing our name to &#8220;Eleven Biotherapeutics, Inc.&#8221; in February 2010 and again to &#8220;Sesen Bio, Inc.&#8221; in May 2018. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada, the shareholders of Viventia named therein (collectively, the "Selling Shareholders") and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;), pursuant to which we agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the "Viventia Acquisition"). In connection with the closing of the Viventia Acquisition, we issued 4.0 million shares of our common stock to the Selling Shareholders according to their pro rata share of Viventia&#8217;s then-outstanding shares of common stock, which represented approximately 19.9% of our voting power as of immediately prior to the issuance of such shares of common stock. Clairmark is an affiliate of Leslie L. Dan, who served on our board of directors until his retirement in July 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Viventia Acquisition, we are obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the acquisition agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the "Purchased Product") in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) and quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Share Purchase Agreement, we, our affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had seventeen full-time employees and no part-time employees. We have no collective bargaining agreements with our employees, and none are represented by labor unions. We have not experienced any work stoppages. We believe our relationship with our employees is satisfactory.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information and Access to SEC Reports</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 245 First Street, Suite 1800, Cambridge, Massachusetts 02142, our telephone number is (617)-444-8550 and our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.sesenbio.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We make our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports, available free of charge in the &#8220;Investors&#8221; section of our website as soon as reasonably practicable after we file these reports with the Securities and Exchange Commission (the &#8220;SEC&#8221;). We routinely post these reports, recent news and announcements, financial results and other important information about our business on our website at www.sesenbio.com. Information contained on our website is not a part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the SEC maintains an Internet website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to substantial risks and uncertainties. The occurrence of any of the following risks and uncertainties, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations or prospects. In these circumstances, the market price of our common shares could decline, and you may lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Risks and uncertainties of general applicability and additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business, financial condition, results of operations or prospects.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Merger with CARISMA Therapeutics Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Exchange Ratio will not change or otherwise be adjusted based on the market price of our common stock as the exchange ratio depends on our net cash at the closing of the Merger and not the market price of our common stock, so the merger consideration at the closing of the Merger may have a greater or lesser value than at the time the Merger Agreement was signed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2022, we, Seahawk Merger Sub, Inc., a Delaware corporation and our wholly-owned subsidiary (&#8220;Merger Sub&#8221;), and CARISMA Therapeutics Inc. (&#8220;Carisma&#8221;), entered into the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (the &#8220;Merger Agreement&#8221;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma continuing as our wholly-owned subsidiary and the surviving corporation of the merger (the &#8220;Merger&#8221;). Subject to the terms and conditions of the Merger Agreement, at the closing of the Merger, (a) each then outstanding share of Carisma common stock and Carisma preferred stock (including shares of Carisma&#8217;s common stock issued in connection with the pre-closing financing described below) will be converted into the right to receive a number of the shares of our common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;). Concurrently with the execution and delivery of the Merger Agreement, Carisma entered into a subscription agreement with certain investors named therein, pursuant to which such investors have agreed, subject to the terms and conditions of such subscription agreement, to purchase prior to the consummation of the Merger shares of Carisma&#8217;s common stock for an aggregate purchase price of approximately $30.6 million (the &#8220;Carisma Pre-Closing Financing&#8221;). The Merger Agreement has set the calculation of the Exchange Ratio for the Carisma capital stock, and the Exchange Ratio is based on the fully-diluted capitalization of Carisma and us, in each case immediately prior to the closing of the Merger (after giving effect to the Carisma Pre-Closing Financing). The Merger Agreement does not include a price-based termination right. Therefore, if before the completion of the Merger the market price of our common stock declines from the market price on the date of the Merger Agreement, then Carisma&#8217;s stockholders could receive merger consideration with substantially lower value than the value of such merger consideration on the date of the Merger Agreement. Similarly, if before the completion of the Merger the market price of our common stock increases from the market price of our common stock on the date of the Merger Agreement, then Carisma&#8217;s stockholders could receive merger consideration with substantially greater value than the value of such merger consideration on the date of the Merger Agreement. Because the Exchange Ratio does not adjust as a direct result of changes in the market price of our common stock, changes in the market price of our common stock will change the value of the total merger consideration payable to Carisma&#8217;s stockholders pursuant to the Merger Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock price changes may result from a variety of factors, including changes in our or Carisma&#8217;s respective businesses, operations and prospects, reductions or changes in United States government spending or budgetary policies, market assessments of the likelihood that the Merger will be completed, interest rates, federal, state and local legislation, governmental regulation, legal developments in the industry segments in which we or Carisma operate, the timing of the Merger, and general market, industry and economic conditions, including pandemics and other public health emergencies. Recent events surrounding the global economy, geopolitics and the COVID-19 pandemic continue to evolve and have introduced unusually high levels of volatility into financial and stock markets, and may affect the value of our common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stockholders and Carisma&#8217;s stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger and the Carisma Pre-Closing Financing and the conversion of the Carisma convertible note. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the combined company is unable to realize the full strategic and financial benefits currently anticipated from the Merger, our stockholders and Carisma&#8217;s stockholders will have experienced substantial dilution of their ownership interests in their respective companies, including as a result of the Carisma Pre-Closing Financing and the conversion of Carisma&#8217;s $35.0 million outstanding convertible note, without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger and the Carisma Pre-Closing Financing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to complete the Merger may result in either us or Carisma paying a termination fee to the other party and could significantly harm the market price of our common stock and negatively affect the future business and operations of each company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Merger is not completed and the Merger Agreement is terminated under certain circumstances, we may be required to pay Carisma a termination fee of $7.6&#160;million and/or reimburse Carisma&#8217;s expenses up to a maximum of $1.75&#160;million, and Carisma may be required to pay us a termination fee of $5.49 million and/or reimburse our expenses up to a maximum of $1.75&#160;million. Even if a termination fee or reimbursement of expenses of the other party are not payable in connection with a termination of the Merger Agreement, each of us and Carisma will have incurred significant fees and expenses, which must be paid whether or not the Merger is completed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the Merger Agreement is terminated and our board of directors determines to seek another business combination, there can be no assurance that we will be able to find a partner and close an alternative transaction on terms that are as favorable or more favorable than the terms set forth in the Merger Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of our common stock to Carisma&#8217;s stockholders pursuant to the Merger Agreement and the resulting change in control from the Merger must be approved by our stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by Carisma's stockholders. Failure to obtain these approvals would prevent the closing of the Merger.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before the Merger can be completed, our stockholders must approve, among other things, the issuance of our common stock to Carisma&#8217;s stockholders pursuant to the Merger Agreement and the resulting change in control from the Merger, and Carisma&#8217;s stockholders must adopt the Merger Agreement and approve the Merger and the related transactions. Failure to obtain the required stockholder approvals may result in a material delay in, or the abandonment of, the Merger. Any delay in completing the Merger may materially adversely affect the timing and benefits that are expected to be achieved from the Merger. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our executive officers and directors have interests in the Merger that are different from our stockholders and that may influence them to support or approve the Merger without regard to the interests of our stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our executive officers and directors participate in arrangements that provide them with interests in the Merger that are different from the interests of our stockholders, including, among others, severance benefits, the acceleration of equity vesting, continued indemnification and the potential ability to sell an increased number of shares of common stock of the combined company in accordance with Rule 144 under the Securities Act of 1933, as amended. These interests, among others, may influence our executive officers and directors to support or approve the Merger.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stockholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the closing of the Merger as compared to their current ownership and voting interest in our company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the proposed Merger is completed, our current stockholders will own a smaller percentage of the combined company than their ownership in our company prior to the Merger. Immediately after the Merger, after taking into account shares of Carisma common stock purchased in connection with the Carisma Pre-Closing Financing and the conversion of Carisma&#8217;s $35.0&#160;million outstanding convertible note, our pre-Merger stockholders and Carisma&#8217;s pre-Merger stockholders are expected to own approximately 24.2% and 75.8%, respectively, of the outstanding shares of capital stock of the combined company, subject to certain assumptions, including our net cash as of the closing of the Merger being greater than or equal to $70.0&#160;million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">During the pendency of the Merger, we may not be able to enter into a business combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect our business prospects</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Merger Agreement impede our ability to make acquisitions during the pendency of the Merger, subject to specified exceptions. As a result, if the Merger is not completed, we may be at a disadvantage to our competitors during such period. In addition, while the Merger Agreement is in effect, we are generally prohibited from soliciting, initiating or knowingly encouraging, inducing or facilitating any inquiries, indications of interest, proposals or offers that constitute or may reasonably be expected to lead to certain transactions involving a third party, including a merger, sale of assets or other business combination, subject to specified exceptions. Any such transactions could be favorable to our stockholders, but we may be unable to pursue them. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain provisions of the Merger Agreement may discourage third parties from submitting alternative takeover proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Merger Agreement prohibit us from soliciting alternative takeover proposals or cooperating with persons making unsolicited takeover proposals, except in limited circumstances when our board of directors determines in good faith that an unsolicited alternative takeover proposal is or is reasonably likely to result in a superior takeover proposal and that failure to cooperate with the proponent of the proposal is reasonably likely to be inconsistent with our board&#8217;s fiduciary duties. Any such transactions could be favorable to our stockholders. In addition, if we terminate the Merger Agreement under certain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances, including terminating because of a decision of ours to enter into a definitive agreement with respect to a superior offer, we would be required to pay a termination fee of $7.6&#160;million to Carisma and/or reimburse Carisma&#8217;s expenses up to a maximum of $1.75&#160;million. This termination fee described above may discourage third parties from submitting alternative takeover proposals to our stockholders, and may cause our board of directors to be less inclined to recommend an alternative takeover proposal. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the lack of a public market for Carisma common stock makes it difficult to evaluate the value of Carisma common stock, the Carisma stockholders may receive shares of our common stock in the Merger that have a value that is less than, or greater than, the fair market value of Carisma common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding common stock of Carisma is privately held and is not traded in any public market. The lack of a public market makes it extremely difficult to determine the fair market value of Carisma. Because the percentage of our common stock to be issued to Carisma&#8217;s stockholders was determined based on negotiations between the parties, it is possible that the value of our common stock to be received by Carisma&#8217;s stockholders will be less than the fair market value of Carisma, or that the value of our common stock to be received by Carisma&#8217;s stockholders may be more than the aggregate fair market value for Carisma.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the conditions to the Merger are not satisfied or waived, the Merger will not occur.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the transactions contemplated by the Merger Agreement are approved by our stockholders and Carisma&#8217;s stockholders, certain other specified conditions set forth in the Merger Agreement must be satisfied, to the extent permitted by applicable law, or waived to complete the Merger, including approval from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) to maintain the listing of our common stock on the Nasdaq Capital Market following the Merger and the listing of the shares of our common stock being issued in the Merger and upon the conversion of the Carisma convertible note. We cannot assure you that all of the conditions will be satisfied or waived. If the conditions are not satisfied or waived, the Merger will not occur or will be delayed, and we may lose some or all of the intended benefits of the Merger. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lawsuits have been filed, and additional lawsuits may be filed in the future, against us and the members of our board of directors arising out of the proposed Merger, which may delay or prevent the proposed Merger.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against us and our board of directors in connection with the transactions contemplated by the Merger Agreement. For example, we have received several letters from purported stockholders demanding that we amend the Registration Statement on Form S-4 filed pursuant to the Merger Agreement (File No. 333-267891) (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) to provide additional disclosures that such stockholders allege were improperly omitted from the Registration Statement, including information regarding the financial projections for Carisma, the financial analyses performed by our financial advisor in support of its fairness opinion, and the background and process leading to the execution of the Merger Agreement. We believe that these demands are without merit and we intend to vigorously defend against them. Additionally, several complaints have been filed asserting claims against us and our board of directors under Section 14(a) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement. The outcome of such demands or any future demands that we may receive or any litigation is uncertain, and we may not be successful in defending against any such claims. Lawsuits that have been and may be filed against us and our board of directors, could delay or prevent the Merger, divert the attention of our management team and employees from our day-to-day business and otherwise adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the Merger is not completed, our board of directors may decide to pursue a dissolution of our company. In a dissolution, there can be no assurances as to the amount or timing of available cash, if any, to distribute to our stockholders after paying our debts and other obligations and setting aside funds for reserves.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have entered into the Merger Agreement with Carisma, the closing of the Merger may be delayed or may not occur at all and there can be no assurance that the Merger will deliver the anticipated benefits we expect or enhance stockholder value. If the Merger is not completed and the Merger Agreement is terminated under certain circumstances, we may be required to pay Carisma a termination fee of $7.6&#160;million and/or reimburse Carisma&#8217;s expenses up to a maximum of $1.75&#160;million. Even if a termination fee is not payable in connection with a termination of the Merger Agreement, we will have incurred significant fees and expenses, which must be paid whether or not the Merger is completed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, for any reason, the Merger does not close, our board of directors may elect to, among other things, attempt to complete another strategic transaction like the Merger, attempt to sell or otherwise dispose of the various assets of ours or resume our research and development activities and continue to operate our business, and/or pursue a dissolution of our company. Any of these alternatives would be costly and time-consuming and may require that we obtain additional funding. We expect that it would be difficult to secure financing in a timely manner, on favorable terms or at all. We can make no assurances that we would be able to obtain additional financing or find a partner and close an alternative transaction on terms that are as favorable or more favorable than the terms set forth in the Merger Agreement or that any such alternatives are possible or would be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">successful, if pursued. To the extent that we seek and are able to raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect their rights as a common stockholder. Debt financing or preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise funds through strategic transactions or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Even if we are able to pursue such alternatives, the failure to complete the Merger may result in negative publicity and/or a negative impression of us in the investment community, could significantly harm the market price of our common stock and may affect our relationship with employees and other partners in the business community.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Merger is not completed, our board of directors may decide that it is in the best interests of our stockholders to dissolve our company under a judicially-supervised process under Delaware law. For example, we may rely on the &#8220;safe harbor&#8221; procedures under Sections 280 and 281(a) of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) which would requires us to, among other things, obtain an order from the Delaware Court of Chancery establishing the amount and form of security for pending claims for which we are a party, contingent or unmatured contract claims for which the holder declined our offer of a security, and unknown claims that, based on facts known to us, are likely to arise or become known within five years filing of a Certificate of Dissolution (or such longer period of time, not to exceed ten years, as the Delaware Court of Chancery may determine). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In that event, the amount of cash available, if any, for distribution to our stockholders would depend heavily on the timing of such decision since the amount of cash available for distribution continues to decrease as we fund our operations and incur fees and expenses related to the Merger. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution of our company, we would be required under the DGCL to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations. In addition, we may be subject to litigation or other claims related to a dissolution of our company. If a dissolution were pursued, our board of directors, in consultation with our advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, our stockholders could lose all or a significant portion of their investment in the event of a dissolution of our company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stockholders may not receive any payment on the CVRs from the proceeds related to either the Roche Asset Purchase Agreement or any sale of our non-cash assets and therefore the CVR may expire valueless or result in lower returns than anticipated or none at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At or prior to the effective time of the Merger, we will enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with a rights agent (the &#8220;Rights Agent&#8221;) pursuant to which we intend to declare a dividend payable to our stockholders of record as of a date agreed to by us and Carisma prior to the effective time of the Merger with respect to the receipt of one contingent value right (each, a &#8220;CVR&#8221;), for each outstanding share of our common stock held by such stockholders on such date. Each CVR will represent the contractual right to receive (i) contingent cash payments upon the receipt by us of certain proceeds payable by Roche, if any, pursuant to the asset purchase agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) (the &#8220;Roche Asset Purchase Agreement&#8221;), upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement as well as (ii) proceeds from any sale of our legacy assets, including Vicineum, subject to certain customary deductions, including for expenses and taxes, in the event any sale occurs prior to March 31, 2027. The right of our stockholders to receive future payment on the CVRs from the proceeds related to the Roche Asset Purchase Agreement will be contingent upon the occurrence of a certain triggering event, entitling CVR holders to a pro rata portion of the $30.0 million milestone payment to be made by Roche to us upon Roche&#8217;s initiation of a Phase 3 clinical trial with legacy IL-6 antagonist antibody technology previously owned by us for a certain indication if initiated prior to December 31, 2026, pursuant to the Roche Asset Purchase Agreement, less certain permitted deductions. We may not receive any future payment pursuant to the Roche Asset Purchase Agreement after the closing of the Merger. If this milestone is not achieved for any reason within the time period specified in the CVR Agreement or the consideration received is not greater than the amounts permitted to be retained or deducted by us, no payments will be made under the CVRs from the proceeds related to the Roche Asset Purchase Agreement, resulting in a lower return for our stockholders with respect to the CVRs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of our stockholders to receive future payment on the CVRs from the proceeds from any sale of our non-cash assets (net of customary deductions) existing as of the date of the Merger Agreement is dependent on our finding a partner to which we can sell, transfer, license, assign or otherwise divest such non-cash assets. With the assistance of a financial advisor, we have initiated a formal process for the potential sale of Vicineum. Given ongoing discussion with potential partners, completing a sale may be challenging. Our board of directors may elect not to divest any of our non-cash assets, resulting in a lower return for our stockholders with respect to the CVRs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if we do not receive any future payment pursuant to the Roche Asset Purchase Agreement and we do not divest any of our non-cash assets, our stockholders will not receive any payments on the CVRs and the CVRs will expire valueless.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the CVRs will be unsecured obligations of the combined company and all payments under the CVRs, all other obligations under the CVR Agreement and the CVRs and any rights or claims relating thereto will be subordinated in right of payment to the prior payment in full of all current or future senior obligations of the combined company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United States federal income tax treatment of the CVRs is unclear and there can be no assurance that the Internal Revenue Service would not assert, or that a court would not sustain, a position that could result in adverse United States federal income tax consequences to holders of the CVRs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States federal income tax treatment of the CVRs is unclear. There is no legal authority directly addressing the United States federal income tax treatment of the receipt of, and payments on, the CVRs, and there can be no assurance that the Internal Revenue Service (the &#8220;IRS&#8221;), would not assert, or that a court would not sustain, a position that could result in adverse United States federal income tax consequences to holders of the CVRs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to treat the issuance of the CVRs as a distribution of property with respect to our stock. However, there is no authority directly addressing whether contingent value rights with characteristics similar to the CVRs should be treated as a distribution of property with respect to the corporation&#8217;s stock, a distribution of equity, a &#8220;debt instrument&#8221; or an &#8220;open transaction&#8221; for United States federal income tax purposes. Although we will estimate the value of the CVRs for purposes of reporting on Form 1099 to our stockholders, the value of the CVRs is uncertain and the IRS or a court could determine that the value of the CVRs at the time of issuance was higher. In such case, our stockholders could be treated as having additional income or gain upon receipt of the CVRs. Further, notwithstanding our position that the receipt of CVRs, the receipt of any cash distributed pursuant to a special cash dividend and the proposed reverse stock split are appropriately treated as separate transactions, it is possible that the IRS or a court could determine that our stockholders&#8217; receipt of the CVRs, the receipt of any cash distributed pursuant to a special cash dividend and the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for United States federal income tax purposes. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to our position, which could result in adverse United States federal income tax consequences to holders of the CVRs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid and, other than in connection with the Merger with Carisma, do not intend to pay any cash dividends in the foreseeable future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on any of our capital stock. Pursuant to the terms of the Merger Agreement, we will, in addition to the CVRs, declare and pay a special cash dividend to our stockholders of record prior to the Merger which would be contingent upon (i) stockholder approval of (a) the issuance of the shares of our common stock in connection with the Merger pursuant to the rules of Nasdaq, and (b) an amendment our amended and restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of our common stock at a ratio of 1-for-20 and (ii) the satisfaction or waiver of other customary closing conditions to the Merger. The amount of the special cash dividend will be $75.0&#160;million, subject to the terms and conditions in the Merger Agreement. Other than such special cash dividend in connection with the closing of the Merger, we do not currently anticipate declaring or paying cash dividends on our capital stock in the foreseeable future. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on our remaining employees to facilitate the consummation of the Merger.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 17 full-time employees. Our ability to successfully complete the Merger depends in large part on our ability to retain certain remaining personnel. Despite our efforts to retain these employees, one or more may terminate their employment with us on short notice. The loss of the services of certain employees could potentially harm our ability to consummate the Merger, to run our day-to-day business operations, as well as to fulfill our reporting obligations as a public company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on Vicineum and our other legacy assets throughout the world would be prohibitively expensive, and our or our licensors&#8217; intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws and practices of countries outside the United States do not protect intellectual property rights to the same extent as federal and state laws in the United States. Moreover, the intellectual property laws of the United States change over time. For example, several United States Supreme Court cases have redefined what is considered to be patentable subject matter. Consequently, we and our licensors may not be able to prevent third parties from practicing our and our licensors&#8217; inventions in all countries, including the United States, or from selling or importing products made using our and our licensors&#8217; inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may export infringing products to territories where we or our licensors have patent protection, but where enforcement is not as strong as in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in non-US jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our or our licensor&#8217;s patents or marketing of competing products in violation of our proprietary rights generally in those countries. Proceedings to enforce our patent rights in non-US jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our and our licensors&#8217; patents at risk of being invalidated or being interpreted narrowly and put our and our licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of certain countries outside of the United States may not protect our rights to the same extent as the laws of the United States, and such laws may also be subject to change. For example, methods of treatment and manufacturing processes may not be patentable in certain jurisdictions, and the requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic and/or biosimilar product manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic or biosimilar product manufacturers may develop, seek approval for, and generic versions or biosimilar versions, respectively, of our products. The United States Food and Drug Administration ("FDA") has published several guidance documents on biosimilar product development. If a biosimilar product is also found to be interchangeable with a reference product, it may be substituted for the reference product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation, which are still being worked out by the FDA. If any of our legacy assets are approved by the FDA, the approval of a biologic product biosimilar to or interchangeable with one of our products could have a material impact on our business. In particular, a biosimilar could be significantly less costly to bring to market and priced significantly lower than our products, if approved by the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including European Union (&#8220;E.U.&#8221;) countries, have compulsory licensing laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our and our licensors&#8217; efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot meet the requirements under our license agreements with Zurich, Micromet and XOMA, we could lose important rights to Vicineum, which could have material adverse effect on our ability to sell Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with the University of Zurich ("Zurich") which grants us exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to our targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). Pursuant to the Zurich License Agreement, we were granted an exclusive license, with the right to sublicense, under certain patents primarily relating, in part, to our targeting agents, EpCAM chimera and immunoconjugates (including aspects of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG) and methods of use, to make, use, sell and import products that would otherwise infringe such patents in the field of the treatment, stasis and palliation of disease in humans. If we fail to meet our obligations under the Zurich License Agreement, Zurich may have the right to terminate our license, and upon the effective date of such termination, our right to use the licensed Zurich patent rights would end. To the extent such licensed technology or patent rights relate to our legacy assets, we would expect to exercise all rights and remedies available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights under the patent rights licensed to us, but we may not be able to do so in a timely manner, at an acceptable cost to us or at all. Any uncured, material breach under the Zurich License Agreement could result in our loss of rights to practice the patent rights licensed to us under the Zurich License Agreement, and to the extent such patent rights and other technology relate to our legacy assets or other of our compounds, it could have a material adverse effect on our ability to sell Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a license agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants us non-exclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the "Micromet License Agreement"). If we fail to meet our obligations under the Micromet License Agreement, Micromet may have the right to terminate our license, and upon the effective date of such termination, our right to use the licensed Micromet patent rights would end. To the extent such licensed technology or patent rights relate to our legacy assets, we would expect to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise all rights and remedies available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights under the patent rights licensed to us, but we may not be able to do so in a timely manner, at an acceptable cost to us or at all. Any uncured, material breach under the Micromet License Agreement could result in our loss of rights to practice the patent rights licensed to us under the Micromet License Agreement, and to the extent such patent rights and other technology relate to our legacy assets or other of our compounds, it could have a material adverse effect on our ability to sell Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a license agreement with XOMA Ireland Limited ("XOMA") which grants us non-exclusive rights, with certain sublicense rights, to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the "XOMA License Agreement"). If we fail to meet our obligations under the XOMA License Agreement, XOMA may have the right to terminate our license, and upon the effective date of such termination, our right to use the licensed XOMA patent rights and related know-how would end. To the extent such licensed technology or patent rights relate to our legacy assets, we would expect to exercise all rights and remedies available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights under the patent rights licensed to us, but we may not be able to do so in a timely manner, at an acceptable cost to us or at all. Any uncured, material breach under the XOMA License Agreement could result in our loss of rights to practice the patent rights licensed to us under the XOMA License Agreement, and to the extent such patent rights and other technology relate to our legacy assets, it could have a material adverse effect on our ability to sell Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, trademarks, or other intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. In a trademark infringement proceeding, we could be enjoined from continued use of a trademark deemed to be infringing and forced to rebrand product packaging, product inserts, market and advertising materials, resulting in a loss of sales and established goodwill in that name or mark. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a trademark. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business and Operations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past few years, we have focused primarily on developing our lead product candidate, Vicineum, which we voluntarily paused development of in July 2022. Since our inception, we have received no revenues from sales of our products, have incurred significant operating losses and expect to continue to incur operating losses for the foreseeable future. We had a net loss of $19.9 million, $0.3 million and $22.4 million for the year ended December 31, 2022, 2021 and 2020, respectively. We incurred positive cash flows from operating activities of $24.9 million for the year ended December 31, 2022. We incurred negative cash flows from operating activities of $68.9 million and $30.8 million for the year ended December 31, 2021 and 2020, respectively. As of December&#160;31, 2022, we had cash, cash equivalents, and marketable securities of $166.9 million, net working capital (current assets less current liabilities) of $158.2 million and an accumulated deficit of $336.1 million. We have financed our operations to date primarily through private placements of our common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, our initial public offering, our follow-on public offerings, sales effected in at-the-market offerings, our out-licensing and former OUS business development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnership agreements and from the Roche Asset Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The majority of our revenue to date has been from milestone payments received under our out-licensing and former OUS business development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnership agreements and from the Roche Asset Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect to continue to incur significant expenses and operating losses for the foreseeable future. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restructuring plans and the associated headcount reductions may not result in anticipated savings, could result in total costs and expenses that are greater than expected.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the Complete Response Letter from the FDA regarding our biologics license application ("BLA") for Vicineum for the treatment of bacillus Calmette-Gu&#233;rin (&#8220;BCG&#8221;)-unresponsive non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;) (the &#8220;2021 Restructuring Plan&#8221;). The 2021 Restructuring Plan included a reduction in our workforce by 18 positions (approximately 35%) as well as additional cost-saving initiatives intended to preserve capital while we continue development of Vicineum. Execution of the 2021 Restructuring Plan was substantially completed by the end of 2021. Restructuring expenses for the year ended December&#160;31, 2021 were $5.5 million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following our decision to voluntarily pause further development of Vicineum in the United States (the &#8220;2022 Restructuring Plan&#8221;). The 2022 Restructuring Plan includes an incremental reduction in our workforce as well as additional cost-saving initiatives intended to preserve capital during the pendency of the proposed Merger with Carisma and while we seek a potential partner for the further development of Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Execution of the 2022 Restructuring Plan is expected to be substantially completed in connection with the closing of the proposed Merger with Carisma, which is expected to occur in the first quarter of 2023. Restructuring expenses for the year ended December&#160;31, 2022 were approximately $11.8 million, consisting primarily of severance and other employee-related costs of $7.0 million and contract termination costs of $4.8 million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition would be adversely affected. Furthermore, our restructuring plan may be disruptive to our operations. For example, we may incur unanticipated charges not currently contemplated as a result of the restructuring plans. If we are unable to realize the expected operational cost savings from the restructuring, our operating results and financial condition would be adversely affected.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to enter into a transaction with a suitable acquiror or licensee for Vicineum or any transaction entered into may not be on terms that are favorable to us.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the United States. As a result of such decision, the primary paths available to derive value from the Vicineum asset are to find a suitable acquiror or licensee for the asset. Supporting diligence activities conducted by potential acquirors or licensees and negotiating the financial and other terms of an agreement or license are typically long and complex processes, and the results of such processes cannot be predicted. There can be no assurance that we will enter into any transaction as a result of this effort or that any transaction entered into will be on terms that are favorable to us.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In connection with our strategic decision to voluntarily pause further development of Vicineum in the United States, we may become involved in disagreements or disputes with our licensees, licensors and other counterparties relating to the development and/or commercialization of Vicineum, which may be time consuming, costly and could divert our efforts and attention from consummating the proposed Merger with Carisma and harm our efforts to seek a partner to continue development of Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various agreements and licenses with licensees, licensors and other counterparties related to the development and/or commercialization of Vicineum. These agreements and licenses impose a variety of obligations on us and the counterparties to such agreements and licenses. On July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the United States. As a result of such decision and our subsequent decision to enter into the proposed Merger with Carisma, we have begun the process of winding-down our operations relating to Vicineum and are seeking a partner for the further development of Vicineum. With the assistance of a financial advisor, we have initiated a formal process for the potential sale of Vicineum to a partner. Given ongoing discussion with potential partners, completing a sale may be challenging. Disagreements and disputes between us and certain counterparties have arisen related to such wind-down efforts and additional disagreements or disputes may arise in the future between us and our counterparties regarding each parties&#8217; obligations under the respective agreement or license relating to Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such disagreement or dispute could become time consuming, costly and could divert our efforts and attention from consummating the Merger with Carisma and harm our efforts to seek a partner to continue development of Vicineum. Any disagreements or disputes with such parties that lead to litigation, arbitration or similar proceedings will result in us incurring significant legal expenses, as well as potential significant legal liability. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any disagreements or disputes over our obligations or intellectual property that we have licensed or acquired may prevent or impair our ability to maintain our current arrangements on acceptable terms. If we fail to meet our obligations under these agreements or licenses in a material respect, the respective counterparty may have the right to terminate the respective </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement or license and to re-obtain the related technology as well as aspects of any intellectual property controlled by us and developed during the period the agreement or license was in force that relates to the applicable technology. While we would expect to exercise our rights and remedies available to us in the event we fail to meet our obligations under such agreement or license in any material respect and otherwise seek to preserve our rights under the technology licensed to or acquired by us, we may not be able to do so in a timely manner, at an acceptable cost or at all. Any uncured, material breach under any agreement or license relating to Vicineum could result in our loss of rights and may lead to a complete termination of the respective agreement or license. Termination of one of these agreements or licenses for any reason could prevent us from completing a transaction to sell or license Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and certain of our officers have been, and may in the future be, named as defendants in lawsuits. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. Any other lawsuits to which we are subject may be costly to defend and are uncertain in their outcome.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bibb v. Sesen Bio, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, et. al., Case No. 1:21-cv-07025, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cizek v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-07309 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman v. Sesen Bio, Inc. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-08308 were filed against us and certain of our officers in the United States District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Sesen Bio, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleged the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. On September 28, 2022, the court issued an order granting preliminary approval of the proposed settlement of the Securities Litigation. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the court issued an order granting final approval of the settlement of the Securities Litigation. Accordingly, this matter is now resolved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myers v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-11538 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">D&#8217;Arcy v. Sesen Bio, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, et. al., Case No. 1:21-cv-11577 were filed against our board of directors and certain of our officers in the United States District Court for the District of Massachusetts, with us named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tang v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in Superior Court in Massachusetts against our board of directors and certain of our officers (the &#8220;State Derivative Litigation&#8221;). The three derivative complaints alleged breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleged unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints sought unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Sesen Bio, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On July 19, 2022, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims (collectively, the &#8220;Derivative Litigation&#8221;). On August 22, 2022, the parties entered into a Stipulation of Settlement to settle the Derivative Litigation, which was filed with the court on August 30, 2022. On September 2, 2022, the court issued an order granting preliminary approval of the Stipulation of Settlement related to the Derivative Litigation. On November 8, 2022, the court issued an order granting final approval of the Stipulation of Settlement related to the Derivative Litigation. Accordingly, this matter is now resolved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 28, 2022, a purported stockholder filed a complaint in the United States District Court for the Southern District of New York against us and our board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keller v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:22-cv-10085 (S.D.N.Y.) (the &#8220;Original Keller Complaint&#8221;). The Original Keller Complaint asserted claims against us and our board of directors under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and sought, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs. On December 20, 2022, the purported stockholder voluntarily dismissed the Original Keller Complaint and on December 21, 2022, filed a new complaint as a putative class action in the Court of Chancery for the State of Delaware, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keller v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 2022-1186 (Del. Ch. Dec. 21, 2022) (the &#8220;New Keller Complaint&#8221;). Along with the complaint, the purported stockholder filed motions for expedited proceedings and for a preliminary injunction to enjoin the special meeting of stockholders scheduled for 10:00 a.m. Eastern Time on March 2, 2023 (the "Special Meeting"). The New Keller Complaint and associated filings contain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially the same assertions as the Original Keller Complaint, and seek, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2023, a purported stockholder filed a complaint in the United States District Court for the District of Delaware against us and our board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumley v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:23-cv-00131 (D. Del.) (the &#8220;Plumley Complaint&#8221;). The Plumley Complaint asserts claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs. On February 7, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against us and our board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Franchi v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 1:23-cv-01041 (S.D.N.Y.) (the &#8220;Franchi Complaint&#8221;). The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. Additionally, on February 9, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against us and our board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Menzer v. Sesen Bio, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, et al., 23-cv-01119 (S.D.N.Y.) (the &#8220;Menzer Complaint&#8221;). The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint and the Franchi Complaint. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be the target of similar litigation in the future. The market price of our common stock has experienced and may continue to experience volatility, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities litigation. Any future litigation could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. We maintain liability insurance; however, if any costs or expenses associated with the pending lawsuits or any other litigation exceed our insurance coverage, we may be forced to bear some or all costs and expenses directly, which could adversely affect our business, financial condition, results of operations or stock price.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to regain compliance with the listing requirements of the Nasdaq Capital Market, our common stock may be delisted from the Nasdaq Capital Market which could have a material adverse effect on our business and could make it more difficult for you to sell your shares of our common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market, and we are therefore subject to Nasdaq's continued listing requirements, including requirements with respect to the market value of publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholders' equity, among others, and requirements relating to board and committee independence. If we fail to satisfy one or more of the requirements, we may be delisted from the Nasdaq Capital Market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2023, we were notified by the Listing Qualifications Department (the &#8220;Staff&#8221;) of Nasdaq that, based upon our non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price Rule&#8221;), our common stock will be delisted from Nasdaq unless we timely request a hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We requested a hearing before the Panel, which stayed any delisting action by the Staff and ensured our common stock remains listed and eligible for trading on Nasdaq pending a determination by the Panel. The hearing had been scheduled for March 16, 2023. On February 24, 2023, we received a determination from the Nasdaq Office of General Counsel that the Panel granted us an exception from our non-compliance with the Bid Price Rule to complete the Merger by March 10, 2023. Pursuant to Nasdaq Listing Rule 5110(a), we must demonstrate compliance with all initial listing requirements of Nasdaq upon the closing of the Merger. We are seeking approval for the Merger and the implementation of a reverse stock split of our common stock at the Special Meeting. In the event we fail to establish compliance with the initial listing standards by March 10, 2023, our common stock will be delisted from Nasdaq, unless granted an additional exception by the Panel.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 24, 2022, we received written notice from the Staff indicating that, based upon the closing bid price for our common stock for the previous 30 consecutive business days, we no longer satisfied the Bid Price Rule and, in accordance with the Nasdaq Listing Rules, were afforded an initial grace period of 180 calendar days, through July 25, 2022, and a second 180-calendar day period, through January 23, 2023, to regain compliance with the Bid Price Rule. We did not regain compliance with the Bid Price Rule by January 23, 2023, which resulted in the Staff&#8217;s January 25, 2023, determination.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delisting from the Nasdaq Capital Market would adversely affect our ability to consummate the Merger and may adversely affect our ability to raise additional financing through the public or private sale of equity securities, significantly affect the ability of investors to trade our common stock, or negatively affect the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest in business development opportunities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are delisted from Nasdaq and we are not able to list our common stock on another exchange, our common stock could be quoted on the OTC Bulletin Board or in the &#8220;pink sheets.&#8221; As a result, we could face significant adverse consequences including, among others:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited availability of market quotations for our common stock;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited amount of news and little or no analyst coverage for us;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we would no longer qualify for exemptions from state securities registration requirements, which may require us to comply with applicable state securities laws; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decreased ability to issue additional securities (including pursuant to short-form registration statements on Form S-3) or obtain additional financing in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our common stock becomes subject to the penny stock rules, it would become more difficult to trade our shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If we do not retain our listing on Nasdaq and if the price of our common stock is less than $5.00, our common stock may be deemed a penny stock. The penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i) the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Properties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located in Cambridge, MA, where we occupy office space under a lease that was executed in October 2016. The lease is currently extended through June 2023.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bibb v. Sesen Bio, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-07025, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cizek v. Sesen Bio, Inc., et. al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-07309 and M</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">arkman v. Sesen Bio, Inc. et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-08308 were filed against us and certain of our officers in the United States District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-5 promulgated thereunder based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Sesen Bio, Inc. Securities Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (collectively, the &#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. On November 24, 2021, defendants filed a motion to transfer venue to the United States District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleged the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022, and that motion was fully briefed on May 6, 2022. On June 3, 2022, before the court ruled on the motion to dismiss, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. On June 30, 2022 and July 6, 2022, we and the plaintiffs engaged in mediation sessions in an attempt to resolve the Securities Litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, we and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to us and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which was filed with the court on August 17, 2022. The Stipulation and Agreement of Settlement related to the Securities Litigation provides for a settlement payment of $21.0 million to the class and the dismissal of all claims against us and the other defendants. On September 1, 2022, the United States District Court for the Southern District of New York issued an order denying the motions to appoint a different lead plaintiff. On September 28, 2022, the court issued an order granting preliminary approval of the proposed settlement of the Securities Litigation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement payment of $21.0&#160;million, including the insurance carriers coverage, was funded into an escrow account in the fourth quarter of 2022. Accordingly, $21.0&#160;million remained in restricted cash on our balance sheet as of December 31, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the court issued an order granting final approval of the settlement of the Securities Litigation. Accordingly, this matter is now resolved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myers v. Sesen Bio</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-11538 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">D&#8217;Arcy v. Sesen Bio, Inc., et. al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-11577 were filed against our board of directors and certain of our officers in the United States District Court for the District of Massachusetts, with us named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tang v. Sesen Bio, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in Superior Court in Massachusetts against our board of directors and certain of our officers (the &#8220;State Derivative Litigation&#8221;). The three derivative complaints alleged breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleged unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints sought unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re Sesen Bio, Inc. Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On July 6, 2022, we and the plaintiffs to the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal Derivative Litigation and the State Derivative Litigation engaged in mediation in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2022, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims (collectively, the &#8220;Derivative Litigation&#8221;). Pursuant to that agreement, the individual defendants will cause us to adopt certain enhancements to our corporate governance policies and procedures. In exchange, plaintiffs will dismiss the Derivative Litigation and, on behalf of us, provide broad customary releases to the individual defendants. On August 22, 2022, the parties entered into a Stipulation of Settlement to settle the Derivative Litigation, which was filed with the court on August 30, 2022. The Stipulation of Settlement related to the Derivative Litigation confirms that we previously adopted certain corporate governance enhancements in response to, among other things, the filing of the Derivative Litigation, and that, subject to final court approval, we will adopt additional corporate governance enhancements. The Stipulation of Settlement also provides for a $630,000 payment for plaintiffs&#8217; attorneys&#8217; fees due to the benefits the corporate governance enhancements are intended to provide to us. The payment of plaintiffs&#8217; attorneys' fees is being funded by us. On September 2, 2022, the court issued an order granting preliminary approval of the Stipulation of Settlement related to the Derivative Litigation.  On November 8, 2022, the court issued an order granting final approval of the Stipulation of Settlement related to the Derivative Litigation. Accordingly, this matter is now resolved. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 28, 2022, a purported stockholder filed a complaint in the United States District Court for the Southern District of New York against us and our board of directors, captioned </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keller v. Sesen Bio, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:22-cv-10085 (S.D.N.Y.) (the &#8220;Original Keller Complaint&#8221;). The Original Keller Complaint asserted claims against us and our board of directors under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement on Form S-4 (File No. 333-267891) (the "Registration Statement") in connection with the proposed merger (the "Merger") with CARISMA Therapeutics Inc. ("Carisma") and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and sought, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs. On December 20, 2022, the purported stockholder voluntarily dismissed the Original Keller Complaint and on December 21, 2022, filed a new complaint as a putative class action in the Court of Chancery for the State of Delaware, captioned </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keller v. Sesen Bio, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 2022-1186 (Del. Ch. Dec. 21, 2022) (the &#8220;New Keller Complaint&#8221;). Along with the complaint, the purported stockholder filed motions for expedited proceedings and for a preliminary injunction to enjoin the Special Meeting. The New Keller Complaint and associated filings contain substantially the same assertions as the Original Keller Complaint, and seek, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2023, a purported stockholder filed a complaint in the United States District Court for the District of Delaware against us and our board of directors, captioned </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumley v. Sesen Bio, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:23-cv-00131 (D. Del.) (the &#8220;Plumley Complaint&#8221;). The Plumley Complaint asserts claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement in connection with the Merger and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against us and our board of directors, captioned </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Franchi v. Sesen Bio, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 1:23-cv-01041 (S.D.N.Y.) (the &#8220;Franchi Complaint&#8221;). The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. Additionally, on February 9, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against us and our board of directors, captioned </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Menzer v. Sesen Bio, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 23-cv-01119 (S.D.N.Y.) (the &#8220;Menzer Complaint&#8221;). The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint and the Franchi Complaint.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2022, November 4, 2022, February 8, 2023, February 13, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(as updated on February 15, 2023)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and February 17, 2023, we received letters from purported stockholders (collectively, the &#8220;Demand Letters&#8221;) demanding that we amend the Registration Statement to provide additional disclosures that such stockholders allege were improperly omitted from the Registration Statement, including information regarding the financial projections for Carisma, the financial analyses performed by our financial advisor in support of its fairness opinion, and the background and process leading to the execution of the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023. In addition, we received a books and records demand, dated November 18, 2022 (the &#8220;Section 220 Demand&#8221;), on behalf of a purported stockholder of ours seeking access to certain relevant books and records of ours pursuant to Section 220 of the Delaware General Corporation Law in connection with the Merger and the securities and derivative litigations arising out of the CRL that we received from the FDA. The Section 220 Demand states that the purpose of the demand is to, among other things, investigate purported questions of director independence and disinterestedness and the possibility of wrongdoing, mismanagement, and/or material non-disclosure related to our board&#8217;s approval of the Merger and the other transactions contemplated thereby and to determine whether suit should be brought in connection therewith.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the claims asserted in the Demand Letters, the Section 220 Demand, the New Keller Complaint, the Plumley Complaint, the Franchi Complaint and the Menzer Complaint are without merit and we intend to vigorously defend against them. At this time, no assessment can be made as to the likely outcome or whether the outcome will be material to us.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_28"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Price</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades under the symbol "SESN" on the Nasdaq Capital Market. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;21, 2023, there were 17 holders of record of our common stock. This number does not include beneficial owners whose shares were held in street name.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our common stock and we do not anticipate paying cash dividends on our common stock for the foreseeable future, other than the special cash dividend that we will pay to our stockholders in connection with the consummation of the merger, subject to our having net cash as of the closing of the merger greater than or equal to $70.0&#160;million. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the merger will be at the discretion of the combined company&#8217;s then-current board of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of directors deems relevant. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Securities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;[Reserved.]</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes thereto and other financial information included elsewhere in this Annual Report on Form 10-K. In addition to historical information, some of the information contained in the following discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. You should review "Item 1A. Risk Factors" of this Annual Report on Form 10-K for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical company that previously focused on advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidate, Vicineum, also known as VB4-845, is a locally administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of non-muscle invasive bladder cancer ("NMIBC"). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the United States Food and Drug Administration ("FDA"), which had implications on the size, timeline and costs of an additional Phase 3 clinical trial, which the FDA previously confirmed would be required for a potential resubmission of a biologics license application ("BLA") for Vicineum for the treatment of NMIBC. As a result of this decision, we turned our primary focus to consummating a strategic transaction with the goal of maximizing stockholder value.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on September 20, 2022, we, Seahawk Merger Sub, Inc., a Delaware corporation and our wholly-owned subsidiary (&#8220;Merger Sub&#8221;), and CARISMA Therapeutics Inc. (&#8220;Carisma&#8221;), entered into the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (the &#8220;Merger Agreement&#8221;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma continuing as our wholly-owned subsidiary and the surviving corporation of the merger (the &#8220;Merger&#8221;). Our board of directors unanimously approved the Merger Agreement and resolved to recommend that our stockholders approve the proposals described in the Merger Agreement. If the Merger is completed, the business of Carisma will continue as the business of the combined company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, we are seeking a partner that can execute further development to realize the full potential of Vicineum. As a result of such decision and our subsequent decision to enter into the proposed Merger with Carisma, we no longer plan to pursue regulatory approval of Vicineum for NMIBC in the European Union (the &#8220;E.U.&#8221;) and have started to wind down certain of our manufacturing operations and business development partnerships. Additionally, we are seeking a partner for the further development of Vicineum and have initiated a formal process and engaged a financial advisor for the potential sale of Vicineum. If the proposed Merger is consummated, the combined company does not expect to pursue further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anticipated Merger with CARISMA Therapeutics Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger is expected to be completed during the first quarter of 2023. In connection with the Merger, we are seeking the approval of our stockholders to, among other things, (a) issue the shares of our common stock issuable in connection with the Merger pursuant to the rules of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), and (b) amend our amended and restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of our common stock at a ratio of 1-for-20 (clauses (a) and (b), collectively, the &#8220;Sesen Bio Voting Proposals&#8221;). The special meeting of stockholders in which our stockholders will be asked to vote on the Sesen Bio Voting Proposals (the &#8220;Special Meeting&#8221;) will be held on March 2, 2023 at 10:00 a.m. Eastern Time. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consummation of the Merger is subject to certain closing conditions, including, among other things, (a) approval by our stockholders of the Sesen Bio Voting Proposals as described in the Merger Agreement, (b) approval by Carisma&#8217;s stockholders of, among other things, the adoption of the Merger Agreement, (c) Nasdaq&#8217;s approval of the listing of the shares of our common stock to be issued in connection with the Merger, (d) the effectiveness of a registration statement on Form S-4 to register the shares of our common stock to be issued in connection with the Merger, and (e) our having net cash as of closing of the Merger greater than or equal to $70.0&#160;million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger Agreement contains certain termination rights of each of us and Carisma. Upon termination of the Merger Agreement under specified circumstances, we may be required to pay Carisma a termination fee of $7.6&#160;million and/or reimburse Carisma&#8217;s expenses up to a maximum of $1.75&#160;million, and Carisma may be required to pay us a termination fee of $5.49&#160;million and/or reimburse our expenses up to a maximum of $1.75 million. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Merger Agreement, at the closing of the Merger, (a) each then outstanding share of Carisma common stock and Carisma preferred stock (including shares of Carisma&#8217;s common stock issued in connection with the pre-closing financing described below) will be converted into the right to receive a number of the shares of our common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), and (b) each then outstanding Carisma stock option to purchase Carisma&#8217;s common stock will be assumed by us, subject to adjustment as set forth in the Merger Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution and delivery of the Merger Agreement, Carisma entered into a subscription agreement with certain investors named therein, pursuant to which such investors have agreed, subject to the terms and conditions of such subscription agreement, to purchase prior to the consummation of the Merger shares of Carisma&#8217;s common stock for an aggregate purchase price of approximately $30.6&#160;million (the &#8220;Carisma Pre-Closing Financing&#8221;). The consummation of the Carisma Pre-Closing Financing is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement. Shares of Carisma&#8217;s common stock issued pursuant to the Carisma Pre-Closing Financing will be converted into shares of our common stock in the Merger in accordance with the Exchange Ratio.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At or prior to the effective time of the Merger, we will enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with a rights agent (the &#8220;Rights Agent&#8221;) pursuant to which we intend to declare a dividend payable to our stockholders of record as of a date agreed to by us and Carisma prior to the effective time of the Merger with respect to the receipt of one contingent value right (each, a &#8220;CVR&#8221;), for each outstanding share of our common stock held by such stockholders on such date. Each CVR will represent the contractual right to receive (i) contingent cash payments upon the receipt by us of certain proceeds payable by Roche, if any, pursuant to the asset purchase agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) (the &#8220;Roche Asset Purchase Agreement&#8221;), upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement as well as (ii) proceeds from any sale of our legacy assets, including Vicineum, subject to certain customary deductions, including for expenses and taxes, in the event any sale occurs prior to March 31, 2027. The contingent payments under the CVR Agreement, if they become due, will be payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance that any cash payment will be made or that any holders of CVRs will receive any amounts with respect thereto.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in connection with the Merger, we intend to declare a one-time $75.0 million cash dividend payable to our stockholders of record as of a date prior to the effective time of the Merger, subject to the terms and condition set forth in the Merger Agreement.   </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2023, a group of our significant stockholders (the &#8220;Investor Group&#8221;) entered into a voting and support agreement with us and Carisma (the &#8220;Support Agreement&#8221;) pursuant to which the Investor Group agreed to vote, at the Special Meeting, any and all of their shares of our common stock in favor of the Merger and related matters, subject to the terms and conditions set forth in the Support Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that we do not complete the Merger with Carisma, we may decide to pursue a dissolution under Delaware law. In a dissolution, there can be no assurances as to the amount or timing of available cash, if any, to distribute to our stockholders after paying our debts and other obligations and setting aside funds for reserves.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Recent Events</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Restructuring Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following the decision to voluntarily pause further development of Vicineum in the United States (the &#8220;2022 Restructuring Plan&#8221;). Execution of the 2022 Restructuring Plan is expected to be substantially completed in connection with the closing of the Merger, which is expected to occur in the first quarter of 2023. The 2022 Restructuring Plan includes an incremental reduction in our workforce as well as additional cost-saving initiatives intended to preserve capital during the pendency of the Merger and while we seek a potential partner for the further development of Vicineum. We also incurred one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Retention Program</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2022, our board of directors and the compensation committee of the board of directors approved a retention program for certain employees pursuant to which we will provide a cash incentive designed to retain such employees (the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;2022 Retention Program&#8221;). Pursuant to the 2022 Retention Program, certain of our employees, including certain executive officers other than our Chief Executive Officer, were to have received a cash bonus award, vesting in full upon the earlier of (a) the completion of a strategic transaction and (b) the termination of such employee without cause, subject to the employee&#8217;s continued employment through that time. On February 7, 2023, the compensation committee of the board of directors approved a modification to the 2022 Retention Program, such that the vesting of the retention bonus awards for employees, other than executive officers, will occur upon the earlier of (a) 5:00 pm Eastern Time on the second business day following the date of the Special Meeting regardless of the results of the Special Meeting and (b) the termination of the Merger Agreement in accordance with its terms. The terms of the 2022 Retention Program for those executive officers participating in the 2022 Retention Program were not modified.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nasdaq Delisting Notice </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2023, we were notified by the Listing Qualifications Department (the &#8220;Staff&#8221;) of Nasdaq that, based upon our non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price Rule&#8221;), our common stock will be delisted from Nasdaq unless we timely request a hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We requested a hearing before the Panel, which stayed any delisting action by the Staff and ensured our common stock remains listed and eligible for trading on Nasdaq pending a determination by the Panel. The hearing had been scheduled for March 16, 2023. On February 24, 2023, we received a determination from the Nasdaq Office of General Counsel that the Panel granted us an exception from our non-compliance with the Bid Price Rule to complete the Merger by March 10, 2023. Pursuant to Nasdaq Listing Rule 5110(a), we must demonstrate compliance with all initial listing requirements of Nasdaq upon the closing of the Merger. We are seeking approval for the Merger and the implementation of a reverse stock split of our common stock at the Special Meeting. In the event we fail to establish compliance with the initial listing standards by March 10, 2023, our common stock will be delisted from Nasdaq, unless granted an additional exception by the Panel.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 24, 2022, we received written notice from the Staff indicating that, based upon the closing bid price for our common stock for the previous 30 consecutive business days, we no longer satisfied the Bid Price Rule and, in accordance with the Nasdaq Listing Rules, were afforded an initial grace period of 180 calendar days, through July 25, 2022, and a second 180-calendar day period, through January 23, 2023, to regain compliance with the Bid Price Rule. We did not regain compliance with the Bid Price Rule by January 23, 2023, which resulted in the Staff&#8217;s January 25, 2023, determination.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of EBI-031 Legacy Technology to Roche</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into a license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which we granted Roche an exclusive, worldwide license, including the right to sublicense, to our patent rights and know-how related to our monoclonal antibody EBI-031 and all other IL-6 anti-IL antagonist monoclonal antibody technology owned by us (collectively, the &#8220;Roche Licensed Intellectual Property&#8221;). Under the Roche License Agreement, Roche was required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody and pursue ongoing patent prosecution, at its cost. At the time of entering into the Roche License Agreement, EBI-031, which was derived using our previous AMP-Rx platform, was in pre-clinical development as an intravitreal injection for diabetic macular edema and uveitis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we entered into the Roche Asset Purchase Agreement pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by us for up to $70.0&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone, or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40.0&#160;million payment to us upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30.0&#160;million payment to us upon Roche&#8217;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with the Merger, each CVR will represent the contractual right to receive contingent cash payments upon the receipt by us of certain proceeds payable by Roche, if any, pursuant to the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement as well as proceeds from any sale of our legacy assets, including Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Historical TFPT Platform </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our historical product candidates are based on our proprietary TFPT platform and are focused on addressing areas of unmet medical need in cancer. Our novel TFPTs have been designed to overcome the efficacy and safety challenges of existing antibody drug conjugates and were being developed for both local and systemic administration. Our TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through our proprietary recombinant one-step, microbial manufacturing process. Our TFPT platform uses antibody </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fragments, which include Fabs, single chain variable domains ("scFvs"), and non-covalent scFv dimers, derived from the domains of antibodies that confer antigen recognition. We selected antibody fragments for our historical product candidates depending upon the target therapeutic indication. We targeted tumor cell surface antigens showing limited expression on normal cells and once bound, is rapidly internalized into the targeted cancer cell. For local administrations, we utilized an immunogenic cytotoxic protein payload designed to both target cancer cells and promote a heightened local immune response against the tumor. Our most advanced locally administered TFPT product candidate was Vicineum, in development for the treatment of non-muscle invasive carcinoma in situ (&#8220;CIS&#8221;) of the bladder in patients previously treated with adequate or less than adequate bacillus Calmette-Gu&#233;rin (&#8220;BCG&#8221;). For systemic administrations, we used deBouganin, a plant-derived, protein payload of reduced immunogenic potential that we believe can be repeatedly administered via infusion without the generation of an efficacy-limiting immune response against the payload.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vicineum for the treatment of NMIBC</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the follow-up stage of our single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the &#8220;VISTA Trial&#8221;) in May 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. In December 2020, we submitted our completed BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target Prescription Drug User Fee Act date for a decision on the BLA of August 18, 2021. On August 13, 2021, we received a Complete Response Letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing, and controls ("CMC") issues pertaining to a pre-approval inspection and product quality. On August 20, 2021, we withdrew our marketing authorization application ("MAA") to the European Medicines Agency (the &#8220;EMA&#8221;) for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the E.U. until there was more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name conditionally approved by the EMA for oportuzumab monatox in the E.U. In October 2021, the EMA issued its Withdrawal Assessment Report relating to its MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The EMA Withdrawal Assessment Report reflected the initial assessment and corresponding questions from the EMA and identified major objections in the areas of quality, good clinical practice, efficacy, and safety. As a result of our decision on July 15, 2022 to pause further development of Vicineum in the United States, we no longer plan to pursue regulatory approval of Vysyneum for NMIBC in the E.U.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 and December 2021, we participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed would be required for a potential resubmission of a BLA. In March 2022, we participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. On July 11, 2022, we participated in a Type B meeting with the FDA to discuss outstanding items related to our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, on July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the United States. If the Merger is consummated, the combined company does not expect to pursue further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Clinical Trial &#8211; VISTA Trial</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2015, in the United States and Canada, through our subsidiary Viventia Bio, Inc., we commenced the VISTA Trial in patients with BCG-unresponsive NMIBC who had received adequate BCG and whose disease was-then BCG-unresponsive, and for whom the then-current standard of care was radical cystectomy. In November 2016, the FDA issued draft guidance regarding appropriate clinical trial design for new drugs and biologics for BCG-unresponsive NMIBC, including the use of single-arm trials. The FDA finalized this guidance in February 2018 and retained many of the recommendations from the 2016 draft guidance regarding clinical trial design, including the use of single-arm trials. We believe that our VISTA Trial design was consistent with these aspects of the FDA&#8217;s guidance. In May 2022, we completed the follow up phase of the VISTA Trial.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary and secondary endpoints for the VISTA Trial were as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:26.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Dose</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">30 mg of Vicineum (in 50 mL of saline)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total enrollment</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">133 patients, including 93 CIS patients whose disease is BCG-unresponsive</span></div></td></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Primary endpoints</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Complete response rate (&#8220;CRR&#8221;) at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive</span></div></td></tr><tr style="height:36pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kaplan-Meier estimate of duration of response (&#8220;DoR&#8221;) for BCG-unresponsive CIS patients who experience a Complete Response (&#8220;CR&#8221;) at 3 months (post-induction)</span></div></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with CIS were considered to have a CR if, at the time of any disease status evaluation (per protocol every 13 weeks or any unscheduled evaluation), there was no evidence of high-grade disease (CIS, high-grade Ta or any grade T1 disease) or disease progression (e.g., to muscle invasive disease). Low-grade disease was not considered a treatment failure in these patients, and they could remain on study treatment following TURBT.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:26.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.921%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="7" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Secondary endpoints</span></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Event-free survival in all patients</span></div></td></tr><tr style="height:30pt"><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CRR at 6, 9, 12, 15, 18, 21 and 24 months in patients with CIS whose disease is BCG-unresponsive</span></div></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Time to cystectomy in all patients</span></div></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Time to disease recurrence in papillary patients</span></div></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Progression free survival (PFS) in all patients</span></div></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Overall Survival (OS) in all patients</span></div></td></tr><tr style="height:15pt"><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Safety and tolerability of Vicineum therapy in all patients</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exploratory endpoint</span></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To evaluate biomarkers that may be associated with response or disease progression or treatment failure, which may include, for example, EpCAM status, tumor subtype morphology, furin levels in tumor cell endosomes, presence of a glycosaminoglycan coat and presence of receptors that could impede a host anti-tumor immune response, such as PD-L1.</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VISTA Trial completed enrollment in April 2018 with a total of 133 patients across three cohorts based on histology and time to disease recurrence after adequate BCG treatment (under 2018 FDA guidance on treatment of NMIBC, adequate BCG is defined as at least one of the following (i) at least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy or (ii) at least five of six doses of an initial induction course plus at least two of six doses of a second induction course):</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 (n=86): Patients with CIS with or without papillary disease that were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined to be r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efractory or recurred within six months of their last course of adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 2 (n=7): Patients with CIS with or without papillary disease that recurred after six months, but less than 11 months, after their last course of adequate BCG; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 3 (n=40): Patients with high-risk (Ta or T1) papillary disease without CIS that recurred within six months of their last course of adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, preliminary primary and secondary endpoint data for each of the trial cohorts were as follows: </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 1 (n=86) Evaluable Population (n=82) Complete Response Rate, for CIS:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39% (28%-50%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26% (17%-36%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20% (12%-30%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-27%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 2 (n=7) Evaluable Population (n=7) Complete Response Rate, for CIS:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">43% (10%-82%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14% (0%-58%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pooled Cohorts 1 and 2 (n=93) Evaluable Population (n=89) Complete Response Rate, for CIS:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 3 Pooled Complete Response Rate vs. Phase 2 Pooled Complete Response Rate:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.245%"><tr><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 3 Pooled CRR (95% Confidence Interval)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 2 Pooled CRR (95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (26%-56%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27% (15%-42%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18% (8%-32%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16% (7%-30%)</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 3 (n=40) Evaluable Population (n=38) Recurrence-Free Rate&#8224;:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recurrence-Free Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">71% (54%-85%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58% (41%-74%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45% (29%-62%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42% (26%-59%)</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8224;Recurrence-free rate is defined as the percentage of patients that are recurrence-free at the given assessment time point.</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duration of Response:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median DoR for patients in Cohort 1 and Cohort 2 combined (n=93) was 287 days (95% CI, 154-NE), using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis of pooled data for all patients with CIS (Cohorts 1 and 2, n=93) showed that among patients who achieved a complete response at 3 months, 52% remained disease-free for a total of 12 months or longer after starting treatment, using the Kaplan-Meier method. DoR is defined as the time from first occurrence of complete response to documentation of treatment failure or death.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted additional analyses for secondary endpoints. These additional data include the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Cystectomy:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all 133 patients treated with Vicineum in the VISTA Trial, greater than 75% of all patients are estimated to remain cystectomy-free at 3 years, using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis showed that approximately 88% of responders are estimated to remain cystectomy-free at 3 years. Time to cystectomy is defined as the time from the date of first dose of study treatment to surgical bladder removal. The first 2018 FDA guidance on treatment of BCG-unresponsive NMIBC patients states that the goal of therapy in such patients is to avoid cystectomy. Therefore, time to cystectomy is a key secondary endpoint in the VISTA Trial. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Disease Recurrence:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> High-grade papillary (Ta or T1) NMIBC is associated with high rates of progression and recurrence. The median time to disease recurrence for patients in Cohort 3 (n=40) was 402 days (95% CI, 170-NE), using the Kaplan-Meier method. Time to disease recurrence is defined as the time from the date of the first dose of study treatment to the first occurrence of treatment failure or death on or prior to treatment discontinuation. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Progression-Free Survival ("PFS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain progression-free for 2 years or greater, using the Kaplan-Meier method. PFS is defined as the time from the date of first dose of study treatment to the first occurrence of disease progression (e.g., T2 or more advanced disease) or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Event-Free Survival:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain event-free at 12 months, using the Kaplan-Meier method. Event-free survival is defined as the time from the date of first dose of study treatment to the first occurrence of disease recurrence, progression or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Overall Survival ("OS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to have an OS of 2 years or greater, using the Kaplan-Meier method. OS is defined as the time from the date of first dose of study treatment to death from any cause.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data is as of the May 29, 2019 data cut from the Phase III VISTA Trial. The clinical data shown are based on the data submitted in the BLA on December 18, 2020. Final numbers</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are pending. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2021, the FD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A issued a CRL for the BLA that included requests for additional clinical and statistical data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Safety Results</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%), all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue consists of revenue recognized pursuant to our former </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements, including the exclusive license agreement entered into with Qilu Pharmaceutical, Co., Ltd. ("Qilu") (the &#8220;Qilu License Agreement&#8221;) and an asset purchase agreement, which is assessed under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 606"). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for the development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which include: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, travel and share-based compensation expense;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations ("CROs") and investigative sites that conduct our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with developing manufacturing capabilities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with transferring manufacturing capabilities to contract manufacturing organizations ("CMOs") for commercial-scale production;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with regulatory activities; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with license milestone fees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate direct research and development expenses, consisting principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical trials, costs related to manufacturing or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchasing clinical trial materials and technology transfer and license milestone fees, to specific product programs. We do not allocate employee and contractor-related costs, costs associated with our platform and facility expenses, including depreciation or other indirect costs, to specific product programs because these costs may be deployed across multiple product programs under research and development and, as such, are separately classified. The table below provides research and development expenses incurred for Vicineum for the treatment of BCG-unresponsive NMIBC and other expenses by category. On July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the United States.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not allocate research and development expenses to any other specific product program during the periods presented (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Programs:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum for the treatment of NMIBC</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct program expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel and other expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee and contractor-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform-related lab expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total personnel and other expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,647&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,202&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Research and Development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel, including share-based compensation and benefits, in executive, operational, finance, business development and human resource functions. Other general and administrative expenses include facility-related costs, professional fees for legal, insurance, investment banking fees, patent, consulting and accounting services, pre-commercial United States market research and pre-launch market readiness for the potential commercial launch of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we approved the 2022 Restructuring Plan to reduce operating expenses and better align our workforce with the needs of our business following the decision to voluntarily pause further development of Vicineum in the United States. Execution of the 2022 Restructuring Plan is expected to be substantially completed in connection with the closing of the Merger, which is expected to occur during the first quarter of 2023. The 2022 Restructuring Plan includes an incremental reduction in our workforce as well as additional cost-saving initiatives intended to preserve capital during the pendency of the Merger and while we seek a potential partner for the further development of Vicineum. We also incurred one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan. Restructuring costs related to the Restructuring Plan were recorded in operating expenses in our Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;2021 Restructuring Plan&#8221;). The 2021 Restructuring Plan included a reduction in our workforce by 18 positions (or approximately 35% of our workforce) as well as additional cost-saving initiatives intended to preserve capital while we continue development of Vicineum. Restructuring costs related to the 2021 Restructuring Plan were recorded in operating expenses in our Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles Impairment Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. We recognize an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or changes in circumstances have occurred which could indicate that the carrying value of our intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed. The fair value of the acquired intangible assets for the United States and E.U. rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region as well as discount rates applied to the projected cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of all outstanding capital stock of Viventia Bio, Inc. in September 2016, we recorded contingent consideration pertaining to the amounts potentially payable to Viventia's shareholders pursuant to the terms of the Share Purchase Agreement among us, Viventia and the other signatories thereto and are based on regulatory approval in certain markets and future revenue levels. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized in earnings (or loss) for the period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists primarily of interest income earned on cash, cash equivalents and marketable securities and, to a lesser extent, any gains or losses on foreign exchange.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit (Provision) for Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit for income taxes is driven by the intangible impairment charge, changing the value of deferred tax liabilities. Provision for income taxes consists of income taxes incurred to non-US jurisdictions pursuant to our former OUS business development partnership agreements, including the Qilu License Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Results of Operations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years ended December&#160;31, 2022 and 2021 </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,909&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,093&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,816&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,909)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,549)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23,759)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,609)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,150)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">176</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,398)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss After Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19,884)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(336)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19,548)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,818</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the year ended December 31, 2022 was $40.0 million, which was due to the execution of the Roche Asset Purchase Agreement for EBI-031 and all other IL-6 antagonist monoclonal antibody technology. Revenue for the year ended December 31, 2021 was $26.5 million, primarily due to the $20.0 million milestone achieved pursuant to the Roche License Agreement upon initiating a Phase II clinical trial, $5.0 million related to the Qilu License Agreement (achievement of the Investigational New Drug application milestone, clinical supply revenue, and license revenue for additional purchase price due to the recovery of VAT), and $1.5 million upfront milestone revenue achieved pursuant to the exclusive license agreement with Hikma Pharmaceuticals LLC (the &#8220;Hikma License Agreement&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $38.6 million for the year ended December 31, 2022, compared to $25.3 million for the year ended December&#160;31, 2021. The increase of $13.3 million was primarily driven by the expense of prepaid balances related to consumables and manufacturing reservations as the balances were deemed to have no future value due to the strategic decision to voluntarily pause further development of Vicineum in the United States ($25.2 million). Additionally, employee-related compensation increased, primarily due to the retention programs implemented in the fourth quarter of 2021 and third quarter of 2022 ($1.0 million). The increase was partially offset by decreased costs associated with manufacturing ($8.9 million), clinical and manufacturing related consulting fees ($2.3 million) and other individually immaterial research and development costs ($0.2 million), driven by the strategic decision to voluntarily pause further development of Vicineum in the United States in the third quarter of 2022. Additionally, one-time regulatory milestone payments ($1.5 million) related to the filing of the BLA to the FDA for Vicineum and MAA to the EMA for Vysyneum were made in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $39.8 million for the year ended December&#160;31, 2022, compared to $29.4 million for the year ended December&#160;31, 2021. The increase of $10.4 million was primarily due to an increase in legal expense ($13.1 million) driven by the settlements of the securities and derivative litigation net of insurance recovery ($8.2 million) and our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment of strategic alternatives ($3.8 million). Additionally, legal fees for securities and derivative litigation counseling ($0.6 million), general business counseling ($0.3 million), and other legal expenses ($0.2 million) increased. We also incurred $1.2 million in connection with the fairness opinions related to the proposed Merger and increased other individually immaterial expenses of ($0.2 million). This was partially offset by decreases in marketing and commercial expenses ($4.1 million), driven by preparation for the commercial launch of Vicineum prior to the issuance of the CRL in August 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we approved the 2022 Restructuring Plan to reduce operating expenses and better align our workforce with the needs of our business following the decision to voluntarily pause further development of Vicineum in the United States. Execution of the 2022 Restructuring Plan is expected to be substantially completed in connection with the closing of the Merger with Carisma, which is expected to occur during the first quarter of 2023. The 2022 Restructuring Plan includes an incremental reduction in our workforce as well as additional cost-saving initiatives intended to preserve capital during the pendency of the Merger with Carisma and while we seek a potential partner for the further development of Vicineum. We also incurred one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we approved the 2021 Restructuring Plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The 2021 Restructuring Plan included a reduction in our workforce by 18 positions (or approximately 35% of our workforce) as well as additional cost-saving initiatives intended to preserve capital while we continue development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructurin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g expenses were $11.8 million for the year ended December&#160;31, 2022, compared to $5.5 million for the year ended December&#160;31, 2021. The expense for the year ended December 31, 2022 consisted of severance and other employee-related costs ($7.0 million) and termination of certain contracts and other associated costs ($4.8 million) following the decision to pause further development of Vicineum in the United States. The expense for the year ended December 31, 2021 consisted of severance and other employee-related costs ($2.8 million) and termination of certain contracts ($2.7 million) following the receipt of the CRL in August 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles Impairment Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles impairment charge was $27.8 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December&#160;31, 2022, compared to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $31.7 million f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, we observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. We also experienced a sustained decline in our share price and a resulting decrease in our market capitalization. On July 15, 2022 we made the strategic decision to voluntarily pause further development in the United States of Vicineum and are seeking a partner for the further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. We identified these changes as potential impairment indicators and performed a quantitative impairment analysis for our intangible asset of Vicineum E.U. rights. As a result of the impairment test, we concluded that the carrying value of our intangible asset of Vicineum E.U. rights of $14.7 million and Goodwill of $13.1 million were fully impaired and written off during the second quarter of 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we received a CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. As a result, an impairment analysis was conducted, which concluded that the carrying value of our intangible asset of Vicineum United States rights of $31.7 million was fully impaired during the third quarter of 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cash change in fair value of contingent consideration was a gain of $52.0 million for the year ended December&#160;31, 2022, compared to gain of $56.8 million for the year ended December&#160;31, 2021. The change in the fair value of contingent consideration of $52.0 million for the year ended December&#160;31, 2022 was driven by our strategic decision to voluntarily pause further development of Vicineum in the United States and our conclusion that we no longer expect to owe any future earnout and milestone payments. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications for the size, timeline and costs for an additional Phase 3 clinical trial for the treatment of NMIBC. Additionally, during the second quarter of 2022, we observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. We continue to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, are seeking a partner that can execute further development to realize the full potential of Vicineum. We expect that any partner who acquires Vicineum from us will be obligated to make any payments to the former shareholders of Viventia under the Share Purchase Agreement. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration was a gain of $56.8 million for the year ended December&#160;31, 2021. This was primarily driven by the receipt of a CRL in August 2021, in which the FDA determined that it could not approve the BLA for Vicineum in its present form. Due to the inherent uncertainty in the path forward for Vicineum at the time, we reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of product launch and possibility of success ("POS"); we expected delays in the start of commercialization and estimated lower POS as a direct result of the CRL. We anticipated needing to conduct an additional clinical trial, which would lead to delays in the start of commercialization globally. We had assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. In addition, we assumed a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. The milestone payments constitute debt-like obligations, and the high-yield debt index rate applied to the milestones in order to determine the estimated fair value was 8.0% as of December&#160;31, 2021. The discount rate applied to the 2% earnout payment due on then-forecasted Vicineum revenues was derived from our estimated weighted average cost of capital ("WACC"), and this WACC-derived discount rate was 9.3% as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $1.9&#160;million for the year ended December&#160;31, 2022, compared to de minimis for the year ended December&#160;31, 2021. The increase was primarily due to higher yield earned on our investment account during 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit from Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, we recorded a benefit from income taxes of $3.9 million. In the second quarter of 2022, we determined that the fair value of the Vicineum E.U. in-process research and development asset was zero, which resulted in an impairment charge of $14.7 million. In connection with this impairment charge, in the second quarter of 2022, we wrote-down the associated deferred tax liability by $3.9 million as a benefit. For the year ended December 31, 2021, we recorded a benefit from income taxes of $8.3 million. In the third quarter of 2021, we determined that the fair value of the Vicineum United States in-process research and development asset was zero, which resulted in an impairment charge of $31.7 million. In connection with this impairment charge, in the third quarter of 2021, we wrote-down the associated deferred tax liability by $8.6 million as a benefit. Please refer to Note 9, "Intangibles and Goodwill," in our consolidated financial statements, which begin on page F-1 of this Annual Report on Form 10-K for further information regarding the impairment charge. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the years ended December&#160;31, 2021 and 2020 </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a comparison of our results of operations for the years ended December&#160;31, 2021 and 2020, see "Part II - Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the United States Securities and Exchange Commission ("SEC") on February 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash, cash equivalents, and marketable securities of $166.9 million, net working capital of $158.2 million and an accumulated deficit of $336.1 million. We incurred positive cash flows from operating activities of $24.9 million for the year ended December&#160;31, 2022 and negative cash flows from operating activities of $68.9 million and $30.8 million for the years ended December 31, 2021 and 2020, respectively. We believe that, based on the wind down of our operations and financial forecasts, our cash, cash equivalents, and marketable securities of $166.9&#160;million as of December&#160;31, 2022, are sufficient to fund operations for at least twelve months from the date of this Form 10-K filing, February 28, 2023. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on September 20, 2022, we entered into the Merger Agreement with Carisma and Merger Sub, pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma continuing as our wholly-owned subsidiary and the surviving corporation of the Merger. Our board of directors unanimously approved the Merger Agreement and resolved to recommend that our stockholders approve the proposals described in the Merger Agreement. If the Merger is completed, the business of Carisma will continue as the business of the combined company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger is expected to be completed during the first quarter of 2023. Consummation of the Merger is subject to certain closing conditions, including, among other things, (a) approval by our stockholders of the proposals described in the Merger Agreement, (b) approval by Carisma&#8217;s stockholders of, among other things, the adoption of the Merger Agreement, (c) Nasdaq&#8217;s approval of the listing of the shares of our common stock to be issued in connection with the Merger, (d) the effectiveness of a registration statement on Form S-4 to register the shares of our common stock to be issued in connection with the Merger, and (e) our having net cash as of closing of the Merger greater than or equal to $70.0 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger Agreement contains certain termination rights of each of us and Carisma. Upon termination of the Merger Agreement under specified circumstances, we may be required to pay Carisma a termination fee of $7.6&#160;million and/or reimburse Carisma&#8217;s expenses up to a maximum of $1.75&#160;million, and Carisma may be required to pay us a termination fee of $5.49&#160;million and/or reimburse our expenses up to a maximum of $1.75&#160;million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that we do not complete the Merger with Carisma, we may continue to explore strategic alternatives, including, without limitation, a dissolution of our company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have received no revenue from sales of our products, and we anticipate that operating losses will continue for the foreseeable future. We have financed our operations to date primarily through private placements of our common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, our IPO, follow-on public offerings, sales effected in ATM offerings, our former OUS business development partnerships and license agreements, sale of assets, and, to a lesser extent, from a collaboration. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into an Open Market Sale Agreement with Jefferies LLC ("Jefferies") dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which we may issue and sell shares of our common stock, par value $0.001 per share from time to time through Jefferies (the "ATM Offering"). In June and July 2021, we filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200.0 million of our common stock pursuant to the Sale Agreement of which $97.8 million of common shares remain available for future issuance as of December 31, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, including but not limited to sales made directly on or through the Nasdaq Stock Market or any other existing trading market for our common stock. We may sell shares of our common stock efficiently from time to time but have no obligation to sell any of our common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon our instructions, which include a prohibition on sales below a minimum price set by us from time to time. We have provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. We did not sell any shares of common stock pursuant to the Sale Agreement during the year ended December 31, 2022</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We raised $175.0 million of net proceeds from the sale of 56.9 million shares of common stock at a weighted-average price of $3.17 per share during the year ended December&#160;31, 2021. Share issue costs, including sales agent commissions, related to the ATM Offering totaled $5.4 million for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on the outcome of the proposed Merger with Carisma.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of risks similar to other clinical companies that have determined to focus primarily on pursuing a strategic transaction, including, but not limited to, those which are described under Part I Item 1A. Risk Factors of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will incur substantial expenses if and as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">address our ongoing litigation related to the Merger;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain and protect our intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce our personnel and incur related severance and employee-related costs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">explore, evaluate and pursue any strategic alternatives if the Merger is not completed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and the timing of the proposed Merger with Carisma;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and timing of any pending or future litigation involving us or our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our obligation to make milestone, royalty, and other payments to third-party licensors under our licensing agreements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, or government or other third-party funding. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we are unable to raise </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional funds when needed, we may be required to delay, limit, reduce or terminate our assessment of strategic alternatives. If we do not successfully consummate the proposed Merger with Carisma, our board of directors may decide to explore other strategic alternatives, including, without limitation, a dissolution of our company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual and Other Obligations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information related to our cash requirements from known contractual and other obligations, see the description of Contingent Consideration in Note 5. &#8220;Fair Value Measure and Financial Instruments,&#8221; as well as the description of our leases in Note 8 &#8220;Property and Equipment,&#8221; and the description of our license agreement and collaborations in Note 18, &#8220;License Agreements,&#8221; in our consolidated financial statements, which begin on page F-1 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our cash flows for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by (Used in) Operating Activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,878)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,837)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,969)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29,073)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating activities was $24.9 million for the year ended December&#160;31, 2022 and consisted primarily of a net loss of $19.9 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjusted for non-cash items including a decrease in the fair value of contingent consideration ($52.0 million), intangible impairment charge of ($27.8 million), share-based compensation ($6.9 million), and a net increase in operating assets and liabilities ($63.0 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $68.9 million for the year ended December&#160;31, 2021 and consisted primarily of a net loss of $0.3 million, which includes $26.5 million of revenue recognized pursuant to the Roche License Agreement upon Roche initiating a Phase II clinical trial, achievement of the IND milestone in China pursuant to the Qilu License Agreement, clinical supply revenue resulting from the delivery of drug product to Qilu, our former OUS partner for Greater China, and license revenue for additional purchase price due to the recovery of VAT by our former OUS business development partner for Greater China, adjusted for non-cash items, including share-based compensation of $5.1 million, a decrease in the fair value of contingent consideration of $56.8 million, impairment charge of $31.7 million and a net decrease in operating assets and liabilities of $48.6 million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $30.8 million for the year ended December&#160;31, 2020 and consisted primarily of a net loss of $22.4 million, adjusted for non-cash items, including share-based compensation of $1.8 million, a change in the fair value of contingent consideration of $11.2 million and a net decrease in operating assets and liabilities of $0.9 million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $54.0 million for the year ended December 31, 2022 and consisted of marketable security purchases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities consisted of de minimis purchases and sales of property and equipment during the years ended December 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was de minimis for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $176.1 million for the year ended December&#160;31, 2021 and consisted of $175.0 million net proceeds from the sale of common stock under the ATM Offering and $1.1 million in proceeds from the exercise of common stock warrants.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $38.1 million for the year ended December&#160;31, 2020 and consisted of $38.0 million net proceeds from the sale of common stock under the ATM Offering and $0.1 million in proceeds from the exercise of common stock warrants.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in accordance with GAAP and the rules and regulations of the SEC require the use of estimates and assumptions, based on complex judgments considered reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Our critical accounting policies are those policies which involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. Management has determined that our most critical accounting policies are those relating to the fair value of indefinite-lived intangible assets, goodwill; contingent consideration; revenue recognition; development and regulatory milestone payments and other costs; and research and development costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consisted of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. We recognize an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of our intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, we observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. We have also experienced a sustained decline in share price and a resulting decrease in our market capitalization. On July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of our intangible asset of Vicineum E.U. rights. We concluded that the carrying value of our intangible asset of Vicineum E.U. rights of $14.7 million was fully impaired as of June 30, 2022 and was reduced to zero in the second quarter of 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we received a CRL from the FDA regarding the BLA for Vicineum for the treatment of NMIBC, our lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and our withdrawal of the MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of our intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the United States market. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on our consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. We recognize a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. We have only one reporting unit. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, we observed continued trends in our market capitalization as compared to the carrying value of our single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, size, length and cost of a clinical trial, and time to potential market launch. We identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of our typical annual assessment date of October 1, 2022. We reassessed the underlying assumptions used to develop our revenue projections, which were then used as significant inputs to determine the fair value of equity. We updated our revenue forecast models based on further expected launch delays in both United States and OUS regions. We also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. We also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, we concluded that the carrying value of our goodwill of $13.1 million was fully impaired as of June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration on our consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the discounted present value of future commercial launch milestones and net sales royalties due to the former shareholders of Viventia pursuant to the Share Purchase Agreement. For additional information on how contingent consideration has changed over the relevant period, see Note 1. "Description of Business," in our consolidated financial statements, which begin on page F-1 of this Annual Report on Form 10-K . Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are unpredictable and inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales were expected to be achieved through 2033, the level of commercial sales of Vicineum then-forecasted for the United States, Europe, Japan, China, and other potential markets. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout was derived from our estimated weighted-average cost of capital, which was 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. We continue to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, we are seeking a partner for the further development of Vicineum. Accordingly, during the second quarter of 2022, we concluded that we are no longer expected to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential 2% earnout payment related to the Greater China region since those territory rights had been out-licensed. We and Qilu were in the process of negotiating a termination of the Qilu License Agreement, which was terminated on December 23, 2022. Accordingly, as of September 30, 2022, we concluded that we no longer expected to owe any future earnout payments related to the Greater China region and reduced our remaining $1.8 million of contingent consideration liabilities to zero as of September 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Regulatory Milestones and Other Payments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, we evaluate whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within our control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, we will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with more than one performance obligation, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocation objective, because management&#8217;s estimate of milestones and royalties approximates the standalone selling price of the license.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we are required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued accounting standards are discussed in Note 4. "Recent Accounting Pronouncements," in our consolidated financial statements, which begin on page F-1 of this Annual Report on Form 10-K.</span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_34"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements, together with the report of our independent registered public accounting firm, appear in the Index to Financial Statements beginning on page F-1 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change of accountants nor any disagreements with accountants on any matter of accounting principles or practices or financial disclosure required to be reported under this Item.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Act Rules 13a-15(e) and 15d-15(e), that are designed to ensure information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principle financial officer, to allow timely decisions regarding required disclosure. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore, the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with the policies and procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of controls, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our system of controls to enhance, where necessary, our control policies and procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as the end of the period covered by this Annual Report on Form 10-K. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December&#160;31, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting ("ICFR"), as defined in Exchange Act Rules 13a-15(f) and 15d-15(f), to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. ICFR includes our policies and procedures, such as our Code of Conduct, which (i) require our employees, officers and directors to adhere to certain ethical standards; (ii) require the maintenance of records, in reasonable detail, to help to ensure that our transactions, assets and liabilities are accurately and fairly recorded; (iii) provide reasonable assurance that transactions are authorized by our management and directors and are recorded as necessary to allow for the accurate preparation of financial statements in accordance with GAAP; and (iv) provide reasonable assurance regarding the safeguarding of our assets and the prevention or timely detection of the unauthorized acquisition, use or disposition of our assets, which could have a material effect on the financial statements. ICFR includes the controls themselves, management's monitoring of those controls, actions taken to correct any deficiencies identified and oversight of our internal control environment by the audit committee of our board of directors. Any system of internal control has inherent limitations and therefore may not prevent or detect misstatements. Projections of any evaluation of the effectiveness of ICFR to future periods are subject to the risk that controls may become inadequate over time because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of our ICFR as of the end of our fiscal year 2022 and has reviewed the results of this assessment with the audit committee of our board of directors. Management based its assessment on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that our ICFR was effective as of December&#160;31, 2022 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been changes in our internal control over financial reporting during the quarter ended December&#160;31, 2022 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_40"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has adopted a written Code of Business Conduct and Ethics applicable to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. The Code of Business Conduct and Ethics covers fundamental ethical and compliance-related principles and practices such as accurate accounting records and financial reporting, avoiding conflicts of interest, the protection and use of our property and information and compliance with legal and regulatory requirements. A current copy of the code is posted on the Corporate Governance section of our website, which is located at&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.sesenbio.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding any substantive amendment to, or waiver from, a provision of this Code and by posting such information on the website address and location specified above.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional information required by this item will be set forth in our 2023 Proxy Statement or in an amendment to this Form 10-K to be filed with the SEC within 120 days of December&#160;31, 2022 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11. &#160;&#160;&#160;&#160;Executive Compensation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2023 Proxy Statement or in an amendment to this Form 10-K to be filed with the SEC within 120 days of December&#160;31, 2022 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12. &#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2023 Proxy Statement or in an amendment to this Form 10-K to be filed with the SEC within 120 days of December&#160;31, 2022 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13. &#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2023 Proxy Statement or in an amendment to this Form 10-K to be filed with the SEC within 120 days of December&#160;31, 2022 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14. &#160;&#160;&#160;&#160;Principal Accountant Fees and Services.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2023 Proxy Statement or in an amendment to this Form 10-K to be filed with the SEC within 120 days of December&#160;31, 2022 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_49"></div><div style="-sec-extract:summary;margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(1)&#160;Consolidated Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements listed in the Index to Financial Statements beginning on page F-1 are filed as part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(2) Financial Statement Schedules</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statement schedule listed in the Index to Financial Statements on page F-1 is filed as part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(3) Exhibits</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Annual Report on Form&#160;10-K are set forth on the Exhibit&#160;Index immediately preceding such exhibits and are incorporated herein by reference.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#94;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312516715368/d261598dex21.htm">Share Purchase Agreement, effective as of September 20, 2016, by and between Eleven Biotherapeutics, Inc., Viventia Bio Inc. and Clairmark Investments Ltd., as representative of the selling shareholders. Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on September 21, 2016 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#94;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000135/exhibit21-projectseahawkxm.htm">Agreement and Plan of Merger, dated as of September 20, 2022, by and among Sesen Bio, Inc., Seahawk Merger Sub, Inc. and Carisma. Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on September 21, 2022 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#94;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000182/projectseahawk-firstamen.htm">First Amendment to Agreement and Plan of Merger and Reorganization, dated as of December 29, 2022, by and among Sesen Bio, Inc., Seahawk Merger Sub, Inc., and Carisma. Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on December 29, 2022 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#94;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923020879/tm236507d1_ex2-1.htm">Second Amendment to Agreement and Plan of Merger and Reorganization, dated as of February 13, 2023, by and among Sesen Bio, Inc., Seahawk Merger Sub, Inc., and Carisma. Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on February 14, 2023 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000135/exhibit102-formofcompanyst.htm">Form of Carisma Support Agreement, by and between the Sesen Bio, Inc., Carisma and certain stockholders of Carisma. Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on September 21, 2022 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000135/exhibit103-formofparentsto.htm">Form of Sesen Bio Support Agreement, by and between the Sesen Bio, Inc., Carisma and certain stockholders of Sesen Bio, Inc. Incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed on September 21, 2022 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000135/exhibit104-formoflockxupag.htm">Form of Lock-Up Agreement, by and between Sesen Bio, Inc., Carisma and certain stockholders of Sesen Bio, Inc. and Carisma. Incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K filed on September 21, 2022 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923020879/tm236507d1_ex2-1.htm">Form of Contingent Value Rights Agreement by and among Sesen Bio, Inc. and the Rights Agent. Incorporated by reference to Exhibit D to Exhibit 2.1 to our Current Report on 8-K filed on February 14, 2023 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514056904/d679756dex31.htm">Restated Certificate of Incorporation of Eleven Biotherapeutics, Inc. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on February 18, 2014 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit31-ebioxcertificate.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000103/ex33-certificateofamendm.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.3 to our Quarterly Report on Form 10-Q filed on May 10, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit32-elevenbiotherape.htm">Amended and Restated By-Laws. Incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit41-fy2021form10xk.htm">Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. </a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex41.htm">Specimen Stock Certificate evidencing the shares of common stock. Incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-1/A filed on January 23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514448885/d704357dex1023.htm">Form of Warrant issued to Silicon Valley Bank and Life Science Loans, LLC dated November 25, 2014. Incorporated by reference to Exhibit 10.23 to our Registration Statement on Form S-1 filed on December 19, 2014 (Reg. No. 333-201176).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500317000132/ex41ebiopre-fundedwarrant1.htm">Form of Common Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on November 3, 2017 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit41.htm">Form of Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on March 23, 2018 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2017warrantamendmenta.htm">Form of 2017 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2018warrantamendmenta.htm">Form of 2018 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.4 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex101.htm">Amended and Restated 2009 Stock Incentive Plan. Incorporated by reference to Exhibit 10.1 to our Registration Statement on Form S-1 filed on December&#160;30, 2013 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex102.htm">Form of Incentive Stock Option Agreement under the Amended and Restated 2009 Stock Incentive Plan. Incorporated by reference to Exhibit 10.2 to our Registration Statement on Form S-1 filed on December&#160;30, 2013 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex103.htm">Form of Non-statutory Stock Option Agreement under the Amended and Restated 2009 Stock Incentive Plan. Incorporated by reference to Exhibit 10.3 to our Registration Statement on Form S-1 filed on December&#160;30, 2013 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000045/sesenbio-2014stockincentiv.htm">2014 Stock Incentive Plan, as amended. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on June 25, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex106.htm">Form of Incentive Stock Option Agreement under 2014 Stock Incentive Plan. Incorporated by reference to Exhibit 10.6 to our Registration Statement on Form S-1/A filed on January&#160;23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex107.htm">Form of Non-statutory Stock Option Agreement under 2014 Stock Incentive Plan. Incorporated by reference to Exhibit&#160;10.7 to our Registration Statement on Form S-1/A filed on January&#160;23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312515239156/d34817dex101.htm">Form of Restricted Stock Unit Agreement under 2014 Stock Incentive Plan. Incorporated by reference to Exhibit&#160;10.1 to our Current Report on Form 8-K filed on June 29, 2015 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit108_formindemnifica.htm">Form of Indemnification Agreement by and between Sesen Bio, Inc. and Each of its Directors and Executive Officers.  Incorporated by reference to Exhibit 10.8 to our Annual Report on Form 10-K, filed on February 28, 2022 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex1013.htm">2014 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 10.13 to our Registration Statement on Form S-1/A filed on January 23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10&#8224;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000063/sesn-ex101xzurichlicenseag.htm">License Agreement, effective January 13, 2003, as amended and restated on October 14, 2015, by and between The University of Zurich and Viventia Bio Inc. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on May 9, 2022 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000120/sesnexhibit101micrometli.htm">Non-Exclusive Product License Agreement, effective as of October 18, 2005, by and between Micromet AG and Viventia Biotech Inc. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 9, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000120/sesnexhibit102xomanonexc.htm">Non-Exclusive License Agreement, effective as of November 30, 2001, by and between XOMA Ireland Limited and Viventia Biotech Inc. Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q filed on November 9, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000105/exhibit101-tcannellemploym.htm">Employment Agreement, dated August 7, 2018, by and between Sesen Bio, Inc. and Thomas R. Cannell. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on August 13, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit101.htm">Form of Securities Purchase Agreement. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on March 23, 2018 (File. No. 001-36296).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-spaamendment.htm">Amendment to Securities Purchase Agreement, dated October 28, 2019, by and among Sesen Bio, Inc. and the undersigned parties thereto. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000015/ex1032sesn-tomcannellstock.htm">Stock Option Award Agreement, dated August 7, 2018, by and between Sesen Bio, Inc. and Thomas R. Cannell, D.V.M. Incorporated by reference to Exhibit 10.32 to our Annual Report on Form 10-K filed on March 1, 2019 (File. No. 001-36296). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">E</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000029/glenmacdonaldebioemploym.htm">mployment Agreement, dated September 20, 2016, by and between Eleven Biotherapeutics, Inc. and Glen Macdonald, as amended on February 21, 2017. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on May 10, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000070/sesenbio-monicaforbesemplo.htm">Employment Agreement, dated August 26, 2019, by and between Monica Forbes and Sesen Bio, Inc. Incorporated herein by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on August 26, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000090/sesn-09302019x10qex101.htm">Employment Agreement, dated July 26, 2019, by and between Mark R. Sullivan and Sesen Bio, Inc. Incorporated herein by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 12, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000090/sesn-09302019x10qex103.htm">Stock Option Award Agreement, dated August 1, 2019, by and between Sesen Bio, Inc. and Monica Forbes. Incorporated herein by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q filed on November 12, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm">Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm">, dated November 2019, by and between Sesen Bio, Inc. and Jefferies LLC. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on November 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm">Amendment No. 1 to the Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm">, dated October 30, 2020, by and between Sesen Bio, Inc. and Jefferies LLC. Incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed on October 30, 2020 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000118/sesn-ex101qilulicensea.htm">Exclusive License Agreement, dated July 30, 2020, by and among Sesen Bio, Inc., Viventia Bio, Inc. and Qilu Pharmaceutical Co., Ltd. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 9, 2020 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm">Amendment No. 2 to the Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm">, dated February 17, 2021, by and between Sesen Bio, Inc. and Jefferies LLC. Incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed on February 17, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.25+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000088/exhibit101-amendmentno2t.htm">Amendment No. 2 to the Sesen Bio, Inc. 2014 Stock Incentive Plan. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 3, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000088/exhibit102-amendmentno1t.htm">Amendment No. 1 to the Sesen Bio, Inc. 2014 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on May 3, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001485003/000148500321000114/sesn-amendmentno3toatmsa.htm">Amendment No. 3 to the Open Market Sale AgreementSM, dated June 1, 2021, by and between Sesen Bio, Inc. and Jefferies LLC. Incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed on June 1, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit1030-rsuandcashrete.htm">Form of RSU Award Agreement for Retention Awards. Incorporated by reference to Exhibit 10.30 to our Annual Report on Form 10-K filed on February 28, 2022 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit1031-performancexba.htm">Form of PSU Award Agreement for Retention Awards. Incorporated by reference to Exhibit 10.31 to our Annual Report on Form 10-K filed on February 28, 2022 (File No. 001-36296). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000092/ex101-sesenrocheassetpur.htm">Asset Purchase Agreement, dated as of July 15, 2022 by and among Sesen Bio, Inc., F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed on July 18, 2022 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000121/sesenbio_minorirosales-e.htm">Employment Agreement, dated January 5, 2022, by and between Sesen Bio, Inc. and Minori Rosales. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q/A filed on August 25, 2022 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#94;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923020879/tm236507d1_ex10-1.htm">Voting and Support Agreement, dated February 13, 2023, by and among the Radoff Family Foundation, Bradley L. Radoff, JEC II Associates, LLC, the K. Peter Heiland 2008 Irrevocable Trust, Michael Torok, CARISMA Therapeutics, Inc. and Sesen Bio, Inc. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on February 14, 2023 (File No. 001-36296).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211-subsidiariesofs.htm">Subsidiaries of Sesen Bio, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231eyfy2023consent_.htm">Consent of Ernst &amp; Young LLP.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-12312022x10kex311.htm">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-12312022x10kex312.htm">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-12312022x10kex321.htm">Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-12312022x10kex322.htm">Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This exhibit is a compensatory plan or arrangement in which our executive officers or directors participate.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#94;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain schedules and exhibits have been omitted pursuant to Item 601 of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16.&#160;&#160;&#160;&#160;Form 10-K Summary.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:142.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:285.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SESEN BIO, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer and Duly Authorized Officer)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.&#160;</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Capacity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas R. Cannell, D.V.M.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Monica Forbes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Elly Ryu</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Controller<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elly Ryu</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jay S. Duker, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay S. Duker, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Carrie L. Bourdow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrie L. Bourdow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Jason A. Keyes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason A. Keyes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter K Honig, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter K Honig, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael A.S. Jewett, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael A.S. Jewett, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:88.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF81OC9mcmFnOmNhNWM5ZTY1MmUyZjQ1NzQ4OTA3OTRjYTAyMjJiYjRmL3RhYmxlOjJhNDVmMWVjNTYzYjQwNjQ5MjcyZjk2ZWViNzIwYmViL3RhYmxlcmFuZ2U6MmE0NWYxZWM1NjNiNDA2NDkyNzJmOTZlZWI3MjBiZWJfMS0wLTEtMS05MjM3NS90ZXh0cmVnaW9uOjY4NjEzNjY2YzljZjQ3MzE4NDUyY2ZlOWQ4ZGM1ZGVmXzcx_c44a4477-5e19-4341-9e74-bee8e54b2f18">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_61">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_64">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_67">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_1171">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_70">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_76">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d755c213f784994a9d98b9e4ebda9e0_79">9</a></span></div></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Sesen Bio, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Sesen Bio, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Impairment Evaluation of Goodwill and Indefinite-Lived Intangible Assets </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 3 and 9 to the consolidated financial statements under the captions &#8220;Indefinite-Lived Intangible Assets&#8221; and &#8220;Goodwill,&#8221; the Company&#8217;s intangible assets consisted of indefinite-lived, acquired in-process research and development (IPR&amp;D) product rights to Vicineum as a result of the acquisition of Viventia in 2016. Goodwill on the Company's consolidated balance sheets was the result of the Company&#8217;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of IPR&amp;D requires management to estimate the future discounted cash flows of the underlying asset.  Impairment testing of goodwill requires management to estimate the future discounted cash flows of the Company&#8217;s one reporting unit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While management concluded the carrying value of its goodwill and IPR&amp;D intangible asset were fully impaired as of June 30, 2022, and recorded impairment charges of $13.1 million and $14.7 million, respectively, the impairment assessments required a high degree of subjectivity to estimate the assumptions underlying Vicineum revenue projections which contributes to the fair value estimates of goodwill and of the IPR&amp;D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the impairment evaluations over goodwill and the IPR&amp;D asset, our audit procedures included, among others, evaluating the methodology and valuation models used and testing the key inputs and significant assumptions discussed above. We evaluated the significant assumptions in light of observable industry data, external data sources, probability of success benchmarks, regulatory factors, and draft term sheets which provided value indication for the business and Vicineum. Our procedures included evaluating the data sources used by management in determining its significant assumptions and included an evaluation of available information that either corroborated or contradicted management&#8217;s conclusions. We involved our valuation professionals to assess the methodology and valuation of the discounted cash flow models, including evaluating the reasonableness of certain significant assumptions. </span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82MS9mcmFnOmIwZTQzMDdmYjRmNTQ0YjQ5NjJhY2Y4OWU1MTY5NjhiL3RleHRyZWdpb246YjBlNDMwN2ZiNGY1NDRiNDk2MmFjZjg5ZTUxNjk2OGJfMzYxMQ_7a0fffde-8bea-4c3a-a9b7-7233c1d4baa4">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2010.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82MS9mcmFnOmIwZTQzMDdmYjRmNTQ0YjQ5NjJhY2Y4OWU1MTY5NjhiL3RleHRyZWdpb246YjBlNDMwN2ZiNGY1NDRiNDk2MmFjZjg5ZTUxNjk2OGJfMzYxMw_c7dd43ef-33e7-4850-a763-25a585a487fe">Boston, Massachusetts</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 28, 2023</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:68.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNC0xLTEtMS05MjM3NQ_47ae4bb5-c833-4bea-b9c9-750bf7c648ee">112,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNC0zLTEtMS05MjM3NQ_edd85c07-479f-47ac-af9a-fa5ee481cd6a">162,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNS0xLTEtMS05Mjc2MA_c78ba154-bfcd-477c-929d-ced01952f84d">54,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNS0zLTEtMS05Mjc2MA_aaf69d72-3e43-4272-9114-3fcf9e388152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNi0xLTEtMS0xMDE2ODM_0c2b1e52-1439-4ca7-971a-4ca5c379e72c">21,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNi0zLTEtMS0xMDE2ODM_b7d6250e-5e4a-4d5f-bb37-baa7850a6390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNS0xLTEtMS05MjM3NQ_dfbce975-646c-484e-b1a9-f1ec35757255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNS0zLTEtMS05MjM3NQ_6994e346-1b50-4378-8ce7-da2ef54718e6">21,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNi0xLTEtMS05MjM3NQ_cdf6cb49-4913-42fb-b69e-6220930c65f1">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNi0zLTEtMS05MjM3NQ_c0213b35-e433-4755-9430-0e955f02cebf">3,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNy0xLTEtMS05MjM3NQ_27de3b8a-342a-403b-b3d0-4f764fc0624e">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNy0zLTEtMS05MjM3NQ_0d00fee7-c3a9-4da6-b42a-62afcc38db6b">18,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfOS0xLTEtMS05MjM3NQ_b952b2eb-abc1-450e-8903-61e58f317ff0">189,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfOS0zLTEtMS05MjM3NQ_6b818617-9569-42e2-8876-2c4f9a8cfa63">205,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTQtMS0xLTEtOTI3NzI_90077c2e-75a2-4da8-8b58-f52e1885d5e2">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTQtMy0xLTEtOTI3NzI_04fc8796-4f69-40fa-aa2e-06301bb05f0b">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTMtMS0xLTEtOTIzNzU_8f18c5e2-4b4a-41b7-9389-ff4579ac62a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTMtMy0xLTEtOTIzNzU_3221c237-1bb0-424a-ae71-6d645f44870d">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTQtMS0xLTEtOTIzNzU_4f2d638e-fb82-419d-98bb-f416401264bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTQtMy0xLTEtOTIzNzU_ee9627fe-7e5d-4058-b203-8fb9ba6ec3f5">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTUtMS0xLTEtOTIzNzU_6668a41b-b749-4172-98f8-7c4a871552f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTUtMy0xLTEtOTIzNzU_575ff15c-36b6-4969-8ee1-44d27d00ffe2">13,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long term prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTYtMS0xLTEtOTIzNzU_16cd5ded-e3f8-451e-8407-864b26185efb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTYtMy0xLTEtOTIzNzU_b546aa78-891f-4fd5-b7f3-98cbc676ca74">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTctMS0xLTEtOTIzNzU_c3ab2a31-e344-4ba0-b863-c8e8e418cc4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTctMy0xLTEtOTIzNzU_3f9d7996-b0c0-45f4-91b5-b69f07de85a6">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTgtMS0xLTEtOTIzNzU_a83fcb90-953e-4001-b0ae-2ac4f4d47f4b">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTgtMy0xLTEtOTIzNzU_960f5478-5e3b-4f48-b232-c882b7473563">35,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTktMS0xLTEtOTIzNzU_05d0403b-e027-4a3c-93c5-45554f5cb558">189,174</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTktMy0xLTEtOTIzNzU_8bbf22a9-b092-41b7-9f68-371865bbcd12">240,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjMtMS0xLTEtOTIzNzU_0596c788-a8e9-43d3-a27e-548d4d2da32d">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjMtMy0xLTEtOTIzNzU_953c263c-b6b5-429e-925c-cdcdddf4bc7c">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjQtMS0xLTEtOTIzNzU_1be2f0f9-80cd-4b77-99c6-1723a6d03f48">29,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjQtMy0xLTEtOTIzNzU_b361e924-14bd-41b0-940f-9e0fb2d78e47">8,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjctMS0xLTEtOTIzNzU_8cb011a9-3c2a-43b5-bf26-035e43198190">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjctMy0xLTEtOTIzNzU_fefad4bc-731e-4106-97f9-1438639724da">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjgtMS0xLTEtOTIzNzU_0c1658d3-01c1-4324-86ef-2bd22c96c2c9">30,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjgtMy0xLTEtOTIzNzU_1c8b675c-faf7-4c17-8173-2386308ba742">11,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzEtMS0xLTEtOTIzNzU_38adb021-668b-4bb5-8b7f-38b4221676a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzEtMy0xLTEtOTIzNzU_7e7f82f5-f7eb-443d-a825-8e35452f6d88">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzItMS0xLTEtOTIzNzU_2467b57a-e7fd-4874-9fb6-86bdbcaf45df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzItMy0xLTEtOTIzNzU_5a153307-9dfa-4303-8dc7-5a81191c6dcd">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzMtMS0xLTEtOTIzNzU_7d990975-ab77-4eb5-9c06-a1eba082ec8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzMtMy0xLTEtOTIzNzU_d79d445d-f1fd-41c6-bebc-c89db3ef3305">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzUtMS0xLTEtOTIzNzU_3c528bdd-ae59-4e6d-8266-d6ba2555c081">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzUtMy0xLTEtOTIzNzU_252a3d7c-00d0-4d1b-8c1a-0330788424aa">57,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzYtMS0xLTEtOTIzNzU_a3058541-472c-4c71-979e-c33304eabc8e">30,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzYtMy0xLTEtOTIzNzU_a37ab1bf-ddb4-4642-b89c-c18638921cba">69,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV8yMQ_1d308b5f-f285-4759-81de-7cbbe4971129"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV8yMQ_25f00a53-9b34-4d78-82c6-bc537eabcb0e">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV80NQ_cb0c4a09-b176-4be9-b9be-1470d9b5c387"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV80NQ_e3ce674b-96c1-4fd3-8ff2-7aeed48c5d3c">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2022 and 2021; <ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV85OA_3c58c179-06bc-498b-9b66-6577029842d7"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV85OA_400dd6dc-2a74-4073-ab35-b5524d742970"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV85OA_9adb3f90-b8fc-4b93-8d91-17317f0bcc18"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV85OA_f99b5b73-8e18-45a1-95c4-d160139f5bdb">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMS0xLTEtOTIzNzU_1d53d161-4c49-4650-a87f-08184ed21d86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMy0xLTEtOTIzNzU_7f545dae-dfc5-4eef-867c-7fe4202af77b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xOA_4f10c2ca-ec77-46ef-9086-0f43c84e9d13"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xOA_707bb638-72a4-4c7a-94ad-fa2ca9f611d5">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl80Mg_1670249e-c53d-457b-bd8f-c164754ed285"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl80Mg_ac1e6063-7fd1-450a-be19-af48a46f17be">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2022 and 2021; <ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xMDE_246c8832-abfd-49ba-b6da-d046c4b423ba"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xMDE_b895e328-b76d-40d1-b6be-5762d7c949d8">202,759,043</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xMDg_8d948737-4317-415f-8bd8-6f7947f9ede5"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xMDg_cecede3c-3b86-4f26-86db-2617af9fba0e">199,463,645</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMS0xLTEtOTIzNzU_c7e5cf47-d758-43b2-9ea5-f963eb3a14e5">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMy0xLTEtOTIzNzU_53e5437f-70f2-4bb0-b298-e13afaee35ce">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDEtMS0xLTEtOTIzNzU_e408827d-185b-4995-ba83-e8e8395e6c74">494,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDEtMy0xLTEtOTIzNzU_b954cd96-ef8b-43b4-b078-b6379971ccba">487,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDItMS0xLTEtOTIzNzU_c9e814e8-6c2d-4627-a49f-f5e0ae37380d">336,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDItMy0xLTEtOTIzNzU_fa2856d5-d664-4cf7-b53e-983e22e33e03">316,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDUtMS0xLTEtOTI3OTE_0992c735-71da-4bbb-8698-a4ad8588751f">546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDUtMy0xLTEtOTI3OTE_6bb9fcb7-b050-4fe2-8a78-9ccfbd7bb5b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stockholders&#8217; Equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDMtMS0xLTEtOTIzNzU_1bae8e8e-0db9-4d96-82d6-1056d0e07a81">158,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDMtMy0xLTEtOTIzNzU_717ec857-a302-4ef3-a0c5-a206c4a9fdb2">171,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDQtMS0xLTEtOTIzNzU_8c25cba4-62b8-4a0b-a834-121f4848e056">189,174</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDQtMy0xLTEtOTIzNzU_9ca42443-e6f6-4501-ba95-566586d6ae4f">240,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0wLTEtMS05MjM3NQ_5772ccbb-05be-4692-8ecd-73c875653a3d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0wLTEtMS05MjM3NQ_c3c9da0a-6e9f-449c-aa05-5f9295a51172"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0wLTEtMS05MjM3NQ_dbe520d3-9099-41ec-b93b-68530628d03e">License and related revenue</span></span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0xLTEtMS05MjM3NQ_09e8e949-3127-4de7-960e-c2c667cba356">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0zLTEtMS05MjM3NQ_eca3271d-4870-4d55-b19a-ea2814072e29">26,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC01LTEtMS05MjM3NQ_b4305978-0b2d-44a7-a2e1-dba8ea4da1d7">11,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNS0xLTEtMS05MjM3NQ_0efbf560-4fee-4895-87f7-1ed73aee8150">40,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNS0zLTEtMS05MjM3NQ_e3f37587-ace5-40be-b17d-f572c41f5821">26,544</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNS01LTEtMS05MjM3NQ_9add7fac-33df-4b38-9e41-59dceedd7f42">11,236</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOC0xLTEtMS05MjM3NQ_d9ee8d9b-c1bd-4da8-9cc5-7d794b929bf1">38,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOC0zLTEtMS05MjM3NQ_85e2d59e-7739-49e1-b140-016f16ca87f7">25,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOC01LTEtMS05MjM3NQ_28f2f524-00e7-47c8-8466-83dfb493b556">29,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOS0xLTEtMS05MjM3NQ_7dc3fe01-2996-48cd-a2ab-48eb0bb9fc8a">39,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOS0zLTEtMS05MjM3NQ_e9b9ea58-fa93-4a19-909c-2c07b4fff6bd">29,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOS01LTEtMS05MjM3NQ_41f6362b-d6e3-415a-93f7-ed8b663cf48c">14,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTAtMS0xLTEtOTIzNzU_d45d7742-5984-4d41-a172-33454e732c40">11,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTAtMy0xLTEtOTIzNzU_b3939fc8-797b-401c-98a8-a59715e2a75e">5,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTAtNS0xLTEtOTIzNzU_860bd9c6-3e2c-4ec0-9575-f5be65c544c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTEtMS0xLTEtOTIzNzU_5eb127b0-18a0-42ab-990a-3e9eb44d1019">27,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d35c30040aa4486b9b15a04bdee6aa2_D20210701-20210930" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTEtMy0xLTEtOTIzNzU_f1dff601-c8d2-4689-887b-fbbd0840e2a1">31,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTEtNS0xLTEtOTIzNzU_5e4064e5-c125-4362-94bc-7cf8888e8645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTItMS0xLTEtOTIzNzU_e056a224-9d0f-42d3-b2b7-1407462a151b">52,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTItMy0xLTEtOTIzNzU_5950ac02-ba40-456d-ae63-227bffa8c954">56,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTItNS0xLTEtOTIzNzU_e57802f0-f307-4bb7-a93c-9d1f708b0fab">11,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTMtMS0xLTEtOTIzNzU_34d9b7aa-7ea4-4bdb-a83d-e6c5f7e3d3b0">65,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTMtMy0xLTEtOTIzNzU_6017f742-7974-4144-ab49-2701ba0e549e">35,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTMtNS0xLTEtOTIzNzU_47a5b4df-5cc9-45ff-bd4d-234d2a1e2c00">32,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTUtMS0xLTEtOTIzNzU_ab2d2920-fb45-4b21-93ea-8640fb265184">25,909</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTUtMy0xLTEtOTIzNzU_6f9f8ca9-8cfc-4a8e-bdc3-5cf51fd18983">8,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTUtNS0xLTEtOTIzNzU_d3b70710-2870-4912-9207-0bc7dabcd684">21,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtMS0xLTEtMTA1Njcx_63268f15-3559-45aa-b6b0-66292a4c91c9">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtMy0xLTEtMTA1Njcx_4a9135e7-da2b-4bc9-a65a-b119701b0dfb">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtNS0xLTEtMTA1Njcx_99c192e5-2af3-4f93-a2a1-7e1ed217ac93">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtMS0xLTEtOTIzNzU_cedf3a44-3e78-4623-88fa-0257961e733b">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtMy0xLTEtOTIzNzU_64198ff7-9b68-49c6-be6f-76bf3168f0e9">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtNS0xLTEtOTIzNzU_52a44a15-8f71-46e1-b1e1-b6cbaa79a335">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss Before Taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTctMS0xLTEtOTIzNzU_7530e168-b81f-4002-a64d-5870e167738e">23,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTctMy0xLTEtOTIzNzU_82f23371-17fd-478a-8b7f-4c43056c3fc5">8,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTctNS0xLTEtOTIzNzU_14e60120-a416-4abc-b853-e21411988268">20,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) from income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTgtMS0xLTEtOTIzNzU_337281f3-696b-4bfa-861e-af5e513cfd25">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTgtMy0xLTEtOTIzNzU_b97ebe4e-5e01-4b60-8db9-f3abc4d7adff">8,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTgtNS0xLTEtOTIzNzU_d3545f7b-0ca0-4f01-ad49-e4ba6abfb6f3">1,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss After Taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTktMS0xLTEtOTIzNzU_b6b7e653-49e5-4c6d-95bf-e0533ec84fe4">19,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTktMy0xLTEtOTIzNzU_fc82e0d6-3371-4dd3-be35-97262f57e8c5">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTktNS0xLTEtOTIzNzU_7c6949ef-d7a0-44f9-9052-c8265afc7e2e">22,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed Dividend</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjEtMS0xLTEtOTIzNzU_5e47878b-ab3c-4e00-926c-7e265ccf4c95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjEtMy0xLTEtOTIzNzU_ec04c1df-de54-4d42-baf6-8abea4f84ffc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjEtNS0xLTEtOTIzNzU_8afa1de3-cafa-4496-8a33-4caffabe64d9">147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMS0xLTEtOTIzNzU_1d741224-4625-42ab-91c9-05faf46a64f4"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMS0xLTEtOTIzNzU_c4447469-0487-41bb-a7f2-11f33c7e42d2"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMS0xLTEtOTIzNzU_c602c2d9-c83a-4a2c-a3eb-d82d2259a4f0">19,884</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMy0xLTEtOTIzNzU_4100ed69-e122-4bcf-af2a-9bbc10f93dd0"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMy0xLTEtOTIzNzU_878391b0-d330-42a4-bf3a-417b7eb8d5f9"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMy0xLTEtOTIzNzU_b94672be-baa9-4bcb-84ac-ae47b01cc7b2">336</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtNS0xLTEtOTIzNzU_2fc54112-e314-4d24-99b4-4485f30a8923"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtNS0xLTEtOTIzNzU_3f9ebd96-7b10-46a0-9362-bb044145fe98"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtNS0xLTEtOTIzNzU_674fdc76-f44c-4f2d-aa9b-0424c3839f73">22,544</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtMS0xLTEtOTI5ODQ_d2110cc3-33d6-4df8-86ac-df9ca26d357c"><ix:nonFraction unitRef="usdPerShare" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtMS0xLTEtOTI5ODQ_f0bc7032-24f6-4490-bbcf-499e72bce820">0.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtMy0xLTEtOTI5ODQ_173c6de9-7e74-4b3c-bd19-0ac348527dc4"><ix:nonFraction unitRef="usdPerShare" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtMy0xLTEtOTI5ODQ_4b469651-84d5-4f05-877e-1203c136c59d">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtNS0xLTEtOTI5ODQ_39f23487-0962-40ff-ae12-ae1f03e2de41"><ix:nonFraction unitRef="usdPerShare" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtNS0xLTEtOTI5ODQ_5510c0a1-7410-47b0-9d4a-8612dc4dbaaa">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctMS0xLTEtOTI5ODQ_90109636-4e34-4da4-bd95-c7c41723cf3d"><ix:nonFraction unitRef="shares" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctMS0xLTEtOTI5ODQ_ced5df9f-886d-43fe-a8ce-85d2e7920e9c">200,546</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctMy0xLTEtOTI5ODQ_26b53172-16dd-449b-823f-9fccd9d8b5cb"><ix:nonFraction unitRef="shares" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctMy0xLTEtOTI5ODQ_7c5449b6-da04-4fc8-9c77-d0274b942cc1">182,323</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctNS0xLTEtOTI5ODQ_5c45c82d-c317-4a4f-9537-0f18a8c40b8d"><ix:nonFraction unitRef="shares" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctNS0xLTEtOTI5ODQ_884f373b-c727-4a08-8eeb-3c6da7c4eff4">118,221</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_1171"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:56.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV8zLTEtMS0xLTk0NTgx_0e31dca4-d679-4bae-89f8-6ec5e260b154">19,884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV8zLTMtMS0xLTk0NTgx_29bc4c41-e6de-43c0-a8ce-91068985f9fc">336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV8zLTUtMS0xLTk0NTgx_5bd6699a-56e0-482a-bd48-c2aa6899864f">22,397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV80LTEtMS0xLTk0NTgx_ce0c18c2-05fe-47b5-bed0-9604632dc856">546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV80LTMtMS0xLTk0NTgx_98f7b46c-e72f-413d-9bbd-b3a1851399e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV80LTUtMS0xLTk0NTgx_9c563600-0ec5-4e2e-ac73-e90d9a0e124a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV81LTEtMS0xLTk1NTI4_4bca5990-c461-4269-a862-1ce5c989e8ca">20,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV81LTMtMS0xLTk1NTI4_3514db49-6ffd-46c3-bbd5-5e5da96818f9">336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV81LTUtMS0xLTk1NTI4_e138c82a-bc27-4d90-a81a-c9d36fb3d502">22,397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:25.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.717%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217;<br/>Equity (Deficit)</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9289325bda434664a6a39b85b67bfae9_I20191231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi0xLTEtMS05MjM3NQ_63211557-d151-42bb-9e16-48d36859eb0b">106,801,409</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9289325bda434664a6a39b85b67bfae9_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi0zLTEtMS05MjM3NQ_ce8f5b3f-3149-4cf2-9ebf-0d58e91eb778">107</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89feec3c1c304077906365e7fa3071f1_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi01LTEtMS05MjM3NQ_d4c80316-6e3f-47eb-bbe5-c7b652c1ff1c">266,717</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09358b4a0bcc4a3385a7f499156e77ad_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi03LTEtMS05MzMzMw_af58be73-ae3a-477e-9f54-3e3189bd5303">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i405074fedfc34261a6aa9a70d2ea0ce6_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi03LTEtMS05MjM3NQ_fd4f9c7b-24fd-4d90-93f4-97f17d4e52f4">293,524</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73c47e791149483dac9b339dd293b4ca_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi05LTEtMS05MjM3NQ_434b713a-bede-4486-b25a-df43b6be0adb">26,700</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id683680be9e042e0acf2733abe0d9cdb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMy03LTEtMS05MjM3NQ_77a158ed-1f0a-4eaa-b902-9eca4390842e">22,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMy05LTEtMS05MjM3NQ_63952d46-d884-4630-8bc9-4f32078f3a23">22,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97dd7567e83c47af9d549f491e6200b0_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNC01LTEtMS05MjM3NQ_a6a533ea-b5f6-4e8c-b953-054370ff0d9c">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNC05LTEtMS05MjM3NQ_534b6cc6-581f-41a4-945a-8bb4c7baf40b">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i887ce3b59fe94c8084e3c22ab03fb7ea_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNS0xLTEtMS05MjM3NQ_8cb4f6e4-f51c-45dc-bdad-710d0fe90b45">12,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97dd7567e83c47af9d549f491e6200b0_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNS01LTEtMS05MjM3NQ_abd8e8b5-70d9-4f02-aefa-2d13975bf2df">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNS05LTEtMS05MjM3NQ_9dc84101-68e7-49e3-b344-1cd50f369192">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of common stock under 2014 ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i887ce3b59fe94c8084e3c22ab03fb7ea_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNi0xLTEtMS05MjM3NQ_104467e3-f873-42a1-bbd0-8732ca2fd150">28,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97dd7567e83c47af9d549f491e6200b0_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNi01LTEtMS05MjM3NQ_2b1797b8-69f5-41b4-8bb2-697d5c91136d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNi05LTEtMS05MjM3NQ_d5bcac2e-ea3f-4766-9370-40db30f6571e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i887ce3b59fe94c8084e3c22ab03fb7ea_D20200101-20201231" decimals="INF" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOC0xLTEtMS05MjM3NQ_9bbf6dfb-89be-4623-bc7f-9e3edd99d71e">238,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97dd7567e83c47af9d549f491e6200b0_D20200101-20201231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOC01LTEtMS05MjM3NQ_7e5e2b3c-5a16-4078-af47-41d7c408d5d1">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOC05LTEtMS05MjM3NQ_c63d7a86-dba4-4279-ad21-676d8526ab23">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i19f82fd2d2e7407a97261cd8548780c9_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS0wLTEtMS05MjM3NS90ZXh0cmVnaW9uOjY4Y2NjZWE3NWNiOTQ2NjU4OTQ4OTlmZWU0ODJlMTM4XzEwOTk1MTE2Mjc4NzQ_d7a2ff47-175e-45d3-8aeb-f11eead87e07">1.2</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib748ce8528614265bc45eb9a76e9bfb0_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS0xLTEtMS05MjM3NQ_8e080b0e-0ed3-409a-b75a-a62660eba43a">33,369,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib748ce8528614265bc45eb9a76e9bfb0_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS0zLTEtMS05MjM3NQ_5578d24d-9fa5-4384-871a-8ee049aaee28">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3799557388394b24b27d06e94128d950_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS01LTEtMS05MjM3NQ_426b8b66-07ed-4559-a690-a5880115bcf8">37,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS05LTEtMS05MjM3NQ_a88054a3-e5f0-4292-bbd9-f7aa84c8a7ff">37,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i295ca9347a54466f93585f285c63b26b_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTAtMS0xLTEtOTIzNzU_13bc959b-2715-4e53-98fd-f9f73944d954">140,449,647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295ca9347a54466f93585f285c63b26b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTAtMy0xLTEtOTIzNzU_254ca864-e4b5-4b93-859d-90deee49165a">140</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e5a066bf5f4ca5a26ac3aa00160ed3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTAtNS0xLTEtOTIzNzU_9c21ee5f-1539-4bcb-848e-c9463df0b7b4">306,554</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib968e3f687d845e2a83107904373ff5c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS03LTEtMS05NTUzMA_38604034-cfc8-4ca2-8aab-5ef7b31c864b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87c1ee91ad034903b0d19285c24c8b19_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTAtNy0xLTEtOTIzNzU_c5d74a1b-b4ba-4773-b8cb-7a23d47fdd8b">315,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTAtOS0xLTEtOTIzNzU_fb8dd4b4-dbb2-497f-a989-bb8bc675e680">9,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3da3a125129480eb2e8ebb6f49f42bf_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTEtNy0xLTEtOTIzNzU_e8b99e7c-dcc8-4b18-8296-80f5b18585c2">336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTEtOS0xLTEtOTIzNzU_2d6aa8ea-bea5-44f6-aa89-97a7e955ef80">336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddcc8cd57e7497282b01d86668e8ae3_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTItNS0xLTEtOTIzNzU_6aca5f05-4d88-403b-9e91-554a292eb6a9">5,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTItOS0xLTEtOTIzNzU_368fd588-b84c-44ce-900a-b3397b7cc901">5,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83051d731ef64fbab70f1bd36b04864c_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTMtMS0xLTEtOTIzNzU_6ee9b880-40cc-4210-82b0-ec87e8df4b83">33,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddcc8cd57e7497282b01d86668e8ae3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTMtNS0xLTEtOTIzNzU_cfe69725-346d-47ae-90c1-1d4920cc4b1f">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTMtOS0xLTEtOTIzNzU_6a32ecfa-2440-47a4-8ccb-488baf25f021">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83051d731ef64fbab70f1bd36b04864c_D20210101-20211231" decimals="INF" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTUtMS0xLTEtOTIzNzU_487b3429-8bcf-4920-8212-c20a0ccc347b">2,048,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83051d731ef64fbab70f1bd36b04864c_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTUtMy0xLTEtOTIzNzU_5bf03c81-c306-44d2-a0a7-c810afa52d13">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddcc8cd57e7497282b01d86668e8ae3_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTUtNS0xLTEtOTIzNzU_44df716a-e7c8-4b9a-84b2-248459cbdaa7">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTUtOS0xLTEtOTIzNzU_0cbf32c9-25d5-491d-9537-4b70f977ee99">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ib200f78d81c84f1caf083a586963ba04_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTYtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjoyMTYyYTVlNjQ1OGY0MzhlYTUyNzllNTNkM2ZjYmZiMl83NA_6630c27a-9747-40f1-a656-fceae530cc95">5.4</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib82c4185c6fb4d92896edaac365482ab_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTYtMS0xLTEtOTIzNzU_2273c059-1525-4584-9ea7-a02d8ee0510b">56,932,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib82c4185c6fb4d92896edaac365482ab_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTYtMy0xLTEtOTIzNzU_0e5809d8-121f-4460-9962-43398682409a">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7947774ff61e417ca66c44d164ba6650_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTYtNS0xLTEtOTIzNzU_ce2a10f8-6587-4e1a-af2e-085a41c49b94">174,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib200f78d81c84f1caf083a586963ba04_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTYtOS0xLTEtOTIzNzU_fa470c7f-61a3-48f9-8f67-c1ebded192b7">174,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4462842a9194410a79f71e762585fbf_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTctMS0xLTEtOTIzNzU_2ecc01d1-a4dd-4a10-a53a-dab27d7c8b25">199,463,645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4462842a9194410a79f71e762585fbf_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTctMy0xLTEtOTIzNzU_790ce5c6-63af-4bd9-a302-a81e04205df1">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbabad301b294437b56c5d188d25d543_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTctNS0xLTEtOTIzNzU_c63e81f0-b076-49fe-97e7-2c05b23189c0">487,768</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if21d4b6455c5495b8488303a238975a0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTUtNy0xLTEtOTQyMDE_f4c58cb8-d999-4055-acf9-3f6d8bb0ccf7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d4fa9f625b54b30b2dff2dc6a1a867b_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTctNy0xLTEtOTIzNzU_75f76c96-61b9-4d05-89cf-d3913885ec77">316,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTctOS0xLTEtOTIzNzU_637c791b-77a3-4e48-b488-131bd9b93b23">171,710</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12d3333974e14f89a7ec3f471522f303_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTgtNy0xLTEtOTIzNzU_c1c1862e-d489-4177-9a0e-f5a58655220f">19,884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTgtOS0xLTEtOTIzNzU_c025fe6e-dc4c-4a0f-b7b1-ae6ef2a895fa">19,884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b86eb7007d470aa9e0586557f94125_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTktNS0xLTEtOTIzNzU_53bce0d5-73f1-4a22-be37-caefa3e31d55">6,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTktOS0xLTEtOTIzNzU_f968f418-ad95-466e-bb48-a5fd12eb01eb">6,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i822d046be15341d59a14431cd169a913_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjAtMS0xLTEtOTIzNzU_3a384e2e-f44c-4f8f-837f-a6cbd4a9d929">2,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b86eb7007d470aa9e0586557f94125_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjAtNS0xLTEtOTIzNzU_51190a7d-cc5d-4076-b194-f4e99f7f1cd6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjAtOS0xLTEtOTIzNzU_15376919-d31f-4d9f-bc76-177082230e7e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i521bc055cda840c99e95281f5864c7ad_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjAtNy0xLTEtOTMzODY_1af16b4f-d8da-40e5-85e8-40db8a06b4f5">546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjMtOS0xLTEtOTIzNzU_922dfca2-3612-430f-9430-1613b4bb5f35">546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for RSU vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i822d046be15341d59a14431cd169a913_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjEtMS0xLTEtOTc4MDc_ce74e9b0-eca6-4b21-ae8e-de27c03ee492">3,293,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i822d046be15341d59a14431cd169a913_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjEtMy0xLTEtOTc4MDc_98dc18af-41f5-4523-9816-338c69515390">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b86eb7007d470aa9e0586557f94125_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjEtNS0xLTEtOTc4MDc_46e6660e-4f71-4680-89ba-5bfd124601a2">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjEtMTEtMS0xLTk4MDI2_d290bd62-28db-4297-b797-072ea8a41823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3abd01beb2944a8aabb8c310e92e38a_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjQtMS0xLTEtOTIzNzU_efb6f7c8-abd5-407c-b722-efff1378c5c4">202,759,043</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3abd01beb2944a8aabb8c310e92e38a_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjQtMy0xLTEtOTIzNzU_d1ff2e0e-6005-4481-be7d-b00c0041d2be">202</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b12428f67b4fb289c73df6c14dd797_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjQtNS0xLTEtOTIzNzU_597ebc9b-3fe5-408f-8b5c-47a4d303bf7d">494,675</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e556b75c0e543168782ac584ea02832_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjEtNy0xLTEtOTQyMDE_e8b4ba28-cff1-4842-9247-5a5b0a95af84">546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c1925aa09c546e6bb1bbc2f922a757c_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjQtNy0xLTEtOTIzNzU_00c31b48-86d9-4711-ab04-d349c07a9313">336,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjQtOS0xLTEtOTIzNzU_526cc3b5-f195-49b4-abda-e43285bd7299">158,190</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:65.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMy0xLTEtMS05MjM3NQ_b912a402-f75f-47c4-a02a-a49bbb2722cb">19,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMy0zLTEtMS05MjM3NQ_ad76c540-7989-4c00-9c61-a521c62c0295">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMy01LTEtMS05MjM3NQ_f3dd22e2-ff72-437f-aef1-d6b9bfe03ca1">22,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNS0xLTEtMS05MjM3NQ_a1e70bea-1efb-4c49-a3a2-181de7af007d">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNS0zLTEtMS05MjM3NQ_bcd5b6d2-e92b-4c7d-b542-645bddcd0b8e">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNS01LTEtMS05MjM3NQ_261dfe35-6a09-43b0-a53e-c694a53fb3ea">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNi0xLTEtMS05MjM3NQ_04b758cc-45dc-4409-afff-2ea8dcdf6a32">6,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNi0zLTEtMS05MjM3NQ_58750120-4c6f-44a0-ac33-75a83104451d">5,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNi01LTEtMS05MjM3NQ_769c67ea-2647-43d5-b2e5-6430324d58f3">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNy0xLTEtMS05MjM3NQ_e056a224-9d0f-42d3-b2b7-1407462a151b">52,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNy0zLTEtMS05MjM3NQ_5950ac02-ba40-456d-ae63-227bffa8c954">56,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNy01LTEtMS05MjM3NQ_e57802f0-f307-4bb7-a93c-9d1f708b0fab">11,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfOS0xLTEtMS05MjM3NQ_3d81b1b9-1084-448f-a165-bd0589c198aa">27,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfOS0zLTEtMS05MjM3NQ_63bf3d6d-72e4-428e-b689-eacb946d5cd7">31,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfOS01LTEtMS05MjM3NQ_90607239-97b5-4ed7-a511-d96f0819aea5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of discounts and premiums on marketable securities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTAtMS0xLTEtMTA1ODYy_b3e89467-f9b8-4fb0-b4e8-4de8cad4d666">913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTAtMy0xLTEtMTA1ODYy_0eb4beed-7986-45f2-9843-c326585e04fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTAtNS0xLTEtMTA1ODYy_a6758e3d-c943-4915-acb9-19f4aac00151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable (net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTEtMS0xLTEtOTIzNzU_1d3cbbe3-0a7e-441d-b3bf-6bd011ad8146">21,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTEtMy0xLTEtOTIzNzU_9b03693d-361b-4f67-bd26-caf78ce3327f">24,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTEtNS0xLTEtOTIzNzU_9cb8164e-9e87-4f58-a754-0cc67f653994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTItMS0xLTEtOTQ2NDY_d8f568d4-cd3f-40a3-8890-5ac06a57c98d">2,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTItMy0xLTEtOTQ2NDY_ad6e36ac-1a62-47da-9df6-632dbe0a1356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTItNS0xLTEtOTQ2NDY_29438f5e-2ef9-4be2-a6ce-e4d7214eb6b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTMtMS0xLTEtOTQ2NDY_e5b4715f-2cd9-46b9-ae4b-44ccfa98d045">18,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTMtMy0xLTEtOTQ2NDY_5ed531fe-269d-483d-aef5-3a73f0cbcc60">17,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTMtNS0xLTEtOTQ2NDY_e668baf9-04c1-4acd-9bf6-4a6d612768f6">1,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtMS0xLTEtOTQ2NDY_98e2d3fa-fb52-45f0-9746-03dfe1e63b35">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtMy0xLTEtOTQ2NDY_0a83ec4a-9558-4381-95bc-be41ab38e2af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtNS0xLTEtOTQ2NDY_a6f33e31-4d16-4629-be5d-ea95b45522cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctMS0xLTEtMTAxNjU0_9eba9788-8cae-4798-b6fe-1f130886ba9e">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctMy0xLTEtMTAxNjU0_bcfc1c56-94e5-4104-8e5b-1e531a0a9377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctNS0xLTEtMTAxNjU0_18df98df-1ddd-4b10-aa1c-107fa5c29faa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtMS0xLTEtOTIzNzU_aca5134c-9a2f-4602-9bd8-e082a1efcd4c">1,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtMy0xLTEtOTIzNzU_64fcb16b-5254-4398-9ab9-35d6124bbc26">249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtNS0xLTEtOTIzNzU_5bbab64d-c843-4d6d-add7-974d9c83f9a1">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTUtMS0xLTEtOTIzNzU_96fe6137-734b-460a-ab91-9133466b782b">17,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTUtMy0xLTEtOTIzNzU_9e76d265-6e19-471c-b664-719e2c0caaf8">4,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTUtNS0xLTEtOTIzNzU_6cb8fa5a-041f-4214-9958-5ca75f8bcf6e">2,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTYtMS0xLTEtOTIzNzU_6fcb7a34-cbd4-4db7-bb39-c6b386d5c2db">1,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTYtMy0xLTEtOTIzNzU_e26e7f93-b718-4fbc-bfb5-e827c67ffe51">1,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTYtNS0xLTEtOTIzNzU_b08c7c42-9220-4a7a-ac68-a0d4ac419ca0">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctMS0xLTEtOTIzNzU_68029adb-7b01-4ae7-b9d9-55aad2f89434">24,895</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctMy0xLTEtOTIzNzU_be8e72d7-51f8-48c9-8cd4-adc67c7c4775">68,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctNS0xLTEtOTIzNzU_ead707a9-a263-4a7d-8105-e33e27eda398">30,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTktMS0xLTEtOTIzNzU_e43711ae-b442-4861-8df7-3e3a2830e679">128,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTktMy0xLTEtOTIzNzU_14078641-ad8b-4566-8081-a2f1172d7ed4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTktNS0xLTEtOTIzNzU_1eeb2b2d-64f9-4759-a2fb-bb78069cd6d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturity of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMS0xLTEtMTA1ODc1_229af2b6-5ef3-407d-86d7-496f147c7b7d">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMy0xLTEtMTA1ODc1_fe35afe1-ac5f-4abe-9e09-aae1b8543eee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtNS0xLTEtMTA1ODc1_90e45241-4fd8-4398-a812-7f66ee8d4c4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposal (purchases) of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMS0xLTEtOTUzOTQ_d66845fe-209e-44b7-9af2-94c32f47450d">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMy0xLTEtOTUzOTQ_aade91ce-4daa-441c-9ef6-e8a3b2f82639">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtNS0xLTEtOTUzOTQ_51a34cae-e1c5-474c-aded-8136b425d60a">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjAtMS0xLTEtOTIzNzU_9214bd9f-01cc-4e4b-829a-cbe40da046c2">53,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjAtMy0xLTEtOTIzNzU_03addc87-b62c-473a-99a6-b2cbe796ff90">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjAtNS0xLTEtOTIzNzU_3815aee5-1484-4ae4-8df5-f16ad695b60c">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under ATM Offering, net of<br/>issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjItMS0xLTEtOTIzNzU_4436d60c-ed36-4627-9c11-081e021fc3ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjItMy0xLTEtOTIzNzU_3180184b-f722-4af2-8c66-0201ae55c454">174,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjItNS0xLTEtOTIzNzU_b13c354b-b9f8-4710-9d0d-6c67d1bdc3b8">37,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjMtMS0xLTEtOTIzNzU_726738de-53d1-4eed-96e8-ce3a505d9cb0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjMtMy0xLTEtOTIzNzU_f4961d3e-af67-408f-9f07-17786736d81c">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjMtNS0xLTEtOTIzNzU_7fdc7245-c916-4f43-b7dd-64881301e6b0">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMS0xLTEtOTIzNzU_e4b44f24-a870-48ae-bb12-5f84bb8fbce1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMy0xLTEtOTIzNzU_108d0345-252a-4375-8540-1e8910415c3c">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtNS0xLTEtOTIzNzU_7beb3d99-01d6-4ace-9937-e5cbab69e95b">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of common stock pursuant to ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjUtMS0xLTEtOTIzNzU_020203b8-3faa-4a62-b811-b79320ad8589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjUtMy0xLTEtOTIzNzU_84cb9305-9598-4af7-8002-b7ddcff9a29b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjUtNS0xLTEtOTIzNzU_189cb72d-2c19-4d97-906c-e2ae01fbcb38">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjctMS0xLTEtOTIzNzU_0b87da98-c88c-4e0a-80b1-ea672c5d7c95">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjctMy0xLTEtOTIzNzU_f0e48d36-a155-42f3-9889-c8bbedc30105">176,129</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjctNS0xLTEtOTIzNzU_f05a4cc7-d7e4-4050-8a69-8e1aad1cd5e1">38,113</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjgtMS0xLTEtOTIzNzU_94abfd34-3e05-4949-af4c-819c2e0c3df6">29,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjgtMy0xLTEtOTIzNzU_a4be89d7-c89c-466c-9ee4-6953bb416220">107,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjgtNS0xLTEtOTIzNzU_1c5a6488-d718-410b-86bc-6a7a3ec7758e">7,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjktMS0xLTEtOTIzNzU_959b757f-13a6-4ceb-95a3-4ff511cc83bb">162,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjktMy0xLTEtOTIzNzU_c4598f0e-646b-419b-a199-010ac9975d77">55,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c47e791149483dac9b339dd293b4ca_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjktNS0xLTEtOTIzNzU_cbd1ca2a-ca52-414a-b134-563f83cb14ad">48,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzAtMS0xLTEtOTIzNzU_795078d6-c70f-428d-8bbc-71906eaf2cce">133,583</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzAtMy0xLTEtOTIzNzU_db9fe28d-ec8e-45ec-a441-230789074f34">162,656</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzAtNS0xLTEtOTIzNzU_f417af19-c079-4219-8c12-bf2b5b27158f">55,409</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzMtMS0xLTEtOTIzNzU_b9967fb6-7861-4466-954a-b4811034d298">112,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzMtMy0xLTEtOTIzNzU_18e36a3b-5d7b-4fd9-b31f-bf4062b5aa97">162,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzMtNS0xLTEtOTIzNzU_59678e59-691e-4831-9df1-c6db73f1a08c">52,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzQtMS0xLTEtOTIzNzU_ad7320f9-7712-48aa-bacd-cb8f0c543a85">21,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzQtMy0xLTEtOTIzNzU_943b827e-2be1-4674-8a3a-436580a09344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzQtNS0xLTEtOTIzNzU_3489877a-f40a-4657-892a-b05be7ec4824">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term restricted cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzUtMS0xLTEtOTIzNzU_649742fa-6417-41d2-ae8f-61b5028f9395">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzUtMy0xLTEtOTIzNzU_6c16e412-fe4d-441a-857f-8fcfc67d7621">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzUtNS0xLTEtOTIzNzU_c0840261-7c2d-4fe5-9039-804bf082be5c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzYtMS0xLTEtOTIzNzU_919ebd45-6d9f-4345-91de-0534e32ebe06">133,583</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzYtMy0xLTEtOTIzNzU_c6569511-5d9e-4123-bdfc-6718ff5e8832">162,656</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzYtNS0xLTEtOTIzNzU_068e238f-dbd7-4fb8-a4ef-1648fe61cfbc">55,409</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental cash flow disclosure:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzktMS0xLTEtOTIzNzU_7a1eeeab-71f6-4f31-b333-ab50f5e0c4e0">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzktMy0xLTEtOTIzNzU_d4c4fb6f-0f6f-4d74-b099-b7dc8aa0735f">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzktNS0xLTEtOTIzNzU_c88fddb9-4ef1-4a3a-9c30-f7be2dbc573f">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDItMS0xLTEtOTIzNzU_42de74e7-4370-4431-a8bf-9b2de3658e85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDItMy0xLTEtOTIzNzU_a092d9f0-8ff1-40e5-a0f2-77ddcde38ff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDItNS0xLTEtOTIzNzU_54e95fdc-422a-47ed-b9a5-852e2144c594">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deemed Dividend on adjustment of exercise price on certain warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="sesn:IssuanceOfWarrantForCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDUtMS0xLTEtOTIzNzU_ee039b32-b2cf-4d6c-9c6e-fd054ca5fadf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="sesn:IssuanceOfWarrantForCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDUtMy0xLTEtOTIzNzU_d443abbe-ebd6-459d-a7db-a793469eaca8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="sesn:IssuanceOfWarrantForCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDUtNS0xLTEtOTIzNzU_de8c9394-198f-42c2-b509-fc5de1a1f9aa">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_82"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfMTY1NDY_d9f8450c-5fe4-4a5b-82ce-d42279fd429b" continuedAt="ibe8959f3ce524613a12eb675775f2ee0" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="ibe8959f3ce524613a12eb675775f2ee0" continuedAt="i4f9823570f5f4c85a67f5361991229ab"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. ("Sesen Bio" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company that previously focused on advancing targeted fusion protein therapeutics (&#8220;TFPTs&#8221;) for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also known as VB4-845, is a locally administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;). On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the United States Food and Drug Administration ("FDA"), which had implications on the size, timeline and costs of an additional Phase 3 clinical trial, which the FDA previously confirmed would be required for a potential resubmission of a biologics license application ("BLA") for Vicineum for the treatment of NMIBC. As a result of this decision, the Company turned its primary focus to consummating a strategic transaction with the goal of maximizing stockholder value. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on September 20, 2022, the Company, Seahawk Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), and CARISMA Therapeutics Inc. (&#8220;Carisma&#8221;), entered into the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (the &#8220;Merger Agreement&#8221;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the &#8220;Merger&#8221;). The Company&#8217;s board of directors unanimously approved the Merger Agreement and resolved to recommend that its stockholders approve the proposals described in the Merger Agreement. If the Merger is completed, the business of Carisma will continue as the business of the combined company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, it is seeking a partner that can execute further development to realize the full potential of Vicineum. As a result of such decision and the Company&#8217;s subsequent decision to enter into the proposed Merger with Carisma, it no longer plans to pursue regulatory approval of Vicineum for NMIBC in the European Union (the &#8220;E.U.&#8221;) and has started to wind down certain of its manufacturing operations and business development partnerships. Additionally, the Company is seeking a partner for the further development of Vicineum and has initiated a formal process and engaged a financial advisor for the potential sale of Vicineum. If the proposed Merger is consummated, the combined company does not expect to pursue further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anticipated Merger with CARISMA Therapeutics Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger is expected to be completed during the first quarter of 2023. In connection with the Merger, the Company is seeking the approval of its stockholders to, among other things, (a) issue the shares of its common stock issuable in connection with the Merger pursuant to the rules of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), and (b) amend its amended and restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;) to effect a reverse stock split of the outstanding shares of its common stock at a ratio of 1-for-20 (clauses (a) and (b), collectively, the &#8220;Sesen Bio Voting Proposals&#8221;). The special meeting of stockholders in which the Company&#8217;s stockholders will be asked to vote on the Sesen Bio Voting Proposals (the &#8220;Special Meeting&#8221;) will be held on March 2, 2023 at 10:00 a.m. Eastern Time.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that Sesen Bio does not complete the Merger with Carisma, Sesen Bio may continue to review and evaluate strategic alternatives, including, without limitation, a dissolution of Sesen Bio.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued <ix:nonFraction unitRef="shares" contextRef="i8207bee1099a4945acebe2cd3e4d4b1c_D20160901-20160930" decimals="-5" name="sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNDI0Ng_7590c77b-a4fd-4a71-8867-e21c5a927409">4.0</ix:nonFraction> million shares of its common stock to the Selling Shareholders, which at that time represented approximately <ix:nonFraction unitRef="number" contextRef="iae93f5204e234406aa4669d7fa75acb3_I20160930" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNDM1MA_4c729918-ad94-4e05-b041-23e3789d26e4">19.9</ix:nonFraction>% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, a director of the Company until his retirement in July 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i4f9823570f5f4c85a67f5361991229ab" continuedAt="i0bab49ee0ebc4867aa913fe1d7629212"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ia2f5bb9a1d474d50a682361408fd22f0_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNDkxNA_d4ff38c9-c4f3-4a33-a0a6-8c28581cc676">12.5</ix:nonFraction> million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i0cdc0620bb5249d1b453c6ee1ee52d9f_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNTA0Mw_c2e8b510-c1c0-46c3-878e-74b42b683719">7.0</ix:nonFraction> million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ifec4efcaaaba4d86ae2f9115d511c3ad_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNTE4OQ_03e78c3a-e6fa-4ad8-99e2-91389089a0d4">3.0</ix:nonFraction> million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to <ix:nonFraction unitRef="number" contextRef="i0d5d00287d2b402c81fe18e1a760ee21_D20160901-20160930" decimals="2" name="sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNTMwMQ_812d9fbe-8c7a-4476-a8e9-b0849ac16bfd">2</ix:nonFraction>% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) <ix:nonNumeric contextRef="i8207bee1099a4945acebe2cd3e4d4b1c_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNTU2OA_ee9d1f66-a0f1-4233-ac85-0a50e25091bd">fifteen years</ix:nonNumeric> after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first <ix:nonNumeric contextRef="i8207bee1099a4945acebe2cd3e4d4b1c_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNTg4Mw_d1bc4b8a-442b-4ac3-812a-31ba99c470e7">seven years</ix:nonNumeric> following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of December&#160;31, 2022, none of these individuals are active employees or members of the Company's board of directors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had cash, cash equivalents, and marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNzE0NjgyNTYyOTI1Nw_fca245c1-c89d-40a1-aeb2-b0abbadb48a0">166.9</ix:nonFraction> million a</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNjU1OA_94083bc1-835e-4cc9-9aff-498fb32002ac">336.1</ix:nonFraction> million. The Company in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">curred positive cash flows from operating acti</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vities of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNjYzMg_7d328e6a-cdd4-421b-a308-dd8e66f166e1">24.9</ix:nonFraction> million for the year ended December&#160;31, 2022.</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">curred negative cash flows from operating acti</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNjYzNg_91b0f8b1-6031-4ec6-8d2f-b1498190af3d">68.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNjY0Mw_7647a88e-0eba-48af-9042-3bd72801f29b">30.8</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively. Since the Company&#8217;s inception, it has received no revenue from sales of its products, and the Company anticipates that operating losses will continue for the foreseeable future as it seeks to close the Merger with Carisma.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has financed its operations to date primarily through private placements of its common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, its initial public offering ("IPO"), follow-on public offerings, sales effected in "at-the-market" ("ATM") offerings, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">out-license agreements and an asset purchase agreement. See &#8220;Note 13. Stockholders&#8217; Equity (Deficit)&#8221; below for information regarding the Company&#8217;s recently completed equity financings. Management believes that the Company&#8217;s cash and cash equivalents as of December&#160;31, 2022 will be sufficient to fund the Company's operations for at least the next twelve months from the date these consolidated financial statements were issued.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's future funding requirements will depend on the outcome of the proposed Merger with Carisma.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other clinical companies that have determined to focus primarily on pursuing a strategic transaction, including, but not limited to, those which are described under Part I Item 1A. Risk Factors of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will incur substantial expenses if and as it:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addresses its ongoing litigation related to the Merger;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintains and protects its intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduces its personnel and incurs related severance and employee-related costs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">explores, evaluates and pursues any strategic alternatives if the Merger is not completed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and the timing of the proposed Merger with Carisma;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and timing of any pending or future litigation involving the Company or its business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of maintaining and enforcing the Company&#8217;s intellectual property rights and defending any intellectual property-related claims; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">its obligation to make milestone, royalty and other payments to third-party licensors under its licensing agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as the Company can generate substantial revenues, the Company expects to finance the cash needs through a combination of equity offerings, debt financings, or government or other third-party funding. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting the Company&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company is unable to raise additional funds when needed, it may be required to delay, limit, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0bab49ee0ebc4867aa913fe1d7629212">reduce or terminate its assessment of strategic alternatives. If the Company does not successfully consummate the proposed Merger with Carisma, its board of directors may decide to explore other strategic alternatives, including, without limitation, a dissolution of the company.</ix:continuation></span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_85"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:BasisOfAccounting" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84NS9mcmFnOmY2NGNiODkwY2ZhMzRlZmE5YzA1MDJkZDIzOWViMjdlL3RleHRyZWdpb246ZjY0Y2I4OTBjZmEzNGVmYTljMDUwMmRkMjM5ZWIyN2VfMjM2MA_5c08326f-f5b7-4047-989f-14c853ae6087" continuedAt="i0d4a112c2d2a44f4a447d964b66957b9" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i0d4a112c2d2a44f4a447d964b66957b9"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").</span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84NS9mcmFnOmY2NGNiODkwY2ZhMzRlZmE5YzA1MDJkZDIzOWViMjdlL3RleHRyZWdpb246ZjY0Y2I4OTBjZmEzNGVmYTljMDUwMmRkMjM5ZWIyN2VfMjM2MQ_c546031f-f394-4100-b5ca-b8ecc100d5d4" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission ("SEC") requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84NS9mcmFnOmY2NGNiODkwY2ZhMzRlZmE5YzA1MDJkZDIzOWViMjdlL3RleHRyZWdpb246ZjY0Y2I4OTBjZmEzNGVmYTljMDUwMmRkMjM5ZWIyN2VfMjM2Mg_d90adebf-2168-4a7c-9ccb-f2128ab926d0" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84NS9mcmFnOmY2NGNiODkwY2ZhMzRlZmE5YzA1MDJkZDIzOWViMjdlL3RleHRyZWdpb246ZjY0Y2I4OTBjZmEzNGVmYTljMDUwMmRkMjM5ZWIyN2VfMjM2Mw_20061656-c0aa-486d-a563-f88e839a4865" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the United States dollar.</span></div></ix:nonNumeric></ix:continuation><div id="i6d755c213f784994a9d98b9e4ebda9e0_88"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMzg_0e328f5d-99ca-4125-b43e-a93521dbe2b3" continuedAt="i0524625c65b54172876cb1175db40af2" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i0524625c65b54172876cb1175db40af2" continuedAt="ief9eabca9625473e895fbed56378c17c"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMTg_fcdd9fe7-5ac9-4b6f-9a28-dfbdb093f368" continuedAt="iefa447daf1104d0c95930224dcd635af" escape="true">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iefa447daf1104d0c95930224dcd635af">The Company's cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMzE3_812d887a-de56-4990-a697-1a97f73ae51c">250,000</ix:nonFraction> per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company's primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company's corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents, marketable securities, and accounts receivable. The Company limited its credit risk associated with cash equivalents and marketable securities by investing in highly-rated money market funds, US government securities, and treasury securities. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial institutions.</ix:continuation> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNTQ5NzU1ODgwMDAw_1a5f37fa-7a57-48c3-a9cb-3261ea782d4f" continuedAt="i8846d4a644784406932247f8137371d1" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8846d4a644784406932247f8137371d1">The Company classifies all of its marketable securities as available-for-sale. The marketable securities consist of holdings in US treasury securities and US government securities, with maturity dates ranging from March 2023 to November 2023, which is consistent with the Company's investment policy. Accordingly, these investments are recorded at fair value which is determined based on quoted market prices. Amortization and accretion of discounts and premiums are recorded as interest income. Realized gains and losses are included in other income (expense), net. Unrealized gains and losses are included in other comprehensive loss as a component of stockholder&#8217;s equity (deficit) until realized.</ix:continuation> </span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMjk_be910785-7c5d-4de2-b97f-918a56f90b60" continuedAt="i20d90014a814438189fa43fbf4aefbb9" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of <ix:nonNumeric contextRef="i1276d33828844073b58b8708d329e283_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMTQxMg_f2435d4b-1ce2-4816-b3b3-89be888dc297">five years</ix:nonNumeric> for lab equipment, <ix:nonNumeric contextRef="ife760fe6115044c2ba0cfc773be36b66_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMTQzNA_653cbfef-2313-4a25-a139-047ad4acc850">four years</ix:nonNumeric> for furniture </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ief9eabca9625473e895fbed56378c17c" continuedAt="i28d3a228a4184d3aa19573e60d097285"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i20d90014a814438189fa43fbf4aefbb9">and fixtures, <ix:nonNumeric contextRef="id1f4a4968e654e81812812835738bfba_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMTQ2NQ_3fd1e18e-5ce6-4c09-8c17-89e67b33c3ea">three years</ix:nonNumeric> for computer equipment and software and the lesser of <ix:nonNumeric contextRef="i2bd951ea3e6843248bca81db2ab27548_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMTUyMg_837dab1f-2f3b-48b0-a6f5-66ffc2c38ac8">five years</ix:nonNumeric> or the remaining lease term for leasehold improvements.</ix:continuation></span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMzk_db564f79-e5ec-4426-951f-2ce8bb13eb10" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consisted of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in share price and a resulting decrease in its market capitalization. On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of its intangible asset of Vicineum E.U. rights. The Company concluded that the carrying value of its intangible asset of Vicineum E.U. rights of $<ix:nonFraction unitRef="usd" contextRef="iff61ad1254204984b2cd73c3460b9b29_D20220401-20220630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODU4OQ_b327b0bd-4419-4fe1-ab38-619f9fec3104">14.7</ix:nonFraction>&#160;million was fully impaired as of June 30, 2022 and was reduced to <ix:nonFraction unitRef="usd" contextRef="ied811451007444bf9c9766b4e6b6f65e_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODYwMw_aaba3b6b-dbc0-46f9-a6f0-a07fc2463dcc">zero</ix:nonFraction> in the second quarter of 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company received a Complete Response Letter ("CRL") from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing, and controls ("CMC") issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's marketing authorization application ("MAA"), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNDE2Mg_3cde8d47-d81a-4b86-82e4-d805cd1dd95a">31.7</ix:nonFraction> million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the United States market.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwNDE_be603711-ab8e-493d-893e-2a9d4ab6e8ff" continuedAt="i59e2da1b84584c179583039b8b71f48c" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheets is the result of the Company&#8217;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. The Company has only <ix:nonFraction unitRef="unit" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNzk3NA_1d499704-242f-4f07-81fa-b75a8835a3d6">one</ix:nonFraction> reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed continued trends in its market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, size, length and cost of a clinical trial, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of its typical annual assessment </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i28d3a228a4184d3aa19573e60d097285" continuedAt="i8d18f24b91544d30b502ea5ef060c71e"><ix:continuation id="i59e2da1b84584c179583039b8b71f48c"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. The Company updated its revenue forecast models based on further expected launch delays in both United States and outside of the United States ("OUS") regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. The Company also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $<ix:nonFraction unitRef="usd" contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNTQ5NzU1ODYzMTE2_243f16b7-0dda-4f54-86fb-8709d2a948fe">13.1</ix:nonFraction>&#160;million was fully impaired as of June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the annual testing and quarterly reviews performed, the Company concluded that there was <ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMTA3NjA_9793a857-795e-463d-9858-6fded67a621d">no</ix:nonFraction> goodwill impairment during the year ended December&#160;31, 2021.</span></div></ix:continuation><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="sesn:ContingentConsiderationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMzM_bbbdc31c-0207-4086-b725-69e66e582a5f" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September 2016. See "Note 1. Description of Business" above for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of its contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales were expected to be achieved through 2033, the level of commercial sales of Vicineum then-forecasted for the United States, Europe, Japan, China and other potential markets. Earnouts were determined using an earnout rate of <ix:nonFraction unitRef="number" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNzY5NjU4MTQzNjI5OA_bef47329-244d-4d3b-a0d9-3f9784fadebe">2</ix:nonFraction>% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the <ix:nonFraction unitRef="number" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNzY5NjU4MTQzNjM5OA_cd6ca8ec-4d15-42e2-a258-cd2bbfe8478a">2</ix:nonFraction>% earnout was derived from the Company's estimated weighted-average cost of capital, which has fluctuated from <ix:nonFraction unitRef="number" contextRef="i6bb37825c3464e0e96f96656c460f0b4_I20211231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNzY5NjU4MTQzNjUwMQ_36f09ead-3dcc-48e5-b174-b5ebd24e31b9">9.3</ix:nonFraction>% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was <ix:nonFraction unitRef="number" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNzY5NjU4MTQzNjcxMA_068e1bd2-bb45-442f-a41f-65f0368e1587">8.0</ix:nonFraction>% as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, it is seeking a partner for the further development of Vicineum. Accordingly, during the second quarter of 2022, the Company concluded that it is no longer expected to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential <ix:nonFraction unitRef="number" contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODYzNQ_cce03128-afa2-43c5-834a-c939f96230c5">2</ix:nonFraction>% earnout payment related to China, Hong Kong, Macau and Taiwan (collectively, &#8220;Greater China&#8221;) region since those territory rights had been out-licensed. Qilu Pharmaceutical, Co., Ltd. ("Qilu") held the exclusive license to develop Vicineum in the Greater China region, and accordingly, the $<ix:nonFraction unitRef="usd" contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODYzOQ_134ad5d6-a303-4b13-ae60-f9b7c4c09083">1.8</ix:nonFraction>&#160;million estimated earnout payment in the Greater China region remained as long-term contingent consideration as of June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, Qilu informed the Company that it no longer intended to commercialize Vicineum, due to additional effort and costs required to gain regulatory approval in that region without prior US approval. As such, the Company and Qilu were in the process of negotiating a termination of the Qilu License Agreement, which was terminated on December 23, 2022. Accordingly, the Company concluded that it no longer expected to owe any future earnout payments related to the Greater China region and reduced its remaining $<ix:nonFraction unitRef="usd" contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODY1Mw_79b76cfe-133b-4ae6-88fb-51a372b1e3af">1.8</ix:nonFraction>&#160;million of contingent consideration liabilities to <ix:nonFraction unitRef="usd" contextRef="i8733b9f5af3744478388e7790ab97043_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODY2Ng_91a645a5-70c1-4e11-af62-55bb25ec0cbf">zero</ix:nonFraction> as of September 30, 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMTU_630ff112-1d8f-4420-abf5-2788ff80a3e6" continuedAt="if949127fc62f4d059526a88143a10578" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio as of December 31, 2022 includes a property lease for its headquarters in Cambridge, MA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company&#8217;s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company's consolidated balance sheet. The short-term and long-term </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i8d18f24b91544d30b502ea5ef060c71e" continuedAt="iceea798428004df68c1b0e1d4186fde2"><ix:continuation id="if949127fc62f4d059526a88143a10578"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability components are recorded in other current liabilities and other liabilities, respectively, on the Company&#8217;s consolidated balance sheet. As of December&#160;31, 2022, the Company did not have any finance leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases.</span></div></ix:continuation><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMTY_13e5836e-a0e7-4d22-afa3-f230809995cd" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMzQ_26edffb4-ddb2-40f7-af08-2f23e8ed182c" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives' stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company&#8217;s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management&#8217;s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each grant of options during the years ended December&#160;31, 2022, 2021 and 2020 was determined using the following methods and assumptions:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term. G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iven the plain vanilla nature of the options granted by the Company, the expected term is determined using the "simplified" method, as prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 ("SAB 107"), whereby the expected life equals the arithmetic average of the vesting term (generally <ix:nonNumeric contextRef="i438fa29ca3bb484a8da013a3e14bb5aa_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjE5NjA_54d0a444-9662-4d4a-b5ce-3c73abb5bbc7">four years</ix:nonNumeric>) and the original contractual term (<ix:nonNumeric contextRef="i438fa29ca3bb484a8da013a3e14bb5aa_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjE5OTk_9319d716-4392-41f9-b1dc-d1e3ee0d6859">ten years</ix:nonNumeric>) of the option, taking into consideration multiple vesting tranches. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company's own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend Yield. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dividend yield is <ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjI2MDM_858bd771-6d77-4b96-b23b-8b9973e4d32f">0</ix:nonFraction>% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwNDI_8fe17a15-4789-49fc-8b03-2446810513ef" continuedAt="i511109cef17f46e4951721f56e3c59e8" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and research and development credit ("R&amp;D credit") carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="iceea798428004df68c1b0e1d4186fde2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i511109cef17f46e4951721f56e3c59e8">(greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&#160;31, 2022 and 2021, the Company did not have any uncertain tax positions.</ix:continuation></span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMzY_0d3eec9f-0967-4b49-aba5-a0a60ba397c5" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded revenue from former out-license agreements and OUS business development partnership agreements, including the former license agreement (the &#8220;Roche License Agreement&#8221;) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) and its former OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)   Identification of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)  Determination of whether the promised goods or services are performance obligations including whether they are                        distinct in the context of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)  Measurement of the transaction price, including the constraint on variable consideration&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)  Allocation of the transaction price to the performance obligations&#894; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)  Recognition of revenue when or as the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Regulatory Milestones and Other Payments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#8217;s estimate of milestones and royalties approximates the standalone selling price of the license.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, a $<ix:nonFraction unitRef="usd" contextRef="i4b69c2d148fb4538a3850c0e09af5f52_D20211201-20211231" decimals="-6" name="sesn:LicenseAgreementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjcxNzM_e3deb570-5570-4979-918d-62ff364a1439">20</ix:nonFraction>&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $<ix:nonFraction unitRef="usd" contextRef="i4b69c2d148fb4538a3850c0e09af5f52_D20211201-20211231" decimals="-6" name="sesn:LicenseAgreementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjcyNzc_0e26b0c3-5962-4750-a3db-d0ee88bd823f">20</ix:nonFraction>&#160;million with payment terms of <ix:nonNumeric contextRef="i4b69c2d148fb4538a3850c0e09af5f52_D20211201-20211231" name="sesn:LicenseAgreementMilestonePaymentTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjczMDI_e9c66b68-501f-43a0-94bf-fc7ca737d261">30</ix:nonNumeric> days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. Management evaluated the transaction under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous periods. Accordingly, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ideb2c67211a74687ab81a95f14fff15e_D20211001-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNTQ5NzU1ODYzMTY4_8ff2934d-f650-4dd1-978e-3a3b111660d4">20</ix:nonFraction>&#160;million as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $<ix:nonFraction unitRef="usd" contextRef="i60b94d2194694dd39ade84abefa3fbd2_D20220101-20220131" decimals="-6" name="sesn:LicenseAgreementProceedsFromMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNTQ5NzU1ODYzMTU1_04855a91-71e1-4963-9e4c-9431542fe65a">20</ix:nonFraction>&#160;million was received. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc3OTQ_74642238-1ef1-4c0a-868c-e816bc48f764">40.0</ix:nonFraction>&#160;million of license revenue related to the asset purchase agreement with Roche during the year ended December 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc5MTU_fe84932d-6ff2-47a1-8d80-98cee5733b1b">26.5</ix:nonFraction>&#160;million of license revenue related to the Roche, Qilu and Hikma License Agreements during the year ended December 31, 2021. </span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTEzMjkwNw_185a1486-e639-4dce-a7b9-6011d70d8f18" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss and other comprehensive loss. For the year ended December 31, 2022, other comprehensive loss included changes in unrealized income and loss on marketable securities. For the years ended December&#160;31, 2021 and 2020 comprehensive loss was equal to net loss.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85MS9mcmFnOjhhNDIwYmUyNjM1NTQ3ODU4NTM3NWRmYmM1ZjgxZTYyL3RleHRyZWdpb246OGE0MjBiZTI2MzU1NDc4NTg1Mzc1ZGZiYzVmODFlNjJfOTM1_005ada6a-7f00-4616-b6ec-c21bc695bc11" continuedAt="i32f8d368874c452abe6000f5bf475775" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS</ix:nonNumeric></span></div><ix:continuation id="i32f8d368874c452abe6000f5bf475775"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85MS9mcmFnOjhhNDIwYmUyNjM1NTQ3ODU4NTM3NWRmYmM1ZjgxZTYyL3RleHRyZWdpb246OGE0MjBiZTI2MzU1NDc4NTg1Mzc1ZGZiYzVmODFlNjJfOTM3_ef5be42d-6313-45de-bf52-e5c5e2b8de35" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share ("EPS") guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div></ix:nonNumeric></ix:continuation><div id="i6d755c213f784994a9d98b9e4ebda9e0_94"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNjAyOA_c827cbac-652d-4061-b925-84b1d6bba691" continuedAt="i3cb89f3557974431ab1ca5a0733bbf89" escape="true">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i3cb89f3557974431ab1ca5a0733bbf89" continuedAt="id4d228f3bcf9489c879c1e971a005704"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNjAyNQ_6fe77d2f-f5a7-45d7-84ec-a96d287934f6" continuedAt="i706d00c1cce143e586d68bd315ff5eb1" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s consolidated balance sheets approximated their fair values as of December&#160;31, 2022 and 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div></ix:nonNumeric><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:continuation id="i706d00c1cce143e586d68bd315ff5eb1" continuedAt="i90213eecb47f49afbc85b83e8c0d19a5">Level 3</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i90213eecb47f49afbc85b83e8c0d19a5">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="id4d228f3bcf9489c879c1e971a005704" continuedAt="i817c5baf475b46f5a9d10bba7e55ab72"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNjAyNg_d6b829de-0b2a-4ec7-8681-dc37d160d59f" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:13pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ea235079af435bad2ec47753289b96_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNC0xLTEtMS05MjM3NQ_7ac8dbcd-bf97-47a6-8bf7-05b9324c863b">76,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i494cedbff9d444cdaac1c2802663fc2b_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNC0zLTEtMS05MjM3NQ_9cf95432-d6dd-4dc1-926c-1b8eccf4ad01">76,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88aacf670d6d4b4d880e4b578f023b29_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNC01LTEtMS05MjM3NQ_b934be9d-255c-4cd3-ada8-6ffb3ddf25df">76,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b14fcd0c3d7431fa4d0dfee8ba33375_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNC03LTEtMS05MjM3NQ_5210d80a-5690-4e7c-af76-dc4d06ea933f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7077879bdc245db95b0560b33dc1e1d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNC05LTEtMS05MjM3NQ_12c18d6f-578c-4bf2-b1a7-b8e5dec3bd3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6b0b19859b4275a8ba10b9aa85008e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNi0xLTEtMS05OTA4Mw_77ab2fac-7f52-4235-9fdb-0c96bcd6adeb">49,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65e64d741e894999bf76a1e7cf64b004_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNi0zLTEtMS05OTA4Mw_7ce36fe0-336b-4ff3-aa58-38f1c0de847b">49,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89820af99a774c6da12e89d3f3b664cc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNi01LTEtMS05OTA4Mw_ed93703d-e39e-4a07-8c33-c3d7a25fb9e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f8f5e0d0c4144a4959bc06d609ca157_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNi03LTEtMS05OTA4Mw_45b4418b-9ced-40ae-a5b9-dae5c19141ca">49,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib898a55a349649d690d06fb7f3e654d8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNi05LTEtMS05OTA4Mw_a844234c-76b7-44e8-b602-a18d440da03a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id74fe8f2daef45e18f8d67cb5c61198b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfOC0xLTEtMS0xMDY2NzQ_60326fa6-a3cd-4599-b4cc-789eb2d35df0">4,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2efef4133dd04188a2f6d5ffc3064dcd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfOC0zLTEtMS0xMDY2NzQ_2c45f38a-1074-455f-afdb-d62f8ea9e373">4,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6f81f8bf0246f39eed469355ba430e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfOC01LTEtMS0xMDY2NzQ_cd07d5a1-26c6-43ca-a9c2-6be16b0e1f6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f40cef73b6f464299f697a3de9e26bc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfOC03LTEtMS0xMDY2NzQ_08386373-61f0-4fe9-9e57-41d39be9678c">4,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074825a299f84fcd81b16f4255ea2ad7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfOC05LTEtMS0xMDY2NzQ_550b33d1-4109-4cd6-b90c-3778aed9de4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917a1b8a73ae45318b8d10a7f14926dd_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNC0xLTEtMS05MjM3NQ_31bfd0e1-1b3e-49ae-9468-168b7e315880">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica10e8f91cd84acdbe3c5774e4168b74_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNC0zLTEtMS05MjM3NQ_37b31b07-dcf1-4266-bc21-188dd5937c64">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a8370652ea34632aa61254cc191c0a1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNC01LTEtMS05MjM3NQ_c04ab1d5-3218-45a3-a1f9-a723704affb9">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b6eb53935e4e5f9644289109556c1c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNC03LTEtMS05MjM3NQ_a582246f-da6e-41ef-85c5-1131d2f83892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c307f87ede64e08ba34df00d1e3be8e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNC05LTEtMS05MjM3NQ_f48d6503-cf25-465b-adc2-adc40067f94d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917a1b8a73ae45318b8d10a7f14926dd_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNy0xLTEtMS05MjM3NQ_90979d24-1824-489b-b4e0-0e2caf454838">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica10e8f91cd84acdbe3c5774e4168b74_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNy0zLTEtMS05MjM3NQ_d7355cab-2152-4ec1-8ec1-024390ad2a7e">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a8370652ea34632aa61254cc191c0a1_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNy01LTEtMS05MjM3NQ_059b851d-ff23-449a-94c5-797f386b8188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b6eb53935e4e5f9644289109556c1c_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNy03LTEtMS05MjM3NQ_a5b9daa7-55de-4536-bfb0-c56335c4d3f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c307f87ede64e08ba34df00d1e3be8e_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNy05LTEtMS05MjM3NQ_bf23753b-26fb-4efb-b405-7e1669e66a4d">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers valuations obtained from third party pricing sources when estimating the fair value of marketable securities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2025 to 2033, and the level of commercial sales of Vicineum then-forecasted for the United States, Europe, Japan, China, and other potential markets. Earnouts were determined using an earnout rate of <ix:nonFraction unitRef="number" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNzY5NjU4MTQwNzU5Nw_bef47329-244d-4d3b-a0d9-3f9784fadebe">2</ix:nonFraction>% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the <ix:nonFraction unitRef="number" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNzY5NjU4MTQwODIyOQ_cd6ca8ec-4d15-42e2-a258-cd2bbfe8478a">2</ix:nonFraction>% earnout was derived from its estimated weighted-average cost of capital, which was <ix:nonFraction unitRef="number" contextRef="i6bb37825c3464e0e96f96656c460f0b4_I20211231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNzY5NjU4MTQwODMxNg_36f09ead-3dcc-48e5-b174-b5ebd24e31b9">9.3</ix:nonFraction>% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was <ix:nonFraction unitRef="number" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNzY5NjU4MTQwODUyNQ_068e1bd2-bb45-442f-a41f-65f0368e1587">8.0</ix:nonFraction>% as of December&#160;31, 2021.</span></div></ix:continuation><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNjAyNw_51fe9992-97c9-404b-87c7-de26e24ea378" continuedAt="i72fa194836af4209aeee51a61e56c43d" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i817c5baf475b46f5a9d10bba7e55ab72"><ix:continuation id="i72fa194836af4209aeee51a61e56c43d"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"></td><td style="width:81.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6d796c44ea43198dc7c3fb8d6ae129_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmE4MjA2NGRmNWQ4NjRiNGRiMDlhN2E5MTFmYjA2YTI3L3RhYmxlcmFuZ2U6YTgyMDY0ZGY1ZDg2NGI0ZGIwOWE3YTkxMWZiMDZhMjdfMC0xLTEtMS05MjM3NQ_439d1c9a-379c-495f-ad88-68ca992177ff">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - long term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a1c5a91084f178b29a4fe51e14ea2_D20220101-20221231" decimals="-3" sign="-" name="sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmE4MjA2NGRmNWQ4NjRiNGRiMDlhN2E5MTFmYjA2YTI3L3RhYmxlcmFuZ2U6YTgyMDY0ZGY1ZDg2NGI0ZGIwOWE3YTkxMWZiMDZhMjdfMi0xLTEtMS05MjM3NQ_67286a7f-2d2c-47e3-8c10-6a845943f927">52,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39409440477849f689c25e277356952c_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmE4MjA2NGRmNWQ4NjRiNGRiMDlhN2E5MTFmYjA2YTI3L3RhYmxlcmFuZ2U6YTgyMDY0ZGY1ZDg2NGI0ZGIwOWE3YTkxMWZiMDZhMjdfMy0xLTEtMS05MjM3NQ_d0afee65-d8aa-4379-9915-cbd66cb1243e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of <ix:nonFraction unitRef="number" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfMjkwMg_5c40d60d-9815-4ef3-be9d-05e6f58a0bfb">2</ix:nonFraction>% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the <ix:nonFraction unitRef="number" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfMzAwMQ_42c7d715-f2cc-4ddd-acf0-af77f336d82e">2</ix:nonFraction>% earnout is derived from the Company&#8217;s weighted average cost of capital, which was <ix:nonFraction unitRef="number" contextRef="i6bb37825c3464e0e96f96656c460f0b4_I20211231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfMzA3NA_9df5d463-2b80-4745-ba8d-551b60e3faaa">9.3</ix:nonFraction>% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate was <ix:nonFraction unitRef="number" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfMzM4Nw_10fc0d5a-0390-4a2d-a51d-8006a469853f">8.0</ix:nonFraction>% as of December&#160;31, 2021. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, it is seeking a partner for the further development of Vicineum. Accordingly, the Company concluded that it is no longer expected to pay related milestone and earnout payments to the former shareholders of Viventia. Therefore, the Company&#8217;s contingent consideration liability as of December 31, 2022 was <ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfMjc0ODc3OTA5NDk5OA_0127d1ef-b142-4b4b-9113-bb3ced6d8e24">zero</ix:nonFraction>.</span></div></ix:continuation><div id="i6d755c213f784994a9d98b9e4ebda9e0_1212"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGV4dHJlZ2lvbjoyMzZlYTZmMTk1MTE0OGMzOTVkNjU2MjhhZTAwZjBhMF8yNzQ4Nzc5MDcxNzI2_9e483544-a034-44f0-8a65-f1897dace3c8" continuedAt="i09aaff00bc294891abf7c528585134b3" escape="true">RESTRICTED CASH AND MARKETABLE  SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i09aaff00bc294891abf7c528585134b3" continuedAt="id61ac74893594c0ea878fe07c334c23a"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's short-term restricted cash balance as of December 31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-5" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGV4dHJlZ2lvbjoyMzZlYTZmMTk1MTE0OGMzOTVkNjU2MjhhZTAwZjBhMF81NDk3NTU4MTY2NTc_5777559f-8c4b-4899-a161-0cacb4f3852d">21.0</ix:nonFraction>&#160;million. This represents the settlement amount of the Securities Litigation (as defined below in Note 11. &#8220;Commitment and Contingencies&#8221;), including the insurance carriers' coverage, which was funded into an escrow account in the fourth quarter of 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the court issued an order granting final approval of the settlement of the Securities Litigation. Accordingly, this matter is now resolved.</span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGV4dHJlZ2lvbjoyMzZlYTZmMTk1MTE0OGMzOTVkNjU2MjhhZTAwZjBhMF8yNzQ4Nzc5MDcyNzcy_6e9d1a9d-bd5b-4efc-85ba-c6d06e4af2be" continuedAt="i166b19904d794f7f994904b8405ef87b" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The  following table sets forth the composition of the Company&#8217;s marketable securities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"></td><td style="width:42.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i426ddaf2851e41c3b2b8a1b26933b3da_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV81LTEtMS0xLTEwNjA4OQ_af8ea22e-e347-4ac2-b525-d2f2fb56ece5">49,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i426ddaf2851e41c3b2b8a1b26933b3da_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV81LTMtMS0xLTEwNjEwMg_9726dc6c-1375-4b70-b2b8-2c3d9bc4b374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i426ddaf2851e41c3b2b8a1b26933b3da_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV81LTUtMS0xLTEwNjExMg_865e2eda-f0c3-4547-83c8-60ca182a4c54">508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i426ddaf2851e41c3b2b8a1b26933b3da_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV81LTctMS0xLTEwNjEyMA_53375022-5f04-4a53-9950-07c941ee92c4">49,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8260e3eaa13f41a3a609d11ef48a8540_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV82LTEtMS0xLTEwNjA4OQ_ca689fdf-6e12-4884-afcf-98ea779de6d2">4,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8260e3eaa13f41a3a609d11ef48a8540_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV82LTMtMS0xLTEwNjEwMg_0510cfb8-a408-4f21-89ac-e66dd9117f84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8260e3eaa13f41a3a609d11ef48a8540_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV82LTUtMS0xLTEwNjExMg_80d72a66-5272-4afa-a4d2-645dde09e201">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8260e3eaa13f41a3a609d11ef48a8540_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV82LTctMS0xLTEwNjEyMA_e4908a32-190a-4331-aaeb-d48c0f94ec01">4,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Marketable Securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV84LTEtMS0xLTEwNjI5OQ_0d9667ab-b6e6-434f-8eb4-9814fb71c71a">54,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV84LTMtMS0xLTEwNjI5OQ_490452d9-0b92-44a6-bfc5-2f5acb08af37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV84LTUtMS0xLTEwNjI5OQ_67955ed9-08e2-4cbe-9960-d9d23f07a127">546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV84LTctMS0xLTEwNjI5OQ_106532fc-1f81-47f5-a73d-5296447237a4">54,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id61ac74893594c0ea878fe07c334c23a"><ix:continuation id="i166b19904d794f7f994904b8405ef87b">The Company had no marketable securities as of December 31, 2021</ix:continuation></ix:continuation>.</span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_97"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMTIzNw_3218f56a-ef21-457d-9a9b-674feabb3ea1" continuedAt="i950c0d3f431546b2b1db8848076cb12f" escape="true">RECEIVABLES </ix:nonNumeric></span></div><ix:continuation id="i950c0d3f431546b2b1db8848076cb12f"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts receivable balance as of December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMjc0ODc3OTA3MjA1Nw_4fde7bad-2fac-47da-87b6-6eae9e034f55">21.0</ix:nonFraction>&#160;million, comprised primarily of a $<ix:nonFraction unitRef="usd" contextRef="if3cd4cc1171943f0abebe901bfe21fec_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMTA5_9db33699-33c2-4c2b-ab48-df8c6d60e5f2">20.0</ix:nonFraction>&#160;million milestone achieved in December 2021 due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $<ix:nonFraction unitRef="usd" contextRef="if3cd4cc1171943f0abebe901bfe21fec_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMjI2_92e2e434-74ab-430d-8e5d-833f166a4279">20.0</ix:nonFraction>&#160;million with payment terms of <ix:nonNumeric contextRef="i93938c1286d6418fb704e36349eb0d31_D20211201-20211231" name="sesn:AccountsReceivablePaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMjUx_1dc5e99d-8575-48a5-9cc2-92a62f71cdff">30</ix:nonNumeric> days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. In January 2022 the payment of $<ix:nonFraction unitRef="usd" contextRef="i9871161ad5a44399978150d031c7b8ce_D20220101-20220131" decimals="-6" name="sesn:LicenseAgreementProceedsFromMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMzk1_26e0d5b8-09d6-4e0a-9d43-63b55e6262ba">20.0</ix:nonFraction>&#160;million was received. Additionally, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". As such, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i71d9693f005d44b68ed0b5546044f4d8_I20210630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfNTk1_fe9aed0f-5858-472e-b34c-c8c543155488">0.9</ix:nonFraction>&#160;million of revenue and accounts receivable for the additional purchase price resulting from Qilu's obligation to pay Sesen Bio an amount equal to its recovery of VAT. The Company received this payment in the second quarter of 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfODk5_7a9ac267-03f9-4fc7-ab91-5acde1213a64">0.8</ix:nonFraction>&#160;million, primarily consisting of German VAT recovery related to drug substance sent to Baxter. The Company expects to collect the remaining balance in 2023. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMjc0ODc3OTA3MTQ5MQ_512e694e-f58e-4564-95ff-d3539418f80e">3.5</ix:nonFraction>&#160;million, primarily consisting of German VAT recovery related to drug substance sent to Baxter.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90ZXh0cmVnaW9uOjBkMTI3ODM2NWIyYzQyNzI5ZjFhNmY4NmJhYTg4NmI0XzI0MA_b216cfc1-3fd4-4a20-a18d-2010ef54ec36" continuedAt="i9bfb3e9b468d42a99ed6c4051e9f5ded" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i9bfb3e9b468d42a99ed6c4051e9f5ded" continuedAt="i2f2bfbb9d84642b7a1e27a376acbaaca"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90ZXh0cmVnaW9uOjBkMTI3ODM2NWIyYzQyNzI5ZjFhNmY4NmJhYTg4NmI0XzI0MQ_b3a6be3a-8ea6-4dc1-a5de-014e15f42b33" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of property and equipment, net as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34f56efef5946f89e9010b83ecc7d97_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzItMS0xLTEtOTIzNzU_1a862949-5121-4a62-9f55-4f95d9f884cf">94</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i611e9ad1d7694553bcda04f42fc4e80b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzItMy0xLTEtOTIzNzU_a9591f16-97c5-4cd2-89d6-96f0ca06f6b0">569</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df7ab1adf0148c78a21e7ce97a4d22f_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzMtMS0xLTEtOTIzNzU_045e1553-667c-4629-87af-076fb6714dde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id44669cb53d947d4ad326771aa7b9afe_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzMtMy0xLTEtOTIzNzU_9b192067-941f-4c20-a281-27465a41514c">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f414a7418a405588fb22be6f30e0c4_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzQtMS0xLTEtOTIzNzU_6da1172c-f5ff-4000-b4fa-820ce0b52c91">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i655ddc8bcc5848c5b1d7a3ff27a40ba1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzQtMy0xLTEtOTIzNzU_543e3aee-8c83-4539-98fe-789bdcd2d35a">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab420bf8ef045078703d770aad32427_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzUtMS0xLTEtOTIzNzU_b3d16cdb-658d-4f04-aad0-2f3bce8205e2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6e3f81d8d1b4f3f97c34c9b3d9b0f02_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzUtMy0xLTEtOTIzNzU_2293ac9b-ae90-4dc6-baea-f99631049e60">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife751660f97f4281991e4b6aa712c73d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzYtMS0xLTEtOTIzNzU_465c7c66-541d-447e-8150-67410168006a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d39b728d0147189730e15e9fd156c6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzYtMy0xLTEtOTIzNzU_7a2871b4-f5c7-42c7-a588-43d210c5e3e6">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzctMS0xLTEtOTIzNzU_849efd66-c1de-47ac-8009-c1a755002f7b">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzctMy0xLTEtOTIzNzU_78dd8640-017b-4e93-b19b-926e6f84c4ed">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzgtMS0xLTEtOTIzNzU_8815deb1-8d07-4db4-bd4c-28f5e3f8a79d">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzgtMy0xLTEtOTIzNzU_c35572d5-89b8-4eda-a72a-0b7592931369">966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Property and Equipment, Net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzktMS0xLTEtOTIzNzU_95ac216c-95d7-4987-bf9b-8a0e5c16304e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzktMy0xLTEtOTIzNzU_af9def2e-e461-4b4d-97e6-274738bbb0c6">43</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f2bfbb9d84642b7a1e27a376acbaaca">Depreciation expense was de minimis, $<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90ZXh0cmVnaW9uOjBkMTI3ODM2NWIyYzQyNzI5ZjFhNmY4NmJhYTg4NmI0XzE3Mg_e0c22616-51ab-439c-b234-fa305b1d9cbf">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90ZXh0cmVnaW9uOjBkMTI3ODM2NWIyYzQyNzI5ZjFhNmY4NmJhYTg4NmI0XzE3OQ_c04d9796-3a8b-461e-8e6c-2b276c3afef5">0.1</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</ix:continuation> </span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_103"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzY5MjA_650998bd-3f07-42d3-a9b2-0de5fce70092" continuedAt="if22142479470439aa399a76b0e13f393" escape="true">INTANGIBLES AND GOODWILL</ix:nonNumeric></span></div><ix:continuation id="if22142479470439aa399a76b0e13f393" continuedAt="i93e1fae0410045ae94073954e77907e7"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's consolidated balance sheet were the result of the Viventia Acquisition in September 2016. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzY5MjE_340f9234-fb16-421a-9b57-11db0075d65c" continuedAt="iaa9a718b7e9242f7b1940a6b238e7043" escape="true">The following table sets forth the composition of intangible assets as of December&#160;31, 2022 and 2021 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><ix:continuation id="iaa9a718b7e9242f7b1940a6b238e7043"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum United States rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c243529fbd4ad2a365269cda0a0347_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzMtMS0xLTEtOTIzNzU_ce8d9d09-29f6-47fc-ae4a-4c79c39beddc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf382fe4d8647e58e6ad3d32e4f377c_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzMtMy0xLTEtOTIzNzU_89b5507b-1b69-4340-bbba-79be397ad399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21ae50c8649402492cc8890f61aece0_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzQtMS0xLTEtOTIzNzU_4a53836c-590d-409b-b31a-88f42a40c579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6fca7ca9a1e4c2bb4c5439eaa2b6d6a_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzQtMy0xLTEtOTIzNzU_22061154-7740-4d27-bbad-fa67d368c8f8">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50aaf5a9d1c54113a3349e45d1378020_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzUtMS0xLTEtOTIzNzU_b70ec735-a95e-455a-8d01-9122b3053fee">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica22b69fbf7d46f5a9b967bc6cee46d9_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzUtMy0xLTEtOTIzNzU_abd5ef05-e64b-4db9-9da2-64b14c226886">14,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired intangible assets for the United States and E.U. rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in share price and a resulting decrease in its market capitalization. On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of its intangible asset of Vicineum E.U. rights. The Company concluded that the carrying value of its intangible asset of Vicineum E.U. rights of $<ix:nonFraction unitRef="usd" contextRef="iff61ad1254204984b2cd73c3460b9b29_D20220401-20220630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzI3NDg3NzkwODgxNDE_709d340a-0f65-46b8-a424-ad5604a2f468">14.7</ix:nonFraction>&#160;million was fully impaired as of June 30, 2022 and was reduced to <ix:nonFraction unitRef="usd" contextRef="ied811451007444bf9c9766b4e6b6f65e_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzI3NDg3NzkwODgxNTU_a120e3e5-ea43-49b7-afcd-df12a07d6968">zero</ix:nonFraction> in the second quarter of 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's MAA, an interim impairment analysis </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i93e1fae0410045ae94073954e77907e7"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0Xzc2OTY1ODE0MDUxNjA_3cde8d47-d81a-4b86-82e4-d805cd1dd95a">31.7</ix:nonFraction> million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the United States market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheet is the result of the Viventia Acquisition in September 2016. Goodwill had <ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzU0OTc1NTgzMjYzOA_8275c674-2104-49ee-9ee7-4f1718727e99">no</ix:nonFraction> carrying value as of December&#160;31, 2022 and had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzQyNDQ_27dcb272-5638-4868-bbba-4a0c0e78f8f6">13.1</ix:nonFraction>&#160;million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed continued trends in its market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, size, length and cost of a clinical trial, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of its typical annual assessment date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. The Company updated its revenue forecast models based on further expected launch delays in both United States and OUS regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. The Company also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $<ix:nonFraction unitRef="usd" contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzU0OTc1NTgzMjY0Mw_07bd440e-6b78-4a20-bc2c-943eec910515">13.1</ix:nonFraction>&#160;million was fully impaired as of June 30, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the annual testing and quarterly reviews performed, the Company concluded that there was <ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0Xzc2OTY1ODE0MTA0MzU_9793a857-795e-463d-9858-6fded67a621d">no</ix:nonFraction> goodwill impairment during the year ended December&#160;31, 2021.</span></div></ix:continuation><div id="i6d755c213f784994a9d98b9e4ebda9e0_106"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90ZXh0cmVnaW9uOjMzMGZkY2ZkOTFiNDQ5MWZiMjZmMmUzZDA5YWMzZjA2XzEyNQ_3498c16d-c881-4033-b17a-75a2a7cdcdbe" continuedAt="i749cb2a1bbd740f8b63ea7ecb66662fa" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="i749cb2a1bbd740f8b63ea7ecb66662fa"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90ZXh0cmVnaW9uOjMzMGZkY2ZkOTFiNDQ5MWZiMjZmMmUzZDA5YWMzZjA2XzEyNg_08dc5ef8-d0d5-4ea8-aa7a-113c75ecd6f1" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:67.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzItMS0xLTEtOTIzNzU_740f0f9f-fd77-4b67-90d6-935c091c528e">40</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzItMy0xLTEtOTIzNzU_fb332504-1c94-4689-a798-d4b3315da829">1,841</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzMtMS0xLTEtOTIzNzU_ba2f3eef-2819-4b4b-97a6-dcf8a88dd939">1,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzMtMy0xLTEtOTIzNzU_acd11e0e-11a4-4407-ae78-9c3837fb088c">2,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzQtMS0xLTEtOTIzNzU_6f905c40-04db-41f1-b5ba-e3d66cfd47d2">5,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzQtMy0xLTEtOTIzNzU_85248e81-e4fc-405b-a286-2f5e6c2f59ef">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzUtMS0xLTEtOTIzNzU_3c2888e0-dd3b-4eb3-81bf-ac34891c3d18">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzUtMy0xLTEtOTIzNzU_ea2ba64f-7e03-477f-9158-4bd3348bee37">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal expenses, including the preliminary securities litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="sesn:AccruedLegalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzYtMS0xLTEtOTQ4NjI_5cb5f849-2596-42b6-b866-2d8cd2ae67ea">21,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="sesn:AccruedLegalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzYtMy0xLTEtOTQ4NjI_bb8b2b45-f429-49d5-8f2e-917fffada3cd">1,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzYtMS0xLTEtOTIzNzU_dfa2cefe-1818-4cf8-bff9-987a0a1912bc">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzYtMy0xLTEtOTIzNzU_f279858f-ed25-4e86-8fc4-73a6a920ca66">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzctMS0xLTEtOTIzNzU_92e38554-53a7-4fb1-8df3-139dfc73038d">29,636</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzctMy0xLTEtOTIzNzU_2b205498-efa0-48cc-89ce-c573f0665b41">8,255</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i6d755c213f784994a9d98b9e4ebda9e0_109"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0NDg_fee58c28-47cf-4885-8cc5-d7bf4f0ce981" continuedAt="i8aa3807d482c409da26732a6ba520bde" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i8aa3807d482c409da26732a6ba520bde" continuedAt="ic514026856d041b58fdeb2f7745bae18"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, <ix:nonFraction unitRef="lawsuit" contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0OTc1NTg1OTkyNg_7d41d685-47ed-4ed5-999e-0cb31aec84dc">three</ix:nonFraction> substantially identical securities class action lawsuits captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bibb v. Sesen Bio, Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., Case No. 1:21-cv-07025, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cizek v. Sesen Bio, Inc., et. al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-07309 and M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">arkman v. Sesen Bio, Inc. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the United States District Court for the Southern District of New York. The <ix:nonFraction unitRef="lawsuit" contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0OTc1NTg1OTk0MQ_584b8a10-fd1f-4162-b070-7bb4b05b0208">three</ix:nonFraction> complaints alleged violations of Sections 10(b) </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ic514026856d041b58fdeb2f7745bae18" continuedAt="ie6d57cb23cea4362b6c64f44c4eb9aa6"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The <ix:nonFraction unitRef="lawsuit" contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0OTc1NTg1OTk0Ng_5503728a-312d-4b24-8f34-9b2455913c82">three</ix:nonFraction> complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the <ix:nonFraction unitRef="lawsuit" contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0OTc1NTg1OTk1MQ_60a85571-2b90-4513-9fa7-1029d0034767">three</ix:nonFraction> cases under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Sesen Bio, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (collectively, the &#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. On November 24, 2021, defendants filed a motion to transfer venue to the United States District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleged the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022, and that motion was fully briefed on May 6, 2022. On June 3, 2022, before the court ruled on the motion to dismiss, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. On June 30, 2022 and July 6, 2022, the Company and the plaintiffs engaged in mediation sessions in an attempt to resolve the Securities Litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which was filed with the court on August 17, 2022. The Stipulation and Agreement of Settlement related to the Securities Litigation provides for a settlement payment of $<ix:nonFraction unitRef="usd" contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231" decimals="-5" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzI3NDg3NzkwOTgzMTU_fe565eb7-aacc-4cd2-a906-aeb8f8b17007">21.0</ix:nonFraction>&#160;million to the class and the dismissal of all claims against the Company and the other defendants. On September 1, 2022, the United States District Court for the Southern District of New York issued an order denying the motions to appoint a different lead plaintiff. On September 28, 2022, the court issued an order granting preliminary approval of the proposed settlement of the Securities Litigation. The settlement payment of $<ix:nonFraction unitRef="usd" contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231" decimals="-5" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzEwOTk1MTE2NzMwMDk_1de92a3a-236f-442f-8ae1-10c1b5781f55">21.0</ix:nonFraction>&#160;million, including the insurance carriers coverage, was funded into an escrow account in the fourth quarter of 2022. Accordingly, $<ix:nonFraction unitRef="usd" contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231" decimals="-5" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzEwOTk1MTE2NzMxNDU_ab6174d9-bc56-459d-99ac-a6f63b4e84bf">21.0</ix:nonFraction>&#160;million remained in restricted cash on the Company's balance sheet as of December 31, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the court issued an order granting final approval of the settlement of the Securities Litigation. Accordingly, this matter is now resolved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myers v. Sesen Bio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-11538 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">D&#8217;Arcy v. Sesen Bio, Inc., et. al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the United States District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tang v. Sesen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers (the &#8220;State Derivative Litigation&#8221;). The <ix:nonFraction unitRef="lawsuit" contextRef="ic2c8425e295a4831bc9d718ca118ecff_I20221231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0OTc1NTg1OTkxMg_7bbfe00d-9a95-41ef-ae8a-55aeb4249b92">three</ix:nonFraction> derivative complaints alleged breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleged unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints sought unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Sesen Bio, Inc. Derivative Litigation, Lead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On July 6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in mediation in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2022, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims (collectively, the &#8220;Derivative Litigation&#8221;). Pursuant to that agreement, the individual defendants will cause the Company to adopt certain enhancements to its corporate governance policies and procedures. In exchange, plaintiffs will dismiss the Derivative Litigation and, on behalf of the Company, provide broad customary releases to the individual defendants. On August 22, 2022, the parties entered into a Stipulation of Settlement to settle the Derivative Litigation, which was filed with the court on August 30, 2022. The Stipulation of Settlement related to the Derivative Litigation confirms that the Company previously adopted certain corporate governance enhancements in response to, among other things, the filing of the Derivative Litigation, and that, subject to final court approval, the Company will adopt additional corporate governance enhancements. The Stipulation of Settlement also provides for a $<ix:nonFraction unitRef="usd" contextRef="ia1c302f137734bc69da3529bc113e959_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzI3NDg3NzkwOTgzMzE_6f893a2e-088c-4b50-8976-35542a0a38da">630,000</ix:nonFraction> payment for plaintiffs&#8217; attorneys' fees due to the benefits the corporate governance enhancements are intended to provide to the Company. The payment of plaintiffs&#8217; attorneys' fees is being funded by the Company. On September 2, 2022, the court issued </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ie6d57cb23cea4362b6c64f44c4eb9aa6"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an order granting preliminary approval of the Stipulation of Settlement related to the Derivative Litigation. On November 8, 2022, the court issued an order granting final approval of the Stipulation of Settlement related to the Derivative Litigation. Accordingly, this matter is now resolved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 28, 2022, a purported stockholder filed a complaint in the United States District Court for the Southern District of New York against the Company and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keller v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:22-cv-10085 (S.D.N.Y.) (the &#8220;Original Keller Complaint&#8221;). The Original Keller Complaint asserted claims against the Company and its board of directors under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement on Form S-4 (File No. 333-267891) (the "Registration Statement") in connection with the Merger and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and sought, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs. On December 20, 2022, the purported stockholder voluntarily dismissed the Original Keller Complaint and on December 21, 2022, filed a new complaint as a putative class action in the Court of Chancery for the State of Delaware, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keller v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 2022-1186 (Del. Ch. Dec. 21, 2022) (the &#8220;New Keller Complaint&#8221;). Along with the complaint, the purported stockholder filed motions for expedited proceedings and for a preliminary injunction to enjoin the Special Meeting. The New Keller Complaint and associated filings contain substantially the same assertions as the Original Keller Complaint, and seek, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2023, a purported stockholder filed a complaint in the United States District Court for the District of Delaware against the Company and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumley v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:23-cv-00131 (D. Del.) (the &#8220;Plumley Complaint&#8221;). The Plumley Complaint asserts claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement in connection with the Merger and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs. On February 7, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against the Company and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Franchi v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 1:23-cv-01041 (S.D.N.Y.) (the &#8220;Franchi Complaint&#8221;). The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. Additionally, on February 9, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against the Company and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Menzer v. Sesen Bio, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, et al., 23-cv-01119 (S.D.N.Y.) (the &#8220;Menzer Complaint&#8221;). The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint and the Franchi Complaint.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2022, November 4, 2022, February 8, 2023, February 13, 2023 (as updated on February 15, 2023) and February 17, 2023, the Company received letters from purported stockholders (collectively, the &#8220;Demand Letters&#8221;) demanding that the Company amend the Registration Statement to provide additional disclosures that such stockholders allege were improperly omitted from the Registration Statement, including information regarding the financial projections for Carisma, the financial analyses performed by the Company&#8217;s financial advisor in support of its fairness opinion, and the background and process leading to the execution of the Merger Agreement. In addition, the Company received a books and records demand, dated November 18, 2022 (the &#8220;Section 220 Demand&#8221;), on behalf of a purported stockholder of the Company seeking access to certain relevant books and records of the Company&#8217;s pursuant to Section 220 of the Delaware General Corporation Law in connection with the Merger and the securities and derivative litigations arising out of the CRL that the Company received from the FDA. The Section 220 Demand states that the purpose of the demand is to, among other things, investigate purported questions of director independence and disinterestedness and the possibility of wrongdoing, mismanagement, and/or material non-disclosure related to the Company board&#8217;s approval of the Merger and the other transactions contemplated thereby and to determine whether suit should be brought in connection therewith.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the claims asserted in the Demand Letters, the Section 220 Demand, the New Keller Complaint, the Plumley Complaint, the Franchi Complaint and the Menzer Complaint are without merit and intends to vigorously defend against them. At this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Employment Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements and offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzIwMjM_a983d3f7-aae2-432f-ba6f-72b899793ba8" continuedAt="id7c87a24b8604cebb0da8324f520cdf9" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="id7c87a24b8604cebb0da8324f520cdf9"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio included an operating lease for its <ix:nonFraction unitRef="sqft" contextRef="iebe3ee0020554764957e449756650c1d_D20220101-20221231" decimals="-2" name="sesn:OperatingLeasesAreaOfOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzE1Mw_77813780-9e09-4ba9-96d3-0c35e2dc29f1">31,100</ix:nonFraction> square foot facility in Winnipeg, Manitoba which consisted of manufacturing, laboratory, warehouse, and office space. During the third quarter of 2022, the Company entered into a Lease Termination Agreement (the &#8220;Lease Termination Agreement&#8221;) pursuant to which the Company terminated its operating lease agreement. As part of the execution of the Lease Termination Agreement, the Company paid the landlord the all-inclusive sum of CAD $<ix:nonFraction unitRef="cad" contextRef="i0673287f84aa4bb4988c54a1565f24ce_D20220701-20220930" decimals="-5" name="sesn:OperatingLeaseLeaseTerminationPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzMzc_91493686-0b58-463d-b583-780564fe7339">1.2</ix:nonFraction>&#160;million (USD $<ix:nonFraction unitRef="usd" contextRef="i0673287f84aa4bb4988c54a1565f24ce_D20220701-20220930" decimals="-5" name="sesn:OperatingLeaseLeaseTerminationPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNTE_1df2c650-3894-46e1-b34b-94eab49f44b9">0.9</ix:nonFraction>&#160;million). Operating lease cost under this lease were $<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzgwMg_98a73225-dcd5-4f1e-9491-78f99354ad51">0.2</ix:nonFraction>&#160;million for the year ended December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzg0NQ_f7e1563b-f9f7-45da-a952-1244b350f803">0.3</ix:nonFraction>&#160;million for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of use asset total was <ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzU0OTc1NTgyNTI3OQ_c7240406-d398-44d0-8eba-4a792d6f965b">zero</ix:nonFraction> as of December 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-2" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNjY_4a45b3ac-40ba-408c-914e-e79cd329e56a">123,300</ix:nonFraction> as of December 31, 2021. As of December 31, 2021, the asset component of the Company&#8217;s operating leases was recorded as operating lease right-of-use assets and reported within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzU_722ba763-9575-481e-82ea-4900d469c804"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzU_e7bf87fd-276f-41e8-a126-4410ad3340e7">other assets</span></span> on the Company's condensed consolidated balance sheets. The short-term lease liability was <ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzU0OTc1NTgyNTI5MQ_a4df5fb3-cd9d-4faf-ac8f-4666488261e7">zero</ix:nonFraction> as of December 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-2" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzg_b891f302-de85-4d85-9f5d-05362c2307e8">123,300</ix:nonFraction> as of December 31, 2021. As of December 31, 2021, the short-term lease liability was recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzODc_0f5642b4-7404-4c0d-8695-7cd3f0d7638d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzODc_e3383e46-0bd5-473a-9c94-1fb2c501553a">other current liabilities</span></span> on the Company&#8217;s condensed consolidated balance sheets. There was no long-term operating lease liability as of December 31, 2022 or December 31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The minimum monthly rent for these office spaces is $<ix:nonFraction unitRef="usd" contextRef="i973f2496cf69482fb40920ac6f30b991_D20220101-20221231" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzcxNDY4MjU1OTEzOTk_e004d9a0-3de2-41d4-b649-4cdbd44809de">2,500</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ibaf5b39852dc407e946c46788b3a04b6_D20220101-20221231" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzcxNDY4MjU1OTE0MDc_af860a68-15ab-4416-ac62-cd6dd0b1e0be">18,000</ix:nonFraction>, respectively. The Company terminated the Philadelphia lease on December 31, 2022 and plans to terminate the Cambridge lease in connection with the closing of the anticipated Merger with Carisma. The short-term lease in Cambridge ends in June 2023.</span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzIwMjY_f11fa54a-9a37-491b-8c85-4ac491ed6b5d" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December&#160;31, 2022 and 2021 is as follows (in thousands):</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease Cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease (including related operating costs)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzItMS0xLTEtOTIzNzU_6ca8e04e-169c-4fb1-87db-fe66a43b8faf">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzItMy0xLTEtOTIzNzU_975beed2-e171-4b3b-b146-470e0977b0d7">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term property leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzMtMS0xLTEtOTIzNzU_de126b50-6ae3-4969-b116-4550f1cfa5a0">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzMtMy0xLTEtOTIzNzU_347b5b31-9544-4535-b512-c303c90eb258">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzQtMS0xLTEtOTIzNzU_d75207ad-83a1-486f-a2af-413d86a8d80c">458</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzQtMy0xLTEtOTIzNzU_79504842-f105-4b2c-ad92-9a7053f3bd17">589</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Supplemental Information:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZTpmZDdlMWU2MWFjZDM0N2NlOGI5M2JlODFmYjAxZjM1YS90YWJsZXJhbmdlOmZkN2UxZTYxYWNkMzQ3Y2U4YjkzYmU4MWZiMDFmMzVhXzEtMS0xLTEtOTIzNzU_368110ea-f46b-462c-84c7-da44aad80f46">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZTpmZDdlMWU2MWFjZDM0N2NlOGI5M2JlODFmYjAxZjM1YS90YWJsZXJhbmdlOmZkN2UxZTYxYWNkMzQ3Y2U4YjkzYmU4MWZiMDFmMzVhXzEtMy0xLTEtOTIzNzU_493d58dd-5910-414d-b4fc-db9740ac7adf">0.75</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZTpmZDdlMWU2MWFjZDM0N2NlOGI5M2JlODFmYjAxZjM1YS90YWJsZXJhbmdlOmZkN2UxZTYxYWNkMzQ3Y2U4YjkzYmU4MWZiMDFmMzVhXzItMS0xLTEtOTIzNzU_919def92-3c36-42cb-bfd0-e5e9ca709386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZTpmZDdlMWU2MWFjZDM0N2NlOGI5M2JlODFmYjAxZjM1YS90YWJsZXJhbmdlOmZkN2UxZTYxYWNkMzQ3Y2U4YjkzYmU4MWZiMDFmMzVhXzItMy0xLTEtOTIzNzU_92042a4d-a7c6-4ac7-8379-da9db782f40b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i6d755c213f784994a9d98b9e4ebda9e0_115"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzExMTYy_758def7b-0924-47b0-89ff-26132202f472" continuedAt="i663fcded38384ea68eef2cc302211d33" escape="true">STOCKHOLDERS' EQUITY (DEFICIT)</ix:nonNumeric></span></div><ix:continuation id="i663fcded38384ea68eef2cc302211d33" continuedAt="i9dfaae1c1b6f4daba9862d338ef973be"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which the Company may issue and sell shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i5f88572fbcae4d3b843b90b31979aadf_I20191130" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI4Mw_87e2d109-084c-430c-98ca-892a0a84e0af">0.001</ix:nonFraction> per share, from time to time (the &#8220;ATM Offering&#8221;) for an aggregate sales price of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i2761fdbe240c456bb83255f46df5df11_D20191101-20191130" decimals="-5" name="sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzU0OTc1NTgyNTc2MQ_ca22101d-f8c4-4944-ab1a-80262975de27">35.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through Jefferies. In October 2020 and February 2021, the Company entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively. Amendments No. 1 and No. 2 modified the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $<ix:nonFraction unitRef="usd" contextRef="i0f7e4670d4c7461595be03c9af5334ba_D20201001-20201031" decimals="-5" name="sesn:SaleOfStockAdditionalSharesAuthorizedForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzcxOQ_d2012f50-3e97-42f2-ab66-f0280afc494b">50.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8cda9cd3a8574fc2a6b9461f91c4497c_D20210201-20210228" decimals="-5" name="sesn:SaleOfStockAdditionalSharesAuthorizedForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzcyNg_ca1590d8-dbdb-435c-97f5-3c926b8c8db8">34.5</ix:nonFraction>&#160;million, respectively. In June 2021, the Company entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i87f4d91941044efabca8fc31db5686f0_D20210601-20210731" decimals="-6" name="sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzExMDc_692c14de-0d45-47e9-a15b-265e76c267a5">200.0</ix:nonFraction>&#160;million of common stock pursuant to the Sale Agreement. Sales are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Capital Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i9dfaae1c1b6f4daba9862d338ef973be" continuedAt="i6e22ad1bd74642a49387333f64cb4589"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to <ix:nonFraction unitRef="number" contextRef="i2761fdbe240c456bb83255f46df5df11_D20191101-20191130" decimals="INF" name="sesn:SaleOfStockCommissionFixedRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzIxMjk_f7b7d584-aae4-449a-b402-93a44e01610f">3.0</ix:nonFraction>% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the year ended December 31, 2022. The Company raised</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i6a4e17d327564862bc9c9d71d1aabc8f_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzIzNzM_703e137b-8daa-4eca-900b-0ad2fbd59f68">175.0</ix:nonFraction> million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="i6a4e17d327564862bc9c9d71d1aabc8f_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI0MDk_baf18886-bb34-4a61-a488-56bfe9f947a6">56.9</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock at a weighted-average price of</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6a4e17d327564862bc9c9d71d1aabc8f_D20210101-20211231" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI0NjY_c2ab01d0-fd11-4e1d-8fc5-e3d13bdf0ca4">3.17</ix:nonFraction></span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share during the year ended December&#160;31, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $<ix:nonFraction unitRef="usd" contextRef="i6a4e17d327564862bc9c9d71d1aabc8f_D20210101-20211231" decimals="-5" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI1OTk_fd1917e3-3f4e-449a-af6e-a881d7f61280">5.4</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the year ended December 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 2019 Financing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company raised $<ix:nonFraction unitRef="usd" contextRef="i8cdc8306a15942548c12172f72054f94_D20190601-20190630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI3MTA_989dfeaf-2667-4eb0-b002-d20b91c84898">27.8</ix:nonFraction> million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="i8cdc8306a15942548c12172f72054f94_D20190601-20190630" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI3NDY_66605fef-645a-4d40-baee-48f223e34913">20.4</ix:nonFraction> million shares of common stock and accompanying warrants to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i84030fd2a4514267a4a2169a1b8e2e55_I20190630" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI4MjQ_350def16-f797-4a0b-9f3e-fd5f89854250">20.4</ix:nonFraction> million shares of common stock in an underwritten public offering (the "June 2019 Financing"). The combined purchase price for each share of common stock and accompanying warrant was $<ix:nonFraction unitRef="usdPerShare" contextRef="i84030fd2a4514267a4a2169a1b8e2e55_I20190630" decimals="2" name="sesn:CommonStockAndWarrantOrRightsPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzMwMDI_48558d87-05ef-4d72-9391-1b70787047ab">1.47</ix:nonFraction>. Subject to certain ownership limitations, the warrants issued in the June 2019 Financing were exercisable immediately upon issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i84030fd2a4514267a4a2169a1b8e2e55_I20190630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzMxNjI_1b7a7928-00e2-4117-94b6-db529186b8f8">1.47</ix:nonFraction> per share, subject to adjustments as provided under the terms of such warrants, and had a <ix:nonNumeric contextRef="i84030fd2a4514267a4a2169a1b8e2e55_I20190630" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzExMTY3_3d90cc7e-17c9-49b0-ba29-2a046d2547fb">one-year</ix:nonNumeric> term that expired on June 21, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Certificate of Incorporation, the Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM0NTU_bab101c1-fdf2-44a6-be70-1a9e8deda731">5.0</ix:nonFraction> million shares of "blank check" preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM0OTk_7ce2a466-ff56-4a05-9905-4b57e6894e9a">0.001</ix:nonFraction> par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had <ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM5NDM_3168377f-803e-4394-b281-ca26ee9f42e5"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM5NDM_55c731f8-cc9f-4e39-b217-153d05301eb7"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM5NDM_572eda60-7669-4884-ad6b-d03e6136c9a6"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM5NDM_714880f6-fe4b-43a1-b40a-650376389c13">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preferred stock issued and outstanding as of December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="i653d509451834b36b0c7c25dd6f1e8ea_I20210502" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyMTQ_bedff809-4c5f-4789-8d1d-ad02da68c547">200</ix:nonFraction>&#160;million to <ix:nonFraction unitRef="shares" contextRef="i26100f264698454388e652d4dcede710_I20210503" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyMjA_ef0056ff-5e9a-49a0-b787-0893cec0f9f3">400</ix:nonFraction>&#160;million, of which</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyMzM_0488ff24-332a-4421-991b-14dde43702ff"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyMzM_170fed70-1f19-4c05-8675-ae1d164c8add">203</ix:nonFraction></ix:nonFraction>&#160;million and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyNDA_5099b3d5-5591-4dcc-80f6-7f471898768b"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyNDA_c6ddb903-39ee-4235-bf7b-a99939a406d8">199</ix:nonFraction></ix:nonFraction>&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of December&#160;31, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzExMTY2_dae48cc5-b495-418b-8e68-51b1f3bbadec" continuedAt="id3c69aaff2cd4ec4b87e4dda548ace58" escape="true">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&#160;31, 2022 and 2021 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:15pt;text-align:center"><ix:continuation id="id3c69aaff2cd4ec4b87e4dda548ace58"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:67.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzItMS0xLTEtOTIzNzU_d1b76ae5-993f-4b07-a395-ac05304bb604">202,759</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzItMy0xLTEtOTIzNzU_165acb63-85cc-43e9-897e-5154e7ddec4d">199,464</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34e59a9de0bb4644baea5c1090868f0b_I20221231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzQtMS0xLTEtOTIzNzU_77143b0f-3b17-4ab8-a35f-03bdaf3fecd5">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1bd6743eae8e4cfdbb03b06c8b121eee_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzQtMy0xLTEtOTIzNzU_1b3973b7-d99b-48b4-bed6-a7288ee8d3ae">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2979721cc12044649222cc680229209d_I20221231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzUtMS0xLTEtOTIzNzU_04d930cc-6238-4295-a86a-a867c4c622aa">15,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fff5776971a48a586881cd89287df3c_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzUtMy0xLTEtOTIzNzU_fa22671b-a27b-45c7-8a58-b3cf277bee18">15,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i106b662daae24333b435aacc7c1a07b0_I20221231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzYtMS0xLTEtOTIzNzU_ac7bca42-3fd1-43a9-8ea3-fb29204b7b83">4,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72d9266aa5eb429b9daf124e3bbc9a6f_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzYtMy0xLTEtOTIzNzU_68bdfbe8-5c18-4304-a012-2e205d3179c3">3,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8327d77c1755491d93d7990856f3cc52_I20221231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzctMS0xLTEtOTIzNzU_de4ca502-a834-4c6a-9832-913ef8a28a65">4,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i019d2729b50e475f80b2f52267d77679_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzctMy0xLTEtOTIzNzU_8fdaa073-1f18-4c1a-a640-92c776ad8741">8,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica9046a3714e4afebe942291c8bb1be6_I20221231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzgtMS0xLTEtOTIzNzU_0d3c42de-21bf-4f67-8b7b-ea1b59b89801">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9f2bff1e4304c31873755098104fc76_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzgtMy0xLTEtOTIzNzU_a334cce5-572c-4096-81c4-740237ac8435">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzktMS0xLTEtOTIzNzU_a0ea51f9-9b89-40ae-8e06-a5667b6d74ce">229,777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzktMy0xLTEtOTIzNzU_4c63562d-892b-4df7-8ebd-f54f4a1a7b51">229,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="i822d046be15341d59a14431cd169a913_D20220101-20221231" decimals="INF" name="sesn:NumberofVotesEntitledForEachShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQ3MTg_2d051f16-89e0-4870-9f2f-4af22f1b989d">one</ix:nonFraction> vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i6e22ad1bd74642a49387333f64cb4589" continuedAt="i2bb92c93f088451a967b58c167ed3712"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 815-40")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzExMTY1_baa883c0-11e0-4d21-bc37-6de8f52e1dd9" continuedAt="i54b4a45f49844b369bcbbb14bfdd0850" escape="true">The following table sets forth the Company's warrant activity for the year ended December&#160;31, 2022 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i54b4a45f49844b369bcbbb14bfdd0850"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i800abfbe2a3a4ff98ee18c6daa3452eb_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItMi0xLTEtOTIzNzU_750b2b8a-0f2c-4b1e-812b-dfe2ed3049d4">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7529f34d71c8489d8eddf8fd724fd5ad_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItNi0xLTEtOTIzNzU_8d459ecb-5e8d-4b8c-871f-9f407878342d">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc78166d67464d8dbbf2a4acfe7206bd_D20220101-20221231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItOC0xLTEtOTIzNzU_89dcf198-1da6-4a5c-b3a3-de5f28136fed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc78166d67464d8dbbf2a4acfe7206bd_D20220101-20221231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItMTAtMS0xLTkyMzc1_7bfaa053-04da-4e7b-8f9b-388d7b893119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc78166d67464d8dbbf2a4acfe7206bd_D20220101-20221231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItMTItMS0xLTkyMzc1_05316fd5-6798-497b-af12-d0cd58aeef90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i800abfbe2a3a4ff98ee18c6daa3452eb_I20221231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItMTQtMS0xLTkyMzc1_fa796eaa-1b82-4261-8632-53fa01b0253c">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8d3704f824a24ee3ab53e3e9b975ae7f_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtMi0xLTEtOTIzNzU_d136a594-19fa-423b-8008-ef2fe4fdf0b1">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6e4124d7d374ca0bc952081d6c500f6_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtNi0xLTEtOTIzNzU_97a02454-20d7-456d-9ff6-a6570e54681f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82a243d92e624ce19e709802a563543c_D20220101-20221231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtOC0xLTEtOTIzNzU_ef50fffc-43a5-4a81-9704-f7bf9758cc7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82a243d92e624ce19e709802a563543c_D20220101-20221231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtMTAtMS0xLTkyMzc1_ab57c438-8caa-4c4e-a80a-ae15d5b2903b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i82a243d92e624ce19e709802a563543c_D20220101-20221231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtMTItMS0xLTkyMzc1_973b0f4e-7fce-4e3e-8715-5bcc9508a2fa">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d3704f824a24ee3ab53e3e9b975ae7f_I20221231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtMTQtMS0xLTkyMzc1_08df287c-d7f7-4faf-a96f-c578c12d5be8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie68ccfa087a542998d3e397047b34a57_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtMi0xLTEtOTIzNzU_02ecfdc1-52c6-457c-9492-c15784ed8a53">11.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdcb7e9d6aeb45f3b64cf0988fbf00e8_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtNi0xLTEtOTIzNzU_f960b86e-d8b7-4d8c-958f-6fcf8b1292c5">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ed2728c8f6640a5b89ab51323c10e96_D20220101-20221231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtOC0xLTEtOTIzNzU_856883e4-a6a3-409e-91a6-3ee948abcf2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ed2728c8f6640a5b89ab51323c10e96_D20220101-20221231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtMTAtMS0xLTkyMzc1_dee793c9-5eae-4f8c-80f2-e689fe2ddba8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ed2728c8f6640a5b89ab51323c10e96_D20220101-20221231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtMTItMS0xLTkyMzc1_40b44ff8-db26-484e-b636-e5839541d84f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie68ccfa087a542998d3e397047b34a57_I20221231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtMTQtMS0xLTkyMzc1_a639d771-4062-448a-a569-22f7ff4ba851">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib00557f6793a464ebb3158651e79e729_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtMi0xLTEtOTIzNzU_dca93f69-2e13-469d-afc9-c4e48f0089a2">11.04</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3c6905ce21c40b18f3059d5f6e237f4_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtNi0xLTEtOTIzNzU_0cc2263a-ae9e-4163-acc9-ef69b019e161">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieeddaa2b96474d13a379ff7566291039_D20220101-20221231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtOC0xLTEtOTIzNzU_8fdab103-1878-4b93-9187-4c81b15c18e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieeddaa2b96474d13a379ff7566291039_D20220101-20221231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtMTAtMS0xLTkyMzc1_8312f6cb-4b94-4da4-a111-062247bde882">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieeddaa2b96474d13a379ff7566291039_D20220101-20221231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtMTItMS0xLTkyMzc1_e86ab7bf-6fdd-4f15-8576-b5bbaa571cb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib00557f6793a464ebb3158651e79e729_I20221231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtMTQtMS0xLTkyMzc1_011593a1-7310-44e4-9ea6-b33b4cf60007">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzYtNi0xLTEtOTIzNzU_ce072475-f17b-45f0-bc62-409bebcde21a">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzYtOC0xLTEtOTIzNzU_322c4b42-16b1-421c-bee5-a14a9be43466">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzYtMTAtMS0xLTkyMzc1_1334d25d-021f-426d-a46b-c305f3890615">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzYtMTItMS0xLTkyMzc1_db48c316-cc5b-4d7d-888c-873259b59126">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzYtMTQtMS0xLTkyMzc1_f3d9887e-b495-4ad7-afd0-c9cfc7a2e2cd">187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification described below and (ii) subject to further adjustment based on down round provision added by amendment described below.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Modifications</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with holders of its outstanding 2018 Warrants and 2017 Warrants to purchase the Company's common stock. At such time, the 2018 Warrants and 2017 Warrants utilized the same form of warrant, which contained a prohibition on variable rate transactions (as defined therein). Warrant holders agreed to waive such prohibition in exchange for certain concessions from the Company. Management evaluated the warrants after modifications and determined that they continued to be equity-classified under the derivative scope exception of ASC 815-40. The warrants were revalued immediately before and immediately after the modifications to calculate the $<ix:nonFraction unitRef="usd" contextRef="i23b7cb6c58024d5b9f676827326355bb_D20191001-20191031" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzcyNzc_6a7263e8-3f77-457e-a91d-0d43a8e737eb">1.1</ix:nonFraction> million incremental value of the modified warrants. The Company considers this incremental value to be akin to an offering cost since the modifications were directly related to enabling the ATM Offering and would not have otherwise been incurred. Therefore, in the fourth quarter of 2019, management initially capitalized the $<ix:nonFraction unitRef="usd" contextRef="iaa5fc09e9b4244549466aede24ab208e_D20191001-20191231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzc1OTg_5e79336f-38cb-447d-9c77-1d9c86a1c591">1.1</ix:nonFraction> million to deferred financing cost asset, with an offsetting credit to additional paid-in capital, and then reclassified the deferred financing cost asset to reduce the ATM Offering proceeds within equity as proceeds were received from sales of common stock under the ATM Offering. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Warrants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with the holders of its outstanding 2018 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2018 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2018 Warrant Amendment Agreements"). As consideration for those holders executing the 2018 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $<ix:nonFraction unitRef="usdPerShare" contextRef="i48ca0d5ad9bd4085818dc426b3589eb2_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg0MDM_56172784-f275-4354-8ccc-f68cdb7d47fb">1.20</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="ib6e50ab15b3f4156bd82e204e7b093e6_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg0MDk_3855cb6a-36c7-4804-a860-7318a59676e9">0.60</ix:nonFraction> per share of the Company's common stock, resulting in proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7a1490314240433882cb0da9a6d1b2de_D20191001-20191031" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg0Nzg_5910e082-6b60-42c8-b397-c12505823ebd">2.0</ix:nonFraction> million from the exercise of <ix:nonFraction unitRef="shares" contextRef="i7a1490314240433882cb0da9a6d1b2de_D20191001-20191031" decimals="-5" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg1MDI_7771c479-048d-4462-ac80-6e7c82fbfcc0">3.4</ix:nonFraction> million warrants. Pursuant to the 2018 Warrant Amendment Agreements, the prohibition on certain variable rate transactions included in the 2018 Warrants was amended to exclude ATM offerings and the exercise price of the warrants was reduced from $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d82589e0dd040a795545a962a2cb1a0_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg3NDM_30dbe1d2-29f7-4710-8eb5-90310544924a">1.20</ix:nonFraction> to the lesser of (a) $<ix:nonFraction unitRef="usdPerShare" contextRef="i015d83f362d9409aaffa4d0d06f715d7_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg3Njc_67647563-cb24-4f27-b25a-81c585aa336d">0.95</ix:nonFraction> per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2018 Warrant Amendment Agreements. During the second quarter of 2020, the anti-dilution provision was triggered to lower the exercise price of the warrants to $<ix:nonFraction unitRef="usdPerShare" contextRef="id958531e2fb946e3920b1cee8b9b3c37_I20200630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzkwNjI_44ac15cc-69cc-4ce9-a657-77cd42626c2b">0.55</ix:nonFraction>; as such, the Company recognized a deemed dividend of approximately $<ix:nonFraction unitRef="usd" contextRef="i5725754243984358952852405d13672b_D20200401-20200630" decimals="-5" name="sesn:OtherDividendAndAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzkxMzM_8048c503-3cc3-4a67-819e-ce73ccd184f3">0.1</ix:nonFraction>&#160;million which reduced the income available to common stockholders. As the Company has an accumulated deficit balance, there is no overall impact to additional paid-in capital, as the deemed dividend is recorded as offsetting debit and credit entries to additional paid-in capital. Therefore, the amounts were not presented on the Statement of Stockholders' Equity (Deficit). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2018 Warrant Exercise Agreements and 2018 Warrant Amendment Agreements, the Company entered into an amendment to the Securities Purchase Agreement dated March 21, 2018 related to the March 2018 Financing, by and among the Company and each purchaser identified on the signature pages thereto, with certain holders representing greater than <ix:nonFraction unitRef="number" contextRef="i56bec24a6f664962bb4939227b4c9cda_D20191001-20191031" decimals="3" name="sesn:ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzk4NjY_9c7c0ba2-fa2e-4864-8952-b29a625c4be0">50.1</ix:nonFraction>% of the securities issued based on initial subscription amounts, pursuant to which the prohibition on variable rate transactions, including ATM offerings, was deleted in its entirety.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i2bb92c93f088451a967b58c167ed3712"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with the holders of its outstanding 2017 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2017 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2017 Warrant Amendment Agreements"). As consideration for those holders executing the 2017 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $<ix:nonFraction unitRef="usdPerShare" contextRef="i05fdf323c4eb41f591b33f27de2e40b4_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzEwNTc5_3ddad621-1de1-42ba-8747-d4fdc7dac284">0.80</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i3f9fd02125934e03bde7e6db929d631b_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzEwNTg1_0afea676-cbb6-49c0-89c8-c54b3fb535c2">0.55</ix:nonFraction> per share of the Company's common stock. Pursuant to the 2017 Warrant Amendment Agreements, the prohibition on certain variable rate transactions, including ATM offerings, included in the 2017 Warrants was deleted in its entirety and the exercise price of the warrants was reduced from $<ix:nonFraction unitRef="usdPerShare" contextRef="i05fdf323c4eb41f591b33f27de2e40b4_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzEwODc0_37656165-6d21-4f06-8113-3b8554adb533">0.80</ix:nonFraction> to the lesser of (a) $<ix:nonFraction unitRef="usdPerShare" contextRef="i3f9fd02125934e03bde7e6db929d631b_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzEwODk4_dd018f33-bfff-42c7-a9bf-ce0aed1d3a01">0.55</ix:nonFraction> per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2017 Warrant Amendment Agreements. As of December&#160;31, 2022, there has been no adjustment to the exercise price of these warrants.</span></div></ix:continuation><div id="i6d755c213f784994a9d98b9e4ebda9e0_118"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90ZXh0cmVnaW9uOjQ3NjVlOWZkMGZjYTQ2ZWE4MTFlZjk2Yzc5MWZlMmU4XzI4MDE_e4a91dd9-253c-4dbd-a40e-2fa9e5ffcb18" continuedAt="icd2864452c904daa83b8dab81ccbf608" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="icd2864452c904daa83b8dab81ccbf608"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods with net income, diluted net earnings per share is calculated by either (i) adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii) the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two-class method was not applied for the twelve months ended December&#160;31, 2022, 2021 and 2020 as the Company&#8217;s participating securities do not have any obligation to absorb net losses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive.</span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90ZXh0cmVnaW9uOjQ3NjVlOWZkMGZjYTQ2ZWE4MTFlZjk2Yzc5MWZlMmU4XzI4MDA_56355aec-6cf6-492d-8663-99ad8e5bb822" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of December&#160;31, 2022, 2021 and 2020 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:53.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9dcf8ba7b1154c71807f93d29f6d1cc8_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzItMS0xLTEtOTIzNzU_7c362cf5-6a50-4895-bcda-8d1ae9423ce0">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia76e658e62f94a39b6fa63c38baf1887_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzItMy0xLTEtOTIzNzU_d41acf13-e3de-4f85-bded-0095c4d3ccb5">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id51afed260f64269a2103be0fab8e386_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzItNS0xLTEtOTIzNzU_c12e9639-14d4-4260-95fd-4114a3ffab67">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacca46a3fbcd45eab8928c23a788895e_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzMtMS0xLTEtOTIzNzU_ebf01158-51e7-42e9-88fa-72a50d0c9748">15,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia69316b9d7f84c72bf9062ad8a344515_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzMtMy0xLTEtOTIzNzU_4d847871-fc92-4547-a469-56a917f35af1">15,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4cad1b5e12a475d81796c7dfd472fba_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzMtNS0xLTEtOTIzNzU_6bcc62e8-1bae-412c-8cbd-d5a7e1d8ee72">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea92dc95dce94ad983cf2eaf1ef27507_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtMS0xLTEtOTUwMzQ_97639c5e-f7fe-46cd-96ee-65eed8aaa4c4">4,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i645aef5340be4c348f095065f63145e6_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtMy0xLTEtOTUwMzQ_6da8f71a-e51b-4f0e-a1da-8bddf624c715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33fae254eac8482dab713b9f73f69e41_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtNS0xLTEtOTUwMzQ_35b31495-56e0-4aad-ba78-cd7a1d63f764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtMS0xLTEtOTIzNzU_cddd2197-3e1b-4ef4-862c-f4a3b71147ca">20,186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtMy0xLTEtOTIzNzU_2a0ddb7b-af68-4f3e-b849-0cd0a9a612bf">15,902</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtNS0xLTEtOTIzNzU_e7f10e81-63b9-4e64-a161-7004d68c0a5b">12,394</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyMzY_1a5f0f3f-0ec8-4262-93d8-36949f6019f9" continuedAt="i8fdefc5cb965405e86148b720fdf8ba2" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i8fdefc5cb965405e86148b720fdf8ba2" continuedAt="idc559c7384374c6eb553d910b8bcb980"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyNDE_80f1bea6-c33a-45f3-b3a0-28d9ae763fa0" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ca9f2083e648768635ed14bf7c4dd2_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzItMS0xLTEtOTIzNzU_4c99eb60-6821-4b30-b006-506a266b9756">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1333cc72fc424e2a8f8774a8f0d872fb_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzItMy0xLTEtOTIzNzU_abab92a0-c572-491a-bcd0-76fc3d44450e">973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa2ee52082f4e3e8053f82bebfa0168_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzItNS0xLTEtOTIzNzU_c9a8373e-ba1b-4493-bfa0-0023b28520d2">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad3615d1132f4e6db8c87630585bb158_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzMtMS0xLTEtOTIzNzU_e26c2310-ee9a-4cee-94d7-39b5e1c5f112">4,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f6527bbe7574825a65695e1c732589c_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzMtMy0xLTEtOTIzNzU_ef04846c-1c19-484d-9d2f-c0ebd567b1f6">4,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic025f71331f24e12b56e608440ce56ce_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzMtNS0xLTEtOTIzNzU_899a0a46-d4ef-44f3-b51f-254afaa23d6e">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzQtMS0xLTEtOTIzNzU_d0aa7ef1-1735-4af2-84b0-42f84a6187cb">6,909</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzQtMy0xLTEtOTIzNzU_bfc71032-fb2b-4d32-84e6-f77419363d3a">5,143</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzQtNS0xLTEtOTIzNzU_68778b6e-b324-4ef2-ac5a-c3c5f86548a5">1,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by <ix:nonFraction unitRef="shares" contextRef="i486533c551a2452c99626829ee478c51_D20190601-20190630" decimals="-5" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzExMDA_6348f999-c17c-47cf-839d-4c3ebf064e94">7.9</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by <ix:nonFraction unitRef="shares" contextRef="i236b00a74d3948dcae1d6b9ffcfa4fcf_D20210501-20210531" decimals="-6" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzE1Njk_dcb1c345-6fcd-48b9-951e-574eca38c119">12</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately <ix:nonFraction unitRef="shares" contextRef="i16c46bb406f14eaa81b7c198dcc44d8a_I20221231" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzE2Nzc_446a95cb-2e88-46e7-9502-9b72de559bb7">4.5</ix:nonFraction>&#160;million shares of common stock available for issuance under the 2014 Plan as of December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a <ix:nonNumeric contextRef="ic44a95cc271a49b0aa716f7ebe2e6879_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyMzM_410428cc-8008-465f-8bd6-c9792a70a170">four-year</ix:nonNumeric> period at the rate of <ix:nonFraction unitRef="number" contextRef="i7a361b7208b64753a71edeaa3c23d956_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzE4NTQ_a6756b61-a339-4b39-a8c3-59189dba653b">25</ix:nonFraction>% of the grant vesting on the first anniversary of the date of grant and <ix:nonFraction unitRef="number" contextRef="i61d80b79fadf491ba762bf6b77e43e6a_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzE5Mjg_18d1a4f5-dd3e-4c78-8806-a13829ccfe55">6.25</ix:nonFraction>% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of <ix:nonNumeric contextRef="ic44a95cc271a49b0aa716f7ebe2e6879_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzIwODc_c800390c-2fcb-4dc0-b307-498bf36d0618">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="i16c46bb406f14eaa81b7c198dcc44d8a_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzIxMzk_e5899bcc-3852-47d4-9973-5f518aa80558">12.2</ix:nonFraction>&#160;million stock options outstanding under the 2014 Plan as of December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#8220;RSU&#8221;) award which vested in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive <ix:nonFraction unitRef="shares" contextRef="iaf581044871b4e4a95de21bdefb73475_I20221231" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI4NjY_04623beb-b01e-47d5-870a-24e345f0e93c">one</ix:nonFraction> share of the Company&#8217;s common stock. The Company recorded an expense of $<ix:nonFraction unitRef="usd" contextRef="ic9a728dfe3c4454cbc533710495f8f5b_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI5NDE_0c9ed2b3-c866-421d-b040-ee3873068b35">2.5</ix:nonFraction>&#160;million for retention-related RSUs for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately <ix:nonFraction unitRef="number" contextRef="ifadff6a5daba493cb2a7db4117d654bf_I20211001" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzMzNjA_dea5e836-1fb6-4445-b590-d82e7157c489">fifty</ix:nonFraction> percent of current base salary. Each PSU represents a contingent right to receive <ix:nonFraction unitRef="shares" contextRef="ifadff6a5daba493cb2a7db4117d654bf_I20211001" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzM0NDU_1f4797a3-4e0e-4ada-9d2b-f476d211589f">one</ix:nonFraction> share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of December 31, 2022, achievement was deemed probable for only the cash management milestone, representing $<ix:nonFraction unitRef="usd" contextRef="ifbcb93bc03d34a29ba0472e96a5c17db_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzkwMTg_1fb44cbd-ddda-41ff-94ec-529bd19c6abb">87,000</ix:nonFraction> (or <ix:nonFraction unitRef="number" contextRef="ifbcb93bc03d34a29ba0472e96a5c17db_I20221231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzkwNDU_1ce93128-7edb-45ae-888a-dbcd5b68853c">20</ix:nonFraction>% of the PSU awards). Therefore, $<ix:nonFraction unitRef="usd" contextRef="iee027c64b36746299c057f499c9540ad_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzkwMzY_df668af3-b77e-4201-99db-cefee060bfc6">55,000</ix:nonFraction> was expensed during the year ended December 31, 2022, and $<ix:nonFraction unitRef="usd" contextRef="i7750d93e565f4062abf14eab356f22e7_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzkwMjc_bb333915-1b92-4b35-9cbe-3379d70c4846">32,000</ix:nonFraction> remains measured but unrecognized.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="idc559c7384374c6eb553d910b8bcb980" continuedAt="ief2c1a2457ad4e13a8c7927512c54d77"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyNDY_75971d2e-2f4a-4511-b1b2-80514a8d436c" continuedAt="id10dbf9c11ef42a1b4dbdf3ccab80c8f" escape="true">A summary of the status of restricted stock units is presented below: </ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="id10dbf9c11ef42a1b4dbdf3ccab80c8f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tr><td style="width:1.0%"></td><td style="width:75.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzEtMS0xLTEtOTIzNzU_25b50503-d8d9-4788-9a22-4f4469887815">3,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idedbd5e4782a4a07988637e4ee0dffc0_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzItMS0xLTEtOTIzNzU_be27ad42-e082-4aae-a34f-a2cd1f4b59f7">4,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i438fa29ca3bb484a8da013a3e14bb5aa_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzMtMS0xLTEtOTIzNzU_0be733af-39bb-48f6-afad-070bd02a682b">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzQtMS0xLTEtOTgyNjI_1acab563-1c99-4b43-806c-b4a87f9f05c4">3,293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzUtMS0xLTEtOTgyNjI_b887ca91-60d6-476e-b1d2-7c3e0a6ef075">217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzQtMS0xLTEtOTIzNzU_52b27d89-3e13-494e-8b71-7a1cf956618f">4,695</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining contractual life of unvested RSUs and PSUs as of December&#160;31, 2022 is <ix:nonNumeric contextRef="idedbd5e4782a4a07988637e4ee0dffc0_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzQyOTQ_98c15bcf-836e-45f1-8d5d-bd851f07c31c"><ix:nonNumeric contextRef="i438fa29ca3bb484a8da013a3e14bb5aa_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzQyOTQ_d256f132-0b7b-4da7-9195-fed4b73ab7cd">2.67</ix:nonNumeric></ix:nonNumeric> years. The weighted average remaining contractual life of unvested RSUs and PSUs as of December&#160;31, 2021 is <ix:nonNumeric contextRef="iac240dff34d54c259fa7dcc1af037866_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzczMjY_4030b874-b525-4adb-90a5-41227742f351"><ix:nonNumeric contextRef="ie548983137d0429b97bbb1a0cea18f7f_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzczMjY_590b7400-2a97-4ee7-8d6d-47153163e95a">9.75</ix:nonNumeric></ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of <ix:nonNumeric contextRef="i3e7114012079469c8021b30d065673e7_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzUzMzc_8b8d927b-fee8-445e-8704-081751dbae68">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="i3e7114012079469c8021b30d065673e7_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzUzODk_a011bb00-f85d-4810-bd1c-ea987095aade">0.1</ix:nonFraction> million fully vested stock options outstanding under the 2009 Plan as of December&#160;31, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately <ix:nonFraction unitRef="shares" contextRef="i1f1e396274dc4a98b5466fd643278d94_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzU4OTc_b5669ab9-c2b8-4b12-9cf0-eb52a15b8eb3">2.9</ix:nonFraction> million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of December&#160;31, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ief2c1a2457ad4e13a8c7927512c54d77"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyMzQ_3da8d328-dcc4-4c93-8c6e-fc10f791703c" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:41.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73c47e791149483dac9b339dd293b4ca_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEtMS0xLTEtOTIzNzU_0de75d6d-3fa9-4ac2-8ffc-8f6b12af1900">6,236</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i73c47e791149483dac9b339dd293b4ca_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEtMy0xLTEtOTIzNzU_ae228450-31f1-4977-92cf-82b507cfa499">1.52</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0fe3f29a701248b9893e3e02d72f5095_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEtNS0xLTEtOTIzNzU_469fe7e2-279b-4089-a471-9a047df0f3e8">8.83</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c47e791149483dac9b339dd293b4ca_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEtNy0xLTEtOTIzNzU_9af31670-0e49-46f5-93d8-7c58ebe0eb0c">358</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzItMS0xLTEtOTIzNzU_5a712cc8-279e-4cce-8154-01ecf7e526c7">4,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzItMy0xLTEtOTIzNzU_d336e9e6-e6f3-44f6-a8b5-0ed2bb28b183">0.87</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzMtMS0xLTEtOTIzNzU_a5ad0421-4118-4482-b5f5-3229b2c758a6">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzMtMy0xLTEtOTIzNzU_a9fd7673-b81c-4f68-869a-210c9743bd4b">1.13</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzQtMS0xLTEtOTIzNzU_6db4a6ab-51f2-4b62-aafc-9aa6ed03692d">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzQtMy0xLTEtOTIzNzU_38df78d5-8dc7-4443-b3ad-e13b4f0ad43a">1.04</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzUtMS0xLTEtOTIzNzU_d98597cc-915f-4233-adba-a337f2f76b6b">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzUtMy0xLTEtOTIzNzU_9e0c6853-aef0-4a32-a833-858f7e13f8c7">1.26</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzUtNS0xLTEtOTIzNzU_b421b176-65a6-44ed-ac36-299171d1dc23">8.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzUtNy0xLTEtOTIzNzU_54a81688-b5ec-4d88-90f1-cfcc4bd62d72">3,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzYtMS0xLTEtOTIzNzU_0d604dc3-2083-4827-9b01-bfb61ce3c862">8,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzYtMy0xLTEtOTIzNzU_e84078c3-3795-4c8c-8a66-aa38796153a8">3.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzctMS0xLTEtOTIzNzU_07b4c657-4bf2-4b1e-83bc-b83208baef10">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzctMy0xLTEtOTIzNzU_92067554-791a-4784-8400-4f1888432a96">1.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzgtMS0xLTEtOTIzNzU_b4eedbc6-c240-434c-9988-3ac330115b61">2,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzgtMy0xLTEtOTIzNzU_ff89e461-72fb-4ddf-8f32-980afe28acbe">3.70</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzktMS0xLTEtOTIzNzU_d81607ec-4b1d-43f1-a372-4c9fdbc6a97a">15,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzktMy0xLTEtOTIzNzU_a6b6980e-b9a2-4899-b20b-30fa23fada06">1.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzktNS0xLTEtOTIzNzU_8e79c000-b1e2-4da7-a168-cc905ef9e392">8.03</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzktNy0xLTEtOTIzNzU_a0391c7f-3177-4e87-9fe8-a9074c0e5759">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEwLTEtMS0xLTkyMzc1_6e6aaef4-5f78-498e-bb5e-6eed177fb8fc">1,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEwLTMtMS0xLTkyMzc1_b6a43f2b-83f9-4421-a94b-6514f4f7b60b">0.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzExLTEtMS0xLTkyMzc1_a8a4f092-8e92-4600-a2d6-c80d34aabb33">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzExLTMtMS0xLTkyMzc1_92624da8-81a4-4b0e-a9cd-aedc5f2dc8dc">0.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEyLTEtMS0xLTkyMzc1_9a7b7ecb-a025-41f4-beb6-b847a36ce7ed">1,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEyLTMtMS0xLTkyMzc1_0c008b54-b3e8-4394-a14c-59479abd3101">1.90</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEzLTEtMS0xLTkyMzc1_d99ce24a-3e55-477a-881b-93b960bd0c94">15,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEzLTMtMS0xLTkyMzc1_8ca7518b-4748-451f-98a7-e103666ec324">1.82</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEzLTUtMS0xLTkyMzc1_9f117140-67a2-4e11-bc3e-db60ac121724">7.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEzLTctMS0xLTkyMzc1_b1e17cd1-4deb-4b23-adab-fb1e4fd16446">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzE0LTEtMS0xLTkyMzc1_28e069fd-7fe0-416b-bcb3-a45e88064afe">10,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzE0LTMtMS0xLTkyMzc1_67509e38-fddb-41cc-b77c-16eb825745fd">1.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzE0LTUtMS0xLTkyMzc1_7496b322-888a-48b5-8d2c-8b38b0d4de21">6.77</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DM</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzU0OTc1NTgyMzU2Ng_5dc18189-3b02-4ecf-8e9a-201494c204ef">6.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzU0OTc1NTgyMzU1Mg_bbb5ce19-96bf-4d74-a85a-ffebcdff56f0">5.1</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzU0OTc1NTgyMzUzOA_45533e4e-f703-43e8-93bf-091a43218f81">1.8</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. The stock option related expenses were $<ix:nonFraction unitRef="usd" contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY0MDE_102d96e6-a6a4-4804-959b-cfd99a8c6fdf">4.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY0MDU_7946db3a-e509-40d6-a4e9-d852c560f546">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY0MTI_9721c874-378e-4a78-8cd8-df5e9c8c1be5">1.8</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. The RSU related expense was $<ix:nonFraction unitRef="usd" contextRef="ic9a728dfe3c4454cbc533710495f8f5b_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY0OTM_0c9ed2b3-c866-421d-b040-ee3873068b35">2.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4cd59fe7a7ec49b7be31865888e57cd0_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzEwOTk1MTE2MzUxODE_4d4ab101-adb9-46be-92b5-fff901996bda">0.5</ix:nonFraction> million for the years ended December&#160;31, 2022 and 2021, respectively. The Company did <ix:nonFraction unitRef="usd" contextRef="i7e820c7440e2402791def7b12470f1f6_D20200101-20201231" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY1MzU_1df3e006-8ba1-459b-9b2f-a5fa3c16274b">no</ix:nonFraction>t record RSU related expenses for the year ended December&#160;31, 2020. As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY2MzI_739ca913-2f8e-4750-9e5d-c877e9b10f24">5.5</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY3ODQ_def4ab2e-33c3-4f4a-ac93-abc0bfd830cf">1.88</ix:nonNumeric> years. The weighted-average grant-date fair value of stock options granted during the year ended December&#160;31, 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY5MDM_55e155b8-5554-416a-bd2c-cddb7325f35b">0.46</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY5MDc_d9b8164d-4af1-46a3-a59e-a7158276feee">2.16</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY5MTQ_60f2f5fe-595e-4b32-9c3e-48af825c9674">0.56</ix:nonFraction>, respectively. The total intrinsic value of stock options exercised for the years ended December&#160;31, 2022, 2021 and 2020 was de minimis.</span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyMzg_c9c3e689-dc62-4550-acc7-78f086227ae3" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzItMS0xLTEtOTIzNzU_61685257-89d6-47c0-a57c-c0932f85f6c8">0.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzItMy0xLTEtOTIzNzU_a40dfc87-8f01-497b-9501-2b03705c04ba">3.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzItNS0xLTEtOTIzNzU_b6f963bc-83a0-4431-a806-24a8fef97c30">0.87</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2979721cc12044649222cc680229209d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzMtMS0xLTEtOTIzNzU_267a8aaf-f7ac-48a8-ae58-c398b2c7f813">0.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2fff5776971a48a586881cd89287df3c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzMtMy0xLTEtOTIzNzU_02b6b01b-898d-4bef-897b-a8e91bb33a6a">3.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ide0c3c6cf2a04d4383911137e51d3b5b_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzMtNS0xLTEtOTIzNzU_cbe6ed12-69e6-4ffe-8290-3d21a15a3810">0.87</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzQtMS0xLTEtOTIzNzU_9c9a89fd-5713-4526-ada7-20ddcbc24416">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzQtMy0xLTEtOTIzNzU_4b0d26f6-46e9-4768-880f-bfeebfe1cdfe">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzQtNS0xLTEtOTIzNzU_acdd3808-bd96-45d2-aa2f-3f39e3ef141e">6.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzUtMS0xLTEtOTIzNzU_2a7e3483-3f20-4685-815b-488c866acafc">2.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzUtMy0xLTEtOTIzNzU_00813a7c-2c6f-4b16-8bbf-0f5a24b981d9">0.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzUtNS0xLTEtOTIzNzU_a6235848-4c68-41d8-a826-b5a4df78bb54">1.3</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzYtMS0xLTEtOTIzNzU_38b3d656-d32d-48e8-93e2-37eee285eca8">71.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzYtMy0xLTEtOTIzNzU_8a36c555-ab78-4da8-856c-c78f0337100e">74.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzYtNS0xLTEtOTIzNzU_372a94b7-f310-4156-9bf9-1e896cf570c7">71.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzctMS0xLTEtOTIzNzU_a1a3a3b5-69e3-49f3-be24-b269dd8e8320">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzctMy0xLTEtOTIzNzU_e3fe721f-449c-4f69-bf13-d3ecd08024bb">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzctNS0xLTEtOTIzNzU_4a2164d0-91e6-4a24-9331-f8d0c2788258">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzI2NTc_4a7ea0bc-bfc5-4e0a-8947-28cc2b4ecf5e" continuedAt="i3455a9a7916d431eab4c5fe10e8d1cee" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i3455a9a7916d431eab4c5fe10e8d1cee" continuedAt="i4ab1c67267f34bca976ad926deb7eec1"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of <ix:nonFraction unitRef="shares" contextRef="i3f2e215c48c94cc88ad545b140478fd4_I20140228" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzM4Ng_4103c136-80f9-4817-8428-8be8daee90d7">0.2</ix:nonFraction>&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by <ix:nonFraction unitRef="shares" contextRef="i50afeb8b2fbe4a90bd225677491dd878_D20210501-20210531" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzYxNg_7189337b-0d1a-4cde-9d7e-b850231c2f17">2.3</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a <ix:nonFraction unitRef="number" contextRef="ic9ccb359bb07464c8b5a4bf7acd0ee69_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzk2Mw_0646332a-d7ac-4cd7-bed6-c1bff5db5b6d">15</ix:nonFraction>% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders' equity (deficit). As of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i81090f1cef414033a4de39f36d28f951_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzEzNzY_449f5735-3ac4-46c7-90a6-948997c126a2">2.3</ix:nonFraction>&#160;million shares of common stock available for sale under the 2014 ESPP. The Company sold a de minimis number of shares under the ESPP for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its United States employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to <ix:nonFraction unitRef="number" contextRef="ieddcde47d6134b21a63f741b8434c23a_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzE4NzE_68d717af-cf60-4958-9bdd-6c9c1ba7fd51">100</ix:nonFraction>% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="ieddcde47d6134b21a63f741b8434c23a_D20220101-20221231" decimals="INF" name="sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzIwNzA_8260d052-bea4-48d8-8e4e-696fb453e5c5">4,000</ix:nonFraction> per year. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4ab1c67267f34bca976ad926deb7eec1">The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first <ix:nonFraction unitRef="number" contextRef="i284162f0c4ac4a84a203966f8ee455b8_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzI0NjI_1c9e97ad-424d-4cf8-b8d7-67a074b7843d">4</ix:nonFraction>% of eligible compensation for its Canadian-based employees to the retirement plan. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2022, 2021 and 2020, respectively.</ix:continuation> </span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_127"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzUzODU_486b41f1-c77e-4731-ac80-0d70704ca5b4" continuedAt="i53bd22bde34d42be92dec3c4b8dc5d41" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="i53bd22bde34d42be92dec3c4b8dc5d41" continuedAt="i692e4a279c854ed2a9de530cc1186360"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzUzODQ_b687bd4d-a7b7-4c3b-ab37-2629c6a3eac8" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice90a69ceeff49f0b8f1ce82d2bb4ded_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzMtMS0xLTEtOTIzNzU_aa67cae5-6b58-4b95-885a-443aa7a36b38">37,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i921a13a0674c431a99d0b747823d5a59_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzMtMy0xLTEtOTIzNzU_47c7b0e5-d951-4c45-a3bd-cb69cf7bb99c">32,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib11ddd9e85084edeb9ff837ed2550dcc_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzMtNS0xLTEtOTIzNzU_da912b3f-b567-414a-ba6e-37dd1774790a">35,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebe3ee0020554764957e449756650c1d_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzQtMS0xLTEtOTIzNzU_fde55794-056c-430e-8365-7a3a49e79612">13,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b74c8246e3465ebe694e85ae1cf30f_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzQtMy0xLTEtOTIzNzU_626e3376-b954-4512-bcb6-72289426f986">24,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1992bb56f84f4d954e523e989b4498_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzQtNS0xLTEtOTIzNzU_c918b6d0-aace-49c5-a443-8fc35761bc18">14,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total Loss Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzUtMS0xLTEtOTIzNzU_ed474ffa-f16b-4637-b4da-4b8eca7478ce">23,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzUtMy0xLTEtOTIzNzU_8dcf175d-b518-4a36-b164-aba3d9a97294">8,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzUtNS0xLTEtOTIzNzU_bcfdd293-3afc-4956-855e-69b31c8fe81d">20,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i692e4a279c854ed2a9de530cc1186360" continuedAt="id0b5fc87c2164be1ab75caaf4f4b00ab"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzU0MDM_800ad440-f7f2-4e55-bf4b-5c7ae8e17e5e" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Tax Provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzMtMS0xLTEtOTIzNzU_a005f7a1-5939-47b9-ae2c-ae3b0743f13f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzMtMy0xLTEtOTIzNzU_9e629a6b-8feb-4bd4-9fed-1ee6ac57175d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzMtNS0xLTEtOTIzNzU_4bfd5210-6e4e-44b2-a680-4d05db656d52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzQtMS0xLTEtOTIzNzU_4c314fd1-6b42-4fbc-9ce6-bf755b71034f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzQtMy0xLTEtOTIzNzU_776c09de-6bae-4e05-802a-e8c5d419ec4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzQtNS0xLTEtOTIzNzU_addbf942-2a16-4502-a912-f476ddb7a17e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzUtMS0xLTEtOTIzNzU_7f1a2332-49e5-4393-85c4-4c7af660d2f5">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzUtMy0xLTEtOTIzNzU_0d52403c-7bfe-4727-b51b-2a59ba66b94e">286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzUtNS0xLTEtOTIzNzU_a6ff4489-9882-4e56-877c-ccb01747267b">1,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current (provision)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzYtMS0xLTEtOTIzNzU_0a84d69a-b1e7-44b1-a2a5-4da7cdd3f38a">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzYtMy0xLTEtOTIzNzU_284e6801-6603-4892-9642-cfd4103a812b">286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzYtNS0xLTEtOTIzNzU_0b2ad2e9-8b81-4728-9514-aff2a150d747">1,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzgtMS0xLTEtOTIzNzU_8ee02c53-6e1a-4150-8cd7-5820435fe504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzgtMy0xLTEtOTIzNzU_5954d210-a630-4488-9342-90da81679664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzgtNS0xLTEtOTIzNzU_9fbbfe26-2b46-4c26-bbe3-15cff76bc203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzktMS0xLTEtOTIzNzU_76c2633d-f03a-4224-8673-2db9787e30e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzktMy0xLTEtOTIzNzU_664ec1db-ad59-484b-b5a8-dffa4549db14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzktNS0xLTEtOTIzNzU_cef8859c-b96a-4cae-9fd1-29b775d59fdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEwLTEtMS0xLTkyMzc1_8174f4bf-bed6-4324-8043-d8c6e85a6b1b">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEwLTMtMS0xLTkyMzc1_c6d04c7c-ef25-4da6-bc92-0fb1932fab35">8,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEwLTUtMS0xLTkyMzc1_df86021f-d083-43ba-b9bb-a26e72250d84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred benefit (provision)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzExLTEtMS0xLTkyMzc1_6586e9fd-0342-4481-a690-e4069decb869">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzExLTMtMS0xLTkyMzc1_91469266-a200-497d-acf5-6449b657a422">8,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzExLTUtMS0xLTkyMzc1_90c417e9-9c21-4fc1-bc84-9088d7608208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Benefit (Provision) </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEzLTEtMS0xLTkyMzc1_561f4887-3875-4951-a56e-06fa8dd17984">3,875</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEzLTMtMS0xLTkyMzc1_9623d37c-8b8c-4318-8c7b-3281089f9fd2">8,273</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEzLTUtMS0xLTkyMzc1_a9615fcc-997c-490c-8bfd-863d2d3e8d4a">1,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzUzODc_ba2138e9-230a-4f52-a022-df976a102d90" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company&#8217;s effective income tax rate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal statutory income tax rate</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzItMS0xLTEtOTIzNzU_ed3c3b8e-8516-401c-a701-a46859eba651">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzItMy0xLTEtOTIzNzU_143f8f37-f8c4-4737-adc0-7640d85c307d">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzItNS0xLTEtOTIzNzU_71a82499-7688-4822-8107-f1a98fa01cc8">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzMtMS0xLTEtOTIzNzU_09fb7739-1af0-4a6d-8292-9f11b7dc2c26">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzMtMy0xLTEtOTIzNzU_54bab78e-fe7f-4fc2-8fad-8efbc03d427d">15.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzMtNS0xLTEtOTIzNzU_d418e672-53df-45ba-8fbe-4c8c9f9d94ae">4.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzQtMS0xLTEtOTIzNzU_b5e27a3d-d54e-4432-947b-b97da95c940a">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzQtMy0xLTEtOTIzNzU_abd66f3f-2657-40e0-959f-39441b1cfef2">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzQtNS0xLTEtOTIzNzU_d7ace37a-f1bd-4bc3-a962-e0bd54c80171">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option cancellations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzUtMS0xLTEtOTIzNzU_734b5b05-592d-41fa-b892-9181347828d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzUtMy0xLTEtOTIzNzU_3796d697-3e74-4818-8e92-f3fb5d2fff7b">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzUtNS0xLTEtOTIzNzU_44484bb6-c65c-4b62-a28e-b2bd16dc6d3e">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzYtMS0xLTEtOTIzNzU_fc209082-26e5-4bde-8216-ebc6f6bf8e74">59.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzYtMy0xLTEtOTIzNzU_ff7c9be7-2d0b-4678-b89a-c1b4ce21dd20">178.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzYtNS0xLTEtOTIzNzU_6a67549b-2232-4492-b1ef-5c78a3388d6d">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzctMS0xLTEtOTIzNzU_fe2f4720-1935-422b-a28b-be56ad961e45">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzctMy0xLTEtOTIzNzU_05d1e3ad-fb4b-49dc-98d9-a8ade0ce1d8b">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzctNS0xLTEtOTIzNzU_40ca1653-b907-42fa-9024-16941d83b896">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill write-off</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="3" sign="-" name="sesn:EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtMS0xLTEtMTA2Nzky_223b999f-c653-4074-834c-39cd25c7af76">14.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtMy0xLTEtMTA2Nzky_f337b7df-345d-4942-bad7-0e97f6f76007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtNS0xLTEtMTA2Nzky_20350efa-1e8f-453b-8918-6f2ad6222f2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="3" sign="-" name="sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtMS0xLTEtOTIzNzU_a559331c-0603-4436-bbfc-ab2f98782091">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="3" sign="-" name="sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtMy0xLTEtOTIzNzU_b5edc145-7386-40f1-b7f3-97f6ea9ee069">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtNS0xLTEtOTIzNzU_0c4db07c-f66b-438b-b6cd-4872901e7f71">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzktMS0xLTEtOTIzNzU_c61378e8-be24-4b34-a529-73186daa133c">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzktMy0xLTEtOTIzNzU_a9b3686c-0378-4d3d-b7cf-d7510adc0451">13.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzktNS0xLTEtOTIzNzU_fa978264-a95e-4be1-a404-056249ca0c9c">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEwLTEtMS0xLTkyMzc1_8c53ec5e-f6b5-49a4-80e4-369ef484d90b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEwLTMtMS0xLTkyMzc1_058b2078-8bf4-4f96-993b-93838562ad35">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEwLTUtMS0xLTkyMzc1_53ad6cf3-9eef-4a87-89e9-8305ee76707b">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzExLTEtMS0xLTkyMzc1_a7f47d2e-75b5-4eed-9dd4-6ee7652247c9">44.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzExLTMtMS0xLTkyMzc1_17e6a5df-f925-4e52-884c-737501e0dd19">72.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzExLTUtMS0xLTkyMzc1_2b888979-4ad7-4de8-a83b-70dd0100fd31">37.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Income Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEyLTEtMS0xLTkyMzc1_d7d938ce-edac-4fe4-91b5-f14f7f9465fa">16.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEyLTMtMS0xLTkyMzc1_98b19526-396f-4ad5-aae2-c6e61709b60b">96.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEyLTUtMS0xLTkyMzc1_5e8215bf-1c06-4165-badd-dc5b2a5484b5">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="id0b5fc87c2164be1ab75caaf4f4b00ab" continuedAt="i76eaa90a6b0c48868d189ff890961deb"><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzU0MDE_708b7f02-4db6-4b95-90f5-c5980f320151" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzMtMS0xLTEtOTIzNzU_7bb03b18-2750-4ac2-b86b-37b48539afe3">66,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzMtMy0xLTEtOTIzNzU_1cb39a10-92e4-43dd-a7ec-34b7a3707c14">63,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzMtNS0xLTEtOTIzNzU_d37c983d-ce51-4945-a0a5-263d57fadba4">57,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;R&amp;D credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzQtMS0xLTEtOTIzNzU_414424f8-ba26-4220-9a4f-768c97b1755d">4,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzQtMy0xLTEtOTIzNzU_f52b4de5-9d33-4bdf-b319-e9fb1941f904">4,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzQtNS0xLTEtOTIzNzU_a3e96f68-78fa-4fd2-97ef-733a546f7d49">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRC 174 Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtMS0xLTEtMTAyMTM2_d82f566a-3ada-4767-9448-ef99b34606ee">6,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtMy0xLTEtMTAyMTM2_10a790ee-340e-4787-b7fd-4b129c2cd019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtNS0xLTEtMTAyMTM2_7a40a9ce-2049-4783-98d8-1ebe53dc7347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accruals and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtMS0xLTEtOTIzNzU_efaedec1-fe59-4565-961e-777f23799917">5,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtMy0xLTEtOTIzNzU_620f8396-b598-4e41-a4b9-b522c31a0408">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtNS0xLTEtOTIzNzU_e084e0ec-3635-4ad0-b48f-facf80dc8183">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Capitalized start-up costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedStartUpCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzYtMS0xLTEtOTIzNzU_420abaeb-2fd8-44c2-8bd4-4b3f0f17f317">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedStartUpCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzYtMy0xLTEtOTIzNzU_4702dd3f-1cd8-4d6b-a521-b6acc0049efd">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedStartUpCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzYtNS0xLTEtOTIzNzU_3bc06733-22bf-4f94-888c-60b10cb01322">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzctMS0xLTEtOTIzNzU_86af66e5-2e1f-4e2c-b111-900f5f0ae5d6">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzctMy0xLTEtOTIzNzU_7f395233-a963-4662-aac5-04aec5d2a230">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzctNS0xLTEtOTIzNzU_c294c2cc-8322-4e33-9fc9-a21d2c5cd9cc">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzgtMS0xLTEtOTIzNzU_e57da831-d420-42f5-a26f-6455f605d5fe">82,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzgtMy0xLTEtOTIzNzU_ce1524ef-4432-43e5-8326-211afa3e4dc8">71,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzgtNS0xLTEtOTIzNzU_cf6e3711-229f-4286-824e-ab347296530d">65,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEwLTEtMS0xLTkyMzc1_67ff877f-73f8-4041-92bc-1ac7f378876a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEwLTMtMS0xLTkyMzc1_2bd92b12-24cf-4d0a-99b2-42843d037f6a">3,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEwLTUtMS0xLTkyMzc1_eea88bc2-88f1-4694-8394-c3920d02b395">12,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEyLTEtMS0xLTkyMzc1_15af9949-767a-45d5-8919-1c0fbb39a132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEyLTMtMS0xLTkyMzc1_ad4ce31e-9713-4140-93e7-2c67795597a3">3,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEyLTUtMS0xLTkyMzc1_3f08b739-36c2-4597-9150-886f97dc3eef">12,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEzLTEtMS0xLTkyMzc1_ca7fe971-286f-4997-abdc-11b1a920e7e2">82,453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEzLTMtMS0xLTkyMzc1_f39dc0e0-6768-444c-a85f-8f2a1a43cfb6">71,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEzLTUtMS0xLTkyMzc1_57fbdb56-f482-4140-8e15-061c7be45913">65,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net Deferred Tax Liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzE0LTEtMS0xLTkyMzc1_9c023684-d543-4d51-a953-1abae81b5f1c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzE0LTMtMS0xLTkyMzc1_c7bc00f5-8b1b-4d59-b335-34486ed016b5">3,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzE0LTUtMS0xLTkyMzc1_54939ebc-8e0e-4500-82ce-c0e05c8434ed">12,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of the Company's deferred tax assets, management considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL and R&amp;D credit carryforwards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company has generated NOLs since its inception, and management believes that it is more likely than not that the Company's deferred tax assets will not be realized. As a result, valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzEzMjk_c0c799c1-7650-40bd-b5ad-db168da1014e">82.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzEzMzM_3d7f7e0f-af0e-459c-a33f-3ce6c086aaff">71.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i01d57c119960482d81011d8c04ff8399_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzEzNDA_e3c4a788-4b52-47c7-9b3f-fe091bf51187">65.6</ix:nonFraction> million have been established as of December&#160;31, 2022, 2021 and 2020, respectively. The $<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzE0MDQ_9aadae0e-5ff2-4331-bede-3304c5566dd8">10.6</ix:nonFraction> million increase in the valuation allowance was attributable to the NOL for the year ended December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzUzOTU_58caf33d-2bc3-4762-a2a3-23c9eab9ec17" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's NOL and R&amp;D and other credit carryforwards in the United States and Canada as of December&#160;31, 2022 (in millions):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Beginning in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards - indefinite</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2917e2d690494115aa405efdcd442035_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzItMS0xLTEtOTIzNzU_6749df4f-a281-4977-a121-cd2540c2dc69">101.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaedc518daaca46d48e4045cf67580747_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzMtMS0xLTEtOTIzNzU_a1dfdc53-7688-4a21-9775-6007b9120b2b">117.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id942c56598a7425a8f604363c0ccee90_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzQtMS0xLTEtOTIzNzU_639d38fe-01ac-4137-91bf-a049014f09c6">138.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal R&amp;D credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce909ec953045fcb9590f2a8585912f_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzUtMS0xLTEtOTIzNzU_27c99c9c-4e88-4adb-bdd3-1c057da0433c">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State R&amp;D credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3541e5363f343a3a43242a6a366098b_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzYtMS0xLTEtOTIzNzU_19c288ea-72fc-43b8-957f-408589d0729c">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal non-capital loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7959f49c234c9eaa2618a72fb438f9_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzgtMS0xLTEtOTIzNzU_031f5c22-ec47-463d-9a0f-e711e43315e7">43.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal scientific research and experimental development<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expense carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3a316709d6476199e3824ccf11239c_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzktMS0xLTEtOTIzNzU_08c08154-a36f-454c-a30f-fdbfee89e9d6">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal and provincial investment tax credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea773b2e97a1449f9f95fa34f634aee4_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzEwLTEtMS0xLTkyMzc1_30201fa4-0be0-426d-ac45-1b0684444918">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i76eaa90a6b0c48868d189ff890961deb"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Reform Act of 1986 (the "Act'), NOL and R&amp;D credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service, and there are similar provisions in certain state and non-US tax laws. NOL and R&amp;D credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interests of significant shareholders over a three-year period in excess of 50 percent, as defined in Sections 382 and 383 of the Internal Revenue Code, respectively. This could limit the amount of tax attributes that can be utilized to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Management completed a Section 382 study through March 31, 2016 and determined that it is more likely than not that the Company's NOL carryforwards are subject to a material limitation. Accordingly, the Company reduced its NOL carryforward by $<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-5" name="sesn:OperatingLossCarryforwardsDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzMwOTg_807a6dc5-f849-4d69-a41f-b7defc8770d0">0.8</ix:nonFraction> million. The Company has continued to raise additional equity capital since March 2016 but has not done any additional analysis to determine whether or not ownership changes, as defined in the Act, have occurred, which would result in additional limitations. There could be additional ownership changes in the future that could further limit the amount of NOL carryforwards that the Company can utilize. The Company has not yet conducted a study of its R&amp;D credit carryforwards. Such a study may result in an adjustment to the Company&#8217;s R&amp;D credit carryforwards; however, until a study is completed, and any adjustment is known, no amount is being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s R&amp;D credit carryforwards, and, if an adjustment is required, it would be offset by an adjustment to the valuation allowance.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it has operations to determine the potential effect on its business and any assumptions it has made about its future taxable income. The Company cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, the Company has no assurance that the provision will be repealed or otherwise modified.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's consolidated statements of operations. Due to NOL and R&amp;D credit carryforwards that remain unutilized, income tax returns filed in the United States, certain states within the United States and Canadian tax jurisdictions from the Company's inception through 2021 remain subject to examination by the taxing jurisdictions. There are currently no audits in process in any of the Company's tax filing jurisdictions.</span></div></ix:continuation><div id="i6d755c213f784994a9d98b9e4ebda9e0_130"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="sesn:LicenseAgreementTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzIwOTQw_43827902-adef-4b94-9db0-761373a8c4db" continuedAt="i160f114bd26f4203a1ccb49f8e7b76d5" escape="true">LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i160f114bd26f4203a1ccb49f8e7b76d5" continuedAt="i5de89e3a05284eb7b0e08b05df4512d1"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. Upon the Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company became obligated to pay $<ix:nonFraction unitRef="usd" contextRef="i5b7c86274f4d47eaa8553199408d4b91_D20220101-20221231" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzY4Mw_1f4242c4-b763-4d76-b5e0-314c1fc3ed55">0.5</ix:nonFraction>&#160;million in a milestone payment to Zurich. The Company is also obligated to pay up to a <ix:nonFraction unitRef="number" contextRef="i15671c3d0d094adaac0c1229062ca074_D20220101-20221231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2NQ_a1fd2f43-f81c-42c3-b85a-95edab06a000">4</ix:nonFraction>% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is <ix:nonFraction unitRef="number" contextRef="i15671c3d0d094adaac0c1229062ca074_D20220101-20221231" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzEwMzY_c3948190-a6e3-451a-94ed-287e64537874">10</ix:nonFraction>% or greater, provided that the royalty rate to Zurich may not be less than <ix:nonFraction unitRef="number" contextRef="i15671c3d0d094adaac0c1229062ca074_D20220101-20221231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzExMTM_35d5844f-2526-4736-8c10-5424a4420b8e">2</ix:nonFraction>% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded expenses of $<ix:nonFraction unitRef="usd" contextRef="i22d0546a2e584012b01ef15556862322_D20201201-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTYwOTI_10a5458a-58c0-4167-956d-46599227ec23">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iced9f5bd4c3647f9a7e60cc7a6ea99ed_D20210801-20210831" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTYxMDY_49f6143f-836f-4222-867c-0504f75e3161">0.5</ix:nonFraction>&#160;million related to meeting a development milestone, the submission of the Company&#8217;s BLA with the FDA in December 2020, and a regulatory milestone, the Company&#8217;s receipt of the CRL from the FDA in August 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents (which are now expired) cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of December&#160;31, 2022, even though the patents have expired, the Company may be obligated to pay up to &#8364;<ix:nonFraction unitRef="eur" contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzIyODc_0a910ab1-b4a8-4c9c-9381-2f2879f49696">2.4</ix:nonFraction>&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $<ix:nonFraction unitRef="usd" contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI0MzQ_f996ba31-7583-4a3f-8899-779078034b54">2.6</ix:nonFraction>&#160;million at exchange rates in effect on December&#160;31, 2022). The Company is also required to pay up to a <ix:nonFraction unitRef="number" contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI1MTc_34399fc6-dc6c-4c01-95b9-b46b0d8bb6e8">3.5</ix:nonFraction>% royalty on the net sales for products covered by the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i5de89e3a05284eb7b0e08b05df4512d1" continuedAt="iae7161941f4a4ae29b80f29eb9106146"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to <ix:nonFraction unitRef="number" contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231" decimals="INF" name="sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI2ODY_b0e4a670-aa1c-480a-bb56-1b0aacaea9fa">1.5</ix:nonFraction>% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;<ix:nonFraction unitRef="eur" contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231" decimals="-3" name="sesn:LicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzMwNzk_9a6dea15-32be-41cd-8332-12c17c00460e">50,000</ix:nonFraction>, which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="i211e8012b6af40e08411ca15f526f29f_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzMyNTQ_f271b4b1-5e9e-4e00-8607-589854b1a406">0.7</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i211e8012b6af40e08411ca15f526f29f_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzMyNTg_ce86ddbc-6ad0-4f2e-84a0-e12fc652e91f">0.9</ix:nonFraction>&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. The Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="i5589d69bf52247d28185c2f78a22516f_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzM0Nzk_a59a29b3-993a-4587-bbda-c7daf4dd77ed">0.5</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i5589d69bf52247d28185c2f78a22516f_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzM0ODM_866163ec-eb82-4123-8fe3-75e228c02bc9">0.6</ix:nonFraction>&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, the Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231" decimals="-3" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzcxNDY4MjU2MjgwODM_1c0fddf5-ae58-4d09-8b2b-aaa29217b065">50,000</ix:nonFraction> ($<ix:nonFraction unitRef="usd" contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231" decimals="-1" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTczMzc_79ee66de-de94-4444-956e-3c44e8bb1730">51,770</ix:nonFraction>) related to the annual license maintenance fee. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vysyneum is the proprietary brand name conditionally approved by the EMA for oportuzumab monatox in the E.U. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights (which are now expired) and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, even though the patents have expired, the Company is required to pay up to $<ix:nonFraction unitRef="usd" contextRef="i672eb9cc12ef4dfabefe71540f49d9d4_D20220101-20221231" decimals="-4" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzQxOTI_58c3b964-5cd7-4080-a30a-3695f5f4f012">0.25</ix:nonFraction>&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. The Company is also required to pay a <ix:nonFraction unitRef="number" contextRef="i672eb9cc12ef4dfabefe71540f49d9d4_D20220101-20221231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzQ1MjI_250cff7a-0fa0-4c91-a36a-a0b26868cb71">2.5</ix:nonFraction>% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than <ix:nonFraction unitRef="number" contextRef="i672eb9cc12ef4dfabefe71540f49d9d4_D20220101-20221231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzQ4NDA_5a8a694a-5b00-482b-a5ae-e3596e4c825b">1.75</ix:nonFraction>% of net sales. In addition, the foregoing royalty rates are reduced by <ix:nonFraction unitRef="number" contextRef="i672eb9cc12ef4dfabefe71540f49d9d4_D20220101-20221231" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzQ5MTM_4589a619-e23d-4fe1-97db-84883a070d0f">50</ix:nonFraction>% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company entered into an asset purchase agreement with Roche (the &#8220;Roche Asset Purchase Agreement&#8221;) pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $<ix:nonFraction unitRef="usd" contextRef="i1eaf6421a30f4d65931441ab3517bbd0_I20220731" decimals="-6" name="sesn:OtherReceivableAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MTU3MDA_cf372f04-7d1e-436a-b581-2111233261d0">70.0</ix:nonFraction>&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $<ix:nonFraction unitRef="usd" contextRef="icabd5c54fc0449559aeac9215c25207e_D20220701-20220731" decimals="-6" name="sesn:ProceedsFromExecutionOfAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MTU5NzE_43614cc5-6962-4dcb-bf93-2abba31270f9">40.0</ix:nonFraction>&#160;million payment to the Company upon execution of the Roche Asset Purchase Agreement, which was recorded as license revenue in the third quarter of 2022. The Roche Asset Purchase Agreement also provides that Roche will make an additional $<ix:nonFraction unitRef="usd" contextRef="ie66655811a134f9b8b6e989ecb525174_I20221231" decimals="-6" name="sesn:OtherReceivableAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MTYyMDQ_8c3bcad9-0818-413d-b091-ae7631489a29">30.0</ix:nonFraction>&#160;million payment to the Company upon Roche&#8217;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026. Pursuant to ASC 606, the variable consideration of $<ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-6" name="sesn:AssetPurchaseAgreementVariableConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MTY0MTM_fc925abc-b1d8-473b-9c6e-9392c80f22b7">30.0</ix:nonFraction>&#160;million is constrained. Therefore, the amount was not recorded as revenue during the year ended December 31, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At or prior to the effective time of the Merger, the Company will enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with a rights agent (&#8220;Rights Agent&#8221;) pursuant to which the Company intends to declare a dividend payable to the Company&#8217;s stockholders of record as of a date agreed to by the Company and Carisma prior to the effective time of the Merger with respect to the receipt of one contingent value right (each, a &#8220;CVR&#8221;) for each outstanding share of the Company&#8217;s common stock held by such stockholders on such date. Each CVR will represent the contractual right to receive (i) contingent cash payments upon the receipt by the Company of certain proceeds payable by Roche, if any, pursuant to the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement, as well as (ii) proceeds from any sale of the Company's legacy assets, including Vicineum, subject to certain customary deductions, including for expenses and taxes, in the event any sale occurs prior to March 31, 2027. The contingent payments under the CVR Agreement, if they become due, will be payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="iae7161941f4a4ae29b80f29eb9106146" continuedAt="i6a0765cb71734daf881c7068e92978e2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement. There can be no assurance that any cash payment will be made or that any holders of CVRs will receive any amounts with respect thereto.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Former OUS Business Development Partnership Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu (the &#8220;Qilu License Agreement&#8221;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="ie9a4679b42de470d95370417666d7ba5_D20200730-20200730" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzExNjQx_3e9603ba-a7c6-457d-ad27-7da3d6e0319c">12</ix:nonFraction>&#160;million, and milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="ie9a4679b42de470d95370417666d7ba5_D20200730-20200730" decimals="-6" name="sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzExNjgz_6cecb178-ba44-4325-a590-8e4c2c5bddc9">23</ix:nonFraction>&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu also agreed to pay the Company a <ix:nonFraction unitRef="number" contextRef="ie9a4679b42de470d95370417666d7ba5_D20200730-20200730" decimals="2" name="sesn:BusinessCombinationRoyaltyPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzExOTg1_e96526e5-e6c9-403a-a14a-183b634102c6">12</ix:nonFraction>% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) <ix:nonNumeric contextRef="i4383d15b8e8f48599512b909df5f7d25_D20200730-20200730" name="sesn:CollaborativeArrangementRoyaltyPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkwOTAzODM_5ec781c1-e801-4492-bbf2-3d16e2a1fc48">twelve years</ix:nonNumeric> after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2022, the Company terminated the Qilu License Agreement. In connection with the termination of the Qilu License Agreement, the Company agreed to make an aggregate payment to Qilu of $<ix:nonFraction unitRef="usd" contextRef="ie9cd9290db5c494b8aac997b30e9f530_D20210801-20210831" decimals="-5" name="sesn:LicenseAgreementTerminationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTYxMjA_97ba5a87-ed56-4001-b59d-a2768847f367">1.4</ix:nonFraction>&#160;million, which consists of a $<ix:nonFraction unitRef="usd" contextRef="i068115fbd385473eaf14a517d80898f9_D20221001-20221231" decimals="-3" name="sesn:LicenseAgreementTerminationPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTYxMzQ_1597fe3f-8e9c-4d79-9578-a524256bf4e6">1.2</ix:nonFraction>&#160;million termination fee payable upon the termination of the Qilu License Agreement, which was paid in the fourth quarter of 2022, and a $<ix:nonFraction unitRef="usd" contextRef="icdcdf96fee1148569a372008cbcbc48f_D20220101-20221231" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTYxNDg_fc84dc20-ccdb-4672-ab65-15a7f262b493">200,000</ix:nonFraction> payment payable upon our receipt of certain clinical data and chemistry, manufacturing, and controls data from Qilu, which such payment was not made as of December 31, 2022. Accordingly, $<ix:nonFraction unitRef="usd" contextRef="icdcdf96fee1148569a372008cbcbc48f_D20220101-20221231" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzEwOTk1MTE2NzQ2ODE_5c7b876d-c541-4b60-81c3-7f1664ccabb6">0.2</ix:nonFraction>&#160;million remained on the Company's balance sheet in accrued liabilities as of December 31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hikma License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region (the "Hikma License Agreement"). The Company retained development and commercialization rights in the rest of the world excluding Greater China, Turkey, and MENA. In consideration for the rights granted by the Company, the counterparty to the Hikma License Agreement agreed to pay to the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i40dde77c20a24756b6c9849cf8a19522_D20201130-20201130" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzEwOTk1MTE2NjMzMjI_1d23ca43-79da-4656-91ba-184978f067c3">3</ix:nonFraction>&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the Hikma License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2022, the Company provided notice of termination of the Hikma License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the United States. In connection with such termination, the Company refunded to Hikma the $<ix:nonFraction unitRef="usd" contextRef="i3078e30e83804e5189a02bd018d21ad5_D20220720-20220720" decimals="-5" name="sesn:PaymentsToRefundLicenseAgreementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzM4NDgyOTA3NDQyMDg_cde0ef46-bbb4-4005-a712-ffbee45fb2fe">3.0</ix:nonFraction>&#160;million upfront payment.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement"). Under the terms of the License Agreement, the Company was entitled to receive an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i4a1663e77ac1498184a0073f406681d3_I20210805" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzE5NDI3_0efb2f9f-c88f-414e-b564-57acc8e23ea0">1.5</ix:nonFraction>&#160;million. The Company and EIP have subsequently amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company would have been eligible to receive additional regulatory and commercial milestone payments of $<ix:nonFraction unitRef="usd" contextRef="iaa658292b071478aa327ee12757b1aec_D20210805-20210805" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MjQ3MzA_5fb66638-ecdd-4b4e-a8e7-f42853406477">2.0</ix:nonFraction>&#160;million and also to receive a <ix:nonFraction unitRef="number" contextRef="ic1294558bb964edc87c70925cf5cde03_I20210805" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MjQ3NTY_2e1913e8-cda1-4af8-a9e7-672e980b84aa">30</ix:nonFraction>% royalty on net sales in Turkey and Northern Cyprus. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6a0765cb71734daf881c7068e92978e2">On July 20, 2022, the Company provided notice of termination of the EIP License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the United States. The EIP License Agreement was terminated on October 20, 2022.</ix:continuation></span></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_136"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90ZXh0cmVnaW9uOjZmNTMxMWVlNzkxOTRjYzRiMmI5MTRkYzdmYjQzNzZiXzEwNzI_87893932-ba47-48d8-97c6-c3437ec037c5" continuedAt="ica4f51cfc0ba47c7b48b642c7080b89a" escape="true">RESTRUCTURING AND RELATED ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="ica4f51cfc0ba47c7b48b642c7080b89a" continuedAt="ia796d11884ea4edd9c5a4b2157ca7b1a"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to voluntarily pause further development of Vicineum in the United States (the &#8220;2022 Restructuring Plan&#8221;). Execution of the 2022 Restructuring Plan is expected to be substantially completed in connection with the closing of the Merger with Carisma, which is expected to occur in the first quarter of 2023. The 2022 Restructuring Plan includes an incremental reduction in the Company&#8217;s workforce as well as additional cost-saving initiatives intended to preserve capital during the pendency of the Merger with Carisma and while the Company seeks a potential partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also incurred one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90ZXh0cmVnaW9uOjZmNTMxMWVlNzkxOTRjYzRiMmI5MTRkYzdmYjQzNzZiXzM4NDgyOTA3MDMxMzQ_8957a3cd-cfe3-47c4-aee8-8ddd7121d59f" continuedAt="ic32769ee015440799f6fd01f7c844857" escape="true">The following is a summary of accrued restructuring costs related to the 2022 Restructuring Plan, (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><ix:continuation id="ic32769ee015440799f6fd01f7c844857" continuedAt="i41c224f3bd604ab9a3599560a716726f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Restructuring Plan </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82aa374295f472f94fa22a817803cf0_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTplOWYxNDBkNjA0OTI0MDBjYmM4YzMxNzZiYjVlZGEyMS90YWJsZXJhbmdlOmU5ZjE0MGQ2MDQ5MjQwMGNiYzhjMzE3NmJiNWVkYTIxXzEtMS0xLTEtOTUyNDM_107e6244-509c-4e82-a393-32e997f726c9">6,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination and other associated costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib391d9ecf3114b2c994998943181cc31_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTplOWYxNDBkNjA0OTI0MDBjYmM4YzMxNzZiYjVlZGEyMS90YWJsZXJhbmdlOmU5ZjE0MGQ2MDQ5MjQwMGNiYzhjMzE3NmJiNWVkYTIxXzItMS0xLTEtOTUyNDM_1f19992a-9296-4f9d-8928-3e9eb55d7569">4,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructurings costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i712c5f7e1c9a4489a1932903418a4389_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTplOWYxNDBkNjA0OTI0MDBjYmM4YzMxNzZiYjVlZGEyMS90YWJsZXJhbmdlOmU5ZjE0MGQ2MDQ5MjQwMGNiYzhjMzE3NmJiNWVkYTIxXzMtMS0xLTEtOTU1NzE_4efcb9d9-5f6c-4ed9-acb2-47c2507325a3">11,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i712c5f7e1c9a4489a1932903418a4389_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTplOWYxNDBkNjA0OTI0MDBjYmM4YzMxNzZiYjVlZGEyMS90YWJsZXJhbmdlOmU5ZjE0MGQ2MDQ5MjQwMGNiYzhjMzE3NmJiNWVkYTIxXzQtMS0xLTEtOTUyNDM_99858c2f-8690-4775-95a6-df75c1699e58">6,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ad0b07f8ff40c5a4c7df314a525778_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTplOWYxNDBkNjA0OTI0MDBjYmM4YzMxNzZiYjVlZGEyMS90YWJsZXJhbmdlOmU5ZjE0MGQ2MDQ5MjQwMGNiYzhjMzE3NmJiNWVkYTIxXzUtMS0xLTEtOTU1NzU_3159ba9f-a7ce-4f42-83a5-0c911f3f0413">5,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs related to the 2022 Restructuring Plan were recorded in operating expenses in the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss in the year ended December 31, 2022. The Company expects that substantially all accrued restructuring costs as of December 31, 2022 will be paid in cash in connection with the closing of the Merger with Carisma, which is expected to be completed in the first quarter of 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;2021 Restructuring Plan&#8221;). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Restructuring Plan included a reduction in the Company&#8217;s workforce by <ix:nonFraction unitRef="position" contextRef="i5532051f20ab4b50a0fedc0c29b03429_D20210830-20210830" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90ZXh0cmVnaW9uOjZmNTMxMWVlNzkxOTRjYzRiMmI5MTRkYzdmYjQzNzZiXzcxNDY4MjU1ODk1MDI_f60aaf7e-e37b-408e-b135-9b1fec6ac6b7">18</ix:nonFraction> positions (or approximately <ix:nonFraction unitRef="number" contextRef="i5532051f20ab4b50a0fedc0c29b03429_D20210830-20210830" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90ZXh0cmVnaW9uOjZmNTMxMWVlNzkxOTRjYzRiMmI5MTRkYzdmYjQzNzZiXzcxNDY4MjU1ODk1MzQ_1c26456d-1aba-4a05-a509-823de5dc126e">35</ix:nonFraction>% of the Company&#8217;s workforce as of the date of the 2021 Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continued development of Vicineum. <ix:continuation id="i41c224f3bd604ab9a3599560a716726f" continuedAt="ib37db97190a2482b81163b87e37f7d30">The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan:</ix:continuation></span></div><div style="margin-bottom:6pt;text-align:justify"><ix:continuation id="ib37db97190a2482b81163b87e37f7d30"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Restructuring Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTo2NjBhYTMzMWE4Mzk0ZTQ3YjEyM2U5MjA4YmMzMzdmMy90YWJsZXJhbmdlOjY2MGFhMzMxYTgzOTRlNDdiMTIzZTkyMDhiYzMzN2YzXzEtMS0xLTEtOTkxMDY_884e0ea9-13cd-4eaf-923d-cf16f3fc2aa9">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTo2NjBhYTMzMWE4Mzk0ZTQ3YjEyM2U5MjA4YmMzMzdmMy90YWJsZXJhbmdlOjY2MGFhMzMxYTgzOTRlNDdiMTIzZTkyMDhiYzMzN2YzXzItMS0xLTEtOTkxMDY_850e1231-717a-402c-b088-68598148e7b6">1,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTo2NjBhYTMzMWE4Mzk0ZTQ3YjEyM2U5MjA4YmMzMzdmMy90YWJsZXJhbmdlOjY2MGFhMzMxYTgzOTRlNDdiMTIzZTkyMDhiYzMzN2YzXzMtMS0xLTEtOTkxMDY_753012a9-bd46-4da7-9d1b-a28fdf763e4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia796d11884ea4edd9c5a4b2157ca7b1a">Restructuring costs related to the 2021 Restructuring Plan were recorded in operating expenses in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss in the year ended December 31, 2021.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><div id="i6d755c213f784994a9d98b9e4ebda9e0_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzkvZnJhZzphNzM3Y2QyMGU0ZDk0NGVmYmIzZjhhYjkxM2E4NTU1YS90ZXh0cmVnaW9uOmE3MzdjZDIwZTRkOTQ0ZWZiYjNmOGFiOTEzYTg1NTVhXzI5ODQ_0b71ee3f-cf93-4b81-a80e-636ca30c483d" continuedAt="i7ecbbe25f9854bd08b33c1d5b7e63425" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i7ecbbe25f9854bd08b33c1d5b7e63425"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nasdaq Delisting Notice</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger with Carisma, the Company is seeking the approval of its stockholders to, among other things, (a) issue the shares of its common stock issuable in connection with the Merger pursuant to the rules of Nasdaq, and (b) amend its amended and restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of its common stock at a ratio of 1-for-20 (clauses (a) and (b), collectively, the &#8220;Sesen Bio Voting Proposals&#8221;). The special meeting of stockholders in which the Company&#8217;s stockholders will be asked to vote on the Sesen Bio Voting Proposals will be held on March 2, 2023 at 10:00 a.m. Eastern Time (the "Special Meeting").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2023, the Company was notified by the Listing Qualifications Department (the &#8220;Staff&#8221;) of Nasdaq that, based upon the Company&#8217;s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price Rule&#8221;), the Company&#8217;s common stock will be delisted from Nasdaq unless it timely requests a hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company requested a hearing before the Panel, which stayed any delisting action by the Staff and ensured the Company&#8217;s common stock remains listed and eligible for trading on Nasdaq pending a determination by the Panel. The hearing had been scheduled for March 16, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2023, the Company received a determination from the Nasdaq Office of General Counsel that the Panel granted the Company an exception from its non-compliance with the Bid Price Rule to complete the Merger by March 10, 2023. Pursuant to Nasdaq Listing Rule 5110(a), the Company must demonstrate compliance with all initial listing requirements of Nasdaq upon the closing of the Merger. The Company is seeking approval for the Merger and the implementation of a reverse stock split of its common stock at the Special Meeting. In the event the Company fails to establish compliance with the initial listing standards by March 10, 2023, the common stock will be delisted from Nasdaq, unless granted an additional exception by the Panel.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 24, 2022, the Company received written notice from the Staff indicating that, based upon the closing bid price for its common stock for the previous 30 consecutive business days, the Company no longer satisfied the Bid Price Rule and, in accordance with the Nasdaq Listing Rules, was afforded an initial grace period of 180 calendar days, through July 25, 2022, and a second 180-calendar day period, through January 23, 2023, to regain compliance with the Bid Price Rule. The Company did not regain compliance with the Bid Price Rule by January 23, 2023, which resulted in the Staff&#8217;s January 25, 2023, determination.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>exhibit211-subsidiariesofs.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ied079f647cfe4d8692692f290ebd3ee4_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 21.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiaries of Sesen Bio, Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.903%"><tr><td style="width:1.0%"></td><td style="width:39.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Viventia Bio Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Province of Ontario, Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Viventia Bio USA Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Province of Ontario, Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Seahawk Merger Sub, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit231eyfy2023consent_.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1f4257f689ed49e492ee185272cd63fe_1"></div><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 23.1</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-8 No. 333-195170) pertaining to the Eleven Biotherapeutics, Inc. Amended and Restated 2009 Stock Incentive Plan, 2014 Stock Incentive Plan and 2014 Employee Stock Purchase Plan&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Post-Effective Amendment No. 1 to Form S-1 on Form S-3 No. 333-201176) of Eleven Biotherapeutics, Inc.&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(3)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-8 No. 333-202677) pertaining to the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(4)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-8 No. 333-210523) pertaining to the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(5)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-8 No. 333-217686) pertaining to the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(6)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-8 No. 333-217687) pertaining to the Eleven Biotherapeutics, Inc. Inducement Stock Option Awards&#59;</font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(7)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Amendment No. 3 to Form S-1 No. 333-220809) of Eleven Biotherapeutics, Inc.&#59;</font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(8)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Form S-3 No. 333-224682) of Eleven Biotherapeutics, Inc.&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(9)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.88pt">Registration Statement (Pre-Effective Amendment No. 1 to Form S-3 No. 333-223750) of Eleven Biotherapeutics, Inc.&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(10)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Post-Effective Amendment No. 1 to Form S-8 No. 333-224959) pertaining to the Sesen Bio, Inc.  2014 Stock Incentive Plan (formerly known as the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan)&#59;</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(11)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Form S-8 No. 333-231644) pertaining to the Sesen Bio, Inc. 2014 Stock Incentive Plan (formerly known as the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan) and Sesen Bio, Inc. Inducement Stock Option Awards&#59; and</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(12)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Form S-8 No. 333-234697) pertaining to the Sesen Bio, Inc. 2014 Stock Incentive Plan (formerly known as the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan) and Sesen Bio, Inc. Inducement Stock Option Awards</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(13)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Form S-8 No. 333-254264) pertaining to the Sesen Bio, Inc. Inducement Stock Option Awards</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(14)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Form S-8 No. 333-255941) pertaining to the Sesen Bio, Inc. 2014 Stock Incentive Plan (as amended effective May 3, 2021) and the Sesen Bio, Inc. 2014 Employee Stock Purchase Plan (as amended effective May 3, 2021)</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(15)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Form S-3 No. 333-255943) of Sesen Bio, Inc.</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(16)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.82pt">Registration Statement (Form S-8 No. 333-263070) pertaining to the Sesen Bio, Inc. Inducement Stock Option Awards </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">of our report dated February 28, 2023, with respect to the consolidated financial statements of Sesen Bio, Inc. included in this Annual Report (Form&#160;10-K) of Sesen Bio, Inc. for the year ended December&#160;31, 2022.</font></div><div style="margin-bottom:6pt;padding-left:4pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Boston, Massachusetts</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">February 28, 2023</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>sesn-12312022x10kex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib26597bdc4294aeeb2e59f8f2d992265_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Thomas R. Cannell, D.V.M., certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 of Sesen Bio, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.777%"><tr><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas R. Cannell, D.V.M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>sesn-12312022x10kex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3057e36eec2b49e79fc8ad66fe0d49d3_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Monica Forbes, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 of Sesen Bio, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>sesn-12312022x10kex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2b26b7eaf1254060bb71616558adcbcc_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Annual Report on Form 10-K of Sesen Bio, Inc. (the &#8220;Company&#8221;) for the fiscal year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the Report fully complies with the requirements of section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas R. Cannell, D.V.M.&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>sesn-12312022x10kex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iad5cdbdbe50b406cbdab171bff9779c8_1"></div><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Annual Report on Form 10-K of Sesen Bio, Inc. (the &#8220;Company&#8221;) for the fiscal year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the Report fully complies with the requirements of section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>sesn-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:cb59ddaf-3c33-4c46-89b9-ef07748101c9,g:f5662b05-afda-41c0-b68c-8f02735bc2a0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sesn="http://www.sesenbio.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sesenbio.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sesenbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.sesenbio.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>0000010 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATION" roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION">
        <link:definition>0000011 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>0000013 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS">
        <link:definition>0000014 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRICTEDCASHANDMARKETABLESECURITIES" roleURI="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIES">
        <link:definition>0000015 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECEIVABLES" roleURI="http://www.sesenbio.com/role/RECEIVABLES">
        <link:definition>0000016 - Disclosure - RECEIVABLES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>0000017 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILL" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL">
        <link:definition>0000018 - Disclosure - INTANGIBLES AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES">
        <link:definition>0000019 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.sesenbio.com/role/LEASES">
        <link:definition>0000021 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT">
        <link:definition>0000022 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>0000023 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>0000024 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>0000025 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.sesenbio.com/role/INCOMETAXES">
        <link:definition>0000026 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTS" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS">
        <link:definition>0000027 - Disclosure - LICENSE AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIES" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES">
        <link:definition>0000028 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000029 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables">
        <link:definition>0000031 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRICTEDCASHANDMARKETABLESECURITIESTables" roleURI="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESTables">
        <link:definition>0000032 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>0000033 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILLTables" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables">
        <link:definition>0000034 - Disclosure - INTANGIBLES AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables">
        <link:definition>0000035 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.sesenbio.com/role/LEASESTables">
        <link:definition>0000036 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITTables" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables">
        <link:definition>0000037 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>0000038 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>0000039 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.sesenbio.com/role/INCOMETAXESTables">
        <link:definition>0000040 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESTables" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables">
        <link:definition>0000041 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>0000042 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>0000043 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000044 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>0000045 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails">
        <link:definition>0000046 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRICTEDCASHANDMARKETABLESECURITIESDetails" roleURI="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESDetails">
        <link:definition>0000047 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails" roleURI="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails">
        <link:definition>0000048 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES - Schedule of Cash, Cash Equivalents, Restricted Cash And Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECEIVABLESDetails" roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails">
        <link:definition>0000049 - Disclosure - RECEIVABLES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails" roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails">
        <link:definition>0000050 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNarrativeDetails" roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails">
        <link:definition>0000051 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails">
        <link:definition>0000052 - Disclosure - INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILLNarrativeDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails">
        <link:definition>0000053 - Disclosure - INTANGIBLES AND GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails">
        <link:definition>0000054 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>0000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails">
        <link:definition>0000056 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseCostsDetails" roleURI="http://www.sesenbio.com/role/LEASESLeaseCostsDetails">
        <link:definition>0000057 - Disclosure - LEASES - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails">
        <link:definition>0000058 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITPreferredStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails">
        <link:definition>0000059 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITCommonStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails">
        <link:definition>0000060 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails">
        <link:definition>0000061 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITWarrantsDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails">
        <link:definition>0000062 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails">
        <link:definition>0000063 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails">
        <link:definition>0000064 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
        <link:definition>0000065 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>0000066 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails">
        <link:definition>0000067 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails">
        <link:definition>0000068 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails">
        <link:definition>0000069 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSDetails" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails">
        <link:definition>0000070 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofPretaxIncomeLossDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails">
        <link:definition>0000071 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofIncomeTaxProvisionsDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails">
        <link:definition>0000072 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails">
        <link:definition>0000073 - Disclosure - INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000074 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>0000075 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofCreditCarryforwardsDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails">
        <link:definition>0000076 - Disclosure - INCOME TAXES - Schedule of Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTSDetails" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails">
        <link:definition>0000077 - Disclosure - LICENSE AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails">
        <link:definition>0000078 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails">
        <link:definition>0000079 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Schedule of Restructuring Reserve by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>0000080 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sesn_NumberofVotesEntitledForEachShare" abstract="false" name="NumberofVotesEntitledForEachShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_RetentionProgramMember" abstract="true" name="RetentionProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_OtherReceivableAssetPurchaseAgreement" abstract="false" name="OtherReceivableAssetPurchaseAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" abstract="true" name="EczacibasiPharmaceuticalsMarketingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" abstract="false" name="SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_MENALicenseAgreementMember" abstract="true" name="MENALicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightIssuedDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" abstract="false" name="ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestoneAchieved" abstract="false" name="LicenseAgreementMilestoneAchieved" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" abstract="false" name="SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember" abstract="true" name="RestrictedStockUnitsPerformanceBasedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseMaintenanceFees" abstract="false" name="LicenseMaintenanceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" abstract="false" name="BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ATMFacilityMember" abstract="true" name="ATMFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SupplementalLeaseInformationAbstract" abstract="true" name="SupplementalLeaseInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_UniversityOfZurichMember" abstract="true" name="UniversityOfZurichMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_LicenseAgreementTextBlock" abstract="false" name="LicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationTable" abstract="true" name="OrganizationAndBasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_SaleOfStockCommissionFixedRate" abstract="false" name="SaleOfStockCommissionFixedRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_StockIncentivePlanTwoThousandFourteenMember" abstract="true" name="StockIncentivePlanTwoThousandFourteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SharesOfCommonStockReservedForIssuanceAbstract" abstract="true" name="SharesOfCommonStockReservedForIssuanceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_A2014EmployeeStockPurchasePlanMember" abstract="true" name="A2014EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_QiluPharmaceuticalCoLtdMember" abstract="true" name="QiluPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SaleOfStockAdditionalSharesAuthorizedForSale" abstract="false" name="SaleOfStockAdditionalSharesAuthorizedForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_AccountsReceivablePaymentTerms" abstract="false" name="AccountsReceivablePaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_CommonStockSharesIssuedAndReservedForFuture" abstract="false" name="CommonStockSharesIssuedAndReservedForFuture" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" abstract="false" name="ProceedsFromExecutionOfAssetPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" abstract="false" name="LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" abstract="false" name="StockIssuedDuringPeriodNewIssuesIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" abstract="false" name="SaleOfStockMaximumAggregateSalesPriceInTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_NetOperatingLossCarryforwardDomain" abstract="true" name="NetOperatingLossCarryforwardDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_OperatingLeaseLeaseTerminationPayment" abstract="false" name="OperatingLeaseLeaseTerminationPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OperatingLossCarryforwardsDecrease" abstract="false" name="OperatingLossCarryforwardsDecrease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedMay2015Member" abstract="true" name="WarrantsExpiringNovember2024IssuedMay2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyRate" abstract="false" name="LicenseAgreementRoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestonePaymentTerm" abstract="false" name="LicenseAgreementMilestonePaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" abstract="false" name="SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_RetentionProgramCashManagementMilestoneMember" abstract="true" name="RetentionProgramCashManagementMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" abstract="false" name="SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_XOMAIrelandLimitedMember" abstract="true" name="XOMAIrelandLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_AssetPurchaseAgreementVariableConsideration" abstract="false" name="AssetPurchaseAgreementVariableConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementTerminationPayment" abstract="false" name="LicenseAgreementTerminationPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OperatingLeasesAreaOfOfficeSpace" abstract="false" name="OperatingLeasesAreaOfOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="sesn_CommonStockAndWarrantOrRightsPricePerShare" abstract="false" name="CommonStockAndWarrantOrRightsPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" abstract="true" name="WarrantsExpiringNovember2024IssuedNovember2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ViventiaBioInc.Member" abstract="true" name="ViventiaBioInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" abstract="false" name="IncreaseDecreaseOfPrepaidExpensesNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_IssuanceOfWarrantForCommonStock" abstract="false" name="IssuanceOfWarrantForCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementTerminationExpense" abstract="false" name="LicenseAgreementTerminationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2022Member" abstract="true" name="WarrantsExpiringNovember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" abstract="false" name="LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" abstract="false" name="RevenueRecognitionMilestoneMethodPotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementProceedsFromMilestoneAchieved" abstract="false" name="LicenseAgreementProceedsFromMilestoneAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_PaymentsToRefundLicenseAgreementDeposits" abstract="false" name="PaymentsToRefundLicenseAgreementDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember" abstract="true" name="InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" abstract="true" name="A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" abstract="false" name="DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OtherDividendAndAdjustments" abstract="false" name="OtherDividendAndAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ViciniumMember" abstract="true" name="ViciniumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_RoyaltyRevenuePercentage" abstract="false" name="RoyaltyRevenuePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sesn_AccruedLegalFeesCurrent" abstract="false" name="AccruedLegalFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WeightedAverageCostOfCapital" abstract="false" name="WeightedAverageCostOfCapital" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_EBI031Member" abstract="true" name="EBI031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_OperatingLeaseMonthlyRent" abstract="false" name="OperatingLeaseMonthlyRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_NetOperatingLossCarryforwardAxis" abstract="true" name="NetOperatingLossCarryforwardAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_FederalDerivativeLitigationMember" abstract="true" name="FederalDerivativeLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedforFutureIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestoneAchievementExpense" abstract="false" name="LicenseAgreementMilestoneAchievementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WarrantsExpiringMarch2023Member" abstract="true" name="WarrantsExpiringMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_WarrantOrRightOutstandingRollForward" abstract="true" name="WarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_StockIncentivePlan2009Member" abstract="true" name="StockIncentivePlan2009Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_DeferredTaxAssetsCapitalizedStartUpCosts" abstract="false" name="DeferredTaxAssetsCapitalizedStartUpCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_ContingentConsiderationPolicyTextBlock" abstract="false" name="ContingentConsiderationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_BusinessCombinationRoyaltyPaymentPercent" abstract="false" name="BusinessCombinationRoyaltyPaymentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationLineItems" abstract="true" name="OrganizationAndBasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_MicrometAGMember" abstract="true" name="MicrometAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRoyaltyPeriod" abstract="false" name="CollaborativeArrangementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" abstract="false" name="RightOfUseAssetRelatedToAdoptionOfAccountingStandard" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_NonCapitalLossCarryforwardMember" abstract="true" name="NonCapitalLossCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_AccruedRestructuringChargesRelatedCurrent" abstract="false" name="AccruedRestructuringChargesRelatedCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" abstract="true" name="CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" abstract="false" name="StockIssuedDuringPeriodExerciseOfWarrantsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_A2022RestructuringPlanMember" abstract="true" name="A2022RestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestonePayment" abstract="false" name="LicenseAgreementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_A2021RestructuringPlanMember" abstract="true" name="A2021RestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NumberOfLawsuits" abstract="false" name="NumberOfLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" abstract="false" name="LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>sesn-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:cb59ddaf-3c33-4c46-89b9-ef07748101c9,g:f5662b05-afda-41c0-b68c-8f02735bc2a0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_925146d5-49a5-49d9-8300-50b6a456f0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_568b7cc9-8cca-4112-b811-8b8cf9df0002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_925146d5-49a5-49d9-8300-50b6a456f0e6" xlink:to="loc_us-gaap_StockholdersEquity_568b7cc9-8cca-4112-b811-8b8cf9df0002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_badc2d52-bd9d-4f6a-8a54-4c7a01dde937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_925146d5-49a5-49d9-8300-50b6a456f0e6" xlink:to="loc_us-gaap_Liabilities_badc2d52-bd9d-4f6a-8a54-4c7a01dde937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_99f1b258-f7a7-471d-a6f3-12319325623c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c9e76127-255c-4dd7-9239-259b7aac7c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_99f1b258-f7a7-471d-a6f3-12319325623c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c9e76127-255c-4dd7-9239-259b7aac7c11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_674916c0-7af9-4192-8480-10dc0022f2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_99f1b258-f7a7-471d-a6f3-12319325623c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_674916c0-7af9-4192-8480-10dc0022f2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_08ef632a-1c6e-4828-83ad-5a77a28908ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_99f1b258-f7a7-471d-a6f3-12319325623c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_08ef632a-1c6e-4828-83ad-5a77a28908ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c002662d-331e-4c19-aeae-5e9a7a1f8289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_19cb03b2-ce7e-4ba1-8a81-79ee30d505b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c002662d-331e-4c19-aeae-5e9a7a1f8289" xlink:to="loc_us-gaap_AssetsNoncurrent_19cb03b2-ce7e-4ba1-8a81-79ee30d505b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_60dcf4ef-5105-4aea-84bc-740abf1e9589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c002662d-331e-4c19-aeae-5e9a7a1f8289" xlink:to="loc_us-gaap_AssetsCurrent_60dcf4ef-5105-4aea-84bc-740abf1e9589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_3d563e08-7d2d-435f-a0d1-bfd5d65a1dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0fb964ba-5e1a-44f2-bbb6-8652ade5558d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3d563e08-7d2d-435f-a0d1-bfd5d65a1dc3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0fb964ba-5e1a-44f2-bbb6-8652ade5558d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7cfb61aa-a6be-4410-831c-b629a843045a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3d563e08-7d2d-435f-a0d1-bfd5d65a1dc3" xlink:to="loc_us-gaap_Goodwill_7cfb61aa-a6be-4410-831c-b629a843045a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bc97e1c3-8ed6-4c73-9f5d-0b82aa65205a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3d563e08-7d2d-435f-a0d1-bfd5d65a1dc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bc97e1c3-8ed6-4c73-9f5d-0b82aa65205a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_c40be0d5-e4b2-4cd3-8db5-da9d2009dec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3d563e08-7d2d-435f-a0d1-bfd5d65a1dc3" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_c40be0d5-e4b2-4cd3-8db5-da9d2009dec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_7da9e0de-834b-4205-aaf5-ece74cc918cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3d563e08-7d2d-435f-a0d1-bfd5d65a1dc3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_7da9e0de-834b-4205-aaf5-ece74cc918cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6dea927c-44b4-4a5c-9815-4ab57283d6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3d563e08-7d2d-435f-a0d1-bfd5d65a1dc3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6dea927c-44b4-4a5c-9815-4ab57283d6e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_afeaa053-0790-4ad1-a3d6-334d615df38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0102f86-7e38-4726-a875-a92a00aa5f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_afeaa053-0790-4ad1-a3d6-334d615df38a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0102f86-7e38-4726-a875-a92a00aa5f3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d66a1aac-81d3-4264-a6fe-975819034efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_afeaa053-0790-4ad1-a3d6-334d615df38a" xlink:to="loc_us-gaap_PreferredStockValue_d66a1aac-81d3-4264-a6fe-975819034efa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6866907b-1950-4106-8f09-35b355394e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_afeaa053-0790-4ad1-a3d6-334d615df38a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6866907b-1950-4106-8f09-35b355394e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8db672e0-e859-437e-825b-f11d7fb0aff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_afeaa053-0790-4ad1-a3d6-334d615df38a" xlink:to="loc_us-gaap_CommonStockValue_8db672e0-e859-437e-825b-f11d7fb0aff0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6af2bea6-45e0-499d-a7e6-1cf211295327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_afeaa053-0790-4ad1-a3d6-334d615df38a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6af2bea6-45e0-499d-a7e6-1cf211295327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bb7db009-cc7a-477d-b72c-517248c3c8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8923478f-48ef-404f-b59f-5f69e63b0396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb7db009-cc7a-477d-b72c-517248c3c8f2" xlink:to="loc_us-gaap_AccountsPayableCurrent_8923478f-48ef-404f-b59f-5f69e63b0396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_84d58a6a-29f9-43f3-8fdb-457b20b35da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb7db009-cc7a-477d-b72c-517248c3c8f2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_84d58a6a-29f9-43f3-8fdb-457b20b35da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8f4b4e65-742c-44ff-bc74-455c3ab1a696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb7db009-cc7a-477d-b72c-517248c3c8f2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8f4b4e65-742c-44ff-bc74-455c3ab1a696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c940b658-2a56-43df-a732-c2e3162c173e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_1f64a45e-d17f-4703-872a-82181300502b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c940b658-2a56-43df-a732-c2e3162c173e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_1f64a45e-d17f-4703-872a-82181300502b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a1c828dd-1bf8-4d8a-85a8-d88835a079e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c940b658-2a56-43df-a732-c2e3162c173e" xlink:to="loc_us-gaap_LiabilitiesCurrent_a1c828dd-1bf8-4d8a-85a8-d88835a079e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf047444-2dc1-45bf-b4d2-0ef3fb299086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_c2c83f80-edea-48e8-b4d9-993b9af07756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf047444-2dc1-45bf-b4d2-0ef3fb299086" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_c2c83f80-edea-48e8-b4d9-993b9af07756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bc3f3b9b-9b69-425f-8d0a-bb3e19cec4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf047444-2dc1-45bf-b4d2-0ef3fb299086" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bc3f3b9b-9b69-425f-8d0a-bb3e19cec4ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_3d3f7fb9-706a-4558-a6cc-a7450286bfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf047444-2dc1-45bf-b4d2-0ef3fb299086" xlink:to="loc_us-gaap_RestrictedCashCurrent_3d3f7fb9-706a-4558-a6cc-a7450286bfcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1b1ba507-5e16-416d-a9a1-537508424184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf047444-2dc1-45bf-b4d2-0ef3fb299086" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1b1ba507-5e16-416d-a9a1-537508424184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7dbb92fd-32fa-4625-b5dc-0809a8fdedf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf047444-2dc1-45bf-b4d2-0ef3fb299086" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7dbb92fd-32fa-4625-b5dc-0809a8fdedf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_38c78c50-1fec-4ff7-a191-6f7deb20f128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf047444-2dc1-45bf-b4d2-0ef3fb299086" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_38c78c50-1fec-4ff7-a191-6f7deb20f128" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_35c00806-0747-4f2f-822d-544ecb3f8ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_ad3b8dc7-b581-42e2-926f-c8e9ac5f1dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_35c00806-0747-4f2f-822d-544ecb3f8ea9" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_ad3b8dc7-b581-42e2-926f-c8e9ac5f1dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a2d757f7-949a-41cb-82d6-641ee2cf0449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_35c00806-0747-4f2f-822d-544ecb3f8ea9" xlink:to="loc_us-gaap_NetIncomeLoss_a2d757f7-949a-41cb-82d6-641ee2cf0449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_001a4621-ae2b-4bc2-94f7-ebc717db1a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0a90139a-6a1c-4a25-89a9-f0e453fced31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_001a4621-ae2b-4bc2-94f7-ebc717db1a4d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0a90139a-6a1c-4a25-89a9-f0e453fced31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_558a126c-cb1c-4623-8ffd-ac674c729983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_001a4621-ae2b-4bc2-94f7-ebc717db1a4d" xlink:to="loc_us-gaap_OperatingIncomeLoss_558a126c-cb1c-4623-8ffd-ac674c729983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ef0ad82c-ef4c-4198-abbb-74f382a9a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_001a4621-ae2b-4bc2-94f7-ebc717db1a4d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ef0ad82c-ef4c-4198-abbb-74f382a9a3ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6079c3e-bb52-46b8-afbb-5e6a14fa4f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_8a07860f-aef0-4f13-a8d9-207518efb07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e6079c3e-bb52-46b8-afbb-5e6a14fa4f9c" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_8a07860f-aef0-4f13-a8d9-207518efb07f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cd792bf0-bdc8-4142-9c93-3fe7ec4cca36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e6079c3e-bb52-46b8-afbb-5e6a14fa4f9c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cd792bf0-bdc8-4142-9c93-3fe7ec4cca36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_590e7096-8ea3-4ca2-afc2-5011fdb2fcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_7121e0d4-c5ec-4d67-98d0-8d79ffbaf8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_590e7096-8ea3-4ca2-afc2-5011fdb2fcfc" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_7121e0d4-c5ec-4d67-98d0-8d79ffbaf8e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9bfa8b89-8192-4f22-9d3f-3220cd1c1839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_590e7096-8ea3-4ca2-afc2-5011fdb2fcfc" xlink:to="loc_us-gaap_NetIncomeLoss_9bfa8b89-8192-4f22-9d3f-3220cd1c1839" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_320bc606-50f5-43d4-a341-08721291bcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7953f4a3-1f58-4411-8630-8b1517d46950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_320bc606-50f5-43d4-a341-08721291bcd5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7953f4a3-1f58-4411-8630-8b1517d46950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ca02278b-d3fc-4fcf-b667-7a85a719de1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_320bc606-50f5-43d4-a341-08721291bcd5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ca02278b-d3fc-4fcf-b667-7a85a719de1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ff6bef6b-f852-4272-be65-bc76ebe5c437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_320bc606-50f5-43d4-a341-08721291bcd5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ff6bef6b-f852-4272-be65-bc76ebe5c437" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_944b9da4-6c78-4250-8c97-90714d3f24b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_320bc606-50f5-43d4-a341-08721291bcd5" xlink:to="loc_us-gaap_RestructuringCharges_944b9da4-6c78-4250-8c97-90714d3f24b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_dc746403-8f4a-41ba-9d5f-eba06b3e1fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_320bc606-50f5-43d4-a341-08721291bcd5" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_dc746403-8f4a-41ba-9d5f-eba06b3e1fb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1dc5b9f2-a5aa-43b9-b999-e86da50acc60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_1cabb82e-a23e-4ed2-8c08-2d023faabed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1dc5b9f2-a5aa-43b9-b999-e86da50acc60" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_1cabb82e-a23e-4ed2-8c08-2d023faabed8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3b770115-2d6b-4e6a-b99c-4066e7fa0df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1dc5b9f2-a5aa-43b9-b999-e86da50acc60" xlink:to="loc_us-gaap_OperatingExpenses_3b770115-2d6b-4e6a-b99c-4066e7fa0df0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc111b7c-d6e1-4f33-958d-315ee2800362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c0570da4-7b96-47cd-8a58-819909209477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc111b7c-d6e1-4f33-958d-315ee2800362" xlink:to="loc_us-gaap_NetIncomeLoss_c0570da4-7b96-47cd-8a58-819909209477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bc94d489-730a-4aca-b5ee-f17d9a57a714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc111b7c-d6e1-4f33-958d-315ee2800362" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bc94d489-730a-4aca-b5ee-f17d9a57a714" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3ec40582-79ec-48aa-88c0-7e4a6490b514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32b65b67-1246-49d5-b03f-ebd142cb498b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3ec40582-79ec-48aa-88c0-7e4a6490b514" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32b65b67-1246-49d5-b03f-ebd142cb498b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4873e9ff-2b5d-4e1e-bac3-21945bd03c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3ec40582-79ec-48aa-88c0-7e4a6490b514" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4873e9ff-2b5d-4e1e-bac3-21945bd03c18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15a087b9-5a13-47dc-950b-480c1c8b9a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3ec40582-79ec-48aa-88c0-7e4a6490b514" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15a087b9-5a13-47dc-950b-480c1c8b9a04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9140b0b3-78cc-48cd-b257-2c38b7fbbe15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9b478476-b090-4e5b-97b5-9dccd8a51444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9140b0b3-78cc-48cd-b257-2c38b7fbbe15" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9b478476-b090-4e5b-97b5-9dccd8a51444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_2b1d66dc-5b6c-4703-8eea-f7f16583dc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9140b0b3-78cc-48cd-b257-2c38b7fbbe15" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_2b1d66dc-5b6c-4703-8eea-f7f16583dc12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_9c680b9e-3aa5-480c-af92-e4c6310277e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9140b0b3-78cc-48cd-b257-2c38b7fbbe15" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_9c680b9e-3aa5-480c-af92-e4c6310277e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a412a06f-d94c-4745-b00b-a4c81bdb11eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9140b0b3-78cc-48cd-b257-2c38b7fbbe15" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a412a06f-d94c-4745-b00b-a4c81bdb11eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02ca9e26-3e65-48e4-9dcd-6bcfde94a9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d2e9e3a-d3e2-413e-bdf3-851207eafced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02ca9e26-3e65-48e4-9dcd-6bcfde94a9e9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d2e9e3a-d3e2-413e-bdf3-851207eafced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_1b1cbf04-32d2-4a96-bdeb-fb3babf8532d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02ca9e26-3e65-48e4-9dcd-6bcfde94a9e9" xlink:to="loc_us-gaap_RestrictedCashCurrent_1b1cbf04-32d2-4a96-bdeb-fb3babf8532d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_0d7f090b-2a98-4ea9-bd3e-f7b2a0ef80ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02ca9e26-3e65-48e4-9dcd-6bcfde94a9e9" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_0d7f090b-2a98-4ea9-bd3e-f7b2a0ef80ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6ca4dbba-2296-4d59-9cc7-2b8a3a04af33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_0a4cce82-105c-4099-b06e-51900e8906d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6ca4dbba-2296-4d59-9cc7-2b8a3a04af33" xlink:to="loc_us-gaap_ProceedsFromStockPlans_0a4cce82-105c-4099-b06e-51900e8906d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_45b21215-45fc-4093-8001-cceb05c90536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6ca4dbba-2296-4d59-9cc7-2b8a3a04af33" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_45b21215-45fc-4093-8001-cceb05c90536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_292e1e24-60ff-4c7e-80d7-fc3a822ab313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6ca4dbba-2296-4d59-9cc7-2b8a3a04af33" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_292e1e24-60ff-4c7e-80d7-fc3a822ab313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_63ae264d-74a6-465d-b1a8-22db962c7396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6ca4dbba-2296-4d59-9cc7-2b8a3a04af33" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_63ae264d-74a6-465d-b1a8-22db962c7396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_338851a6-080f-4139-8184-548f2f0c3b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_338851a6-080f-4139-8184-548f2f0c3b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_16078248-a1b9-4b46-9d51-e2bb8055d29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_16078248-a1b9-4b46-9d51-e2bb8055d29f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ba3d7d3d-3028-4f47-a89a-4fe98bbf83c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_DepreciationAndAmortization_ba3d7d3d-3028-4f47-a89a-4fe98bbf83c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b025aa14-b847-44b4-8f09-63ffa3ef49a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b025aa14-b847-44b4-8f09-63ffa3ef49a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_bd750a3d-fcf7-4115-ba8f-7ea567d4d5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_bd750a3d-fcf7-4115-ba8f-7ea567d4d5a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_65d0d803-1662-406b-afd7-96ea49b25591" xlink:href="sesn-20221231.xsd#sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_65d0d803-1662-406b-afd7-96ea49b25591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ca35e115-82ef-43fe-ac01-2738f6b2a802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_AssetImpairmentCharges_ca35e115-82ef-43fe-ac01-2738f6b2a802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2663262c-e129-41ae-bb5e-a0465b692bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_NetIncomeLoss_2663262c-e129-41ae-bb5e-a0465b692bce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_335ec7f1-6f01-46e5-a920-dc2e8639ed71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_335ec7f1-6f01-46e5-a920-dc2e8639ed71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_22f8ead2-3eba-4d32-bfbb-a4fa6414a14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_22f8ead2-3eba-4d32-bfbb-a4fa6414a14e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f6ca4adc-75c8-49cf-9f7e-ae183fddbd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_ShareBasedCompensation_f6ca4adc-75c8-49cf-9f7e-ae183fddbd3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_974f6615-b216-4384-b356-89a1e5296bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_974f6615-b216-4384-b356-89a1e5296bd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_706a64d5-cb0d-4ac9-b988-92b80ef0a0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_706a64d5-cb0d-4ac9-b988-92b80ef0a0b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a23bcd3c-0124-424c-9f9c-6d8531c43261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4efd554f-49dc-4001-83c8-29d7da55d1ee" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a23bcd3c-0124-424c-9f9c-6d8531c43261" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e45ac505-a812-4e63-a1da-4c25f529ddc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8e8bb86-4dca-4062-b40b-f36b86b171f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e45ac505-a812-4e63-a1da-4c25f529ddc6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8e8bb86-4dca-4062-b40b-f36b86b171f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d2a6398a-a996-4eca-aa97-2e2b3e64b207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e45ac505-a812-4e63-a1da-4c25f529ddc6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d2a6398a-a996-4eca-aa97-2e2b3e64b207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fd2d8f42-3115-4bec-bfd3-304fe4734def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e45ac505-a812-4e63-a1da-4c25f529ddc6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fd2d8f42-3115-4bec-bfd3-304fe4734def" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_375cb401-ec0d-47f6-b223-bae620579611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_166fbcea-181f-4809-baed-7db676976cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_375cb401-ec0d-47f6-b223-bae620579611" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_166fbcea-181f-4809-baed-7db676976cdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a98ba9f1-5a8c-4387-9b05-0efb6b299019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_375cb401-ec0d-47f6-b223-bae620579611" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a98ba9f1-5a8c-4387-9b05-0efb6b299019" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_542d9106-97fe-4a5e-a22f-38dc13d90d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_681de06e-1556-4e7e-b685-9340e1da8f78" xlink:href="sesn-20221231.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_542d9106-97fe-4a5e-a22f-38dc13d90d77" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_681de06e-1556-4e7e-b685-9340e1da8f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_8f914b93-5c06-404a-9da5-60b80bcb43cb" xlink:href="sesn-20221231.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_542d9106-97fe-4a5e-a22f-38dc13d90d77" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_8f914b93-5c06-404a-9da5-60b80bcb43cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ce18865e-2874-40d8-a8f9-9cda99178fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_542d9106-97fe-4a5e-a22f-38dc13d90d77" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ce18865e-2874-40d8-a8f9-9cda99178fa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_964e6200-8fa8-4c15-8eb9-6b6528fd3f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_542d9106-97fe-4a5e-a22f-38dc13d90d77" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_964e6200-8fa8-4c15-8eb9-6b6528fd3f17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedLegalFeesCurrent_10baa50c-5ca3-4d33-a6b7-212582324581" xlink:href="sesn-20221231.xsd#sesn_AccruedLegalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_542d9106-97fe-4a5e-a22f-38dc13d90d77" xlink:to="loc_sesn_AccruedLegalFeesCurrent_10baa50c-5ca3-4d33-a6b7-212582324581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_903f67d7-1680-4311-a1c0-437a80435da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_542d9106-97fe-4a5e-a22f-38dc13d90d77" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_903f67d7-1680-4311-a1c0-437a80435da2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESLeaseCostsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#LEASESLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/LEASESLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_cdc415e0-8f05-49e4-84bc-fb84a811a205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_79363654-0983-4609-a133-ae74eead8eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_cdc415e0-8f05-49e4-84bc-fb84a811a205" xlink:to="loc_us-gaap_OperatingLeaseCost_79363654-0983-4609-a133-ae74eead8eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_dc4ff1be-034a-47be-b62d-806acb751d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_cdc415e0-8f05-49e4-84bc-fb84a811a205" xlink:to="loc_us-gaap_ShortTermLeaseCost_dc4ff1be-034a-47be-b62d-806acb751d92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_0ad37890-cda3-4195-9d06-e7ffc473ee46" xlink:href="sesn-20221231.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6437983b-649b-4f1a-844d-9a66e01aeadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_0ad37890-cda3-4195-9d06-e7ffc473ee46" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6437983b-649b-4f1a-844d-9a66e01aeadd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a1abcb81-ae6d-455e-991a-89879f3275fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_0ad37890-cda3-4195-9d06-e7ffc473ee46" xlink:to="loc_us-gaap_CommonStockSharesIssued_a1abcb81-ae6d-455e-991a-89879f3275fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19a71134-1680-48d0-af6b-4df1f1bb5798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_9996ec28-0d61-45d8-ab97-64f07487c3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19a71134-1680-48d0-af6b-4df1f1bb5798" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_9996ec28-0d61-45d8-ab97-64f07487c3dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_22dab1af-da85-4571-b568-396bc566ad61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19a71134-1680-48d0-af6b-4df1f1bb5798" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_22dab1af-da85-4571-b568-396bc566ad61" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESComponentsofIncomeTaxProvisionsDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c6bf48a8-f374-447c-bcb3-0f41ae2948e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1e533537-5f26-42fc-8dc0-18ce42231129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c6bf48a8-f374-447c-bcb3-0f41ae2948e8" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1e533537-5f26-42fc-8dc0-18ce42231129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b196d7be-43d6-41d3-bb4b-f15f545c0074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c6bf48a8-f374-447c-bcb3-0f41ae2948e8" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b196d7be-43d6-41d3-bb4b-f15f545c0074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_337f5f57-c47b-4454-a1bf-df20634acb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c6bf48a8-f374-447c-bcb3-0f41ae2948e8" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_337f5f57-c47b-4454-a1bf-df20634acb2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ab40bf60-dce9-4659-9e71-df487e38998c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ef3a8e88-5bf3-4b88-b3c0-6d535cdf0fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab40bf60-dce9-4659-9e71-df487e38998c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ef3a8e88-5bf3-4b88-b3c0-6d535cdf0fbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b0a43f02-b6d2-4369-a415-fb5df6f3cb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab40bf60-dce9-4659-9e71-df487e38998c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b0a43f02-b6d2-4369-a415-fb5df6f3cb7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_88017617-7901-47cf-b2b5-73895697b88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_44695641-bce7-4cc8-b03b-b05d09b3a44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_88017617-7901-47cf-b2b5-73895697b88b" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_44695641-bce7-4cc8-b03b-b05d09b3a44f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ef794a5b-cb9d-4273-8dcb-27441fe34197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_88017617-7901-47cf-b2b5-73895697b88b" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ef794a5b-cb9d-4273-8dcb-27441fe34197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_8c5a446b-5dee-4a7b-ad90-1fec51f136f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_88017617-7901-47cf-b2b5-73895697b88b" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_8c5a446b-5dee-4a7b-ad90-1fec51f136f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ebeeb624-d133-42ba-8807-c127241dd71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ebeeb624-d133-42ba-8807-c127241dd71e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4212c29b-b232-401b-880f-19f47d9eacc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4212c29b-b232-401b-880f-19f47d9eacc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bc08f6f9-6372-452b-8eb3-edf0a30014fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bc08f6f9-6372-452b-8eb3-edf0a30014fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_3711338a-d81d-410b-bb95-5bb58845cf01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_3711338a-d81d-410b-bb95-5bb58845cf01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_8866f85a-6697-484f-919b-c4796db7ab67" xlink:href="sesn-20221231.xsd#sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:to="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_8866f85a-6697-484f-919b-c4796db7ab67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_ff29f3bc-4610-4c63-989a-fdff06e8fe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_ff29f3bc-4610-4c63-989a-fdff06e8fe6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_417e8768-c609-45ab-9f67-f012490394a1" xlink:href="sesn-20221231.xsd#sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:to="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_417e8768-c609-45ab-9f67-f012490394a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b7219fae-91c2-42cc-b903-3af44c2c2306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b7219fae-91c2-42cc-b903-3af44c2c2306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7bee2e9a-a80d-4a8e-9375-ba1bc87ad588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7bee2e9a-a80d-4a8e-9375-ba1bc87ad588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6489a897-2e50-4b47-a67b-7ce75cc2ccb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6489a897-2e50-4b47-a67b-7ce75cc2ccb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent_61629352-60cc-4e17-ab21-641152251bc9" xlink:href="sesn-20221231.xsd#sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0966bf0f-5884-4ef3-b2e2-6a93b288821f" xlink:to="loc_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent_61629352-60cc-4e17-ab21-641152251bc9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6cdf15ee-b553-41cd-8df3-2e4ecc5be375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_47a5c992-979e-49cd-b576-eb579e87deeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cdf15ee-b553-41cd-8df3-2e4ecc5be375" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_47a5c992-979e-49cd-b576-eb579e87deeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_c8f55980-b3ef-49b9-9d9c-64eefdeac800" xlink:href="sesn-20221231.xsd#sesn_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cdf15ee-b553-41cd-8df3-2e4ecc5be375" xlink:to="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_c8f55980-b3ef-49b9-9d9c-64eefdeac800" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_baa86c42-cf2b-4d2a-bf22-d3635facc19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cdf15ee-b553-41cd-8df3-2e4ecc5be375" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_baa86c42-cf2b-4d2a-bf22-d3635facc19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d3a2a735-d3d5-4a2d-a018-e45ce88790b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cdf15ee-b553-41cd-8df3-2e4ecc5be375" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d3a2a735-d3d5-4a2d-a018-e45ce88790b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_739fbf96-2e50-4444-9fef-5cd683299346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cdf15ee-b553-41cd-8df3-2e4ecc5be375" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_739fbf96-2e50-4444-9fef-5cd683299346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment_5162e66a-d5b5-4184-b75a-b5d82f9f4e00" xlink:href="sesn-20221231.xsd#sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cdf15ee-b553-41cd-8df3-2e4ecc5be375" xlink:to="loc_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment_5162e66a-d5b5-4184-b75a-b5d82f9f4e00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_a86359bf-3aa8-450d-90fe-6552949094aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_28cdef68-27fb-4757-845f-3fc34b48ca78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_a86359bf-3aa8-450d-90fe-6552949094aa" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_28cdef68-27fb-4757-845f-3fc34b48ca78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8dd4b761-20c1-42c2-bbaf-0fb190e4174e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_a86359bf-3aa8-450d-90fe-6552949094aa" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8dd4b761-20c1-42c2-bbaf-0fb190e4174e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3906222e-871b-45cb-a0b9-a624ef6a2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_a86359bf-3aa8-450d-90fe-6552949094aa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3906222e-871b-45cb-a0b9-a624ef6a2d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5de3b20e-54e8-46ce-abe7-4b597a8f6d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_00b4481c-4119-4d39-98cf-22924f2f27cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5de3b20e-54e8-46ce-abe7-4b597a8f6d34" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_00b4481c-4119-4d39-98cf-22924f2f27cf" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>sesn-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:cb59ddaf-3c33-4c46-89b9-ef07748101c9,g:f5662b05-afda-41c0-b68c-8f02735bc2a0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="icd0cd45fad404c45a17e8db1fa066fdd_CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_de248e55-b98a-42d3-897c-b59b43dd18c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de248e55-b98a-42d3-897c-b59b43dd18c6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_67ad351b-5e31-4990-931e-7e20026386ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_CommonStockSharesIssued_67ad351b-5e31-4990-931e-7e20026386ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a52c1ce4-7df0-4059-a554-c5fad9e2f155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockholdersEquity_a52c1ce4-7df0-4059-a554-c5fad9e2f155" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed64c515-1c96-40c3-a679-5b632705d31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_NetIncomeLoss_ed64c515-1c96-40c3-a679-5b632705d31c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f855338-2340-4051-ad65-e289b23a79ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f855338-2340-4051-ad65-e289b23a79ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16a97c59-687c-44f7-b11d-766db079b1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16a97c59-687c-44f7-b11d-766db079b1d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7935f65e-e343-4ff3-99ae-f6e2c960d45c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7935f65e-e343-4ff3-99ae-f6e2c960d45c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cde5c5eb-e548-4080-96c2-db39d68bca1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cde5c5eb-e548-4080-96c2-db39d68bca1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7a11861f-7570-4e1c-a692-d5688c771552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7a11861f-7570-4e1c-a692-d5688c771552" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_649cbd89-9d85-4554-aeeb-3568622e29b3" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_649cbd89-9d85-4554-aeeb-3568622e29b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_60336f0b-0e7c-46dc-8836-f7d8fed72df3" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_60336f0b-0e7c-46dc-8836-f7d8fed72df3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c1dfdbf7-7bd9-44e3-b609-46df53245ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c1dfdbf7-7bd9-44e3-b609-46df53245ecd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ec03103-f0a6-43f0-93d2-50b07a28d6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ec03103-f0a6-43f0-93d2-50b07a28d6f8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7fe8a93c-5153-4ae5-a587-b76192bd3f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7fe8a93c-5153-4ae5-a587-b76192bd3f7a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_aebdb743-79bf-4f02-a804-47bc4d76c933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_aebdb743-79bf-4f02-a804-47bc4d76c933" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a87abdc8-b4fb-4427-8248-f016289f13f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a87abdc8-b4fb-4427-8248-f016289f13f3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_688a9580-6c89-448f-a060-1a6281625e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2aaf1907-e218-419d-aa93-9311e68d4e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ee1ac5aa-6e99-4ba3-8cc8-96c37dec7bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_de248e55-b98a-42d3-897c-b59b43dd18c6" xlink:to="loc_us-gaap_StatementTable_ee1ac5aa-6e99-4ba3-8cc8-96c37dec7bf7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4ce36b1f-26ac-4eb9-ae10-1745fdf0077f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ee1ac5aa-6e99-4ba3-8cc8-96c37dec7bf7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4ce36b1f-26ac-4eb9-ae10-1745fdf0077f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4ce36b1f-26ac-4eb9-ae10-1745fdf0077f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4ce36b1f-26ac-4eb9-ae10-1745fdf0077f" xlink:to="loc_us-gaap_EquityComponentDomain_4ce36b1f-26ac-4eb9-ae10-1745fdf0077f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4ce36b1f-26ac-4eb9-ae10-1745fdf0077f" xlink:to="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_84e1b06b-647f-4502-818f-fa98d1d9f355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:to="loc_us-gaap_CommonStockMember_84e1b06b-647f-4502-818f-fa98d1d9f355" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ca58aefe-9aea-44d9-9285-f2df4feb9a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ca58aefe-9aea-44d9-9285-f2df4feb9a59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e8ffc3d-c2c6-4048-8b30-381c593f0748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e8ffc3d-c2c6-4048-8b30-381c593f0748" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fda273c3-d043-45b5-8576-0ef3a8d417ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:to="loc_us-gaap_RetainedEarningsMember_fda273c3-d043-45b5-8576-0ef3a8d417ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_406ce4b7-91bb-461a-9106-1978ec069318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ee1ac5aa-6e99-4ba3-8cc8-96c37dec7bf7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_406ce4b7-91bb-461a-9106-1978ec069318" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_406ce4b7-91bb-461a-9106-1978ec069318_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_406ce4b7-91bb-461a-9106-1978ec069318" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_406ce4b7-91bb-461a-9106-1978ec069318_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_519c5d0b-6618-435f-9634-2f14faca6671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_406ce4b7-91bb-461a-9106-1978ec069318" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_519c5d0b-6618-435f-9634-2f14faca6671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_75bc0953-3280-4678-8a06-011a19ea395d" xlink:href="sesn-20221231.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_519c5d0b-6618-435f-9634-2f14faca6671" xlink:to="loc_sesn_ATMFacilityMember_75bc0953-3280-4678-8a06-011a19ea395d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="extended" id="ic45b3b75575b4b54ba98c23dd9577f18_CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e096b34c-f6fa-400f-afde-0d4ed83ca108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d97b9803-b48b-44f4-81dc-0d70eeea41f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e096b34c-f6fa-400f-afde-0d4ed83ca108" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d97b9803-b48b-44f4-81dc-0d70eeea41f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0f6587a8-1de9-4d0c-abd5-fcfb4436fabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e096b34c-f6fa-400f-afde-0d4ed83ca108" xlink:to="loc_us-gaap_StatementTable_0f6587a8-1de9-4d0c-abd5-fcfb4436fabc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e6d9da50-2b98-4ba0-9879-6575719d2a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0f6587a8-1de9-4d0c-abd5-fcfb4436fabc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e6d9da50-2b98-4ba0-9879-6575719d2a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6d9da50-2b98-4ba0-9879-6575719d2a90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e6d9da50-2b98-4ba0-9879-6575719d2a90" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6d9da50-2b98-4ba0-9879-6575719d2a90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02e75c16-6af5-47e5-808b-91635118706c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e6d9da50-2b98-4ba0-9879-6575719d2a90" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02e75c16-6af5-47e5-808b-91635118706c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_76b02723-34ad-45f5-9392-0ffc9663328b" xlink:href="sesn-20221231.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02e75c16-6af5-47e5-808b-91635118706c" xlink:to="loc_sesn_ATMFacilityMember_76b02723-34ad-45f5-9392-0ffc9663328b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended" id="i9ebf022c1afd419ea753c6bec80a6ccb_DESCRIPTIONOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_67f5ab00-bde3-45b3-9b3b-af4f79528eac" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_67f5ab00-bde3-45b3-9b3b-af4f79528eac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8c4e38b9-90f1-437a-ab69-0cda6634dbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8c4e38b9-90f1-437a-ab69-0cda6634dbd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_0a58ab19-2022-483f-87b6-da3af84b4e8b" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_0a58ab19-2022-483f-87b6-da3af84b4e8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_adf7eac7-ffc1-4cc7-8525-c16090575654" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_adf7eac7-ffc1-4cc7-8525-c16090575654" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_66a21eda-b03b-4061-a6f6-66a688f091ed" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_66a21eda-b03b-4061-a6f6-66a688f091ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_29d68e4a-d127-4621-bab4-c5802f0f2221" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_29d68e4a-d127-4621-bab4-c5802f0f2221" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b8b3658e-7700-4ca2-af9c-427f41a0074c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b8b3658e-7700-4ca2-af9c-427f41a0074c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_40a706b7-528a-47c8-a551-ab440af8e6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_40a706b7-528a-47c8-a551-ab440af8e6d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e3aadbd-3048-498b-9fd0-7da954d260d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e3aadbd-3048-498b-9fd0-7da954d260d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_94f6b7b5-e090-40f2-a668-0cfd51e8f551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_94f6b7b5-e090-40f2-a668-0cfd51e8f551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94f6b7b5-e090-40f2-a668-0cfd51e8f551_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94f6b7b5-e090-40f2-a668-0cfd51e8f551" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94f6b7b5-e090-40f2-a668-0cfd51e8f551_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b66c0ba4-4e2b-4155-b5ac-9f7018fb0a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94f6b7b5-e090-40f2-a668-0cfd51e8f551" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b66c0ba4-4e2b-4155-b5ac-9f7018fb0a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member_c849b8bb-c827-43c9-907d-27a64bf02325" xlink:href="sesn-20221231.xsd#sesn_ViventiaBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b66c0ba4-4e2b-4155-b5ac-9f7018fb0a91" xlink:to="loc_sesn_ViventiaBioInc.Member_c849b8bb-c827-43c9-907d-27a64bf02325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7e0cecb-1ae8-4ecb-a8ac-0fd67ab926e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:to="loc_srt_ProductOrServiceAxis_d7e0cecb-1ae8-4ecb-a8ac-0fd67ab926e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7e0cecb-1ae8-4ecb-a8ac-0fd67ab926e6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d7e0cecb-1ae8-4ecb-a8ac-0fd67ab926e6" xlink:to="loc_srt_ProductsAndServicesDomain_d7e0cecb-1ae8-4ecb-a8ac-0fd67ab926e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2511b9e-7d98-4a30-a209-dbce8c6777b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d7e0cecb-1ae8-4ecb-a8ac-0fd67ab926e6" xlink:to="loc_srt_ProductsAndServicesDomain_d2511b9e-7d98-4a30-a209-dbce8c6777b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_7a92d546-3ec9-443e-b0d6-ff32db44ce47" xlink:href="sesn-20221231.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2511b9e-7d98-4a30-a209-dbce8c6777b9" xlink:to="loc_sesn_ViciniumMember_7a92d546-3ec9-443e-b0d6-ff32db44ce47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dfdc8f26-c643-4bbe-98d7-870596ec8e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dfdc8f26-c643-4bbe-98d7-870596ec8e0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfdc8f26-c643-4bbe-98d7-870596ec8e0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dfdc8f26-c643-4bbe-98d7-870596ec8e0f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfdc8f26-c643-4bbe-98d7-870596ec8e0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c4f39a02-6fed-406e-89b4-2d58f94ac428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dfdc8f26-c643-4bbe-98d7-870596ec8e0f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c4f39a02-6fed-406e-89b4-2d58f94ac428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_298083ca-81ea-4d46-b2b5-66b243eff1e8" xlink:href="sesn-20221231.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c4f39a02-6fed-406e-89b4-2d58f94ac428" xlink:to="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_298083ca-81ea-4d46-b2b5-66b243eff1e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8ecbccc3-c3d4-43a8-9521-42cc765c1373" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:to="loc_srt_StatementGeographicalAxis_8ecbccc3-c3d4-43a8-9521-42cc765c1373" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8ecbccc3-c3d4-43a8-9521-42cc765c1373_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8ecbccc3-c3d4-43a8-9521-42cc765c1373" xlink:to="loc_srt_SegmentGeographicalDomain_8ecbccc3-c3d4-43a8-9521-42cc765c1373_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9e944a40-e36c-44ae-8315-117191daeead" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8ecbccc3-c3d4-43a8-9521-42cc765c1373" xlink:to="loc_srt_SegmentGeographicalDomain_9e944a40-e36c-44ae-8315-117191daeead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_52247b91-1c42-44d4-a141-07bfe7fd4cdf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9e944a40-e36c-44ae-8315-117191daeead" xlink:to="loc_country_US_52247b91-1c42-44d4-a141-07bfe7fd4cdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_90a56798-f54f-493f-ade9-dbda02a6d6c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9e944a40-e36c-44ae-8315-117191daeead" xlink:to="loc_srt_EuropeMember_90a56798-f54f-493f-ade9-dbda02a6d6c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_044fa85b-f4d3-4f0e-8412-86e8cb254986" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9e944a40-e36c-44ae-8315-117191daeead" xlink:to="loc_country_JP_044fa85b-f4d3-4f0e-8412-86e8cb254986" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended" id="i392a20c136904359af285ead0298dffe_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_7a0917d3-60f0-4e1f-b29d-fef790a49817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_7a0917d3-60f0-4e1f-b29d-fef790a49817" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a333c74d-3269-4e05-92f5-d3b4a6b63165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a333c74d-3269-4e05-92f5-d3b4a6b63165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_093e6250-ec3d-4ae3-b6fd-473f28ed5043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_093e6250-ec3d-4ae3-b6fd-473f28ed5043" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_43a24535-cd38-435b-a5eb-4c01b0786200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_43a24535-cd38-435b-a5eb-4c01b0786200" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_ded7fa4c-482b-4d78-bdca-10c73e3d5f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_NumberOfReportingUnits_ded7fa4c-482b-4d78-bdca-10c73e3d5f7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_16abeeec-a472-4094-8570-c35e0bb3684d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_Goodwill_16abeeec-a472-4094-8570-c35e0bb3684d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d252119b-01bb-437a-b9af-a9a90b1c10e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d252119b-01bb-437a-b9af-a9a90b1c10e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_33be421c-91a7-4bf3-acbe-8cdc5a31ebae" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_33be421c-91a7-4bf3-acbe-8cdc5a31ebae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_938219be-a8aa-4ce6-ad87-8e86596612c8" xlink:href="sesn-20221231.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_sesn_WeightedAverageCostOfCapital_938219be-a8aa-4ce6-ad87-8e86596612c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_af252104-aac4-4011-ad04-51ec70362d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_af252104-aac4-4011-ad04-51ec70362d92" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_01953f13-c4df-4b2c-9ea4-7cc5d099c523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_01953f13-c4df-4b2c-9ea4-7cc5d099c523" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_44619563-5096-4514-8bb9-8ad70c01e24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_44619563-5096-4514-8bb9-8ad70c01e24a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_107775a6-43a8-425d-8948-3420995a686d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_107775a6-43a8-425d-8948-3420995a686d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bee541fe-2648-499c-9adf-9b65a63ae6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bee541fe-2648-499c-9adf-9b65a63ae6c3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePayment_69ff40df-0520-4844-9c95-14c49c8082e3" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_sesn_LicenseAgreementMilestonePayment_69ff40df-0520-4844-9c95-14c49c8082e3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePaymentTerm_caf09794-322b-404e-93d7-dd8044cc93ea" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestonePaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_sesn_LicenseAgreementMilestonePaymentTerm_caf09794-322b-404e-93d7-dd8044cc93ea" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_45a34ab2-47d1-4f42-b6c3-83510bc6f924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_45a34ab2-47d1-4f42-b6c3-83510bc6f924" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_48e258c0-04bd-4de6-9a38-24f76b690438" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_48e258c0-04bd-4de6-9a38-24f76b690438" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885182a1-faf0-4232-ad75-70d9c4bacb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885182a1-faf0-4232-ad75-70d9c4bacb73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_885182a1-faf0-4232-ad75-70d9c4bacb73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885182a1-faf0-4232-ad75-70d9c4bacb73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_885182a1-faf0-4232-ad75-70d9c4bacb73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885182a1-faf0-4232-ad75-70d9c4bacb73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f414aabd-48d6-4569-8652-e404b51f2ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:to="loc_us-gaap_EquipmentMember_f414aabd-48d6-4569-8652-e404b51f2ab9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_42614e7e-3e47-414e-acb4-678dbb5c5ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_42614e7e-3e47-414e-acb4-678dbb5c5ef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_c93594df-28ef-43b0-b626-63f8b431afed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:to="loc_us-gaap_ComputerEquipmentMember_c93594df-28ef-43b0-b626-63f8b431afed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0edfef7d-17b7-443c-9c94-2827a316c4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0edfef7d-17b7-443c-9c94-2827a316c4d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_170278d8-0de1-4810-ab66-a0b330f9ade2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_srt_ProductOrServiceAxis_170278d8-0de1-4810-ab66-a0b330f9ade2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_170278d8-0de1-4810-ab66-a0b330f9ade2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_170278d8-0de1-4810-ab66-a0b330f9ade2" xlink:to="loc_srt_ProductsAndServicesDomain_170278d8-0de1-4810-ab66-a0b330f9ade2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_245b5b67-b829-4e71-9fec-287daf748df5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_170278d8-0de1-4810-ab66-a0b330f9ade2" xlink:to="loc_srt_ProductsAndServicesDomain_245b5b67-b829-4e71-9fec-287daf748df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_e2dcd3b7-d919-4662-8213-26fe1307dbf8" xlink:href="sesn-20221231.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245b5b67-b829-4e71-9fec-287daf748df5" xlink:to="loc_sesn_ViciniumMember_e2dcd3b7-d919-4662-8213-26fe1307dbf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_b8cca84d-ad38-47f2-ab2d-aa5f4496226a" xlink:href="sesn-20221231.xsd#sesn_EBI031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245b5b67-b829-4e71-9fec-287daf748df5" xlink:to="loc_sesn_EBI031Member_b8cca84d-ad38-47f2-ab2d-aa5f4496226a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c532a7ed-c747-4469-8872-ef075898917d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_srt_StatementGeographicalAxis_c532a7ed-c747-4469-8872-ef075898917d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c532a7ed-c747-4469-8872-ef075898917d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c532a7ed-c747-4469-8872-ef075898917d" xlink:to="loc_srt_SegmentGeographicalDomain_c532a7ed-c747-4469-8872-ef075898917d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6bbc5de7-aec8-41cd-8496-a441933f0e64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c532a7ed-c747-4469-8872-ef075898917d" xlink:to="loc_srt_SegmentGeographicalDomain_6bbc5de7-aec8-41cd-8496-a441933f0e64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5c60d9b6-8079-4f19-a73d-db6ec5e7d3c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6bbc5de7-aec8-41cd-8496-a441933f0e64" xlink:to="loc_srt_EuropeMember_5c60d9b6-8079-4f19-a73d-db6ec5e7d3c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0574798e-2d83-4013-a680-4f40df8c3e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0574798e-2d83-4013-a680-4f40df8c3e51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0574798e-2d83-4013-a680-4f40df8c3e51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0574798e-2d83-4013-a680-4f40df8c3e51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0574798e-2d83-4013-a680-4f40df8c3e51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad238182-f0f9-4b6e-b855-4705df4503bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0574798e-2d83-4013-a680-4f40df8c3e51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad238182-f0f9-4b6e-b855-4705df4503bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4b282b9f-b538-4423-963b-af06459621a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad238182-f0f9-4b6e-b855-4705df4503bc" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4b282b9f-b538-4423-963b-af06459621a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_91b79a78-77e2-45ea-8a10-c1f25c459cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad238182-f0f9-4b6e-b855-4705df4503bc" xlink:to="loc_us-gaap_LicensingAgreementsMember_91b79a78-77e2-45ea-8a10-c1f25c459cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac5b997e-5fab-4b8c-8167-523bc4d87227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_us-gaap_AwardTypeAxis_ac5b997e-5fab-4b8c-8167-523bc4d87227" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac5b997e-5fab-4b8c-8167-523bc4d87227_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ac5b997e-5fab-4b8c-8167-523bc4d87227" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac5b997e-5fab-4b8c-8167-523bc4d87227_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e613c024-fb46-48df-900e-69f7d01d92c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ac5b997e-5fab-4b8c-8167-523bc4d87227" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e613c024-fb46-48df-900e-69f7d01d92c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0b05e0db-9225-41e1-967e-61cbc9bd13b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e613c024-fb46-48df-900e-69f7d01d92c1" xlink:to="loc_us-gaap_PerformanceSharesMember_0b05e0db-9225-41e1-967e-61cbc9bd13b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_78b1a40c-b606-411c-8bff-c1e7855a7c36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_srt_CounterpartyNameAxis_78b1a40c-b606-411c-8bff-c1e7855a7c36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78b1a40c-b606-411c-8bff-c1e7855a7c36_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_78b1a40c-b606-411c-8bff-c1e7855a7c36" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78b1a40c-b606-411c-8bff-c1e7855a7c36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_600040dd-c61a-44c0-8110-ed2dc0dbdca8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_78b1a40c-b606-411c-8bff-c1e7855a7c36" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_600040dd-c61a-44c0-8110-ed2dc0dbdca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_c8a484dc-d03b-4b50-8c8f-7f18a47a11f4" xlink:href="sesn-20221231.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_600040dd-c61a-44c0-8110-ed2dc0dbdca8" xlink:to="loc_sesn_RocheMember_c8a484dc-d03b-4b50-8c8f-7f18a47a11f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_50b1a469-cd35-4114-ba87-8b2ef85dd728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_50b1a469-cd35-4114-ba87-8b2ef85dd728" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_50b1a469-cd35-4114-ba87-8b2ef85dd728_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_50b1a469-cd35-4114-ba87-8b2ef85dd728" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_50b1a469-cd35-4114-ba87-8b2ef85dd728_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_34aac33c-92c2-4e63-8af3-eb72438dde78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_50b1a469-cd35-4114-ba87-8b2ef85dd728" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_34aac33c-92c2-4e63-8af3-eb72438dde78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8b69dba8-e06c-43a1-963e-5eeceedf423d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_34aac33c-92c2-4e63-8af3-eb72438dde78" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8b69dba8-e06c-43a1-963e-5eeceedf423d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="idcf1c17526f74204b01c6d0ec1a77e2e_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_665156ce-f775-4491-990f-66b6bd9d4aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_4ac8f225-e929-4632-8be6-fc0a8253bb22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_665156ce-f775-4491-990f-66b6bd9d4aa0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_4ac8f225-e929-4632-8be6-fc0a8253bb22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_446653cb-cdd4-4b5f-9e19-43a4a855e41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4ac8f225-e929-4632-8be6-fc0a8253bb22" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_446653cb-cdd4-4b5f-9e19-43a4a855e41c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f9f932da-3ceb-4011-8cdd-93e0f402fc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4ac8f225-e929-4632-8be6-fc0a8253bb22" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f9f932da-3ceb-4011-8cdd-93e0f402fc72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4be40083-cc15-4eda-9291-e351198c56e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_665156ce-f775-4491-990f-66b6bd9d4aa0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4be40083-cc15-4eda-9291-e351198c56e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_184ef185-1d74-4eca-98b3-7c6746729c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4be40083-cc15-4eda-9291-e351198c56e9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_184ef185-1d74-4eca-98b3-7c6746729c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_665156ce-f775-4491-990f-66b6bd9d4aa0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9f8f4b-4130-473c-8d02-30b701132490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9f8f4b-4130-473c-8d02-30b701132490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ce9f8f4b-4130-473c-8d02-30b701132490_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9f8f4b-4130-473c-8d02-30b701132490" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ce9f8f4b-4130-473c-8d02-30b701132490_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_65aade8b-87f4-4e1a-86ba-993e34201710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9f8f4b-4130-473c-8d02-30b701132490" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_65aade8b-87f4-4e1a-86ba-993e34201710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f058d6d6-f497-4c34-b6a6-809eb391a36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_65aade8b-87f4-4e1a-86ba-993e34201710" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f058d6d6-f497-4c34-b6a6-809eb391a36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_38610500-9bff-430e-825a-e85451961e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f058d6d6-f497-4c34-b6a6-809eb391a36c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_38610500-9bff-430e-825a-e85451961e5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_08d1755d-b1fc-4162-9111-a3bfe23b8052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f058d6d6-f497-4c34-b6a6-809eb391a36c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_08d1755d-b1fc-4162-9111-a3bfe23b8052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3f9756-9bc1-4b0b-9202-b00234f25efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3f9756-9bc1-4b0b-9202-b00234f25efe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b3f9756-9bc1-4b0b-9202-b00234f25efe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3f9756-9bc1-4b0b-9202-b00234f25efe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b3f9756-9bc1-4b0b-9202-b00234f25efe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_01c3bc6e-c787-4d16-9f31-3a12f835292d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3f9756-9bc1-4b0b-9202-b00234f25efe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_01c3bc6e-c787-4d16-9f31-3a12f835292d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_35580638-f31d-47b1-a627-a1f232447da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_01c3bc6e-c787-4d16-9f31-3a12f835292d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_35580638-f31d-47b1-a627-a1f232447da5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eb1af5ab-6df0-4d53-b9ee-78f63e647b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eb1af5ab-6df0-4d53-b9ee-78f63e647b0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eb1af5ab-6df0-4d53-b9ee-78f63e647b0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eb1af5ab-6df0-4d53-b9ee-78f63e647b0e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eb1af5ab-6df0-4d53-b9ee-78f63e647b0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0a8d806-71e4-4a78-aa95-05733c0cca04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eb1af5ab-6df0-4d53-b9ee-78f63e647b0e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0a8d806-71e4-4a78-aa95-05733c0cca04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f83a358d-fbc2-4ba1-aba2-bfe6114cb730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0a8d806-71e4-4a78-aa95-05733c0cca04" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f83a358d-fbc2-4ba1-aba2-bfe6114cb730" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5ea9792b-eb71-4e52-900a-b09f000ab569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0a8d806-71e4-4a78-aa95-05733c0cca04" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5ea9792b-eb71-4e52-900a-b09f000ab569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f997b67a-3a1f-49f0-bc53-aca8dee41daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0a8d806-71e4-4a78-aa95-05733c0cca04" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f997b67a-3a1f-49f0-bc53-aca8dee41daf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_94d6ade4-d538-41b1-8302-bff8c2f8fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:to="loc_us-gaap_FinancialInstrumentAxis_94d6ade4-d538-41b1-8302-bff8c2f8fa62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94d6ade4-d538-41b1-8302-bff8c2f8fa62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94d6ade4-d538-41b1-8302-bff8c2f8fa62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94d6ade4-d538-41b1-8302-bff8c2f8fa62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13ebd40a-4f04-4012-bad5-0fdd237a9d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94d6ade4-d538-41b1-8302-bff8c2f8fa62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13ebd40a-4f04-4012-bad5-0fdd237a9d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0de4b0e1-c679-4d03-96ca-8b2cf8643233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13ebd40a-4f04-4012-bad5-0fdd237a9d31" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0de4b0e1-c679-4d03-96ca-8b2cf8643233" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_31e80bcb-bf27-4489-aedb-f1891df58357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13ebd40a-4f04-4012-bad5-0fdd237a9d31" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_31e80bcb-bf27-4489-aedb-f1891df58357" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended" id="id04252928de9444aa56df11da989051e_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_edb83080-314b-4df1-aa6b-f9b16fba3850" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_edb83080-314b-4df1-aa6b-f9b16fba3850" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_3d641ea6-6234-4f8a-b870-5f6c97d9bc51" xlink:href="sesn-20221231.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:to="loc_sesn_WeightedAverageCostOfCapital_3d641ea6-6234-4f8a-b870-5f6c97d9bc51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8c1a1b3e-a6b0-43b0-8300-122ead936bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8c1a1b3e-a6b0-43b0-8300-122ead936bb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_883aca1d-dc6b-4e3f-b2e0-26a6592505fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_883aca1d-dc6b-4e3f-b2e0-26a6592505fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_d320d70b-02a7-4eea-b9d2-cc47c4f32261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_d320d70b-02a7-4eea-b9d2-cc47c4f32261" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c5ae0ab8-7d97-4050-9d72-145ea7e85407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_d320d70b-02a7-4eea-b9d2-cc47c4f32261" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c5ae0ab8-7d97-4050-9d72-145ea7e85407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c5ae0ab8-7d97-4050-9d72-145ea7e85407_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c5ae0ab8-7d97-4050-9d72-145ea7e85407" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c5ae0ab8-7d97-4050-9d72-145ea7e85407_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6c98c2bf-cdbd-449d-9ef2-b1f04f44a0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c5ae0ab8-7d97-4050-9d72-145ea7e85407" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6c98c2bf-cdbd-449d-9ef2-b1f04f44a0bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9412a0d4-a429-4c1e-9eb9-85d602918f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6c98c2bf-cdbd-449d-9ef2-b1f04f44a0bf" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9412a0d4-a429-4c1e-9eb9-85d602918f48" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="extended" id="i7fb5bc3b40a84d72b41b4efd22283393_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_325487ee-a787-4cb1-923e-ba4152e14269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a93154da-79bd-4fd5-bb2e-8eeae9de3f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_325487ee-a787-4cb1-923e-ba4152e14269" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a93154da-79bd-4fd5-bb2e-8eeae9de3f59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f740c9ec-6252-4a0e-bc04-7bc5dfbecd26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a93154da-79bd-4fd5-bb2e-8eeae9de3f59" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f740c9ec-6252-4a0e-bc04-7bc5dfbecd26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_c629e4d5-845e-4eb9-a6f0-ddacf6cd468b" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a93154da-79bd-4fd5-bb2e-8eeae9de3f59" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_c629e4d5-845e-4eb9-a6f0-ddacf6cd468b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9824e94a-f267-47a3-83b6-68499d0fab36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b61ce139-38a5-4ebb-9463-36211a23e901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_325487ee-a787-4cb1-923e-ba4152e14269" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b61ce139-38a5-4ebb-9463-36211a23e901" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_100e3360-c468-4b6c-80cf-4f9123bb8936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b61ce139-38a5-4ebb-9463-36211a23e901" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_100e3360-c468-4b6c-80cf-4f9123bb8936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_100e3360-c468-4b6c-80cf-4f9123bb8936_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_100e3360-c468-4b6c-80cf-4f9123bb8936" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_100e3360-c468-4b6c-80cf-4f9123bb8936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_739236ac-dc0b-43be-a3a3-7fa9cc1241d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_100e3360-c468-4b6c-80cf-4f9123bb8936" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_739236ac-dc0b-43be-a3a3-7fa9cc1241d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9256d756-27b0-4c9c-9d02-424a35f30b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_739236ac-dc0b-43be-a3a3-7fa9cc1241d8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9256d756-27b0-4c9c-9d02-424a35f30b4a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails" xlink:type="extended" id="ibff6aa2a051943739916f1504101095b_RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_167194a1-a52c-4531-8442-f3089a2bd00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_167194a1-a52c-4531-8442-f3089a2bd00b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_66e81f26-daf3-4471-9f59-4e88b3e04bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_66e81f26-daf3-4471-9f59-4e88b3e04bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b47ac609-a97d-4a38-8d6c-9315a649954f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b47ac609-a97d-4a38-8d6c-9315a649954f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_26f06ab8-629d-4595-8454-4c4e00c94ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_26f06ab8-629d-4595-8454-4c4e00c94ed7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fd6d242e-c595-4ed5-9a38-587fc5cf803f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fd6d242e-c595-4ed5-9a38-587fc5cf803f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_82c34066-e3c2-409f-a687-e93f2517c7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fd6d242e-c595-4ed5-9a38-587fc5cf803f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_82c34066-e3c2-409f-a687-e93f2517c7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82c34066-e3c2-409f-a687-e93f2517c7a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_82c34066-e3c2-409f-a687-e93f2517c7a7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82c34066-e3c2-409f-a687-e93f2517c7a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f8760b2-6ca7-4f80-9880-c23b941b2e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_82c34066-e3c2-409f-a687-e93f2517c7a7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f8760b2-6ca7-4f80-9880-c23b941b2e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a15514ce-b030-4cba-90d7-f8497badd519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f8760b2-6ca7-4f80-9880-c23b941b2e05" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a15514ce-b030-4cba-90d7-f8497badd519" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_01bca44b-7a53-4cb2-b51a-52a3340bf647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f8760b2-6ca7-4f80-9880-c23b941b2e05" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_01bca44b-7a53-4cb2-b51a-52a3340bf647" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#RECEIVABLESDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="extended" id="i028e45d2f31f4ae3aa2c3078f22b0b97_RECEIVABLESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_adf8b3d4-e90f-48c7-8ca8-24b0803d1eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_adf8b3d4-e90f-48c7-8ca8-24b0803d1eba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_862d9015-a41a-4775-9ee1-c348ff95dd25" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_862d9015-a41a-4775-9ee1-c348ff95dd25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_2d28ecee-a56b-4e59-a507-a82af65d54cd" xlink:href="sesn-20221231.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_2d28ecee-a56b-4e59-a507-a82af65d54cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_6b7ff9d0-b815-436f-8108-5a8ff9229dd5" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_6b7ff9d0-b815-436f-8108-5a8ff9229dd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_7a2b9639-0e04-43b5-8a5d-d7e39c8889d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_7a2b9639-0e04-43b5-8a5d-d7e39c8889d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6d74e7a3-9afe-4c61-af05-243fed64373d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6d74e7a3-9afe-4c61-af05-243fed64373d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_59439e90-a738-4e8e-be14-ebd0f9cdb767" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6d74e7a3-9afe-4c61-af05-243fed64373d" xlink:to="loc_srt_CounterpartyNameAxis_59439e90-a738-4e8e-be14-ebd0f9cdb767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59439e90-a738-4e8e-be14-ebd0f9cdb767_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_59439e90-a738-4e8e-be14-ebd0f9cdb767" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59439e90-a738-4e8e-be14-ebd0f9cdb767_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c40ff6-f032-4ace-97e5-93a026e188b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_59439e90-a738-4e8e-be14-ebd0f9cdb767" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c40ff6-f032-4ace-97e5-93a026e188b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_af5e4753-d08d-491e-92cf-95497d802743" xlink:href="sesn-20221231.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c40ff6-f032-4ace-97e5-93a026e188b5" xlink:to="loc_sesn_RocheMember_af5e4753-d08d-491e-92cf-95497d802743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_4feddad4-8a9a-45d6-b775-7ba3a1ee23cc" xlink:href="sesn-20221231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c40ff6-f032-4ace-97e5-93a026e188b5" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_4feddad4-8a9a-45d6-b775-7ba3a1ee23cc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails" xlink:type="extended" id="id7683067be7c4237976f906e85a9492e_PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dadce98a-3198-4594-8227-577abea619f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_aabb6d05-266a-40a9-bc7d-2a45f7d5335e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dadce98a-3198-4594-8227-577abea619f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_aabb6d05-266a-40a9-bc7d-2a45f7d5335e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a50f0781-00fe-4143-acb9-80cf18db4735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dadce98a-3198-4594-8227-577abea619f9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a50f0781-00fe-4143-acb9-80cf18db4735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fc1169fc-f293-42fc-a715-009e17f42369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dadce98a-3198-4594-8227-577abea619f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fc1169fc-f293-42fc-a715-009e17f42369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f9c6f8f0-3340-4ed3-a3c2-f069152614af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dadce98a-3198-4594-8227-577abea619f9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f9c6f8f0-3340-4ed3-a3c2-f069152614af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_db37ae11-d370-4862-984d-cc6b0185bf46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f9c6f8f0-3340-4ed3-a3c2-f069152614af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_db37ae11-d370-4862-984d-cc6b0185bf46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db37ae11-d370-4862-984d-cc6b0185bf46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_db37ae11-d370-4862-984d-cc6b0185bf46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db37ae11-d370-4862-984d-cc6b0185bf46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_db37ae11-d370-4862-984d-cc6b0185bf46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_afe3a94b-20e4-4ae2-9cbf-c374f483008b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:to="loc_us-gaap_EquipmentMember_afe3a94b-20e4-4ae2-9cbf-c374f483008b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c55be462-27f0-45c1-8757-8007b59bbf85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c55be462-27f0-45c1-8757-8007b59bbf85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_acc0c33e-0c40-4546-a41b-d4ddeb2991e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:to="loc_us-gaap_ComputerEquipmentMember_acc0c33e-0c40-4546-a41b-d4ddeb2991e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_ef1c83f1-8639-472d-8353-5726e1203a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_ef1c83f1-8639-472d-8353-5726e1203a19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1415696a-69e7-467a-a1a8-5c3c1613ad8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1415696a-69e7-467a-a1a8-5c3c1613ad8c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="extended" id="i8e643963f8604650b0102377a382669a_INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cbeb17e8-5681-4d30-8355-f8361308c800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_445dc26b-0fe2-4162-8c61-c655845e636b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cbeb17e8-5681-4d30-8355-f8361308c800" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_445dc26b-0fe2-4162-8c61-c655845e636b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e808fa0-f4f0-446b-9eed-885e56686800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cbeb17e8-5681-4d30-8355-f8361308c800" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e808fa0-f4f0-446b-9eed-885e56686800" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e83da1b9-ca9b-4c2b-a442-043b0ac08fd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e808fa0-f4f0-446b-9eed-885e56686800" xlink:to="loc_srt_StatementGeographicalAxis_e83da1b9-ca9b-4c2b-a442-043b0ac08fd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e83da1b9-ca9b-4c2b-a442-043b0ac08fd0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e83da1b9-ca9b-4c2b-a442-043b0ac08fd0" xlink:to="loc_srt_SegmentGeographicalDomain_e83da1b9-ca9b-4c2b-a442-043b0ac08fd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a248fe01-1a84-44b7-8d19-d1dd23fd00f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e83da1b9-ca9b-4c2b-a442-043b0ac08fd0" xlink:to="loc_srt_SegmentGeographicalDomain_a248fe01-1a84-44b7-8d19-d1dd23fd00f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_09fa85f3-ee7e-44e6-824a-c4f381f8ae5c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a248fe01-1a84-44b7-8d19-d1dd23fd00f0" xlink:to="loc_country_US_09fa85f3-ee7e-44e6-824a-c4f381f8ae5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_490c59a5-c482-4349-81f1-c92bff20bfae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a248fe01-1a84-44b7-8d19-d1dd23fd00f0" xlink:to="loc_srt_EuropeMember_490c59a5-c482-4349-81f1-c92bff20bfae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2d8195a6-1f28-4949-b010-3083e19748f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e808fa0-f4f0-446b-9eed-885e56686800" xlink:to="loc_srt_ProductOrServiceAxis_2d8195a6-1f28-4949-b010-3083e19748f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2d8195a6-1f28-4949-b010-3083e19748f1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2d8195a6-1f28-4949-b010-3083e19748f1" xlink:to="loc_srt_ProductsAndServicesDomain_2d8195a6-1f28-4949-b010-3083e19748f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2dc8e4ac-935a-4816-82a0-dea354716df8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2d8195a6-1f28-4949-b010-3083e19748f1" xlink:to="loc_srt_ProductsAndServicesDomain_2dc8e4ac-935a-4816-82a0-dea354716df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_35210401-a7f1-4f87-b8bb-41d8d1eeeb9c" xlink:href="sesn-20221231.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2dc8e4ac-935a-4816-82a0-dea354716df8" xlink:to="loc_sesn_ViciniumMember_35210401-a7f1-4f87-b8bb-41d8d1eeeb9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14fe6505-eb47-4082-a6e8-61b5782328bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e808fa0-f4f0-446b-9eed-885e56686800" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14fe6505-eb47-4082-a6e8-61b5782328bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_14fe6505-eb47-4082-a6e8-61b5782328bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14fe6505-eb47-4082-a6e8-61b5782328bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_14fe6505-eb47-4082-a6e8-61b5782328bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0edd8ac2-3808-40f1-81b2-81affe9cd826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14fe6505-eb47-4082-a6e8-61b5782328bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0edd8ac2-3808-40f1-81b2-81affe9cd826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a1a469e0-f76c-4346-8a3d-3df485f3947d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0edd8ac2-3808-40f1-81b2-81affe9cd826" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a1a469e0-f76c-4346-8a3d-3df485f3947d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INTANGIBLESANDGOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="extended" id="i0ff294dfb88548ffa603305e8fca37ac_INTANGIBLESANDGOODWILLNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8dee9387-a0bf-46e4-a1c7-1be3e420cc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8dee9387-a0bf-46e4-a1c7-1be3e420cc7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_6f0f2585-ee1b-497d-9521-276b6fb80737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_6f0f2585-ee1b-497d-9521-276b6fb80737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5df4ba2e-798d-4bcb-b794-023b6035b1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:to="loc_us-gaap_Goodwill_5df4ba2e-798d-4bcb-b794-023b6035b1c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_168ae5fd-5ba2-43b0-9e81-35143bd333ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_168ae5fd-5ba2-43b0-9e81-35143bd333ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0fd77f9c-7a5d-4d79-a3be-847b6fee1664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0fd77f9c-7a5d-4d79-a3be-847b6fee1664" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cd240337-5323-483d-82ca-a207ea7c69f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0fd77f9c-7a5d-4d79-a3be-847b6fee1664" xlink:to="loc_srt_ProductOrServiceAxis_cd240337-5323-483d-82ca-a207ea7c69f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cd240337-5323-483d-82ca-a207ea7c69f5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cd240337-5323-483d-82ca-a207ea7c69f5" xlink:to="loc_srt_ProductsAndServicesDomain_cd240337-5323-483d-82ca-a207ea7c69f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5bcae088-aa12-4d99-a502-ca68746cce3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cd240337-5323-483d-82ca-a207ea7c69f5" xlink:to="loc_srt_ProductsAndServicesDomain_5bcae088-aa12-4d99-a502-ca68746cce3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_75ebdb20-b122-4dd2-a1e6-f37bb1376e4c" xlink:href="sesn-20221231.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5bcae088-aa12-4d99-a502-ca68746cce3b" xlink:to="loc_sesn_ViciniumMember_75ebdb20-b122-4dd2-a1e6-f37bb1376e4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0896f090-f7cb-40f3-b7a8-4d543446b585" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0fd77f9c-7a5d-4d79-a3be-847b6fee1664" xlink:to="loc_srt_StatementGeographicalAxis_0896f090-f7cb-40f3-b7a8-4d543446b585" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0896f090-f7cb-40f3-b7a8-4d543446b585_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0896f090-f7cb-40f3-b7a8-4d543446b585" xlink:to="loc_srt_SegmentGeographicalDomain_0896f090-f7cb-40f3-b7a8-4d543446b585_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_187ec542-c08e-4719-b8ae-44479ea7e604" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0896f090-f7cb-40f3-b7a8-4d543446b585" xlink:to="loc_srt_SegmentGeographicalDomain_187ec542-c08e-4719-b8ae-44479ea7e604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_fcfe2628-f223-492f-affd-a0173a76aede" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_187ec542-c08e-4719-b8ae-44479ea7e604" xlink:to="loc_srt_EuropeMember_fcfe2628-f223-492f-affd-a0173a76aede" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3a93aa45-3d85-4269-ab2e-96cb3c5eff0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0fd77f9c-7a5d-4d79-a3be-847b6fee1664" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3a93aa45-3d85-4269-ab2e-96cb3c5eff0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3a93aa45-3d85-4269-ab2e-96cb3c5eff0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3a93aa45-3d85-4269-ab2e-96cb3c5eff0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3a93aa45-3d85-4269-ab2e-96cb3c5eff0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0d6e54a-68a9-46c9-9140-cc02f78cd46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3a93aa45-3d85-4269-ab2e-96cb3c5eff0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0d6e54a-68a9-46c9-9140-cc02f78cd46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf8a9dc8-bf2b-44c7-a45e-3a5b7f6fddca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0d6e54a-68a9-46c9-9140-cc02f78cd46a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf8a9dc8-bf2b-44c7-a45e-3a5b7f6fddca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="i83d9644088ac41fc94c73d37ffaed351_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfLawsuits_a4e35932-edaf-4c14-8b8f-b193b82f52e5" xlink:href="sesn-20221231.xsd#sesn_NumberOfLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:to="loc_sesn_NumberOfLawsuits_a4e35932-edaf-4c14-8b8f-b193b82f52e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_d7317550-fe9a-4b16-a6af-526f6942757a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:to="loc_us-gaap_LitigationReserve_d7317550-fe9a-4b16-a6af-526f6942757a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_d9e68177-3a00-4b0c-a56c-43273c84e6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:to="loc_us-gaap_RestrictedCashCurrent_d9e68177-3a00-4b0c-a56c-43273c84e6ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_4db9a3da-5122-4f5e-ab9c-60d45a628658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_4db9a3da-5122-4f5e-ab9c-60d45a628658" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fae1a485-79d5-44cf-a8c9-fae0af1d6ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:to="loc_us-gaap_LossContingenciesTable_fae1a485-79d5-44cf-a8c9-fae0af1d6ec8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5f85f36f-1f71-4076-ab80-95b537fa1db8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fae1a485-79d5-44cf-a8c9-fae0af1d6ec8" xlink:to="loc_srt_LitigationCaseAxis_5f85f36f-1f71-4076-ab80-95b537fa1db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5f85f36f-1f71-4076-ab80-95b537fa1db8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_5f85f36f-1f71-4076-ab80-95b537fa1db8" xlink:to="loc_srt_LitigationCaseTypeDomain_5f85f36f-1f71-4076-ab80-95b537fa1db8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_99068119-c23b-4cd2-b107-38394205515e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_5f85f36f-1f71-4076-ab80-95b537fa1db8" xlink:to="loc_srt_LitigationCaseTypeDomain_99068119-c23b-4cd2-b107-38394205515e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember_882c3374-19b3-4f67-834d-1a9aa3cd5a91" xlink:href="sesn-20221231.xsd#sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_99068119-c23b-4cd2-b107-38394205515e" xlink:to="loc_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember_882c3374-19b3-4f67-834d-1a9aa3cd5a91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FederalDerivativeLitigationMember_0db65d80-8e2f-4350-b926-1203565db9e1" xlink:href="sesn-20221231.xsd#sesn_FederalDerivativeLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_99068119-c23b-4cd2-b107-38394205515e" xlink:to="loc_sesn_FederalDerivativeLitigationMember_0db65d80-8e2f-4350-b926-1203565db9e1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="extended" id="iea0d844099a04fc89f96af67a33fb422_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_8c0296d9-14f6-490d-91b3-2f58c7775760" xlink:href="sesn-20221231.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_8c0296d9-14f6-490d-91b3-2f58c7775760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseLeaseTerminationPayment_cea9ce3a-e8b8-42ab-8e92-559d00c9c380" xlink:href="sesn-20221231.xsd#sesn_OperatingLeaseLeaseTerminationPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_sesn_OperatingLeaseLeaseTerminationPayment_cea9ce3a-e8b8-42ab-8e92-559d00c9c380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_949ebcda-66a8-42bf-813b-997d93fc1983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_ShortTermLeaseCost_949ebcda-66a8-42bf-813b-997d93fc1983" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f5c76d0c-1953-414e-988d-9ff963400520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_OperatingLeaseCost_f5c76d0c-1953-414e-988d-9ff963400520" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed6dac9a-4354-41c1-a389-444e37d584da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed6dac9a-4354-41c1-a389-444e37d584da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_74e5fba2-28d9-47a6-b717-5496e3285086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_74e5fba2-28d9-47a6-b717-5496e3285086" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bcb51cc3-50f3-424d-a1ac-89a2f2d4ad2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bcb51cc3-50f3-424d-a1ac-89a2f2d4ad2d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_9881db14-b4e1-4905-a9c2-e8d213b68414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_9881db14-b4e1-4905-a9c2-e8d213b68414" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_9995fc0d-aa21-4c95-b5c8-0251ed814706" xlink:href="sesn-20221231.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_9995fc0d-aa21-4c95-b5c8-0251ed814706" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d88df94e-48ed-430c-a3b1-5beef1c9223e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d88df94e-48ed-430c-a3b1-5beef1c9223e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2f11147a-4f75-4edb-98da-016753d6e193" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d88df94e-48ed-430c-a3b1-5beef1c9223e" xlink:to="loc_srt_StatementGeographicalAxis_2f11147a-4f75-4edb-98da-016753d6e193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2f11147a-4f75-4edb-98da-016753d6e193_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2f11147a-4f75-4edb-98da-016753d6e193" xlink:to="loc_srt_SegmentGeographicalDomain_2f11147a-4f75-4edb-98da-016753d6e193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6c8d5de7-f15d-4202-86e2-4be239934020" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2f11147a-4f75-4edb-98da-016753d6e193" xlink:to="loc_srt_SegmentGeographicalDomain_6c8d5de7-f15d-4202-86e2-4be239934020" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_50dd1fb3-76c8-456e-b235-50776dafa4d5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6c8d5de7-f15d-4202-86e2-4be239934020" xlink:to="loc_country_CA_50dd1fb3-76c8-456e-b235-50776dafa4d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_4508e6e0-18b8-451e-a0e9-172a65f45193" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6c8d5de7-f15d-4202-86e2-4be239934020" xlink:to="loc_stpr_MA_4508e6e0-18b8-451e-a0e9-172a65f45193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_e4940d6f-d9ed-4e4d-8f64-0ecbb8688da2" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6c8d5de7-f15d-4202-86e2-4be239934020" xlink:to="loc_stpr_PA_e4940d6f-d9ed-4e4d-8f64-0ecbb8688da2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="extended" id="i59617949ac6042b7a734eecdc1ad975b_STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_efae2e91-6e11-428e-9fda-5393912bd8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_efae2e91-6e11-428e-9fda-5393912bd8f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_d4f6bf68-59c3-445c-9263-217511f49882" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockAdditionalSharesAuthorizedForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_d4f6bf68-59c3-445c-9263-217511f49882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_05b9a055-a7f1-42c7-a37c-e4531d1c6332" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_05b9a055-a7f1-42c7-a37c-e4531d1c6332" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_f035d7d1-bb7d-4988-9089-f526fabf1d67" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_f035d7d1-bb7d-4988-9089-f526fabf1d67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aefc1626-1211-4026-b378-4043c55ecb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aefc1626-1211-4026-b378-4043c55ecb33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f5d593ca-08d3-4682-b63d-a5d0d34e25b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f5d593ca-08d3-4682-b63d-a5d0d34e25b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_a81f4d94-94ea-4c86-b10c-d1963479b99f" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_a81f4d94-94ea-4c86-b10c-d1963479b99f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_0d062752-b256-4525-a46d-3c69fa85b241" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_0d062752-b256-4525-a46d-3c69fa85b241" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c9f611cf-99f7-4cc5-967c-8b7a0163645f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c9f611cf-99f7-4cc5-967c-8b7a0163645f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare_fa95f1b6-6fca-4062-b2c7-07f8a2089ae4" xlink:href="sesn-20221231.xsd#sesn_CommonStockAndWarrantOrRightsPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare_fa95f1b6-6fca-4062-b2c7-07f8a2089ae4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c4eb509b-602f-4fb8-b8bb-368c9f5b318f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c4eb509b-602f-4fb8-b8bb-368c9f5b318f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2a8826bd-01a6-4c94-846f-4400b62e2d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2a8826bd-01a6-4c94-846f-4400b62e2d73" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_56f233d4-ecfa-4e54-ac00-a53a5efbb8db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_56f233d4-ecfa-4e54-ac00-a53a5efbb8db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0ce66004-3f68-4bbe-ad13-c78c0ca9a4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_56f233d4-ecfa-4e54-ac00-a53a5efbb8db" xlink:to="loc_us-gaap_CreditFacilityAxis_0ce66004-3f68-4bbe-ad13-c78c0ca9a4cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0ce66004-3f68-4bbe-ad13-c78c0ca9a4cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_0ce66004-3f68-4bbe-ad13-c78c0ca9a4cf" xlink:to="loc_us-gaap_CreditFacilityDomain_0ce66004-3f68-4bbe-ad13-c78c0ca9a4cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1d38d62c-896f-4cef-8e65-05970eeb26e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_0ce66004-3f68-4bbe-ad13-c78c0ca9a4cf" xlink:to="loc_us-gaap_CreditFacilityDomain_1d38d62c-896f-4cef-8e65-05970eeb26e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_d1fae4ef-1aed-4548-be73-f32363649b89" xlink:href="sesn-20221231.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1d38d62c-896f-4cef-8e65-05970eeb26e8" xlink:to="loc_sesn_ATMFacilityMember_d1fae4ef-1aed-4548-be73-f32363649b89" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails" xlink:type="extended" id="i1725b8a102f34774bde1ee31dc31c016_STOCKHOLDERSEQUITYDEFICITCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_40a354c7-dad8-4f54-aed6-a34f08668b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_40a354c7-dad8-4f54-aed6-a34f08668b5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4d47a254-255b-435e-b31c-c09401c1ad42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:to="loc_us-gaap_CommonStockSharesIssued_4d47a254-255b-435e-b31c-c09401c1ad42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_60159e06-a695-4ebd-8c76-5d26ea083f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_60159e06-a695-4ebd-8c76-5d26ea083f3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare_6efd1dd8-b690-41da-b99d-86a7ac61608a" xlink:href="sesn-20221231.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:to="loc_sesn_NumberofVotesEntitledForEachShare_6efd1dd8-b690-41da-b99d-86a7ac61608a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_97ecaedc-55b3-4644-b84b-f0a03fa08bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_97ecaedc-55b3-4644-b84b-f0a03fa08bd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_26719165-3db8-45df-af4f-7c3a7edaa0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_97ecaedc-55b3-4644-b84b-f0a03fa08bd0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_26719165-3db8-45df-af4f-7c3a7edaa0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_26719165-3db8-45df-af4f-7c3a7edaa0aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_26719165-3db8-45df-af4f-7c3a7edaa0aa" xlink:to="loc_us-gaap_EquityComponentDomain_26719165-3db8-45df-af4f-7c3a7edaa0aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30f3db24-8715-4dd3-822e-de7d35590554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_26719165-3db8-45df-af4f-7c3a7edaa0aa" xlink:to="loc_us-gaap_EquityComponentDomain_30f3db24-8715-4dd3-822e-de7d35590554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_097b0cfd-657c-4efb-b649-df89ba6ab95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_30f3db24-8715-4dd3-822e-de7d35590554" xlink:to="loc_us-gaap_CommonStockMember_097b0cfd-657c-4efb-b649-df89ba6ab95c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended" id="i3a7a5d954f1244428b1d6f4533422f61_STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5c1cb39-ec33-4108-8def-6b137a0df217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3607a630-981b-4dc2-a02e-39e009261f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5c1cb39-ec33-4108-8def-6b137a0df217" xlink:to="loc_us-gaap_CommonStockSharesIssued_3607a630-981b-4dc2-a02e-39e009261f36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_527134ad-fefb-4b0a-a044-5d053f0a5622" xlink:href="sesn-20221231.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5c1cb39-ec33-4108-8def-6b137a0df217" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_527134ad-fefb-4b0a-a044-5d053f0a5622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d7be97c3-c197-4a95-a4ac-ce3924ae63ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_527134ad-fefb-4b0a-a044-5d053f0a5622" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d7be97c3-c197-4a95-a4ac-ce3924ae63ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_29c8f762-ad52-4cef-9cdf-2c34bfe8309c" xlink:href="sesn-20221231.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_527134ad-fefb-4b0a-a044-5d053f0a5622" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_29c8f762-ad52-4cef-9cdf-2c34bfe8309c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e9e87a40-3e13-4d10-9293-8d5268046c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5c1cb39-ec33-4108-8def-6b137a0df217" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e9e87a40-3e13-4d10-9293-8d5268046c30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_402d67dd-8601-488f-b744-b44a980550df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e9e87a40-3e13-4d10-9293-8d5268046c30" xlink:to="loc_us-gaap_AwardTypeAxis_402d67dd-8601-488f-b744-b44a980550df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402d67dd-8601-488f-b744-b44a980550df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_402d67dd-8601-488f-b744-b44a980550df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402d67dd-8601-488f-b744-b44a980550df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_402d67dd-8601-488f-b744-b44a980550df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_d96fb30b-1972-44ed-8eb0-c1f1e6da6547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:to="loc_us-gaap_WarrantMember_d96fb30b-1972-44ed-8eb0-c1f1e6da6547" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0ea432c4-ed8c-402f-821a-8b0e3fb0e805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0ea432c4-ed8c-402f-821a-8b0e3fb0e805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0dd527af-5b4d-4dfc-96a5-bab1e4e07533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0dd527af-5b4d-4dfc-96a5-bab1e4e07533" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9b58dfbb-50a2-4390-a123-eed1caaca4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:to="loc_us-gaap_StockCompensationPlanMember_9b58dfbb-50a2-4390-a123-eed1caaca4d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_12c2c30a-5b8b-498b-b024-b7708fb73a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:to="loc_us-gaap_EmployeeStockMember_12c2c30a-5b8b-498b-b024-b7708fb73a08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e6d596d-74c6-4ac9-963a-c151edb86be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e9e87a40-3e13-4d10-9293-8d5268046c30" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e6d596d-74c6-4ac9-963a-c151edb86be2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2e6d596d-74c6-4ac9-963a-c151edb86be2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e6d596d-74c6-4ac9-963a-c151edb86be2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2e6d596d-74c6-4ac9-963a-c151edb86be2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4f42aad5-d5d5-4e26-9498-2b15d91b4082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e6d596d-74c6-4ac9-963a-c151edb86be2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4f42aad5-d5d5-4e26-9498-2b15d91b4082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ccc28ff0-7f46-41f0-97ce-54e5f1e60056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4f42aad5-d5d5-4e26-9498-2b15d91b4082" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ccc28ff0-7f46-41f0-97ce-54e5f1e60056" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="extended" id="i4b7119fc53c042ff9194889470a7c15a_STOCKHOLDERSEQUITYDEFICITWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_a391fdad-c337-4493-a3c8-29e4c3fca360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_91a0df07-139a-44e3-bea4-4973a44f2d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a391fdad-c337-4493-a3c8-29e4c3fca360" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_91a0df07-139a-44e3-bea4-4973a44f2d3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:href="sesn-20221231.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a391fdad-c337-4493-a3c8-29e4c3fca360" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9219b791-f993-4140-8c6d-219cc82cd62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9219b791-f993-4140-8c6d-219cc82cd62d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_f9691bc2-6440-49d4-9586-3eaa113a5b35" xlink:href="sesn-20221231.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_f9691bc2-6440-49d4-9586-3eaa113a5b35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_84248d6a-5c11-4165-a594-f40a50320814" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_84248d6a-5c11-4165-a594-f40a50320814" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_cd542126-4e19-474b-9af2-4648ae9fb021" xlink:href="sesn-20221231.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_cd542126-4e19-474b-9af2-4648ae9fb021" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_96f92c0e-c4e1-476c-a950-73cf1094c5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_c82cae9b-1b94-4c7d-8a66-4d636dbf76d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a391fdad-c337-4493-a3c8-29e4c3fca360" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_c82cae9b-1b94-4c7d-8a66-4d636dbf76d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_19962c56-f77f-447e-b2db-bcf3e7dd7955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_c82cae9b-1b94-4c7d-8a66-4d636dbf76d1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_19962c56-f77f-447e-b2db-bcf3e7dd7955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_19962c56-f77f-447e-b2db-bcf3e7dd7955_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_19962c56-f77f-447e-b2db-bcf3e7dd7955" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_19962c56-f77f-447e-b2db-bcf3e7dd7955_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_19962c56-f77f-447e-b2db-bcf3e7dd7955" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_ee07d9ca-f7d2-494d-ae9c-8a69a00379d5" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_ee07d9ca-f7d2-494d-ae9c-8a69a00379d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_8134b159-1c32-46cc-92d7-1c67ea77d96b" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_8134b159-1c32-46cc-92d7-1c67ea77d96b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_3e4f93a1-aa8f-4332-8abc-84dcfd3a22e4" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_3e4f93a1-aa8f-4332-8abc-84dcfd3a22e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_37b9600f-0c99-4be7-aacb-51e248b69eb2" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_37b9600f-0c99-4be7-aacb-51e248b69eb2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails" xlink:type="extended" id="i072a16c207424e9f9e1cb3048eb35102_STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6ad20a02-f0ee-46dd-b4b3-c1fa6a77fa93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6ad20a02-f0ee-46dd-b4b3-c1fa6a77fa93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c726e3ec-dcac-424c-82cc-25ae1b673346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c726e3ec-dcac-424c-82cc-25ae1b673346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_b5c7e026-c814-4cdc-a74a-c7fefe5a0c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_b5c7e026-c814-4cdc-a74a-c7fefe5a0c4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_c3847112-f449-48ce-b1fe-5aa56d131080" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_c3847112-f449-48ce-b1fe-5aa56d131080" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherDividendAndAdjustments_4848f88d-a6ef-4f93-bc99-f223d2f24a1b" xlink:href="sesn-20221231.xsd#sesn_OtherDividendAndAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_sesn_OtherDividendAndAdjustments_4848f88d-a6ef-4f93-bc99-f223d2f24a1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_7ec5be65-96eb-4725-b3d3-0a32828a06f1" xlink:href="sesn-20221231.xsd#sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_7ec5be65-96eb-4725-b3d3-0a32828a06f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e24dc31a-6669-42e4-8c34-97f1f3822d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e24dc31a-6669-42e4-8c34-97f1f3822d32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d15cb5b8-bc21-42c1-9ffe-325327bb503d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e24dc31a-6669-42e4-8c34-97f1f3822d32" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d15cb5b8-bc21-42c1-9ffe-325327bb503d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d15cb5b8-bc21-42c1-9ffe-325327bb503d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d15cb5b8-bc21-42c1-9ffe-325327bb503d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d15cb5b8-bc21-42c1-9ffe-325327bb503d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4e7382e5-9942-4c5c-8f92-517d21195ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d15cb5b8-bc21-42c1-9ffe-325327bb503d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4e7382e5-9942-4c5c-8f92-517d21195ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_964d4e8a-9c40-4e99-91cc-1c8c6951e79a" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4e7382e5-9942-4c5c-8f92-517d21195ca3" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_964d4e8a-9c40-4e99-91cc-1c8c6951e79a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_9e43deed-4c02-4dd5-8236-4188fc7be16a" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4e7382e5-9942-4c5c-8f92-517d21195ca3" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_9e43deed-4c02-4dd5-8236-4188fc7be16a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_451262d4-3ff6-4072-b0bd-d993f6bae55a" xlink:href="sesn-20221231.xsd#sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4e7382e5-9942-4c5c-8f92-517d21195ca3" xlink:to="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_451262d4-3ff6-4072-b0bd-d993f6bae55a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bf7d66c6-ed76-49a9-bb90-e55e997d0192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e24dc31a-6669-42e4-8c34-97f1f3822d32" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bf7d66c6-ed76-49a9-bb90-e55e997d0192" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bf7d66c6-ed76-49a9-bb90-e55e997d0192_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bf7d66c6-ed76-49a9-bb90-e55e997d0192" xlink:to="loc_us-gaap_EquityComponentDomain_bf7d66c6-ed76-49a9-bb90-e55e997d0192_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4fd4759f-3471-4d88-b981-c5b25f2f16f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bf7d66c6-ed76-49a9-bb90-e55e997d0192" xlink:to="loc_us-gaap_EquityComponentDomain_4fd4759f-3471-4d88-b981-c5b25f2f16f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a8796763-75be-4495-aeb3-3969d43d7d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4fd4759f-3471-4d88-b981-c5b25f2f16f4" xlink:to="loc_us-gaap_CommonStockMember_a8796763-75be-4495-aeb3-3969d43d7d77" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended" id="i966eb918a8004b6dbb65a5c6af5c5f1b_EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6328811-5aa6-4e74-929d-2a6c678250c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47113576-5264-41c6-9e67-edd2e3928810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6328811-5aa6-4e74-929d-2a6c678250c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47113576-5264-41c6-9e67-edd2e3928810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d159e07-1b38-480f-82c0-d2ffaac89200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6328811-5aa6-4e74-929d-2a6c678250c4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d159e07-1b38-480f-82c0-d2ffaac89200" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_31b8762a-d1e6-4736-87cc-91449c90e177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d159e07-1b38-480f-82c0-d2ffaac89200" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_31b8762a-d1e6-4736-87cc-91449c90e177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31b8762a-d1e6-4736-87cc-91449c90e177_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_31b8762a-d1e6-4736-87cc-91449c90e177" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31b8762a-d1e6-4736-87cc-91449c90e177_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0790fdd1-c909-47b9-a1f3-05e306fad23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_31b8762a-d1e6-4736-87cc-91449c90e177" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0790fdd1-c909-47b9-a1f3-05e306fad23e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6697bf6f-4e73-4525-ba31-db6884225d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0790fdd1-c909-47b9-a1f3-05e306fad23e" xlink:to="loc_us-gaap_WarrantMember_6697bf6f-4e73-4525-ba31-db6884225d0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_04b20aad-b51c-4d6e-8af3-9ebe48952a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0790fdd1-c909-47b9-a1f3-05e306fad23e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_04b20aad-b51c-4d6e-8af3-9ebe48952a65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember_5aaf016f-7f11-42a0-9927-eead36fd3a35" xlink:href="sesn-20221231.xsd#sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0790fdd1-c909-47b9-a1f3-05e306fad23e" xlink:to="loc_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember_5aaf016f-7f11-42a0-9927-eead36fd3a35" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended" id="icbc53787b31047d68e8495b1271b3664_SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c183c623-67f8-47a1-a032-b75c319cd81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc5407f6-56a3-419d-89d2-87ef35ea7f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c183c623-67f8-47a1-a032-b75c319cd81c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc5407f6-56a3-419d-89d2-87ef35ea7f1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67d92f8c-c21e-4375-95fe-95b1202345b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c183c623-67f8-47a1-a032-b75c319cd81c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67d92f8c-c21e-4375-95fe-95b1202345b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2951c474-505f-4453-9ac7-a09e7fc7266f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67d92f8c-c21e-4375-95fe-95b1202345b7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2951c474-505f-4453-9ac7-a09e7fc7266f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2951c474-505f-4453-9ac7-a09e7fc7266f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2951c474-505f-4453-9ac7-a09e7fc7266f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2951c474-505f-4453-9ac7-a09e7fc7266f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5b12c4c9-d013-4c41-a699-f35231e8be9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2951c474-505f-4453-9ac7-a09e7fc7266f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5b12c4c9-d013-4c41-a699-f35231e8be9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4417cf9f-4682-4a00-923d-a6a3d2bb9b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5b12c4c9-d013-4c41-a699-f35231e8be9e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4417cf9f-4682-4a00-923d-a6a3d2bb9b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_90b38dbc-3bda-4e11-ae65-88cc857dac68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5b12c4c9-d013-4c41-a699-f35231e8be9e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_90b38dbc-3bda-4e11-ae65-88cc857dac68" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i69fa944b8cb0452c85d5f9c69bb8c48f_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_8e0efab7-1de7-4d67-bbd4-1ab70df35df6" xlink:href="sesn-20221231.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_8e0efab7-1de7-4d67-bbd4-1ab70df35df6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_80ce0790-3943-402a-b947-6c4a021d43db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_80ce0790-3943-402a-b947-6c4a021d43db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ff2dc793-2954-4848-8402-3df9cd0077d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ff2dc793-2954-4848-8402-3df9cd0077d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2f64d16b-add8-4474-a69c-cdcb36fe61c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2f64d16b-add8-4474-a69c-cdcb36fe61c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0a000abf-e19c-4cee-affb-e8d282697168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0a000abf-e19c-4cee-affb-e8d282697168" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_143395fd-c456-479f-ba8b-253ff55f6931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_143395fd-c456-479f-ba8b-253ff55f6931" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_803d448d-399c-45c8-a5f8-b7dd86d15e0e" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_803d448d-399c-45c8-a5f8-b7dd86d15e0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c2d4286a-c3c5-4f61-a9a3-69fa8b2db448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c2d4286a-c3c5-4f61-a9a3-69fa8b2db448" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_74049375-df45-4361-a68b-a60daf7a5246" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_74049375-df45-4361-a68b-a60daf7a5246" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_56cd1bc3-f60c-4b78-9c98-bc331088874c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_56cd1bc3-f60c-4b78-9c98-bc331088874c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_34fa9234-3665-4b6e-90f6-6231a6b02ea5" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_34fa9234-3665-4b6e-90f6-6231a6b02ea5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_71fe1b35-74e4-4adf-b41b-d28aa23ef2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_71fe1b35-74e4-4adf-b41b-d28aa23ef2d2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_123d1da1-45af-4a05-8f18-a7e9336619a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_123d1da1-45af-4a05-8f18-a7e9336619a0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10e5afb4-c2b3-4957-bde5-c33355313356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10e5afb4-c2b3-4957-bde5-c33355313356" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_608a900d-b182-43bc-b87a-2f5e038e7162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_608a900d-b182-43bc-b87a-2f5e038e7162" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_201963ba-d937-42e7-b572-6399ea7620b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_201963ba-d937-42e7-b572-6399ea7620b0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_bf3cb2a1-9e24-4943-a6c1-cc8d18f21f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:to="loc_us-gaap_VestingAxis_bf3cb2a1-9e24-4943-a6c1-cc8d18f21f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_bf3cb2a1-9e24-4943-a6c1-cc8d18f21f10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_bf3cb2a1-9e24-4943-a6c1-cc8d18f21f10" xlink:to="loc_us-gaap_VestingDomain_bf3cb2a1-9e24-4943-a6c1-cc8d18f21f10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_4444ff92-91f4-485b-8a71-f76ca67b8941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_bf3cb2a1-9e24-4943-a6c1-cc8d18f21f10" xlink:to="loc_us-gaap_VestingDomain_4444ff92-91f4-485b-8a71-f76ca67b8941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4a5018d7-7bec-482f-95b5-97565aeec228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_4444ff92-91f4-485b-8a71-f76ca67b8941" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4a5018d7-7bec-482f-95b5-97565aeec228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b1b2b5dc-1ea3-4a87-9455-7b6a56bce4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_4444ff92-91f4-485b-8a71-f76ca67b8941" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b1b2b5dc-1ea3-4a87-9455-7b6a56bce4ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_dbe9d979-6e66-4856-ba47-78a3b7c901d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:to="loc_us-gaap_PlanNameAxis_dbe9d979-6e66-4856-ba47-78a3b7c901d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dbe9d979-6e66-4856-ba47-78a3b7c901d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_dbe9d979-6e66-4856-ba47-78a3b7c901d5" xlink:to="loc_us-gaap_PlanNameDomain_dbe9d979-6e66-4856-ba47-78a3b7c901d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_47a09247-c995-44a9-b8ce-40fa2a9eebbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_dbe9d979-6e66-4856-ba47-78a3b7c901d5" xlink:to="loc_us-gaap_PlanNameDomain_47a09247-c995-44a9-b8ce-40fa2a9eebbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_17fb153f-918d-40f4-8ea3-2f81ca15e2ac" xlink:href="sesn-20221231.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_47a09247-c995-44a9-b8ce-40fa2a9eebbe" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_17fb153f-918d-40f4-8ea3-2f81ca15e2ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember_ef4bb87d-db56-4ac9-ac9d-bc223a97243d" xlink:href="sesn-20221231.xsd#sesn_RetentionProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_47a09247-c995-44a9-b8ce-40fa2a9eebbe" xlink:to="loc_sesn_RetentionProgramMember_ef4bb87d-db56-4ac9-ac9d-bc223a97243d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramCashManagementMilestoneMember_9660f443-e358-4d51-bb59-d639c6d2dd69" xlink:href="sesn-20221231.xsd#sesn_RetentionProgramCashManagementMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_RetentionProgramMember_ef4bb87d-db56-4ac9-ac9d-bc223a97243d" xlink:to="loc_sesn_RetentionProgramCashManagementMilestoneMember_9660f443-e358-4d51-bb59-d639c6d2dd69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_a98e8930-b374-4a5c-8b71-ec0c8e6d382c" xlink:href="sesn-20221231.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_47a09247-c995-44a9-b8ce-40fa2a9eebbe" xlink:to="loc_sesn_StockIncentivePlan2009Member_a98e8930-b374-4a5c-8b71-ec0c8e6d382c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_103ccc59-49b6-4417-9638-29bf054962e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:to="loc_us-gaap_AwardTypeAxis_103ccc59-49b6-4417-9638-29bf054962e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ccc59-49b6-4417-9638-29bf054962e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_103ccc59-49b6-4417-9638-29bf054962e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ccc59-49b6-4417-9638-29bf054962e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c6152bb-a918-4c47-ac59-0f82f4a5690b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_103ccc59-49b6-4417-9638-29bf054962e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c6152bb-a918-4c47-ac59-0f82f4a5690b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8429370c-3da9-486f-835e-5545b15a91bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c6152bb-a918-4c47-ac59-0f82f4a5690b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8429370c-3da9-486f-835e-5545b15a91bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aa66bb35-062a-4f9e-966b-743d34e4740c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c6152bb-a918-4c47-ac59-0f82f4a5690b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aa66bb35-062a-4f9e-966b-743d34e4740c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1efc5896-6edb-4273-aa64-d297780a8289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c6152bb-a918-4c47-ac59-0f82f4a5690b" xlink:to="loc_us-gaap_PerformanceSharesMember_1efc5896-6edb-4273-aa64-d297780a8289" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_7ecb53ea-f53d-4dd7-b6d7-3d68da1dab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:to="loc_us-gaap_GranteeStatusAxis_7ecb53ea-f53d-4dd7-b6d7-3d68da1dab1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_7ecb53ea-f53d-4dd7-b6d7-3d68da1dab1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_7ecb53ea-f53d-4dd7-b6d7-3d68da1dab1a" xlink:to="loc_us-gaap_GranteeStatusDomain_7ecb53ea-f53d-4dd7-b6d7-3d68da1dab1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_4ef23377-6522-46b9-9ca2-23b2c19b0ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_7ecb53ea-f53d-4dd7-b6d7-3d68da1dab1a" xlink:to="loc_us-gaap_GranteeStatusDomain_4ef23377-6522-46b9-9ca2-23b2c19b0ce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_b402fb3e-6953-41a0-9a43-bba9da619e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_4ef23377-6522-46b9-9ca2-23b2c19b0ce2" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_b402fb3e-6953-41a0-9a43-bba9da619e3b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="extended" id="i3870de3933544450b7454fe774f741d8_SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9547fabc-71c9-4d25-a9be-39a591f92cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9547fabc-71c9-4d25-a9be-39a591f92cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75b5a541-e519-4e43-9a38-5d8c9cb52898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75b5a541-e519-4e43-9a38-5d8c9cb52898" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c50ad3d1-62ce-489e-bd9a-1bb37cda2e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c50ad3d1-62ce-489e-bd9a-1bb37cda2e36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b0259eda-09fb-4e38-b244-d07b1337b4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b0259eda-09fb-4e38-b244-d07b1337b4fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7c1089e1-f5bf-4033-83e3-fe33fb586dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7c1089e1-f5bf-4033-83e3-fe33fb586dd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d8532ee-62a4-46b7-a6ad-543971536516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddbf405-1728-4fb8-a4c5-a4f4ec12aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9547fabc-71c9-4d25-a9be-39a591f92cbf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddbf405-1728-4fb8-a4c5-a4f4ec12aec0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_098991f9-eedd-4dad-81b8-f62fba0ddad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddbf405-1728-4fb8-a4c5-a4f4ec12aec0" xlink:to="loc_us-gaap_AwardTypeAxis_098991f9-eedd-4dad-81b8-f62fba0ddad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_098991f9-eedd-4dad-81b8-f62fba0ddad4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_098991f9-eedd-4dad-81b8-f62fba0ddad4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_098991f9-eedd-4dad-81b8-f62fba0ddad4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33e23208-29db-41a7-abcf-093da62fbd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_098991f9-eedd-4dad-81b8-f62fba0ddad4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33e23208-29db-41a7-abcf-093da62fbd9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fb694d44-b256-4c45-9bcd-9fbb496f6c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33e23208-29db-41a7-abcf-093da62fbd9d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fb694d44-b256-4c45-9bcd-9fbb496f6c5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4b689a58-3477-4546-ba20-f597ace5c854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33e23208-29db-41a7-abcf-093da62fbd9d" xlink:to="loc_us-gaap_PerformanceSharesMember_4b689a58-3477-4546-ba20-f597ace5c854" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="extended" id="i6dc5c7449ef549e1be095bf44a7cd7a3_SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_51b37194-c71a-4a5f-b522-d0876a34c64c" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_51b37194-c71a-4a5f-b522-d0876a34c64c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_05cc6356-a687-421d-a495-b401d1443da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_05cc6356-a687-421d-a495-b401d1443da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_549ea0c1-dc0f-4106-a76b-ceb27043bd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_549ea0c1-dc0f-4106-a76b-ceb27043bd6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_48cf78d0-2d8b-47df-8b0d-2b376e396f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_48cf78d0-2d8b-47df-8b0d-2b376e396f2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5f14f770-b6f4-472f-b1cf-7e47ac6c8a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5f14f770-b6f4-472f-b1cf-7e47ac6c8a5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bc8fac3d-a664-44f9-a535-0369492aae39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bc8fac3d-a664-44f9-a535-0369492aae39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f08f00-7922-48e8-b046-4533bc9365f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f08f00-7922-48e8-b046-4533bc9365f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c9d36ec-a140-4d12-b233-97a3cb24be83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f08f00-7922-48e8-b046-4533bc9365f4" xlink:to="loc_us-gaap_AwardTypeAxis_7c9d36ec-a140-4d12-b233-97a3cb24be83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c9d36ec-a140-4d12-b233-97a3cb24be83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7c9d36ec-a140-4d12-b233-97a3cb24be83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c9d36ec-a140-4d12-b233-97a3cb24be83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1d284c4-4436-4ab1-97c7-9cd935733011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7c9d36ec-a140-4d12-b233-97a3cb24be83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1d284c4-4436-4ab1-97c7-9cd935733011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7129037c-7a0b-4ae0-84bb-4e19a20a2bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1d284c4-4436-4ab1-97c7-9cd935733011" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7129037c-7a0b-4ae0-84bb-4e19a20a2bbb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended" id="i0a14c20e51d04b6f84edf953a69d99c2_EMPLOYEEBENEFITPLANSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63394b28-c75e-45fc-b9ca-28f5844fe4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63394b28-c75e-45fc-b9ca-28f5844fe4f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_95053cff-642d-41c6-b720-2a35bd60c6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_95053cff-642d-41c6-b720-2a35bd60c6d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_4a373308-2b1d-41d4-9df8-2bb575e4bb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_4a373308-2b1d-41d4-9df8-2bb575e4bb8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_03efe711-5d60-4a80-b687-2a5b441d3fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_03efe711-5d60-4a80-b687-2a5b441d3fe7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1bafe372-2e3b-4254-9f2d-244b19fbbead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1bafe372-2e3b-4254-9f2d-244b19fbbead" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_5c44fe96-88df-496f-bf8f-4c0dc9274778" xlink:href="sesn-20221231.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_5c44fe96-88df-496f-bf8f-4c0dc9274778" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_79701c46-c571-4e3a-8d2a-2e6832a033cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_79701c46-c571-4e3a-8d2a-2e6832a033cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fe0b1685-05c6-45e1-b7d6-df916f848a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fe0b1685-05c6-45e1-b7d6-df916f848a47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ef8ef262-8f1e-42d6-bbd9-1edd435dc36d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fe0b1685-05c6-45e1-b7d6-df916f848a47" xlink:to="loc_us-gaap_PlanNameAxis_ef8ef262-8f1e-42d6-bbd9-1edd435dc36d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ef8ef262-8f1e-42d6-bbd9-1edd435dc36d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ef8ef262-8f1e-42d6-bbd9-1edd435dc36d" xlink:to="loc_us-gaap_PlanNameDomain_ef8ef262-8f1e-42d6-bbd9-1edd435dc36d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_da7f46ab-5a13-41b1-8d10-668ed942f8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ef8ef262-8f1e-42d6-bbd9-1edd435dc36d" xlink:to="loc_us-gaap_PlanNameDomain_da7f46ab-5a13-41b1-8d10-668ed942f8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_aaafdfcd-7fd7-4257-a4bf-a78733f78b09" xlink:href="sesn-20221231.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_da7f46ab-5a13-41b1-8d10-668ed942f8e4" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_aaafdfcd-7fd7-4257-a4bf-a78733f78b09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f329d502-2286-4f0c-9edf-30c8f96d849c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fe0b1685-05c6-45e1-b7d6-df916f848a47" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f329d502-2286-4f0c-9edf-30c8f96d849c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_f329d502-2286-4f0c-9edf-30c8f96d849c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f329d502-2286-4f0c-9edf-30c8f96d849c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_f329d502-2286-4f0c-9edf-30c8f96d849c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5b8c0146-1460-4042-8608-0e2e89ad4cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f329d502-2286-4f0c-9edf-30c8f96d849c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5b8c0146-1460-4042-8608-0e2e89ad4cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f1786b7a-6b8e-45da-ba0f-1f93aca7455d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5b8c0146-1460-4042-8608-0e2e89ad4cb6" xlink:to="loc_us-gaap_DomesticPlanMember_f1786b7a-6b8e-45da-ba0f-1f93aca7455d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a523f8eb-6922-49fa-8f32-35096dbf902f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_f1786b7a-6b8e-45da-ba0f-1f93aca7455d" xlink:to="loc_country_US_a523f8eb-6922-49fa-8f32-35096dbf902f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_4b25ee5c-7844-4836-88e7-678201205e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5b8c0146-1460-4042-8608-0e2e89ad4cb6" xlink:to="loc_us-gaap_ForeignPlanMember_4b25ee5c-7844-4836-88e7-678201205e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_f9413b79-a237-4c7d-b3eb-56f30f9e60f8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_4b25ee5c-7844-4836-88e7-678201205e34" xlink:to="loc_country_CA_f9413b79-a237-4c7d-b3eb-56f30f9e60f8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended" id="ia833963b02854fef835a801ec53091e6_INCOMETAXESComponentsofPretaxIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_7b8323f1-2346-4e58-abe2-231b51712c95" xlink:href="sesn-20221231.xsd#sesn_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_484d802c-91ce-45d1-834d-1d811626f7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_7b8323f1-2346-4e58-abe2-231b51712c95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_484d802c-91ce-45d1-834d-1d811626f7d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2fb7f915-9d64-4cbc-94c1-a6551374fbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_7b8323f1-2346-4e58-abe2-231b51712c95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2fb7f915-9d64-4cbc-94c1-a6551374fbcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b832e224-f7f6-4cd5-831b-e67d5518bef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_7b8323f1-2346-4e58-abe2-231b51712c95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b832e224-f7f6-4cd5-831b-e67d5518bef5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_5790d61f-397f-4119-9427-235d127f040a" xlink:href="sesn-20221231.xsd#sesn_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_IncomeTaxesLineItems_7b8323f1-2346-4e58-abe2-231b51712c95" xlink:to="loc_sesn_IncomeTaxesTable_5790d61f-397f-4119-9427-235d127f040a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd23b15d-72e4-456b-8c1f-87e88436447a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_5790d61f-397f-4119-9427-235d127f040a" xlink:to="loc_srt_StatementGeographicalAxis_cd23b15d-72e4-456b-8c1f-87e88436447a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd23b15d-72e4-456b-8c1f-87e88436447a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cd23b15d-72e4-456b-8c1f-87e88436447a" xlink:to="loc_srt_SegmentGeographicalDomain_cd23b15d-72e4-456b-8c1f-87e88436447a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d7855d54-5cd6-4a48-bb61-22848d9545cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cd23b15d-72e4-456b-8c1f-87e88436447a" xlink:to="loc_srt_SegmentGeographicalDomain_d7855d54-5cd6-4a48-bb61-22848d9545cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0a45b3db-2669-488e-8dec-997dac25dea9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d7855d54-5cd6-4a48-bb61-22848d9545cf" xlink:to="loc_country_US_0a45b3db-2669-488e-8dec-997dac25dea9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_ae5f3a17-6302-4103-ae25-1d2516f54a57" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d7855d54-5cd6-4a48-bb61-22848d9545cf" xlink:to="loc_country_CA_ae5f3a17-6302-4103-ae25-1d2516f54a57" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESScheduleofCreditCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails" xlink:type="extended" id="if375805155c74a678dc1b1c829190546_INCOMETAXESScheduleofCreditCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_42e83966-44a4-4862-8096-aae96bdb0cbc" xlink:href="sesn-20221231.xsd#sesn_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2ee87cf8-8f55-4109-b918-04f61131fdcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_42e83966-44a4-4862-8096-aae96bdb0cbc" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2ee87cf8-8f55-4109-b918-04f61131fdcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_31f2cd7a-3f28-4719-b778-cc44916c72c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_42e83966-44a4-4862-8096-aae96bdb0cbc" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_31f2cd7a-3f28-4719-b778-cc44916c72c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:href="sesn-20221231.xsd#sesn_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_IncomeTaxesLineItems_42e83966-44a4-4862-8096-aae96bdb0cbc" xlink:to="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_e4cc9536-c947-4faa-bc3f-bd716be43382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_e4cc9536-c947-4faa-bc3f-bd716be43382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_e4cc9536-c947-4faa-bc3f-bd716be43382_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_e4cc9536-c947-4faa-bc3f-bd716be43382" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_e4cc9536-c947-4faa-bc3f-bd716be43382_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_87c039aa-d69b-40e6-a32b-4293cebba6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_e4cc9536-c947-4faa-bc3f-bd716be43382" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_87c039aa-d69b-40e6-a32b-4293cebba6ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_06b75913-6b23-452d-afac-8963dcd150dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_87c039aa-d69b-40e6-a32b-4293cebba6ff" xlink:to="loc_us-gaap_ResearchMember_06b75913-6b23-452d-afac-8963dcd150dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NonCapitalLossCarryforwardMember_812b742a-91ef-446b-93d3-e0cff00de444" xlink:href="sesn-20221231.xsd#sesn_NonCapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_87c039aa-d69b-40e6-a32b-4293cebba6ff" xlink:to="loc_sesn_NonCapitalLossCarryforwardMember_812b742a-91ef-446b-93d3-e0cff00de444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCreditMember_45198b13-faff-4f8d-bfcd-81dc61885109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_87c039aa-d69b-40e6-a32b-4293cebba6ff" xlink:to="loc_us-gaap_InvestmentCreditMember_45198b13-faff-4f8d-bfcd-81dc61885109" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardAxis_a3c6be25-060d-484e-93a4-cce9be0f2f04" xlink:href="sesn-20221231.xsd#sesn_NetOperatingLossCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:to="loc_sesn_NetOperatingLossCarryforwardAxis_a3c6be25-060d-484e-93a4-cce9be0f2f04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardDomain_a3c6be25-060d-484e-93a4-cce9be0f2f04_default" xlink:href="sesn-20221231.xsd#sesn_NetOperatingLossCarryforwardDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sesn_NetOperatingLossCarryforwardAxis_a3c6be25-060d-484e-93a4-cce9be0f2f04" xlink:to="loc_sesn_NetOperatingLossCarryforwardDomain_a3c6be25-060d-484e-93a4-cce9be0f2f04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardDomain_4aa3ec14-20a1-4847-9ad2-62915444504a" xlink:href="sesn-20221231.xsd#sesn_NetOperatingLossCarryforwardDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sesn_NetOperatingLossCarryforwardAxis_a3c6be25-060d-484e-93a4-cce9be0f2f04" xlink:to="loc_sesn_NetOperatingLossCarryforwardDomain_4aa3ec14-20a1-4847-9ad2-62915444504a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IndefiniteMember_741af363-361c-4de2-8f7a-23d3533d50e1" xlink:href="sesn-20221231.xsd#sesn_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_NetOperatingLossCarryforwardDomain_4aa3ec14-20a1-4847-9ad2-62915444504a" xlink:to="loc_sesn_IndefiniteMember_741af363-361c-4de2-8f7a-23d3533d50e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f50c27fa-a07c-4e7c-b066-b234b1418999" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:to="loc_srt_StatementGeographicalAxis_f50c27fa-a07c-4e7c-b066-b234b1418999" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f50c27fa-a07c-4e7c-b066-b234b1418999_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f50c27fa-a07c-4e7c-b066-b234b1418999" xlink:to="loc_srt_SegmentGeographicalDomain_f50c27fa-a07c-4e7c-b066-b234b1418999_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d8a0610c-1731-4217-b1eb-640f33b02d4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f50c27fa-a07c-4e7c-b066-b234b1418999" xlink:to="loc_srt_SegmentGeographicalDomain_d8a0610c-1731-4217-b1eb-640f33b02d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6d189028-efdc-4a80-90b5-4c9da4952d6e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d8a0610c-1731-4217-b1eb-640f33b02d4b" xlink:to="loc_country_US_6d189028-efdc-4a80-90b5-4c9da4952d6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_ae55cb2f-7998-42bc-94e9-65e48410a833" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d8a0610c-1731-4217-b1eb-640f33b02d4b" xlink:to="loc_country_CA_ae55cb2f-7998-42bc-94e9-65e48410a833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ba890a47-d9e9-4ea7-803c-e2f38727d636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ba890a47-d9e9-4ea7-803c-e2f38727d636" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ba890a47-d9e9-4ea7-803c-e2f38727d636_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ba890a47-d9e9-4ea7-803c-e2f38727d636" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ba890a47-d9e9-4ea7-803c-e2f38727d636_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e4d7cc76-6cdf-4312-be7d-70d555661069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ba890a47-d9e9-4ea7-803c-e2f38727d636" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e4d7cc76-6cdf-4312-be7d-70d555661069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_1a5b982e-3908-4c90-97c0-51405f64f0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e4d7cc76-6cdf-4312-be7d-70d555661069" xlink:to="loc_us-gaap_DomesticCountryMember_1a5b982e-3908-4c90-97c0-51405f64f0ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_294e5466-a5ca-449b-92e4-ae4fc6becf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e4d7cc76-6cdf-4312-be7d-70d555661069" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_294e5466-a5ca-449b-92e4-ae4fc6becf1c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#LICENSEAGREEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="extended" id="i709d014702b649b2a390db8fdfc6a6c4_LICENSEAGREEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:href="sesn-20221231.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_78d41f03-593e-4e8b-8132-b479deb987ff" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_78d41f03-593e-4e8b-8132-b479deb987ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_8e3f3787-81e6-4478-8019-c5730102f701" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_8e3f3787-81e6-4478-8019-c5730102f701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_6a437beb-bdc0-4710-949d-5c4730e42dc4" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_6a437beb-bdc0-4710-949d-5c4730e42dc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_e3c9ea88-8917-43e7-8de4-9c838dec4059" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_e3c9ea88-8917-43e7-8de4-9c838dec4059" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_1d442a81-b2a0-4111-a5b7-eaad0bfb4681" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_1d442a81-b2a0-4111-a5b7-eaad0bfb4681" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_5fcdd50e-eade-4a41-ba7c-88d09aa86268" xlink:href="sesn-20221231.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_5fcdd50e-eade-4a41-ba7c-88d09aa86268" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_6afb211c-1651-410b-82bf-c4e8f44eb522" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_6afb211c-1651-410b-82bf-c4e8f44eb522" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_e835f405-e838-42df-a777-69426d27f105" xlink:href="sesn-20221231.xsd#sesn_LicenseMaintenanceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseMaintenanceFees_e835f405-e838-42df-a777-69426d27f105" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement_0fa3084e-62a8-40ee-b5b9-d773ab1709a2" xlink:href="sesn-20221231.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_OtherReceivableAssetPurchaseAgreement_0fa3084e-62a8-40ee-b5b9-d773ab1709a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_148ba726-9d0d-4883-9ea2-c47b8100b787" xlink:href="sesn-20221231.xsd#sesn_ProceedsFromExecutionOfAssetPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_148ba726-9d0d-4883-9ea2-c47b8100b787" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AssetPurchaseAgreementVariableConsideration_3e26fa2e-3060-4bc0-bed3-9eb9cc39fca1" xlink:href="sesn-20221231.xsd#sesn_AssetPurchaseAgreementVariableConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_AssetPurchaseAgreementVariableConsideration_3e26fa2e-3060-4bc0-bed3-9eb9cc39fca1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3ee3edbe-259a-4eb9-bed9-aa52e906d97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3ee3edbe-259a-4eb9-bed9-aa52e906d97e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_bb202b78-2213-4c0d-9dfd-946e1a36045a" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_bb202b78-2213-4c0d-9dfd-946e1a36045a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_445ea3b3-0713-418f-8e6a-e2a8df5d9b9d" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_445ea3b3-0713-418f-8e6a-e2a8df5d9b9d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod_2558cc4b-cb99-4fbd-9481-4a9066f0e525" xlink:href="sesn-20221231.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_CollaborativeArrangementRoyaltyPeriod_2558cc4b-cb99-4fbd-9481-4a9066f0e525" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTerminationExpense_279e879c-2fe0-4ce3-9c24-916130ea81b8" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementTerminationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementTerminationExpense_279e879c-2fe0-4ce3-9c24-916130ea81b8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTerminationPayment_5ab46558-daf0-42a5-b3d3-9f4ba8b3ba59" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementTerminationPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementTerminationPayment_5ab46558-daf0-42a5-b3d3-9f4ba8b3ba59" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_PaymentsToRefundLicenseAgreementDeposits_285a8c8d-0444-4095-8b75-dce4ece1c3fc" xlink:href="sesn-20221231.xsd#sesn_PaymentsToRefundLicenseAgreementDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_PaymentsToRefundLicenseAgreementDeposits_285a8c8d-0444-4095-8b75-dce4ece1c3fc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_717060b7-1122-4ad4-b2a9-e2a9e03ed964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_717060b7-1122-4ad4-b2a9-e2a9e03ed964" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_04e311e5-dda0-4963-82f5-bff2c8fe4ebb" xlink:href="sesn-20221231.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_RoyaltyRevenuePercentage_04e311e5-dda0-4963-82f5-bff2c8fe4ebb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:href="sesn-20221231.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2eaecc6b-6484-410e-8f07-56f92659826d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_srt_CounterpartyNameAxis_2eaecc6b-6484-410e-8f07-56f92659826d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaecc6b-6484-410e-8f07-56f92659826d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2eaecc6b-6484-410e-8f07-56f92659826d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaecc6b-6484-410e-8f07-56f92659826d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2eaecc6b-6484-410e-8f07-56f92659826d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_f7ef1304-21e2-46cf-b7bd-5058877543d1" xlink:href="sesn-20221231.xsd#sesn_UniversityOfZurichMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_UniversityOfZurichMember_f7ef1304-21e2-46cf-b7bd-5058877543d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_8e6b1a2f-48ad-44e8-bfd1-e5eb38df0de0" xlink:href="sesn-20221231.xsd#sesn_MicrometAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_MicrometAGMember_8e6b1a2f-48ad-44e8-bfd1-e5eb38df0de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_77bec1ed-e6bd-4a1d-a505-0d9cd233ba5f" xlink:href="sesn-20221231.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_XOMAIrelandLimitedMember_77bec1ed-e6bd-4a1d-a505-0d9cd233ba5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_efdd67d8-5109-466c-9948-cddf5faf0de3" xlink:href="sesn-20221231.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_RocheMember_efdd67d8-5109-466c-9948-cddf5faf0de3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_5dffe208-2f89-42a9-8f1d-4d9d3a8e3dda" xlink:href="sesn-20221231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_5dffe208-2f89-42a9-8f1d-4d9d3a8e3dda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_516aa04d-7a1e-452e-910f-3b08525b81cb" xlink:href="sesn-20221231.xsd#sesn_MENALicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_MENALicenseAgreementMember_516aa04d-7a1e-452e-910f-3b08525b81cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_d937d4e7-3d63-4b17-939b-bf074c4bf92d" xlink:href="sesn-20221231.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_d937d4e7-3d63-4b17-939b-bf074c4bf92d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b0bd7297-a3a2-490d-a158-4b6fcd9bd707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b0bd7297-a3a2-490d-a158-4b6fcd9bd707" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0bd7297-a3a2-490d-a158-4b6fcd9bd707_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b0bd7297-a3a2-490d-a158-4b6fcd9bd707" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0bd7297-a3a2-490d-a158-4b6fcd9bd707_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fcf0005-90e1-4193-9cd2-00f5d6755d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b0bd7297-a3a2-490d-a158-4b6fcd9bd707" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fcf0005-90e1-4193-9cd2-00f5d6755d3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_f3d78acb-a035-4d89-bca5-44abe2bd345e" xlink:href="sesn-20221231.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fcf0005-90e1-4193-9cd2-00f5d6755d3e" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_f3d78acb-a035-4d89-bca5-44abe2bd345e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad9d4e25-af06-4e13-8e03-8558b2266ee2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_srt_ProductOrServiceAxis_ad9d4e25-af06-4e13-8e03-8558b2266ee2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ad9d4e25-af06-4e13-8e03-8558b2266ee2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ad9d4e25-af06-4e13-8e03-8558b2266ee2" xlink:to="loc_srt_ProductsAndServicesDomain_ad9d4e25-af06-4e13-8e03-8558b2266ee2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73c614e5-c5d8-4d5a-9585-4c879eaa71c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ad9d4e25-af06-4e13-8e03-8558b2266ee2" xlink:to="loc_srt_ProductsAndServicesDomain_73c614e5-c5d8-4d5a-9585-4c879eaa71c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_29a8602b-756d-4fa8-a1fe-a000e26df420" xlink:href="sesn-20221231.xsd#sesn_EBI031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73c614e5-c5d8-4d5a-9585-4c879eaa71c8" xlink:to="loc_sesn_EBI031Member_29a8602b-756d-4fa8-a1fe-a000e26df420" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ad92725d-5e38-4ac5-b336-640440929977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ad92725d-5e38-4ac5-b336-640440929977" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad92725d-5e38-4ac5-b336-640440929977_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ad92725d-5e38-4ac5-b336-640440929977" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad92725d-5e38-4ac5-b336-640440929977_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc46b6b3-4839-44f6-aead-c2b8860c9f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ad92725d-5e38-4ac5-b336-640440929977" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc46b6b3-4839-44f6-aead-c2b8860c9f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_c68e7590-bb23-445c-921d-2388f7d50bc9" xlink:href="sesn-20221231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc46b6b3-4839-44f6-aead-c2b8860c9f9b" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_c68e7590-bb23-445c-921d-2388f7d50bc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c4164f4c-2964-46d3-b0b1-abfa02fcf4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c4164f4c-2964-46d3-b0b1-abfa02fcf4e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c4164f4c-2964-46d3-b0b1-abfa02fcf4e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c4164f4c-2964-46d3-b0b1-abfa02fcf4e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c4164f4c-2964-46d3-b0b1-abfa02fcf4e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b14749d7-0139-4efa-b485-cf0bc10927a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c4164f4c-2964-46d3-b0b1-abfa02fcf4e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b14749d7-0139-4efa-b485-cf0bc10927a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_8ba9b43c-06c6-459a-9468-4a411f8fa00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b14749d7-0139-4efa-b485-cf0bc10927a8" xlink:to="loc_us-gaap_LicensingAgreementsMember_8ba9b43c-06c6-459a-9468-4a411f8fa00b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8a0213c5-7acd-41de-8fa2-25f4516d60e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_srt_StatementGeographicalAxis_8a0213c5-7acd-41de-8fa2-25f4516d60e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8a0213c5-7acd-41de-8fa2-25f4516d60e5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8a0213c5-7acd-41de-8fa2-25f4516d60e5" xlink:to="loc_srt_SegmentGeographicalDomain_8a0213c5-7acd-41de-8fa2-25f4516d60e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d9ad1220-8d5d-48e4-9c31-3543ea2aec7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8a0213c5-7acd-41de-8fa2-25f4516d60e5" xlink:to="loc_srt_SegmentGeographicalDomain_d9ad1220-8d5d-48e4-9c31-3543ea2aec7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_c3229502-be63-43ec-9374-08f255dba32c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d9ad1220-8d5d-48e4-9c31-3543ea2aec7d" xlink:to="loc_country_TR_c3229502-be63-43ec-9374-08f255dba32c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="extended" id="i963fd92e3aa44ef887007d7dc10a6d8c_RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_02dd0c83-e10a-4cbb-8e30-b5209fd6184c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_56bb4476-ea19-4769-8908-b9f49fda5067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_02dd0c83-e10a-4cbb-8e30-b5209fd6184c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_56bb4476-ea19-4769-8908-b9f49fda5067" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_8cf7310b-f832-4db1-bf4a-8fe188c4773d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_02dd0c83-e10a-4cbb-8e30-b5209fd6184c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_8cf7310b-f832-4db1-bf4a-8fe188c4773d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ba42a824-e5b5-4e20-bdb9-0e42be60daeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_02dd0c83-e10a-4cbb-8e30-b5209fd6184c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ba42a824-e5b5-4e20-bdb9-0e42be60daeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_b947d12c-bff6-43b4-b30d-c6863e52286c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ba42a824-e5b5-4e20-bdb9-0e42be60daeb" xlink:to="loc_us-gaap_RestructuringPlanAxis_b947d12c-bff6-43b4-b30d-c6863e52286c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b947d12c-bff6-43b4-b30d-c6863e52286c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_b947d12c-bff6-43b4-b30d-c6863e52286c" xlink:to="loc_us-gaap_RestructuringPlanDomain_b947d12c-bff6-43b4-b30d-c6863e52286c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e8082dd5-65f3-42a6-8431-9af8836a5cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_b947d12c-bff6-43b4-b30d-c6863e52286c" xlink:to="loc_us-gaap_RestructuringPlanDomain_e8082dd5-65f3-42a6-8431-9af8836a5cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2021RestructuringPlanMember_d80e34a7-8e6d-4481-b4fd-f2e5a6917316" xlink:href="sesn-20221231.xsd#sesn_A2021RestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_e8082dd5-65f3-42a6-8431-9af8836a5cb1" xlink:to="loc_sesn_A2021RestructuringPlanMember_d80e34a7-8e6d-4481-b4fd-f2e5a6917316" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended" id="i08fd7fe432f34c0e83faab8f71086a17_RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bc35742e-6d40-442a-af51-1ae7dab33c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_406e7184-45d9-46ea-a6f1-204a40d0eda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bc35742e-6d40-442a-af51-1ae7dab33c38" xlink:to="loc_us-gaap_RestructuringReserve_406e7184-45d9-46ea-a6f1-204a40d0eda5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9abb4414-6017-435b-b4b1-3eec415874ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bc35742e-6d40-442a-af51-1ae7dab33c38" xlink:to="loc_us-gaap_RestructuringCharges_9abb4414-6017-435b-b4b1-3eec415874ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_80ef0a9c-a1ca-44e2-9f52-e9a8668589ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bc35742e-6d40-442a-af51-1ae7dab33c38" xlink:to="loc_us-gaap_PaymentsForRestructuring_80ef0a9c-a1ca-44e2-9f52-e9a8668589ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_9febc469-defd-4571-9526-22793d622982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ffc5309-fe75-4a37-8c39-11ed84659f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bc35742e-6d40-442a-af51-1ae7dab33c38" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ffc5309-fe75-4a37-8c39-11ed84659f2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_e2bce7e9-3e9c-4663-be60-27c27cfee184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ffc5309-fe75-4a37-8c39-11ed84659f2b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_e2bce7e9-3e9c-4663-be60-27c27cfee184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e2bce7e9-3e9c-4663-be60-27c27cfee184_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e2bce7e9-3e9c-4663-be60-27c27cfee184" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e2bce7e9-3e9c-4663-be60-27c27cfee184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e0247ac8-cefd-47cf-b7a1-14dadf421755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e2bce7e9-3e9c-4663-be60-27c27cfee184" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e0247ac8-cefd-47cf-b7a1-14dadf421755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_5fff500b-99fa-4c0b-94b8-466d9649836b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e0247ac8-cefd-47cf-b7a1-14dadf421755" xlink:to="loc_us-gaap_EmployeeSeveranceMember_5fff500b-99fa-4c0b-94b8-466d9649836b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_34cd2549-3d3b-4271-a3ab-b9245f2927a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractTerminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e0247ac8-cefd-47cf-b7a1-14dadf421755" xlink:to="loc_us-gaap_ContractTerminationMember_34cd2549-3d3b-4271-a3ab-b9245f2927a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_790fac94-eed3-4ec6-9422-dc8d8f5fe919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ffc5309-fe75-4a37-8c39-11ed84659f2b" xlink:to="loc_us-gaap_RestructuringPlanAxis_790fac94-eed3-4ec6-9422-dc8d8f5fe919" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_790fac94-eed3-4ec6-9422-dc8d8f5fe919_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_790fac94-eed3-4ec6-9422-dc8d8f5fe919" xlink:to="loc_us-gaap_RestructuringPlanDomain_790fac94-eed3-4ec6-9422-dc8d8f5fe919_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6cbbf4cd-0405-40e7-9670-fb1b87055685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_790fac94-eed3-4ec6-9422-dc8d8f5fe919" xlink:to="loc_us-gaap_RestructuringPlanDomain_6cbbf4cd-0405-40e7-9670-fb1b87055685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2021RestructuringPlanMember_502f22f6-18c9-4ae4-a219-c873983c9185" xlink:href="sesn-20221231.xsd#sesn_A2021RestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_6cbbf4cd-0405-40e7-9670-fb1b87055685" xlink:to="loc_sesn_A2021RestructuringPlanMember_502f22f6-18c9-4ae4-a219-c873983c9185" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2022RestructuringPlanMember_a42f47ee-e2ce-4164-9a1d-d713d9b4d7f9" xlink:href="sesn-20221231.xsd#sesn_A2022RestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_6cbbf4cd-0405-40e7-9670-fb1b87055685" xlink:to="loc_sesn_A2022RestructuringPlanMember_a42f47ee-e2ce-4164-9a1d-d713d9b4d7f9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="id9f41ed21c174ade84863e68a613f00a_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_27ffc15b-fc0f-4865-a805-e89f1e3a6931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8191be5c-f04d-4677-b045-3bb0e8a7cdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_27ffc15b-fc0f-4865-a805-e89f1e3a6931" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8191be5c-f04d-4677-b045-3bb0e8a7cdd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_3c099d9d-6292-48d8-b5ce-13306fa84abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_27ffc15b-fc0f-4865-a805-e89f1e3a6931" xlink:to="loc_us-gaap_SubsequentEventTable_3c099d9d-6292-48d8-b5ce-13306fa84abb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_76b335bd-5dc2-466d-9be4-b069d748d85b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3c099d9d-6292-48d8-b5ce-13306fa84abb" xlink:to="loc_srt_StatementScenarioAxis_76b335bd-5dc2-466d-9be4-b069d748d85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_76b335bd-5dc2-466d-9be4-b069d748d85b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_76b335bd-5dc2-466d-9be4-b069d748d85b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_76b335bd-5dc2-466d-9be4-b069d748d85b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_95eaa5f9-bad5-4fff-9181-6042d42bf129" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_76b335bd-5dc2-466d-9be4-b069d748d85b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_95eaa5f9-bad5-4fff-9181-6042d42bf129" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_cd579371-579d-405e-a770-cf1c3ecbb2e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_95eaa5f9-bad5-4fff-9181-6042d42bf129" xlink:to="loc_srt_ScenarioForecastMember_cd579371-579d-405e-a770-cf1c3ecbb2e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>sesn-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:cb59ddaf-3c33-4c46-89b9-ef07748101c9,g:f5662b05-afda-41c0-b68c-8f02735bc2a0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_1ad5ca94-a9e3-4e5b-b870-85d622dec8dc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_92cd3b7a-846c-475d-aedc-1aabbc7f2bf9_terseLabel_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_label_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited [Member]</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_documentation_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember" xlink:href="sesn-20221231.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_XOMAIrelandLimitedMember" xlink:to="lab_sesn_XOMAIrelandLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember_e1024644-d034-43cd-b812-9148625a0040_terseLabel_en-US" xlink:label="lab_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Litigation</link:label>
    <link:label id="lab_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember_label_en-US" xlink:label="lab_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH [Member]</link:label>
    <link:label id="lab_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember_documentation_en-US" xlink:label="lab_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember" xlink:href="sesn-20221231.xsd#sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember" xlink:to="lab_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_296b3482-2d66-4d8d-afb5-a960c5233b70_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_5e6d3597-3524-4795-bfbd-09f49f11ef61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_287ccf34-d5e6-4316-b251-18a5ad9383c1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AuditInformationAbstract_label_en-US" xlink:label="lab_sesn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_sesn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_sesn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AuditInformationAbstract" xlink:href="sesn-20221231.xsd#sesn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AuditInformationAbstract" xlink:to="lab_sesn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1564084e-c740-492e-8dbc-b7c89bd73bcd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_bf83e88c-6fbd-44e7-bbd3-9cef6fb01535_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_9fc84c97-e741-4574-8d9c-8a8c7dba04b9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_f7474121-5c6f-42c3-8cc8-df6f87ba5573_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_326c89a8-4370-413c-8283-3041526471ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_51c21f87-2120-454c-bc70-ba9be17c795b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_316f8e85-f389-40ac-abb8-2ff3b42d1d46_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_f47def45-82cb-4a1e-a86e-506761561fc7_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_fe91852e-d1fb-49ce-a354-39c4250d3c9b_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received per award (in shares)</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_17def606-09b6-44ee-bf03-2b0654b314e8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7721d13f-6bd6-458c-a0ec-ca0454f7852c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505f40fc-68af-48f1-82fe-8349e6414cdd_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_78461b5a-d855-4bba-a6b0-b6919c1cccf1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_bbc5e7ef-584b-4395-a17c-263708edcd7f_terseLabel_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue, percentage</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_label_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_documentation_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage" xlink:href="sesn-20221231.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RoyaltyRevenuePercentage" xlink:to="lab_sesn_RoyaltyRevenuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17e85440-bc5f-4be0-ba71-2a93aaf60819_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a6d30d54-fa13-4c87-9a38-79abacb71011_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_eeaad442-b82a-472d-91eb-e97724ed7134_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate - operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c44c8d80-327c-418b-bdbb-a0cbd8896dee_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dec14db3-4f0a-4743-88bc-47eca3a2e7a8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_76bcfccd-ca73-4bed-808a-4a66544a6348_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_6ccb82d7-4b2c-4139-a0d2-e508903714e2_terseLabel_en-US" xlink:label="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of securities issued</link:label>
    <link:label id="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_label_en-US" xlink:label="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Minimum Percentage of Securities Issued</link:label>
    <link:label id="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_documentation_en-US" xlink:label="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Minimum Percentage of Securities Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:href="sesn-20221231.xsd#sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:to="lab_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_e775f013-cb65-4b82-a58e-330578f81226_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_3ea3b039-2127-49ed-becf-acfb9b27141e_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party minimum ownership, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_59cd38cf-35fa-4c65-ab59-feb7f2cd6855_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7da55b75-12c2-44e8-aa36-2572264926f2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss After Taxes</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fa5bee9f-00cd-4ab6-92a7-91af188b3828_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f207edc6-2b32-4ea4-86e2-e2ff2325c496_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_e22e2208-53ed-49db-b796-aed1c835700b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_25b55434-fcab-41d6-9510-5950b9d02160_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e1b4d67e-47df-4d39-b3ae-eb9bdee0ba32_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6bd913ee-91d3-4be8-95a3-09d59da9259e_netLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardDomain_017d8339-77f7-4168-adee-5eaebd45cb8b_terseLabel_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward [Domain]</link:label>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardDomain_label_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward [Domain]</link:label>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardDomain_documentation_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Net Operating Loss Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardDomain" xlink:href="sesn-20221231.xsd#sesn_NetOperatingLossCarryforwardDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NetOperatingLossCarryforwardDomain" xlink:to="lab_sesn_NetOperatingLossCarryforwardDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b5f7664a-7c46-4965-a159-9fcb95239fee_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_40406ad4-1d8c-43c6-94a7-4495dbc2549b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_01daa787-d260-4c58-8cad-06d3dce3b34d_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_cb6284ef-95d0-4cf0-bfee-9760e79eab70_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_17b0d5a7-2cae-4ca8-a64f-9d757d00b5a9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_163628fb-ad87-41bd-bd39-c2f53b6303d3_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space (in square feet)</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_label_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_documentation_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:href="sesn-20221231.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:to="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fcdd217d-fa63-44d7-8bfc-c9e366f55143_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original number of shares subject to the option vesting</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_4f5e6afa-a639-4c94-a435-af1b1c291677_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_407d01a9-c45a-4dbf-95ec-0f9befc11997_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_7dc868c4-b986-436a-b7a3-b885bfae3d83_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation:</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_1c529831-49ec-4245-9fa6-c44eb3334416_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9db6de41-3c60-466b-ae90-4980c8afd168_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b373594d-34a7-48df-8d4c-122a5e0ff649_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_02046bd3-1238-4945-ba5f-12b5290a39de_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_add8bbcd-b715-4ec5-9ce8-56c36421a183_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_37fe2cfc-cd8c-49e9-a43c-01049c925a40_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_07b99c9d-2ec4-408d-918f-9a93a62ac8f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1b438f04-338b-47b7-afa8-8d4d4a482bcb_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_de22b475-61d9-4b96-9ead-0d57867c6a52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6c465840-093b-4f9c-a815-9154f76c4473_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4c255a6f-e4ad-4fc6-8811-06883f10c7da_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_fb94319e-7b8d-4c11-a2a5-db642567a2fb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestonePayment_92cc70d5-41ab-41b0-b00a-dfb00cd490dc_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestonePayment_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestonePayment_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePayment" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestonePayment" xlink:to="lab_sesn_LicenseAgreementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_98ec37a4-2fe4-403c-9da3-fcca648fb601_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b95df1ed-80d4-4833-b8a0-fe9ef356f4f4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_31ab96df-eca0-4606-a3b0-3906b7d7a2ad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_10010cbf-af17-4790-b1ba-e8a47ccac5fb_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_A2022RestructuringPlanMember_079d259b-adfa-469d-b4e9-a557dbf6223f_terseLabel_en-US" xlink:label="lab_sesn_A2022RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Restructuring Plan</link:label>
    <link:label id="lab_sesn_A2022RestructuringPlanMember_label_en-US" xlink:label="lab_sesn_A2022RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Restructuring Plan [Member]</link:label>
    <link:label id="lab_sesn_A2022RestructuringPlanMember_documentation_en-US" xlink:label="lab_sesn_A2022RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2022RestructuringPlanMember" xlink:href="sesn-20221231.xsd#sesn_A2022RestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_A2022RestructuringPlanMember" xlink:to="lab_sesn_A2022RestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_3300c881-40e0-457b-8c3b-b89d38c964a2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for sale under 2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_04bceab9-5310-4abd-8924-24737498e00f_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_e75f0683-7477-4404-a7b7-acdd9ea28a43_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4f834b89-980e-4ce7-8379-b30e9db73f83_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_960be0bb-2c27-4f92-b490-cbdb5d1aea58_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Negative cash flows from operating activities incurred</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_44cc9e51-d20a-4135-b09e-fa75404ff574_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party maximum ownership, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:to="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_1bec1377-c2a7-45a4-9a7b-34339c981366_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_ade58b15-ca74-4dd6-95b3-22193f8ed3d6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0fd843bf-74ba-4936-a1bc-058cd63c55b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_fd1e9834-8afc-4d90-8f49-8a8a55d97665_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_9721ee02-354d-40a1-9c92-ba985bcb1cd1_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D intangible assets:</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fad439ff-d9ca-41bc-9b0f-b24f75592c52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_bfaddf7a-9606-4fed-87d9-0dbc6ea9bb7a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution retirement plan, maximum employee contribution deferred</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_37895dce-1d26-478b-b524-809b5e487e25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_d41a475a-c21b-442b-8215-9cb9119359f7_terseLabel_en-US" xlink:label="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized start-up costs</link:label>
    <link:label id="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_label_en-US" xlink:label="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Capitalized Start Up Costs</link:label>
    <link:label id="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_documentation_en-US" xlink:label="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Capitalized Start Up Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:href="sesn-20221231.xsd#sesn_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:to="lab_sesn_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_65f59c46-9e2e-42f1-be50-cef63baea6a6_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_4def9a32-18e4-4fe1-bb40-0b01eff389cc_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECEIVABLES</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b5994570-37fb-4e99-9efd-1df9c90fd8e5_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e7c5ab81-293e-4017-a3a8-7327c45cceb7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment_f716fe1f-633a-4aa2-9e0e-caf713ec954a_terseLabel_en-US" xlink:label="lab_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRC 174 Capitalized R&amp;D</link:label>
    <link:label id="lab_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment_label_en-US" xlink:label="lab_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Research and Development</link:label>
    <link:label id="lab_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment_documentation_en-US" xlink:label="lab_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:href="sesn-20221231.xsd#sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="lab_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80c0c546-4add-4497-9eeb-c5633be69820_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_93fca708-3fa0-4a21-9516-0b2eed3d1237_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a2e2060d-ca15-4bb6-8c69-ebac1cac0a25_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_839110f8-ad14-4453-9322-34ddc044db9e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_d42de4ca-45bc-46da-a646-c87a8ae39913_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment, percentage</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_label_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:to="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1b159f2d-63bd-4e69-a2e6-773815543e8f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e32f27e4-e5fc-44dc-ae8c-71b13810ff3f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b044d163-dcb9-4d70-a08d-dadf46377ae7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Composition of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f405852f-6de3-41d9-8981-b37600720fa0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_fcd75d1d-43cb-447f-b4b3-da90cf32c779_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_209e64ae-6147-4929-aa77-38cebc1f7268_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0c5480ec-4bfa-42e2-b693-7a3ca307a039_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_40295f21-3a7c-47cd-b6cd-07e8dc0c90c5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_77d2dd8a-c4bc-450a-99d8-3ab25fa80d70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_e10928bf-8ae7-4089-96de-8144b8a7313f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1bdf383-b5f6-4df7-9c9b-48eaae6707bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_047ecaeb-7b42-4250-b353-17f21c64823c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestonePaymentTerm_8843fad7-25b8-4204-b103-f57905f42dac_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment term</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestonePaymentTerm_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment Term</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestonePaymentTerm_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestonePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePaymentTerm" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestonePaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestonePaymentTerm" xlink:to="lab_sesn_LicenseAgreementMilestonePaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_ca0e05ee-0a35-484d-8135-29c4d31761fe_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c9eac29-3041-4e8c-8663-f38349cda012_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_FederalDerivativeLitigationMember_56ecb585-83f7-44a2-a565-beaf1c30ef97_terseLabel_en-US" xlink:label="lab_sesn_FederalDerivativeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Derivative Litigation</link:label>
    <link:label id="lab_sesn_FederalDerivativeLitigationMember_label_en-US" xlink:label="lab_sesn_FederalDerivativeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Derivative Litigation [Member]</link:label>
    <link:label id="lab_sesn_FederalDerivativeLitigationMember_documentation_en-US" xlink:label="lab_sesn_FederalDerivativeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Derivative Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FederalDerivativeLitigationMember" xlink:href="sesn-20221231.xsd#sesn_FederalDerivativeLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_FederalDerivativeLitigationMember" xlink:to="lab_sesn_FederalDerivativeLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_8db5f7c8-1ac2-4521-8856-e3fb652e604f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_1e4093ce-c4e2-4473-a2e1-26eb560c82e2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_20df6a6a-7f65-41e4-93cd-ec4ee3a8f663_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_58bb5cd2-53be-44ae-b189-38f15d834567_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0592dff8-d997-41c7-af19-7181c226286d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred benefit (provision)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_41b9e008-ed09-415e-8906-327fa0a57fc7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_9ded64ea-2ea5-4e20-9880-afeffd2b2d1c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RetentionProgramCashManagementMilestoneMember_450676f2-86ba-4ad7-8b9d-814b3868966f_terseLabel_en-US" xlink:label="lab_sesn_RetentionProgramCashManagementMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program, cash management milestone</link:label>
    <link:label id="lab_sesn_RetentionProgramCashManagementMilestoneMember_label_en-US" xlink:label="lab_sesn_RetentionProgramCashManagementMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program, Cash Management Milestone [Member]</link:label>
    <link:label id="lab_sesn_RetentionProgramCashManagementMilestoneMember_documentation_en-US" xlink:label="lab_sesn_RetentionProgramCashManagementMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program, Cash Management Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramCashManagementMilestoneMember" xlink:href="sesn-20221231.xsd#sesn_RetentionProgramCashManagementMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RetentionProgramCashManagementMilestoneMember" xlink:to="lab_sesn_RetentionProgramCashManagementMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_eadebe00-ae2b-420a-b01c-edd5d206a4cd_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_9dcf325f-fc65-447b-a2f3-2791f0261245_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_32069e3c-ef9c-4e07-ada6-3f5db5396abd_terseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_label_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009 [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member" xlink:href="sesn-20221231.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlan2009Member" xlink:to="lab_sesn_StockIncentivePlan2009Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6aecddeb-fbf2-44ab-b8ec-7f3e8c43beb5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberOfLawsuits_1d16b1aa-22ee-4e3b-853e-25bbfe67cf4b_terseLabel_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_sesn_NumberOfLawsuits_label_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits</link:label>
    <link:label id="lab_sesn_NumberOfLawsuits_documentation_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfLawsuits" xlink:href="sesn-20221231.xsd#sesn_NumberOfLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberOfLawsuits" xlink:to="lab_sesn_NumberOfLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_266b95a8-2574-4fb0-8d7c-02b1b66cb7fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting on the First Anniversary of Date of Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_591a0b51-11f6-4330-bcd0-a63a8d73d09a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_9ac1e80e-44e6-496f-b390-b34896cade14_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1a4534c6-8b44-4569-81da-708a6531780f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3e1b15ca-48a4-491d-85b9-f761f7df8ece_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7f778b81-2a01-4012-b013-e84fdf826d12_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_66c88eba-49e9-4a63-8583-07e37faf5d28_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_7f23f220-5088-4b19-b5f4-5a9375865192_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_106cbbfa-0583-4fb2-9c13-ab1899a54372_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_27a791f4-a535-42ac-99b3-a24ff2b98b29_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_0a9d1075-d57c-4308-82b0-9d96edae1465_terseLabel_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary match per participating employee, maximum</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_label_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_documentation_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:href="sesn-20221231.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:to="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cb382e1e-75b5-452a-9b03-bc96ccfc4cb5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractTerminationMember_e28b8939-9e54-42ba-b399-94f44aa64e8b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination and other associated costs</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_label_en-US" xlink:label="lab_us-gaap_ContractTerminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Termination [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractTerminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractTerminationMember" xlink:to="lab_us-gaap_ContractTerminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1552e5ec-2df4-420f-927d-74e3c74bd915_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a32bca35-6817-4c40-bd41-df51d46a8aa9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_23d67d58-3134-4582-9c3b-1dc0eeb5eef1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1d2d1175-7fdf-4523-8221-bddb8560137d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_24fd5d9f-973e-4728-93b6-0cfc330f9f33_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_91919bcd-1e38-41dd-a1bd-abdd9621d000_terseLabel_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:href="sesn-20221231.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:to="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_87195c0b-53dd-4a8d-8661-3c68d0960965_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_049cd753-6d4a-46a9-86e3-9b92afd7d5b0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_20b3c57b-6bee-4361-a0d1-884564b37788_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2269bc4a-f8f8-4167-a1ca-97bc45761f53_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_653e32bf-7439-46d6-825a-7208e060ab38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_515f1127-0026-4dd9-bc78-6e7f557ba9e9_terseLabel_en-US" xlink:label="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from execution of asset purchase agreement</link:label>
    <link:label id="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_label_en-US" xlink:label="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Execution Of Asset Purchase Agreement</link:label>
    <link:label id="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_documentation_en-US" xlink:label="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Execution Of Asset Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:href="sesn-20221231.xsd#sesn_ProceedsFromExecutionOfAssetPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:to="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_c4011a01-9590-464b-a24a-c2032a70e87d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Benefit (Provision)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OtherDividendAndAdjustments_7f83acab-7949-4f0d-a08b-980c7e5d449c_terseLabel_en-US" xlink:label="lab_sesn_OtherDividendAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend</link:label>
    <link:label id="lab_sesn_OtherDividendAndAdjustments_label_en-US" xlink:label="lab_sesn_OtherDividendAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Dividend And Adjustments</link:label>
    <link:label id="lab_sesn_OtherDividendAndAdjustments_documentation_en-US" xlink:label="lab_sesn_OtherDividendAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Dividend And Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherDividendAndAdjustments" xlink:href="sesn-20221231.xsd#sesn_OtherDividendAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OtherDividendAndAdjustments" xlink:to="lab_sesn_OtherDividendAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3f2bf08-dee8-4208-91c5-6a4833e29ce6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5f346f88-78ff-42ba-9826-e955ea19b07d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_09b5597a-e739-4ad6-90b0-364072d2f08d_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_13bb2be2-bc45-4582-82b0-e05f467a871c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ff6c2acd-96fd-4b0f-8c68-4cb8bc9cdac4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period unvested stock to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a0fcea27-0215-43f0-96a1-99b3f76fbf17_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedLegalFeesCurrent_f528aac6-e774-44d7-9753-a3246564f49c_terseLabel_en-US" xlink:label="lab_sesn_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal expenses, including the preliminary securities litigation settlement</link:label>
    <link:label id="lab_sesn_AccruedLegalFeesCurrent_label_en-US" xlink:label="lab_sesn_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Fees, Current</link:label>
    <link:label id="lab_sesn_AccruedLegalFeesCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedLegalFeesCurrent" xlink:href="sesn-20221231.xsd#sesn_AccruedLegalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedLegalFeesCurrent" xlink:to="lab_sesn_AccruedLegalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_9e1a88fe-27e6-43b7-a450-52da3bd520d0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_0f24fbcb-ec5d-4fac-b638-ef81638b99f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock pursuant to ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_a43fdaa5-76f3-45a5-add1-f02aef975d24_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for RSU vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_30cd2e0f-a547-42cd-a059-a87c87784c1b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_feef5a45-e4e0-4eb5-aa41-2bfb6942f016_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_0041b37b-bbba-4c63-8eab-2d79f7503107_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate sales price</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_label_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_documentation_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:to="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_c55966c6-4b9d-461b-9624-594c7814b7ab_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d3dda89e-6ec7-4a20-ab3b-a13ea30059d6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3b38efc4-1278-42f2-9dd2-bb0b35e8ed1e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4764da9f-1154-4551-bf46-ba3f80ab348d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4187b8e6-d980-4fca-8eb1-664293cf2257_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46d0bd1f-bab3-40b9-9771-658a6da260dd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_6aa8a1ba-be18-45b9-b88a-7a65ec7729bc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_de2cfff1-1ae6-4368-a9e9-2bfb0b837baf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3b665191-9761-48df-8e03-b08f2edf2c34_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_2fe370e1-55cf-4beb-9dbc-54fbbabdbc57_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4bbc1cc7-d869-4063-baf7-91158db9d122_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ContingentConsiderationPolicyTextBlock_9c470809-13a4-4283-baf8-6d9222b399b0_terseLabel_en-US" xlink:label="lab_sesn_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_sesn_ContingentConsiderationPolicyTextBlock_label_en-US" xlink:label="lab_sesn_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:label id="lab_sesn_ContingentConsiderationPolicyTextBlock_documentation_en-US" xlink:label="lab_sesn_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ContingentConsiderationPolicyTextBlock" xlink:href="sesn-20221231.xsd#sesn_ContingentConsiderationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ContingentConsiderationPolicyTextBlock" xlink:to="lab_sesn_ContingentConsiderationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_a6ccd456-e2fb-4132-a6be-b513312c1ed9_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from milestone achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_label_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Proceeds From Milestone Achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Proceeds From Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:to="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5193850c-4d4c-45e2-aadf-08ae8e82a965_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b73c5305-e9a7-4263-a892-c88821ba87f5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_935f095a-7c48-4d5e-b89a-ff2a9c66692e_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_32f5fbd6-99b0-498b-bd0e-4dcf2799282b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e4a9cd76-97a9-417e-8a7c-d825e2bac6ec_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_59680426-51a0-4547-9cda-901df634e489_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:href="sesn-20221231.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AssetPurchaseAgreementVariableConsideration_f9632a40-adc5-4aa3-bde6-955c873b60ab_terseLabel_en-US" xlink:label="lab_sesn_AssetPurchaseAgreementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement, variable consideration</link:label>
    <link:label id="lab_sesn_AssetPurchaseAgreementVariableConsideration_label_en-US" xlink:label="lab_sesn_AssetPurchaseAgreementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Variable Consideration</link:label>
    <link:label id="lab_sesn_AssetPurchaseAgreementVariableConsideration_documentation_en-US" xlink:label="lab_sesn_AssetPurchaseAgreementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Variable Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AssetPurchaseAgreementVariableConsideration" xlink:href="sesn-20221231.xsd#sesn_AssetPurchaseAgreementVariableConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AssetPurchaseAgreementVariableConsideration" xlink:to="lab_sesn_AssetPurchaseAgreementVariableConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_ed6cd5dc-93ee-44f1-8af6-1adde369a888_terseLabel_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_label_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_documentation_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms" xlink:href="sesn-20221231.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccountsReceivablePaymentTerms" xlink:to="lab_sesn_AccountsReceivablePaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_44390df3-77d5-471b-a014-f76763252d2e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1392dcc2-dd9c-4da6-839b-cdc622149561_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_93d8e2ec-780e-4de5-b14b-c96e5d2a5e51_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_69887e66-34fe-4733-a043-b586306f16e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_18b5e3c6-9569-4d74-8e92-083490c3d23a_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_62ad52c6-5ba6-473d-b67a-a6342541c590_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_31081068-a49a-43b2-aabf-a23bcd46a9b3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_148d59dd-abb7-4a66-ba13-6fc413872555_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration - long term</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:to="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b6633cdb-8647-466e-970b-91f55a6d891a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_feb6961f-98af-430f-b4eb-433d358fe765_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_39d2072c-fa48-4b34-b6b1-9cda888ea0c9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_220ff274-61c9-4403-8d58-28acda7c73cb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_e764ff4d-50d2-40f0-a38c-67ffd0f5a5c6_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_fbd4a459-98ad-4527-97c1-708a53c81611_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_f2361bc0-e883-4941-920b-04eb41e338df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_6847a70a-97ac-4fb2-94f9-2337e315cf0e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits and other credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_f827f0eb-02f1-4d09-ae08-6e7c180150ad_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D credit carryforwards</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1ba4b12c-e102-4a83-b369-97d788721c41_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b99dde35-eaf1-4720-8f1b-beab49e4565b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ca3f7b1-1f7c-4e5b-ac33-b65bad6b1705_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_40b71ae7-ec3e-4d31-b211-ab9ca677623c_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Credit Carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_3fecddc6-3d5e-4a66-b9b1-6912aecfba3e_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fixed rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_label_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_documentation_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockCommissionFixedRate" xlink:to="lab_sesn_SaleOfStockCommissionFixedRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_A2021RestructuringPlanMember_7d796e31-e792-4524-8dce-c3e7f5ae42a5_terseLabel_en-US" xlink:label="lab_sesn_A2021RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Restructuring Plan</link:label>
    <link:label id="lab_sesn_A2021RestructuringPlanMember_label_en-US" xlink:label="lab_sesn_A2021RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Restructuring Plan [Member]</link:label>
    <link:label id="lab_sesn_A2021RestructuringPlanMember_documentation_en-US" xlink:label="lab_sesn_A2021RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2021RestructuringPlanMember" xlink:href="sesn-20221231.xsd#sesn_A2021RestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_A2021RestructuringPlanMember" xlink:to="lab_sesn_A2021RestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_1fefaae8-dd10-48f7-a812-432b6329cadd_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsCurrent" xlink:to="lab_us-gaap_IntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_327ca349-7958-4f2d-98a0-fb4779d3c765_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ce7c67a5-c2fd-4153-b370-c5a53891d379_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_cf46e94e-c9cd-4a57-bbe8-32ab068cf0f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_d2c7328a-7af2-495e-ac6e-9b43b77256a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_57c66d23-b84c-4b54-b5ed-4454c0703601_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_4a7c4b71-812d-4b53-beeb-900ee87bce30_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8d41742a-f70b-4208-864a-f129a8b499da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a25556ab-862f-4891-8448-2e3d1c801212_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_168c2874-5811-4cac-86e9-e3092e9440cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_bdf16a56-c64b-4646-8d85-8c676a04f9bb_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_ab6c8dcb-96f8-4638-acd0-859831637c3a_terseLabel_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_label_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_documentation_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:href="sesn-20221231.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:to="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardAxis_f03423d8-185f-4474-ba13-c8ce113d7d9f_terseLabel_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward [Axis]</link:label>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardAxis_label_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward [Axis]</link:label>
    <link:label id="lab_sesn_NetOperatingLossCarryforwardAxis_documentation_en-US" xlink:label="lab_sesn_NetOperatingLossCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardAxis" xlink:href="sesn-20221231.xsd#sesn_NetOperatingLossCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NetOperatingLossCarryforwardAxis" xlink:to="lab_sesn_NetOperatingLossCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_895ce96e-c764-4284-85a4-bacdb5fb1d27_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_fd84cab0-022e-48d3-bd62-c26475aedee2_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_a4dfad59-f48f-4868-88e2-86eb9425eecd_terseLabel_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_label_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Contingent Consideration, Percent</link:label>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_documentation_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Contingent Consideration, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:href="sesn-20221231.xsd#sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:to="lab_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_5c2ff54b-fcec-4e36-a0f6-f440342da391_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_87898d17-7a7b-4569-9738-3f336f60a386_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7bfc9bcb-e05c-432b-af35-8b4882c2ad11_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_61a293ff-8ffd-4e80-9f29-41d327b51b69_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e05b785c-f9d5-40c7-9954-3d0535331211_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5ea802d5-f2f3-45e2-961d-b16ef4418c70_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_4d197a10-64f3-496d-989b-29b066a35c7e_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_76cabe11-24e2-4e4e-bee0-0c53282dde61_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_e2feea0c-f0bd-4de6-bd88-54537a7d0e40_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_a77a87ea-b83e-48c3-b52e-aa8a589156d2_totalLabel_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock issued and reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_label_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_documentation_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:href="sesn-20221231.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:to="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bcd1b31c-4633-42a1-abc9-9247f934c3f8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bb613ae8-b61c-4bcd-8551-925dea33e687_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of units issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_bf923ad9-945d-4648-b6c4-146bf2dc888b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0d1f121c-ce3f-44c1-b21b-7ca60a4f5aea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7084c9e4-5ca4-45ee-979a-ccc9b66cf99e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseLeaseTerminationPayment_332196d8-8952-4317-98ab-28befee55bb6_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseLeaseTerminationPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, termination expense</link:label>
    <link:label id="lab_sesn_OperatingLeaseLeaseTerminationPayment_label_en-US" xlink:label="lab_sesn_OperatingLeaseLeaseTerminationPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Termination Payment</link:label>
    <link:label id="lab_sesn_OperatingLeaseLeaseTerminationPayment_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseLeaseTerminationPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Termination Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseLeaseTerminationPayment" xlink:href="sesn-20221231.xsd#sesn_OperatingLeaseLeaseTerminationPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseLeaseTerminationPayment" xlink:to="lab_sesn_OperatingLeaseLeaseTerminationPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_09c73549-7f4f-48a5-a20e-a0ece2670e01_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ab926c7d-59bf-49a6-91b1-ad38e7b5a729_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_c8851657-5691-433f-a33b-b3051c19bda2_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_fe965a15-f47b-4116-8339-ba3fd4390621_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_label_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent" xlink:href="sesn-20221231.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseMonthlyRent" xlink:to="lab_sesn_OperatingLeaseMonthlyRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_559566d6-640f-4678-a418-4f1a85e44b30_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_177460f9-059f-4616-a13f-bd286253cfc1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bc8083a1-1fc6-4bd6-bf63-b5299dbd2369_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_d3f0b7dc-fbac-44fa-946e-092c7f5b2e70_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e519d79b-7df2-47d4-a2b4-b0a676d00983_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for sale (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_f660c3d7-c5f9-4aa1-992a-af3bbb672777_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_f27d95b6-8366-4046-9f4b-86b905fae5d8_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_20ba6cb4-5de9-43e5-a259-04712f262559_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_52c134d8-c2b0-4302-8272-cf37ace9794a_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued to the selling shareholders (in shares)</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_label_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:to="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a97bd473-d828-457f-9c24-95c6db948f17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Status of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_bc6d7faa-c6b3-44f0-8251-351191cc7070_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_0087942d-3621-4419-963d-40b740370243_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_aa401736-82c6-45a8-b69a-dd682e0b4371_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_4bb9895b-a9d8-45ef-be7a-c33e35c066fb_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_a39434b0-f4e9-4bcb-9198-1c1839c5efe3_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Tax Provision</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_380559ee-d2fd-46ed-b636-b8003589a165_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_1b76b042-df76-4952-8bd4-215df3ad6659_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9b7b86bb-f8f2-4bf5-b408-7c847ac8802b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e8986cc0-1c61-4d38-b466-7aaef534f090_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_ec74dd88-41dd-406b-9ae3-650599b7d4ba_terseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:href="sesn-20221231.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_0cc61e1c-77b3-4a0f-b48c-e8c1eeddb012_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:href="sesn-20221231.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_e241b894-2e4d-41e7-a6a5-08ae35531da5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_ce772091-1f47-4de8-a5bd-cd0b165e73c0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_5fecabf1-223b-485f-99d4-5c434bde6a2d_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b178eabb-4f62-4c82-a3e1-c60b2c5d0a5f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1bd5a3a2-c404-444d-8026-c821af6235be_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_d73fa390-5b77-4d98-ab59-c124db2cfb5c_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyRate" xlink:to="lab_sesn_LicenseAgreementRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_434106a6-0b34-4302-9662-5e51d9e60101_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f0a91758-8893-4156-9e10-2ce763dd68f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_594179d7-dbf8-4a17-9df9-3cbda58ec769_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_dc32de39-3e97-4fc5-812f-0dc2eba212b6_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0f78ea3d-4f1a-4d8b-9d10-ae62f0be6d9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_4929ed01-c41d-427c-b72e-1575fb9ea617_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1d1eb400-0f3f-4a4f-8d2b-d7491a1c8900_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7a78007f-bab9-4a9e-8f7e-951bf07876f7_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_80982f2a-dba9-4cb0-9fc3-046908546e97_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_cad07987-37dc-4915-9266-3e7d5d9c3161_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_351d95e9-8cb8-4aed-8a4f-85292b9e2b5b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_1bd867eb-5974-45f5-80a7-dc026ea53c87_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time milestone payment upon first sale of product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:to="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e37616df-50d0-44b9-95b8-4621c0e789ff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_2c97d882-1532-4b1e-adad-20c047a48f07_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of base salary</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_71ada7d4-0e9e-4058-a87b-8ad8be5dfe28_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_713c95f5-4a50-4147-b547-478c20c7e3b5_verboseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Warrants</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringMarch2023Member" xlink:to="lab_sesn_WarrantsExpiringMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_ce3dc41a-8b30-4c80-ba28-ef95d6a578ce_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_da8c0f29-596b-49c4-8b8b-522bf1b008eb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_79b0c143-5c3c-4fc7-9d28-c0febd9ed037_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d8fea05e-6ff9-4911-9941-68fbb078ad45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_774257df-6733-4d88-9c8d-20b5c8674cf5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_2a9deb61-a5c8-4390-985c-c2558c8c5fa8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ATMFacilityMember_185f19ab-d106-4357-ba6a-d13d498744ff_terseLabel_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_label_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility [Member]</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_documentation_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember" xlink:href="sesn-20221231.xsd#sesn_ATMFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ATMFacilityMember" xlink:to="lab_sesn_ATMFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f629f82a-88d3-4faf-affc-5f4cd7f9e3d5_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_7c2a4e24-f4cd-40be-8ba8-f4ee8719d17c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current (provision)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ad562278-6405-4ec7-be84-daad29f07a02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1c34c3ce-5afe-423f-bca8-edf1248855f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_e5a076b8-e357-4a01-8234-4ed1ecd26845_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_285667c7-f2dc-483d-ba94-2408ee71bc69_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss Investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RetentionProgramMember_7cb9c8f1-e653-4d1f-a813-3a9f4d474193_terseLabel_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program</link:label>
    <link:label id="lab_sesn_RetentionProgramMember_label_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program [Member]</link:label>
    <link:label id="lab_sesn_RetentionProgramMember_documentation_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember" xlink:href="sesn-20221231.xsd#sesn_RetentionProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RetentionProgramMember" xlink:to="lab_sesn_RetentionProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_3b9b78ea-04ad-4d42-af97-729a6332a6f3_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_70892f83-7b40-46dd-96f1-f260757f1a5a_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalty Period</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:href="sesn-20221231.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:to="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_b0eb6351-6e24-4938-81e7-0a76cc7df568_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SupplementalLeaseInformationAbstract_de02958e-8086-4d72-91cb-7aea93906fef_terseLabel_en-US" xlink:label="lab_sesn_SupplementalLeaseInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Information:</link:label>
    <link:label id="lab_sesn_SupplementalLeaseInformationAbstract_label_en-US" xlink:label="lab_sesn_SupplementalLeaseInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Lease Information [Abstract]</link:label>
    <link:label id="lab_sesn_SupplementalLeaseInformationAbstract_documentation_en-US" xlink:label="lab_sesn_SupplementalLeaseInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Lease Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SupplementalLeaseInformationAbstract" xlink:href="sesn-20221231.xsd#sesn_SupplementalLeaseInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SupplementalLeaseInformationAbstract" xlink:to="lab_sesn_SupplementalLeaseInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_bbc3c52d-f62a-4be2-a388-cee35879dc8f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_adb01e87-0d0c-4c03-b205-902de4792a59_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_88ab22ff-4c87-4d95-b203-aedab1803860_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4aa2c959-4e71-434e-815d-08fcffa3c117_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_cd03a378-f78b-44d2-b829-d6535068e65e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from Operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_PaymentsToRefundLicenseAgreementDeposits_631a4804-2072-4f38-99de-547f2940fc57_terseLabel_en-US" xlink:label="lab_sesn_PaymentsToRefundLicenseAgreementDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to refund license agreement deposits</link:label>
    <link:label id="lab_sesn_PaymentsToRefundLicenseAgreementDeposits_label_en-US" xlink:label="lab_sesn_PaymentsToRefundLicenseAgreementDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Refund License Agreement Deposits</link:label>
    <link:label id="lab_sesn_PaymentsToRefundLicenseAgreementDeposits_documentation_en-US" xlink:label="lab_sesn_PaymentsToRefundLicenseAgreementDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Refund License Agreement Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_PaymentsToRefundLicenseAgreementDeposits" xlink:href="sesn-20221231.xsd#sesn_PaymentsToRefundLicenseAgreementDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_PaymentsToRefundLicenseAgreementDeposits" xlink:to="lab_sesn_PaymentsToRefundLicenseAgreementDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2433e17f-e373-487a-870b-8cf94f275ca6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e653f5b5-67b4-4e75-997d-2bcce32e96f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_35b81d83-13bf-4c95-b582-2e4ca6f2e50f_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b8e72ca5-a81e-4675-a2cb-0cc9c7a4a86c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_699c76ae-5f21-49c7-a20d-51ec3608d2d5_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d404847-186e-4177-8f4e-3078ddc2f6bf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_48c35db9-aa80-4c30-8774-15bf56ae5641_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d9d09ee1-2f6e-4a6d-a4bc-69ea9d08bfed_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLES AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4ca687ab-9d19-47fa-8dd3-e6dee9ca5fdb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cfbac8ac-4aa4-492c-b38a-1a14f4e60256_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_251ea488-1c4c-4481-8721-e9344b8c0079_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_29fe09bd-ac49-4537-a2fd-d766439e4f54_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_603cd843-314c-46aa-93fd-d8dcb2b45c10_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_641504ac-d18d-49d5-aeac-4a865f411af2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_72bf66eb-ba84-4348-adcb-0600dce45227_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c4be3143-42e5-476d-a058-b9716acf4eb4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_a0ee39e8-c049-4222-b458-ddc15fc29234_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_867ab8e2-c02c-4bd8-8220-d89a3328b498_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_ea6c5449-3227-45d5-9f77-e3d8e879f834_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f99c6c40-5339-40ee-9b0f-b61a7e61f231_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_bbeee75d-d943-4695-a86a-cf48a61e92b1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementTerminationExpense_64dd46f1-c155-45aa-a8dd-b16744a7b779_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementTerminationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License termination fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementTerminationExpense_label_en-US" xlink:label="lab_sesn_LicenseAgreementTerminationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Termination Expense</link:label>
    <link:label id="lab_sesn_LicenseAgreementTerminationExpense_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementTerminationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Termination Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTerminationExpense" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementTerminationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementTerminationExpense" xlink:to="lab_sesn_LicenseAgreementTerminationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_e4299f46-f637-4d28-a32e-2852118e991c_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_83b8d3b4-65c6-46ea-a920-5393157c658a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_c795c8b3-5870-4eda-bf8e-14f52f3ae803_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCreditMember_5b199b85-a2b5-4eaf-9136-bd0bb959ac12_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_InvestmentCreditMember_label_en-US" xlink:label="lab_us-gaap_InvestmentCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCreditMember" xlink:to="lab_us-gaap_InvestmentCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_4b9e4d8e-c584-4b8d-b5ab-011779a1b3c2_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestoneAchieved" xlink:to="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d3959a3-f99d-4f2c-9d0b-86f3bf12ecbd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding for diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_49cc214f-0e6e-400f-867d-24613fde1323_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_6f094063-bf3d-435f-bbf8-1dbec22664f6_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value (in dollars per share)</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0fc6f579-a26f-4e7b-b3fb-9a39353f03f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_4ad0b647-f1a7-4a03-a948-f0d97d7800a6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c20b312e-46a7-40cb-ad73-4f01ae78e331_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_5e1e8e97-1b56-4a3c-9c8f-93e1d8d9ae31_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement deemed probable, percent</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8d4e5b09-4ab5-4f63-9f0b-6b9eabca078c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_81bc6e14-1e8f-428e-b078-d8ab5efee23c_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_02fb9809-5a03-466a-8a9f-9e62b8a8a685_terseLabel_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes</link:label>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_label_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Entitled For Each Share</link:label>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_documentation_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Entitled For Each Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare" xlink:href="sesn-20221231.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberofVotesEntitledForEachShare" xlink:to="lab_sesn_NumberofVotesEntitledForEachShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_08f11971-5bf9-4924-b802-f0075a42a2e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 400,000,000 shares authorized at December&#160;31, 2022 and 2021; 202,759,043 and 199,463,645 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_32b2ace7-ecdd-48bf-a0bb-d242568d0bd7_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_43fbeaca-ec98-49d4-b141-e07ca9274145_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_14d9c069-e56f-4cfc-b666-ae02ab7c3b78_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_e5a90f8f-61fe-43e9-8fc9-df0370f3f06c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for RSU vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1476293a-b438-43af-a6af-40a317900661_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Excluded from Diluted Loss Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8f63a4c7-970b-47ae-8628-1784b5a896b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Fair Values of Financial Instruments Measured</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_7dae48c5-a034-46fc-ba5f-df3b1e988c2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term property leases</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b35a9b8a-647d-441e-9ea2-4720aa486423_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_5ea310c7-3dbb-4185-b13b-5b7a08586703_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_09570582-4c74-43c8-9399-8332c16e4b37_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_942bbfd3-094a-4ba4-b3f5-dc2ca29abafd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_179621a8-8bc6-4d72-816e-2953a042bbd2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_09090b83-2651-4a58-bd3a-785f6f11dff2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax income (loss) Canada</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_2295c25f-26ca-42f6-b2c8-536576d3b771_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:href="sesn-20221231.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_61cdd4f5-231f-4b7c-89fe-2f40aab075a6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in warrant value</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0160e239-763a-4f1e-8f8d-cea4a66e10b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_112d9345-0b0c-4e77-ac08-5d0278849bd7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_37c3b897-0db7-4132-bd8a-6077b6322924_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d92e785f-6066-44e7-bc31-28a4c1ac53d6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7ddeb864-0ada-42e4-93a5-fd2dd80bf8fc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4c640401-f0a4-4319-a722-dce3a4231f10_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9dc484cc-2273-430b-a789-e713aa226fd2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_648df636-22a7-425f-8fa4-9fb84d083ea7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' eligible compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_e53c99fd-a95c-4bb6-b987-64ec2fdd9d49_terseLabel_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_label_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_documentation_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:href="sesn-20221231.xsd#sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="lab_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_508211dd-5626-4d97-b6d8-11d0b596ae19_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2159e9c2-c1b5-455a-9cf8-2dd8c303dc85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c76f8634-5dac-4157-9c65-b626b65df949_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_c6127098-0cda-4afa-8df3-9fae476bc584_negatedTerseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Cancelled (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:href="sesn-20221231.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fbb56d95-4068-4f67-94ef-18aee43a2c85_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_cecf7205-17ca-4bd5-9bbc-093f675de2e5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c83ac27e-0c1d-4c59-94a2-2ddf2d7bc92e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease (including related operating costs)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_feac6279-e7d1-42e9-b82c-2e83270c1b3b_terseLabel_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge related</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_label_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:href="sesn-20221231.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:to="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_f905be6a-321e-4710-b00c-d8571c62a501_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Consideration Liability</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6602186e-47e4-42cd-a0f6-dc59242141de_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of common stock under 2014 ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b94bc690-d85f-415a-9248-a9bcc9865da3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_0fda7e51-436c-42a4-b177-5faa21f04b2e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d6676a99-1792-4a1a-8084-854bc97ae456_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ca1ef908-5708-4fd4-a0d6-44cb4e3e6468_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_851f6163-8eb0-43c0-91ef-7bf67ba9dd9f_terseLabel_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance for:</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_label_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_documentation_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:href="sesn-20221231.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:to="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_31cbc059-f066-466b-b373-f00811603fc5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_da4d09a6-8cf1-487f-b849-38248ea51886_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_84ad1cd1-ba33-4563-b955-e1be6246288e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_01fede88-2a4c-4d88-bb4d-eefbf9898dcf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_6057c05b-31b2-4ffd-bef7-070bfb75023d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6a6d6fdf-8fa1-44c8-85c1-c025e5f85075_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_145c4686-3c33-4256-9899-949ace654241_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and benefits costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_97e6c58e-a933-4508-baec-988a1c33d47b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_0dae1121-c45a-413e-a1db-ec36aef83ba9_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d34dd847-8844-456f-9454-8d4a738a652f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of common stock under 2014 ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f521871c-5dc7-42f4-960f-44155b09603d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_742e06b9-f5fd-4903-a85e-72dd5e0f2005_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e0c500ec-ed5c-44e2-b41d-07719ce438b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dffb558e-3e42-45f1-9531-9a7cdf439e35_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_424c729b-f191-4e8b-a5ea-7c0accbcd2aa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option cancellations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_2a0eeb78-8205-4345-8511-03dd440934d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ee72c0de-3051-4aea-afe3-ca8b4baf6b42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EBI031Member_c42d85b6-9ee3-4837-ac1b-0139c6d33899_terseLabel_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031</link:label>
    <link:label id="lab_sesn_EBI031Member_label_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:label id="lab_sesn_EBI031Member_documentation_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member" xlink:href="sesn-20221231.xsd#sesn_EBI031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EBI031Member" xlink:to="lab_sesn_EBI031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_24fe7758-355a-4eed-9497-0de72e3e943a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_807a37e5-d5bf-4711-be3f-414a7a529723_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_80a72abe-fd11-4582-ab7c-42f9a0364ac3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f4bdbb35-6c23-4f58-ad91-d6d2331c1dab_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_8f38e37b-ae87-4276-b66d-9e002cd6d537_negatedTerseLabel_en-US" xlink:label="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term prepaid expenses</link:label>
    <link:label id="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_label_en-US" xlink:label="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) of Prepaid Expenses, Noncurrent</link:label>
    <link:label id="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_documentation_en-US" xlink:label="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) of Prepaid Expenses, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:href="sesn-20221231.xsd#sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:to="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_7127d036-eb38-4136-8d59-f764cd5251a1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_adab3d69-22e9-45c9-bfe5-cfbf7ef36d28_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_55020495-b435-402e-9ff7-0b5dfa60339d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_89b5a4cf-8556-4e2d-9a91-12547d618813_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_62fdf87f-00c0-4fc8-92d3-565b95de3512_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2c3e3eb3-4db9-4313-b676-2d6406e9c80c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3497babb-03a6-4fc2-9103-1feb4f49433b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1f665f6d-5713-4df2-899e-b357482e363e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_95f55ebb-2eaa-4c04-80d8-4303f751e2b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0ef40ad1-e2c9-4403-b69a-29354f5f5285_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING AND RELATED ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a7e2c977-516b-4014-96a1-30aef97b08e0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_431222af-7e1e-4310-b268-7db07191134e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2abec453-eba8-46de-a2d6-eceb6cc88279_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration - long term</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_e1d83be1-8465-453c-b764-a9652619a648_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_5d86ce29-8f2c-4039-987a-b4b1ee72f185_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_b07beb7a-3604-4084-a34f-733c2672f58a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2197ebde-6091-4b44-b6e3-8db5d813b8ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OtherReceivableAssetPurchaseAgreement_ea56fc03-078b-4f40-b86e-6fb45355125c_terseLabel_en-US" xlink:label="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivable, asset purchase agreement</link:label>
    <link:label id="lab_sesn_OtherReceivableAssetPurchaseAgreement_label_en-US" xlink:label="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivable, Asset Purchase Agreement</link:label>
    <link:label id="lab_sesn_OtherReceivableAssetPurchaseAgreement_documentation_en-US" xlink:label="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivable, Asset Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement" xlink:href="sesn-20221231.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OtherReceivableAssetPurchaseAgreement" xlink:to="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_8a8526b1-03f8-46da-a52a-de7e35e9a42c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_f08fd891-3091-40c3-bbca-18794a2018dc_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant under 2014 Stock Incentive Plan</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f5fd33e3-6e9d-4f6c-9ac6-2d753dd63d60_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ee7c57b-b9bc-48f0-8ad1-2ecfddbdb873_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ab69ae6a-6a17-44e8-89f0-2a084056fa6a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncomeTaxesLineItems_92f412fd-1fa8-41f0-a5c4-af969f63a12f_terseLabel_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sesn_IncomeTaxesLineItems_label_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sesn_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems" xlink:href="sesn-20221231.xsd#sesn_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncomeTaxesLineItems" xlink:to="lab_sesn_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_1d2af3f1-0413-473d-9dbd-3bbd5e7bd561_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of litigation fees</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a17144a4-4424-45bb-94b7-d9afa36c6fba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_45542f8d-e096-4ada-9038-b5c14ff12859_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_18ccca7c-bcb6-4219-864b-c6cffe54737a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_13c02761-0378-4b6d-a446-150fc48a2b9c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants Outstanding and Warrant Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_fbdd53e3-c2b7-4571-ad67-29653b2570e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_c6fc7f15-6d8e-4d7e-9b6e-62eb71d84449_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cf2b7416-76aa-42f0-b64c-f626f1096ac2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY DEFICIT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4d53dd08-2603-40b7-ad7a-7d536c56a0fd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_eff71068-97b0-4b44-b377-02e360217d36_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_f9fc12d4-4348-4777-8882-3230d923461d_verboseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_756e0bac-83f6-4a63-a625-97146df56bbe_negatedTerseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_d685fc56-1ca2-4cda-be06-ce3ce0af3520_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock warrants (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a5d9afc8-07b3-4992-9acb-bf2d3dfc3f01_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, non-vested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6f1f7744-1dd5-44c2-ae97-c6dd86edb7c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares under Option (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_37ab0534-221e-4089-9310-195c70c08957_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_d419c186-0e0c-42a1-8347-c252791b5418_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales of quarterly earn-out payments during earn-out periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:to="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_51df00a2-a7a8-4144-82f2-4abd492c32cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d4add767-a9e7-43dd-9b93-cbfb882a2f19_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_a548b699-35b3-4f28-878a-f75b10bf9146_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_16f2396d-72a4-4a43-8385-af94693070b3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_4ec6396a-1d9e-4e06-ac02-b7a07b658da3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_64c4146e-69e3-417f-a83c-9443ea249df2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_6e6f58c7-4d45-4c45-86bb-e300a9ef571d_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_46c8e0ae-3962-4245-9555-d670af430e7a_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, issuance cost</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:to="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_815bd7a0-28dc-4287-b873-90a21917e97f_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_03fc000f-79ef-44a8-97db-ebb3f973d32d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_c58a24f6-0e6b-49f7-ad13-8f80ccf3b9ea_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be issued</link:label>
    <link:label id="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_label_en-US" xlink:label="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Additional Shares Authorized For Sale</link:label>
    <link:label id="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_documentation_en-US" xlink:label="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Additional Shares Authorized For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockAdditionalSharesAuthorizedForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:to="lab_sesn_SaleOfStockAdditionalSharesAuthorizedForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_aad8c3e2-6941-4de7-9eb9-f5d4dde9d220_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:to="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_ff143d9b-dbaf-4a8e-a73d-98630119d24b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_287c0004-75d9-440e-a604-d9f424075cf9_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_73eeac31-4876-4ac1-ba97-ced0bb75eae4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d9e0a41c-0fe1-41ba-bf8c-80c72f52adfd_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_cf96c54c-6e63-4549-99f9-9e33d5879480_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c35d13d1-51f9-4e2a-acb4-882333bd91bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization of discounts and premiums on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IssuanceOfWarrantForCommonStock_dcf7492f-0fda-493f-8c9a-b933f8bbd413_terseLabel_en-US" xlink:label="lab_sesn_IssuanceOfWarrantForCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend on adjustment of exercise price on certain warrants</link:label>
    <link:label id="lab_sesn_IssuanceOfWarrantForCommonStock_label_en-US" xlink:label="lab_sesn_IssuanceOfWarrantForCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Warrant For Common Stock</link:label>
    <link:label id="lab_sesn_IssuanceOfWarrantForCommonStock_documentation_en-US" xlink:label="lab_sesn_IssuanceOfWarrantForCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Warrant For Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IssuanceOfWarrantForCommonStock" xlink:href="sesn-20221231.xsd#sesn_IssuanceOfWarrantForCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IssuanceOfWarrantForCommonStock" xlink:to="lab_sesn_IssuanceOfWarrantForCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_285de9bd-6e63-407d-8c50-915f21645e49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Composition of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_9713c1fa-b19a-4780-86b4-d93adc7187e8_terseLabel_en-US" xlink:label="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Warrant Amendment, Amendment to Securities Purchase Agreement</link:label>
    <link:label id="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Warrant Amendment, Amendment to Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Warrant Amendment, Amendment to Securities Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:href="sesn-20221231.xsd#sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:to="lab_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_c1fd998e-92ad-486b-a59b-0619a8d754b0_terseLabel_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_label_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement [Member]</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_documentation_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:href="sesn-20221231.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:to="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_a75b1387-8c14-46d1-82ba-0185a5fe4fb2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_baa037d6-abc1-43d4-89e1-cca321f21289_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_52bcc27d-0e10-4af6-bc4e-c8fc977e5f8b_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_01a195e7-5193-4b79-b8f2-0341ced4681a_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70809738-6f07-44c1-943d-e18973e806fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0199477b-8a48-4b27-87d1-c9f994751a21_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cc0accf-52b9-44eb-a238-fb257b399253_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a223076d-c3b2-4ccc-8a09-a1b101202f96_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c0c4adbe-65f5-401b-8f4d-8b358061c838_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_1af6bcfe-b681-4b59-a38a-0227ef770202_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9e961adc-cc53-4595-a86b-1ebbe06e4717_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_7537dd1e-c8ff-4e73-843d-db2a2a075387_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_4485f275-357e-4317-8601-f4460f1f6594_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_54439ad3-0035-43d7-94be-8a6032325f9c_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_99c0d1a3-a31c-4088-b704-e0e8f859601c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_beb028a0-ee1b-4a89-bf97-a9ad14d32393_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_bc8ad609-a938-4093-82b7-28dc08766634_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare_ace92c7f-872c-44ff-8ffd-f6f0fc11b31c_terseLabel_en-US" xlink:label="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock and warrants price per share (in dollars per share)</link:label>
    <link:label id="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare_label_en-US" xlink:label="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Warrant Or Rights, Price Per Share</link:label>
    <link:label id="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare_documentation_en-US" xlink:label="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Warrant Or Rights, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:href="sesn-20221231.xsd#sesn_CommonStockAndWarrantOrRightsPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:to="lab_sesn_CommonStockAndWarrantOrRightsPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_eaf7eded-1f4b-43f8-9781-9e6c7d58f37f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6ac35a0d-a412-4826-810d-0f4e72e1c8e9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_1bcd8224-98f8-4dab-b0a5-07ebb067833a_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to achievement of development milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:to="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_907193ac-e76d-44fb-b259-f377e854eba3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_eed682dd-ce81-49bc-843c-8a4ae1f61493_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_8b212e77-f85e-451b-875d-c4cad70af99e_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States:</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_UniversityOfZurichMember_8bea5c87-e17f-4de4-a16c-b8fe1bddb7e2_terseLabel_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_label_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich [Member]</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_documentation_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember" xlink:href="sesn-20221231.xsd#sesn_UniversityOfZurichMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_UniversityOfZurichMember" xlink:to="lab_sesn_UniversityOfZurichMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_a9908494-85c5-4e2f-b386-09d95b3758b8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7ff657cb-2e4c-4763-9b34-cfb7381b4d9f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Share Based Compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7bc5f12c-17cb-4edd-b29a-c29a918e51ad_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3e7b768e-a128-47d0-899d-279546f9a2fc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a12e01f6-39cf-4b94-9a15-405f39b1516a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_74cddaec-3f7a-41aa-8f1c-61341a6e383b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_4d02e3cb-316b-48aa-a86b-a791a044cec1_verboseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Stock Incentive Plan</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_label_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:href="sesn-20221231.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:to="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_bcb49c14-86e2-489e-abc4-c205136d6288_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:href="sesn-20221231.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_cb361291-47b4-4868-a85b-17f2015ee95c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e2476bc7-489d-461b-be25-4341e97c6bc6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at December&#160;31, 2022 and 2021; no shares issued and outstanding at December&#160;31, 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_c36ae6c8-6a15-4f62-96ab-569c8cf8a83f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_bf497be6-b9cb-483f-b3c8-d3c0d503b99b_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_efcdac0e-7b50-4d56-8b75-4f96d7322ffc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3e716542-cad7-478d-a082-e31105ffaf79_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_eb6d6eee-33c6-4041-bc5e-0cec8e2fec15_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RocheMember_a2c576b7-4511-4871-bbfe-31bf4a6504c7_terseLabel_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_sesn_RocheMember_label_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_sesn_RocheMember_documentation_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember" xlink:href="sesn-20221231.xsd#sesn_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RocheMember" xlink:to="lab_sesn_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_9d45e9c7-33bf-42c9-9ce5-1bbac1b2e83f_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of common stock warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:to="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_bfb733c0-7bb8-47e7-8fb2-d356af48a339_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0441ad79-f95f-454d-9ac7-822a27c1a92e_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_674b645a-02d6-40fe-bceb-f128106f6de6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_520f4f94-7bb5-47f9-9a62-89dbe983509e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_7a572e48-db2e-464e-aaa4-02ff447a8380_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_TR_69a7dcfe-2352-472d-873c-e5aeacbd745d_terseLabel_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TURKEY</link:label>
    <link:label id="lab_country_TR_label_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TURKEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TR" xlink:to="lab_country_TR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_70808f3e-b259-4011-9cef-bdc90cbf8997_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2b429d28-3369-466f-bb8f-e8622c09ca9d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_d427eeec-ed7c-4056-9479-6adbaa4d5a9a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_8014fc27-6ec9-41bc-9963-3f6dacb4fa99_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_3a7fe26e-d1ca-4021-8bec-f1a3b9f680a8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_d9d0cbfa-70aa-4983-8610-fdd69b9826ee_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_fad7182e-bf1b-4afe-b8e2-1b10662b40cc_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_dbef8beb-19b2-4d66-bc9c-b8e7876dfa20_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b68e4c3a-2657-4f3c-8e23-b9d66fe84f6a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_ded2e4e8-5155-45a1-8f20-a46f864008c3_terseLabel_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:href="sesn-20221231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:to="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_14d1d0a6-b8e3-4518-8945-80cc0308d5b9_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2776be7e-7ce9-42bc-8dc4-97b7526e9cc2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_e49df66f-870a-487e-add8-084510ccfe4e_terseLabel_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average cost of capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_label_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_documentation_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital" xlink:href="sesn-20221231.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WeightedAverageCostOfCapital" xlink:to="lab_sesn_WeightedAverageCostOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_547dfc74-8272-4b1e-b0ce-79dd502bbbe5_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_c17324b5-d1a4-459a-8561-5167da59ea64_terseLabel_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:href="sesn-20221231.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:to="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_faf4702f-49f0-44ae-8b30-65041d08a2df_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c9f8a006-afc6-4caa-9250-719d8adf3d80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Components of Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1b2685ed-db86-4239-93bb-a640981c9c40_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViventiaBioInc.Member_7852178f-b289-42fc-8bd3-48a1e337dbc7_terseLabel_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio Inc.</link:label>
    <link:label id="lab_sesn_ViventiaBioInc.Member_label_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc. [Member]</link:label>
    <link:label id="lab_sesn_ViventiaBioInc.Member_documentation_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member" xlink:href="sesn-20221231.xsd#sesn_ViventiaBioInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViventiaBioInc.Member" xlink:to="lab_sesn_ViventiaBioInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_PA_e14d73bf-520c-44e2-9bbf-a8c935047d89_terseLabel_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_stpr_PA_label_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENNSYLVANIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_PA" xlink:to="lab_stpr_PA" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLossCarryforwardsDecrease_12f8e80b-6e35-4566-9fb0-c0b60c101d91_terseLabel_en-US" xlink:label="lab_sesn_OperatingLossCarryforwardsDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforward reduced amount</link:label>
    <link:label id="lab_sesn_OperatingLossCarryforwardsDecrease_label_en-US" xlink:label="lab_sesn_OperatingLossCarryforwardsDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Decrease</link:label>
    <link:label id="lab_sesn_OperatingLossCarryforwardsDecrease_documentation_en-US" xlink:label="lab_sesn_OperatingLossCarryforwardsDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Decrease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLossCarryforwardsDecrease" xlink:href="sesn-20221231.xsd#sesn_OperatingLossCarryforwardsDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLossCarryforwardsDecrease" xlink:to="lab_sesn_OperatingLossCarryforwardsDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93dda8c4-ca12-4b1d-b157-d0448d08bebf_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c73001b1-033f-4a7f-b2d5-33a36105fa67_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_fae902fe-5a69-44dc-a02c-512b710175bb_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment obligation, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_87dbe4e9-2b78-4ebb-8951-de02d27ac93e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Pre-tax Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9179c932-6067-4fb2-8645-d7d79956b0e3_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4d435fc4-e1a9-4f08-8596-60bd8eada9ba_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_692a2ecd-bf57-469c-a17c-7000fcf8502f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember_8ab61c5d-444b-4c20-ab45-a0e4abba3c02_terseLabel_en-US" xlink:label="lab_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember_label_en-US" xlink:label="lab_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units &amp; Performance Based Stock Units [Member]</link:label>
    <link:label id="lab_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember_documentation_en-US" xlink:label="lab_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units &amp; Performance Based Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember" xlink:href="sesn-20221231.xsd#sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember" xlink:to="lab_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_f181c0b0-7999-471f-b52c-f7596e266540_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseMaintenanceFees_760c1ef9-6d77-43cb-a3af-f5890c7aacc6_terseLabel_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License maintenance fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_label_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_documentation_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees" xlink:href="sesn-20221231.xsd#sesn_LicenseMaintenanceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseMaintenanceFees" xlink:to="lab_sesn_LicenseMaintenanceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_ea1aa497-5b2c-44e1-a6c3-f0c143ad62fb_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_055163c6-779a-40ce-8448-337975789c8a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2a5848a5-28c9-4ee6-876a-0e4f59b63f26_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fd142fa4-b1ec-463f-a8c1-6cdf03b78539_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_63ae4144-cb69-4519-a69d-7fb7d5ca2eb7_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3acf4311-e65f-4283-8047-072d6bff5249_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_81db7ba5-15c5-440e-a8bd-e89c07f7874a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting at End of Each Successive Three-Month Period Thereafter</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e1d1bdf9-7a7e-4a1c-95cf-7fe3f164368e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e4fc538d-e3c4-4bde-8ce9-0ade57fde898_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_35f70c68-86d3-43f8-adcc-738eccfa1cb2_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_a0082fa4-e545-421a-a08e-687d30da25ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ba5f5706-075d-4ebe-b473-385d344ce14d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_f2133b6a-a783-4c1d-9278-6ad85c7ff5aa_terseLabel_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="sesn-20221231.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a4306ba4-6ee3-45dd-951a-c665e2d21698_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_7a859d17-20c2-405c-8d8e-fe9b3b827256_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_e4568a1d-61c5-44a2-b058-ecbff78ca665_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_35640d01-78e1-4d89-bfce-13da181c04a3_terseLabel_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_label_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_documentation_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:href="sesn-20221231.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:to="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_3804e022-33e7-47c2-b23c-1c73093c5dec_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_33700d64-e98c-47d7-b1f3-70fb5354a722_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax income (loss) U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b14fdaf7-9e11-4944-99ee-9f1940cfd5aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_edd03d01-c08e-4886-a36a-d788d98e625f_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_eca7e38b-8691-446c-bedd-c775add638a6_verboseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Warrants</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2022Member" xlink:to="lab_sesn_WarrantsExpiringNovember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d6d168e7-d90a-4ccf-a0e6-f51de2f6d029_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cb74730e-b315-40b3-b73c-33b4454445fb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_857c86f2-93b9-4859-b5f8-7329b95a4695_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_7b76b39f-b65b-4ebe-ba59-3b9a19e6f0db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_efe7766f-b420-4af8-9b11-f8a9ce9c6e78_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_c74411e3-7a11-4c14-b0b9-0ea2397b208a_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSE AGREEMENTS</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_label_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementTextBlock" xlink:to="lab_sesn_LicenseAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_1b76d392-d8c6-4715-932d-0cab1894d818_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_5ee9af0e-3e4c-406a-97a9-f7114f50350d_verboseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9581fc15-c2d5-4ba1-b51d-116058c53d4f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance change</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a092a51f-36c2-4ea6-9e86-47062ae511a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_f6822c36-e635-4d00-8677-727b894428dd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_4d730384-ff83-446d-af29-7df14f35e081_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6bbb81ae-610a-4909-9fdf-4bea53b10aeb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d9d11827-5531-4cf4-a161-2686f66831b1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5d6538b7-b696-4c62-b12a-ab00baec0031_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ea27ee13-955c-4f51-86e4-a34b4155de5f_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_f80f1682-cff9-4d1f-81ed-e7825d98aa74_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_ad920d4d-56f7-4f9a-96f8-9d1efcf646dc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a645a74c-6d1c-4f40-be0a-92c2ec0a880b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_3d848751-e5df-42b9-b4ca-61b4658556b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_03f5cc3e-1ba2-4b53-a292-d525615ee530_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_b2f265fc-e426-4f57-9b8d-5626f9c62bb1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_e0706d11-ac9a-4cec-95c1-47b37151cc5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase price, discount rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_0e37ef97-8af7-4be9-85a3-6084da3e71c8_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average stock price per share (in dollars per share)</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_abc8e047-b71e-4e24-812e-9d0241d56e83_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncomeTaxesTable_98ff7588-9958-4374-a509-8631ca68cd4e_terseLabel_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sesn_IncomeTaxesTable_label_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sesn_IncomeTaxesTable_documentation_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable" xlink:href="sesn-20221231.xsd#sesn_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncomeTaxesTable" xlink:to="lab_sesn_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MicrometAGMember_f11412b7-9220-4d8e-b238-eeebfccedaed_terseLabel_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG</link:label>
    <link:label id="lab_sesn_MicrometAGMember_label_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG [Member]</link:label>
    <link:label id="lab_sesn_MicrometAGMember_documentation_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember" xlink:href="sesn-20221231.xsd#sesn_MicrometAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MicrometAGMember" xlink:to="lab_sesn_MicrometAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_dd890981-3814-481b-9246-f93cdb072084_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Expected Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ed1fcd20-1257-4ef8-9028-0f5db952b7fe_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NonCapitalLossCarryforwardMember_1b1f4563-a555-4481-a072-ef36e9846f1b_terseLabel_en-US" xlink:label="lab_sesn_NonCapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-capital loss carryforwards</link:label>
    <link:label id="lab_sesn_NonCapitalLossCarryforwardMember_label_en-US" xlink:label="lab_sesn_NonCapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Capital Loss Carryforward [Member]</link:label>
    <link:label id="lab_sesn_NonCapitalLossCarryforwardMember_documentation_en-US" xlink:label="lab_sesn_NonCapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NonCapitalLossCarryforwardMember" xlink:href="sesn-20221231.xsd#sesn_NonCapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NonCapitalLossCarryforwardMember" xlink:to="lab_sesn_NonCapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IndefiniteMember_f46b8f0d-eac5-4f8f-8bf6-6a54f218282d_terseLabel_en-US" xlink:label="lab_sesn_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_sesn_IndefiniteMember_label_en-US" xlink:label="lab_sesn_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_sesn_IndefiniteMember_documentation_en-US" xlink:label="lab_sesn_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IndefiniteMember" xlink:href="sesn-20221231.xsd#sesn_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IndefiniteMember" xlink:to="lab_sesn_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_eeed553b-3b86-492d-9959-f703e58ea35f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_78637988-a8fc-4908-a87e-5880cc85b92d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_ed452d07-b0df-40dd-aa44-b7a0d9c34ce7_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRICTED CASH AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_136e2276-0169-4a52-b48a-76906dbc377c_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which quarterly earn-outs are payable after date of net sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:to="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_475cf803-4b76-4b95-b570-03384208e5fd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3c2457d7-2b6a-418d-aebe-52731a8aa735_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_057a73e3-33c0-4d91-9d14-95110c736899_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2562d08d-d7b5-4c68-b5e7-f9014ab176bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_23f51a2d-0a7f-4de2-a680-44aea13b5c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2a7fb9eb-f327-4d01-b675-f1b9d92383ee_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent_44fe17ee-3f34-482f-bdd0-7d44a6b6f5d6_terseLabel_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill write-off</link:label>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent_label_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Goodwill Write-off, Percent</link:label>
    <link:label id="lab_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent_documentation_en-US" xlink:label="lab_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Goodwill Write-off, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent" xlink:href="sesn-20221231.xsd#sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent" xlink:to="lab_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a558aad-c59e-4eb0-9bc7-cf48e48df377_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_cb5f0513-e816-43c5-9d01-dae999efa89b_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, amount payable upon achievement of specified milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_label_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:to="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_e9aaa923-c747-4232-b087-6dacb56bf2ca_terseLabel_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_label_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Related To Adoption of Accounting Standard</link:label>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_documentation_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Related To Adoption of Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:href="sesn-20221231.xsd#sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:to="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViciniumMember_c39a1888-1d2f-4a05-aa40-5d20cd8c4f5c_terseLabel_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium</link:label>
    <link:label id="lab_sesn_ViciniumMember_label_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium [Member]</link:label>
    <link:label id="lab_sesn_ViciniumMember_documentation_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember" xlink:href="sesn-20221231.xsd#sesn_ViciniumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViciniumMember" xlink:to="lab_sesn_ViciniumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1373e4cd-7607-43b2-a119-5261cb19a64b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_d67e6f5b-6d21-4584-93df-dca8764de3ae_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_577e15e8-2549-40bc-aef2-96e35aa2ac98_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated litigation liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_7e81a71a-0340-4e84-a15c-4bb5061da5dc_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty payment, reduction, conditions not met</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:to="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_404dcb71-2573-409b-8d29-f07f2c82b997_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_86ae5c8c-f924-4c5c-aab0-9ca69d7bf565_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_b2c76d67-57ed-46ad-bead-f06a26e9584e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a17b7c8c-dce7-4fcd-aeb9-bf7552abeea9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_10983176-05f6-4193-8858-abdd36c40776_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_16dd5eab-2190-404d-be4b-5816e0ae32de_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_745d32ee-4517-4000-8b82-83e8ad0e510e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_dd0f0e62-756f-4c0f-85ff-01c62685f08d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0da45ab1-cf21-4f17-ad70-9fc4697d2371_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a1eca7ca-73ef-407d-b09f-9cccbd9b4856_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_64cf0986-c97d-4047-a0dc-cefc60824209_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_d5a99d52-e4bf-49bd-ba98-256823737da8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_509b45c6-fb47-4bd0-85b5-2b799b8286c2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MENALicenseAgreementMember_d43cff55-7e27-4300-a3ed-cd3c07a917ba_terseLabel_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_label_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement [Member]</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_documentation_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember" xlink:href="sesn-20221231.xsd#sesn_MENALicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MENALicenseAgreementMember" xlink:to="lab_sesn_MENALicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_a0a8f8c1-7fd3-454b-a7ba-d9f3c67cbba9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles impairment charge</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_b51bf281-9668-4b37-ac18-687407e62be0_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total milestone payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_label_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:to="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_35740d3c-dad9-48bf-9f39-260d25a4d13e_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_a2ea9215-41e4-466a-854d-2edfa66e824f_terseLabel_en-US" xlink:label="lab_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance coverage limit</link:label>
    <link:label id="lab_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_label_en-US" xlink:label="lab_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Deposits, at or Above FDIC Insurance Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:to="lab_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c365574b-0da6-40d2-84a7-639432a83e48_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_931bb887-14c7-4f3f-8fd0-9eae84a76d8b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementTerminationPayment_38b50142-b67f-44b1-96b6-9376b610dc44_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementTerminationPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License termination payment</link:label>
    <link:label id="lab_sesn_LicenseAgreementTerminationPayment_label_en-US" xlink:label="lab_sesn_LicenseAgreementTerminationPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Termination Payment</link:label>
    <link:label id="lab_sesn_LicenseAgreementTerminationPayment_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementTerminationPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Termination Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTerminationPayment" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementTerminationPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementTerminationPayment" xlink:to="lab_sesn_LicenseAgreementTerminationPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_a02e66ff-5d95-4e73-845d-6451e13f98fb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated, period percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>sesn-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:cb59ddaf-3c33-4c46-89b9-ef07748101c9,g:f5662b05-afda-41c0-b68c-8f02735bc2a0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/Cover" xlink:type="simple" xlink:href="sesn-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_42e7b2ce-8fe4-4eb5-868f-4f98360812ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_DocumentType_42e7b2ce-8fe4-4eb5-868f-4f98360812ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_153c7299-e7b1-4597-8e23-98600acc48c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_DocumentAnnualReport_153c7299-e7b1-4597-8e23-98600acc48c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cdaa5aab-20fd-4a1d-8c09-e77d4791f3a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_DocumentPeriodEndDate_cdaa5aab-20fd-4a1d-8c09-e77d4791f3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1125b8ad-0903-42d2-a812-75fe0f92f064" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_CurrentFiscalYearEndDate_1125b8ad-0903-42d2-a812-75fe0f92f064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_38efe450-f301-4a78-80b4-f7bbbfa8bed7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_DocumentTransitionReport_38efe450-f301-4a78-80b4-f7bbbfa8bed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_58b6ca27-80a3-42ce-b741-5638ff693929" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityFileNumber_58b6ca27-80a3-42ce-b741-5638ff693929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_41b35322-80b3-46d2-96b6-02b7e2550376" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityRegistrantName_41b35322-80b3-46d2-96b6-02b7e2550376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6aa7550b-9fa3-40ff-beb5-169b7ede65e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6aa7550b-9fa3-40ff-beb5-169b7ede65e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a3593f01-a20f-4df1-8f95-df3d735c0524" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityTaxIdentificationNumber_a3593f01-a20f-4df1-8f95-df3d735c0524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_acb81bd8-ee36-40cf-b723-886943c620cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityAddressAddressLine1_acb81bd8-ee36-40cf-b723-886943c620cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_2fde06c8-ebb5-488f-a3bb-a5216d09f110" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityAddressAddressLine2_2fde06c8-ebb5-488f-a3bb-a5216d09f110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_32ad2e53-33ce-4082-a1f3-906b018c8175" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityAddressCityOrTown_32ad2e53-33ce-4082-a1f3-906b018c8175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f69ecd5c-60f8-45d6-9167-939a5d56e1e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityAddressStateOrProvince_f69ecd5c-60f8-45d6-9167-939a5d56e1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_309607ae-de0c-44d9-8855-46d5fdd8da24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityAddressPostalZipCode_309607ae-de0c-44d9-8855-46d5fdd8da24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a457ce73-2f89-4a53-b320-fc6e338ff10b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_CityAreaCode_a457ce73-2f89-4a53-b320-fc6e338ff10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b70ec6eb-90d8-4176-88ae-087b3ee4ee25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_LocalPhoneNumber_b70ec6eb-90d8-4176-88ae-087b3ee4ee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8a42dde2-d9f3-4d2d-bf03-0ca5bf5930ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_Security12bTitle_8a42dde2-d9f3-4d2d-bf03-0ca5bf5930ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b573ad2b-8a97-4f90-ae85-b248488b0362" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_TradingSymbol_b573ad2b-8a97-4f90-ae85-b248488b0362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c31ac1d0-ca96-4a5a-af9a-1c4d3c9f454c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_SecurityExchangeName_c31ac1d0-ca96-4a5a-af9a-1c4d3c9f454c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_48e892f4-2bc7-4ca9-b85d-4f7de7fad84a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_48e892f4-2bc7-4ca9-b85d-4f7de7fad84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_5bcee314-6942-443b-a196-538a96453a80" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityVoluntaryFilers_5bcee314-6942-443b-a196-538a96453a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_aa98de3a-88e0-43ac-b016-75cf1dcda1f2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityCurrentReportingStatus_aa98de3a-88e0-43ac-b016-75cf1dcda1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_00842faf-4a26-4970-8174-da21c0809078" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityInteractiveDataCurrent_00842faf-4a26-4970-8174-da21c0809078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c2b7b779-dea4-4d65-a71d-573326e4f3c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityFilerCategory_c2b7b779-dea4-4d65-a71d-573326e4f3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2c084002-743e-4e06-b4d1-acc041ecad79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntitySmallBusiness_2c084002-743e-4e06-b4d1-acc041ecad79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d6359fd5-d450-43e1-808a-97249eef511b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityEmergingGrowthCompany_d6359fd5-d450-43e1-808a-97249eef511b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_d08ad1a0-1c54-43e9-aef9-01f4db563fd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_IcfrAuditorAttestationFlag_d08ad1a0-1c54-43e9-aef9-01f4db563fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5188e078-cfd7-4f40-b8c6-2ffea620c5d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityShellCompany_5188e078-cfd7-4f40-b8c6-2ffea620c5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_1e8567e4-ea0e-4692-a6da-f3db4624d0e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityPublicFloat_1e8567e4-ea0e-4692-a6da-f3db4624d0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f4ffb6ba-da54-45df-8799-6549edba5a25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f4ffb6ba-da54-45df-8799-6549edba5a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c60c2742-44d6-452a-a660-7916d673455a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c60c2742-44d6-452a-a660-7916d673455a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_821f8c1b-a722-4828-a382-9cbb86799a28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_EntityCentralIndexKey_821f8c1b-a722-4828-a382-9cbb86799a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_572bdee0-81fa-4820-9105-ffb75bb3b4bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_DocumentFiscalYearFocus_572bdee0-81fa-4820-9105-ffb75bb3b4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6fa238e4-8772-420c-9a6c-00ddf9be46da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6fa238e4-8772-420c-9a6c-00ddf9be46da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5c269901-c247-4afd-b21a-7af19213e9fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8192ea92-d539-4345-8e93-30338a8c8322" xlink:to="loc_dei_AmendmentFlag_5c269901-c247-4afd-b21a-7af19213e9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/AuditInformation" xlink:type="simple" xlink:href="sesn-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AuditInformationAbstract_1a44fac9-8bfb-4d73-8505-da8df7bde5ac" xlink:href="sesn-20221231.xsd#sesn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_464b8a4c-97be-4a74-b996-c03e46523edc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_AuditInformationAbstract_1a44fac9-8bfb-4d73-8505-da8df7bde5ac" xlink:to="loc_dei_AuditorFirmId_464b8a4c-97be-4a74-b996-c03e46523edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_df54b52a-2b5f-48f0-a935-aa04fcd1239b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_AuditInformationAbstract_1a44fac9-8bfb-4d73-8505-da8df7bde5ac" xlink:to="loc_dei_AuditorName_df54b52a-2b5f-48f0-a935-aa04fcd1239b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_0e301cba-21b3-451b-953a-b36a254ee1f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_AuditInformationAbstract_1a44fac9-8bfb-4d73-8505-da8df7bde5ac" xlink:to="loc_dei_AuditorLocation_0e301cba-21b3-451b-953a-b36a254ee1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_043db3bd-74be-4931-9046-300b4c87ebd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_99795c16-9ea7-4fff-88ea-e75d1a6be6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_043db3bd-74be-4931-9046-300b4c87ebd3" xlink:to="loc_us-gaap_AssetsAbstract_99795c16-9ea7-4fff-88ea-e75d1a6be6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6df58996-53f0-4103-b3ce-e968fca38a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99795c16-9ea7-4fff-88ea-e75d1a6be6ff" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6df58996-53f0-4103-b3ce-e968fca38a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fa718f9e-633b-4726-abee-010edec244bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6df58996-53f0-4103-b3ce-e968fca38a2e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fa718f9e-633b-4726-abee-010edec244bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_f05140a9-e468-41a8-b41d-67b116193bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6df58996-53f0-4103-b3ce-e968fca38a2e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_f05140a9-e468-41a8-b41d-67b116193bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_07670e06-a273-4968-a281-00744af22a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6df58996-53f0-4103-b3ce-e968fca38a2e" xlink:to="loc_us-gaap_RestrictedCashCurrent_07670e06-a273-4968-a281-00744af22a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7d2dd88d-12d0-4947-b50b-bfe2518728bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6df58996-53f0-4103-b3ce-e968fca38a2e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7d2dd88d-12d0-4947-b50b-bfe2518728bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_5993e2b9-7d65-450d-a798-cdef6069edf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6df58996-53f0-4103-b3ce-e968fca38a2e" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_5993e2b9-7d65-450d-a798-cdef6069edf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4fffc28c-745c-4d9b-970c-7e04ea636b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6df58996-53f0-4103-b3ce-e968fca38a2e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4fffc28c-745c-4d9b-970c-7e04ea636b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_56df4f93-e6ac-4af0-a5d1-52c1166158f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6df58996-53f0-4103-b3ce-e968fca38a2e" xlink:to="loc_us-gaap_AssetsCurrent_56df4f93-e6ac-4af0-a5d1-52c1166158f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_43197913-b8f3-4601-88a2-95070701a086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99795c16-9ea7-4fff-88ea-e75d1a6be6ff" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_43197913-b8f3-4601-88a2-95070701a086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_87c64a95-e317-420d-9ec5-9d8f81edbcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_43197913-b8f3-4601-88a2-95070701a086" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_87c64a95-e317-420d-9ec5-9d8f81edbcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_aa83ca05-63a5-4874-96fb-018588f359eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_43197913-b8f3-4601-88a2-95070701a086" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_aa83ca05-63a5-4874-96fb-018588f359eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_53c106e1-8970-4dc7-b005-90b1bc40b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_43197913-b8f3-4601-88a2-95070701a086" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_53c106e1-8970-4dc7-b005-90b1bc40b7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b2badc1e-d982-4306-935c-37f6f3895121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_43197913-b8f3-4601-88a2-95070701a086" xlink:to="loc_us-gaap_Goodwill_b2badc1e-d982-4306-935c-37f6f3895121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_d8b5d55c-b5c5-41f6-9d16-4eeedaa5cc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_43197913-b8f3-4601-88a2-95070701a086" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_d8b5d55c-b5c5-41f6-9d16-4eeedaa5cc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d3cafd84-3f9d-4d8d-8a05-bb5e8ec6145d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_43197913-b8f3-4601-88a2-95070701a086" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d3cafd84-3f9d-4d8d-8a05-bb5e8ec6145d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_d6977745-9981-43c5-8c70-75c1859baab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_43197913-b8f3-4601-88a2-95070701a086" xlink:to="loc_us-gaap_AssetsNoncurrent_d6977745-9981-43c5-8c70-75c1859baab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_11da8586-7c9f-4f3d-969d-088068071f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99795c16-9ea7-4fff-88ea-e75d1a6be6ff" xlink:to="loc_us-gaap_Assets_11da8586-7c9f-4f3d-969d-088068071f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52119048-652d-47ff-abb8-aaa0e95aad0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_043db3bd-74be-4931-9046-300b4c87ebd3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52119048-652d-47ff-abb8-aaa0e95aad0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4cf30408-eb81-4949-a474-2a9e21859a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52119048-652d-47ff-abb8-aaa0e95aad0d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4cf30408-eb81-4949-a474-2a9e21859a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9824201b-b212-4a6c-8bdd-a1a8e4264087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4cf30408-eb81-4949-a474-2a9e21859a65" xlink:to="loc_us-gaap_AccountsPayableCurrent_9824201b-b212-4a6c-8bdd-a1a8e4264087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9e134a48-588b-4183-a9a5-9a40748e536d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4cf30408-eb81-4949-a474-2a9e21859a65" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9e134a48-588b-4183-a9a5-9a40748e536d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_fa97dcd2-4c32-40a2-9d5a-a30dce4e246d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4cf30408-eb81-4949-a474-2a9e21859a65" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_fa97dcd2-4c32-40a2-9d5a-a30dce4e246d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a52f7bb2-fc1d-4d40-b64d-0edf438cdb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4cf30408-eb81-4949-a474-2a9e21859a65" xlink:to="loc_us-gaap_LiabilitiesCurrent_a52f7bb2-fc1d-4d40-b64d-0edf438cdb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_7ee8d872-cced-4c36-9627-a115364486ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52119048-652d-47ff-abb8-aaa0e95aad0d" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_7ee8d872-cced-4c36-9627-a115364486ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f9ed1a1c-9135-4f69-a713-990bf7556db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7ee8d872-cced-4c36-9627-a115364486ef" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f9ed1a1c-9135-4f69-a713-990bf7556db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5b9facab-90d5-43a5-bdc5-1cac10198f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7ee8d872-cced-4c36-9627-a115364486ef" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5b9facab-90d5-43a5-bdc5-1cac10198f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_051e034c-b8c4-42a8-943b-8f08662cf1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7ee8d872-cced-4c36-9627-a115364486ef" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_051e034c-b8c4-42a8-943b-8f08662cf1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_e2c98864-727f-48be-81b1-71c6e3b8ee89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7ee8d872-cced-4c36-9627-a115364486ef" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_e2c98864-727f-48be-81b1-71c6e3b8ee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_da1f2582-25f6-4746-863d-d85e1ad30314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52119048-652d-47ff-abb8-aaa0e95aad0d" xlink:to="loc_us-gaap_Liabilities_da1f2582-25f6-4746-863d-d85e1ad30314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0043953b-6304-4c63-bc4f-2a1a079d7561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52119048-652d-47ff-abb8-aaa0e95aad0d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0043953b-6304-4c63-bc4f-2a1a079d7561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7a79a05f-72a8-4a1d-93c9-d997134eba3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0043953b-6304-4c63-bc4f-2a1a079d7561" xlink:to="loc_us-gaap_PreferredStockValue_7a79a05f-72a8-4a1d-93c9-d997134eba3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c738c766-78b5-47e1-bc58-810b6a9c6d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0043953b-6304-4c63-bc4f-2a1a079d7561" xlink:to="loc_us-gaap_CommonStockValue_c738c766-78b5-47e1-bc58-810b6a9c6d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c3c48e88-3595-4a77-8181-bde169141e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0043953b-6304-4c63-bc4f-2a1a079d7561" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c3c48e88-3595-4a77-8181-bde169141e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_454733d6-0dc1-429b-9713-3c63f3db1742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0043953b-6304-4c63-bc4f-2a1a079d7561" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_454733d6-0dc1-429b-9713-3c63f3db1742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_12665761-8f45-4757-bdcf-65a765e786fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0043953b-6304-4c63-bc4f-2a1a079d7561" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_12665761-8f45-4757-bdcf-65a765e786fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_65d9350b-dbf2-4913-afef-aa278614917e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0043953b-6304-4c63-bc4f-2a1a079d7561" xlink:to="loc_us-gaap_StockholdersEquity_65d9350b-dbf2-4913-afef-aa278614917e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_79c80a8b-defb-4a2c-9c0f-eccd61a59a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52119048-652d-47ff-abb8-aaa0e95aad0d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_79c80a8b-defb-4a2c-9c0f-eccd61a59a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_08dd62a4-7683-426f-bd72-a2b1a2f83f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_179e6d78-aadb-4db8-979b-9f4b8b4ae1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08dd62a4-7683-426f-bd72-a2b1a2f83f24" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_179e6d78-aadb-4db8-979b-9f4b8b4ae1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_40f17238-05f8-45ba-8599-6b219f991a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08dd62a4-7683-426f-bd72-a2b1a2f83f24" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_40f17238-05f8-45ba-8599-6b219f991a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e26408cc-b915-4019-8675-168e58b11ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08dd62a4-7683-426f-bd72-a2b1a2f83f24" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e26408cc-b915-4019-8675-168e58b11ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_de6b69bd-714f-49a9-9ee7-2e7d5f624a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08dd62a4-7683-426f-bd72-a2b1a2f83f24" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_de6b69bd-714f-49a9-9ee7-2e7d5f624a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fb1eecaa-8e06-4327-886b-fac3afda56c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08dd62a4-7683-426f-bd72-a2b1a2f83f24" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fb1eecaa-8e06-4327-886b-fac3afda56c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_86f026f3-637a-4bb1-a800-f8bdb6f1e1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08dd62a4-7683-426f-bd72-a2b1a2f83f24" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_86f026f3-637a-4bb1-a800-f8bdb6f1e1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c52050c7-34b8-4bc9-a42d-e2922b9d134f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08dd62a4-7683-426f-bd72-a2b1a2f83f24" xlink:to="loc_us-gaap_CommonStockSharesIssued_c52050c7-34b8-4bc9-a42d-e2922b9d134f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_47a67d90-7d5d-4047-994f-fd5fa8b7b7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08dd62a4-7683-426f-bd72-a2b1a2f83f24" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_47a67d90-7d5d-4047-994f-fd5fa8b7b7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_dc7b037b-513f-4342-8b0f-449510fd05f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_dc7b037b-513f-4342-8b0f-449510fd05f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e1a9465b-4d8a-4cb6-8b80-30053a64cef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e1a9465b-4d8a-4cb6-8b80-30053a64cef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_44f6b11d-b0f0-46d5-ad2b-7d0c9f5f8ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1a9465b-4d8a-4cb6-8b80-30053a64cef9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_44f6b11d-b0f0-46d5-ad2b-7d0c9f5f8ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_480b3a6d-e954-4371-b1be-785a37d9bc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1a9465b-4d8a-4cb6-8b80-30053a64cef9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_480b3a6d-e954-4371-b1be-785a37d9bc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f9c46d81-80b7-4985-a0b5-6cf32be82ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1a9465b-4d8a-4cb6-8b80-30053a64cef9" xlink:to="loc_us-gaap_RestructuringCharges_f9c46d81-80b7-4985-a0b5-6cf32be82ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_683945ea-33db-48a3-ae4b-7bae51374758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1a9465b-4d8a-4cb6-8b80-30053a64cef9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_683945ea-33db-48a3-ae4b-7bae51374758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a9e95b24-79d6-4e09-bf35-96ba3e7a1f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1a9465b-4d8a-4cb6-8b80-30053a64cef9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a9e95b24-79d6-4e09-bf35-96ba3e7a1f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f918200e-d96d-4dd4-b7ba-9b928284b03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1a9465b-4d8a-4cb6-8b80-30053a64cef9" xlink:to="loc_us-gaap_OperatingExpenses_f918200e-d96d-4dd4-b7ba-9b928284b03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d7ed0371-f45c-40e5-9565-6f4cb65bf8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_OperatingIncomeLoss_d7ed0371-f45c-40e5-9565-6f4cb65bf8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_957f0d15-7bf1-43a5-a722-3180b1ae1c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_InvestmentIncomeInterest_957f0d15-7bf1-43a5-a722-3180b1ae1c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e24e9d6e-52d1-4131-a6b6-d4521ba74bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e24e9d6e-52d1-4131-a6b6-d4521ba74bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_2d506f7e-7f3d-45bc-a871-98864e1e9d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_2d506f7e-7f3d-45bc-a871-98864e1e9d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f4a32f73-a78e-4259-ab5d-c2eb17ebb6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f4a32f73-a78e-4259-ab5d-c2eb17ebb6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ef77e369-d3f5-423c-a96c-7944b0fec92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_NetIncomeLoss_ef77e369-d3f5-423c-a96c-7944b0fec92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_980efb53-0680-4d8e-a956-5a34f57cd927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_980efb53-0680-4d8e-a956-5a34f57cd927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_74a8d174-8c81-4ad1-99e7-f6875ed15b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_74a8d174-8c81-4ad1-99e7-f6875ed15b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2dc2caca-1cf3-4953-b1ba-4b064d3dd721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2dc2caca-1cf3-4953-b1ba-4b064d3dd721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f376b659-80d0-4ff7-a12a-6434413855df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_EarningsPerShareBasic_f376b659-80d0-4ff7-a12a-6434413855df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7f4e793c-9e8a-4ff9-a9dc-4478ae2541c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7f4e793c-9e8a-4ff9-a9dc-4478ae2541c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ecd79cfc-36af-4b45-8768-d21a921ab807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ecd79cfc-36af-4b45-8768-d21a921ab807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8591950b-fb14-444b-a1b1-fd4d66494887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8591950b-fb14-444b-a1b1-fd4d66494887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_958760b0-9103-4ef9-9fcb-7f75ce1b476d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec71187b-3954-432e-9ef6-3d290a6d54b4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_958760b0-9103-4ef9-9fcb-7f75ce1b476d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39274c73-df6d-429b-a7ad-9336dadb2d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b9564019-ff18-4706-a19f-147df6675ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39274c73-df6d-429b-a7ad-9336dadb2d79" xlink:to="loc_us-gaap_NetIncomeLoss_b9564019-ff18-4706-a19f-147df6675ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_47a43f6e-c80e-4906-bfc1-f38c65cb8092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39274c73-df6d-429b-a7ad-9336dadb2d79" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_47a43f6e-c80e-4906-bfc1-f38c65cb8092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5893d6b0-ed41-4a05-ac1b-1394d03089fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39274c73-df6d-429b-a7ad-9336dadb2d79" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5893d6b0-ed41-4a05-ac1b-1394d03089fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4b904d42-37cf-44a5-8fb1-a65ce6380a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ee1ac5aa-6e99-4ba3-8cc8-96c37dec7bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4b904d42-37cf-44a5-8fb1-a65ce6380a62" xlink:to="loc_us-gaap_StatementTable_ee1ac5aa-6e99-4ba3-8cc8-96c37dec7bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4ce36b1f-26ac-4eb9-ae10-1745fdf0077f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee1ac5aa-6e99-4ba3-8cc8-96c37dec7bf7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4ce36b1f-26ac-4eb9-ae10-1745fdf0077f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4ce36b1f-26ac-4eb9-ae10-1745fdf0077f" xlink:to="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_84e1b06b-647f-4502-818f-fa98d1d9f355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:to="loc_us-gaap_CommonStockMember_84e1b06b-647f-4502-818f-fa98d1d9f355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ca58aefe-9aea-44d9-9285-f2df4feb9a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ca58aefe-9aea-44d9-9285-f2df4feb9a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e8ffc3d-c2c6-4048-8b30-381c593f0748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e8ffc3d-c2c6-4048-8b30-381c593f0748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fda273c3-d043-45b5-8576-0ef3a8d417ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e0581a79-033c-47ef-8f90-30d3d9294e88" xlink:to="loc_us-gaap_RetainedEarningsMember_fda273c3-d043-45b5-8576-0ef3a8d417ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_406ce4b7-91bb-461a-9106-1978ec069318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee1ac5aa-6e99-4ba3-8cc8-96c37dec7bf7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_406ce4b7-91bb-461a-9106-1978ec069318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_519c5d0b-6618-435f-9634-2f14faca6671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_406ce4b7-91bb-461a-9106-1978ec069318" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_519c5d0b-6618-435f-9634-2f14faca6671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_75bc0953-3280-4678-8a06-011a19ea395d" xlink:href="sesn-20221231.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_519c5d0b-6618-435f-9634-2f14faca6671" xlink:to="loc_sesn_ATMFacilityMember_75bc0953-3280-4678-8a06-011a19ea395d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_de248e55-b98a-42d3-897c-b59b43dd18c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee1ac5aa-6e99-4ba3-8cc8-96c37dec7bf7" xlink:to="loc_us-gaap_StatementLineItems_de248e55-b98a-42d3-897c-b59b43dd18c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de248e55-b98a-42d3-897c-b59b43dd18c6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_67ad351b-5e31-4990-931e-7e20026386ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_CommonStockSharesIssued_67ad351b-5e31-4990-931e-7e20026386ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a52c1ce4-7df0-4059-a554-c5fad9e2f155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockholdersEquity_a52c1ce4-7df0-4059-a554-c5fad9e2f155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed64c515-1c96-40c3-a679-5b632705d31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_NetIncomeLoss_ed64c515-1c96-40c3-a679-5b632705d31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f855338-2340-4051-ad65-e289b23a79ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f855338-2340-4051-ad65-e289b23a79ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16a97c59-687c-44f7-b11d-766db079b1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16a97c59-687c-44f7-b11d-766db079b1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7935f65e-e343-4ff3-99ae-f6e2c960d45c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7935f65e-e343-4ff3-99ae-f6e2c960d45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cde5c5eb-e548-4080-96c2-db39d68bca1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cde5c5eb-e548-4080-96c2-db39d68bca1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7a11861f-7570-4e1c-a692-d5688c771552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7a11861f-7570-4e1c-a692-d5688c771552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_649cbd89-9d85-4554-aeeb-3568622e29b3" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_649cbd89-9d85-4554-aeeb-3568622e29b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_60336f0b-0e7c-46dc-8836-f7d8fed72df3" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_60336f0b-0e7c-46dc-8836-f7d8fed72df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c1dfdbf7-7bd9-44e3-b609-46df53245ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c1dfdbf7-7bd9-44e3-b609-46df53245ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ec03103-f0a6-43f0-93d2-50b07a28d6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ec03103-f0a6-43f0-93d2-50b07a28d6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7fe8a93c-5153-4ae5-a587-b76192bd3f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7fe8a93c-5153-4ae5-a587-b76192bd3f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_aebdb743-79bf-4f02-a804-47bc4d76c933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_aebdb743-79bf-4f02-a804-47bc4d76c933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a87abdc8-b4fb-4427-8248-f016289f13f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a87abdc8-b4fb-4427-8248-f016289f13f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_688a9580-6c89-448f-a060-1a6281625e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_CommonStockSharesIssued_688a9580-6c89-448f-a060-1a6281625e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2aaf1907-e218-419d-aa93-9311e68d4e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03cabc8b-c20a-489c-9b0d-56effb7d04c5" xlink:to="loc_us-gaap_StockholdersEquity_2aaf1907-e218-419d-aa93-9311e68d4e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8499d7ac-3408-4145-b9dd-75d576f63735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0f6587a8-1de9-4d0c-abd5-fcfb4436fabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8499d7ac-3408-4145-b9dd-75d576f63735" xlink:to="loc_us-gaap_StatementTable_0f6587a8-1de9-4d0c-abd5-fcfb4436fabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e6d9da50-2b98-4ba0-9879-6575719d2a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0f6587a8-1de9-4d0c-abd5-fcfb4436fabc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e6d9da50-2b98-4ba0-9879-6575719d2a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02e75c16-6af5-47e5-808b-91635118706c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e6d9da50-2b98-4ba0-9879-6575719d2a90" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02e75c16-6af5-47e5-808b-91635118706c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_76b02723-34ad-45f5-9392-0ffc9663328b" xlink:href="sesn-20221231.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02e75c16-6af5-47e5-808b-91635118706c" xlink:to="loc_sesn_ATMFacilityMember_76b02723-34ad-45f5-9392-0ffc9663328b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e096b34c-f6fa-400f-afde-0d4ed83ca108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0f6587a8-1de9-4d0c-abd5-fcfb4436fabc" xlink:to="loc_us-gaap_StatementLineItems_e096b34c-f6fa-400f-afde-0d4ed83ca108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d97b9803-b48b-44f4-81dc-0d70eeea41f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e096b34c-f6fa-400f-afde-0d4ed83ca108" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d97b9803-b48b-44f4-81dc-0d70eeea41f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_30408dcf-e38d-4db9-82f7-3d2712b3a668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_30408dcf-e38d-4db9-82f7-3d2712b3a668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2506f568-5d13-4882-9682-e673127b90b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_30408dcf-e38d-4db9-82f7-3d2712b3a668" xlink:to="loc_us-gaap_NetIncomeLoss_2506f568-5d13-4882-9682-e673127b90b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eeb5e82e-9bd0-4c75-b8ce-8d319fa66aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_30408dcf-e38d-4db9-82f7-3d2712b3a668" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eeb5e82e-9bd0-4c75-b8ce-8d319fa66aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_106ce4c5-3573-4fef-8a83-ff1ca1285e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eeb5e82e-9bd0-4c75-b8ce-8d319fa66aba" xlink:to="loc_us-gaap_DepreciationAndAmortization_106ce4c5-3573-4fef-8a83-ff1ca1285e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e10a3c28-afad-4d9d-8796-554ebd5a9f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eeb5e82e-9bd0-4c75-b8ce-8d319fa66aba" xlink:to="loc_us-gaap_ShareBasedCompensation_e10a3c28-afad-4d9d-8796-554ebd5a9f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ac2ac6c1-2516-417e-b089-8b7b3d7c8731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eeb5e82e-9bd0-4c75-b8ce-8d319fa66aba" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ac2ac6c1-2516-417e-b089-8b7b3d7c8731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3bcde351-7d87-4a4a-bc0e-86da32f563dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eeb5e82e-9bd0-4c75-b8ce-8d319fa66aba" xlink:to="loc_us-gaap_AssetImpairmentCharges_3bcde351-7d87-4a4a-bc0e-86da32f563dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_51703454-f4f2-4fc8-801d-d1358a17087d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eeb5e82e-9bd0-4c75-b8ce-8d319fa66aba" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_51703454-f4f2-4fc8-801d-d1358a17087d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99938ff9-9541-4865-b2a4-67a6d2ececfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eeb5e82e-9bd0-4c75-b8ce-8d319fa66aba" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99938ff9-9541-4865-b2a4-67a6d2ececfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fbd57711-4e38-4272-9e1f-95dd795f00a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99938ff9-9541-4865-b2a4-67a6d2ececfb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fbd57711-4e38-4272-9e1f-95dd795f00a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_71a2079f-2c96-4127-a50e-edf74ddee593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99938ff9-9541-4865-b2a4-67a6d2ececfb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_71a2079f-2c96-4127-a50e-edf74ddee593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_33de55dc-a6ce-42ba-b2c3-272c134869fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99938ff9-9541-4865-b2a4-67a6d2ececfb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_33de55dc-a6ce-42ba-b2c3-272c134869fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_67b428f5-1bb6-4d8b-9318-48ea782671e2" xlink:href="sesn-20221231.xsd#sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99938ff9-9541-4865-b2a4-67a6d2ececfb" xlink:to="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_67b428f5-1bb6-4d8b-9318-48ea782671e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7bb40ac2-dbe5-4e4c-9bf5-93d2831dc2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99938ff9-9541-4865-b2a4-67a6d2ececfb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7bb40ac2-dbe5-4e4c-9bf5-93d2831dc2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fbd8978d-691c-4602-aac8-e8e9075df8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99938ff9-9541-4865-b2a4-67a6d2ececfb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fbd8978d-691c-4602-aac8-e8e9075df8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_56435f62-4996-4f7a-8819-005b28217200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99938ff9-9541-4865-b2a4-67a6d2ececfb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_56435f62-4996-4f7a-8819-005b28217200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_550de181-8a0b-4e24-9e75-5f711f3588e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99938ff9-9541-4865-b2a4-67a6d2ececfb" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_550de181-8a0b-4e24-9e75-5f711f3588e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73211b02-832a-440e-93e1-be0246e2856e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_30408dcf-e38d-4db9-82f7-3d2712b3a668" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73211b02-832a-440e-93e1-be0246e2856e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_869eb723-3d02-4663-b052-890775591632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_869eb723-3d02-4663-b052-890775591632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e22cf401-9970-4886-9daa-f7222aa01648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_869eb723-3d02-4663-b052-890775591632" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e22cf401-9970-4886-9daa-f7222aa01648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_27894db7-cbd3-4d7f-a3a8-08708e6a6e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_869eb723-3d02-4663-b052-890775591632" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_27894db7-cbd3-4d7f-a3a8-08708e6a6e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_5b6a76c6-dbfc-49f4-9119-3f1e56f3fc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_869eb723-3d02-4663-b052-890775591632" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_5b6a76c6-dbfc-49f4-9119-3f1e56f3fc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_4916b7c1-fe28-4468-b790-ed08edf0757f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_869eb723-3d02-4663-b052-890775591632" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_4916b7c1-fe28-4468-b790-ed08edf0757f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5dfd8be8-0fe8-4ec1-adfc-6c1ce67d38d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_869eb723-3d02-4663-b052-890775591632" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5dfd8be8-0fe8-4ec1-adfc-6c1ce67d38d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_947d1b95-ada9-4a66-b777-3f4b72e29914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_947d1b95-ada9-4a66-b777-3f4b72e29914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d83ad63d-7008-4fad-ae5d-cece25f1a4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_947d1b95-ada9-4a66-b777-3f4b72e29914" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d83ad63d-7008-4fad-ae5d-cece25f1a4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d88a291d-1b4e-4a68-bb45-ac4f9ada9b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_947d1b95-ada9-4a66-b777-3f4b72e29914" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d88a291d-1b4e-4a68-bb45-ac4f9ada9b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_025cd0e5-63e5-4081-8f7f-a76b33b4450e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_947d1b95-ada9-4a66-b777-3f4b72e29914" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_025cd0e5-63e5-4081-8f7f-a76b33b4450e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_f6fd3763-bc95-4f10-aa78-e90c9277267f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_947d1b95-ada9-4a66-b777-3f4b72e29914" xlink:to="loc_us-gaap_ProceedsFromStockPlans_f6fd3763-bc95-4f10-aa78-e90c9277267f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f27cfbaa-b81a-4747-afbf-3cc8d177fd75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f27cfbaa-b81a-4747-afbf-3cc8d177fd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_368782ce-9ff6-4534-8b3c-16fe8c40a0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_368782ce-9ff6-4534-8b3c-16fe8c40a0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_375f28b5-1243-456a-b566-1eb12ed740a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_375f28b5-1243-456a-b566-1eb12ed740a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2924e3e-a11b-4763-b50a-a7e615b2d212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2924e3e-a11b-4763-b50a-a7e615b2d212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_56505432-98d7-4a04-915e-d35bf3c48096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_56505432-98d7-4a04-915e-d35bf3c48096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8334649f-ca07-4454-910f-cb8b1f0a745f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_56505432-98d7-4a04-915e-d35bf3c48096" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8334649f-ca07-4454-910f-cb8b1f0a745f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_1f7ec08b-0d67-49e9-921b-9e535215efd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_56505432-98d7-4a04-915e-d35bf3c48096" xlink:to="loc_us-gaap_RestrictedCashCurrent_1f7ec08b-0d67-49e9-921b-9e535215efd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e1a432bc-7814-49a4-8ee7-4cca2b1bbf81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_56505432-98d7-4a04-915e-d35bf3c48096" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e1a432bc-7814-49a4-8ee7-4cca2b1bbf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c277ed94-0021-4853-ba64-4345a76023ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_56505432-98d7-4a04-915e-d35bf3c48096" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c277ed94-0021-4853-ba64-4345a76023ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_edd4f6ca-a02b-446d-9c71-340cf5aaebf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_edd4f6ca-a02b-446d-9c71-340cf5aaebf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_223ab6c3-2f18-44c9-a93e-0b3c505e9e79" xlink:href="sesn-20221231.xsd#sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_edd4f6ca-a02b-446d-9c71-340cf5aaebf4" xlink:to="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_223ab6c3-2f18-44c9-a93e-0b3c505e9e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f5995172-6e1b-457f-9274-fabb0f25e38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f5995172-6e1b-457f-9274-fabb0f25e38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_de9f8a93-7d3e-4ad7-bab3-0e6610889997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f5995172-6e1b-457f-9274-fabb0f25e38b" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_de9f8a93-7d3e-4ad7-bab3-0e6610889997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_38fdca57-0c05-4b37-897e-86fbedcc92fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f662e665-3d79-436d-b7aa-c4693cd2441c" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_38fdca57-0c05-4b37-897e-86fbedcc92fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IssuanceOfWarrantForCommonStock_ce340099-c56b-49ae-a59b-8104b5e16f54" xlink:href="sesn-20221231.xsd#sesn_IssuanceOfWarrantForCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_38fdca57-0c05-4b37-897e-86fbedcc92fe" xlink:to="loc_sesn_IssuanceOfWarrantForCommonStock_ce340099-c56b-49ae-a59b-8104b5e16f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="sesn-20221231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9ab19600-e5e4-4917-a128-0f2b75e87e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_c485e8d7-bdfc-41c3-bba7-5524f62fceeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9ab19600-e5e4-4917-a128-0f2b75e87e82" xlink:to="loc_us-gaap_NatureOfOperations_c485e8d7-bdfc-41c3-bba7-5524f62fceeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="sesn-20221231.xsd#BASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1dc7cfcd-bebe-4971-bf9e-90ff7ed6e868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_b042b688-6ac2-4cfe-87af-1a1afe63f6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1dc7cfcd-bebe-4971-bf9e-90ff7ed6e868" xlink:to="loc_us-gaap_BasisOfAccounting_b042b688-6ac2-4cfe-87af-1a1afe63f6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sesn-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a5d59f10-5af7-4859-bea6-fc6006999b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1a823e55-6011-4812-b032-1e4712ff600e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a5d59f10-5af7-4859-bea6-fc6006999b7e" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1a823e55-6011-4812-b032-1e4712ff600e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="sesn-20221231.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_4f9b44f4-48cb-4594-8fd4-d80eb4082fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_1021373a-194a-4389-bb5e-bcc9b66b734f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_4f9b44f4-48cb-4594-8fd4-d80eb4082fbd" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_1021373a-194a-4389-bb5e-bcc9b66b734f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="sesn-20221231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9ee303ce-7879-42f3-a080-8a4f5744ec37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b49d14fe-1aef-4f9d-b27e-a5b3eac1cc04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9ee303ce-7879-42f3-a080-8a4f5744ec37" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b49d14fe-1aef-4f9d-b27e-a5b3eac1cc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRICTEDCASHANDMARKETABLESECURITIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_9a37d321-18e0-41e2-8919-99ed974e276b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_4043c95b-aefe-49fc-aa3c-2287969a6af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_9a37d321-18e0-41e2-8919-99ed974e276b" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_4043c95b-aefe-49fc-aa3c-2287969a6af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLES" xlink:type="simple" xlink:href="sesn-20221231.xsd#RECEIVABLES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECEIVABLES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_2893f495-df0d-4cf4-80cb-dbe57cf39c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_84d20567-e300-4d38-b295-bc5f8d56209e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_2893f495-df0d-4cf4-80cb-dbe57cf39c34" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_84d20567-e300-4d38-b295-bc5f8d56209e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="sesn-20221231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8f96a240-28bc-4dde-8a16-9d7b5b4b8dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6259b7fe-999f-4b17-bb9b-38763384a1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8f96a240-28bc-4dde-8a16-9d7b5b4b8dbf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6259b7fe-999f-4b17-bb9b-38763384a1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL" xlink:type="simple" xlink:href="sesn-20221231.xsd#INTANGIBLESANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_286173ab-297b-4f0b-b8c6-a9c5f32a4d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4905df8f-e3f1-4f64-acdf-9f21034f2ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_286173ab-297b-4f0b-b8c6-a9c5f32a4d66" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4905df8f-e3f1-4f64-acdf-9f21034f2ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="sesn-20221231.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3c53787a-60a0-43bd-a651-c4554acb2ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_025b2a8c-9781-4686-9e5f-b8876733ae0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3c53787a-60a0-43bd-a651-c4554acb2ea2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_025b2a8c-9781-4686-9e5f-b8876733ae0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sesn-20221231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1b2f03cc-9a49-4c84-8ab2-2c6051377ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9d8a069a-2a82-4fe1-8689-2ac182f7b23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1b2f03cc-9a49-4c84-8ab2-2c6051377ce4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9d8a069a-2a82-4fe1-8689-2ac182f7b23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASES" xlink:type="simple" xlink:href="sesn-20221231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_99ea2066-4b19-499f-9ed1-dbb0fedeb038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0c08a48f-6c03-4a7f-bfb2-778ac78d75ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_99ea2066-4b19-499f-9ed1-dbb0fedeb038" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0c08a48f-6c03-4a7f-bfb2-778ac78d75ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_86a25fc0-afb8-4482-aa3c-6a91a7b586a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_86357bc4-5941-495b-b6d8-75e21ddfa77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_86a25fc0-afb8-4482-aa3c-6a91a7b586a9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_86357bc4-5941-495b-b6d8-75e21ddfa77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="sesn-20221231.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_43e0d9f7-635f-4415-9c72-dd355ba3a895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_717dcbf5-77dc-400d-afcb-ce1688deb790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_43e0d9f7-635f-4415-9c72-dd355ba3a895" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_717dcbf5-77dc-400d-afcb-ce1688deb790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="sesn-20221231.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d58d169b-82a8-450a-a6ef-e7da7467bf74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d2bd95e7-0c01-447b-be22-f5dd9ebb2573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d58d169b-82a8-450a-a6ef-e7da7467bf74" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d2bd95e7-0c01-447b-be22-f5dd9ebb2573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="sesn-20221231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_61c19ebd-9519-47b7-8e4e-e8cd87ed787c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_be77a7ab-dca1-4de0-8903-cc1eda52a645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_61c19ebd-9519-47b7-8e4e-e8cd87ed787c" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_be77a7ab-dca1-4de0-8903-cc1eda52a645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cf89fdfa-8764-48c5-add0-b92c8e31aba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_6a173654-5ce0-44d4-8ba9-114f23a48e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cf89fdfa-8764-48c5-add0-b92c8e31aba5" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_6a173654-5ce0-44d4-8ba9-114f23a48e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="simple" xlink:href="sesn-20221231.xsd#LICENSEAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2274fe8-9bbe-4231-9786-3e8d1230775d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock_9500b20e-85f3-47a7-83e8-3e4e1797d2bc" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2274fe8-9bbe-4231-9786-3e8d1230775d" xlink:to="loc_sesn_LicenseAgreementTextBlock_9500b20e-85f3-47a7-83e8-3e4e1797d2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRUCTURINGANDRELATEDACTIVITIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_12bda64a-6d45-4136-b233-d006ea85af5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7d26cf72-fd05-45cb-9237-d88c6da2f5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_12bda64a-6d45-4136-b233-d006ea85af5b" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7d26cf72-fd05-45cb-9237-d88c6da2f5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sesn-20221231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ea7b624f-b4cb-4aca-b5c8-d86f5ef43ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_cb7fbb22-4cbf-44af-b78b-211a88594102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ea7b624f-b4cb-4aca-b5c8-d86f5ef43ae4" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_cb7fbb22-4cbf-44af-b78b-211a88594102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sesn-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_dc658dcf-d7f3-42ce-bc56-f3fb5748e837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_UseOfEstimates_dc658dcf-d7f3-42ce-bc56-f3fb5748e837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4b4c0b92-65b5-42af-aaa9-b8fac9fe84a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4b4c0b92-65b5-42af-aaa9-b8fac9fe84a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ac7e2deb-0ee8-49d9-a382-67e85d5fd216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ac7e2deb-0ee8-49d9-a382-67e85d5fd216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a8609510-c4a1-4b40-a700-6f5d0f472926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a8609510-c4a1-4b40-a700-6f5d0f472926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_d3104480-50dd-4216-9ed8-4ffa805e5715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_d3104480-50dd-4216-9ed8-4ffa805e5715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e8293b04-173c-44c5-bf8c-a88c7682c100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e8293b04-173c-44c5-bf8c-a88c7682c100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_106d3404-f5f2-4fcf-98d6-9566dd2da8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_106d3404-f5f2-4fcf-98d6-9566dd2da8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_dc95def4-f287-4e01-a0e0-0127c1a5ed47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_dc95def4-f287-4e01-a0e0-0127c1a5ed47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ContingentConsiderationPolicyTextBlock_773bdcbe-2bde-4d1e-86b3-1811705f293d" xlink:href="sesn-20221231.xsd#sesn_ContingentConsiderationPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_sesn_ContingentConsiderationPolicyTextBlock_773bdcbe-2bde-4d1e-86b3-1811705f293d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1b297b62-847a-4aa0-bc1b-1f694eac093b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1b297b62-847a-4aa0-bc1b-1f694eac093b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4b176589-39f8-49d3-815c-2b9e914dc3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4b176589-39f8-49d3-815c-2b9e914dc3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_83c439c4-3c4c-4ae8-937a-eacaabc1e882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_83c439c4-3c4c-4ae8-937a-eacaabc1e882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3c4473af-5980-4786-8e42-9403dec7b7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_3c4473af-5980-4786-8e42-9403dec7b7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9d61806b-2259-4ac8-9d0d-db038c76a397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9d61806b-2259-4ac8-9d0d-db038c76a397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_eddf6de2-d5a8-4f21-ad39-c1d636523ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_eddf6de2-d5a8-4f21-ad39-c1d636523ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3ae9fc8b-f05f-459d-a5e4-16e5b0a78bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3ae9fc8b-f05f-459d-a5e4-16e5b0a78bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c364c284-7cf4-4f46-a6cb-d624b05e4f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4205fc2d-4d3a-418e-a567-e9702f3008cb" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c364c284-7cf4-4f46-a6cb-d624b05e4f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="sesn-20221231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_17e5f7c7-522a-4956-a86a-5160f44d2e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_45e502f2-6020-4d28-a1a9-37cdbe34666c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_17e5f7c7-522a-4956-a86a-5160f44d2e52" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_45e502f2-6020-4d28-a1a9-37cdbe34666c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_588b3de7-cd04-4ed1-bcf6-4ac1ecdccba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_17e5f7c7-522a-4956-a86a-5160f44d2e52" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_588b3de7-cd04-4ed1-bcf6-4ac1ecdccba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRICTEDCASHANDMARKETABLESECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_941b9b2c-704e-440a-b05e-b37570a07096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8e5de803-4e87-4d6d-9768-73fe2bbb5859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_941b9b2c-704e-440a-b05e-b37570a07096" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8e5de803-4e87-4d6d-9768-73fe2bbb5859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="sesn-20221231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_45063c09-e19c-425e-b755-f920a7608423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_de565e77-bb27-4e43-aa68-f2afb9f46752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_45063c09-e19c-425e-b755-f920a7608423" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_de565e77-bb27-4e43-aa68-f2afb9f46752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables" xlink:type="simple" xlink:href="sesn-20221231.xsd#INTANGIBLESANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69f5df84-d928-42b1-aec4-d44e86c11ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_57878d24-4107-4bb9-a855-67c15a7eacc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69f5df84-d928-42b1-aec4-d44e86c11ee3" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_57878d24-4107-4bb9-a855-67c15a7eacc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="sesn-20221231.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_60d841be-2e17-4f54-b748-5da8f574b6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a4432349-3c1a-4f5d-8f63-561cacd3f9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_60d841be-2e17-4f54-b748-5da8f574b6cf" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a4432349-3c1a-4f5d-8f63-561cacd3f9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESTables" xlink:type="simple" xlink:href="sesn-20221231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_047a2512-594c-41cc-af08-1040b99ec3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c00e3254-377c-4af7-92c4-26f7927499c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_047a2512-594c-41cc-af08-1040b99ec3c1" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c00e3254-377c-4af7-92c4-26f7927499c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b4dd59c2-f979-4422-a079-b1250a0ccbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_1adb2b47-be22-4d79-8715-cb7f97d1e7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b4dd59c2-f979-4422-a079-b1250a0ccbf8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_1adb2b47-be22-4d79-8715-cb7f97d1e7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_829eb726-2538-4a92-a970-32b4bd853892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b4dd59c2-f979-4422-a079-b1250a0ccbf8" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_829eb726-2538-4a92-a970-32b4bd853892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="sesn-20221231.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_55fe5cc2-f938-4c0b-a124-d0fce70f0016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e1cc867a-6afa-4b4f-8e93-25f7258b5408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_55fe5cc2-f938-4c0b-a124-d0fce70f0016" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e1cc867a-6afa-4b4f-8e93-25f7258b5408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sesn-20221231.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6a17ea8-2f64-4185-a20b-30c24cebcb23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d405e455-e3a6-4fe5-8863-e04e3171a8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6a17ea8-2f64-4185-a20b-30c24cebcb23" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d405e455-e3a6-4fe5-8863-e04e3171a8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_3e219975-8f1b-4da4-899f-b62c96653134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6a17ea8-2f64-4185-a20b-30c24cebcb23" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_3e219975-8f1b-4da4-899f-b62c96653134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3a6e16e0-b1b4-4d0b-bacf-b70d3e8ba785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6a17ea8-2f64-4185-a20b-30c24cebcb23" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3a6e16e0-b1b4-4d0b-bacf-b70d3e8ba785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fc7adc21-7461-4596-8990-6cb7dae6fc53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6a17ea8-2f64-4185-a20b-30c24cebcb23" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fc7adc21-7461-4596-8990-6cb7dae6fc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d808fa25-93c7-496f-98bd-2aca461d0132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_237af248-534b-49a1-8d59-c68342955d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d808fa25-93c7-496f-98bd-2aca461d0132" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_237af248-534b-49a1-8d59-c68342955d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_c8e36db2-3fd2-40c5-8b91-d57d1be1c394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d808fa25-93c7-496f-98bd-2aca461d0132" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_c8e36db2-3fd2-40c5-8b91-d57d1be1c394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8ec8ea1f-8d8b-42ba-b1f2-9bf75d29a105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d808fa25-93c7-496f-98bd-2aca461d0132" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8ec8ea1f-8d8b-42ba-b1f2-9bf75d29a105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3a773a96-d807-447a-b154-16028fa0d067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d808fa25-93c7-496f-98bd-2aca461d0132" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3a773a96-d807-447a-b154-16028fa0d067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_15a0f9ab-ead9-4150-b844-b3e60b690c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d808fa25-93c7-496f-98bd-2aca461d0132" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_15a0f9ab-ead9-4150-b844-b3e60b690c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRUCTURINGANDRELATEDACTIVITIESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5a905399-d681-4691-9d3b-70c4e434392b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_374135d9-d9bc-4e93-8f36-a6796ddc1d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5a905399-d681-4691-9d3b-70c4e434392b" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_374135d9-d9bc-4e93-8f36-a6796ddc1d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8a8572dc-b819-45ee-8768-1e27c234c1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8a8572dc-b819-45ee-8768-1e27c234c1be" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_94f6b7b5-e090-40f2-a668-0cfd51e8f551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_94f6b7b5-e090-40f2-a668-0cfd51e8f551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b66c0ba4-4e2b-4155-b5ac-9f7018fb0a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94f6b7b5-e090-40f2-a668-0cfd51e8f551" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b66c0ba4-4e2b-4155-b5ac-9f7018fb0a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member_c849b8bb-c827-43c9-907d-27a64bf02325" xlink:href="sesn-20221231.xsd#sesn_ViventiaBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b66c0ba4-4e2b-4155-b5ac-9f7018fb0a91" xlink:to="loc_sesn_ViventiaBioInc.Member_c849b8bb-c827-43c9-907d-27a64bf02325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7e0cecb-1ae8-4ecb-a8ac-0fd67ab926e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:to="loc_srt_ProductOrServiceAxis_d7e0cecb-1ae8-4ecb-a8ac-0fd67ab926e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2511b9e-7d98-4a30-a209-dbce8c6777b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d7e0cecb-1ae8-4ecb-a8ac-0fd67ab926e6" xlink:to="loc_srt_ProductsAndServicesDomain_d2511b9e-7d98-4a30-a209-dbce8c6777b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_7a92d546-3ec9-443e-b0d6-ff32db44ce47" xlink:href="sesn-20221231.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2511b9e-7d98-4a30-a209-dbce8c6777b9" xlink:to="loc_sesn_ViciniumMember_7a92d546-3ec9-443e-b0d6-ff32db44ce47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dfdc8f26-c643-4bbe-98d7-870596ec8e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dfdc8f26-c643-4bbe-98d7-870596ec8e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c4f39a02-6fed-406e-89b4-2d58f94ac428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dfdc8f26-c643-4bbe-98d7-870596ec8e0f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c4f39a02-6fed-406e-89b4-2d58f94ac428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_298083ca-81ea-4d46-b2b5-66b243eff1e8" xlink:href="sesn-20221231.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c4f39a02-6fed-406e-89b4-2d58f94ac428" xlink:to="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_298083ca-81ea-4d46-b2b5-66b243eff1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8ecbccc3-c3d4-43a8-9521-42cc765c1373" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:to="loc_srt_StatementGeographicalAxis_8ecbccc3-c3d4-43a8-9521-42cc765c1373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9e944a40-e36c-44ae-8315-117191daeead" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8ecbccc3-c3d4-43a8-9521-42cc765c1373" xlink:to="loc_srt_SegmentGeographicalDomain_9e944a40-e36c-44ae-8315-117191daeead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_52247b91-1c42-44d4-a141-07bfe7fd4cdf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9e944a40-e36c-44ae-8315-117191daeead" xlink:to="loc_country_US_52247b91-1c42-44d4-a141-07bfe7fd4cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_90a56798-f54f-493f-ade9-dbda02a6d6c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9e944a40-e36c-44ae-8315-117191daeead" xlink:to="loc_srt_EuropeMember_90a56798-f54f-493f-ade9-dbda02a6d6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_044fa85b-f4d3-4f0e-8412-86e8cb254986" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9e944a40-e36c-44ae-8315-117191daeead" xlink:to="loc_country_JP_044fa85b-f4d3-4f0e-8412-86e8cb254986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_da549c9c-ced3-49a8-980f-e49e0d000553" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_67f5ab00-bde3-45b3-9b3b-af4f79528eac" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_67f5ab00-bde3-45b3-9b3b-af4f79528eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8c4e38b9-90f1-437a-ab69-0cda6634dbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8c4e38b9-90f1-437a-ab69-0cda6634dbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_0a58ab19-2022-483f-87b6-da3af84b4e8b" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_0a58ab19-2022-483f-87b6-da3af84b4e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_adf7eac7-ffc1-4cc7-8525-c16090575654" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_adf7eac7-ffc1-4cc7-8525-c16090575654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_66a21eda-b03b-4061-a6f6-66a688f091ed" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_66a21eda-b03b-4061-a6f6-66a688f091ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_29d68e4a-d127-4621-bab4-c5802f0f2221" xlink:href="sesn-20221231.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_29d68e4a-d127-4621-bab4-c5802f0f2221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b8b3658e-7700-4ca2-af9c-427f41a0074c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b8b3658e-7700-4ca2-af9c-427f41a0074c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_40a706b7-528a-47c8-a551-ab440af8e6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_40a706b7-528a-47c8-a551-ab440af8e6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e3aadbd-3048-498b-9fd0-7da954d260d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5f68195f-ffe9-4819-a5b6-95fb50f5f2a5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e3aadbd-3048-498b-9fd0-7da954d260d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c5155d1d-f473-4e9e-a51e-a54b92d3e40b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5155d1d-f473-4e9e-a51e-a54b92d3e40b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885182a1-faf0-4232-ad75-70d9c4bacb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885182a1-faf0-4232-ad75-70d9c4bacb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_885182a1-faf0-4232-ad75-70d9c4bacb73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f414aabd-48d6-4569-8652-e404b51f2ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:to="loc_us-gaap_EquipmentMember_f414aabd-48d6-4569-8652-e404b51f2ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_42614e7e-3e47-414e-acb4-678dbb5c5ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_42614e7e-3e47-414e-acb4-678dbb5c5ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_c93594df-28ef-43b0-b626-63f8b431afed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:to="loc_us-gaap_ComputerEquipmentMember_c93594df-28ef-43b0-b626-63f8b431afed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0edfef7d-17b7-443c-9c94-2827a316c4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_352a0587-e45e-4c05-8781-e6e39bebf98f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0edfef7d-17b7-443c-9c94-2827a316c4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_170278d8-0de1-4810-ab66-a0b330f9ade2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_srt_ProductOrServiceAxis_170278d8-0de1-4810-ab66-a0b330f9ade2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_245b5b67-b829-4e71-9fec-287daf748df5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_170278d8-0de1-4810-ab66-a0b330f9ade2" xlink:to="loc_srt_ProductsAndServicesDomain_245b5b67-b829-4e71-9fec-287daf748df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_e2dcd3b7-d919-4662-8213-26fe1307dbf8" xlink:href="sesn-20221231.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245b5b67-b829-4e71-9fec-287daf748df5" xlink:to="loc_sesn_ViciniumMember_e2dcd3b7-d919-4662-8213-26fe1307dbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_b8cca84d-ad38-47f2-ab2d-aa5f4496226a" xlink:href="sesn-20221231.xsd#sesn_EBI031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245b5b67-b829-4e71-9fec-287daf748df5" xlink:to="loc_sesn_EBI031Member_b8cca84d-ad38-47f2-ab2d-aa5f4496226a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c532a7ed-c747-4469-8872-ef075898917d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_srt_StatementGeographicalAxis_c532a7ed-c747-4469-8872-ef075898917d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6bbc5de7-aec8-41cd-8496-a441933f0e64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c532a7ed-c747-4469-8872-ef075898917d" xlink:to="loc_srt_SegmentGeographicalDomain_6bbc5de7-aec8-41cd-8496-a441933f0e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5c60d9b6-8079-4f19-a73d-db6ec5e7d3c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6bbc5de7-aec8-41cd-8496-a441933f0e64" xlink:to="loc_srt_EuropeMember_5c60d9b6-8079-4f19-a73d-db6ec5e7d3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0574798e-2d83-4013-a680-4f40df8c3e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0574798e-2d83-4013-a680-4f40df8c3e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad238182-f0f9-4b6e-b855-4705df4503bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0574798e-2d83-4013-a680-4f40df8c3e51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad238182-f0f9-4b6e-b855-4705df4503bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4b282b9f-b538-4423-963b-af06459621a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad238182-f0f9-4b6e-b855-4705df4503bc" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4b282b9f-b538-4423-963b-af06459621a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_91b79a78-77e2-45ea-8a10-c1f25c459cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad238182-f0f9-4b6e-b855-4705df4503bc" xlink:to="loc_us-gaap_LicensingAgreementsMember_91b79a78-77e2-45ea-8a10-c1f25c459cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac5b997e-5fab-4b8c-8167-523bc4d87227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_us-gaap_AwardTypeAxis_ac5b997e-5fab-4b8c-8167-523bc4d87227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e613c024-fb46-48df-900e-69f7d01d92c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ac5b997e-5fab-4b8c-8167-523bc4d87227" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e613c024-fb46-48df-900e-69f7d01d92c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0b05e0db-9225-41e1-967e-61cbc9bd13b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e613c024-fb46-48df-900e-69f7d01d92c1" xlink:to="loc_us-gaap_PerformanceSharesMember_0b05e0db-9225-41e1-967e-61cbc9bd13b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_78b1a40c-b606-411c-8bff-c1e7855a7c36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_srt_CounterpartyNameAxis_78b1a40c-b606-411c-8bff-c1e7855a7c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_600040dd-c61a-44c0-8110-ed2dc0dbdca8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_78b1a40c-b606-411c-8bff-c1e7855a7c36" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_600040dd-c61a-44c0-8110-ed2dc0dbdca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_c8a484dc-d03b-4b50-8c8f-7f18a47a11f4" xlink:href="sesn-20221231.xsd#sesn_RocheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_600040dd-c61a-44c0-8110-ed2dc0dbdca8" xlink:to="loc_sesn_RocheMember_c8a484dc-d03b-4b50-8c8f-7f18a47a11f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_50b1a469-cd35-4114-ba87-8b2ef85dd728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_50b1a469-cd35-4114-ba87-8b2ef85dd728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_34aac33c-92c2-4e63-8af3-eb72438dde78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_50b1a469-cd35-4114-ba87-8b2ef85dd728" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_34aac33c-92c2-4e63-8af3-eb72438dde78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8b69dba8-e06c-43a1-963e-5eeceedf423d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_34aac33c-92c2-4e63-8af3-eb72438dde78" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8b69dba8-e06c-43a1-963e-5eeceedf423d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43a28356-9e44-4247-b99c-a37d743df69b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_7a0917d3-60f0-4e1f-b29d-fef790a49817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_7a0917d3-60f0-4e1f-b29d-fef790a49817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a333c74d-3269-4e05-92f5-d3b4a6b63165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a333c74d-3269-4e05-92f5-d3b4a6b63165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_093e6250-ec3d-4ae3-b6fd-473f28ed5043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_093e6250-ec3d-4ae3-b6fd-473f28ed5043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_43a24535-cd38-435b-a5eb-4c01b0786200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_43a24535-cd38-435b-a5eb-4c01b0786200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_ded7fa4c-482b-4d78-bdca-10c73e3d5f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_NumberOfReportingUnits_ded7fa4c-482b-4d78-bdca-10c73e3d5f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_16abeeec-a472-4094-8570-c35e0bb3684d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_Goodwill_16abeeec-a472-4094-8570-c35e0bb3684d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d252119b-01bb-437a-b9af-a9a90b1c10e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d252119b-01bb-437a-b9af-a9a90b1c10e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_33be421c-91a7-4bf3-acbe-8cdc5a31ebae" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_33be421c-91a7-4bf3-acbe-8cdc5a31ebae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_938219be-a8aa-4ce6-ad87-8e86596612c8" xlink:href="sesn-20221231.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_sesn_WeightedAverageCostOfCapital_938219be-a8aa-4ce6-ad87-8e86596612c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_af252104-aac4-4011-ad04-51ec70362d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_af252104-aac4-4011-ad04-51ec70362d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_01953f13-c4df-4b2c-9ea4-7cc5d099c523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_01953f13-c4df-4b2c-9ea4-7cc5d099c523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_44619563-5096-4514-8bb9-8ad70c01e24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_44619563-5096-4514-8bb9-8ad70c01e24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_107775a6-43a8-425d-8948-3420995a686d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_107775a6-43a8-425d-8948-3420995a686d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bee541fe-2648-499c-9adf-9b65a63ae6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bee541fe-2648-499c-9adf-9b65a63ae6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePayment_69ff40df-0520-4844-9c95-14c49c8082e3" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestonePayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_sesn_LicenseAgreementMilestonePayment_69ff40df-0520-4844-9c95-14c49c8082e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestonePaymentTerm_caf09794-322b-404e-93d7-dd8044cc93ea" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestonePaymentTerm"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_sesn_LicenseAgreementMilestonePaymentTerm_caf09794-322b-404e-93d7-dd8044cc93ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_45a34ab2-47d1-4f42-b6c3-83510bc6f924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_45a34ab2-47d1-4f42-b6c3-83510bc6f924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_48e258c0-04bd-4de6-9a38-24f76b690438" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7b8695e4-5615-4b56-b97c-0374bc115a93" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_48e258c0-04bd-4de6-9a38-24f76b690438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_88f0d48b-8d38-4ef0-90c9-60ab94bcb26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_88f0d48b-8d38-4ef0-90c9-60ab94bcb26d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9f8f4b-4130-473c-8d02-30b701132490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9f8f4b-4130-473c-8d02-30b701132490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_65aade8b-87f4-4e1a-86ba-993e34201710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ce9f8f4b-4130-473c-8d02-30b701132490" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_65aade8b-87f4-4e1a-86ba-993e34201710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f058d6d6-f497-4c34-b6a6-809eb391a36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_65aade8b-87f4-4e1a-86ba-993e34201710" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f058d6d6-f497-4c34-b6a6-809eb391a36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_38610500-9bff-430e-825a-e85451961e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f058d6d6-f497-4c34-b6a6-809eb391a36c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_38610500-9bff-430e-825a-e85451961e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_08d1755d-b1fc-4162-9111-a3bfe23b8052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f058d6d6-f497-4c34-b6a6-809eb391a36c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_08d1755d-b1fc-4162-9111-a3bfe23b8052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3f9756-9bc1-4b0b-9202-b00234f25efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3f9756-9bc1-4b0b-9202-b00234f25efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_01c3bc6e-c787-4d16-9f31-3a12f835292d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3f9756-9bc1-4b0b-9202-b00234f25efe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_01c3bc6e-c787-4d16-9f31-3a12f835292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_35580638-f31d-47b1-a627-a1f232447da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_01c3bc6e-c787-4d16-9f31-3a12f835292d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_35580638-f31d-47b1-a627-a1f232447da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eb1af5ab-6df0-4d53-b9ee-78f63e647b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eb1af5ab-6df0-4d53-b9ee-78f63e647b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0a8d806-71e4-4a78-aa95-05733c0cca04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eb1af5ab-6df0-4d53-b9ee-78f63e647b0e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0a8d806-71e4-4a78-aa95-05733c0cca04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f83a358d-fbc2-4ba1-aba2-bfe6114cb730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0a8d806-71e4-4a78-aa95-05733c0cca04" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f83a358d-fbc2-4ba1-aba2-bfe6114cb730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5ea9792b-eb71-4e52-900a-b09f000ab569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0a8d806-71e4-4a78-aa95-05733c0cca04" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5ea9792b-eb71-4e52-900a-b09f000ab569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f997b67a-3a1f-49f0-bc53-aca8dee41daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0a8d806-71e4-4a78-aa95-05733c0cca04" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f997b67a-3a1f-49f0-bc53-aca8dee41daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_94d6ade4-d538-41b1-8302-bff8c2f8fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:to="loc_us-gaap_FinancialInstrumentAxis_94d6ade4-d538-41b1-8302-bff8c2f8fa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13ebd40a-4f04-4012-bad5-0fdd237a9d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94d6ade4-d538-41b1-8302-bff8c2f8fa62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13ebd40a-4f04-4012-bad5-0fdd237a9d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0de4b0e1-c679-4d03-96ca-8b2cf8643233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13ebd40a-4f04-4012-bad5-0fdd237a9d31" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0de4b0e1-c679-4d03-96ca-8b2cf8643233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_31e80bcb-bf27-4489-aedb-f1891df58357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13ebd40a-4f04-4012-bad5-0fdd237a9d31" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_31e80bcb-bf27-4489-aedb-f1891df58357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_665156ce-f775-4491-990f-66b6bd9d4aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_51ed61f5-6264-4b5b-964d-ccfd2cdcd361" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_665156ce-f775-4491-990f-66b6bd9d4aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_4ac8f225-e929-4632-8be6-fc0a8253bb22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_665156ce-f775-4491-990f-66b6bd9d4aa0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_4ac8f225-e929-4632-8be6-fc0a8253bb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_446653cb-cdd4-4b5f-9e19-43a4a855e41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4ac8f225-e929-4632-8be6-fc0a8253bb22" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_446653cb-cdd4-4b5f-9e19-43a4a855e41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f9f932da-3ceb-4011-8cdd-93e0f402fc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4ac8f225-e929-4632-8be6-fc0a8253bb22" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f9f932da-3ceb-4011-8cdd-93e0f402fc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4be40083-cc15-4eda-9291-e351198c56e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_665156ce-f775-4491-990f-66b6bd9d4aa0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4be40083-cc15-4eda-9291-e351198c56e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_184ef185-1d74-4eca-98b3-7c6746729c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4be40083-cc15-4eda-9291-e351198c56e9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_184ef185-1d74-4eca-98b3-7c6746729c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6549a65d-1dd4-4c0e-a722-b75e5e991670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_d320d70b-02a7-4eea-b9d2-cc47c4f32261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6549a65d-1dd4-4c0e-a722-b75e5e991670" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_d320d70b-02a7-4eea-b9d2-cc47c4f32261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c5ae0ab8-7d97-4050-9d72-145ea7e85407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_d320d70b-02a7-4eea-b9d2-cc47c4f32261" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c5ae0ab8-7d97-4050-9d72-145ea7e85407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6c98c2bf-cdbd-449d-9ef2-b1f04f44a0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c5ae0ab8-7d97-4050-9d72-145ea7e85407" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6c98c2bf-cdbd-449d-9ef2-b1f04f44a0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9412a0d4-a429-4c1e-9eb9-85d602918f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6c98c2bf-cdbd-449d-9ef2-b1f04f44a0bf" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9412a0d4-a429-4c1e-9eb9-85d602918f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_d320d70b-02a7-4eea-b9d2-cc47c4f32261" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_edb83080-314b-4df1-aa6b-f9b16fba3850" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_edb83080-314b-4df1-aa6b-f9b16fba3850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_3d641ea6-6234-4f8a-b870-5f6c97d9bc51" xlink:href="sesn-20221231.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:to="loc_sesn_WeightedAverageCostOfCapital_3d641ea6-6234-4f8a-b870-5f6c97d9bc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8c1a1b3e-a6b0-43b0-8300-122ead936bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8c1a1b3e-a6b0-43b0-8300-122ead936bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_883aca1d-dc6b-4e3f-b2e0-26a6592505fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_76e94f23-e3f2-4a63-8c54-3d045d391723" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_883aca1d-dc6b-4e3f-b2e0-26a6592505fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4169383d-9a5d-4ced-9287-318be4502b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b61ce139-38a5-4ebb-9463-36211a23e901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4169383d-9a5d-4ced-9287-318be4502b71" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b61ce139-38a5-4ebb-9463-36211a23e901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_100e3360-c468-4b6c-80cf-4f9123bb8936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b61ce139-38a5-4ebb-9463-36211a23e901" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_100e3360-c468-4b6c-80cf-4f9123bb8936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_739236ac-dc0b-43be-a3a3-7fa9cc1241d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_100e3360-c468-4b6c-80cf-4f9123bb8936" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_739236ac-dc0b-43be-a3a3-7fa9cc1241d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9256d756-27b0-4c9c-9d02-424a35f30b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_739236ac-dc0b-43be-a3a3-7fa9cc1241d8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9256d756-27b0-4c9c-9d02-424a35f30b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_325487ee-a787-4cb1-923e-ba4152e14269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b61ce139-38a5-4ebb-9463-36211a23e901" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_325487ee-a787-4cb1-923e-ba4152e14269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a93154da-79bd-4fd5-bb2e-8eeae9de3f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_325487ee-a787-4cb1-923e-ba4152e14269" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a93154da-79bd-4fd5-bb2e-8eeae9de3f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f740c9ec-6252-4a0e-bc04-7bc5dfbecd26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a93154da-79bd-4fd5-bb2e-8eeae9de3f59" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f740c9ec-6252-4a0e-bc04-7bc5dfbecd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_c629e4d5-845e-4eb9-a6f0-ddacf6cd468b" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a93154da-79bd-4fd5-bb2e-8eeae9de3f59" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_c629e4d5-845e-4eb9-a6f0-ddacf6cd468b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9824e94a-f267-47a3-83b6-68499d0fab36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a93154da-79bd-4fd5-bb2e-8eeae9de3f59" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9824e94a-f267-47a3-83b6-68499d0fab36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRICTEDCASHANDMARKETABLESECURITIESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_96fa8497-70b6-489f-ab0c-0f1ae2eb1a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_0c1d246a-2173-48a8-a501-6613fd4722b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_96fa8497-70b6-489f-ab0c-0f1ae2eb1a95" xlink:to="loc_us-gaap_RestrictedCashCurrent_0c1d246a-2173-48a8-a501-6613fd4722b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_d8a3576d-b5b6-4270-8363-cfde8f457821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fd6d242e-c595-4ed5-9a38-587fc5cf803f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d8a3576d-b5b6-4270-8363-cfde8f457821" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fd6d242e-c595-4ed5-9a38-587fc5cf803f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_82c34066-e3c2-409f-a687-e93f2517c7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fd6d242e-c595-4ed5-9a38-587fc5cf803f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_82c34066-e3c2-409f-a687-e93f2517c7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f8760b2-6ca7-4f80-9880-c23b941b2e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_82c34066-e3c2-409f-a687-e93f2517c7a7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f8760b2-6ca7-4f80-9880-c23b941b2e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a15514ce-b030-4cba-90d7-f8497badd519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f8760b2-6ca7-4f80-9880-c23b941b2e05" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a15514ce-b030-4cba-90d7-f8497badd519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_01bca44b-7a53-4cb2-b51a-52a3340bf647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f8760b2-6ca7-4f80-9880-c23b941b2e05" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_01bca44b-7a53-4cb2-b51a-52a3340bf647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fd6d242e-c595-4ed5-9a38-587fc5cf803f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_167194a1-a52c-4531-8442-f3089a2bd00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_167194a1-a52c-4531-8442-f3089a2bd00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_66e81f26-daf3-4471-9f59-4e88b3e04bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_66e81f26-daf3-4471-9f59-4e88b3e04bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b47ac609-a97d-4a38-8d6c-9315a649954f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b47ac609-a97d-4a38-8d6c-9315a649954f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_26f06ab8-629d-4595-8454-4c4e00c94ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d84b035-81e8-4af4-966b-ab1e684e04fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_26f06ab8-629d-4595-8454-4c4e00c94ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#RECEIVABLESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_379ff7a7-d672-479e-a73c-890b619e362e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6d74e7a3-9afe-4c61-af05-243fed64373d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_379ff7a7-d672-479e-a73c-890b619e362e" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6d74e7a3-9afe-4c61-af05-243fed64373d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_59439e90-a738-4e8e-be14-ebd0f9cdb767" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6d74e7a3-9afe-4c61-af05-243fed64373d" xlink:to="loc_srt_CounterpartyNameAxis_59439e90-a738-4e8e-be14-ebd0f9cdb767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c40ff6-f032-4ace-97e5-93a026e188b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_59439e90-a738-4e8e-be14-ebd0f9cdb767" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c40ff6-f032-4ace-97e5-93a026e188b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_af5e4753-d08d-491e-92cf-95497d802743" xlink:href="sesn-20221231.xsd#sesn_RocheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c40ff6-f032-4ace-97e5-93a026e188b5" xlink:to="loc_sesn_RocheMember_af5e4753-d08d-491e-92cf-95497d802743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_4feddad4-8a9a-45d6-b775-7ba3a1ee23cc" xlink:href="sesn-20221231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c40ff6-f032-4ace-97e5-93a026e188b5" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_4feddad4-8a9a-45d6-b775-7ba3a1ee23cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6d74e7a3-9afe-4c61-af05-243fed64373d" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_adf8b3d4-e90f-48c7-8ca8-24b0803d1eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_adf8b3d4-e90f-48c7-8ca8-24b0803d1eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_862d9015-a41a-4775-9ee1-c348ff95dd25" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_862d9015-a41a-4775-9ee1-c348ff95dd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_2d28ecee-a56b-4e59-a507-a82af65d54cd" xlink:href="sesn-20221231.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_2d28ecee-a56b-4e59-a507-a82af65d54cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_6b7ff9d0-b815-436f-8108-5a8ff9229dd5" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_6b7ff9d0-b815-436f-8108-5a8ff9229dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_7a2b9639-0e04-43b5-8a5d-d7e39c8889d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_edf48755-7d51-486f-9ada-e4e153c1718b" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_7a2b9639-0e04-43b5-8a5d-d7e39c8889d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ae911b11-e94c-445f-a0ae-7e7964b6f909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f9c6f8f0-3340-4ed3-a3c2-f069152614af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ae911b11-e94c-445f-a0ae-7e7964b6f909" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f9c6f8f0-3340-4ed3-a3c2-f069152614af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_db37ae11-d370-4862-984d-cc6b0185bf46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f9c6f8f0-3340-4ed3-a3c2-f069152614af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_db37ae11-d370-4862-984d-cc6b0185bf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_db37ae11-d370-4862-984d-cc6b0185bf46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_afe3a94b-20e4-4ae2-9cbf-c374f483008b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:to="loc_us-gaap_EquipmentMember_afe3a94b-20e4-4ae2-9cbf-c374f483008b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c55be462-27f0-45c1-8757-8007b59bbf85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c55be462-27f0-45c1-8757-8007b59bbf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_acc0c33e-0c40-4546-a41b-d4ddeb2991e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:to="loc_us-gaap_ComputerEquipmentMember_acc0c33e-0c40-4546-a41b-d4ddeb2991e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_ef1c83f1-8639-472d-8353-5726e1203a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_ef1c83f1-8639-472d-8353-5726e1203a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1415696a-69e7-467a-a1a8-5c3c1613ad8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab26beab-4ca6-4b4c-907f-f07252e94033" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1415696a-69e7-467a-a1a8-5c3c1613ad8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dadce98a-3198-4594-8227-577abea619f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f9c6f8f0-3340-4ed3-a3c2-f069152614af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dadce98a-3198-4594-8227-577abea619f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_aabb6d05-266a-40a9-bc7d-2a45f7d5335e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dadce98a-3198-4594-8227-577abea619f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_aabb6d05-266a-40a9-bc7d-2a45f7d5335e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a50f0781-00fe-4143-acb9-80cf18db4735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dadce98a-3198-4594-8227-577abea619f9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a50f0781-00fe-4143-acb9-80cf18db4735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fc1169fc-f293-42fc-a715-009e17f42369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dadce98a-3198-4594-8227-577abea619f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fc1169fc-f293-42fc-a715-009e17f42369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#PROPERTYANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7ef2d8ce-735f-49e8-a46b-f70d3751e100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_3dfb93dd-e772-4d77-a8c7-2ab5fcf80331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7ef2d8ce-735f-49e8-a46b-f70d3751e100" xlink:to="loc_us-gaap_DepreciationAndAmortization_3dfb93dd-e772-4d77-a8c7-2ab5fcf80331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bb73a91-765c-4e57-8601-1a5c5ee2d22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e808fa0-f4f0-446b-9eed-885e56686800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bb73a91-765c-4e57-8601-1a5c5ee2d22d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e808fa0-f4f0-446b-9eed-885e56686800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e83da1b9-ca9b-4c2b-a442-043b0ac08fd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e808fa0-f4f0-446b-9eed-885e56686800" xlink:to="loc_srt_StatementGeographicalAxis_e83da1b9-ca9b-4c2b-a442-043b0ac08fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a248fe01-1a84-44b7-8d19-d1dd23fd00f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e83da1b9-ca9b-4c2b-a442-043b0ac08fd0" xlink:to="loc_srt_SegmentGeographicalDomain_a248fe01-1a84-44b7-8d19-d1dd23fd00f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_09fa85f3-ee7e-44e6-824a-c4f381f8ae5c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a248fe01-1a84-44b7-8d19-d1dd23fd00f0" xlink:to="loc_country_US_09fa85f3-ee7e-44e6-824a-c4f381f8ae5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_490c59a5-c482-4349-81f1-c92bff20bfae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a248fe01-1a84-44b7-8d19-d1dd23fd00f0" xlink:to="loc_srt_EuropeMember_490c59a5-c482-4349-81f1-c92bff20bfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2d8195a6-1f28-4949-b010-3083e19748f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e808fa0-f4f0-446b-9eed-885e56686800" xlink:to="loc_srt_ProductOrServiceAxis_2d8195a6-1f28-4949-b010-3083e19748f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2dc8e4ac-935a-4816-82a0-dea354716df8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2d8195a6-1f28-4949-b010-3083e19748f1" xlink:to="loc_srt_ProductsAndServicesDomain_2dc8e4ac-935a-4816-82a0-dea354716df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_35210401-a7f1-4f87-b8bb-41d8d1eeeb9c" xlink:href="sesn-20221231.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2dc8e4ac-935a-4816-82a0-dea354716df8" xlink:to="loc_sesn_ViciniumMember_35210401-a7f1-4f87-b8bb-41d8d1eeeb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14fe6505-eb47-4082-a6e8-61b5782328bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e808fa0-f4f0-446b-9eed-885e56686800" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14fe6505-eb47-4082-a6e8-61b5782328bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0edd8ac2-3808-40f1-81b2-81affe9cd826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14fe6505-eb47-4082-a6e8-61b5782328bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0edd8ac2-3808-40f1-81b2-81affe9cd826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a1a469e0-f76c-4346-8a3d-3df485f3947d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0edd8ac2-3808-40f1-81b2-81affe9cd826" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a1a469e0-f76c-4346-8a3d-3df485f3947d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cbeb17e8-5681-4d30-8355-f8361308c800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e808fa0-f4f0-446b-9eed-885e56686800" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cbeb17e8-5681-4d30-8355-f8361308c800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_445dc26b-0fe2-4162-8c61-c655845e636b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cbeb17e8-5681-4d30-8355-f8361308c800" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_445dc26b-0fe2-4162-8c61-c655845e636b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INTANGIBLESANDGOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bcd802ba-a991-4e6e-8a38-0155523adc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0fd77f9c-7a5d-4d79-a3be-847b6fee1664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bcd802ba-a991-4e6e-8a38-0155523adc01" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0fd77f9c-7a5d-4d79-a3be-847b6fee1664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cd240337-5323-483d-82ca-a207ea7c69f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0fd77f9c-7a5d-4d79-a3be-847b6fee1664" xlink:to="loc_srt_ProductOrServiceAxis_cd240337-5323-483d-82ca-a207ea7c69f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5bcae088-aa12-4d99-a502-ca68746cce3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cd240337-5323-483d-82ca-a207ea7c69f5" xlink:to="loc_srt_ProductsAndServicesDomain_5bcae088-aa12-4d99-a502-ca68746cce3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_75ebdb20-b122-4dd2-a1e6-f37bb1376e4c" xlink:href="sesn-20221231.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5bcae088-aa12-4d99-a502-ca68746cce3b" xlink:to="loc_sesn_ViciniumMember_75ebdb20-b122-4dd2-a1e6-f37bb1376e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0896f090-f7cb-40f3-b7a8-4d543446b585" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0fd77f9c-7a5d-4d79-a3be-847b6fee1664" xlink:to="loc_srt_StatementGeographicalAxis_0896f090-f7cb-40f3-b7a8-4d543446b585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_187ec542-c08e-4719-b8ae-44479ea7e604" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0896f090-f7cb-40f3-b7a8-4d543446b585" xlink:to="loc_srt_SegmentGeographicalDomain_187ec542-c08e-4719-b8ae-44479ea7e604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_fcfe2628-f223-492f-affd-a0173a76aede" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_187ec542-c08e-4719-b8ae-44479ea7e604" xlink:to="loc_srt_EuropeMember_fcfe2628-f223-492f-affd-a0173a76aede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3a93aa45-3d85-4269-ab2e-96cb3c5eff0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0fd77f9c-7a5d-4d79-a3be-847b6fee1664" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3a93aa45-3d85-4269-ab2e-96cb3c5eff0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0d6e54a-68a9-46c9-9140-cc02f78cd46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3a93aa45-3d85-4269-ab2e-96cb3c5eff0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0d6e54a-68a9-46c9-9140-cc02f78cd46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf8a9dc8-bf2b-44c7-a45e-3a5b7f6fddca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0d6e54a-68a9-46c9-9140-cc02f78cd46a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf8a9dc8-bf2b-44c7-a45e-3a5b7f6fddca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0fd77f9c-7a5d-4d79-a3be-847b6fee1664" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8dee9387-a0bf-46e4-a1c7-1be3e420cc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8dee9387-a0bf-46e4-a1c7-1be3e420cc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_6f0f2585-ee1b-497d-9521-276b6fb80737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_6f0f2585-ee1b-497d-9521-276b6fb80737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5df4ba2e-798d-4bcb-b794-023b6035b1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:to="loc_us-gaap_Goodwill_5df4ba2e-798d-4bcb-b794-023b6035b1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_168ae5fd-5ba2-43b0-9e81-35143bd333ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8f9916f-0e0e-40aa-a1f6-1ca6c4561fa9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_168ae5fd-5ba2-43b0-9e81-35143bd333ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_614039b2-37bb-483f-b39b-6395c0f174a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_5d075621-d7d2-43ce-8b41-b969a15cb4e2" xlink:href="sesn-20221231.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_614039b2-37bb-483f-b39b-6395c0f174a5" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_5d075621-d7d2-43ce-8b41-b969a15cb4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_24bf1500-360a-4f7b-81ae-d80e8c2aff9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_614039b2-37bb-483f-b39b-6395c0f174a5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_24bf1500-360a-4f7b-81ae-d80e8c2aff9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_f727b438-e860-407f-b1d6-20498782b2e1" xlink:href="sesn-20221231.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_614039b2-37bb-483f-b39b-6395c0f174a5" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_f727b438-e860-407f-b1d6-20498782b2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d22042f0-d65f-4b6b-8d48-ebdb6462a758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_614039b2-37bb-483f-b39b-6395c0f174a5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d22042f0-d65f-4b6b-8d48-ebdb6462a758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedLegalFeesCurrent_e70adfc6-bc74-4f0b-bfd6-1f0aba19bc39" xlink:href="sesn-20221231.xsd#sesn_AccruedLegalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_614039b2-37bb-483f-b39b-6395c0f174a5" xlink:to="loc_sesn_AccruedLegalFeesCurrent_e70adfc6-bc74-4f0b-bfd6-1f0aba19bc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2806346a-a63d-4355-b7d6-d514fe900afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_614039b2-37bb-483f-b39b-6395c0f174a5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2806346a-a63d-4355-b7d6-d514fe900afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a8e2b6e9-34d8-4cb8-a8f4-cb206cc1353d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_614039b2-37bb-483f-b39b-6395c0f174a5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a8e2b6e9-34d8-4cb8-a8f4-cb206cc1353d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72aae920-07f9-42fc-a043-4b99eab5f26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fae1a485-79d5-44cf-a8c9-fae0af1d6ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72aae920-07f9-42fc-a043-4b99eab5f26b" xlink:to="loc_us-gaap_LossContingenciesTable_fae1a485-79d5-44cf-a8c9-fae0af1d6ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5f85f36f-1f71-4076-ab80-95b537fa1db8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fae1a485-79d5-44cf-a8c9-fae0af1d6ec8" xlink:to="loc_srt_LitigationCaseAxis_5f85f36f-1f71-4076-ab80-95b537fa1db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_99068119-c23b-4cd2-b107-38394205515e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_5f85f36f-1f71-4076-ab80-95b537fa1db8" xlink:to="loc_srt_LitigationCaseTypeDomain_99068119-c23b-4cd2-b107-38394205515e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember_882c3374-19b3-4f67-834d-1a9aa3cd5a91" xlink:href="sesn-20221231.xsd#sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_99068119-c23b-4cd2-b107-38394205515e" xlink:to="loc_sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember_882c3374-19b3-4f67-834d-1a9aa3cd5a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FederalDerivativeLitigationMember_0db65d80-8e2f-4350-b926-1203565db9e1" xlink:href="sesn-20221231.xsd#sesn_FederalDerivativeLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_99068119-c23b-4cd2-b107-38394205515e" xlink:to="loc_sesn_FederalDerivativeLitigationMember_0db65d80-8e2f-4350-b926-1203565db9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fae1a485-79d5-44cf-a8c9-fae0af1d6ec8" xlink:to="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfLawsuits_a4e35932-edaf-4c14-8b8f-b193b82f52e5" xlink:href="sesn-20221231.xsd#sesn_NumberOfLawsuits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:to="loc_sesn_NumberOfLawsuits_a4e35932-edaf-4c14-8b8f-b193b82f52e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_d7317550-fe9a-4b16-a6af-526f6942757a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:to="loc_us-gaap_LitigationReserve_d7317550-fe9a-4b16-a6af-526f6942757a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_d9e68177-3a00-4b0c-a56c-43273c84e6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:to="loc_us-gaap_RestrictedCashCurrent_d9e68177-3a00-4b0c-a56c-43273c84e6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_4db9a3da-5122-4f5e-ab9c-60d45a628658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4f40ba08-504d-40e3-9724-68774d026ba7" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_4db9a3da-5122-4f5e-ab9c-60d45a628658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_00af0607-72d8-402c-bacb-af5b93a1af51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d88df94e-48ed-430c-a3b1-5beef1c9223e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_00af0607-72d8-402c-bacb-af5b93a1af51" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d88df94e-48ed-430c-a3b1-5beef1c9223e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2f11147a-4f75-4edb-98da-016753d6e193" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d88df94e-48ed-430c-a3b1-5beef1c9223e" xlink:to="loc_srt_StatementGeographicalAxis_2f11147a-4f75-4edb-98da-016753d6e193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6c8d5de7-f15d-4202-86e2-4be239934020" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2f11147a-4f75-4edb-98da-016753d6e193" xlink:to="loc_srt_SegmentGeographicalDomain_6c8d5de7-f15d-4202-86e2-4be239934020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_50dd1fb3-76c8-456e-b235-50776dafa4d5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6c8d5de7-f15d-4202-86e2-4be239934020" xlink:to="loc_country_CA_50dd1fb3-76c8-456e-b235-50776dafa4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_4508e6e0-18b8-451e-a0e9-172a65f45193" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6c8d5de7-f15d-4202-86e2-4be239934020" xlink:to="loc_stpr_MA_4508e6e0-18b8-451e-a0e9-172a65f45193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_e4940d6f-d9ed-4e4d-8f64-0ecbb8688da2" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6c8d5de7-f15d-4202-86e2-4be239934020" xlink:to="loc_stpr_PA_e4940d6f-d9ed-4e4d-8f64-0ecbb8688da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d88df94e-48ed-430c-a3b1-5beef1c9223e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_8c0296d9-14f6-490d-91b3-2f58c7775760" xlink:href="sesn-20221231.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_8c0296d9-14f6-490d-91b3-2f58c7775760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseLeaseTerminationPayment_cea9ce3a-e8b8-42ab-8e92-559d00c9c380" xlink:href="sesn-20221231.xsd#sesn_OperatingLeaseLeaseTerminationPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_sesn_OperatingLeaseLeaseTerminationPayment_cea9ce3a-e8b8-42ab-8e92-559d00c9c380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_949ebcda-66a8-42bf-813b-997d93fc1983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_ShortTermLeaseCost_949ebcda-66a8-42bf-813b-997d93fc1983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f5c76d0c-1953-414e-988d-9ff963400520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_OperatingLeaseCost_f5c76d0c-1953-414e-988d-9ff963400520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed6dac9a-4354-41c1-a389-444e37d584da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed6dac9a-4354-41c1-a389-444e37d584da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_74e5fba2-28d9-47a6-b717-5496e3285086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_74e5fba2-28d9-47a6-b717-5496e3285086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bcb51cc3-50f3-424d-a1ac-89a2f2d4ad2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bcb51cc3-50f3-424d-a1ac-89a2f2d4ad2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_9881db14-b4e1-4905-a9c2-e8d213b68414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_9881db14-b4e1-4905-a9c2-e8d213b68414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_9995fc0d-aa21-4c95-b5c8-0251ed814706" xlink:href="sesn-20221231.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2f18b09f-a670-4aa3-89c5-6bfc55069d9a" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_9995fc0d-aa21-4c95-b5c8-0251ed814706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESLeaseCostsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#LEASESLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASESLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_659d6fc0-360b-4285-be17-6b625bbfe190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_f8f0b2f8-a1d0-4d92-a81c-10fa00dc25ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_659d6fc0-360b-4285-be17-6b625bbfe190" xlink:to="loc_us-gaap_LeaseCostAbstract_f8f0b2f8-a1d0-4d92-a81c-10fa00dc25ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3092ba40-77d7-4a2c-a280-5c40e02bd1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_f8f0b2f8-a1d0-4d92-a81c-10fa00dc25ef" xlink:to="loc_us-gaap_OperatingLeaseCost_3092ba40-77d7-4a2c-a280-5c40e02bd1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_71bd395e-4d08-410e-a7c7-cff96f93df04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_f8f0b2f8-a1d0-4d92-a81c-10fa00dc25ef" xlink:to="loc_us-gaap_ShortTermLeaseCost_71bd395e-4d08-410e-a7c7-cff96f93df04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_e7c04f71-cd51-48b0-bc74-0485f700b836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_f8f0b2f8-a1d0-4d92-a81c-10fa00dc25ef" xlink:to="loc_us-gaap_LeaseCost_e7c04f71-cd51-48b0-bc74-0485f700b836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SupplementalLeaseInformationAbstract_4b392cea-ec60-4034-b494-02379715fd46" xlink:href="sesn-20221231.xsd#sesn_SupplementalLeaseInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_659d6fc0-360b-4285-be17-6b625bbfe190" xlink:to="loc_sesn_SupplementalLeaseInformationAbstract_4b392cea-ec60-4034-b494-02379715fd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f8220661-1d3f-4e52-bac6-dfe184add254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SupplementalLeaseInformationAbstract_4b392cea-ec60-4034-b494-02379715fd46" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f8220661-1d3f-4e52-bac6-dfe184add254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_40a78db2-eb06-4835-9ee9-38e5415c57dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SupplementalLeaseInformationAbstract_4b392cea-ec60-4034-b494-02379715fd46" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_40a78db2-eb06-4835-9ee9-38e5415c57dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_85915327-f3be-400f-a90e-b02b795fbd95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_56f233d4-ecfa-4e54-ac00-a53a5efbb8db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_85915327-f3be-400f-a90e-b02b795fbd95" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_56f233d4-ecfa-4e54-ac00-a53a5efbb8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0ce66004-3f68-4bbe-ad13-c78c0ca9a4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_56f233d4-ecfa-4e54-ac00-a53a5efbb8db" xlink:to="loc_us-gaap_CreditFacilityAxis_0ce66004-3f68-4bbe-ad13-c78c0ca9a4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1d38d62c-896f-4cef-8e65-05970eeb26e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_0ce66004-3f68-4bbe-ad13-c78c0ca9a4cf" xlink:to="loc_us-gaap_CreditFacilityDomain_1d38d62c-896f-4cef-8e65-05970eeb26e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_d1fae4ef-1aed-4548-be73-f32363649b89" xlink:href="sesn-20221231.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1d38d62c-896f-4cef-8e65-05970eeb26e8" xlink:to="loc_sesn_ATMFacilityMember_d1fae4ef-1aed-4548-be73-f32363649b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_56f233d4-ecfa-4e54-ac00-a53a5efbb8db" xlink:to="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_efae2e91-6e11-428e-9fda-5393912bd8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_efae2e91-6e11-428e-9fda-5393912bd8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_d4f6bf68-59c3-445c-9263-217511f49882" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockAdditionalSharesAuthorizedForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_SaleOfStockAdditionalSharesAuthorizedForSale_d4f6bf68-59c3-445c-9263-217511f49882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_05b9a055-a7f1-42c7-a37c-e4531d1c6332" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_05b9a055-a7f1-42c7-a37c-e4531d1c6332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_f035d7d1-bb7d-4988-9089-f526fabf1d67" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_f035d7d1-bb7d-4988-9089-f526fabf1d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aefc1626-1211-4026-b378-4043c55ecb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aefc1626-1211-4026-b378-4043c55ecb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f5d593ca-08d3-4682-b63d-a5d0d34e25b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f5d593ca-08d3-4682-b63d-a5d0d34e25b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_a81f4d94-94ea-4c86-b10c-d1963479b99f" xlink:href="sesn-20221231.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_a81f4d94-94ea-4c86-b10c-d1963479b99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_0d062752-b256-4525-a46d-3c69fa85b241" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_0d062752-b256-4525-a46d-3c69fa85b241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c9f611cf-99f7-4cc5-967c-8b7a0163645f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c9f611cf-99f7-4cc5-967c-8b7a0163645f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare_fa95f1b6-6fca-4062-b2c7-07f8a2089ae4" xlink:href="sesn-20221231.xsd#sesn_CommonStockAndWarrantOrRightsPricePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_sesn_CommonStockAndWarrantOrRightsPricePerShare_fa95f1b6-6fca-4062-b2c7-07f8a2089ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c4eb509b-602f-4fb8-b8bb-368c9f5b318f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c4eb509b-602f-4fb8-b8bb-368c9f5b318f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2a8826bd-01a6-4c94-846f-4400b62e2d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6471b15-6e64-4069-8d71-f6029f9d7001" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2a8826bd-01a6-4c94-846f-4400b62e2d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e59a1106-69fc-4aa3-8190-84871a6b26ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a2f744b4-9008-4e30-a1d1-cbe0d86e3f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e59a1106-69fc-4aa3-8190-84871a6b26ee" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a2f744b4-9008-4e30-a1d1-cbe0d86e3f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e9102dca-c05a-4d25-b591-fc5a26ce14b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e59a1106-69fc-4aa3-8190-84871a6b26ee" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e9102dca-c05a-4d25-b591-fc5a26ce14b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_09212c62-5496-4c00-ae94-b3da16aab335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e59a1106-69fc-4aa3-8190-84871a6b26ee" xlink:to="loc_us-gaap_PreferredStockSharesIssued_09212c62-5496-4c00-ae94-b3da16aab335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c4d5ada6-a2a9-4bd0-8fc9-217a9a36a48a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e59a1106-69fc-4aa3-8190-84871a6b26ee" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c4d5ada6-a2a9-4bd0-8fc9-217a9a36a48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0c503d94-2e4a-437f-bb17-40698838d83f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_97ecaedc-55b3-4644-b84b-f0a03fa08bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0c503d94-2e4a-437f-bb17-40698838d83f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_97ecaedc-55b3-4644-b84b-f0a03fa08bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_26719165-3db8-45df-af4f-7c3a7edaa0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_97ecaedc-55b3-4644-b84b-f0a03fa08bd0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_26719165-3db8-45df-af4f-7c3a7edaa0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30f3db24-8715-4dd3-822e-de7d35590554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_26719165-3db8-45df-af4f-7c3a7edaa0aa" xlink:to="loc_us-gaap_EquityComponentDomain_30f3db24-8715-4dd3-822e-de7d35590554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_097b0cfd-657c-4efb-b649-df89ba6ab95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_30f3db24-8715-4dd3-822e-de7d35590554" xlink:to="loc_us-gaap_CommonStockMember_097b0cfd-657c-4efb-b649-df89ba6ab95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_97ecaedc-55b3-4644-b84b-f0a03fa08bd0" xlink:to="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_40a354c7-dad8-4f54-aed6-a34f08668b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_40a354c7-dad8-4f54-aed6-a34f08668b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4d47a254-255b-435e-b31c-c09401c1ad42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:to="loc_us-gaap_CommonStockSharesIssued_4d47a254-255b-435e-b31c-c09401c1ad42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_60159e06-a695-4ebd-8c76-5d26ea083f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_60159e06-a695-4ebd-8c76-5d26ea083f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare_6efd1dd8-b690-41da-b99d-86a7ac61608a" xlink:href="sesn-20221231.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4e1abac-f40d-4a89-b67f-4bd8d0f51fbc" xlink:to="loc_sesn_NumberofVotesEntitledForEachShare_6efd1dd8-b690-41da-b99d-86a7ac61608a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_240a25dc-c10b-45ea-9cde-b8a52239cbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e9e87a40-3e13-4d10-9293-8d5268046c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_240a25dc-c10b-45ea-9cde-b8a52239cbcf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e9e87a40-3e13-4d10-9293-8d5268046c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_402d67dd-8601-488f-b744-b44a980550df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e9e87a40-3e13-4d10-9293-8d5268046c30" xlink:to="loc_us-gaap_AwardTypeAxis_402d67dd-8601-488f-b744-b44a980550df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_402d67dd-8601-488f-b744-b44a980550df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_d96fb30b-1972-44ed-8eb0-c1f1e6da6547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:to="loc_us-gaap_WarrantMember_d96fb30b-1972-44ed-8eb0-c1f1e6da6547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0ea432c4-ed8c-402f-821a-8b0e3fb0e805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0ea432c4-ed8c-402f-821a-8b0e3fb0e805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0dd527af-5b4d-4dfc-96a5-bab1e4e07533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0dd527af-5b4d-4dfc-96a5-bab1e4e07533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9b58dfbb-50a2-4390-a123-eed1caaca4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:to="loc_us-gaap_StockCompensationPlanMember_9b58dfbb-50a2-4390-a123-eed1caaca4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_12c2c30a-5b8b-498b-b024-b7708fb73a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaa0657-7ce2-4ddb-81a3-ca10b77e9a79" xlink:to="loc_us-gaap_EmployeeStockMember_12c2c30a-5b8b-498b-b024-b7708fb73a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e6d596d-74c6-4ac9-963a-c151edb86be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e9e87a40-3e13-4d10-9293-8d5268046c30" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e6d596d-74c6-4ac9-963a-c151edb86be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4f42aad5-d5d5-4e26-9498-2b15d91b4082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e6d596d-74c6-4ac9-963a-c151edb86be2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4f42aad5-d5d5-4e26-9498-2b15d91b4082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ccc28ff0-7f46-41f0-97ce-54e5f1e60056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4f42aad5-d5d5-4e26-9498-2b15d91b4082" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ccc28ff0-7f46-41f0-97ce-54e5f1e60056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5c1cb39-ec33-4108-8def-6b137a0df217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e9e87a40-3e13-4d10-9293-8d5268046c30" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5c1cb39-ec33-4108-8def-6b137a0df217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3607a630-981b-4dc2-a02e-39e009261f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5c1cb39-ec33-4108-8def-6b137a0df217" xlink:to="loc_us-gaap_CommonStockSharesIssued_3607a630-981b-4dc2-a02e-39e009261f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_527134ad-fefb-4b0a-a044-5d053f0a5622" xlink:href="sesn-20221231.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5c1cb39-ec33-4108-8def-6b137a0df217" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_527134ad-fefb-4b0a-a044-5d053f0a5622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d7be97c3-c197-4a95-a4ac-ce3924ae63ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_527134ad-fefb-4b0a-a044-5d053f0a5622" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d7be97c3-c197-4a95-a4ac-ce3924ae63ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_29c8f762-ad52-4cef-9cdf-2c34bfe8309c" xlink:href="sesn-20221231.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_527134ad-fefb-4b0a-a044-5d053f0a5622" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_29c8f762-ad52-4cef-9cdf-2c34bfe8309c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_27d1aa63-ffd4-4a4e-a21a-9bf51f698786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_c82cae9b-1b94-4c7d-8a66-4d636dbf76d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27d1aa63-ffd4-4a4e-a21a-9bf51f698786" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_c82cae9b-1b94-4c7d-8a66-4d636dbf76d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_19962c56-f77f-447e-b2db-bcf3e7dd7955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_c82cae9b-1b94-4c7d-8a66-4d636dbf76d1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_19962c56-f77f-447e-b2db-bcf3e7dd7955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_19962c56-f77f-447e-b2db-bcf3e7dd7955" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_ee07d9ca-f7d2-494d-ae9c-8a69a00379d5" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_ee07d9ca-f7d2-494d-ae9c-8a69a00379d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_8134b159-1c32-46cc-92d7-1c67ea77d96b" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_8134b159-1c32-46cc-92d7-1c67ea77d96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_3e4f93a1-aa8f-4332-8abc-84dcfd3a22e4" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_3e4f93a1-aa8f-4332-8abc-84dcfd3a22e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_37b9600f-0c99-4be7-aacb-51e248b69eb2" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eefd51f2-bdf6-4114-95e7-be8f425e5761" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_37b9600f-0c99-4be7-aacb-51e248b69eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_a391fdad-c337-4493-a3c8-29e4c3fca360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_c82cae9b-1b94-4c7d-8a66-4d636dbf76d1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_a391fdad-c337-4493-a3c8-29e4c3fca360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_91a0df07-139a-44e3-bea4-4973a44f2d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a391fdad-c337-4493-a3c8-29e4c3fca360" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_91a0df07-139a-44e3-bea4-4973a44f2d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:href="sesn-20221231.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a391fdad-c337-4493-a3c8-29e4c3fca360" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9219b791-f993-4140-8c6d-219cc82cd62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9219b791-f993-4140-8c6d-219cc82cd62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_f9691bc2-6440-49d4-9586-3eaa113a5b35" xlink:href="sesn-20221231.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_f9691bc2-6440-49d4-9586-3eaa113a5b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_84248d6a-5c11-4165-a594-f40a50320814" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_84248d6a-5c11-4165-a594-f40a50320814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_cd542126-4e19-474b-9af2-4648ae9fb021" xlink:href="sesn-20221231.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_cd542126-4e19-474b-9af2-4648ae9fb021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_96f92c0e-c4e1-476c-a950-73cf1094c5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_8c65befd-eac0-419b-83f4-e82cf798c22a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_96f92c0e-c4e1-476c-a950-73cf1094c5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5d112e7b-ad40-4f65-8f0f-645cf509cd95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e24dc31a-6669-42e4-8c34-97f1f3822d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5d112e7b-ad40-4f65-8f0f-645cf509cd95" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e24dc31a-6669-42e4-8c34-97f1f3822d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d15cb5b8-bc21-42c1-9ffe-325327bb503d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e24dc31a-6669-42e4-8c34-97f1f3822d32" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d15cb5b8-bc21-42c1-9ffe-325327bb503d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4e7382e5-9942-4c5c-8f92-517d21195ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d15cb5b8-bc21-42c1-9ffe-325327bb503d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4e7382e5-9942-4c5c-8f92-517d21195ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_964d4e8a-9c40-4e99-91cc-1c8c6951e79a" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4e7382e5-9942-4c5c-8f92-517d21195ca3" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_964d4e8a-9c40-4e99-91cc-1c8c6951e79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_9e43deed-4c02-4dd5-8236-4188fc7be16a" xlink:href="sesn-20221231.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4e7382e5-9942-4c5c-8f92-517d21195ca3" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_9e43deed-4c02-4dd5-8236-4188fc7be16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_451262d4-3ff6-4072-b0bd-d993f6bae55a" xlink:href="sesn-20221231.xsd#sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4e7382e5-9942-4c5c-8f92-517d21195ca3" xlink:to="loc_sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember_451262d4-3ff6-4072-b0bd-d993f6bae55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bf7d66c6-ed76-49a9-bb90-e55e997d0192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e24dc31a-6669-42e4-8c34-97f1f3822d32" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bf7d66c6-ed76-49a9-bb90-e55e997d0192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4fd4759f-3471-4d88-b981-c5b25f2f16f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bf7d66c6-ed76-49a9-bb90-e55e997d0192" xlink:to="loc_us-gaap_EquityComponentDomain_4fd4759f-3471-4d88-b981-c5b25f2f16f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a8796763-75be-4495-aeb3-3969d43d7d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4fd4759f-3471-4d88-b981-c5b25f2f16f4" xlink:to="loc_us-gaap_CommonStockMember_a8796763-75be-4495-aeb3-3969d43d7d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e24dc31a-6669-42e4-8c34-97f1f3822d32" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6ad20a02-f0ee-46dd-b4b3-c1fa6a77fa93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6ad20a02-f0ee-46dd-b4b3-c1fa6a77fa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c726e3ec-dcac-424c-82cc-25ae1b673346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c726e3ec-dcac-424c-82cc-25ae1b673346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_b5c7e026-c814-4cdc-a74a-c7fefe5a0c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_b5c7e026-c814-4cdc-a74a-c7fefe5a0c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_c3847112-f449-48ce-b1fe-5aa56d131080" xlink:href="sesn-20221231.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_c3847112-f449-48ce-b1fe-5aa56d131080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherDividendAndAdjustments_4848f88d-a6ef-4f93-bc99-f223d2f24a1b" xlink:href="sesn-20221231.xsd#sesn_OtherDividendAndAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_sesn_OtherDividendAndAdjustments_4848f88d-a6ef-4f93-bc99-f223d2f24a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_7ec5be65-96eb-4725-b3d3-0a32828a06f1" xlink:href="sesn-20221231.xsd#sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_056e8604-0e39-44af-ac69-2ccfdf932cbd" xlink:to="loc_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued_7ec5be65-96eb-4725-b3d3-0a32828a06f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7486ee88-d446-4c34-ace1-1f24f9eece44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d159e07-1b38-480f-82c0-d2ffaac89200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7486ee88-d446-4c34-ace1-1f24f9eece44" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d159e07-1b38-480f-82c0-d2ffaac89200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_31b8762a-d1e6-4736-87cc-91449c90e177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d159e07-1b38-480f-82c0-d2ffaac89200" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_31b8762a-d1e6-4736-87cc-91449c90e177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0790fdd1-c909-47b9-a1f3-05e306fad23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_31b8762a-d1e6-4736-87cc-91449c90e177" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0790fdd1-c909-47b9-a1f3-05e306fad23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6697bf6f-4e73-4525-ba31-db6884225d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0790fdd1-c909-47b9-a1f3-05e306fad23e" xlink:to="loc_us-gaap_WarrantMember_6697bf6f-4e73-4525-ba31-db6884225d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_04b20aad-b51c-4d6e-8af3-9ebe48952a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0790fdd1-c909-47b9-a1f3-05e306fad23e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_04b20aad-b51c-4d6e-8af3-9ebe48952a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember_5aaf016f-7f11-42a0-9927-eead36fd3a35" xlink:href="sesn-20221231.xsd#sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0790fdd1-c909-47b9-a1f3-05e306fad23e" xlink:to="loc_sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember_5aaf016f-7f11-42a0-9927-eead36fd3a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6328811-5aa6-4e74-929d-2a6c678250c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d159e07-1b38-480f-82c0-d2ffaac89200" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6328811-5aa6-4e74-929d-2a6c678250c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47113576-5264-41c6-9e67-edd2e3928810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6328811-5aa6-4e74-929d-2a6c678250c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47113576-5264-41c6-9e67-edd2e3928810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0645d5da-ce54-464e-b21d-59fcc4d69cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67d92f8c-c21e-4375-95fe-95b1202345b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0645d5da-ce54-464e-b21d-59fcc4d69cd5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67d92f8c-c21e-4375-95fe-95b1202345b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2951c474-505f-4453-9ac7-a09e7fc7266f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67d92f8c-c21e-4375-95fe-95b1202345b7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2951c474-505f-4453-9ac7-a09e7fc7266f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5b12c4c9-d013-4c41-a699-f35231e8be9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2951c474-505f-4453-9ac7-a09e7fc7266f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5b12c4c9-d013-4c41-a699-f35231e8be9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4417cf9f-4682-4a00-923d-a6a3d2bb9b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5b12c4c9-d013-4c41-a699-f35231e8be9e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4417cf9f-4682-4a00-923d-a6a3d2bb9b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_90b38dbc-3bda-4e11-ae65-88cc857dac68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5b12c4c9-d013-4c41-a699-f35231e8be9e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_90b38dbc-3bda-4e11-ae65-88cc857dac68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c183c623-67f8-47a1-a032-b75c319cd81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67d92f8c-c21e-4375-95fe-95b1202345b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c183c623-67f8-47a1-a032-b75c319cd81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc5407f6-56a3-419d-89d2-87ef35ea7f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c183c623-67f8-47a1-a032-b75c319cd81c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc5407f6-56a3-419d-89d2-87ef35ea7f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bc280ad-519c-4dd4-992d-48c09de120e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bc280ad-519c-4dd4-992d-48c09de120e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_bf3cb2a1-9e24-4943-a6c1-cc8d18f21f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:to="loc_us-gaap_VestingAxis_bf3cb2a1-9e24-4943-a6c1-cc8d18f21f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_4444ff92-91f4-485b-8a71-f76ca67b8941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_bf3cb2a1-9e24-4943-a6c1-cc8d18f21f10" xlink:to="loc_us-gaap_VestingDomain_4444ff92-91f4-485b-8a71-f76ca67b8941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4a5018d7-7bec-482f-95b5-97565aeec228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_4444ff92-91f4-485b-8a71-f76ca67b8941" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4a5018d7-7bec-482f-95b5-97565aeec228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b1b2b5dc-1ea3-4a87-9455-7b6a56bce4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_4444ff92-91f4-485b-8a71-f76ca67b8941" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b1b2b5dc-1ea3-4a87-9455-7b6a56bce4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_dbe9d979-6e66-4856-ba47-78a3b7c901d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:to="loc_us-gaap_PlanNameAxis_dbe9d979-6e66-4856-ba47-78a3b7c901d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_47a09247-c995-44a9-b8ce-40fa2a9eebbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_dbe9d979-6e66-4856-ba47-78a3b7c901d5" xlink:to="loc_us-gaap_PlanNameDomain_47a09247-c995-44a9-b8ce-40fa2a9eebbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_17fb153f-918d-40f4-8ea3-2f81ca15e2ac" xlink:href="sesn-20221231.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_47a09247-c995-44a9-b8ce-40fa2a9eebbe" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_17fb153f-918d-40f4-8ea3-2f81ca15e2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember_ef4bb87d-db56-4ac9-ac9d-bc223a97243d" xlink:href="sesn-20221231.xsd#sesn_RetentionProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_47a09247-c995-44a9-b8ce-40fa2a9eebbe" xlink:to="loc_sesn_RetentionProgramMember_ef4bb87d-db56-4ac9-ac9d-bc223a97243d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramCashManagementMilestoneMember_9660f443-e358-4d51-bb59-d639c6d2dd69" xlink:href="sesn-20221231.xsd#sesn_RetentionProgramCashManagementMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_RetentionProgramMember_ef4bb87d-db56-4ac9-ac9d-bc223a97243d" xlink:to="loc_sesn_RetentionProgramCashManagementMilestoneMember_9660f443-e358-4d51-bb59-d639c6d2dd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_a98e8930-b374-4a5c-8b71-ec0c8e6d382c" xlink:href="sesn-20221231.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_47a09247-c995-44a9-b8ce-40fa2a9eebbe" xlink:to="loc_sesn_StockIncentivePlan2009Member_a98e8930-b374-4a5c-8b71-ec0c8e6d382c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_103ccc59-49b6-4417-9638-29bf054962e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:to="loc_us-gaap_AwardTypeAxis_103ccc59-49b6-4417-9638-29bf054962e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c6152bb-a918-4c47-ac59-0f82f4a5690b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_103ccc59-49b6-4417-9638-29bf054962e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c6152bb-a918-4c47-ac59-0f82f4a5690b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8429370c-3da9-486f-835e-5545b15a91bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c6152bb-a918-4c47-ac59-0f82f4a5690b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8429370c-3da9-486f-835e-5545b15a91bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aa66bb35-062a-4f9e-966b-743d34e4740c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c6152bb-a918-4c47-ac59-0f82f4a5690b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aa66bb35-062a-4f9e-966b-743d34e4740c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1efc5896-6edb-4273-aa64-d297780a8289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c6152bb-a918-4c47-ac59-0f82f4a5690b" xlink:to="loc_us-gaap_PerformanceSharesMember_1efc5896-6edb-4273-aa64-d297780a8289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_7ecb53ea-f53d-4dd7-b6d7-3d68da1dab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:to="loc_us-gaap_GranteeStatusAxis_7ecb53ea-f53d-4dd7-b6d7-3d68da1dab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_4ef23377-6522-46b9-9ca2-23b2c19b0ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_7ecb53ea-f53d-4dd7-b6d7-3d68da1dab1a" xlink:to="loc_us-gaap_GranteeStatusDomain_4ef23377-6522-46b9-9ca2-23b2c19b0ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_b402fb3e-6953-41a0-9a43-bba9da619e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_4ef23377-6522-46b9-9ca2-23b2c19b0ce2" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_b402fb3e-6953-41a0-9a43-bba9da619e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f3a1c6-ddaf-4cc2-ad93-8dab610140db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_8e0efab7-1de7-4d67-bbd4-1ab70df35df6" xlink:href="sesn-20221231.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_8e0efab7-1de7-4d67-bbd4-1ab70df35df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_80ce0790-3943-402a-b947-6c4a021d43db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_80ce0790-3943-402a-b947-6c4a021d43db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ff2dc793-2954-4848-8402-3df9cd0077d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ff2dc793-2954-4848-8402-3df9cd0077d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2f64d16b-add8-4474-a69c-cdcb36fe61c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2f64d16b-add8-4474-a69c-cdcb36fe61c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0a000abf-e19c-4cee-affb-e8d282697168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0a000abf-e19c-4cee-affb-e8d282697168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_143395fd-c456-479f-ba8b-253ff55f6931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_143395fd-c456-479f-ba8b-253ff55f6931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_803d448d-399c-45c8-a5f8-b7dd86d15e0e" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_803d448d-399c-45c8-a5f8-b7dd86d15e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c2d4286a-c3c5-4f61-a9a3-69fa8b2db448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c2d4286a-c3c5-4f61-a9a3-69fa8b2db448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_74049375-df45-4361-a68b-a60daf7a5246" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_74049375-df45-4361-a68b-a60daf7a5246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_56cd1bc3-f60c-4b78-9c98-bc331088874c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_56cd1bc3-f60c-4b78-9c98-bc331088874c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_34fa9234-3665-4b6e-90f6-6231a6b02ea5" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_34fa9234-3665-4b6e-90f6-6231a6b02ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_71fe1b35-74e4-4adf-b41b-d28aa23ef2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_71fe1b35-74e4-4adf-b41b-d28aa23ef2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_123d1da1-45af-4a05-8f18-a7e9336619a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_123d1da1-45af-4a05-8f18-a7e9336619a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10e5afb4-c2b3-4957-bde5-c33355313356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10e5afb4-c2b3-4957-bde5-c33355313356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_608a900d-b182-43bc-b87a-2f5e038e7162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_608a900d-b182-43bc-b87a-2f5e038e7162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_201963ba-d937-42e7-b572-6399ea7620b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cac3efb8-8bb9-413a-8978-0126e4f06c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_201963ba-d937-42e7-b572-6399ea7620b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14271d9b-5387-4d0e-ad81-5f1660365c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddbf405-1728-4fb8-a4c5-a4f4ec12aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14271d9b-5387-4d0e-ad81-5f1660365c82" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddbf405-1728-4fb8-a4c5-a4f4ec12aec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_098991f9-eedd-4dad-81b8-f62fba0ddad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddbf405-1728-4fb8-a4c5-a4f4ec12aec0" xlink:to="loc_us-gaap_AwardTypeAxis_098991f9-eedd-4dad-81b8-f62fba0ddad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33e23208-29db-41a7-abcf-093da62fbd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_098991f9-eedd-4dad-81b8-f62fba0ddad4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33e23208-29db-41a7-abcf-093da62fbd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fb694d44-b256-4c45-9bcd-9fbb496f6c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33e23208-29db-41a7-abcf-093da62fbd9d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fb694d44-b256-4c45-9bcd-9fbb496f6c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4b689a58-3477-4546-ba20-f597ace5c854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33e23208-29db-41a7-abcf-093da62fbd9d" xlink:to="loc_us-gaap_PerformanceSharesMember_4b689a58-3477-4546-ba20-f597ace5c854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9547fabc-71c9-4d25-a9be-39a591f92cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddbf405-1728-4fb8-a4c5-a4f4ec12aec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9547fabc-71c9-4d25-a9be-39a591f92cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9547fabc-71c9-4d25-a9be-39a591f92cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75b5a541-e519-4e43-9a38-5d8c9cb52898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75b5a541-e519-4e43-9a38-5d8c9cb52898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c50ad3d1-62ce-489e-bd9a-1bb37cda2e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c50ad3d1-62ce-489e-bd9a-1bb37cda2e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b0259eda-09fb-4e38-b244-d07b1337b4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b0259eda-09fb-4e38-b244-d07b1337b4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7c1089e1-f5bf-4033-83e3-fe33fb586dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7c1089e1-f5bf-4033-83e3-fe33fb586dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d8532ee-62a4-46b7-a6ad-543971536516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47766983-42c3-4e93-9946-0b1b90ca11cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d8532ee-62a4-46b7-a6ad-543971536516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0349f5b2-2fb0-4990-afb4-453d37300025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68b71e7f-59b5-44f6-bd80-528106355c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0349f5b2-2fb0-4990-afb4-453d37300025" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68b71e7f-59b5-44f6-bd80-528106355c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ee693a7e-22a4-4ee0-bd18-65bf9e63ff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68b71e7f-59b5-44f6-bd80-528106355c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ee693a7e-22a4-4ee0-bd18-65bf9e63ff0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d2689bf2-f14c-42e3-b3ed-b943cb5d6692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68b71e7f-59b5-44f6-bd80-528106355c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d2689bf2-f14c-42e3-b3ed-b943cb5d6692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a0b811f0-8515-4348-af12-b85e11e01ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68b71e7f-59b5-44f6-bd80-528106355c57" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a0b811f0-8515-4348-af12-b85e11e01ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d8c424e3-cdc4-4285-a995-93cea4dea44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68b71e7f-59b5-44f6-bd80-528106355c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d8c424e3-cdc4-4285-a995-93cea4dea44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e9fcf5c7-62a6-4356-8c60-a6d3ba42be43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68b71e7f-59b5-44f6-bd80-528106355c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e9fcf5c7-62a6-4356-8c60-a6d3ba42be43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d834f924-c2c5-400b-bc9a-a184d4f6ab28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0349f5b2-2fb0-4990-afb4-453d37300025" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d834f924-c2c5-400b-bc9a-a184d4f6ab28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aceef824-a5a7-467c-ac0f-7f4fc4c59239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0349f5b2-2fb0-4990-afb4-453d37300025" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aceef824-a5a7-467c-ac0f-7f4fc4c59239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d3a6c7a1-34ae-4b11-b7aa-4edd4c5064ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aceef824-a5a7-467c-ac0f-7f4fc4c59239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d3a6c7a1-34ae-4b11-b7aa-4edd4c5064ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1512089e-5c0d-4d69-998d-c075d66644d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aceef824-a5a7-467c-ac0f-7f4fc4c59239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1512089e-5c0d-4d69-998d-c075d66644d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6dd14b97-a2ca-4658-927b-a9d629870f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aceef824-a5a7-467c-ac0f-7f4fc4c59239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6dd14b97-a2ca-4658-927b-a9d629870f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_847062a0-9984-4fee-ad15-49d64c16da59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aceef824-a5a7-467c-ac0f-7f4fc4c59239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_847062a0-9984-4fee-ad15-49d64c16da59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e2f09f7-a763-4d7d-b589-9e4487cd742f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aceef824-a5a7-467c-ac0f-7f4fc4c59239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e2f09f7-a763-4d7d-b589-9e4487cd742f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2fe96dc4-3d33-4f48-8aa1-f836afeec37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0349f5b2-2fb0-4990-afb4-453d37300025" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2fe96dc4-3d33-4f48-8aa1-f836afeec37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d5324a2-52bd-43c2-84de-8f320a1c01b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0349f5b2-2fb0-4990-afb4-453d37300025" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d5324a2-52bd-43c2-84de-8f320a1c01b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_53887147-2ca9-4e9f-a742-5871871f6579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d5324a2-52bd-43c2-84de-8f320a1c01b8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_53887147-2ca9-4e9f-a742-5871871f6579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_52b89ab0-4cec-4edf-be62-b3a83159086e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d5324a2-52bd-43c2-84de-8f320a1c01b8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_52b89ab0-4cec-4edf-be62-b3a83159086e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4f8af3cb-7a83-4999-b26b-ce0c5c856cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0d5324a2-52bd-43c2-84de-8f320a1c01b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4f8af3cb-7a83-4999-b26b-ce0c5c856cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_029edc64-b1bd-4697-94c6-f73bd7d08bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f08f00-7922-48e8-b046-4533bc9365f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_029edc64-b1bd-4697-94c6-f73bd7d08bed" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f08f00-7922-48e8-b046-4533bc9365f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c9d36ec-a140-4d12-b233-97a3cb24be83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f08f00-7922-48e8-b046-4533bc9365f4" xlink:to="loc_us-gaap_AwardTypeAxis_7c9d36ec-a140-4d12-b233-97a3cb24be83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1d284c4-4436-4ab1-97c7-9cd935733011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7c9d36ec-a140-4d12-b233-97a3cb24be83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1d284c4-4436-4ab1-97c7-9cd935733011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7129037c-7a0b-4ae0-84bb-4e19a20a2bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1d284c4-4436-4ab1-97c7-9cd935733011" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7129037c-7a0b-4ae0-84bb-4e19a20a2bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88f08f00-7922-48e8-b046-4533bc9365f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_51b37194-c71a-4a5f-b522-d0876a34c64c" xlink:href="sesn-20221231.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_51b37194-c71a-4a5f-b522-d0876a34c64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_05cc6356-a687-421d-a495-b401d1443da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_05cc6356-a687-421d-a495-b401d1443da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_549ea0c1-dc0f-4106-a76b-ceb27043bd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_549ea0c1-dc0f-4106-a76b-ceb27043bd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_48cf78d0-2d8b-47df-8b0d-2b376e396f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_48cf78d0-2d8b-47df-8b0d-2b376e396f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5f14f770-b6f4-472f-b1cf-7e47ac6c8a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5f14f770-b6f4-472f-b1cf-7e47ac6c8a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bc8fac3d-a664-44f9-a535-0369492aae39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66a436f2-72a8-472d-8532-669ec0afc1ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bc8fac3d-a664-44f9-a535-0369492aae39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6275411d-fd39-4219-8376-d4da7b4461cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fe0b1685-05c6-45e1-b7d6-df916f848a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6275411d-fd39-4219-8376-d4da7b4461cd" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fe0b1685-05c6-45e1-b7d6-df916f848a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ef8ef262-8f1e-42d6-bbd9-1edd435dc36d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fe0b1685-05c6-45e1-b7d6-df916f848a47" xlink:to="loc_us-gaap_PlanNameAxis_ef8ef262-8f1e-42d6-bbd9-1edd435dc36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_da7f46ab-5a13-41b1-8d10-668ed942f8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ef8ef262-8f1e-42d6-bbd9-1edd435dc36d" xlink:to="loc_us-gaap_PlanNameDomain_da7f46ab-5a13-41b1-8d10-668ed942f8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_aaafdfcd-7fd7-4257-a4bf-a78733f78b09" xlink:href="sesn-20221231.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_da7f46ab-5a13-41b1-8d10-668ed942f8e4" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_aaafdfcd-7fd7-4257-a4bf-a78733f78b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f329d502-2286-4f0c-9edf-30c8f96d849c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fe0b1685-05c6-45e1-b7d6-df916f848a47" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f329d502-2286-4f0c-9edf-30c8f96d849c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5b8c0146-1460-4042-8608-0e2e89ad4cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f329d502-2286-4f0c-9edf-30c8f96d849c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5b8c0146-1460-4042-8608-0e2e89ad4cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f1786b7a-6b8e-45da-ba0f-1f93aca7455d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5b8c0146-1460-4042-8608-0e2e89ad4cb6" xlink:to="loc_us-gaap_DomesticPlanMember_f1786b7a-6b8e-45da-ba0f-1f93aca7455d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a523f8eb-6922-49fa-8f32-35096dbf902f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_f1786b7a-6b8e-45da-ba0f-1f93aca7455d" xlink:to="loc_country_US_a523f8eb-6922-49fa-8f32-35096dbf902f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_4b25ee5c-7844-4836-88e7-678201205e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5b8c0146-1460-4042-8608-0e2e89ad4cb6" xlink:to="loc_us-gaap_ForeignPlanMember_4b25ee5c-7844-4836-88e7-678201205e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_f9413b79-a237-4c7d-b3eb-56f30f9e60f8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_4b25ee5c-7844-4836-88e7-678201205e34" xlink:to="loc_country_CA_f9413b79-a237-4c7d-b3eb-56f30f9e60f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fe0b1685-05c6-45e1-b7d6-df916f848a47" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63394b28-c75e-45fc-b9ca-28f5844fe4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63394b28-c75e-45fc-b9ca-28f5844fe4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_95053cff-642d-41c6-b720-2a35bd60c6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_95053cff-642d-41c6-b720-2a35bd60c6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_4a373308-2b1d-41d4-9df8-2bb575e4bb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_4a373308-2b1d-41d4-9df8-2bb575e4bb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_03efe711-5d60-4a80-b687-2a5b441d3fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_03efe711-5d60-4a80-b687-2a5b441d3fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1bafe372-2e3b-4254-9f2d-244b19fbbead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1bafe372-2e3b-4254-9f2d-244b19fbbead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_5c44fe96-88df-496f-bf8f-4c0dc9274778" xlink:href="sesn-20221231.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_5c44fe96-88df-496f-bf8f-4c0dc9274778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_79701c46-c571-4e3a-8d2a-2e6832a033cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d52182fc-63ec-4552-8078-e95e094425a7" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_79701c46-c571-4e3a-8d2a-2e6832a033cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0441b175-4e34-4730-b7a9-f21a5e0f0ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_5790d61f-397f-4119-9427-235d127f040a" xlink:href="sesn-20221231.xsd#sesn_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0441b175-4e34-4730-b7a9-f21a5e0f0ed7" xlink:to="loc_sesn_IncomeTaxesTable_5790d61f-397f-4119-9427-235d127f040a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd23b15d-72e4-456b-8c1f-87e88436447a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_5790d61f-397f-4119-9427-235d127f040a" xlink:to="loc_srt_StatementGeographicalAxis_cd23b15d-72e4-456b-8c1f-87e88436447a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d7855d54-5cd6-4a48-bb61-22848d9545cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cd23b15d-72e4-456b-8c1f-87e88436447a" xlink:to="loc_srt_SegmentGeographicalDomain_d7855d54-5cd6-4a48-bb61-22848d9545cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0a45b3db-2669-488e-8dec-997dac25dea9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d7855d54-5cd6-4a48-bb61-22848d9545cf" xlink:to="loc_country_US_0a45b3db-2669-488e-8dec-997dac25dea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_ae5f3a17-6302-4103-ae25-1d2516f54a57" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d7855d54-5cd6-4a48-bb61-22848d9545cf" xlink:to="loc_country_CA_ae5f3a17-6302-4103-ae25-1d2516f54a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_7b8323f1-2346-4e58-abe2-231b51712c95" xlink:href="sesn-20221231.xsd#sesn_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_5790d61f-397f-4119-9427-235d127f040a" xlink:to="loc_sesn_IncomeTaxesLineItems_7b8323f1-2346-4e58-abe2-231b51712c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_484d802c-91ce-45d1-834d-1d811626f7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_7b8323f1-2346-4e58-abe2-231b51712c95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_484d802c-91ce-45d1-834d-1d811626f7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2fb7f915-9d64-4cbc-94c1-a6551374fbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_7b8323f1-2346-4e58-abe2-231b51712c95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2fb7f915-9d64-4cbc-94c1-a6551374fbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b832e224-f7f6-4cd5-831b-e67d5518bef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_7b8323f1-2346-4e58-abe2-231b51712c95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b832e224-f7f6-4cd5-831b-e67d5518bef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESComponentsofIncomeTaxProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_68a6032d-3542-4324-809d-90ae81d6d824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_c07093ae-4a8a-4a28-9e3f-6f6c5568a306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_68a6032d-3542-4324-809d-90ae81d6d824" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_c07093ae-4a8a-4a28-9e3f-6f6c5568a306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_106d58aa-7721-43da-b1a2-47904685acec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_c07093ae-4a8a-4a28-9e3f-6f6c5568a306" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_106d58aa-7721-43da-b1a2-47904685acec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ac7cdd1f-d791-4c5e-b46d-5d64234ee227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_c07093ae-4a8a-4a28-9e3f-6f6c5568a306" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ac7cdd1f-d791-4c5e-b46d-5d64234ee227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_fee4ef1c-306f-4c4f-9aab-ee16a0ae372e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_c07093ae-4a8a-4a28-9e3f-6f6c5568a306" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_fee4ef1c-306f-4c4f-9aab-ee16a0ae372e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f9fe3fe3-b710-4a14-8d21-e098a5dc0dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_c07093ae-4a8a-4a28-9e3f-6f6c5568a306" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f9fe3fe3-b710-4a14-8d21-e098a5dc0dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_078c0c76-a0ac-4c71-906c-972fe515cad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_68a6032d-3542-4324-809d-90ae81d6d824" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_078c0c76-a0ac-4c71-906c-972fe515cad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a529f436-9ad3-4bf6-a727-7adfae069792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_078c0c76-a0ac-4c71-906c-972fe515cad3" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a529f436-9ad3-4bf6-a727-7adfae069792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_09f23d9b-d3b0-4da6-8308-b64615b182f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_078c0c76-a0ac-4c71-906c-972fe515cad3" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_09f23d9b-d3b0-4da6-8308-b64615b182f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cd4e164f-5355-43da-9c09-f803d8914f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_078c0c76-a0ac-4c71-906c-972fe515cad3" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cd4e164f-5355-43da-9c09-f803d8914f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_83b7d8d5-f03b-4b9c-8b04-b498d6785fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_078c0c76-a0ac-4c71-906c-972fe515cad3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_83b7d8d5-f03b-4b9c-8b04-b498d6785fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dc05b1b8-9ddd-4dc6-a584-572ed4353ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_68a6032d-3542-4324-809d-90ae81d6d824" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dc05b1b8-9ddd-4dc6-a584-572ed4353ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_92170f8b-226a-41e7-8f2f-5bbb199a33d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_92170f8b-226a-41e7-8f2f-5bbb199a33d0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e2b93a44-ca4e-4af0-bb7e-9a9d92e81b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e2b93a44-ca4e-4af0-bb7e-9a9d92e81b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c55c172e-b553-499d-85df-1592936fb70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c55c172e-b553-499d-85df-1592936fb70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_42d15897-cb63-45f6-ad68-77e6feeff74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_42d15897-cb63-45f6-ad68-77e6feeff74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_03066095-8ab1-4f3b-983a-529174bc586d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_03066095-8ab1-4f3b-983a-529174bc586d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_0b3c6764-f2ea-4a8d-8526-5ef93233d589" xlink:href="sesn-20221231.xsd#sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_0b3c6764-f2ea-4a8d-8526-5ef93233d589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_fee76fc6-81a3-4a99-acbd-f3770dd1f8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_fee76fc6-81a3-4a99-acbd-f3770dd1f8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent_58d21df1-ca56-4e59-a2f2-cc599db81880" xlink:href="sesn-20221231.xsd#sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent_58d21df1-ca56-4e59-a2f2-cc599db81880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_7ca48bf8-1b4f-4421-b46b-e3cacee9c2dd" xlink:href="sesn-20221231.xsd#sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_7ca48bf8-1b4f-4421-b46b-e3cacee9c2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e195355d-44c0-4410-a3ca-e0beb062dca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e195355d-44c0-4410-a3ca-e0beb062dca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_178dc35b-364e-4d89-89d4-887300190f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_178dc35b-364e-4d89-89d4-887300190f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8559c493-805b-447a-9269-d3d75c48cc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8559c493-805b-447a-9269-d3d75c48cc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a7bce0cf-a9ac-423f-9579-d8151a074d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_29aaccc7-e928-4b8b-b32f-0bcb9abe7c7f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a7bce0cf-a9ac-423f-9579-d8151a074d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9e32db2c-465c-4cbf-9f41-b4e91cf5cd62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_66a04f34-4c74-4fa1-8880-c50904197126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9e32db2c-465c-4cbf-9f41-b4e91cf5cd62" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_66a04f34-4c74-4fa1-8880-c50904197126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_83c0fb2c-333f-4a5f-a195-a1311ad28431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_66a04f34-4c74-4fa1-8880-c50904197126" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_83c0fb2c-333f-4a5f-a195-a1311ad28431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b66971cb-a708-412c-b7dd-3f976500d24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_66a04f34-4c74-4fa1-8880-c50904197126" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b66971cb-a708-412c-b7dd-3f976500d24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment_4f9fc8b3-32da-491e-b275-9913c91de188" xlink:href="sesn-20221231.xsd#sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_66a04f34-4c74-4fa1-8880-c50904197126" xlink:to="loc_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment_4f9fc8b3-32da-491e-b275-9913c91de188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_dc866a3c-82e2-46ea-96ec-268190fcfa08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_66a04f34-4c74-4fa1-8880-c50904197126" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_dc866a3c-82e2-46ea-96ec-268190fcfa08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_b854e9b8-e43b-48e1-911f-05992aa00873" xlink:href="sesn-20221231.xsd#sesn_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_66a04f34-4c74-4fa1-8880-c50904197126" xlink:to="loc_sesn_DeferredTaxAssetsCapitalizedStartUpCosts_b854e9b8-e43b-48e1-911f-05992aa00873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ccba41ab-73f1-46d2-99c0-132ce36d11b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_66a04f34-4c74-4fa1-8880-c50904197126" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ccba41ab-73f1-46d2-99c0-132ce36d11b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e0d044c4-383b-42cc-8559-727793d96acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_66a04f34-4c74-4fa1-8880-c50904197126" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e0d044c4-383b-42cc-8559-727793d96acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dfec60c6-8505-4af0-bc22-935b96ee82fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9e32db2c-465c-4cbf-9f41-b4e91cf5cd62" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dfec60c6-8505-4af0-bc22-935b96ee82fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_311c9bd3-4f87-494e-9010-75c912f8bb16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dfec60c6-8505-4af0-bc22-935b96ee82fc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_311c9bd3-4f87-494e-9010-75c912f8bb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b3af7c27-91c9-4507-8b51-6bc76f7b0e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dfec60c6-8505-4af0-bc22-935b96ee82fc" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b3af7c27-91c9-4507-8b51-6bc76f7b0e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d780e188-6ab3-48a9-b6a2-99a6f5a8d383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dfec60c6-8505-4af0-bc22-935b96ee82fc" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d780e188-6ab3-48a9-b6a2-99a6f5a8d383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_e0a4d354-5f41-46db-975e-8e70ae46f2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_dfec60c6-8505-4af0-bc22-935b96ee82fc" xlink:to="loc_us-gaap_DeferredTaxLiabilities_e0a4d354-5f41-46db-975e-8e70ae46f2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2d174444-cbb7-42f7-acb8-114ca568820b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8af3c3ac-7cd1-44e1-b731-a44a9458c500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d174444-cbb7-42f7-acb8-114ca568820b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8af3c3ac-7cd1-44e1-b731-a44a9458c500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_79252bf7-cd44-4e2f-85eb-28150300023d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d174444-cbb7-42f7-acb8-114ca568820b" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_79252bf7-cd44-4e2f-85eb-28150300023d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLossCarryforwardsDecrease_ae336d99-f27a-4bcd-9bdd-c7709c104991" xlink:href="sesn-20221231.xsd#sesn_OperatingLossCarryforwardsDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d174444-cbb7-42f7-acb8-114ca568820b" xlink:to="loc_sesn_OperatingLossCarryforwardsDecrease_ae336d99-f27a-4bcd-9bdd-c7709c104991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#INCOMETAXESScheduleofCreditCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9e2a3562-f934-444b-a13d-656a09ddb47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:href="sesn-20221231.xsd#sesn_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9e2a3562-f934-444b-a13d-656a09ddb47a" xlink:to="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_e4cc9536-c947-4faa-bc3f-bd716be43382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_e4cc9536-c947-4faa-bc3f-bd716be43382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_87c039aa-d69b-40e6-a32b-4293cebba6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_e4cc9536-c947-4faa-bc3f-bd716be43382" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_87c039aa-d69b-40e6-a32b-4293cebba6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_06b75913-6b23-452d-afac-8963dcd150dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_87c039aa-d69b-40e6-a32b-4293cebba6ff" xlink:to="loc_us-gaap_ResearchMember_06b75913-6b23-452d-afac-8963dcd150dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NonCapitalLossCarryforwardMember_812b742a-91ef-446b-93d3-e0cff00de444" xlink:href="sesn-20221231.xsd#sesn_NonCapitalLossCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_87c039aa-d69b-40e6-a32b-4293cebba6ff" xlink:to="loc_sesn_NonCapitalLossCarryforwardMember_812b742a-91ef-446b-93d3-e0cff00de444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCreditMember_45198b13-faff-4f8d-bfcd-81dc61885109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_87c039aa-d69b-40e6-a32b-4293cebba6ff" xlink:to="loc_us-gaap_InvestmentCreditMember_45198b13-faff-4f8d-bfcd-81dc61885109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardAxis_a3c6be25-060d-484e-93a4-cce9be0f2f04" xlink:href="sesn-20221231.xsd#sesn_NetOperatingLossCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:to="loc_sesn_NetOperatingLossCarryforwardAxis_a3c6be25-060d-484e-93a4-cce9be0f2f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NetOperatingLossCarryforwardDomain_4aa3ec14-20a1-4847-9ad2-62915444504a" xlink:href="sesn-20221231.xsd#sesn_NetOperatingLossCarryforwardDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_NetOperatingLossCarryforwardAxis_a3c6be25-060d-484e-93a4-cce9be0f2f04" xlink:to="loc_sesn_NetOperatingLossCarryforwardDomain_4aa3ec14-20a1-4847-9ad2-62915444504a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IndefiniteMember_741af363-361c-4de2-8f7a-23d3533d50e1" xlink:href="sesn-20221231.xsd#sesn_IndefiniteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_NetOperatingLossCarryforwardDomain_4aa3ec14-20a1-4847-9ad2-62915444504a" xlink:to="loc_sesn_IndefiniteMember_741af363-361c-4de2-8f7a-23d3533d50e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f50c27fa-a07c-4e7c-b066-b234b1418999" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:to="loc_srt_StatementGeographicalAxis_f50c27fa-a07c-4e7c-b066-b234b1418999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d8a0610c-1731-4217-b1eb-640f33b02d4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f50c27fa-a07c-4e7c-b066-b234b1418999" xlink:to="loc_srt_SegmentGeographicalDomain_d8a0610c-1731-4217-b1eb-640f33b02d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6d189028-efdc-4a80-90b5-4c9da4952d6e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d8a0610c-1731-4217-b1eb-640f33b02d4b" xlink:to="loc_country_US_6d189028-efdc-4a80-90b5-4c9da4952d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_ae55cb2f-7998-42bc-94e9-65e48410a833" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d8a0610c-1731-4217-b1eb-640f33b02d4b" xlink:to="loc_country_CA_ae55cb2f-7998-42bc-94e9-65e48410a833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ba890a47-d9e9-4ea7-803c-e2f38727d636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ba890a47-d9e9-4ea7-803c-e2f38727d636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e4d7cc76-6cdf-4312-be7d-70d555661069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ba890a47-d9e9-4ea7-803c-e2f38727d636" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e4d7cc76-6cdf-4312-be7d-70d555661069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_1a5b982e-3908-4c90-97c0-51405f64f0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e4d7cc76-6cdf-4312-be7d-70d555661069" xlink:to="loc_us-gaap_DomesticCountryMember_1a5b982e-3908-4c90-97c0-51405f64f0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_294e5466-a5ca-449b-92e4-ae4fc6becf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e4d7cc76-6cdf-4312-be7d-70d555661069" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_294e5466-a5ca-449b-92e4-ae4fc6becf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_42e83966-44a4-4862-8096-aae96bdb0cbc" xlink:href="sesn-20221231.xsd#sesn_IncomeTaxesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_ec80b16e-7adf-4e69-b5a3-053813b9b5cc" xlink:to="loc_sesn_IncomeTaxesLineItems_42e83966-44a4-4862-8096-aae96bdb0cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2ee87cf8-8f55-4109-b918-04f61131fdcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_42e83966-44a4-4862-8096-aae96bdb0cbc" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2ee87cf8-8f55-4109-b918-04f61131fdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_31f2cd7a-3f28-4719-b778-cc44916c72c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_42e83966-44a4-4862-8096-aae96bdb0cbc" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_31f2cd7a-3f28-4719-b778-cc44916c72c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#LICENSEAGREEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_313130bb-c294-477b-8a32-e452e3e5b7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:href="sesn-20221231.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_313130bb-c294-477b-8a32-e452e3e5b7d7" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2eaecc6b-6484-410e-8f07-56f92659826d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_srt_CounterpartyNameAxis_2eaecc6b-6484-410e-8f07-56f92659826d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2eaecc6b-6484-410e-8f07-56f92659826d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_f7ef1304-21e2-46cf-b7bd-5058877543d1" xlink:href="sesn-20221231.xsd#sesn_UniversityOfZurichMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_UniversityOfZurichMember_f7ef1304-21e2-46cf-b7bd-5058877543d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_8e6b1a2f-48ad-44e8-bfd1-e5eb38df0de0" xlink:href="sesn-20221231.xsd#sesn_MicrometAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_MicrometAGMember_8e6b1a2f-48ad-44e8-bfd1-e5eb38df0de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_77bec1ed-e6bd-4a1d-a505-0d9cd233ba5f" xlink:href="sesn-20221231.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_XOMAIrelandLimitedMember_77bec1ed-e6bd-4a1d-a505-0d9cd233ba5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_efdd67d8-5109-466c-9948-cddf5faf0de3" xlink:href="sesn-20221231.xsd#sesn_RocheMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_RocheMember_efdd67d8-5109-466c-9948-cddf5faf0de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_5dffe208-2f89-42a9-8f1d-4d9d3a8e3dda" xlink:href="sesn-20221231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_5dffe208-2f89-42a9-8f1d-4d9d3a8e3dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_516aa04d-7a1e-452e-910f-3b08525b81cb" xlink:href="sesn-20221231.xsd#sesn_MENALicenseAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_MENALicenseAgreementMember_516aa04d-7a1e-452e-910f-3b08525b81cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_d937d4e7-3d63-4b17-939b-bf074c4bf92d" xlink:href="sesn-20221231.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6690de1-e56a-48c8-8725-4ad629ad93e1" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_d937d4e7-3d63-4b17-939b-bf074c4bf92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b0bd7297-a3a2-490d-a158-4b6fcd9bd707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b0bd7297-a3a2-490d-a158-4b6fcd9bd707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fcf0005-90e1-4193-9cd2-00f5d6755d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b0bd7297-a3a2-490d-a158-4b6fcd9bd707" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fcf0005-90e1-4193-9cd2-00f5d6755d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_f3d78acb-a035-4d89-bca5-44abe2bd345e" xlink:href="sesn-20221231.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fcf0005-90e1-4193-9cd2-00f5d6755d3e" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_f3d78acb-a035-4d89-bca5-44abe2bd345e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad9d4e25-af06-4e13-8e03-8558b2266ee2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_srt_ProductOrServiceAxis_ad9d4e25-af06-4e13-8e03-8558b2266ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73c614e5-c5d8-4d5a-9585-4c879eaa71c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ad9d4e25-af06-4e13-8e03-8558b2266ee2" xlink:to="loc_srt_ProductsAndServicesDomain_73c614e5-c5d8-4d5a-9585-4c879eaa71c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_29a8602b-756d-4fa8-a1fe-a000e26df420" xlink:href="sesn-20221231.xsd#sesn_EBI031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73c614e5-c5d8-4d5a-9585-4c879eaa71c8" xlink:to="loc_sesn_EBI031Member_29a8602b-756d-4fa8-a1fe-a000e26df420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ad92725d-5e38-4ac5-b336-640440929977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ad92725d-5e38-4ac5-b336-640440929977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc46b6b3-4839-44f6-aead-c2b8860c9f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ad92725d-5e38-4ac5-b336-640440929977" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc46b6b3-4839-44f6-aead-c2b8860c9f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_c68e7590-bb23-445c-921d-2388f7d50bc9" xlink:href="sesn-20221231.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc46b6b3-4839-44f6-aead-c2b8860c9f9b" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_c68e7590-bb23-445c-921d-2388f7d50bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c4164f4c-2964-46d3-b0b1-abfa02fcf4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c4164f4c-2964-46d3-b0b1-abfa02fcf4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b14749d7-0139-4efa-b485-cf0bc10927a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c4164f4c-2964-46d3-b0b1-abfa02fcf4e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b14749d7-0139-4efa-b485-cf0bc10927a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_8ba9b43c-06c6-459a-9468-4a411f8fa00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b14749d7-0139-4efa-b485-cf0bc10927a8" xlink:to="loc_us-gaap_LicensingAgreementsMember_8ba9b43c-06c6-459a-9468-4a411f8fa00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8a0213c5-7acd-41de-8fa2-25f4516d60e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_srt_StatementGeographicalAxis_8a0213c5-7acd-41de-8fa2-25f4516d60e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d9ad1220-8d5d-48e4-9c31-3543ea2aec7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8a0213c5-7acd-41de-8fa2-25f4516d60e5" xlink:to="loc_srt_SegmentGeographicalDomain_d9ad1220-8d5d-48e4-9c31-3543ea2aec7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_c3229502-be63-43ec-9374-08f255dba32c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d9ad1220-8d5d-48e4-9c31-3543ea2aec7d" xlink:to="loc_country_TR_c3229502-be63-43ec-9374-08f255dba32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:href="sesn-20221231.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_8eef1c81-5986-4ea0-ba0e-431321302e04" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_78d41f03-593e-4e8b-8132-b479deb987ff" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_78d41f03-593e-4e8b-8132-b479deb987ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_8e3f3787-81e6-4478-8019-c5730102f701" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_8e3f3787-81e6-4478-8019-c5730102f701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_6a437beb-bdc0-4710-949d-5c4730e42dc4" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_6a437beb-bdc0-4710-949d-5c4730e42dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_e3c9ea88-8917-43e7-8de4-9c838dec4059" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_e3c9ea88-8917-43e7-8de4-9c838dec4059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_1d442a81-b2a0-4111-a5b7-eaad0bfb4681" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_1d442a81-b2a0-4111-a5b7-eaad0bfb4681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_5fcdd50e-eade-4a41-ba7c-88d09aa86268" xlink:href="sesn-20221231.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_5fcdd50e-eade-4a41-ba7c-88d09aa86268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_6afb211c-1651-410b-82bf-c4e8f44eb522" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_6afb211c-1651-410b-82bf-c4e8f44eb522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_e835f405-e838-42df-a777-69426d27f105" xlink:href="sesn-20221231.xsd#sesn_LicenseMaintenanceFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseMaintenanceFees_e835f405-e838-42df-a777-69426d27f105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement_0fa3084e-62a8-40ee-b5b9-d773ab1709a2" xlink:href="sesn-20221231.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_OtherReceivableAssetPurchaseAgreement_0fa3084e-62a8-40ee-b5b9-d773ab1709a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_148ba726-9d0d-4883-9ea2-c47b8100b787" xlink:href="sesn-20221231.xsd#sesn_ProceedsFromExecutionOfAssetPurchaseAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_148ba726-9d0d-4883-9ea2-c47b8100b787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AssetPurchaseAgreementVariableConsideration_3e26fa2e-3060-4bc0-bed3-9eb9cc39fca1" xlink:href="sesn-20221231.xsd#sesn_AssetPurchaseAgreementVariableConsideration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_AssetPurchaseAgreementVariableConsideration_3e26fa2e-3060-4bc0-bed3-9eb9cc39fca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3ee3edbe-259a-4eb9-bed9-aa52e906d97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3ee3edbe-259a-4eb9-bed9-aa52e906d97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_bb202b78-2213-4c0d-9dfd-946e1a36045a" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_bb202b78-2213-4c0d-9dfd-946e1a36045a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_445ea3b3-0713-418f-8e6a-e2a8df5d9b9d" xlink:href="sesn-20221231.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_445ea3b3-0713-418f-8e6a-e2a8df5d9b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod_2558cc4b-cb99-4fbd-9481-4a9066f0e525" xlink:href="sesn-20221231.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_CollaborativeArrangementRoyaltyPeriod_2558cc4b-cb99-4fbd-9481-4a9066f0e525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTerminationExpense_279e879c-2fe0-4ce3-9c24-916130ea81b8" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementTerminationExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementTerminationExpense_279e879c-2fe0-4ce3-9c24-916130ea81b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTerminationPayment_5ab46558-daf0-42a5-b3d3-9f4ba8b3ba59" xlink:href="sesn-20221231.xsd#sesn_LicenseAgreementTerminationPayment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_LicenseAgreementTerminationPayment_5ab46558-daf0-42a5-b3d3-9f4ba8b3ba59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_PaymentsToRefundLicenseAgreementDeposits_285a8c8d-0444-4095-8b75-dce4ece1c3fc" xlink:href="sesn-20221231.xsd#sesn_PaymentsToRefundLicenseAgreementDeposits"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_PaymentsToRefundLicenseAgreementDeposits_285a8c8d-0444-4095-8b75-dce4ece1c3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_717060b7-1122-4ad4-b2a9-e2a9e03ed964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_717060b7-1122-4ad4-b2a9-e2a9e03ed964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_04e311e5-dda0-4963-82f5-bff2c8fe4ebb" xlink:href="sesn-20221231.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_8a89d2c6-ba3a-40b7-aefe-a9b3c44dbcd7" xlink:to="loc_sesn_RoyaltyRevenuePercentage_04e311e5-dda0-4963-82f5-bff2c8fe4ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0f5d17f1-4df3-4f84-97c4-4111cae213dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ba42a824-e5b5-4e20-bdb9-0e42be60daeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0f5d17f1-4df3-4f84-97c4-4111cae213dd" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ba42a824-e5b5-4e20-bdb9-0e42be60daeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_b947d12c-bff6-43b4-b30d-c6863e52286c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ba42a824-e5b5-4e20-bdb9-0e42be60daeb" xlink:to="loc_us-gaap_RestructuringPlanAxis_b947d12c-bff6-43b4-b30d-c6863e52286c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e8082dd5-65f3-42a6-8431-9af8836a5cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_b947d12c-bff6-43b4-b30d-c6863e52286c" xlink:to="loc_us-gaap_RestructuringPlanDomain_e8082dd5-65f3-42a6-8431-9af8836a5cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2021RestructuringPlanMember_d80e34a7-8e6d-4481-b4fd-f2e5a6917316" xlink:href="sesn-20221231.xsd#sesn_A2021RestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_e8082dd5-65f3-42a6-8431-9af8836a5cb1" xlink:to="loc_sesn_A2021RestructuringPlanMember_d80e34a7-8e6d-4481-b4fd-f2e5a6917316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_02dd0c83-e10a-4cbb-8e30-b5209fd6184c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ba42a824-e5b5-4e20-bdb9-0e42be60daeb" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_02dd0c83-e10a-4cbb-8e30-b5209fd6184c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_56bb4476-ea19-4769-8908-b9f49fda5067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_02dd0c83-e10a-4cbb-8e30-b5209fd6184c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_56bb4476-ea19-4769-8908-b9f49fda5067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_8cf7310b-f832-4db1-bf4a-8fe188c4773d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_02dd0c83-e10a-4cbb-8e30-b5209fd6184c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_8cf7310b-f832-4db1-bf4a-8fe188c4773d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_437f85eb-3a4e-4ea5-ad8c-76890d6c32b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ffc5309-fe75-4a37-8c39-11ed84659f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_437f85eb-3a4e-4ea5-ad8c-76890d6c32b6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ffc5309-fe75-4a37-8c39-11ed84659f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_e2bce7e9-3e9c-4663-be60-27c27cfee184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ffc5309-fe75-4a37-8c39-11ed84659f2b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_e2bce7e9-3e9c-4663-be60-27c27cfee184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e0247ac8-cefd-47cf-b7a1-14dadf421755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e2bce7e9-3e9c-4663-be60-27c27cfee184" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e0247ac8-cefd-47cf-b7a1-14dadf421755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_5fff500b-99fa-4c0b-94b8-466d9649836b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e0247ac8-cefd-47cf-b7a1-14dadf421755" xlink:to="loc_us-gaap_EmployeeSeveranceMember_5fff500b-99fa-4c0b-94b8-466d9649836b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractTerminationMember_34cd2549-3d3b-4271-a3ab-b9245f2927a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractTerminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e0247ac8-cefd-47cf-b7a1-14dadf421755" xlink:to="loc_us-gaap_ContractTerminationMember_34cd2549-3d3b-4271-a3ab-b9245f2927a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_790fac94-eed3-4ec6-9422-dc8d8f5fe919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ffc5309-fe75-4a37-8c39-11ed84659f2b" xlink:to="loc_us-gaap_RestructuringPlanAxis_790fac94-eed3-4ec6-9422-dc8d8f5fe919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6cbbf4cd-0405-40e7-9670-fb1b87055685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_790fac94-eed3-4ec6-9422-dc8d8f5fe919" xlink:to="loc_us-gaap_RestructuringPlanDomain_6cbbf4cd-0405-40e7-9670-fb1b87055685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2021RestructuringPlanMember_502f22f6-18c9-4ae4-a219-c873983c9185" xlink:href="sesn-20221231.xsd#sesn_A2021RestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_6cbbf4cd-0405-40e7-9670-fb1b87055685" xlink:to="loc_sesn_A2021RestructuringPlanMember_502f22f6-18c9-4ae4-a219-c873983c9185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2022RestructuringPlanMember_a42f47ee-e2ce-4164-9a1d-d713d9b4d7f9" xlink:href="sesn-20221231.xsd#sesn_A2022RestructuringPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_6cbbf4cd-0405-40e7-9670-fb1b87055685" xlink:to="loc_sesn_A2022RestructuringPlanMember_a42f47ee-e2ce-4164-9a1d-d713d9b4d7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bc35742e-6d40-442a-af51-1ae7dab33c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ffc5309-fe75-4a37-8c39-11ed84659f2b" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_bc35742e-6d40-442a-af51-1ae7dab33c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_406e7184-45d9-46ea-a6f1-204a40d0eda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bc35742e-6d40-442a-af51-1ae7dab33c38" xlink:to="loc_us-gaap_RestructuringReserve_406e7184-45d9-46ea-a6f1-204a40d0eda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9abb4414-6017-435b-b4b1-3eec415874ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bc35742e-6d40-442a-af51-1ae7dab33c38" xlink:to="loc_us-gaap_RestructuringCharges_9abb4414-6017-435b-b4b1-3eec415874ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_80ef0a9c-a1ca-44e2-9f52-e9a8668589ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bc35742e-6d40-442a-af51-1ae7dab33c38" xlink:to="loc_us-gaap_PaymentsForRestructuring_80ef0a9c-a1ca-44e2-9f52-e9a8668589ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_9febc469-defd-4571-9526-22793d622982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bc35742e-6d40-442a-af51-1ae7dab33c38" xlink:to="loc_us-gaap_RestructuringReserve_9febc469-defd-4571-9526-22793d622982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sesn-20221231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_7b6234d3-e9a7-4668-b860-edc7069ed4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_3c099d9d-6292-48d8-b5ce-13306fa84abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_7b6234d3-e9a7-4668-b860-edc7069ed4a6" xlink:to="loc_us-gaap_SubsequentEventTable_3c099d9d-6292-48d8-b5ce-13306fa84abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_76b335bd-5dc2-466d-9be4-b069d748d85b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3c099d9d-6292-48d8-b5ce-13306fa84abb" xlink:to="loc_srt_StatementScenarioAxis_76b335bd-5dc2-466d-9be4-b069d748d85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_95eaa5f9-bad5-4fff-9181-6042d42bf129" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_76b335bd-5dc2-466d-9be4-b069d748d85b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_95eaa5f9-bad5-4fff-9181-6042d42bf129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_cd579371-579d-405e-a770-cf1c3ecbb2e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_95eaa5f9-bad5-4fff-9181-6042d42bf129" xlink:to="loc_srt_ScenarioForecastMember_cd579371-579d-405e-a770-cf1c3ecbb2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_27ffc15b-fc0f-4865-a805-e89f1e3a6931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3c099d9d-6292-48d8-b5ce-13306fa84abb" xlink:to="loc_us-gaap_SubsequentEventLineItems_27ffc15b-fc0f-4865-a805-e89f1e3a6931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8191be5c-f04d-4677-b045-3bb0e8a7cdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_27ffc15b-fc0f-4865-a805-e89f1e3a6931" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8191be5c-f04d-4677-b045-3bb0e8a7cdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245379491840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sesen Bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2025616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245 First Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">444-8550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SESN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,492,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders ("2023 Proxy Statement") or an amendment to this Annual Report on Form 10-K are incorporated by reference into Part III of this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant will file the 2023 Proxy Statement or an amendment to this Annual Report on Form 10-K with the Securities and Exchange Commission within 120 days of December&#160;31, 2022.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245379325728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245381174992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 112,553<span></span>
</td>
<td class="nump">$ 162,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short term marketable securities</a></td>
<td class="nump">54,366<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">18,476<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">189,144<span></span>
</td>
<td class="nump">205,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long term prepaid expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">35,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">189,174<span></span>
</td>
<td class="nump">240,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">2,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">29,636<span></span>
</td>
<td class="nump">8,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">30,984<span></span>
</td>
<td class="nump">11,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">30,984<span></span>
</td>
<td class="nump">69,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at December&#160;31, 2022 and 2021; no shares issued and outstanding at December&#160;31, 2022 and 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 400,000,000 shares authorized at December&#160;31, 2022 and 2021; 202,759,043 and 199,463,645 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">494,675<span></span>
</td>
<td class="nump">487,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(336,141)<span></span>
</td>
<td class="num">(316,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(546)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">158,190<span></span>
</td>
<td class="nump">171,710<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 189,174<span></span>
</td>
<td class="nump">$ 240,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245379700304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 03, 2021</div></th>
<th class="th"><div>May 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">202,759,043<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">202,759,043<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245379299472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 26,544<span></span>
</td>
<td class="nump">$ 11,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">38,594<span></span>
</td>
<td class="nump">25,312<span></span>
</td>
<td class="nump">29,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">39,787<span></span>
</td>
<td class="nump">29,393<span></span>
</td>
<td class="nump">14,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">11,764<span></span>
</td>
<td class="nump">5,528<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">27,764<span></span>
</td>
<td class="nump">31,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(52,000)<span></span>
</td>
<td class="num">(56,840)<span></span>
</td>
<td class="num">(11,180)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">65,909<span></span>
</td>
<td class="nump">35,093<span></span>
</td>
<td class="nump">32,313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(25,909)<span></span>
</td>
<td class="num">(8,549)<span></span>
</td>
<td class="num">(21,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">296<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss Before Taxes</a></td>
<td class="num">(23,759)<span></span>
</td>
<td class="num">(8,609)<span></span>
</td>
<td class="num">(20,952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) from income taxes</a></td>
<td class="nump">3,875<span></span>
</td>
<td class="nump">8,273<span></span>
</td>
<td class="num">(1,445)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss After Taxes</a></td>
<td class="num">(19,884)<span></span>
</td>
<td class="num">(336)<span></span>
</td>
<td class="num">(22,397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Deemed Dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders - basic</a></td>
<td class="num">(19,884)<span></span>
</td>
<td class="num">(336)<span></span>
</td>
<td class="num">(22,544)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders - diluted</a></td>
<td class="num">$ (19,884)<span></span>
</td>
<td class="num">$ (336)<span></span>
</td>
<td class="num">$ (22,544)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">200,546<span></span>
</td>
<td class="nump">182,323<span></span>
</td>
<td class="nump">118,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding for diluted (in shares)</a></td>
<td class="nump">200,546<span></span>
</td>
<td class="nump">182,323<span></span>
</td>
<td class="nump">118,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245379330304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,884)<span></span>
</td>
<td class="num">$ (336)<span></span>
</td>
<td class="num">$ (22,397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (20,430)<span></span>
</td>
<td class="num">$ (336)<span></span>
</td>
<td class="num">$ (22,397)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245377936496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>ATM Facility</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>ATM Facility</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>ATM Facility</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss Investments</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,801,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (26,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (293,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of stock options (in shares)</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Sales of common stock under 2014 ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Sales of common stock under 2014 ESPP</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue', window );">Exercises of common stock warrants</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,369,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="nump">37,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="num">(9,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(315,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 5,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of stock options (in shares)</a></td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,048,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue', window );">Exercises of common stock warrants</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,932,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 171,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(316,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,884)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 6,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of stock options (in shares)</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock for RSU vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,293,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock for RSU vesting</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">$ (546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">202,759,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,759,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 158,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 494,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (546)<span></span>
</td>
<td class="num">$ (336,141)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Exercise Of Warrants, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245384920640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sesn_ATMFacilityMember', window );">ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sesn_ATMFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sesn_ATMFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245382210272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,884)<span></span>
</td>
<td class="num">$ (336)<span></span>
</td>
<td class="num">$ (22,397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">6,909<span></span>
</td>
<td class="nump">5,143<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(52,000)<span></span>
</td>
<td class="num">(56,840)<span></span>
</td>
<td class="num">(11,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Intangibles impairment charge</a></td>
<td class="nump">27,764<span></span>
</td>
<td class="nump">31,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of discounts and premiums on marketable securities</a></td>
<td class="num">(913)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable (net)</a></td>
<td class="nump">21,010<span></span>
</td>
<td class="num">(24,493)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">2,658<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">18,076<span></span>
</td>
<td class="num">(17,964)<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent', window );">Long term prepaid expenses</a></td>
<td class="nump">7,192<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,620)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">17,067<span></span>
</td>
<td class="num">(4,424)<span></span>
</td>
<td class="num">(2,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">24,895<span></span>
</td>
<td class="num">(68,878)<span></span>
</td>
<td class="num">(30,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(128,999)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturity of marketable securities</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Disposal of equipment</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchases of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(53,969)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">174,962<span></span>
</td>
<td class="nump">37,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from sale of common stock pursuant to ESPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">176,129<span></span>
</td>
<td class="nump">38,113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(29,073)<span></span>
</td>
<td class="nump">107,247<span></span>
</td>
<td class="nump">7,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning of period</a></td>
<td class="nump">162,656<span></span>
</td>
<td class="nump">55,409<span></span>
</td>
<td class="nump">48,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end of period</a></td>
<td class="nump">133,583<span></span>
</td>
<td class="nump">162,656<span></span>
</td>
<td class="nump">55,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">112,553<span></span>
</td>
<td class="nump">162,636<span></span>
</td>
<td class="nump">52,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short term restricted cash</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long term restricted cash</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">133,583<span></span>
</td>
<td class="nump">162,656<span></span>
</td>
<td class="nump">55,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IssuanceOfWarrantForCommonStock', window );">Deemed Dividend on adjustment of exercise price on certain warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) of Prepaid Expenses, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IssuanceOfWarrantForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Warrant For Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IssuanceOfWarrantForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Related To Adoption of Accounting Standard</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245386599856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. ("Sesen Bio" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company that previously focused on advancing targeted fusion protein therapeutics (&#8220;TFPTs&#8221;) for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also known as VB4-845, is a locally administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;). On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the United States Food and Drug Administration ("FDA"), which had implications on the size, timeline and costs of an additional Phase 3 clinical trial, which the FDA previously confirmed would be required for a potential resubmission of a biologics license application ("BLA") for Vicineum for the treatment of NMIBC. As a result of this decision, the Company turned its primary focus to consummating a strategic transaction with the goal of maximizing stockholder value. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on September 20, 2022, the Company, Seahawk Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), and CARISMA Therapeutics Inc. (&#8220;Carisma&#8221;), entered into the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (the &#8220;Merger Agreement&#8221;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the &#8220;Merger&#8221;). The Company&#8217;s board of directors unanimously approved the Merger Agreement and resolved to recommend that its stockholders approve the proposals described in the Merger Agreement. If the Merger is completed, the business of Carisma will continue as the business of the combined company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, it is seeking a partner that can execute further development to realize the full potential of Vicineum. As a result of such decision and the Company&#8217;s subsequent decision to enter into the proposed Merger with Carisma, it no longer plans to pursue regulatory approval of Vicineum for NMIBC in the European Union (the &#8220;E.U.&#8221;) and has started to wind down certain of its manufacturing operations and business development partnerships. Additionally, the Company is seeking a partner for the further development of Vicineum and has initiated a formal process and engaged a financial advisor for the potential sale of Vicineum. If the proposed Merger is consummated, the combined company does not expect to pursue further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anticipated Merger with CARISMA Therapeutics Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger is expected to be completed during the first quarter of 2023. In connection with the Merger, the Company is seeking the approval of its stockholders to, among other things, (a) issue the shares of its common stock issuable in connection with the Merger pursuant to the rules of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), and (b) amend its amended and restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;) to effect a reverse stock split of the outstanding shares of its common stock at a ratio of 1-for-20 (clauses (a) and (b), collectively, the &#8220;Sesen Bio Voting Proposals&#8221;). The special meeting of stockholders in which the Company&#8217;s stockholders will be asked to vote on the Sesen Bio Voting Proposals (the &#8220;Special Meeting&#8221;) will be held on March 2, 2023 at 10:00 a.m. Eastern Time.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that Sesen Bio does not complete the Merger with Carisma, Sesen Bio may continue to review and evaluate strategic alternatives, including, without limitation, a dissolution of Sesen Bio.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0 million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, a director of the Company until his retirement in July 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of December&#160;31, 2022, none of these individuals are active employees or members of the Company's board of directors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had cash, cash equivalents, and marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $166.9 million a</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd an accumulated deficit of $336.1 million. The Company in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">curred positive cash flows from operating acti</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vities of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $24.9 million for the year ended December&#160;31, 2022.</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">curred negative cash flows from operating acti</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$68.9 million and $30.8 million for the years ended December 31, 2021 and 2020, respectively. Since the Company&#8217;s inception, it has received no revenue from sales of its products, and the Company anticipates that operating losses will continue for the foreseeable future as it seeks to close the Merger with Carisma.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has financed its operations to date primarily through private placements of its common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, its initial public offering ("IPO"), follow-on public offerings, sales effected in "at-the-market" ("ATM") offerings, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">out-license agreements and an asset purchase agreement. See &#8220;Note 13. Stockholders&#8217; Equity (Deficit)&#8221; below for information regarding the Company&#8217;s recently completed equity financings. Management believes that the Company&#8217;s cash and cash equivalents as of December&#160;31, 2022 will be sufficient to fund the Company's operations for at least the next twelve months from the date these consolidated financial statements were issued.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's future funding requirements will depend on the outcome of the proposed Merger with Carisma.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other clinical companies that have determined to focus primarily on pursuing a strategic transaction, including, but not limited to, those which are described under Part I Item 1A. Risk Factors of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will incur substantial expenses if and as it:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addresses its ongoing litigation related to the Merger;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintains and protects its intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduces its personnel and incurs related severance and employee-related costs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">explores, evaluates and pursues any strategic alternatives if the Merger is not completed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and the timing of the proposed Merger with Carisma;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and timing of any pending or future litigation involving the Company or its business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of maintaining and enforcing the Company&#8217;s intellectual property rights and defending any intellectual property-related claims; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">its obligation to make milestone, royalty and other payments to third-party licensors under its licensing agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as the Company can generate substantial revenues, the Company expects to finance the cash needs through a combination of equity offerings, debt financings, or government or other third-party funding. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting the Company&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company is unable to raise additional funds when needed, it may be required to delay, limit, </span></div>reduce or terminate its assessment of strategic alternatives. If the Company does not successfully consummate the proposed Merger with Carisma, its board of directors may decide to explore other strategic alternatives, including, without limitation, a dissolution of the company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245384113792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
<td class="text">BASIS OF PRESENTATION<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission ("SEC") requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the United States dollar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245379297760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company's primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company's corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents, marketable securities, and accounts receivable. The Company limited its credit risk associated with cash equivalents and marketable securities by investing in highly-rated money market funds, US government securities, and treasury securities. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial institutions. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its marketable securities as available-for-sale. The marketable securities consist of holdings in US treasury securities and US government securities, with maturity dates ranging from March 2023 to November 2023, which is consistent with the Company's investment policy. Accordingly, these investments are recorded at fair value which is determined based on quoted market prices. Amortization and accretion of discounts and premiums are recorded as interest income. Realized gains and losses are included in other income (expense), net. Unrealized gains and losses are included in other comprehensive loss as a component of stockholder&#8217;s equity (deficit) until realized. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of five years for lab equipment, four years for furniture </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and fixtures, three years for computer equipment and software and the lesser of five years or the remaining lease term for leasehold improvements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consisted of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in share price and a resulting decrease in its market capitalization. On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of its intangible asset of Vicineum E.U. rights. The Company concluded that the carrying value of its intangible asset of Vicineum E.U. rights of $14.7&#160;million was fully impaired as of June 30, 2022 and was reduced to zero in the second quarter of 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company received a Complete Response Letter ("CRL") from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing, and controls ("CMC") issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's marketing authorization application ("MAA"), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the United States market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheets is the result of the Company&#8217;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. The Company has only one reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed continued trends in its market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, size, length and cost of a clinical trial, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of its typical annual assessment </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. The Company updated its revenue forecast models based on further expected launch delays in both United States and outside of the United States ("OUS") regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. The Company also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired as of June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September 2016. See "Note 1. Description of Business" above for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of its contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales were expected to be achieved through 2033, the level of commercial sales of Vicineum then-forecasted for the United States, Europe, Japan, China and other potential markets. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout was derived from the Company's estimated weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, it is seeking a partner for the further development of Vicineum. Accordingly, during the second quarter of 2022, the Company concluded that it is no longer expected to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential 2% earnout payment related to China, Hong Kong, Macau and Taiwan (collectively, &#8220;Greater China&#8221;) region since those territory rights had been out-licensed. Qilu Pharmaceutical, Co., Ltd. ("Qilu") held the exclusive license to develop Vicineum in the Greater China region, and accordingly, the $1.8&#160;million estimated earnout payment in the Greater China region remained as long-term contingent consideration as of June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, Qilu informed the Company that it no longer intended to commercialize Vicineum, due to additional effort and costs required to gain regulatory approval in that region without prior US approval. As such, the Company and Qilu were in the process of negotiating a termination of the Qilu License Agreement, which was terminated on December 23, 2022. Accordingly, the Company concluded that it no longer expected to owe any future earnout payments related to the Greater China region and reduced its remaining $1.8&#160;million of contingent consideration liabilities to zero as of September 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio as of December 31, 2022 includes a property lease for its headquarters in Cambridge, MA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company&#8217;s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company's consolidated balance sheet. The short-term and long-term </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability components are recorded in other current liabilities and other liabilities, respectively, on the Company&#8217;s consolidated balance sheet. As of December&#160;31, 2022, the Company did not have any finance leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives' stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company&#8217;s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management&#8217;s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each grant of options during the years ended December&#160;31, 2022, 2021 and 2020 was determined using the following methods and assumptions:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term. G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iven the plain vanilla nature of the options granted by the Company, the expected term is determined using the "simplified" method, as prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 ("SAB 107"), whereby the expected life equals the arithmetic average of the vesting term (generally four years) and the original contractual term (ten years) of the option, taking into consideration multiple vesting tranches. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company's own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend Yield. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dividend yield is 0% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and research and development credit ("R&amp;D credit") carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&#160;31, 2022 and 2021, the Company did not have any uncertain tax positions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded revenue from former out-license agreements and OUS business development partnership agreements, including the former license agreement (the &#8220;Roche License Agreement&#8221;) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) and its former OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)   Identification of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)  Determination of whether the promised goods or services are performance obligations including whether they are                        distinct in the context of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)  Measurement of the transaction price, including the constraint on variable consideration&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)  Allocation of the transaction price to the performance obligations&#894; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)  Recognition of revenue when or as the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Regulatory Milestones and Other Payments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#8217;s estimate of milestones and royalties approximates the standalone selling price of the license.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. Management evaluated the transaction under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous periods. Accordingly, the Company recorded $20&#160;million as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $40.0&#160;million of license revenue related to the asset purchase agreement with Roche during the year ended December 31, 2022 and $26.5&#160;million of license revenue related to the Roche, Qilu and Hikma License Agreements during the year ended December 31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss and other comprehensive loss. For the year ended December 31, 2022, other comprehensive loss included changes in unrealized income and loss on marketable securities. For the years ended December&#160;31, 2021 and 2020 comprehensive loss was equal to net loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383924480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share ("EPS") guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245380273184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s consolidated balance sheets approximated their fair values as of December&#160;31, 2022 and 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:13pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers valuations obtained from third party pricing sources when estimating the fair value of marketable securities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2025 to 2033, and the level of commercial sales of Vicineum then-forecasted for the United States, Europe, Japan, China, and other potential markets. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout was derived from its estimated weighted-average cost of capital, which was 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - long term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#8217;s weighted average cost of capital, which was 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, it is seeking a partner for the further development of Vicineum. Accordingly, the Company concluded that it is no longer expected to pay related milestone and earnout payments to the former shareholders of Viventia. Therefore, the Company&#8217;s contingent consideration liability as of December 31, 2022 was zero.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245380300368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRICTED CASH AND MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">RESTRICTED CASH AND MARKETABLE SECURITIES</a></td>
<td class="text">RESTRICTED CASH AND MARKETABLE  SECURITIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's short-term restricted cash balance as of December 31, 2022 was $21.0&#160;million. This represents the settlement amount of the Securities Litigation (as defined below in Note 11. &#8220;Commitment and Contingencies&#8221;), including the insurance carriers' coverage, which was funded into an escrow account in the fourth quarter of 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the court issued an order granting final approval of the settlement of the Securities Litigation. Accordingly, this matter is now resolved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The  following table sets forth the composition of the Company&#8217;s marketable securities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"/><td style="width:42.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Marketable Securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company had no marketable securities as of December 31, 2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245380285280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECEIVABLES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">RECEIVABLES</a></td>
<td class="text">RECEIVABLES <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts receivable balance as of December 31, 2021 was $21.0&#160;million, comprised primarily of a $20.0&#160;million milestone achieved in December 2021 due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $20.0&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. In January 2022 the payment of $20.0&#160;million was received. Additionally, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". As such, the Company recorded $0.9&#160;million of revenue and accounts receivable for the additional purchase price resulting from Qilu's obligation to pay Sesen Bio an amount equal to its recovery of VAT. The Company received this payment in the second quarter of 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of December&#160;31, 2022 was $0.8&#160;million, primarily consisting of German VAT recovery related to drug substance sent to Baxter. The Company expects to collect the remaining balance in 2023. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of December&#160;31, 2021 was $3.5&#160;million, primarily consisting of German VAT recovery related to drug substance sent to Baxter.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245380349856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of property and equipment, net as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Property and Equipment, Net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation expense was de minimis, $0.1 million and $0.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245380300368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLES AND GOODWILL</a></td>
<td class="text">INTANGIBLES AND GOODWILL<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's consolidated balance sheet were the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum United States rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired intangible assets for the United States and E.U. rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in share price and a resulting decrease in its market capitalization. On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of its intangible asset of Vicineum E.U. rights. The Company concluded that the carrying value of its intangible asset of Vicineum E.U. rights of $14.7&#160;million was fully impaired as of June 30, 2022 and was reduced to zero in the second quarter of 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's MAA, an interim impairment analysis </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the United States market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheet is the result of the Viventia Acquisition in September 2016. Goodwill had no carrying value as of December&#160;31, 2022 and had a carrying value of $13.1&#160;million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed continued trends in its market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, size, length and cost of a clinical trial, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of its typical annual assessment date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. The Company updated its revenue forecast models based on further expected launch delays in both United States and OUS regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. The Company also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired as of June 30, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383924480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:67.067%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal expenses, including the preliminary securities litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245380285280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bibb v. Sesen Bio, Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., Case No. 1:21-cv-07025, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cizek v. Sesen Bio, Inc., et. al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-07309 and M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">arkman v. Sesen Bio, Inc. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the United States District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Sesen Bio, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (collectively, the &#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. On November 24, 2021, defendants filed a motion to transfer venue to the United States District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleged the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022, and that motion was fully briefed on May 6, 2022. On June 3, 2022, before the court ruled on the motion to dismiss, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. On June 30, 2022 and July 6, 2022, the Company and the plaintiffs engaged in mediation sessions in an attempt to resolve the Securities Litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which was filed with the court on August 17, 2022. The Stipulation and Agreement of Settlement related to the Securities Litigation provides for a settlement payment of $21.0&#160;million to the class and the dismissal of all claims against the Company and the other defendants. On September 1, 2022, the United States District Court for the Southern District of New York issued an order denying the motions to appoint a different lead plaintiff. On September 28, 2022, the court issued an order granting preliminary approval of the proposed settlement of the Securities Litigation. The settlement payment of $21.0&#160;million, including the insurance carriers coverage, was funded into an escrow account in the fourth quarter of 2022. Accordingly, $21.0&#160;million remained in restricted cash on the Company's balance sheet as of December 31, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the court issued an order granting final approval of the settlement of the Securities Litigation. Accordingly, this matter is now resolved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myers v. Sesen Bio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-11538 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">D&#8217;Arcy v. Sesen Bio, Inc., et. al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the United States District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tang v. Sesen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers (the &#8220;State Derivative Litigation&#8221;). The three derivative complaints alleged breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleged unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints sought unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Sesen Bio, Inc. Derivative Litigation, Lead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On July 6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in mediation in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2022, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims (collectively, the &#8220;Derivative Litigation&#8221;). Pursuant to that agreement, the individual defendants will cause the Company to adopt certain enhancements to its corporate governance policies and procedures. In exchange, plaintiffs will dismiss the Derivative Litigation and, on behalf of the Company, provide broad customary releases to the individual defendants. On August 22, 2022, the parties entered into a Stipulation of Settlement to settle the Derivative Litigation, which was filed with the court on August 30, 2022. The Stipulation of Settlement related to the Derivative Litigation confirms that the Company previously adopted certain corporate governance enhancements in response to, among other things, the filing of the Derivative Litigation, and that, subject to final court approval, the Company will adopt additional corporate governance enhancements. The Stipulation of Settlement also provides for a $630,000 payment for plaintiffs&#8217; attorneys' fees due to the benefits the corporate governance enhancements are intended to provide to the Company. The payment of plaintiffs&#8217; attorneys' fees is being funded by the Company. On September 2, 2022, the court issued </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an order granting preliminary approval of the Stipulation of Settlement related to the Derivative Litigation. On November 8, 2022, the court issued an order granting final approval of the Stipulation of Settlement related to the Derivative Litigation. Accordingly, this matter is now resolved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 28, 2022, a purported stockholder filed a complaint in the United States District Court for the Southern District of New York against the Company and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keller v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:22-cv-10085 (S.D.N.Y.) (the &#8220;Original Keller Complaint&#8221;). The Original Keller Complaint asserted claims against the Company and its board of directors under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement on Form S-4 (File No. 333-267891) (the "Registration Statement") in connection with the Merger and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and sought, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs. On December 20, 2022, the purported stockholder voluntarily dismissed the Original Keller Complaint and on December 21, 2022, filed a new complaint as a putative class action in the Court of Chancery for the State of Delaware, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keller v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 2022-1186 (Del. Ch. Dec. 21, 2022) (the &#8220;New Keller Complaint&#8221;). Along with the complaint, the purported stockholder filed motions for expedited proceedings and for a preliminary injunction to enjoin the Special Meeting. The New Keller Complaint and associated filings contain substantially the same assertions as the Original Keller Complaint, and seek, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2023, a purported stockholder filed a complaint in the United States District Court for the District of Delaware against the Company and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumley v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:23-cv-00131 (D. Del.) (the &#8220;Plumley Complaint&#8221;). The Plumley Complaint asserts claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement in connection with the Merger and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs. On February 7, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against the Company and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Franchi v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 1:23-cv-01041 (S.D.N.Y.) (the &#8220;Franchi Complaint&#8221;). The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. Additionally, on February 9, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against the Company and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Menzer v. Sesen Bio, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, et al., 23-cv-01119 (S.D.N.Y.) (the &#8220;Menzer Complaint&#8221;). The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint and the Franchi Complaint.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2022, November 4, 2022, February 8, 2023, February 13, 2023 (as updated on February 15, 2023) and February 17, 2023, the Company received letters from purported stockholders (collectively, the &#8220;Demand Letters&#8221;) demanding that the Company amend the Registration Statement to provide additional disclosures that such stockholders allege were improperly omitted from the Registration Statement, including information regarding the financial projections for Carisma, the financial analyses performed by the Company&#8217;s financial advisor in support of its fairness opinion, and the background and process leading to the execution of the Merger Agreement. In addition, the Company received a books and records demand, dated November 18, 2022 (the &#8220;Section 220 Demand&#8221;), on behalf of a purported stockholder of the Company seeking access to certain relevant books and records of the Company&#8217;s pursuant to Section 220 of the Delaware General Corporation Law in connection with the Merger and the securities and derivative litigations arising out of the CRL that the Company received from the FDA. The Section 220 Demand states that the purpose of the demand is to, among other things, investigate purported questions of director independence and disinterestedness and the possibility of wrongdoing, mismanagement, and/or material non-disclosure related to the Company board&#8217;s approval of the Merger and the other transactions contemplated thereby and to determine whether suit should be brought in connection therewith.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the claims asserted in the Demand Letters, the Section 220 Demand, the New Keller Complaint, the Plumley Complaint, the Franchi Complaint and the Menzer Complaint are without merit and intends to vigorously defend against them. At this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Employment Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements and offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383898208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio included an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consisted of manufacturing, laboratory, warehouse, and office space. During the third quarter of 2022, the Company entered into a Lease Termination Agreement (the &#8220;Lease Termination Agreement&#8221;) pursuant to which the Company terminated its operating lease agreement. As part of the execution of the Lease Termination Agreement, the Company paid the landlord the all-inclusive sum of CAD $1.2&#160;million (USD $0.9&#160;million). Operating lease cost under this lease were $0.2&#160;million for the year ended December&#160;31, 2022 and $0.3&#160;million for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of use asset total was zero as of December 31, 2022 and $123,300 as of December 31, 2021. As of December 31, 2021, the asset component of the Company&#8217;s operating leases was recorded as operating lease right-of-use assets and reported within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzU_722ba763-9575-481e-82ea-4900d469c804"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzU_e7bf87fd-276f-41e8-a126-4410ad3340e7">other assets</span></span> on the Company's condensed consolidated balance sheets. The short-term lease liability was zero as of December 31, 2022 and $123,300 as of December 31, 2021. As of December 31, 2021, the short-term lease liability was recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzODc_0f5642b4-7404-4c0d-8695-7cd3f0d7638d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzODc_e3383e46-0bd5-473a-9c94-1fb2c501553a">other current liabilities</span></span> on the Company&#8217;s condensed consolidated balance sheets. There was no long-term operating lease liability as of December 31, 2022 or December 31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The minimum monthly rent for these office spaces is $2,500 and $18,000, respectively. The Company terminated the Philadelphia lease on December 31, 2022 and plans to terminate the Cambridge lease in connection with the closing of the anticipated Merger with Carisma. The short-term lease in Cambridge ends in June 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December&#160;31, 2022 and 2021 is as follows (in thousands):</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease Cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease (including related operating costs)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term property leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">458</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Supplemental Information:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383945088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY DEFICIT</a></td>
<td class="text">STOCKHOLDERS' EQUITY (DEFICIT)<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time (the &#8220;ATM Offering&#8221;) for an aggregate sales price of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $35.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through Jefferies. In October 2020 and February 2021, the Company entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively. Amendments No. 1 and No. 2 modified the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $50.0&#160;million and $34.5&#160;million, respectively. In June 2021, the Company entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200.0&#160;million of common stock pursuant to the Sale Agreement. Sales are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Capital Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the year ended December 31, 2022. The Company raised</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$175.0 million of net proceeds from the sale of 56.9 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock at a weighted-average price of</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.17</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share during the year ended December&#160;31, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $5.4 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the year ended December 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 2019 Financing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company raised $27.8 million of net proceeds from the sale of 20.4 million shares of common stock and accompanying warrants to purchase an additional 20.4 million shares of common stock in an underwritten public offering (the "June 2019 Financing"). The combined purchase price for each share of common stock and accompanying warrant was $1.47. Subject to certain ownership limitations, the warrants issued in the June 2019 Financing were exercisable immediately upon issuance at an exercise price of $1.47 per share, subject to adjustments as provided under the terms of such warrants, and had a one-year term that expired on June 21, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Certificate of Incorporation, the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">203&#160;million and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of December&#160;31, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:67.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.100%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,759</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 815-40")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's warrant activity for the year ended December&#160;31, 2022 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification described below and (ii) subject to further adjustment based on down round provision added by amendment described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Modifications</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with holders of its outstanding 2018 Warrants and 2017 Warrants to purchase the Company's common stock. At such time, the 2018 Warrants and 2017 Warrants utilized the same form of warrant, which contained a prohibition on variable rate transactions (as defined therein). Warrant holders agreed to waive such prohibition in exchange for certain concessions from the Company. Management evaluated the warrants after modifications and determined that they continued to be equity-classified under the derivative scope exception of ASC 815-40. The warrants were revalued immediately before and immediately after the modifications to calculate the $1.1 million incremental value of the modified warrants. The Company considers this incremental value to be akin to an offering cost since the modifications were directly related to enabling the ATM Offering and would not have otherwise been incurred. Therefore, in the fourth quarter of 2019, management initially capitalized the $1.1 million to deferred financing cost asset, with an offsetting credit to additional paid-in capital, and then reclassified the deferred financing cost asset to reduce the ATM Offering proceeds within equity as proceeds were received from sales of common stock under the ATM Offering. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Warrants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with the holders of its outstanding 2018 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2018 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2018 Warrant Amendment Agreements"). As consideration for those holders executing the 2018 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $1.20 to $0.60 per share of the Company's common stock, resulting in proceeds of $2.0 million from the exercise of 3.4 million warrants. Pursuant to the 2018 Warrant Amendment Agreements, the prohibition on certain variable rate transactions included in the 2018 Warrants was amended to exclude ATM offerings and the exercise price of the warrants was reduced from $1.20 to the lesser of (a) $0.95 per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2018 Warrant Amendment Agreements. During the second quarter of 2020, the anti-dilution provision was triggered to lower the exercise price of the warrants to $0.55; as such, the Company recognized a deemed dividend of approximately $0.1&#160;million which reduced the income available to common stockholders. As the Company has an accumulated deficit balance, there is no overall impact to additional paid-in capital, as the deemed dividend is recorded as offsetting debit and credit entries to additional paid-in capital. Therefore, the amounts were not presented on the Statement of Stockholders' Equity (Deficit). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2018 Warrant Exercise Agreements and 2018 Warrant Amendment Agreements, the Company entered into an amendment to the Securities Purchase Agreement dated March 21, 2018 related to the March 2018 Financing, by and among the Company and each purchaser identified on the signature pages thereto, with certain holders representing greater than 50.1% of the securities issued based on initial subscription amounts, pursuant to which the prohibition on variable rate transactions, including ATM offerings, was deleted in its entirety.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with the holders of its outstanding 2017 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2017 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2017 Warrant Amendment Agreements"). As consideration for those holders executing the 2017 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $0.80 to $0.55 per share of the Company's common stock. Pursuant to the 2017 Warrant Amendment Agreements, the prohibition on certain variable rate transactions, including ATM offerings, included in the 2017 Warrants was deleted in its entirety and the exercise price of the warrants was reduced from $0.80 to the lesser of (a) $0.55 per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2017 Warrant Amendment Agreements. As of December&#160;31, 2022, there has been no adjustment to the exercise price of these warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383895776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods with net income, diluted net earnings per share is calculated by either (i) adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii) the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two-class method was not applied for the twelve months ended December&#160;31, 2022, 2021 and 2020 as the Company&#8217;s participating securities do not have any obligation to absorb net losses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of December&#160;31, 2022, 2021 and 2020 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:53.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,902</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245380285280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"/><td style="width:277.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,909</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 4.5&#160;million shares of common stock available for issuance under the 2014 Plan as of December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 12.2&#160;million stock options outstanding under the 2014 Plan as of December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#8220;RSU&#8221;) award which vested in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock. The Company recorded an expense of $2.5&#160;million for retention-related RSUs for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately fifty percent of current base salary. Each PSU represents a contingent right to receive one share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of December 31, 2022, achievement was deemed probable for only the cash management milestone, representing $87,000 (or 20% of the PSU awards). Therefore, $55,000 was expensed during the year ended December 31, 2022, and $32,000 remains measured but unrecognized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A summary of the status of restricted stock units is presented below: </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tr><td style="width:1.0%"/><td style="width:75.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining contractual life of unvested RSUs and PSUs as of December&#160;31, 2022 is 2.67 years. The weighted average remaining contractual life of unvested RSUs and PSUs as of December&#160;31, 2021 is 9.75 years.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of December&#160;31, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately 2.9 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:41.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.52</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.93</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.90</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,304&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.77</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DM</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense of $6.9&#160;million, $5.1&#160;million, and $1.8&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. The stock option related expenses were $4.3 million, $4.6 million and $1.8 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. The RSU related expense was $2.5&#160;million and $0.5 million for the years ended December&#160;31, 2022 and 2021, respectively. The Company did not record RSU related expenses for the year ended December&#160;31, 2020. As of December&#160;31, 2022, there was $5.5 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 1.88 years. The weighted-average grant-date fair value of stock options granted during the year ended December&#160;31, 2022, 2021 and 2020 were $0.46, $2.16 and $0.56, respectively. The total intrinsic value of stock options exercised for the years ended December&#160;31, 2022, 2021 and 2020 was de minimis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383901632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders' equity (deficit). As of December&#160;31, 2022, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company sold a de minimis number of shares under the ESPP for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its United States employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div>The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383994848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total Loss Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23,759)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,952)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Tax Provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current (provision)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred benefit (provision)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,559&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Benefit (Provision) </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,875</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company&#8217;s effective income tax rate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal statutory income tax rate</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option cancellations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill write-off</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Income Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;R&amp;D credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRC 174 Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accruals and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Capitalized start-up costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,969)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,969)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,453)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,849)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,631)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net Deferred Tax Liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,969)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of the Company's deferred tax assets, management considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL and R&amp;D credit carryforwards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company has generated NOLs since its inception, and management believes that it is more likely than not that the Company's deferred tax assets will not be realized. As a result, valuation allowances of $82.5 million, $71.8 million and $65.6 million have been established as of December&#160;31, 2022, 2021 and 2020, respectively. The $10.6 million increase in the valuation allowance was attributable to the NOL for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's NOL and R&amp;D and other credit carryforwards in the United States and Canada as of December&#160;31, 2022 (in millions):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Beginning in</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards - indefinite</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal R&amp;D credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State R&amp;D credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal non-capital loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal scientific research and experimental development<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expense carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal and provincial investment tax credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Reform Act of 1986 (the "Act'), NOL and R&amp;D credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service, and there are similar provisions in certain state and non-US tax laws. NOL and R&amp;D credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interests of significant shareholders over a three-year period in excess of 50 percent, as defined in Sections 382 and 383 of the Internal Revenue Code, respectively. This could limit the amount of tax attributes that can be utilized to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Management completed a Section 382 study through March 31, 2016 and determined that it is more likely than not that the Company's NOL carryforwards are subject to a material limitation. Accordingly, the Company reduced its NOL carryforward by $0.8 million. The Company has continued to raise additional equity capital since March 2016 but has not done any additional analysis to determine whether or not ownership changes, as defined in the Act, have occurred, which would result in additional limitations. There could be additional ownership changes in the future that could further limit the amount of NOL carryforwards that the Company can utilize. The Company has not yet conducted a study of its R&amp;D credit carryforwards. Such a study may result in an adjustment to the Company&#8217;s R&amp;D credit carryforwards; however, until a study is completed, and any adjustment is known, no amount is being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s R&amp;D credit carryforwards, and, if an adjustment is required, it would be offset by an adjustment to the valuation allowance.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it has operations to determine the potential effect on its business and any assumptions it has made about its future taxable income. The Company cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, the Company has no assurance that the provision will be repealed or otherwise modified.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's consolidated statements of operations. Due to NOL and R&amp;D credit carryforwards that remain unutilized, income tax returns filed in the United States, certain states within the United States and Canadian tax jurisdictions from the Company's inception through 2021 remain subject to examination by the taxing jurisdictions. There are currently no audits in process in any of the Company's tax filing jurisdictions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383949808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementTextBlock', window );">LICENSE AGREEMENTS</a></td>
<td class="text">LICENSE AGREEMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. Upon the Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company became obligated to pay $0.5&#160;million in a milestone payment to Zurich. The Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded expenses of $0.3&#160;million and $0.5&#160;million related to meeting a development milestone, the submission of the Company&#8217;s BLA with the FDA in December 2020, and a regulatory milestone, the Company&#8217;s receipt of the CRL from the FDA in August 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents (which are now expired) cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of December&#160;31, 2022, even though the patents have expired, the Company may be obligated to pay up to &#8364;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.6&#160;million at exchange rates in effect on December&#160;31, 2022). The Company is also required to pay up to a 3.5% royalty on the net sales for products covered by the </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;50,000, which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#8364;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. The Company recorded an expense of &#8364;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, the Company recorded an expense of &#8364;50,000 ($51,770) related to the annual license maintenance fee. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vysyneum is the proprietary brand name conditionally approved by the EMA for oportuzumab monatox in the E.U. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights (which are now expired) and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, even though the patents have expired, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company entered into an asset purchase agreement with Roche (the &#8220;Roche Asset Purchase Agreement&#8221;) pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $70.0&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40.0&#160;million payment to the Company upon execution of the Roche Asset Purchase Agreement, which was recorded as license revenue in the third quarter of 2022. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30.0&#160;million payment to the Company upon Roche&#8217;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026. Pursuant to ASC 606, the variable consideration of $30.0&#160;million is constrained. Therefore, the amount was not recorded as revenue during the year ended December 31, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At or prior to the effective time of the Merger, the Company will enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with a rights agent (&#8220;Rights Agent&#8221;) pursuant to which the Company intends to declare a dividend payable to the Company&#8217;s stockholders of record as of a date agreed to by the Company and Carisma prior to the effective time of the Merger with respect to the receipt of one contingent value right (each, a &#8220;CVR&#8221;) for each outstanding share of the Company&#8217;s common stock held by such stockholders on such date. Each CVR will represent the contractual right to receive (i) contingent cash payments upon the receipt by the Company of certain proceeds payable by Roche, if any, pursuant to the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement, as well as (ii) proceeds from any sale of the Company's legacy assets, including Vicineum, subject to certain customary deductions, including for expenses and taxes, in the event any sale occurs prior to March 31, 2027. The contingent payments under the CVR Agreement, if they become due, will be payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement. There can be no assurance that any cash payment will be made or that any holders of CVRs will receive any amounts with respect thereto.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Former OUS Business Development Partnership Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu (the &#8220;Qilu License Agreement&#8221;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2022, the Company terminated the Qilu License Agreement. In connection with the termination of the Qilu License Agreement, the Company agreed to make an aggregate payment to Qilu of $1.4&#160;million, which consists of a $1.2&#160;million termination fee payable upon the termination of the Qilu License Agreement, which was paid in the fourth quarter of 2022, and a $200,000 payment payable upon our receipt of certain clinical data and chemistry, manufacturing, and controls data from Qilu, which such payment was not made as of December 31, 2022. Accordingly, $0.2&#160;million remained on the Company's balance sheet in accrued liabilities as of December 31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hikma License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region (the "Hikma License Agreement"). The Company retained development and commercialization rights in the rest of the world excluding Greater China, Turkey, and MENA. In consideration for the rights granted by the Company, the counterparty to the Hikma License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the Hikma License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2022, the Company provided notice of termination of the Hikma License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the United States. In connection with such termination, the Company refunded to Hikma the $3.0&#160;million upfront payment.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement"). Under the terms of the License Agreement, the Company was entitled to receive an upfront payment of $1.5&#160;million. The Company and EIP have subsequently amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company would have been eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and also to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </span></div>On July 20, 2022, the Company provided notice of termination of the EIP License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the United States. The EIP License Agreement was terminated on October 20, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383892048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING AND RELATED ACTIVITIES</a></td>
<td class="text">RESTRUCTURING AND RELATED ACTIVITIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to voluntarily pause further development of Vicineum in the United States (the &#8220;2022 Restructuring Plan&#8221;). Execution of the 2022 Restructuring Plan is expected to be substantially completed in connection with the closing of the Merger with Carisma, which is expected to occur in the first quarter of 2023. The 2022 Restructuring Plan includes an incremental reduction in the Company&#8217;s workforce as well as additional cost-saving initiatives intended to preserve capital during the pendency of the Merger with Carisma and while the Company seeks a potential partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also incurred one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan. The following is a summary of accrued restructuring costs related to the 2022 Restructuring Plan, (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Restructuring Plan </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination and other associated costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructurings costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs related to the 2022 Restructuring Plan were recorded in operating expenses in the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss in the year ended December 31, 2022. The Company expects that substantially all accrued restructuring costs as of December 31, 2022 will be paid in cash in connection with the closing of the Merger with Carisma, which is expected to be completed in the first quarter of 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;2021 Restructuring Plan&#8221;). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Restructuring Plan included a reduction in the Company&#8217;s workforce by 18 positions (or approximately 35% of the Company&#8217;s workforce as of the date of the 2021 Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continued development of Vicineum. The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Restructuring Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Restructuring costs related to the 2021 Restructuring Plan were recorded in operating expenses in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss in the year ended December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245380273184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nasdaq Delisting Notice</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger with Carisma, the Company is seeking the approval of its stockholders to, among other things, (a) issue the shares of its common stock issuable in connection with the Merger pursuant to the rules of Nasdaq, and (b) amend its amended and restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of its common stock at a ratio of 1-for-20 (clauses (a) and (b), collectively, the &#8220;Sesen Bio Voting Proposals&#8221;). The special meeting of stockholders in which the Company&#8217;s stockholders will be asked to vote on the Sesen Bio Voting Proposals will be held on March 2, 2023 at 10:00 a.m. Eastern Time (the "Special Meeting").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2023, the Company was notified by the Listing Qualifications Department (the &#8220;Staff&#8221;) of Nasdaq that, based upon the Company&#8217;s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price Rule&#8221;), the Company&#8217;s common stock will be delisted from Nasdaq unless it timely requests a hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company requested a hearing before the Panel, which stayed any delisting action by the Staff and ensured the Company&#8217;s common stock remains listed and eligible for trading on Nasdaq pending a determination by the Panel. The hearing had been scheduled for March 16, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2023, the Company received a determination from the Nasdaq Office of General Counsel that the Panel granted the Company an exception from its non-compliance with the Bid Price Rule to complete the Merger by March 10, 2023. Pursuant to Nasdaq Listing Rule 5110(a), the Company must demonstrate compliance with all initial listing requirements of Nasdaq upon the closing of the Merger. The Company is seeking approval for the Merger and the implementation of a reverse stock split of its common stock at the Special Meeting. In the event the Company fails to establish compliance with the initial listing standards by March 10, 2023, the common stock will be delisted from Nasdaq, unless granted an additional exception by the Panel.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 24, 2022, the Company received written notice from the Staff indicating that, based upon the closing bid price for its common stock for the previous 30 consecutive business days, the Company no longer satisfied the Bid Price Rule and, in accordance with the Nasdaq Listing Rules, was afforded an initial grace period of 180 calendar days, through July 25, 2022, and a second 180-calendar day period, through January 23, 2023, to regain compliance with the Bid Price Rule. The Company did not regain compliance with the Bid Price Rule by January 23, 2023, which resulted in the Staff&#8217;s January 25, 2023, determination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245376855536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission ("SEC") requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the United States dollar.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk</a></td>
<td class="text">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit RiskThe Company's cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company's primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company's corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents, marketable securities, and accounts receivable. The Company limited its credit risk associated with cash equivalents and marketable securities by investing in highly-rated money market funds, US government securities, and treasury securities. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial institutions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">Marketable SecuritiesThe Company classifies all of its marketable securities as available-for-sale. The marketable securities consist of holdings in US treasury securities and US government securities, with maturity dates ranging from March 2023 to November 2023, which is consistent with the Company's investment policy. Accordingly, these investments are recorded at fair value which is determined based on quoted market prices. Amortization and accretion of discounts and premiums are recorded as interest income. Realized gains and losses are included in other income (expense), net. Unrealized gains and losses are included in other comprehensive loss as a component of stockholder&#8217;s equity (deficit) until realized.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of five years for lab equipment, four years for furniture </span></div>and fixtures, three years for computer equipment and software and the lesser of five years or the remaining lease term for leasehold improvements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets consisted of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in share price and a resulting decrease in its market capitalization. On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of its intangible asset of Vicineum E.U. rights. The Company concluded that the carrying value of its intangible asset of Vicineum E.U. rights of $14.7&#160;million was fully impaired as of June 30, 2022 and was reduced to zero in the second quarter of 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company received a Complete Response Letter ("CRL") from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing, and controls ("CMC") issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's marketing authorization application ("MAA"), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the United States market.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheets is the result of the Company&#8217;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. The Company has only one reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed continued trends in its market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, size, length and cost of a clinical trial, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of its typical annual assessment </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. The Company updated its revenue forecast models based on further expected launch delays in both United States and outside of the United States ("OUS") regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. The Company also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired as of June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September 2016. See "Note 1. Description of Business" above for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of its contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales were expected to be achieved through 2033, the level of commercial sales of Vicineum then-forecasted for the United States, Europe, Japan, China and other potential markets. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout was derived from the Company's estimated weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, it is seeking a partner for the further development of Vicineum. Accordingly, during the second quarter of 2022, the Company concluded that it is no longer expected to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential 2% earnout payment related to China, Hong Kong, Macau and Taiwan (collectively, &#8220;Greater China&#8221;) region since those territory rights had been out-licensed. Qilu Pharmaceutical, Co., Ltd. ("Qilu") held the exclusive license to develop Vicineum in the Greater China region, and accordingly, the $1.8&#160;million estimated earnout payment in the Greater China region remained as long-term contingent consideration as of June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, Qilu informed the Company that it no longer intended to commercialize Vicineum, due to additional effort and costs required to gain regulatory approval in that region without prior US approval. As such, the Company and Qilu were in the process of negotiating a termination of the Qilu License Agreement, which was terminated on December 23, 2022. Accordingly, the Company concluded that it no longer expected to owe any future earnout payments related to the Greater China region and reduced its remaining $1.8&#160;million of contingent consideration liabilities to zero as of September 30, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease portfolio as of December 31, 2022 includes a property lease for its headquarters in Cambridge, MA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company&#8217;s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company's consolidated balance sheet. The short-term and long-term </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability components are recorded in other current liabilities and other liabilities, respectively, on the Company&#8217;s consolidated balance sheet. As of December&#160;31, 2022, the Company did not have any finance leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives' stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company&#8217;s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management&#8217;s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each grant of options during the years ended December&#160;31, 2022, 2021 and 2020 was determined using the following methods and assumptions:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term. G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iven the plain vanilla nature of the options granted by the Company, the expected term is determined using the "simplified" method, as prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 ("SAB 107"), whereby the expected life equals the arithmetic average of the vesting term (generally four years) and the original contractual term (ten years) of the option, taking into consideration multiple vesting tranches. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company's own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend Yield. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dividend yield is 0% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and research and development credit ("R&amp;D credit") carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not </span></div>(greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&#160;31, 2022 and 2021, the Company did not have any uncertain tax positions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded revenue from former out-license agreements and OUS business development partnership agreements, including the former license agreement (the &#8220;Roche License Agreement&#8221;) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) and its former OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)   Identification of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)  Determination of whether the promised goods or services are performance obligations including whether they are                        distinct in the context of the contract&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)  Measurement of the transaction price, including the constraint on variable consideration&#894;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)  Allocation of the transaction price to the performance obligations&#894; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)  Recognition of revenue when or as the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Regulatory Milestones and Other Payments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#8217;s estimate of milestones and royalties approximates the standalone selling price of the license.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss and other comprehensive loss. For the year ended December 31, 2022, other comprehensive loss included changes in unrealized income and loss on marketable securities. For the years ended December&#160;31, 2021 and 2020 comprehensive loss was equal to net loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share ("EPS") guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s consolidated balance sheets approximated their fair values as of December&#160;31, 2022 and 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div>Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245380290848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Carrying Amounts and Fair Values of Financial Instruments Measured</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:13pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of Contingent Consideration Liability</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - long term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383920000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRICTED CASH AND MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The  following table sets forth the composition of the Company&#8217;s marketable securities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"/><td style="width:42.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government securities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Marketable Securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company had no marketable securities as of December 31, 2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383904064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Composition of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of property and equipment, net as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Property and Equipment, Net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383904064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Composition of Intangible Assets</a></td>
<td class="text">The following table sets forth the composition of intangible assets as of December&#160;31, 2022 and 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum United States rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245383985088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Components of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:67.067%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal expenses, including the preliminary securities litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245382220976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Cost</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December&#160;31, 2022 and 2021 is as follows (in thousands):</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease Cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease (including related operating costs)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term property leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">458</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Supplemental Information:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245384712832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Common Stock</a></td>
<td class="text">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&#160;31, 2022 and 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:67.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.100%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,759</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding and Warrant Activity</a></td>
<td class="text">The following table sets forth the Company's warrant activity for the year ended December&#160;31, 2022 (in thousands):<div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification described below and (ii) subject to further adjustment based on down round provision added by amendment described below.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245380340448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Diluted Loss Calculation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of December&#160;31, 2022, 2021 and 2020 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:53.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,902</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245384232240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"/><td style="width:277.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,909</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of the Status of Restricted Stock Units</a></td>
<td class="text">A summary of the status of restricted stock units is presented below: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tr><td style="width:1.0%"/><td style="width:75.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:41.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.52</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.93</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.90</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,304&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.77</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DM</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245385045488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Pre-tax Loss</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total Loss Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23,759)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,952)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Benefit (Provision)</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Tax Provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current (provision)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred benefit (provision)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,559&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Benefit (Provision) </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,875</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Expected Income Tax Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company&#8217;s effective income tax rate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal statutory income tax rate</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option cancellations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill write-off</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Income Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule Components of Deferred Tax Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;R&amp;D credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRC 174 Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accruals and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Capitalized start-up costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,969)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,969)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,453)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,849)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,631)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net Deferred Tax Liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,969)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,528)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of Credit Carryforwards</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's NOL and R&amp;D and other credit carryforwards in the United States and Canada as of December&#160;31, 2022 (in millions):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Beginning in</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards - indefinite</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal R&amp;D credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;State R&amp;D credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal non-capital loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal scientific research and experimental development<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expense carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Federal and provincial investment tax credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245380341680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text">The following is a summary of accrued restructuring costs related to the 2022 Restructuring Plan, (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Restructuring Plan </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination and other associated costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructurings costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table>The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Restructuring Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245379391776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details) - USD ($)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,141<span></span>
</td>
<td class="nump">$ 316,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Negative cash flows from operating activities incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24,895)<span></span>
</td>
<td class="nump">$ 68,878<span></span>
</td>
<td class="nump">$ 30,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare', window );">Shares of common stock issued to the selling shareholders (in shares)</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales', window );">Period during which quarterly earn-outs are payable after date of net sales</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations', window );">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods', window );">Percentage of net sales of quarterly earn-out payments during earn-out periods</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245377363056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>unit</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit', window );">Insurance coverage limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="nump">$ 27,764,000<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,064,000<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="nump">$ 13,064,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">13,064,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="nump">$ 26,544,000<span></span>
</td>
<td class="nump">$ 11,236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WeightedAverageCostOfCapital', window );">Weighted-average cost of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved', window );">Proceeds from milestone achieved</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementMilestonePaymentTerm', window );">Milestone payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_ViciniumMember', window );">Vicinium | Europe | IPR&amp;D intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_EBI031Member', window );">EBI-031 | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved', window );">Proceeds from milestone achieved</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestonePaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestonePaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Proceeds From Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementProceedsFromMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Cost of Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116652737&amp;loc=d3e64164-112818<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_EBI031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_EBI031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245378483184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 54,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">76,728<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets (Level&#160;1) | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets (Level&#160;1) | US treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level&#160;2) | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level&#160;2) | US treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level&#160;3) | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level&#160;3) | US treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">76,728<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Recurring | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Recurring | US treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">76,728<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration - long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Recurring | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Recurring | US treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 4,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245376707744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WeightedAverageCostOfCapital', window );">Weighted-average cost of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Cost of Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245381194944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">52,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent', window );">Change in fair value of contingent consideration - long term</a></td>
<td class="num">(52,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245379374480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTRICTED CASH AND MARKETABLE SECURITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short term restricted cash</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245376791408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTRICTED CASH AND MARKETABLE SECURITIES - Schedule of Cash, Cash Equivalents, Restricted Cash And Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 54,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(546)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">54,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">49,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 4,935<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245377979392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECEIVABLES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,011<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_AccountsReceivablePaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved', window );">Proceeds from milestone achieved</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccountsReceivablePaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccountsReceivablePaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Proceeds From Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementProceedsFromMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245373713936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(966)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total Property and Equipment, Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245385834320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245384686160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details) - IPR&amp;D intangible assets: - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Vicinium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">European Union | Vicinium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245377950944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="nump">$ 27,764,000<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,064,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_ViciniumMember', window );">Vicinium | Europe | IPR&amp;D intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245378117744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES - Components of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 1,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll-related expenses</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_AccruedRestructuringChargesRelatedCurrent', window );">Restructuring charge related</a></td>
<td class="nump">5,733<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_AccruedLegalFeesCurrent', window );">Legal expenses, including the preliminary securities litigation settlement</a></td>
<td class="nump">21,919<span></span>
</td>
<td class="nump">1,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Expenses</a></td>
<td class="nump">$ 29,636<span></span>
</td>
<td class="nump">$ 8,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedRestructuringChargesRelatedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Restructuring Charges Related, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedRestructuringChargesRelatedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245377952896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember', window );">Securities Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_NumberOfLawsuits', window );">Number of lawsuits | lawsuit</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated litigation liability</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sesn_FederalDerivativeLitigationMember', window );">Federal Derivative Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_NumberOfLawsuits', window );">Number of lawsuits | lawsuit</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payment of litigation fees</a></td>
<td class="nump">$ 630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberOfLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberOfLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sesn_FederalDerivativeLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sesn_FederalDerivativeLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245381035856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term property leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="nump">$ 262,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease (including related operating costs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 123,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short term lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 123,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OperatingLeasesAreaOfOfficeSpace', window );">Office space (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OperatingLeaseLeaseTerminationPayment', window );">Operating lease, termination expense</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseLeaseTerminationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Termination Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseLeaseTerminationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeasesAreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Area Of Office Space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeasesAreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245384530288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease (including related operating costs)</a></td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">$ 327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term property leases</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">$ 589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SupplementalLeaseInformationAbstract', window );"><strong>Supplemental Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SupplementalLeaseInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Lease Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SupplementalLeaseInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245378360624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction', window );">Aggregate sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of units issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_CommonStockAndWarrantOrRightsPricePerShare', window );">Stock and warrants price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember', window );">ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SaleOfStockAdditionalSharesAuthorizedForSale', window );">Additional shares to be issued</a></td>
<td class="nump">$ 34.5<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction', window );">Aggregate sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SaleOfStockCommissionFixedRate', window );">Commission fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of units issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts', window );">Issuance of common stock, issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockAndWarrantOrRightsPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock And Warrant Or Rights, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockAndWarrantOrRightsPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockAdditionalSharesAuthorizedForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Additional Shares Authorized For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockAdditionalSharesAuthorizedForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockCommissionFixedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission Fixed Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockCommissionFixedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Sales Price In Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Weighted-Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, New Issues, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245384331344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245384685712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 03, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 02, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">202,759,043<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">202,759,043<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">202,759,043<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
<td class="nump">106,801,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_NumberofVotesEntitledForEachShare', window );">Number of votes | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberofVotesEntitledForEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Votes Entitled For Each Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberofVotesEntitledForEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245379400800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">202,759,043<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_CommonStockSharesIssuedAndReservedForFuture', window );">Total shares of common stock issued and reserved for issuance (in shares)</a></td>
<td class="nump">229,777,000<span></span>
</td>
<td class="nump">229,640,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">187,000<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">15,304,000<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">4,695,000<span></span>
</td>
<td class="nump">3,041,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Shares available for grant under 2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">4,532,000<span></span>
</td>
<td class="nump">8,933,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for sale under 2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockSharesIssuedAndReservedForFuture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Issued And Reserved For Future</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockSharesIssuedAndReservedForFuture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Of Common Stock Reserved For Issuance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharesOfCommonStockReservedForIssuanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245378488768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member', window );">Warrants, Expiring March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member', window );">Warrants, Expiring November 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member', window );">Warrants, Expiring November 2024, Issued May 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 11.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member', window );">Warrants, Expiring November 2024, Issued November 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 11.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued During The Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Number Of Expirations During The Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Or Right Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245376976416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Increase in warrant value</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,126<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OtherDividendAndAdjustments', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,048,059<span></span>
</td>
<td class="nump">238,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member', window );">2018 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member', window );">2018 Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of common stock warrants</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of stock warrants (in shares)</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member', window );">2017 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member', window );">2017 Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember', window );">2018 Warrant Amendment, Amendment to Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued', window );">Minimum percentage of securities issued</a></td>
<td class="nump">50.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember', window );">2018 Warrant Amendment, Amendment to Securities Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Minimum Percentage of Securities Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OtherDividendAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Dividend And Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OtherDividendAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245377916800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">20,186<span></span>
</td>
<td class="nump">15,902<span></span>
</td>
<td class="nump">12,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">2,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">15,304<span></span>
</td>
<td class="nump">15,703<span></span>
</td>
<td class="nump">10,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember', window );">RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">4,695<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245379436096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">$ 6,909<span></span>
</td>
<td class="nump">$ 5,143<span></span>
</td>
<td class="nump">$ 1,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">1,985<span></span>
</td>
<td class="nump">973<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">$ 4,924<span></span>
</td>
<td class="nump">$ 4,170<span></span>
</td>
<td class="nump">$ 1,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245373298832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,304,000<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
<td class="nump">10,147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,236,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,909,000<span></span>
</td>
<td class="nump">$ 5,143,000<span></span>
</td>
<td class="nump">$ 1,757,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost, non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period unvested stock to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,304,000<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,695,000<span></span>
</td>
<td class="nump">3,041,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 1 day<span></span>
</td>
<td class="text">9 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 1 day<span></span>
</td>
<td class="text">9 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember', window );">2014 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_RetentionProgramMember', window );">Retention Program | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward', window );">Shares received per award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_RetentionProgramMember', window );">Retention Program | Performance-Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward', window );">Shares received per award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary', window );">Percent of base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_RetentionProgramCashManagementMilestoneMember', window );">Retention Program, cash management milestone | Performance-Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent', window );">Achievement deemed probable, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member', window );">Stock Incentive Plan 2009 | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting on the First Anniversary of Date of Grant | 2014 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of original number of shares subject to the option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting at End of Each Successive Three-Month Period Thereafter | 2014 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of original number of shares subject to the option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_RetentionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_RetentionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_RetentionProgramCashManagementMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_RetentionProgramCashManagementMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245379391472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, beginning balance (in shares)</a></td>
<td class="nump">3,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(3,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled or forfeited (in shares)</a></td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, ending balance (in shares)</a></td>
<td class="nump">4,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">4,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245378321392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Options (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares under Option (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">15,703<span></span>
</td>
<td class="nump">10,147<span></span>
</td>
<td class="nump">6,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,510<span></span>
</td>
<td class="nump">8,273<span></span>
</td>
<td class="nump">4,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled or forfeited (in shares)</a></td>
<td class="num">(1,907)<span></span>
</td>
<td class="num">(2,683)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">15,304<span></span>
</td>
<td class="nump">15,703<span></span>
</td>
<td class="nump">10,147<span></span>
</td>
<td class="nump">6,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">10,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0.72<span></span>
</td>
<td class="nump">3.32<span></span>
</td>
<td class="nump">0.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0.32<span></span>
</td>
<td class="nump">1.23<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">1.90<span></span>
</td>
<td class="nump">3.70<span></span>
</td>
<td class="nump">1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">1.82<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Life (in years), Outstanding</a></td>
<td class="text">7 years 2 months 8 days<span></span>
</td>
<td class="text">8 years 10 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">8 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Life (in years), Exercisable</a></td>
<td class="text">6 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 3,160<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245468067984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue', window );">Fair market value (in dollars per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 3.32<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 3.32<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">71.80%<span></span>
</td>
<td class="nump">74.60%<span></span>
</td>
<td class="nump">71.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245377956576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution retirement plan, maximum employee contribution deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee', window );">Discretionary match per participating employee, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Common stock purchase price, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for sale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245381117312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Pre-tax Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total Loss Before Income Taxes</a></td>
<td class="num">$ (23,759)<span></span>
</td>
<td class="num">$ (8,609)<span></span>
</td>
<td class="num">$ (20,952)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Pre-tax income (loss) U.S.</a></td>
<td class="num">(37,289)<span></span>
</td>
<td class="num">(32,757)<span></span>
</td>
<td class="num">(35,529)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Pre-tax income (loss) Canada</a></td>
<td class="nump">$ 13,530<span></span>
</td>
<td class="nump">$ 24,148<span></span>
</td>
<td class="nump">$ 14,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245373679088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Income Tax Provisions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current Tax Provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="num">(1,445)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current (provision)</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="num">(1,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred tax provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">3,969<span></span>
</td>
<td class="nump">8,559<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred benefit (provision)</a></td>
<td class="nump">3,969<span></span>
</td>
<td class="nump">8,559<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) from income taxes</a></td>
<td class="nump">$ 3,875<span></span>
</td>
<td class="nump">$ 8,273<span></span>
</td>
<td class="num">$ (1,445)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245377975568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">United States federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Impact of foreign rate differential</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="num">(15.90%)<span></span>
</td>
<td class="num">(4.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock option cancellations</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent', window );">Contingent consideration</a></td>
<td class="nump">59.10%<span></span>
</td>
<td class="nump">178.20%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">General business credits and other credits</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent', window );">Goodwill write-off</a></td>
<td class="num">(14.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Other</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(13.80%)<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Foreign taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(3.30%)<span></span>
</td>
<td class="num">(6.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in valuation allowance</a></td>
<td class="num">(44.60%)<span></span>
</td>
<td class="num">(72.30%)<span></span>
</td>
<td class="num">(37.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate</a></td>
<td class="nump">16.70%<span></span>
</td>
<td class="nump">96.10%<span></span>
</td>
<td class="num">(6.90%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Contingent Consideration, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Goodwill Write-off, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245378106256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 66,374<span></span>
</td>
<td class="nump">$ 63,381<span></span>
</td>
<td class="nump">$ 57,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit carryforwards</a></td>
<td class="nump">4,489<span></span>
</td>
<td class="nump">4,316<span></span>
</td>
<td class="nump">3,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">IRC 174 Capitalized R&amp;D</a></td>
<td class="nump">6,214<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Accruals and other</a></td>
<td class="nump">5,326<span></span>
</td>
<td class="nump">4,058<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_DeferredTaxAssetsCapitalizedStartUpCosts', window );">Capitalized start-up costs</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">82,453<span></span>
</td>
<td class="nump">71,849<span></span>
</td>
<td class="nump">65,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,969)<span></span>
</td>
<td class="num">(12,528)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,969)<span></span>
</td>
<td class="num">(12,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(82,453)<span></span>
</td>
<td class="num">(71,849)<span></span>
</td>
<td class="num">(65,631)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net Deferred Tax Liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,969)<span></span>
</td>
<td class="num">$ (12,528)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DeferredTaxAssetsCapitalizedStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capitalized Start Up Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DeferredTaxAssetsCapitalizedStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245381122144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 82,453<span></span>
</td>
<td class="nump">$ 71,849<span></span>
</td>
<td class="nump">$ 65,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance change</a></td>
<td class="nump">10,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OperatingLossCarryforwardsDecrease', window );">NOL carryforward reduced amount</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLossCarryforwardsDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Decrease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLossCarryforwardsDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245377894880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Credit Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States: | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 117.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States: | State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">138.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_NetOperatingLossCarryforwardAxis=sesn_IndefiniteMember', window );">Indefinite | United States: | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">101.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">R&amp;D credit carryforwards | United States: | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">R&amp;D credit carryforwards | United States: | State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">R&amp;D credit carryforwards | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=sesn_NonCapitalLossCarryforwardMember', window );">Non-capital loss carryforwards | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">43.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember', window );">Investment tax credit carryforwards | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NetOperatingLossCarryforwardAxis=sesn_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NetOperatingLossCarryforwardAxis=sesn_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=sesn_NonCapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=sesn_NonCapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245372350144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 20, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_AssetPurchaseAgreementVariableConsideration', window );">Asset purchase agreement, variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_PaymentsToRefundLicenseAgreementDeposits', window );">Payments to refund license agreement deposits</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount', window );">Total milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_BusinessCombinationRoyaltyPaymentPercent', window );">Royalty payment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">Third party maximum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">Third party minimum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember', window );">Micromet AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="nump">$ 51,770<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">&#8364; 2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent', window );">License agreement, royalty payment, reduction, conditions not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseMaintenanceFees', window );">License maintenance fees | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember', window );">XOMA Ireland Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">Third party maximum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">Third party minimum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OtherReceivableAssetPurchaseAgreement', window );">Other receivable, asset purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement', window );">Proceeds from execution of asset purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OtherReceivableAssetPurchaseAgreement', window );">Other receivable, asset purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_CollaborativeArrangementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementTerminationExpense', window );">License termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementTerminationPayment', window );">License termination payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember', window );">MENA License Agreement | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">Eczacibasi Pharmaceuticals Marketing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">Eczacibasi Pharmaceuticals Marketing Agreement | TURKEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_RoyaltyRevenuePercentage', window );">Royalty revenue, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AssetPurchaseAgreementVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Variable Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AssetPurchaseAgreementVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Long-term Purchase Commitment, Milestone Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationRoyaltyPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Royalty Payment Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationRoyaltyPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CollaborativeArrangementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CollaborativeArrangementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Amount Payable Upon Achievement of Specified Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchievementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achievement Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchievementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty On Net Product Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty on Net Product Sales, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementTerminationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Termination Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementTerminationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementTerminationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Termination Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementTerminationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Maintenance Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OrganizationAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization And Basis Of Presentation [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OrganizationAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OtherReceivableAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Receivable, Asset Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OtherReceivableAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_PaymentsToRefundLicenseAgreementDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Refund License Agreement Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_PaymentsToRefundLicenseAgreementDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Execution Of Asset Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ProceedsFromExecutionOfAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RoyaltyRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Revenue, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RoyaltyRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MicrometAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_EBI031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_EBI031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245384640832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details) - 2021 Restructuring Plan<br></strong></div></th>
<th class="th">
<div>Aug. 30, 2021 </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of positions eliminated</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated, period percent</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=sesn_A2021RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=sesn_A2021RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245377275104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES - Schedule of Restructuring Reserve by Type of Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 1,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">11,764<span></span>
</td>
<td class="nump">$ 5,528<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(1,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sesn_A2022RestructuringPlanMember', window );">2022 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">11,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(6,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">5,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance and benefits costs | 2022 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">6,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Contract termination and other associated costs | 2022 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="nump">$ 4,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=sesn_A2022RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=sesn_A2022RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140245384088176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br></strong></div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>sesn-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sesn="http://www.sesenbio.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sesn-20221231.xsd" xlink:type="simple"/>
    <context id="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6fb401e67dfc467b98d93144d057b5fc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2e57ab72df0c4d23813023acb9286a55_I20230221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-02-21</instant>
        </period>
    </context>
    <context id="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a787f6e1c15471ebea82677593dbf11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d35c30040aa4486b9b15a04bdee6aa2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9289325bda434664a6a39b85b67bfae9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i89feec3c1c304077906365e7fa3071f1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i09358b4a0bcc4a3385a7f499156e77ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i405074fedfc34261a6aa9a70d2ea0ce6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i73c47e791149483dac9b339dd293b4ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id683680be9e042e0acf2733abe0d9cdb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i97dd7567e83c47af9d549f491e6200b0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i887ce3b59fe94c8084e3c22ab03fb7ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i19f82fd2d2e7407a97261cd8548780c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib748ce8528614265bc45eb9a76e9bfb0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3799557388394b24b27d06e94128d950_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i295ca9347a54466f93585f285c63b26b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9e5a066bf5f4ca5a26ac3aa00160ed3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib968e3f687d845e2a83107904373ff5c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87c1ee91ad034903b0d19285c24c8b19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01d57c119960482d81011d8c04ff8399_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3da3a125129480eb2e8ebb6f49f42bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6ddcc8cd57e7497282b01d86668e8ae3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i83051d731ef64fbab70f1bd36b04864c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib200f78d81c84f1caf083a586963ba04_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib82c4185c6fb4d92896edaac365482ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7947774ff61e417ca66c44d164ba6650_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4462842a9194410a79f71e762585fbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbabad301b294437b56c5d188d25d543_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if21d4b6455c5495b8488303a238975a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d4fa9f625b54b30b2dff2dc6a1a867b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12d3333974e14f89a7ec3f471522f303_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1b86eb7007d470aa9e0586557f94125_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i822d046be15341d59a14431cd169a913_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i521bc055cda840c99e95281f5864c7ad_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib3abd01beb2944a8aabb8c310e92e38a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i40b12428f67b4fb289c73df6c14dd797_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e556b75c0e543168782ac584ea02832_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c1925aa09c546e6bb1bbc2f922a757c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8207bee1099a4945acebe2cd3e4d4b1c_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="iae93f5204e234406aa4669d7fa75acb3_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="ia2f5bb9a1d474d50a682361408fd22f0_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i0cdc0620bb5249d1b453c6ee1ee52d9f_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="ifec4efcaaaba4d86ae2f9115d511c3ad_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i0d5d00287d2b402c81fe18e1a760ee21_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i1276d33828844073b58b8708d329e283_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ife760fe6115044c2ba0cfc773be36b66_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1f4a4968e654e81812812835738bfba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2bd951ea3e6843248bca81db2ab27548_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iff61ad1254204984b2cd73c3460b9b29_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ied811451007444bf9c9766b4e6b6f65e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6bb37825c3464e0e96f96656c460f0b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8733b9f5af3744478388e7790ab97043_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i438fa29ca3bb484a8da013a3e14bb5aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4b69c2d148fb4538a3850c0e09af5f52_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ideb2c67211a74687ab81a95f14fff15e_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i60b94d2194694dd39ade84abefa3fbd2_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i38ea235079af435bad2ec47753289b96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i494cedbff9d444cdaac1c2802663fc2b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88aacf670d6d4b4d880e4b578f023b29_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b14fcd0c3d7431fa4d0dfee8ba33375_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic7077879bdc245db95b0560b33dc1e1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b6b0b19859b4275a8ba10b9aa85008e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i65e64d741e894999bf76a1e7cf64b004_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89820af99a774c6da12e89d3f3b664cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f8f5e0d0c4144a4959bc06d609ca157_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib898a55a349649d690d06fb7f3e654d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id74fe8f2daef45e18f8d67cb5c61198b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2efef4133dd04188a2f6d5ffc3064dcd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc6f81f8bf0246f39eed469355ba430e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f40cef73b6f464299f697a3de9e26bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i074825a299f84fcd81b16f4255ea2ad7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i917a1b8a73ae45318b8d10a7f14926dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica10e8f91cd84acdbe3c5774e4168b74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a8370652ea34632aa61254cc191c0a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4b6eb53935e4e5f9644289109556c1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c307f87ede64e08ba34df00d1e3be8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd6d796c44ea43198dc7c3fb8d6ae129_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c2a1c5a91084f178b29a4fe51e14ea2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i39409440477849f689c25e277356952c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i426ddaf2851e41c3b2b8a1b26933b3da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8260e3eaa13f41a3a609d11ef48a8540_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3cd4cc1171943f0abebe901bfe21fec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93938c1286d6418fb704e36349eb0d31_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9871161ad5a44399978150d031c7b8ce_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i71d9693f005d44b68ed0b5546044f4d8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if34f56efef5946f89e9010b83ecc7d97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i611e9ad1d7694553bcda04f42fc4e80b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1df7ab1adf0148c78a21e7ce97a4d22f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id44669cb53d947d4ad326771aa7b9afe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4f414a7418a405588fb22be6f30e0c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i655ddc8bcc5848c5b1d7a3ff27a40ba1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ab420bf8ef045078703d770aad32427_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6e3f81d8d1b4f3f97c34c9b3d9b0f02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife751660f97f4281991e4b6aa712c73d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25d39b728d0147189730e15e9fd156c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94c243529fbd4ad2a365269cda0a0347_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bf382fe4d8647e58e6ad3d32e4f377c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id21ae50c8649402492cc8890f61aece0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie6fca7ca9a1e4c2bb4c5439eaa2b6d6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50aaf5a9d1c54113a3349e45d1378020_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica22b69fbf7d46f5a9b967bc6cee46d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6a7b597081d4512984c70d7af968aac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sesn:InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2c8425e295a4831bc9d718ca118ecff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sesn:FederalDerivativeLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1c302f137734bc69da3529bc113e959_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sesn:FederalDerivativeLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iebe3ee0020554764957e449756650c1d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0673287f84aa4bb4988c54a1565f24ce_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i973f2496cf69482fb40920ac6f30b991_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibaf5b39852dc407e946c46788b3a04b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5f88572fbcae4d3b843b90b31979aadf_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i2761fdbe240c456bb83255f46df5df11_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i0f7e4670d4c7461595be03c9af5334ba_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i8cda9cd3a8574fc2a6b9461f91c4497c_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i87f4d91941044efabca8fc31db5686f0_D20210601-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i6a4e17d327564862bc9c9d71d1aabc8f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8cdc8306a15942548c12172f72054f94_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i84030fd2a4514267a4a2169a1b8e2e55_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i653d509451834b36b0c7c25dd6f1e8ea_I20210502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-05-02</instant>
        </period>
    </context>
    <context id="i26100f264698454388e652d4dcede710_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="i34e59a9de0bb4644baea5c1090868f0b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bd6743eae8e4cfdbb03b06c8b121eee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2979721cc12044649222cc680229209d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2fff5776971a48a586881cd89287df3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i106b662daae24333b435aacc7c1a07b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72d9266aa5eb429b9daf124e3bbc9a6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8327d77c1755491d93d7990856f3cc52_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i019d2729b50e475f80b2f52267d77679_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica9046a3714e4afebe942291c8bb1be6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9f2bff1e4304c31873755098104fc76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i800abfbe2a3a4ff98ee18c6daa3452eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7529f34d71c8489d8eddf8fd724fd5ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc78166d67464d8dbbf2a4acfe7206bd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8d3704f824a24ee3ab53e3e9b975ae7f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia6e4124d7d374ca0bc952081d6c500f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82a243d92e624ce19e709802a563543c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie68ccfa087a542998d3e397047b34a57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifdcb7e9d6aeb45f3b64cf0988fbf00e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ed2728c8f6640a5b89ab51323c10e96_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib00557f6793a464ebb3158651e79e729_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie3c6905ce21c40b18f3059d5f6e237f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieeddaa2b96474d13a379ff7566291039_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i23b7cb6c58024d5b9f676827326355bb_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="iaa5fc09e9b4244549466aede24ab208e_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48ca0d5ad9bd4085818dc426b3589eb2_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib6e50ab15b3f4156bd82e204e7b093e6_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i7a1490314240433882cb0da9a6d1b2de_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i7d82589e0dd040a795545a962a2cb1a0_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i015d83f362d9409aaffa4d0d06f715d7_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="id958531e2fb946e3920b1cee8b9b3c37_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5725754243984358952852405d13672b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i56bec24a6f664962bb4939227b4c9cda_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i05fdf323c4eb41f591b33f27de2e40b4_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3f9fd02125934e03bde7e6db929d631b_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i9dcf8ba7b1154c71807f93d29f6d1cc8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia76e658e62f94a39b6fa63c38baf1887_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id51afed260f64269a2103be0fab8e386_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iacca46a3fbcd45eab8928c23a788895e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia69316b9d7f84c72bf9062ad8a344515_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4cad1b5e12a475d81796c7dfd472fba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iea92dc95dce94ad983cf2eaf1ef27507_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sesn:RestrictedStockUnitsPerformanceBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i645aef5340be4c348f095065f63145e6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sesn:RestrictedStockUnitsPerformanceBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i33fae254eac8482dab713b9f73f69e41_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sesn:RestrictedStockUnitsPerformanceBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70ca9f2083e648768635ed14bf7c4dd2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1333cc72fc424e2a8f8774a8f0d872fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieaa2ee52082f4e3e8053f82bebfa0168_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad3615d1132f4e6db8c87630585bb158_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7f6527bbe7574825a65695e1c732589c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic025f71331f24e12b56e608440ce56ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i486533c551a2452c99626829ee478c51_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i236b00a74d3948dcae1d6b9ffcfa4fcf_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i16c46bb406f14eaa81b7c198dcc44d8a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic44a95cc271a49b0aa716f7ebe2e6879_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7a361b7208b64753a71edeaa3c23d956_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61d80b79fadf491ba762bf6b77e43e6a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaf581044871b4e4a95de21bdefb73475_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9a728dfe3c4454cbc533710495f8f5b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifadff6a5daba493cb2a7db4117d654bf_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ifbcb93bc03d34a29ba0472e96a5c17db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramCashManagementMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee027c64b36746299c057f499c9540ad_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7750d93e565f4062abf14eab356f22e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idedbd5e4782a4a07988637e4ee0dffc0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac240dff34d54c259fa7dcc1af037866_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie548983137d0429b97bbb1a0cea18f7f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e7114012079469c8021b30d065673e7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1f1e396274dc4a98b5466fd643278d94_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0fe3f29a701248b9893e3e02d72f5095_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id1249ce1aca94aa89687426119ea9780_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4cd59fe7a7ec49b7be31865888e57cd0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e820c7440e2402791def7b12470f1f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide0c3c6cf2a04d4383911137e51d3b5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f2e215c48c94cc88ad545b140478fd4_I20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-28</instant>
        </period>
    </context>
    <context id="i50afeb8b2fbe4a90bd225677491dd878_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ic9ccb359bb07464c8b5a4bf7acd0ee69_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i81090f1cef414033a4de39f36d28f951_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieddcde47d6134b21a63f741b8434c23a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i284162f0c4ac4a84a203966f8ee455b8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ice90a69ceeff49f0b8f1ce82d2bb4ded_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i921a13a0674c431a99d0b747823d5a59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib11ddd9e85084edeb9ff837ed2550dcc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7b74c8246e3465ebe694e85ae1cf30f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idc1992bb56f84f4d954e523e989b4498_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2917e2d690494115aa405efdcd442035_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sesn:NetOperatingLossCarryforwardAxis">sesn:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaedc518daaca46d48e4045cf67580747_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id942c56598a7425a8f604363c0ccee90_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ce909ec953045fcb9590f2a8585912f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3541e5363f343a3a43242a6a366098b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a7959f49c234c9eaa2618a72fb438f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sesn:NonCapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idd3a316709d6476199e3824ccf11239c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea773b2e97a1449f9f95fa34f634aee4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b7c86274f4d47eaa8553199408d4b91_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i15671c3d0d094adaac0c1229062ca074_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i22d0546a2e584012b01ef15556862322_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iced9f5bd4c3647f9a7e60cc7a6ea99ed_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i211e8012b6af40e08411ca15f526f29f_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5589d69bf52247d28185c2f78a22516f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i672eb9cc12ef4dfabefe71540f49d9d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1eaf6421a30f4d65931441ab3517bbd0_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="icabd5c54fc0449559aeac9215c25207e_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="ie66655811a134f9b8b6e989ecb525174_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie9a4679b42de470d95370417666d7ba5_D20200730-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i4383d15b8e8f48599512b909df5f7d25_D20200730-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="ie9cd9290db5c494b8aac997b30e9f530_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i068115fbd385473eaf14a517d80898f9_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icdcdf96fee1148569a372008cbcbc48f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i40dde77c20a24756b6c9849cf8a19522_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i3078e30e83804e5189a02bd018d21ad5_D20220720-20220720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2022-07-20</startDate>
            <endDate>2022-07-20</endDate>
        </period>
    </context>
    <context id="i4a1663e77ac1498184a0073f406681d3_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="iaa658292b071478aa327ee12757b1aec_D20210805-20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="ic1294558bb964edc87c70925cf5cde03_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="ia82aa374295f472f94fa22a817803cf0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sesn:A2022RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib391d9ecf3114b2c994998943181cc31_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sesn:A2022RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i712c5f7e1c9a4489a1932903418a4389_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sesn:A2022RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if2ad0b07f8ff40c5a4c7df314a525778_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sesn:A2022RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5532051f20ab4b50a0fedc0c29b03429_D20210830-20210830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sesn:A2021RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="i9b7c25990186472f9eefe41ce144971d_D20230302-20230302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="unit">
        <measure>sesn:unit</measure>
    </unit>
    <unit id="lawsuit">
        <measure>sesn:lawsuit</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="vote">
        <measure>sesn:vote</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="position">
        <measure>sesn:position</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF80L2ZyYWc6OWZmOWM3OGY3NzYyNDliY2E4ODM2Nzk1MTdkNWZlYjQvdGFibGU6MmQ4MzdkMjYwYzk0NGE2ZDk3YWNjN2Q5M2RlZDUzZDMvdGFibGVyYW5nZToyZDgzN2QyNjBjOTQ0YTZkOTdhY2M3ZDkzZGVkNTNkM181LTEtMS0xLTkyMzc1_d72eeab9-7c4e-4a92-8b5d-8282876ec8a1">0001485003</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF80L2ZyYWc6OWZmOWM3OGY3NzYyNDliY2E4ODM2Nzk1MTdkNWZlYjQvdGFibGU6MmQ4MzdkMjYwYzk0NGE2ZDk3YWNjN2Q5M2RlZDUzZDMvdGFibGVyYW5nZToyZDgzN2QyNjBjOTQ0YTZkOTdhY2M3ZDkzZGVkNTNkM183LTEtMS0xLTkyMzc1_99adb8a8-c224-4071-8a4e-bdee5b5aa779">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF80L2ZyYWc6OWZmOWM3OGY3NzYyNDliY2E4ODM2Nzk1MTdkNWZlYjQvdGFibGU6MmQ4MzdkMjYwYzk0NGE2ZDk3YWNjN2Q5M2RlZDUzZDMvdGFibGVyYW5nZToyZDgzN2QyNjBjOTQ0YTZkOTdhY2M3ZDkzZGVkNTNkM184LTEtMS0xLTkyMzc1_b4412a16-d909-4837-9700-2bf552fc9384">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF80L2ZyYWc6OWZmOWM3OGY3NzYyNDliY2E4ODM2Nzk1MTdkNWZlYjQvdGFibGU6MmQ4MzdkMjYwYzk0NGE2ZDk3YWNjN2Q5M2RlZDUzZDMvdGFibGVyYW5nZToyZDgzN2QyNjBjOTQ0YTZkOTdhY2M3ZDkzZGVkNTNkM185LTEtMS0xLTkyMzc1_a8cf9118-2623-43d7-b967-a4fdfacf6709">false</dei:AmendmentFlag>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0wLTEtMS05MjM3NQ_5772ccbb-05be-4692-8ecd-73c875653a3d">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0wLTEtMS05MjM3NQ_c3c9da0a-6e9f-449c-aa05-5f9295a51172">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0wLTEtMS05MjM3NQ_dbe520d3-9099-41ec-b93b-68530628d03e">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:DepreciationAndAmortization
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzA1L2ZyYWc6MjU5Y2NiODAzZGVmNDI2ZGE4NzFjNjg1ZTJiM2FlM2QvdGV4dHJlZ2lvbjoyNTljY2I4MDNkZWY0MjZkYTg3MWM2ODVlMmIzYWUzZF81NDk3NTU4MTM5MzI_a7289bd8-890c-4d0e-ad9f-c448aa6961f8"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzU_722ba763-9575-481e-82ea-4900d469c804">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzU_e7bf87fd-276f-41e8-a126-4410ad3340e7">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzODc_0f5642b4-7404-4c0d-8695-7cd3f0d7638d">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzODc_e3383e46-0bd5-473a-9c94-1fb2c501553a">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i9b7c25990186472f9eefe41ce144971d_D20230302-20230302"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjM3L2ZyYWc6ZDVhOTQ4MmFkZTlkNDkwZDg5MDJhMzY0NTBjNWE5ZTEvdGV4dHJlZ2lvbjpkNWE5NDgyYWRlOWQ0OTBkODkwMmEzNjQ1MGM1YTllMV81NDk3NTU4MTM5ODk_a7ff2e96-6e77-482e-90d6-984cd826cc2f"
      unitRef="number">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjM1_3f4fb906-c666-4164-809a-1ec4f90e3e50">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6YmViMzliN2JhODU1NGIwZDkzMzU3M2FjNzVkZDkyOWIvdGFibGVyYW5nZTpiZWIzOWI3YmE4NTU0YjBkOTMzNTczYWM3NWRkOTI5Yl8wLTAtMS0xLTkyMzc1_011d32f0-9df7-43bf-8981-61c156d61546">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8xMzE_1ef4c990-cb7a-4e76-941f-8d3a0bdfe99f">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8xMzE_7b8c1d35-de5d-47f7-aed6-5e1f2dfaa72a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6ZmNjNzA5YTNiMjk0NGU3OWFkNjRlODAzZjVmZWNhMDMvdGFibGVyYW5nZTpmY2M3MDlhM2IyOTQ0ZTc5YWQ2NGU4MDNmNWZlY2EwM18wLTAtMS0xLTkyMzc1_3693dc61-a884-4420-902f-25dfbe5f53e2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQz_89a32ee1-a440-4003-9335-15570c93eabc">001-36296</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjM5_813ae05c-e153-485b-8ff8-58fcc4bda765">Sesen Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6NmIwZjZiNWE0YTY1NDllZDgzMjkyNmM0YmE1ZjNhZWQvdGFibGVyYW5nZTo2YjBmNmI1YTRhNjU0OWVkODMyOTI2YzRiYTVmM2FlZF8wLTAtMS0xLTkyMzc1_f3ef3c52-1e10-478e-960a-bee2557cd38e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6NmIwZjZiNWE0YTY1NDllZDgzMjkyNmM0YmE1ZjNhZWQvdGFibGVyYW5nZTo2YjBmNmI1YTRhNjU0OWVkODMyOTI2YzRiYTVmM2FlZF8wLTEtMS0xLTkyMzc1_93667a39-a824-47c2-b299-26eaf3950d76">26-2025616</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MTUwZDA3NTg2M2M0NDk5NmJhNWExOThiNWFkYTgxZjcvdGFibGVyYW5nZToxNTBkMDc1ODYzYzQ0OTk2YmE1YTE5OGI1YWRhODFmN18wLTAtMS0xLTkyMzc1L3RleHRyZWdpb246ODFlYTI4MGMxYWY0NDliNzg1YWI5ZTBiNjc4OTQzZjZfNA_393c3a8b-37b6-4ba7-8c29-87e9293ed744">245 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MTUwZDA3NTg2M2M0NDk5NmJhNWExOThiNWFkYTgxZjcvdGFibGVyYW5nZToxNTBkMDc1ODYzYzQ0OTk2YmE1YTE5OGI1YWRhODFmN18wLTAtMS0xLTkyMzc1L3RleHRyZWdpb246ODFlYTI4MGMxYWY0NDliNzg1YWI5ZTBiNjc4OTQzZjZfOA_5b8eebd3-3b36-47a0-9fc5-69f59ef92632">Suite 1800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MTUwZDA3NTg2M2M0NDk5NmJhNWExOThiNWFkYTgxZjcvdGFibGVyYW5nZToxNTBkMDc1ODYzYzQ0OTk2YmE1YTE5OGI1YWRhODFmN18wLTAtMS0xLTkyMzc1L3RleHRyZWdpb246ODFlYTI4MGMxYWY0NDliNzg1YWI5ZTBiNjc4OTQzZjZfMTE_e2dfef00-959e-4281-b87f-88697db8c07d">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MTUwZDA3NTg2M2M0NDk5NmJhNWExOThiNWFkYTgxZjcvdGFibGVyYW5nZToxNTBkMDc1ODYzYzQ0OTk2YmE1YTE5OGI1YWRhODFmN18wLTAtMS0xLTkyMzc1L3RleHRyZWdpb246ODFlYTI4MGMxYWY0NDliNzg1YWI5ZTBiNjc4OTQzZjZfMTU_bd413e8e-5c1b-4dbc-a463-4fd1cdcb37e8">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MTUwZDA3NTg2M2M0NDk5NmJhNWExOThiNWFkYTgxZjcvdGFibGVyYW5nZToxNTBkMDc1ODYzYzQ0OTk2YmE1YTE5OGI1YWRhODFmN18wLTEtMS0xLTkyMzc1_1d4922c9-bdd1-4991-949c-f52fcc66eef7">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zNTE_5ba6486e-5d7c-425e-aadc-471c403b9d02">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjM2_8f111dea-5b4c-4cb4-a621-26e6c80e5f3a">444-8550</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6NWM1NDlmYmY4MGM4NDExZjliMGUzODY2NzUyMjdlMTgvdGFibGVyYW5nZTo1YzU0OWZiZjgwYzg0MTFmOWIwZTM4NjY3NTIyN2UxOF8xLTAtMS0xLTkyMzc1_bef0faf5-d4a2-4e6f-beba-6dbebe6eb061">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6NWM1NDlmYmY4MGM4NDExZjliMGUzODY2NzUyMjdlMTgvdGFibGVyYW5nZTo1YzU0OWZiZjgwYzg0MTFmOWIwZTM4NjY3NTIyN2UxOF8xLTEtMS0xLTkyMzc1_48b43de9-6a22-4795-bd3e-111ae52f7f3b">SESN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6NWM1NDlmYmY4MGM4NDExZjliMGUzODY2NzUyMjdlMTgvdGFibGVyYW5nZTo1YzU0OWZiZjgwYzg0MTFmOWIwZTM4NjY3NTIyN2UxOF8xLTItMS0xLTkyMzc1_61825b7e-ffa6-46e3-bdf0-843333432273">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQw_e749678a-5010-40f8-a91a-b1137861039b">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQx_d2f2d9a1-692f-44e5-9d84-0c32419fe923">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQ2_3c8bf5b5-e8af-4438-b94d-d8a3682d9119">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQ3_94837c8e-3a82-4eb7-bdbf-e35e0fd10f87">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MjA5NGQzZTNkNWVhNGQwMWE3MmFlYjk4Yjc3ZTJiNTcvdGFibGVyYW5nZToyMDk0ZDNlM2Q1ZWE0ZDAxYTcyYWViOThiNzdlMmI1N18wLTMtMS0xLTkyMzc1_da5a3ddc-19ab-4413-8107-f88fa5205980">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MjA5NGQzZTNkNWVhNGQwMWE3MmFlYjk4Yjc3ZTJiNTcvdGFibGVyYW5nZToyMDk0ZDNlM2Q1ZWE0ZDAxYTcyYWViOThiNzdlMmI1N18xLTMtMS0xLTkyMzc1_c7298eea-5edb-4570-ab8a-7862ff9237b6">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityFilerCategory
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGFibGU6MjA5NGQzZTNkNWVhNGQwMWE3MmFlYjk4Yjc3ZTJiNTcvdGFibGVyYW5nZToyMDk0ZDNlM2Q1ZWE0ZDAxYTcyYWViOThiNzdlMmI1N18yLTAtMS0xLTEwNzE3MA_ccdffb92-a8de-46ef-ae55-a0c0e22b1604">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8xMDk5NTExNjMxNDcz_230604dc-d9bd-4e6d-b6dc-59d16762796e">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjM4_622a80f8-69ee-4c7d-9724-ce5c8d3afe73">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl83Njk2NTgxMzk3NzI4_8e594aa7-93c8-4533-abb6-0fd27817d9bd"
      unitRef="usd">161600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2e57ab72df0c4d23813023acb9286a55_I20230221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8yNzQ4Nzc5MDc1NDcw_9d8c4146-5475-4143-986a-685bc3ea75c4"
      unitRef="shares">203492202</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xL2ZyYWc6NWZlOGVkMTQxNDBkNDNmN2ExMWUzMWY4ZWFlNDZhNmIvdGV4dHJlZ2lvbjo1ZmU4ZWQxNDE0MGQ0M2Y3YTExZTMxZjhlYWU0NmE2Yl8zMjQ0_1c83c024-8873-40e1-b185-156c757d0596">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s Definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders ("2023 Proxy Statement") or an amendment to this Annual Report on Form 10-K are incorporated by reference into Part III of this Annual Report on Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The registrant will file the 2023 Proxy Statement or an amendment to this Annual Report on Form 10-K with the Securities and Exchange Commission within 120 days of December&#160;31, 2022.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF81OC9mcmFnOmNhNWM5ZTY1MmUyZjQ1NzQ4OTA3OTRjYTAyMjJiYjRmL3RhYmxlOjJhNDVmMWVjNTYzYjQwNjQ5MjcyZjk2ZWViNzIwYmViL3RhYmxlcmFuZ2U6MmE0NWYxZWM1NjNiNDA2NDkyNzJmOTZlZWI3MjBiZWJfMS0wLTEtMS05MjM3NS90ZXh0cmVnaW9uOjY4NjEzNjY2YzljZjQ3MzE4NDUyY2ZlOWQ4ZGM1ZGVmXzcx_c44a4477-5e19-4341-9e74-bee8e54b2f18">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82MS9mcmFnOmIwZTQzMDdmYjRmNTQ0YjQ5NjJhY2Y4OWU1MTY5NjhiL3RleHRyZWdpb246YjBlNDMwN2ZiNGY1NDRiNDk2MmFjZjg5ZTUxNjk2OGJfMzYxMQ_7a0fffde-8bea-4c3a-a9b7-7233c1d4baa4">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82MS9mcmFnOmIwZTQzMDdmYjRmNTQ0YjQ5NjJhY2Y4OWU1MTY5NjhiL3RleHRyZWdpb246YjBlNDMwN2ZiNGY1NDRiNDk2MmFjZjg5ZTUxNjk2OGJfMzYxMw_c7dd43ef-33e7-4850-a763-25a585a487fe">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNC0xLTEtMS05MjM3NQ_47ae4bb5-c833-4bea-b9c9-750bf7c648ee"
      unitRef="usd">112553000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNC0zLTEtMS05MjM3NQ_edd85c07-479f-47ac-af9a-fa5ee481cd6a"
      unitRef="usd">162636000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNS0xLTEtMS05Mjc2MA_c78ba154-bfcd-477c-929d-ced01952f84d"
      unitRef="usd">54366000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNS0zLTEtMS05Mjc2MA_aaf69d72-3e43-4272-9114-3fcf9e388152"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNi0xLTEtMS0xMDE2ODM_0c2b1e52-1439-4ca7-971a-4ca5c379e72c"
      unitRef="usd">21000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNi0zLTEtMS0xMDE2ODM_b7d6250e-5e4a-4d5f-bb37-baa7850a6390"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNS0xLTEtMS05MjM3NQ_dfbce975-646c-484e-b1a9-f1ec35757255"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNS0zLTEtMS05MjM3NQ_6994e346-1b50-4378-8ce7-da2ef54718e6"
      unitRef="usd">21011000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNi0xLTEtMS05MjM3NQ_cdf6cb49-4913-42fb-b69e-6220930c65f1"
      unitRef="usd">825000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNi0zLTEtMS05MjM3NQ_c0213b35-e433-4755-9430-0e955f02cebf"
      unitRef="usd">3482000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNy0xLTEtMS05MjM3NQ_27de3b8a-342a-403b-b3d0-4f764fc0624e"
      unitRef="usd">400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNy0zLTEtMS05MjM3NQ_0d00fee7-c3a9-4da6-b42a-62afcc38db6b"
      unitRef="usd">18476000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfOS0xLTEtMS05MjM3NQ_b952b2eb-abc1-450e-8903-61e58f317ff0"
      unitRef="usd">189144000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfOS0zLTEtMS05MjM3NQ_6b818617-9569-42e2-8876-2c4f9a8cfa63"
      unitRef="usd">205605000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTQtMS0xLTEtOTI3NzI_90077c2e-75a2-4da8-8b58-f52e1885d5e2"
      unitRef="usd">30000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTQtMy0xLTEtOTI3NzI_04fc8796-4f69-40fa-aa2e-06301bb05f0b"
      unitRef="usd">20000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTMtMS0xLTEtOTIzNzU_8f18c5e2-4b4a-41b7-9389-ff4579ac62a0"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTMtMy0xLTEtOTIzNzU_3221c237-1bb0-424a-ae71-6d645f44870d"
      unitRef="usd">43000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTQtMS0xLTEtOTIzNzU_4f2d638e-fb82-419d-98bb-f416401264bf"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTQtMy0xLTEtOTIzNzU_ee9627fe-7e5d-4058-b203-8fb9ba6ec3f5"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTUtMS0xLTEtOTIzNzU_6668a41b-b749-4172-98f8-7c4a871552f8"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTUtMy0xLTEtOTIzNzU_575ff15c-36b6-4969-8ee1-44d27d00ffe2"
      unitRef="usd">13064000</us-gaap:Goodwill>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTYtMS0xLTEtOTIzNzU_16cd5ded-e3f8-451e-8407-864b26185efb"
      unitRef="usd">0</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTYtMy0xLTEtOTIzNzU_b546aa78-891f-4fd5-b7f3-98cbc676ca74"
      unitRef="usd">7192000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTctMS0xLTEtOTIzNzU_c3ab2a31-e344-4ba0-b863-c8e8e418cc4a"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTctMy0xLTEtOTIzNzU_3f9d7996-b0c0-45f4-91b5-b69f07de85a6"
      unitRef="usd">123000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTgtMS0xLTEtOTIzNzU_a83fcb90-953e-4001-b0ae-2ac4f4d47f4b"
      unitRef="usd">30000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTgtMy0xLTEtOTIzNzU_960f5478-5e3b-4f48-b232-c882b7473563"
      unitRef="usd">35142000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTktMS0xLTEtOTIzNzU_05d0403b-e027-4a3c-93c5-45554f5cb558"
      unitRef="usd">189174000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMTktMy0xLTEtOTIzNzU_8bbf22a9-b092-41b7-9f68-371865bbcd12"
      unitRef="usd">240747000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjMtMS0xLTEtOTIzNzU_0596c788-a8e9-43d3-a27e-548d4d2da32d"
      unitRef="usd">1233000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjMtMy0xLTEtOTIzNzU_953c263c-b6b5-429e-925c-cdcdddf4bc7c"
      unitRef="usd">2853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjQtMS0xLTEtOTIzNzU_1be2f0f9-80cd-4b77-99c6-1723a6d03f48"
      unitRef="usd">29636000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjQtMy0xLTEtOTIzNzU_b361e924-14bd-41b0-940f-9e0fb2d78e47"
      unitRef="usd">8255000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjctMS0xLTEtOTIzNzU_8cb011a9-3c2a-43b5-bf26-035e43198190"
      unitRef="usd">115000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjctMy0xLTEtOTIzNzU_fefad4bc-731e-4106-97f9-1438639724da"
      unitRef="usd">460000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjgtMS0xLTEtOTIzNzU_0c1658d3-01c1-4324-86ef-2bd22c96c2c9"
      unitRef="usd">30984000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMjgtMy0xLTEtOTIzNzU_1c8b675c-faf7-4c17-8173-2386308ba742"
      unitRef="usd">11568000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzEtMS0xLTEtOTIzNzU_38adb021-668b-4bb5-8b7f-38b4221676a9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzEtMy0xLTEtOTIzNzU_7e7f82f5-f7eb-443d-a825-8e35452f6d88"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzItMS0xLTEtOTIzNzU_2467b57a-e7fd-4874-9fb6-86bdbcaf45df"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzItMy0xLTEtOTIzNzU_5a153307-9dfa-4303-8dc7-5a81191c6dcd"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzMtMS0xLTEtOTIzNzU_7d990975-ab77-4eb5-9c06-a1eba082ec8a"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzMtMy0xLTEtOTIzNzU_d79d445d-f1fd-41c6-bebc-c89db3ef3305"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzUtMS0xLTEtOTIzNzU_3c528bdd-ae59-4e6d-8266-d6ba2555c081"
      unitRef="usd">0</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzUtMy0xLTEtOTIzNzU_252a3d7c-00d0-4d1b-8c1a-0330788424aa"
      unitRef="usd">57469000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzYtMS0xLTEtOTIzNzU_a3058541-472c-4c71-979e-c33304eabc8e"
      unitRef="usd">30984000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzYtMy0xLTEtOTIzNzU_a37ab1bf-ddb4-4642-b89c-c18638921cba"
      unitRef="usd">69037000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV8yMQ_1d308b5f-f285-4759-81de-7cbbe4971129"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV8yMQ_25f00a53-9b34-4d78-82c6-bc537eabcb0e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV80NQ_cb0c4a09-b176-4be9-b9be-1470d9b5c387"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV80NQ_e3ce674b-96c1-4fd3-8ff2-7aeed48c5d3c"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV85OA_3c58c179-06bc-498b-9b66-6577029842d7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV85OA_400dd6dc-2a74-4073-ab35-b5524d742970"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV85OA_9adb3f90-b8fc-4b93-8d91-17317f0bcc18"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjpjYjBjNTJkNzVjMDQ0Y2YzODBjM2YwYmMxMDkzNDQyNV85OA_f99b5b73-8e18-45a1-95c4-d160139f5bdb"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMS0xLTEtOTIzNzU_1d53d161-4c49-4650-a87f-08184ed21d86"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfMzktMy0xLTEtOTIzNzU_7f545dae-dfc5-4eef-867c-7fe4202af77b"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xOA_4f10c2ca-ec77-46ef-9086-0f43c84e9d13"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xOA_707bb638-72a4-4c7a-94ad-fa2ca9f611d5"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl80Mg_1670249e-c53d-457b-bd8f-c164754ed285"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl80Mg_ac1e6063-7fd1-450a-be19-af48a46f17be"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xMDE_246c8832-abfd-49ba-b6da-d046c4b423ba"
      unitRef="shares">202759043</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xMDE_b895e328-b76d-40d1-b6be-5762d7c949d8"
      unitRef="shares">202759043</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xMDg_8d948737-4317-415f-8bd8-6f7947f9ede5"
      unitRef="shares">199463645</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjplN2ZlYjk2NWJkNGQ0MjI5OGZjZDdiZjhlYjExMzFlMl8xMDg_cecede3c-3b86-4f26-86db-2617af9fba0e"
      unitRef="shares">199463645</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMS0xLTEtOTIzNzU_c7e5cf47-d758-43b2-9ea5-f963eb3a14e5"
      unitRef="usd">202000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDAtMy0xLTEtOTIzNzU_53e5437f-70f2-4bb0-b298-e13afaee35ce"
      unitRef="usd">199000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDEtMS0xLTEtOTIzNzU_e408827d-185b-4995-ba83-e8e8395e6c74"
      unitRef="usd">494675000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDEtMy0xLTEtOTIzNzU_b954cd96-ef8b-43b4-b078-b6379971ccba"
      unitRef="usd">487768000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDItMS0xLTEtOTIzNzU_c9e814e8-6c2d-4627-a49f-f5e0ae37380d"
      unitRef="usd">-336141000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDItMy0xLTEtOTIzNzU_fa2856d5-d664-4cf7-b53e-983e22e33e03"
      unitRef="usd">-316257000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDUtMS0xLTEtOTI3OTE_0992c735-71da-4bbb-8698-a4ad8588751f"
      unitRef="usd">-546000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDUtMy0xLTEtOTI3OTE_6bb9fcb7-b050-4fe2-8a78-9ccfbd7bb5b0"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDMtMS0xLTEtOTIzNzU_1bae8e8e-0db9-4d96-82d6-1056d0e07a81"
      unitRef="usd">158190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDMtMy0xLTEtOTIzNzU_717ec857-a302-4ef3-a0c5-a206c4a9fdb2"
      unitRef="usd">171710000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDQtMS0xLTEtOTIzNzU_8c25cba4-62b8-4a0b-a834-121f4848e056"
      unitRef="usd">189174000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82NC9mcmFnOmQ3YjJmY2NkODk0ZTQxZDA4ODliZjhiMWQ5YzgyNWQ0L3RhYmxlOjJhOGMyZmFiYjA5YTRiYmRiZmQ4ZWM5MGI3OTljYWQyL3RhYmxlcmFuZ2U6MmE4YzJmYWJiMDlhNGJiZGJmZDhlYzkwYjc5OWNhZDJfNDQtMy0xLTEtOTIzNzU_9ca42443-e6f6-4501-ba95-566586d6ae4f"
      unitRef="usd">240747000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0xLTEtMS05MjM3NQ_09e8e949-3127-4de7-960e-c2c667cba356"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC0zLTEtMS05MjM3NQ_eca3271d-4870-4d55-b19a-ea2814072e29"
      unitRef="usd">26544000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNC01LTEtMS05MjM3NQ_b4305978-0b2d-44a7-a2e1-dba8ea4da1d7"
      unitRef="usd">11236000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNS0xLTEtMS05MjM3NQ_0efbf560-4fee-4895-87f7-1ed73aee8150"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNS0zLTEtMS05MjM3NQ_e3f37587-ace5-40be-b17d-f572c41f5821"
      unitRef="usd">26544000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfNS01LTEtMS05MjM3NQ_9add7fac-33df-4b38-9e41-59dceedd7f42"
      unitRef="usd">11236000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOC0xLTEtMS05MjM3NQ_d9ee8d9b-c1bd-4da8-9cc5-7d794b929bf1"
      unitRef="usd">38594000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOC0zLTEtMS05MjM3NQ_85e2d59e-7739-49e1-b140-016f16ca87f7"
      unitRef="usd">25312000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOC01LTEtMS05MjM3NQ_28f2f524-00e7-47c8-8466-83dfb493b556"
      unitRef="usd">29191000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOS0xLTEtMS05MjM3NQ_7dc3fe01-2996-48cd-a2ab-48eb0bb9fc8a"
      unitRef="usd">39787000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOS0zLTEtMS05MjM3NQ_e9b9ea58-fa93-4a19-909c-2c07b4fff6bd"
      unitRef="usd">29393000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfOS01LTEtMS05MjM3NQ_41f6362b-d6e3-415a-93f7-ed8b663cf48c"
      unitRef="usd">14302000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTAtMS0xLTEtOTIzNzU_d45d7742-5984-4d41-a172-33454e732c40"
      unitRef="usd">11764000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTAtMy0xLTEtOTIzNzU_b3939fc8-797b-401c-98a8-a59715e2a75e"
      unitRef="usd">5528000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTAtNS0xLTEtOTIzNzU_860bd9c6-3e2c-4ec0-9575-f5be65c544c2"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTEtMS0xLTEtOTIzNzU_5eb127b0-18a0-42ab-990a-3e9eb44d1019"
      unitRef="usd">27764000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i3d35c30040aa4486b9b15a04bdee6aa2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTEtMy0xLTEtOTIzNzU_f1dff601-c8d2-4689-887b-fbbd0840e2a1"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTEtNS0xLTEtOTIzNzU_5e4064e5-c125-4362-94bc-7cf8888e8645"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTItMS0xLTEtOTIzNzU_e056a224-9d0f-42d3-b2b7-1407462a151b"
      unitRef="usd">-52000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTItMy0xLTEtOTIzNzU_5950ac02-ba40-456d-ae63-227bffa8c954"
      unitRef="usd">-56840000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTItNS0xLTEtOTIzNzU_e57802f0-f307-4bb7-a93c-9d1f708b0fab"
      unitRef="usd">-11180000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTMtMS0xLTEtOTIzNzU_34d9b7aa-7ea4-4bdb-a83d-e6c5f7e3d3b0"
      unitRef="usd">65909000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTMtMy0xLTEtOTIzNzU_6017f742-7974-4144-ab49-2701ba0e549e"
      unitRef="usd">35093000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTMtNS0xLTEtOTIzNzU_47a5b4df-5cc9-45ff-bd4d-234d2a1e2c00"
      unitRef="usd">32313000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTUtMS0xLTEtOTIzNzU_ab2d2920-fb45-4b21-93ea-8640fb265184"
      unitRef="usd">-25909000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTUtMy0xLTEtOTIzNzU_6f9f8ca9-8cfc-4a8e-bdc3-5cf51fd18983"
      unitRef="usd">-8549000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTUtNS0xLTEtOTIzNzU_d3b70710-2870-4912-9207-0bc7dabcd684"
      unitRef="usd">-21077000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtMS0xLTEtMTA1Njcx_63268f15-3559-45aa-b6b0-66292a4c91c9"
      unitRef="usd">1854000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtMy0xLTEtMTA1Njcx_4a9135e7-da2b-4bc9-a65a-b119701b0dfb"
      unitRef="usd">17000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtNS0xLTEtMTA1Njcx_99c192e5-2af3-4f93-a2a1-7e1ed217ac93"
      unitRef="usd">224000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtMS0xLTEtOTIzNzU_cedf3a44-3e78-4623-88fa-0257961e733b"
      unitRef="usd">296000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtMy0xLTEtOTIzNzU_64198ff7-9b68-49c6-be6f-76bf3168f0e9"
      unitRef="usd">-77000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTYtNS0xLTEtOTIzNzU_52a44a15-8f71-46e1-b1e1-b6cbaa79a335"
      unitRef="usd">-99000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTctMS0xLTEtOTIzNzU_7530e168-b81f-4002-a64d-5870e167738e"
      unitRef="usd">-23759000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTctMy0xLTEtOTIzNzU_82f23371-17fd-478a-8b7f-4c43056c3fc5"
      unitRef="usd">-8609000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTctNS0xLTEtOTIzNzU_14e60120-a416-4abc-b853-e21411988268"
      unitRef="usd">-20952000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTgtMS0xLTEtOTIzNzU_337281f3-696b-4bfa-861e-af5e513cfd25"
      unitRef="usd">-3875000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTgtMy0xLTEtOTIzNzU_b97ebe4e-5e01-4b60-8db9-f3abc4d7adff"
      unitRef="usd">-8273000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTgtNS0xLTEtOTIzNzU_d3545f7b-0ca0-4f01-ad49-e4ba6abfb6f3"
      unitRef="usd">1445000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTktMS0xLTEtOTIzNzU_b6b7e653-49e5-4c6d-95bf-e0533ec84fe4"
      unitRef="usd">-19884000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTktMy0xLTEtOTIzNzU_fc82e0d6-3371-4dd3-be35-97262f57e8c5"
      unitRef="usd">-336000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMTktNS0xLTEtOTIzNzU_7c6949ef-d7a0-44f9-9052-c8265afc7e2e"
      unitRef="usd">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjEtMS0xLTEtOTIzNzU_5e47878b-ab3c-4e00-926c-7e265ccf4c95"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjEtMy0xLTEtOTIzNzU_ec04c1df-de54-4d42-baf6-8abea4f84ffc"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjEtNS0xLTEtOTIzNzU_8afa1de3-cafa-4496-8a33-4caffabe64d9"
      unitRef="usd">147000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMS0xLTEtOTIzNzU_1d741224-4625-42ab-91c9-05faf46a64f4"
      unitRef="usd">-19884000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMS0xLTEtOTIzNzU_c4447469-0487-41bb-a7f2-11f33c7e42d2"
      unitRef="usd">-19884000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMS0xLTEtOTIzNzU_c602c2d9-c83a-4a2c-a3eb-d82d2259a4f0"
      unitRef="usd">-19884000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMy0xLTEtOTIzNzU_4100ed69-e122-4bcf-af2a-9bbc10f93dd0"
      unitRef="usd">-336000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMy0xLTEtOTIzNzU_878391b0-d330-42a4-bf3a-417b7eb8d5f9"
      unitRef="usd">-336000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtMy0xLTEtOTIzNzU_b94672be-baa9-4bcb-84ac-ae47b01cc7b2"
      unitRef="usd">-336000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtNS0xLTEtOTIzNzU_2fc54112-e314-4d24-99b4-4485f30a8923"
      unitRef="usd">-22544000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtNS0xLTEtOTIzNzU_3f9ebd96-7b10-46a0-9362-bb044145fe98"
      unitRef="usd">-22544000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjMtNS0xLTEtOTIzNzU_674fdc76-f44c-4f2d-aa9b-0424c3839f73"
      unitRef="usd">-22544000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtMS0xLTEtOTI5ODQ_d2110cc3-33d6-4df8-86ac-df9ca26d357c"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtMS0xLTEtOTI5ODQ_f0bc7032-24f6-4490-bbcf-499e72bce820"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtMy0xLTEtOTI5ODQ_173c6de9-7e74-4b3c-bd19-0ac348527dc4"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtMy0xLTEtOTI5ODQ_4b469651-84d5-4f05-877e-1203c136c59d"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtNS0xLTEtOTI5ODQ_39f23487-0962-40ff-ae12-ae1f03e2de41"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjYtNS0xLTEtOTI5ODQ_5510c0a1-7410-47b0-9d4a-8612dc4dbaaa"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctMS0xLTEtOTI5ODQ_90109636-4e34-4da4-bd95-c7c41723cf3d"
      unitRef="shares">200546000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctMS0xLTEtOTI5ODQ_ced5df9f-886d-43fe-a8ce-85d2e7920e9c"
      unitRef="shares">200546000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctMy0xLTEtOTI5ODQ_26b53172-16dd-449b-823f-9fccd9d8b5cb"
      unitRef="shares">182323000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctMy0xLTEtOTI5ODQ_7c5449b6-da04-4fc8-9c77-d0274b942cc1"
      unitRef="shares">182323000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctNS0xLTEtOTI5ODQ_5c45c82d-c317-4a4f-9537-0f18a8c40b8d"
      unitRef="shares">118221000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF82Ny9mcmFnOjBjYTBhYmZlOGNkMDQzN2JhMDZjYmRmYjNlMmRlOGY1L3RhYmxlOjk3ZDgyZTNmYzk2NDQ4MjZhYzc3Y2E4YjU0MjkyMTcxL3RhYmxlcmFuZ2U6OTdkODJlM2ZjOTY0NDgyNmFjNzdjYThiNTQyOTIxNzFfMjctNS0xLTEtOTI5ODQ_884f373b-c727-4a08-8eeb-3c6da7c4eff4"
      unitRef="shares">118221000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV8zLTEtMS0xLTk0NTgx_0e31dca4-d679-4bae-89f8-6ec5e260b154"
      unitRef="usd">-19884000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV8zLTMtMS0xLTk0NTgx_29bc4c41-e6de-43c0-a8ce-91068985f9fc"
      unitRef="usd">-336000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV8zLTUtMS0xLTk0NTgx_5bd6699a-56e0-482a-bd48-c2aa6899864f"
      unitRef="usd">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV80LTEtMS0xLTk0NTgx_ce0c18c2-05fe-47b5-bed0-9604632dc856"
      unitRef="usd">-546000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV80LTMtMS0xLTk0NTgx_98f7b46c-e72f-413d-9bbd-b3a1851399e5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV80LTUtMS0xLTk0NTgx_9c563600-0ec5-4e2e-ac73-e90d9a0e124a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV81LTEtMS0xLTk1NTI4_4bca5990-c461-4269-a862-1ce5c989e8ca"
      unitRef="usd">-20430000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV81LTMtMS0xLTk1NTI4_3514db49-6ffd-46c3-bbd5-5e5da96818f9"
      unitRef="usd">-336000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTcxL2ZyYWc6N2U4OGYwNzI2MjA2NGIzNGI4NDJiNGIxYjkzNGJjODEvdGFibGU6OTMzM2RlMGQyZDY3NDhmNTg2OTkxOWZmZTY1YWZmMGEvdGFibGVyYW5nZTo5MzMzZGUwZDJkNjc0OGY1ODY5OTE5ZmZlNjVhZmYwYV81LTUtMS0xLTk1NTI4_e138c82a-bc27-4d90-a81a-c9d36fb3d502"
      unitRef="usd">-22397000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9289325bda434664a6a39b85b67bfae9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi0xLTEtMS05MjM3NQ_63211557-d151-42bb-9e16-48d36859eb0b"
      unitRef="shares">106801409</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i9289325bda434664a6a39b85b67bfae9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi0zLTEtMS05MjM3NQ_ce8f5b3f-3149-4cf2-9ebf-0d58e91eb778"
      unitRef="usd">107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i89feec3c1c304077906365e7fa3071f1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi01LTEtMS05MjM3NQ_d4c80316-6e3f-47eb-bbe5-c7b652c1ff1c"
      unitRef="usd">266717000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i09358b4a0bcc4a3385a7f499156e77ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi03LTEtMS05MzMzMw_af58be73-ae3a-477e-9f54-3e3189bd5303"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i405074fedfc34261a6aa9a70d2ea0ce6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi03LTEtMS05MjM3NQ_fd4f9c7b-24fd-4d90-93f4-97f17d4e52f4"
      unitRef="usd">-293524000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73c47e791149483dac9b339dd293b4ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMi05LTEtMS05MjM3NQ_434b713a-bede-4486-b25a-df43b6be0adb"
      unitRef="usd">-26700000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id683680be9e042e0acf2733abe0d9cdb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMy03LTEtMS05MjM3NQ_77a158ed-1f0a-4eaa-b902-9eca4390842e"
      unitRef="usd">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMy05LTEtMS05MjM3NQ_63952d46-d884-4630-8bc9-4f32078f3a23"
      unitRef="usd">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i97dd7567e83c47af9d549f491e6200b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNC01LTEtMS05MjM3NQ_a6a533ea-b5f6-4e8c-b953-054370ff0d9c"
      unitRef="usd">1757000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNC05LTEtMS05MjM3NQ_534b6cc6-581f-41a4-945a-8bb4c7baf40b"
      unitRef="usd">1757000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i887ce3b59fe94c8084e3c22ab03fb7ea_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNS0xLTEtMS05MjM3NQ_8cb4f6e4-f51c-45dc-bdad-710d0fe90b45"
      unitRef="shares">12000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i97dd7567e83c47af9d549f491e6200b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNS01LTEtMS05MjM3NQ_abd8e8b5-70d9-4f02-aefa-2d13975bf2df"
      unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNS05LTEtMS05MjM3NQ_9dc84101-68e7-49e3-b344-1cd50f369192"
      unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i887ce3b59fe94c8084e3c22ab03fb7ea_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNi0xLTEtMS05MjM3NQ_104467e3-f873-42a1-bbd0-8732ca2fd150"
      unitRef="shares">28186</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i97dd7567e83c47af9d549f491e6200b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNi01LTEtMS05MjM3NQ_2b1797b8-69f5-41b4-8bb2-697d5c91136d"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfNi05LTEtMS05MjM3NQ_d5bcac2e-ea3f-4766-9370-40db30f6571e"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i887ce3b59fe94c8084e3c22ab03fb7ea_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOC0xLTEtMS05MjM3NQ_9bbf6dfb-89be-4623-bc7f-9e3edd99d71e"
      unitRef="shares">238110</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i97dd7567e83c47af9d549f491e6200b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOC01LTEtMS05MjM3NQ_7e5e2b3c-5a16-4078-af47-41d7c408d5d1"
      unitRef="usd">131000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOC05LTEtMS05MjM3NQ_c63d7a86-dba4-4279-ad21-676d8526ab23"
      unitRef="usd">131000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i19f82fd2d2e7407a97261cd8548780c9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS0wLTEtMS05MjM3NS90ZXh0cmVnaW9uOjY4Y2NjZWE3NWNiOTQ2NjU4OTQ4OTlmZWU0ODJlMTM4XzEwOTk1MTE2Mjc4NzQ_d7a2ff47-175e-45d3-8aeb-f11eead87e07"
      unitRef="usd">1200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib748ce8528614265bc45eb9a76e9bfb0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS0xLTEtMS05MjM3NQ_8e080b0e-0ed3-409a-b75a-a62660eba43a"
      unitRef="shares">33369942</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib748ce8528614265bc45eb9a76e9bfb0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS0zLTEtMS05MjM3NQ_5578d24d-9fa5-4384-871a-8ee049aaee28"
      unitRef="usd">33000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3799557388394b24b27d06e94128d950_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS01LTEtMS05MjM3NQ_426b8b66-07ed-4559-a690-a5880115bcf8"
      unitRef="usd">37925000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS05LTEtMS05MjM3NQ_a88054a3-e5f0-4292-bbd9-f7aa84c8a7ff"
      unitRef="usd">37958000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesIssued
      contextRef="i295ca9347a54466f93585f285c63b26b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTAtMS0xLTEtOTIzNzU_13bc959b-2715-4e53-98fd-f9f73944d954"
      unitRef="shares">140449647</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i295ca9347a54466f93585f285c63b26b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTAtMy0xLTEtOTIzNzU_254ca864-e4b5-4b93-859d-90deee49165a"
      unitRef="usd">140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if9e5a066bf5f4ca5a26ac3aa00160ed3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTAtNS0xLTEtOTIzNzU_9c21ee5f-1539-4bcb-848e-c9463df0b7b4"
      unitRef="usd">306554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib968e3f687d845e2a83107904373ff5c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfOS03LTEtMS05NTUzMA_38604034-cfc8-4ca2-8aab-5ef7b31c864b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i87c1ee91ad034903b0d19285c24c8b19_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTAtNy0xLTEtOTIzNzU_c5d74a1b-b4ba-4773-b8cb-7a23d47fdd8b"
      unitRef="usd">-315921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTAtOS0xLTEtOTIzNzU_fb8dd4b4-dbb2-497f-a989-bb8bc675e680"
      unitRef="usd">-9227000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id3da3a125129480eb2e8ebb6f49f42bf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTEtNy0xLTEtOTIzNzU_e8b99e7c-dcc8-4b18-8296-80f5b18585c2"
      unitRef="usd">-336000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTEtOS0xLTEtOTIzNzU_2d6aa8ea-bea5-44f6-aa89-97a7e955ef80"
      unitRef="usd">-336000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6ddcc8cd57e7497282b01d86668e8ae3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTItNS0xLTEtOTIzNzU_6aca5f05-4d88-403b-9e91-554a292eb6a9"
      unitRef="usd">5143000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTItOS0xLTEtOTIzNzU_368fd588-b84c-44ce-900a-b3397b7cc901"
      unitRef="usd">5143000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i83051d731ef64fbab70f1bd36b04864c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTMtMS0xLTEtOTIzNzU_6ee9b880-40cc-4210-82b0-ec87e8df4b83"
      unitRef="shares">33610</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6ddcc8cd57e7497282b01d86668e8ae3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTMtNS0xLTEtOTIzNzU_cfe69725-346d-47ae-90c1-1d4920cc4b1f"
      unitRef="usd">42000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTMtOS0xLTEtOTIzNzU_6a32ecfa-2440-47a4-8ccb-488baf25f021"
      unitRef="usd">42000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i83051d731ef64fbab70f1bd36b04864c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTUtMS0xLTEtOTIzNzU_487b3429-8bcf-4920-8212-c20a0ccc347b"
      unitRef="shares">2048059</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i83051d731ef64fbab70f1bd36b04864c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTUtMy0xLTEtOTIzNzU_5bf03c81-c306-44d2-a0a7-c810afa52d13"
      unitRef="usd">2000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i6ddcc8cd57e7497282b01d86668e8ae3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTUtNS0xLTEtOTIzNzU_44df716a-e7c8-4b9a-84b2-248459cbdaa7"
      unitRef="usd">1124000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTUtOS0xLTEtOTIzNzU_0cbf32c9-25d5-491d-9537-4b70f977ee99"
      unitRef="usd">1126000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ib200f78d81c84f1caf083a586963ba04_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTYtMC0xLTEtOTIzNzUvdGV4dHJlZ2lvbjoyMTYyYTVlNjQ1OGY0MzhlYTUyNzllNTNkM2ZjYmZiMl83NA_6630c27a-9747-40f1-a656-fceae530cc95"
      unitRef="usd">5400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib82c4185c6fb4d92896edaac365482ab_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTYtMS0xLTEtOTIzNzU_2273c059-1525-4584-9ea7-a02d8ee0510b"
      unitRef="shares">56932329</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib82c4185c6fb4d92896edaac365482ab_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTYtMy0xLTEtOTIzNzU_0e5809d8-121f-4460-9962-43398682409a"
      unitRef="usd">57000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7947774ff61e417ca66c44d164ba6650_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTYtNS0xLTEtOTIzNzU_ce2a10f8-6587-4e1a-af2e-085a41c49b94"
      unitRef="usd">174905000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib200f78d81c84f1caf083a586963ba04_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTYtOS0xLTEtOTIzNzU_fa470c7f-61a3-48f9-8f67-c1ebded192b7"
      unitRef="usd">174962000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib4462842a9194410a79f71e762585fbf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTctMS0xLTEtOTIzNzU_2ecc01d1-a4dd-4a10-a53a-dab27d7c8b25"
      unitRef="shares">199463645</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib4462842a9194410a79f71e762585fbf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTctMy0xLTEtOTIzNzU_790ce5c6-63af-4bd9-a302-a81e04205df1"
      unitRef="usd">199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibbabad301b294437b56c5d188d25d543_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTctNS0xLTEtOTIzNzU_c63e81f0-b076-49fe-97e7-2c05b23189c0"
      unitRef="usd">487768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if21d4b6455c5495b8488303a238975a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTUtNy0xLTEtOTQyMDE_f4c58cb8-d999-4055-acf9-3f6d8bb0ccf7"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d4fa9f625b54b30b2dff2dc6a1a867b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTctNy0xLTEtOTIzNzU_75f76c96-61b9-4d05-89cf-d3913885ec77"
      unitRef="usd">-316257000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTctOS0xLTEtOTIzNzU_637c791b-77a3-4e48-b488-131bd9b93b23"
      unitRef="usd">171710000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i12d3333974e14f89a7ec3f471522f303_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTgtNy0xLTEtOTIzNzU_c1c1862e-d489-4177-9a0e-f5a58655220f"
      unitRef="usd">-19884000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTgtOS0xLTEtOTIzNzU_c025fe6e-dc4c-4a0f-b7b1-ae6ef2a895fa"
      unitRef="usd">-19884000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id1b86eb7007d470aa9e0586557f94125_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTktNS0xLTEtOTIzNzU_53bce0d5-73f1-4a22-be37-caefa3e31d55"
      unitRef="usd">6909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMTktOS0xLTEtOTIzNzU_f968f418-ad95-466e-bb48-a5fd12eb01eb"
      unitRef="usd">6909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i822d046be15341d59a14431cd169a913_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjAtMS0xLTEtOTIzNzU_3a384e2e-f44c-4f8f-837f-a6cbd4a9d929"
      unitRef="shares">2031</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id1b86eb7007d470aa9e0586557f94125_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjAtNS0xLTEtOTIzNzU_51190a7d-cc5d-4076-b194-f4e99f7f1cd6"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjAtOS0xLTEtOTIzNzU_15376919-d31f-4d9f-bc76-177082230e7e"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i521bc055cda840c99e95281f5864c7ad_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjAtNy0xLTEtOTMzODY_1af16b4f-d8da-40e5-85e8-40db8a06b4f5"
      unitRef="usd">-546000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjMtOS0xLTEtOTIzNzU_922dfca2-3612-430f-9430-1613b4bb5f35"
      unitRef="usd">-546000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i822d046be15341d59a14431cd169a913_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjEtMS0xLTEtOTc4MDc_ce74e9b0-eca6-4b21-ae8e-de27c03ee492"
      unitRef="shares">3293367</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i822d046be15341d59a14431cd169a913_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjEtMy0xLTEtOTc4MDc_98dc18af-41f5-4523-9816-338c69515390"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="id1b86eb7007d470aa9e0586557f94125_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjEtNS0xLTEtOTc4MDc_46e6660e-4f71-4680-89ba-5bfd124601a2"
      unitRef="usd">-3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjEtMTEtMS0xLTk4MDI2_d290bd62-28db-4297-b797-072ea8a41823"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib3abd01beb2944a8aabb8c310e92e38a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjQtMS0xLTEtOTIzNzU_efb6f7c8-abd5-407c-b722-efff1378c5c4"
      unitRef="shares">202759043</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib3abd01beb2944a8aabb8c310e92e38a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjQtMy0xLTEtOTIzNzU_d1ff2e0e-6005-4481-be7d-b00c0041d2be"
      unitRef="usd">202000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40b12428f67b4fb289c73df6c14dd797_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjQtNS0xLTEtOTIzNzU_597ebc9b-3fe5-408f-8b5c-47a4d303bf7d"
      unitRef="usd">494675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e556b75c0e543168782ac584ea02832_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjEtNy0xLTEtOTQyMDE_e8b4ba28-cff1-4842-9247-5a5b0a95af84"
      unitRef="usd">-546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c1925aa09c546e6bb1bbc2f922a757c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjQtNy0xLTEtOTIzNzU_00c31b48-86d9-4711-ab04-d349c07a9313"
      unitRef="usd">-336141000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83MC9mcmFnOmNhNTFhYjM5MjBmOTRlMTViZGFkNDNiYmFjNjk5ZDFhL3RhYmxlOjQ4ZTE2Mzg3MWE5NDRjN2ZiM2RjOTNkODU0YjhhYWNmL3RhYmxlcmFuZ2U6NDhlMTYzODcxYTk0NGM3ZmIzZGM5M2Q4NTRiOGFhY2ZfMjQtOS0xLTEtOTIzNzU_526cc3b5-f195-49b4-abda-e43285bd7299"
      unitRef="usd">158190000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMy0xLTEtMS05MjM3NQ_b912a402-f75f-47c4-a02a-a49bbb2722cb"
      unitRef="usd">-19884000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMy0zLTEtMS05MjM3NQ_ad76c540-7989-4c00-9c61-a521c62c0295"
      unitRef="usd">-336000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMy01LTEtMS05MjM3NQ_f3dd22e2-ff72-437f-aef1-d6b9bfe03ca1"
      unitRef="usd">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNS0xLTEtMS05MjM3NQ_a1e70bea-1efb-4c49-a3a2-181de7af007d"
      unitRef="usd">13000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNS0zLTEtMS05MjM3NQ_bcd5b6d2-e92b-4c7d-b542-645bddcd0b8e"
      unitRef="usd">85000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNS01LTEtMS05MjM3NQ_261dfe35-6a09-43b0-a53e-c694a53fb3ea"
      unitRef="usd">122000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNi0xLTEtMS05MjM3NQ_04b758cc-45dc-4409-afff-2ea8dcdf6a32"
      unitRef="usd">6909000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNi0zLTEtMS05MjM3NQ_58750120-4c6f-44a0-ac33-75a83104451d"
      unitRef="usd">5143000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNi01LTEtMS05MjM3NQ_769c67ea-2647-43d5-b2e5-6430324d58f3"
      unitRef="usd">1757000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNy0xLTEtMS05MjM3NQ_e056a224-9d0f-42d3-b2b7-1407462a151b"
      unitRef="usd">-52000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNy0zLTEtMS05MjM3NQ_5950ac02-ba40-456d-ae63-227bffa8c954"
      unitRef="usd">-56840000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNy01LTEtMS05MjM3NQ_e57802f0-f307-4bb7-a93c-9d1f708b0fab"
      unitRef="usd">-11180000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AssetImpairmentCharges
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfOS0xLTEtMS05MjM3NQ_3d81b1b9-1084-448f-a165-bd0589c198aa"
      unitRef="usd">27764000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfOS0zLTEtMS05MjM3NQ_63bf3d6d-72e4-428e-b689-eacb946d5cd7"
      unitRef="usd">31700000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfOS01LTEtMS05MjM3NQ_90607239-97b5-4ed7-a511-d96f0819aea5"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTAtMS0xLTEtMTA1ODYy_b3e89467-f9b8-4fb0-b4e8-4de8cad4d666"
      unitRef="usd">913000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTAtMy0xLTEtMTA1ODYy_0eb4beed-7986-45f2-9843-c326585e04fb"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTAtNS0xLTEtMTA1ODYy_a6758e3d-c943-4915-acb9-19f4aac00151"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTEtMS0xLTEtOTIzNzU_1d3cbbe3-0a7e-441d-b3bf-6bd011ad8146"
      unitRef="usd">-21010000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTEtMy0xLTEtOTIzNzU_9b03693d-361b-4f67-bd26-caf78ce3327f"
      unitRef="usd">24493000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTEtNS0xLTEtOTIzNzU_9cb8164e-9e87-4f58-a754-0cc67f653994"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTItMS0xLTEtOTQ2NDY_d8f568d4-cd3f-40a3-8890-5ac06a57c98d"
      unitRef="usd">-2658000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTItMy0xLTEtOTQ2NDY_ad6e36ac-1a62-47da-9df6-632dbe0a1356"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTItNS0xLTEtOTQ2NDY_29438f5e-2ef9-4be2-a6ce-e4d7214eb6b2"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTMtMS0xLTEtOTQ2NDY_e5b4715f-2cd9-46b9-ae4b-44ccfa98d045"
      unitRef="usd">-18076000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTMtMy0xLTEtOTQ2NDY_5ed531fe-269d-483d-aef5-3a73f0cbcc60"
      unitRef="usd">17964000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTMtNS0xLTEtOTQ2NDY_e668baf9-04c1-4acd-9bf6-4a6d612768f6"
      unitRef="usd">1304000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtMS0xLTEtOTQ2NDY_98e2d3fa-fb52-45f0-9746-03dfe1e63b35"
      unitRef="usd">-7192000</sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent>
    <sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtMy0xLTEtOTQ2NDY_0a83ec4a-9558-4381-95bc-be41ab38e2af"
      unitRef="usd">0</sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent>
    <sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtNS0xLTEtOTQ2NDY_a6f33e31-4d16-4629-be5d-ea95b45522cb"
      unitRef="usd">0</sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctMS0xLTEtMTAxNjU0_9eba9788-8cae-4798-b6fe-1f130886ba9e"
      unitRef="usd">-123000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctMy0xLTEtMTAxNjU0_bcfc1c56-94e5-4104-8e5b-1e531a0a9377"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctNS0xLTEtMTAxNjU0_18df98df-1ddd-4b10-aa1c-107fa5c29faa"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtMS0xLTEtOTIzNzU_aca5134c-9a2f-4602-9bd8-e082a1efcd4c"
      unitRef="usd">-1620000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtMy0xLTEtOTIzNzU_64fcb16b-5254-4398-9ab9-35d6124bbc26"
      unitRef="usd">-249000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTQtNS0xLTEtOTIzNzU_5bbab64d-c843-4d6d-add7-974d9c83f9a1"
      unitRef="usd">1200000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTUtMS0xLTEtOTIzNzU_96fe6137-734b-460a-ab91-9133466b782b"
      unitRef="usd">17067000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTUtMy0xLTEtOTIzNzU_9e76d265-6e19-471c-b664-719e2c0caaf8"
      unitRef="usd">-4424000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTUtNS0xLTEtOTIzNzU_6cb8fa5a-041f-4214-9958-5ca75f8bcf6e"
      unitRef="usd">-2035000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTYtMS0xLTEtOTIzNzU_6fcb7a34-cbd4-4db7-bb39-c6b386d5c2db"
      unitRef="usd">-1500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTYtMy0xLTEtOTIzNzU_e26e7f93-b718-4fbc-bfb5-e827c67ffe51"
      unitRef="usd">-1500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTYtNS0xLTEtOTIzNzU_b08c7c42-9220-4a7a-ac68-a0d4ac419ca0"
      unitRef="usd">3000000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctMS0xLTEtOTIzNzU_68029adb-7b01-4ae7-b9d9-55aad2f89434"
      unitRef="usd">24895000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctMy0xLTEtOTIzNzU_be8e72d7-51f8-48c9-8cd4-adc67c7c4775"
      unitRef="usd">-68878000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTctNS0xLTEtOTIzNzU_ead707a9-a263-4a7d-8105-e33e27eda398"
      unitRef="usd">-30837000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTktMS0xLTEtOTIzNzU_e43711ae-b442-4861-8df7-3e3a2830e679"
      unitRef="usd">128999000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTktMy0xLTEtOTIzNzU_14078641-ad8b-4566-8081-a2f1172d7ed4"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMTktNS0xLTEtOTIzNzU_1eeb2b2d-64f9-4759-a2fb-bb78069cd6d4"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMS0xLTEtMTA1ODc1_229af2b6-5ef3-407d-86d7-496f147c7b7d"
      unitRef="usd">75000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMy0xLTEtMTA1ODc1_fe35afe1-ac5f-4abe-9e09-aae1b8543eee"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtNS0xLTEtMTA1ODc1_90e45241-4fd8-4398-a812-7f66ee8d4c4d"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMS0xLTEtOTUzOTQ_d66845fe-209e-44b7-9af2-94c32f47450d"
      unitRef="usd">30000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMy0xLTEtOTUzOTQ_aade91ce-4daa-441c-9ef6-e8a3b2f82639"
      unitRef="usd">4000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtNS0xLTEtOTUzOTQ_51a34cae-e1c5-474c-aded-8136b425d60a"
      unitRef="usd">8000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjAtMS0xLTEtOTIzNzU_9214bd9f-01cc-4e4b-829a-cbe40da046c2"
      unitRef="usd">-53969000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjAtMy0xLTEtOTIzNzU_03addc87-b62c-473a-99a6-b2cbe796ff90"
      unitRef="usd">-4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjAtNS0xLTEtOTIzNzU_3815aee5-1484-4ae4-8df5-f16ad695b60c"
      unitRef="usd">-8000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjItMS0xLTEtOTIzNzU_4436d60c-ed36-4627-9c11-081e021fc3ce"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjItMy0xLTEtOTIzNzU_3180184b-f722-4af2-8c66-0201ae55c454"
      unitRef="usd">174962000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjItNS0xLTEtOTIzNzU_b13c354b-b9f8-4710-9d0d-6c67d1bdc3b8"
      unitRef="usd">37958000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjMtMS0xLTEtOTIzNzU_726738de-53d1-4eed-96e8-ce3a505d9cb0"
      unitRef="usd">1000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjMtMy0xLTEtOTIzNzU_f4961d3e-af67-408f-9f07-17786736d81c"
      unitRef="usd">42000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjMtNS0xLTEtOTIzNzU_7fdc7245-c916-4f43-b7dd-64881301e6b0"
      unitRef="usd">13000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMS0xLTEtOTIzNzU_e4b44f24-a870-48ae-bb12-5f84bb8fbce1"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtMy0xLTEtOTIzNzU_108d0345-252a-4375-8540-1e8910415c3c"
      unitRef="usd">1126000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjQtNS0xLTEtOTIzNzU_7beb3d99-01d6-4ace-9937-e5cbab69e95b"
      unitRef="usd">131000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjUtMS0xLTEtOTIzNzU_020203b8-3faa-4a62-b811-b79320ad8589"
      unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjUtMy0xLTEtOTIzNzU_84cb9305-9598-4af7-8002-b7ddcff9a29b"
      unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjUtNS0xLTEtOTIzNzU_189cb72d-2c19-4d97-906c-e2ae01fbcb38"
      unitRef="usd">11000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjctMS0xLTEtOTIzNzU_0b87da98-c88c-4e0a-80b1-ea672c5d7c95"
      unitRef="usd">1000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjctMy0xLTEtOTIzNzU_f0e48d36-a155-42f3-9889-c8bbedc30105"
      unitRef="usd">176129000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjctNS0xLTEtOTIzNzU_f05a4cc7-d7e4-4050-8a69-8e1aad1cd5e1"
      unitRef="usd">38113000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjgtMS0xLTEtOTIzNzU_94abfd34-3e05-4949-af4c-819c2e0c3df6"
      unitRef="usd">-29073000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjgtMy0xLTEtOTIzNzU_a4be89d7-c89c-466c-9ee4-6953bb416220"
      unitRef="usd">107247000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjgtNS0xLTEtOTIzNzU_1c5a6488-d718-410b-86bc-6a7a3ec7758e"
      unitRef="usd">7268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjktMS0xLTEtOTIzNzU_959b757f-13a6-4ceb-95a3-4ff511cc83bb"
      unitRef="usd">162656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjktMy0xLTEtOTIzNzU_c4598f0e-646b-419b-a199-010ac9975d77"
      unitRef="usd">55409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i73c47e791149483dac9b339dd293b4ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMjktNS0xLTEtOTIzNzU_cbd1ca2a-ca52-414a-b134-563f83cb14ad"
      unitRef="usd">48141000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzAtMS0xLTEtOTIzNzU_795078d6-c70f-428d-8bbc-71906eaf2cce"
      unitRef="usd">133583000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzAtMy0xLTEtOTIzNzU_db9fe28d-ec8e-45ec-a441-230789074f34"
      unitRef="usd">162656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzAtNS0xLTEtOTIzNzU_f417af19-c079-4219-8c12-bf2b5b27158f"
      unitRef="usd">55409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzMtMS0xLTEtOTIzNzU_b9967fb6-7861-4466-954a-b4811034d298"
      unitRef="usd">112553000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzMtMy0xLTEtOTIzNzU_18e36a3b-5d7b-4fd9-b31f-bf4062b5aa97"
      unitRef="usd">162636000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzMtNS0xLTEtOTIzNzU_59678e59-691e-4831-9df1-c6db73f1a08c"
      unitRef="usd">52389000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzQtMS0xLTEtOTIzNzU_ad7320f9-7712-48aa-bacd-cb8f0c543a85"
      unitRef="usd">21000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzQtMy0xLTEtOTIzNzU_943b827e-2be1-4674-8a3a-436580a09344"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzQtNS0xLTEtOTIzNzU_3489877a-f40a-4657-892a-b05be7ec4824"
      unitRef="usd">3000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzUtMS0xLTEtOTIzNzU_649742fa-6417-41d2-ae8f-61b5028f9395"
      unitRef="usd">30000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzUtMy0xLTEtOTIzNzU_6c16e412-fe4d-441a-857f-8fcfc67d7621"
      unitRef="usd">20000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzUtNS0xLTEtOTIzNzU_c0840261-7c2d-4fe5-9039-804bf082be5c"
      unitRef="usd">20000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzYtMS0xLTEtOTIzNzU_919ebd45-6d9f-4345-91de-0534e32ebe06"
      unitRef="usd">133583000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzYtMy0xLTEtOTIzNzU_c6569511-5d9e-4123-bdfc-6718ff5e8832"
      unitRef="usd">162656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzYtNS0xLTEtOTIzNzU_068e238f-dbd7-4fb8-a4ef-1648fe61cfbc"
      unitRef="usd">55409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzktMS0xLTEtOTIzNzU_7a1eeeab-71f6-4f31-b333-ab50f5e0c4e0"
      unitRef="usd">127000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzktMy0xLTEtOTIzNzU_d4c4fb6f-0f6f-4d74-b099-b7dc8aa0735f"
      unitRef="usd">174000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfMzktNS0xLTEtOTIzNzU_c88fddb9-4ef1-4a3a-9c30-f7be2dbc573f"
      unitRef="usd">154000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDItMS0xLTEtOTIzNzU_42de74e7-4370-4431-a8bf-9b2de3658e85"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDItMy0xLTEtOTIzNzU_a092d9f0-8ff1-40e5-a0f2-77ddcde38ff5"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDItNS0xLTEtOTIzNzU_54e95fdc-422a-47ed-b9a5-852e2144c594"
      unitRef="usd">290000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <sesn:IssuanceOfWarrantForCommonStock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDUtMS0xLTEtOTIzNzU_ee039b32-b2cf-4d6c-9c6e-fd054ca5fadf"
      unitRef="usd">0</sesn:IssuanceOfWarrantForCommonStock>
    <sesn:IssuanceOfWarrantForCommonStock
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDUtMy0xLTEtOTIzNzU_d443abbe-ebd6-459d-a7db-a793469eaca8"
      unitRef="usd">0</sesn:IssuanceOfWarrantForCommonStock>
    <sesn:IssuanceOfWarrantForCommonStock
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF83Ni9mcmFnOjQ2NjliZjViNGFjNzRiZThhNGU4YzU4NGY0NDUwN2UwL3RhYmxlOjkwMDJjOTczODY2ODRmYjY5NDAxYmMzMGRkY2VjYTE4L3RhYmxlcmFuZ2U6OTAwMmM5NzM4NjY4NGZiNjk0MDFiYzMwZGRjZWNhMThfNDUtNS0xLTEtOTIzNzU_de8c9394-198f-42c2-b509-fc5de1a1f9aa"
      unitRef="usd">147000</sesn:IssuanceOfWarrantForCommonStock>
    <us-gaap:NatureOfOperations
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfMTY1NDY_d9f8450c-5fe4-4a5b-82ce-d42279fd429b">DESCRIPTION OF BUSINESS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sesen Bio, Inc. ("Sesen Bio" or the &#x201c;Company&#x201d;), a Delaware corporation formed in February 2008, is a late-stage clinical company that previously focused on advancing targeted fusion protein therapeutics (&#x201c;TFPTs&#x201d;) for the treatment of patients with cancer. The Company&#x2019;s most advanced product candidate, Vicineum&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, also known as VB4-845, is a locally administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pseudomonas exotoxin A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of non-muscle invasive bladder cancer (&#x201c;NMIBC&#x201d;). On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the United States Food and Drug Administration ("FDA"), which had implications on the size, timeline and costs of an additional Phase 3 clinical trial, which the FDA previously confirmed would be required for a potential resubmission of a biologics license application ("BLA") for Vicineum for the treatment of NMIBC. As a result of this decision, the Company turned its primary focus to consummating a strategic transaction with the goal of maximizing stockholder value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on September 20, 2022, the Company, Seahawk Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;), and CARISMA Therapeutics Inc. (&#x201c;Carisma&#x201d;), entered into the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Carisma, with Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the &#x201c;Merger&#x201d;). The Company&#x2019;s board of directors unanimously approved the Merger Agreement and resolved to recommend that its stockholders approve the proposals described in the Merger Agreement. If the Merger is completed, the business of Carisma will continue as the business of the combined company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, it is seeking a partner that can execute further development to realize the full potential of Vicineum. As a result of such decision and the Company&#x2019;s subsequent decision to enter into the proposed Merger with Carisma, it no longer plans to pursue regulatory approval of Vicineum for NMIBC in the European Union (the &#x201c;E.U.&#x201d;) and has started to wind down certain of its manufacturing operations and business development partnerships. Additionally, the Company is seeking a partner for the further development of Vicineum and has initiated a formal process and engaged a financial advisor for the potential sale of Vicineum. If the proposed Merger is consummated, the combined company does not expect to pursue further development of Vicineum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Anticipated Merger with CARISMA Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger is expected to be completed during the first quarter of 2023. In connection with the Merger, the Company is seeking the approval of its stockholders to, among other things, (a) issue the shares of its common stock issuable in connection with the Merger pursuant to the rules of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;), and (b) amend its amended and restated Certificate of Incorporation (the &#x201c;Certificate of Incorporation&#x201d;) to effect a reverse stock split of the outstanding shares of its common stock at a ratio of 1-for-20 (clauses (a) and (b), collectively, the &#x201c;Sesen Bio Voting Proposals&#x201d;). The special meeting of stockholders in which the Company&#x2019;s stockholders will be asked to vote on the Sesen Bio Voting Proposals (the &#x201c;Special Meeting&#x201d;) will be held on March 2, 2023 at 10:00 a.m. Eastern Time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sesen Bio&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that Sesen Bio does not complete the Merger with Carisma, Sesen Bio may continue to review and evaluate strategic alternatives, including, without limitation, a dissolution of Sesen Bio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Viventia Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#x201c;Selling Shareholders&#x201d;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#x201c;Clairmark&#x201d;) (the &#x201c;Share Purchase Agreement&#x201d;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#x201c;Viventia Acquisition&#x201d;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0 million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, a director of the Company until his retirement in July 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the &#x201c;Purchased Product&#x201d;), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of December&#160;31, 2022, none of these individuals are active employees or members of the Company's board of directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of $166.9 million a&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd an accumulated deficit of $336.1 million. The Company in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;curred positive cash flows from operating acti&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vities of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $24.9 million for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;curred negative cash flows from operating acti&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$68.9 million and $30.8 million for the years ended December 31, 2021 and 2020, respectively. Since the Company&#x2019;s inception, it has received no revenue from sales of its products, and the Company anticipates that operating losses will continue for the foreseeable future as it seeks to close the Merger with Carisma.&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has financed its operations to date primarily through private placements of its common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, its initial public offering ("IPO"), follow-on public offerings, sales effected in "at-the-market" ("ATM") offerings, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercialization partnership, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;out-license agreements and an asset purchase agreement. See &#x201c;Note 13. Stockholders&#x2019; Equity (Deficit)&#x201d; below for information regarding the Company&#x2019;s recently completed equity financings. Management believes that the Company&#x2019;s cash and cash equivalents as of December&#160;31, 2022 will be sufficient to fund the Company's operations for at least the next twelve months from the date these consolidated financial statements were issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Funding Requirements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's future funding requirements will depend on the outcome of the proposed Merger with Carisma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks similar to other clinical companies that have determined to focus primarily on pursuing a strategic transaction, including, but not limited to, those which are described under Part I Item 1A. Risk Factors of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will incur substantial expenses if and as it:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;addresses its ongoing litigation related to the Merger;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;maintains and protects its intellectual property portfolio;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;reduces its personnel and incurs related severance and employee-related costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;explores, evaluates and pursues any strategic alternatives if the Merger is not completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's future capital requirements will depend on many factors, including:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the outcome and the timing of the proposed Merger with Carisma;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the outcome and timing of any pending or future litigation involving the Company or its business;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the costs and timing of maintaining and enforcing the Company&#x2019;s intellectual property rights and defending any intellectual property-related claims; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;its obligation to make milestone, royalty and other payments to third-party licensors under its licensing agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Until such time, if ever, as the Company can generate substantial revenues, the Company expects to finance the cash needs through a combination of equity offerings, debt financings, or government or other third-party funding. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting the Company&#x2019;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company is unable to raise additional funds when needed, it may be required to delay, limit, &lt;/span&gt;&lt;/div&gt;reduce or terminate its assessment of strategic alternatives. If the Company does not successfully consummate the proposed Merger with Carisma, its board of directors may decide to explore other strategic alternatives, including, without limitation, a dissolution of the company.</us-gaap:NatureOfOperations>
    <sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare
      contextRef="i8207bee1099a4945acebe2cd3e4d4b1c_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNDI0Ng_7590c77b-a4fd-4a71-8867-e21c5a927409"
      unitRef="shares">4000000</sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="iae93f5204e234406aa4669d7fa75acb3_I20160930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNDM1MA_4c729918-ad94-4e05-b041-23e3789d26e4"
      unitRef="number">0.199</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="ia2f5bb9a1d474d50a682361408fd22f0_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNDkxNA_d4ff38c9-c4f3-4a33-a0a6-8c28581cc676"
      unitRef="usd">12500000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="i0cdc0620bb5249d1b453c6ee1ee52d9f_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNTA0Mw_c2e8b510-c1c0-46c3-878e-74b42b683719"
      unitRef="usd">7000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="ifec4efcaaaba4d86ae2f9115d511c3ad_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNTE4OQ_03e78c3a-e6fa-4ad8-99e2-91389089a0d4"
      unitRef="usd">3000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods
      contextRef="i0d5d00287d2b402c81fe18e1a760ee21_D20160901-20160930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNTMwMQ_812d9fbe-8c7a-4476-a8e9-b0849ac16bfd"
      unitRef="number">0.02</sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods>
    <sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales
      contextRef="i8207bee1099a4945acebe2cd3e4d4b1c_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNTU2OA_ee9d1f66-a0f1-4233-ac85-0a50e25091bd">P15Y</sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales>
    <sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations
      contextRef="i8207bee1099a4945acebe2cd3e4d4b1c_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNTg4Mw_d1bc4b8a-442b-4ac3-812a-31ba99c470e7">P7Y</sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNzE0NjgyNTYyOTI1Nw_fca245c1-c89d-40a1-aeb2-b0abbadb48a0"
      unitRef="usd">166900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNjU1OA_94083bc1-835e-4cc9-9aff-498fb32002ac"
      unitRef="usd">-336100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNjYzMg_7d328e6a-cdd4-421b-a308-dd8e66f166e1"
      unitRef="usd">24900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNjYzNg_91b0f8b1-6031-4ec6-8d2f-b1498190af3d"
      unitRef="usd">-68900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84Mi9mcmFnOmFjZjMxMDA0ODczZDQwM2NhOGZjNjlhMzc3ZjY0MTNkL3RleHRyZWdpb246YWNmMzEwMDQ4NzNkNDAzY2E4ZmM2OWEzNzdmNjQxM2RfNjY0Mw_7647a88e-0eba-48af-9042-3bd72801f29b"
      unitRef="usd">-30800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:BasisOfAccounting
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84NS9mcmFnOmY2NGNiODkwY2ZhMzRlZmE5YzA1MDJkZDIzOWViMjdlL3RleHRyZWdpb246ZjY0Y2I4OTBjZmEzNGVmYTljMDUwMmRkMjM5ZWIyN2VfMjM2MA_5c08326f-f5b7-4047-989f-14c853ae6087">BASIS OF PRESENTATION&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission ("SEC") requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the United States dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:UseOfEstimates
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84NS9mcmFnOmY2NGNiODkwY2ZhMzRlZmE5YzA1MDJkZDIzOWViMjdlL3RleHRyZWdpb246ZjY0Y2I4OTBjZmEzNGVmYTljMDUwMmRkMjM5ZWIyN2VfMjM2MQ_c546031f-f394-4100-b5ca-b8ecc100d5d4">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission ("SEC") requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84NS9mcmFnOmY2NGNiODkwY2ZhMzRlZmE5YzA1MDJkZDIzOWViMjdlL3RleHRyZWdpb246ZjY0Y2I4OTBjZmEzNGVmYTljMDUwMmRkMjM5ZWIyN2VfMjM2Mg_d90adebf-2168-4a7c-9ccb-f2128ab926d0">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84NS9mcmFnOmY2NGNiODkwY2ZhMzRlZmE5YzA1MDJkZDIzOWViMjdlL3RleHRyZWdpb246ZjY0Y2I4OTBjZmEzNGVmYTljMDUwMmRkMjM5ZWIyN2VfMjM2Mw_20061656-c0aa-486d-a563-f88e839a4865">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the United States dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMzg_0e328f5d-99ca-4125-b43e-a93521dbe2b3">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company's primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company's corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents, marketable securities, and accounts receivable. The Company limited its credit risk associated with cash equivalents and marketable securities by investing in highly-rated money market funds, US government securities, and treasury securities. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial institutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all of its marketable securities as available-for-sale. The marketable securities consist of holdings in US treasury securities and US government securities, with maturity dates ranging from March 2023 to November 2023, which is consistent with the Company's investment policy. Accordingly, these investments are recorded at fair value which is determined based on quoted market prices. Amortization and accretion of discounts and premiums are recorded as interest income. Realized gains and losses are included in other income (expense), net. Unrealized gains and losses are included in other comprehensive loss as a component of stockholder&#x2019;s equity (deficit) until realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of five years for lab equipment, four years for furniture &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and fixtures, three years for computer equipment and software and the lesser of five years or the remaining lease term for leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets consisted of indefinite-lived, acquired in-process research and development ("IPR&amp;amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in share price and a resulting decrease in its market capitalization. On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of its intangible asset of Vicineum E.U. rights. The Company concluded that the carrying value of its intangible asset of Vicineum E.U. rights of $14.7&#160;million was fully impaired as of June 30, 2022 and was reduced to zero in the second quarter of 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company received a Complete Response Letter ("CRL") from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing, and controls ("CMC") issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's marketing authorization application ("MAA"), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#x2019;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the United States market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill on the Company's consolidated balance sheets is the result of the Company&#x2019;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#x2019;s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. The Company has only one reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022, the Company observed continued trends in its market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, size, length and cost of a clinical trial, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of its typical annual assessment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. The Company updated its revenue forecast models based on further expected launch delays in both United States and outside of the United States ("OUS") regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. The Company also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September 2016. See "Note 1. Description of Business" above for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of its contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales were expected to be achieved through 2033, the level of commercial sales of Vicineum then-forecasted for the United States, Europe, Japan, China and other potential markets. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout was derived from the Company's estimated weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, it is seeking a partner for the further development of Vicineum. Accordingly, during the second quarter of 2022, the Company concluded that it is no longer expected to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential 2% earnout payment related to China, Hong Kong, Macau and Taiwan (collectively, &#x201c;Greater China&#x201d;) region since those territory rights had been out-licensed. Qilu Pharmaceutical, Co., Ltd. ("Qilu") held the exclusive license to develop Vicineum in the Greater China region, and accordingly, the $1.8&#160;million estimated earnout payment in the Greater China region remained as long-term contingent consideration as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, Qilu informed the Company that it no longer intended to commercialize Vicineum, due to additional effort and costs required to gain regulatory approval in that region without prior US approval. As such, the Company and Qilu were in the process of negotiating a termination of the Qilu License Agreement, which was terminated on December 23, 2022. Accordingly, the Company concluded that it no longer expected to owe any future earnout payments related to the Greater China region and reduced its remaining $1.8&#160;million of contingent consideration liabilities to zero as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for operating leases under ASC Topic 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease portfolio as of December 31, 2022 includes a property lease for its headquarters in Cambridge, MA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company&#x2019;s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company's consolidated balance sheet. The short-term and long-term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liability components are recorded in other current liabilities and other liabilities, respectively, on the Company&#x2019;s consolidated balance sheet. As of December&#160;31, 2022, the Company did not have any finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives' stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company&#x2019;s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management&#x2019;s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each grant of options during the years ended December&#160;31, 2022, 2021 and 2020 was determined using the following methods and assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Term. G&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iven the plain vanilla nature of the options granted by the Company, the expected term is determined using the "simplified" method, as prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 ("SAB 107"), whereby the expected life equals the arithmetic average of the vesting term (generally four years) and the original contractual term (ten years) of the option, taking into consideration multiple vesting tranches. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk-Free Interest Rate.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Volatility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company's own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Dividend Yield. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dividend yield is 0% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and research and development credit ("R&amp;amp;D credit") carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&#160;31, 2022 and 2021, the Company did not have any uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded revenue from former out-license agreements and OUS business development partnership agreements, including the former license agreement (the &#x201c;Roche License Agreement&#x201d;) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#x201c;Roche&#x201d;) and its former OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1)   Identification of the contract&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2)  Determination of whether the promised goods or services are performance obligations including whether they are                        distinct in the context of the contract&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3)  Measurement of the transaction price, including the constraint on variable consideration&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4)  Allocation of the transaction price to the performance obligations&#x37e; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5)  Recognition of revenue when or as the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Development and Regulatory Milestones and Other Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#x2019;s estimate of milestones and royalties approximates the standalone selling price of the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. Management evaluated the transaction under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous periods. Accordingly, the Company recorded $20&#160;million as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $40.0&#160;million of license revenue related to the asset purchase agreement with Roche during the year ended December 31, 2022 and $26.5&#160;million of license revenue related to the Roche, Qilu and Hikma License Agreements during the year ended December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss and other comprehensive loss. For the year ended December 31, 2022, other comprehensive loss included changes in unrealized income and loss on marketable securities. For the years ended December&#160;31, 2021 and 2020 comprehensive loss was equal to net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMTg_fcdd9fe7-5ac9-4b6f-9a28-dfbdb093f368">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit RiskThe Company's cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company's primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company's corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents, marketable securities, and accounts receivable. The Company limited its credit risk associated with cash equivalents and marketable securities by investing in highly-rated money market funds, US government securities, and treasury securities. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial institutions.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMzE3_812d887a-de56-4990-a697-1a97f73ae51c"
      unitRef="usd">250000</us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNTQ5NzU1ODgwMDAw_1a5f37fa-7a57-48c3-a9cb-3261ea782d4f">Marketable SecuritiesThe Company classifies all of its marketable securities as available-for-sale. The marketable securities consist of holdings in US treasury securities and US government securities, with maturity dates ranging from March 2023 to November 2023, which is consistent with the Company's investment policy. Accordingly, these investments are recorded at fair value which is determined based on quoted market prices. Amortization and accretion of discounts and premiums are recorded as interest income. Realized gains and losses are included in other income (expense), net. Unrealized gains and losses are included in other comprehensive loss as a component of stockholder&#x2019;s equity (deficit) until realized.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMjk_be910785-7c5d-4de2-b97f-918a56f90b60">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of five years for lab equipment, four years for furniture &lt;/span&gt;&lt;/div&gt;and fixtures, three years for computer equipment and software and the lesser of five years or the remaining lease term for leasehold improvements.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1276d33828844073b58b8708d329e283_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMTQxMg_f2435d4b-1ce2-4816-b3b3-89be888dc297">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ife760fe6115044c2ba0cfc773be36b66_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMTQzNA_653cbfef-2313-4a25-a139-047ad4acc850">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id1f4a4968e654e81812812835738bfba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMTQ2NQ_3fd1e18e-5ce6-4c09-8c17-89e67b33c3ea">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2bd951ea3e6843248bca81db2ab27548_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMTUyMg_837dab1f-2f3b-48b0-a6f5-66ffc2c38ac8">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMzk_db564f79-e5ec-4426-951f-2ce8bb13eb10">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets consisted of indefinite-lived, acquired in-process research and development ("IPR&amp;amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in share price and a resulting decrease in its market capitalization. On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of its intangible asset of Vicineum E.U. rights. The Company concluded that the carrying value of its intangible asset of Vicineum E.U. rights of $14.7&#160;million was fully impaired as of June 30, 2022 and was reduced to zero in the second quarter of 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company received a Complete Response Letter ("CRL") from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing, and controls ("CMC") issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's marketing authorization application ("MAA"), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#x2019;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the United States market.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="iff61ad1254204984b2cd73c3460b9b29_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODU4OQ_b327b0bd-4419-4fe1-ab38-619f9fec3104"
      unitRef="usd">14700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ied811451007444bf9c9766b4e6b6f65e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODYwMw_aaba3b6b-dbc0-46f9-a6f0-a07fc2463dcc"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNDE2Mg_3cde8d47-d81a-4b86-82e4-d805cd1dd95a"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwNDE_be603711-ab8e-493d-893e-2a9d4ab6e8ff">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill on the Company's consolidated balance sheets is the result of the Company&#x2019;s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#x2019;s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. The Company has only one reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022, the Company observed continued trends in its market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, size, length and cost of a clinical trial, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of its typical annual assessment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. The Company updated its revenue forecast models based on further expected launch delays in both United States and outside of the United States ("OUS") regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. The Company also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNzk3NA_1d499704-242f-4f07-81fa-b75a8835a3d6"
      unitRef="unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:Goodwill
      contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNTQ5NzU1ODYzMTE2_243f16b7-0dda-4f54-86fb-8709d2a948fe"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMTA3NjA_9793a857-795e-463d-9858-6fded67a621d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <sesn:ContingentConsiderationPolicyTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMzM_bbbdc31c-0207-4086-b725-69e66e582a5f">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September 2016. See "Note 1. Description of Business" above for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of its contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales were expected to be achieved through 2033, the level of commercial sales of Vicineum then-forecasted for the United States, Europe, Japan, China and other potential markets. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout was derived from the Company's estimated weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, it is seeking a partner for the further development of Vicineum. Accordingly, during the second quarter of 2022, the Company concluded that it is no longer expected to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential 2% earnout payment related to China, Hong Kong, Macau and Taiwan (collectively, &#x201c;Greater China&#x201d;) region since those territory rights had been out-licensed. Qilu Pharmaceutical, Co., Ltd. ("Qilu") held the exclusive license to develop Vicineum in the Greater China region, and accordingly, the $1.8&#160;million estimated earnout payment in the Greater China region remained as long-term contingent consideration as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, Qilu informed the Company that it no longer intended to commercialize Vicineum, due to additional effort and costs required to gain regulatory approval in that region without prior US approval. As such, the Company and Qilu were in the process of negotiating a termination of the Qilu License Agreement, which was terminated on December 23, 2022. Accordingly, the Company concluded that it no longer expected to owe any future earnout payments related to the Greater China region and reduced its remaining $1.8&#160;million of contingent consideration liabilities to zero as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;</sesn:ContingentConsiderationPolicyTextBlock>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNzY5NjU4MTQzNjI5OA_bef47329-244d-4d3b-a0d9-3f9784fadebe"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNzY5NjU4MTQzNjM5OA_cd6ca8ec-4d15-42e2-a258-cd2bbfe8478a"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i6bb37825c3464e0e96f96656c460f0b4_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNzY5NjU4MTQzNjUwMQ_36f09ead-3dcc-48e5-b174-b5ebd24e31b9"
      unitRef="number">0.093</sesn:WeightedAverageCostOfCapital>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNzY5NjU4MTQzNjcxMA_068e1bd2-bb45-442f-a41f-65f0368e1587"
      unitRef="number">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODYzNQ_cce03128-afa2-43c5-834a-c939f96230c5"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODYzOQ_134ad5d6-a303-4b13-ae60-f9b7c4c09083"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODY1Mw_79b76cfe-133b-4ae6-88fb-51a372b1e3af"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8733b9f5af3744478388e7790ab97043_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTExODY2Ng_91a645a5-70c1-4e11-af62-55bb25ec0cbf"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMTU_630ff112-1d8f-4420-abf5-2788ff80a3e6">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for operating leases under ASC Topic 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease portfolio as of December 31, 2022 includes a property lease for its headquarters in Cambridge, MA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company&#x2019;s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company's consolidated balance sheet. The short-term and long-term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liability components are recorded in other current liabilities and other liabilities, respectively, on the Company&#x2019;s consolidated balance sheet. As of December&#160;31, 2022, the Company did not have any finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMTY_13e5836e-a0e7-4d22-afa3-f230809995cd">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMzQ_26edffb4-ddb2-40f7-af08-2f23e8ed182c">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives' stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company&#x2019;s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management&#x2019;s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each grant of options during the years ended December&#160;31, 2022, 2021 and 2020 was determined using the following methods and assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Term. G&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iven the plain vanilla nature of the options granted by the Company, the expected term is determined using the "simplified" method, as prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 ("SAB 107"), whereby the expected life equals the arithmetic average of the vesting term (generally four years) and the original contractual term (ten years) of the option, taking into consideration multiple vesting tranches. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk-Free Interest Rate.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Volatility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company's own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Dividend Yield. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dividend yield is 0% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i438fa29ca3bb484a8da013a3e14bb5aa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjE5NjA_54d0a444-9662-4d4a-b5ce-3c73abb5bbc7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i438fa29ca3bb484a8da013a3e14bb5aa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjE5OTk_9319d716-4392-41f9-b1dc-d1e3ee0d6859">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjI2MDM_858bd771-6d77-4b96-b23b-8b9973e4d32f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwNDI_8fe17a15-4789-49fc-8b03-2446810513ef">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and research and development credit ("R&amp;amp;D credit") carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not &lt;/span&gt;&lt;/div&gt;(greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&#160;31, 2022 and 2021, the Company did not have any uncertain tax positions.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjgwMzY_0d3eec9f-0967-4b49-aba5-a0a60ba397c5">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded revenue from former out-license agreements and OUS business development partnership agreements, including the former license agreement (the &#x201c;Roche License Agreement&#x201d;) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#x201c;Roche&#x201d;) and its former OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1)   Identification of the contract&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2)  Determination of whether the promised goods or services are performance obligations including whether they are                        distinct in the context of the contract&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3)  Measurement of the transaction price, including the constraint on variable consideration&#x37e;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4)  Allocation of the transaction price to the performance obligations&#x37e; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5)  Recognition of revenue when or as the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Development and Regulatory Milestones and Other Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management&#x2019;s estimate of milestones and royalties approximates the standalone selling price of the license.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sesn:LicenseAgreementMilestonePayment
      contextRef="i4b69c2d148fb4538a3850c0e09af5f52_D20211201-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjcxNzM_e3deb570-5570-4979-918d-62ff364a1439"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestonePayment>
    <sesn:LicenseAgreementMilestonePayment
      contextRef="i4b69c2d148fb4538a3850c0e09af5f52_D20211201-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjcyNzc_0e26b0c3-5962-4750-a3db-d0ee88bd823f"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestonePayment>
    <sesn:LicenseAgreementMilestonePaymentTerm
      contextRef="i4b69c2d148fb4538a3850c0e09af5f52_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjczMDI_e9c66b68-501f-43a0-94bf-fc7ca737d261">P30D</sesn:LicenseAgreementMilestonePaymentTerm>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ideb2c67211a74687ab81a95f14fff15e_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNTQ5NzU1ODYzMTY4_8ff2934d-f650-4dd1-978e-3a3b111660d4"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:LicenseAgreementProceedsFromMilestoneAchieved
      contextRef="i60b94d2194694dd39ade84abefa3fbd2_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfNTQ5NzU1ODYzMTU1_04855a91-71e1-4963-9e4c-9431542fe65a"
      unitRef="usd">20000000</sesn:LicenseAgreementProceedsFromMilestoneAchieved>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc3OTQ_74642238-1ef1-4c0a-868c-e816bc48f764"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc5MTU_fe84932d-6ff2-47a1-8d80-98cee5733b1b"
      unitRef="usd">26500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF84OC9mcmFnOmE2NGI4YzVmYTY1ZjQxNmU5ZWQ1YTZmMzRhZmRkYTRlL3RleHRyZWdpb246YTY0YjhjNWZhNjVmNDE2ZTllZDVhNmYzNGFmZGRhNGVfMjc0ODc3OTEzMjkwNw_185a1486-e639-4dce-a7b9-6011d70d8f18">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss and other comprehensive loss. For the year ended December 31, 2022, other comprehensive loss included changes in unrealized income and loss on marketable securities. For the years ended December&#160;31, 2021 and 2020 comprehensive loss was equal to net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85MS9mcmFnOjhhNDIwYmUyNjM1NTQ3ODU4NTM3NWRmYmM1ZjgxZTYyL3RleHRyZWdpb246OGE0MjBiZTI2MzU1NDc4NTg1Mzc1ZGZiYzVmODFlNjJfOTM1_005ada6a-7f00-4616-b6ec-c21bc695bc11">RECENT ACCOUNTING PRONOUNCEMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-06")&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#x2019;s own equity. The ASU also amends the diluted earnings per share ("EPS") guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2021-04")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-04 clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85MS9mcmFnOjhhNDIwYmUyNjM1NTQ3ODU4NTM3NWRmYmM1ZjgxZTYyL3RleHRyZWdpb246OGE0MjBiZTI2MzU1NDc4NTg1Mzc1ZGZiYzVmODFlNjJfOTM3_ef5be42d-6313-45de-bf52-e5c5e2b8de35">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-06")&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#x2019;s own equity. The ASU also amends the diluted earnings per share ("EPS") guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2021-04")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-04 clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNjAyOA_c827cbac-652d-4061-b925-84b1d6bba691">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s consolidated balance sheets approximated their fair values as of December&#160;31, 2022 and 2021 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers valuations obtained from third party pricing sources when estimating the fair value of marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company&#x2019;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2025 to 2033, and the level of commercial sales of Vicineum then-forecasted for the United States, Europe, Japan, China, and other potential markets. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout was derived from its estimated weighted-average cost of capital, which was 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#x2019;s weighted average cost of capital, which was 9.3% as of December&#160;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. The Company continues to believe that Vicineum has benefits for patients and healthcare providers that can be maximized through a company with a larger infrastructure, and as such, it is seeking a partner for the further development of Vicineum. Accordingly, the Company concluded that it is no longer expected to pay related milestone and earnout payments to the former shareholders of Viventia. Therefore, the Company&#x2019;s contingent consideration liability as of December 31, 2022 was zero.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNjAyNQ_6fe77d2f-f5a7-45d7-84ec-a96d287934f6">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s consolidated balance sheets approximated their fair values as of December&#160;31, 2022 and 2021 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNjAyNg_d6b829de-0b2a-4ec7-8681-dc37d160d59f">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i38ea235079af435bad2ec47753289b96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNC0xLTEtMS05MjM3NQ_7ac8dbcd-bf97-47a6-8bf7-05b9324c863b"
      unitRef="usd">76728000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i494cedbff9d444cdaac1c2802663fc2b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNC0zLTEtMS05MjM3NQ_9cf95432-d6dd-4dc1-926c-1b8eccf4ad01"
      unitRef="usd">76728000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i88aacf670d6d4b4d880e4b578f023b29_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNC01LTEtMS05MjM3NQ_b934be9d-255c-4cd3-ada8-6ffb3ddf25df"
      unitRef="usd">76728000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5b14fcd0c3d7431fa4d0dfee8ba33375_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNC03LTEtMS05MjM3NQ_5210d80a-5690-4e7c-af76-dc4d06ea933f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic7077879bdc245db95b0560b33dc1e1d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNC05LTEtMS05MjM3NQ_12c18d6f-578c-4bf2-b1a7-b8e5dec3bd3c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b6b0b19859b4275a8ba10b9aa85008e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNi0xLTEtMS05OTA4Mw_77ab2fac-7f52-4235-9fdb-0c96bcd6adeb"
      unitRef="usd">49431000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65e64d741e894999bf76a1e7cf64b004_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNi0zLTEtMS05OTA4Mw_7ce36fe0-336b-4ff3-aa58-38f1c0de847b"
      unitRef="usd">49431000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89820af99a774c6da12e89d3f3b664cc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNi01LTEtMS05OTA4Mw_ed93703d-e39e-4a07-8c33-c3d7a25fb9e7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f8f5e0d0c4144a4959bc06d609ca157_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNi03LTEtMS05OTA4Mw_45b4418b-9ced-40ae-a5b9-dae5c19141ca"
      unitRef="usd">49431000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib898a55a349649d690d06fb7f3e654d8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfNi05LTEtMS05OTA4Mw_a844234c-76b7-44e8-b602-a18d440da03a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id74fe8f2daef45e18f8d67cb5c61198b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfOC0xLTEtMS0xMDY2NzQ_60326fa6-a3cd-4599-b4cc-789eb2d35df0"
      unitRef="usd">4935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2efef4133dd04188a2f6d5ffc3064dcd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfOC0zLTEtMS0xMDY2NzQ_2c45f38a-1074-455f-afdb-d62f8ea9e373"
      unitRef="usd">4935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc6f81f8bf0246f39eed469355ba430e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfOC01LTEtMS0xMDY2NzQ_cd07d5a1-26c6-43ca-a9c2-6be16b0e1f6a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6f40cef73b6f464299f697a3de9e26bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfOC03LTEtMS0xMDY2NzQ_08386373-61f0-4fe9-9e57-41d39be9678c"
      unitRef="usd">4935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i074825a299f84fcd81b16f4255ea2ad7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmM3NWIyN2JjODJlZjQzOGZiMjE5N2I1NGU3MTViNzhlL3RhYmxlcmFuZ2U6Yzc1YjI3YmM4MmVmNDM4ZmIyMTk3YjU0ZTcxNWI3OGVfOC05LTEtMS0xMDY2NzQ_550b33d1-4109-4cd6-b90c-3778aed9de4d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i917a1b8a73ae45318b8d10a7f14926dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNC0xLTEtMS05MjM3NQ_31bfd0e1-1b3e-49ae-9468-168b7e315880"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ica10e8f91cd84acdbe3c5774e4168b74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNC0zLTEtMS05MjM3NQ_37b31b07-dcf1-4266-bc21-188dd5937c64"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6a8370652ea34632aa61254cc191c0a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNC01LTEtMS05MjM3NQ_c04ab1d5-3218-45a3-a1f9-a723704affb9"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if4b6eb53935e4e5f9644289109556c1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNC03LTEtMS05MjM3NQ_a582246f-da6e-41ef-85c5-1131d2f83892"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7c307f87ede64e08ba34df00d1e3be8e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNC05LTEtMS05MjM3NQ_f48d6503-cf25-465b-adc2-adc40067f94d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i917a1b8a73ae45318b8d10a7f14926dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNy0xLTEtMS05MjM3NQ_90979d24-1824-489b-b4e0-0e2caf454838"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ica10e8f91cd84acdbe3c5774e4168b74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNy0zLTEtMS05MjM3NQ_d7355cab-2152-4ec1-8ec1-024390ad2a7e"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i6a8370652ea34632aa61254cc191c0a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNy01LTEtMS05MjM3NQ_059b851d-ff23-449a-94c5-797f386b8188"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="if4b6eb53935e4e5f9644289109556c1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNy03LTEtMS05MjM3NQ_a5b9daa7-55de-4536-bfb0-c56335c4d3f5"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7c307f87ede64e08ba34df00d1e3be8e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmEyOWVmYTllNTQwZDQxMTQ5Y2ZlM2VkMzYyNmM1Mjg4L3RhYmxlcmFuZ2U6YTI5ZWZhOWU1NDBkNDExNDljZmUzZWQzNjI2YzUyODhfNy05LTEtMS05MjM3NQ_bf23753b-26fb-4efb-b405-7e1669e66a4d"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNzY5NjU4MTQwNzU5Nw_bef47329-244d-4d3b-a0d9-3f9784fadebe"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNzY5NjU4MTQwODIyOQ_cd6ca8ec-4d15-42e2-a258-cd2bbfe8478a"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i6bb37825c3464e0e96f96656c460f0b4_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNzY5NjU4MTQwODMxNg_36f09ead-3dcc-48e5-b174-b5ebd24e31b9"
      unitRef="number">0.093</sesn:WeightedAverageCostOfCapital>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNzY5NjU4MTQwODUyNQ_068e1bd2-bb45-442f-a41f-65f0368e1587"
      unitRef="number">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfNjAyNw_51fe9992-97c9-404b-87c7-de26e24ea378">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration - long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icd6d796c44ea43198dc7c3fb8d6ae129_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmE4MjA2NGRmNWQ4NjRiNGRiMDlhN2E5MTFmYjA2YTI3L3RhYmxlcmFuZ2U6YTgyMDY0ZGY1ZDg2NGI0ZGIwOWE3YTkxMWZiMDZhMjdfMC0xLTEtMS05MjM3NQ_439d1c9a-379c-495f-ad88-68ca992177ff"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent
      contextRef="i5c2a1c5a91084f178b29a4fe51e14ea2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmE4MjA2NGRmNWQ4NjRiNGRiMDlhN2E5MTFmYjA2YTI3L3RhYmxlcmFuZ2U6YTgyMDY0ZGY1ZDg2NGI0ZGIwOWE3YTkxMWZiMDZhMjdfMi0xLTEtMS05MjM3NQ_67286a7f-2d2c-47e3-8c10-6a845943f927"
      unitRef="usd">-52000000</sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i39409440477849f689c25e277356952c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RhYmxlOmE4MjA2NGRmNWQ4NjRiNGRiMDlhN2E5MTFmYjA2YTI3L3RhYmxlcmFuZ2U6YTgyMDY0ZGY1ZDg2NGI0ZGIwOWE3YTkxMWZiMDZhMjdfMy0xLTEtMS05MjM3NQ_d0afee65-d8aa-4379-9915-cbd66cb1243e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfMjkwMg_5c40d60d-9815-4ef3-be9d-05e6f58a0bfb"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfMzAwMQ_42c7d715-f2cc-4ddd-acf0-af77f336d82e"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:WeightedAverageCostOfCapital
      contextRef="i6bb37825c3464e0e96f96656c460f0b4_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfMzA3NA_9df5d463-2b80-4745-ba8d-551b60e3faaa"
      unitRef="number">0.093</sesn:WeightedAverageCostOfCapital>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfMzM4Nw_10fc0d5a-0390-4a2d-a51d-8006a469853f"
      unitRef="number">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85NC9mcmFnOjE0OWNkNTMzYTI1ZDQ4MjRiZDVmMDA4MGQzYjE1YTg1L3RleHRyZWdpb246MTQ5Y2Q1MzNhMjVkNDgyNGJkNWYwMDgwZDNiMTVhODVfMjc0ODc3OTA5NDk5OA_0127d1ef-b142-4b4b-9113-bb3ced6d8e24"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGV4dHJlZ2lvbjoyMzZlYTZmMTk1MTE0OGMzOTVkNjU2MjhhZTAwZjBhMF8yNzQ4Nzc5MDcxNzI2_9e483544-a034-44f0-8a65-f1897dace3c8">RESTRICTED CASH AND MARKETABLE  SECURITIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's short-term restricted cash balance as of December 31, 2022 was $21.0&#160;million. This represents the settlement amount of the Securities Litigation (as defined below in Note 11. &#x201c;Commitment and Contingencies&#x201d;), including the insurance carriers' coverage, which was funded into an escrow account in the fourth quarter of 2022. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 31, 2023, the court issued an order granting final approval of the settlement of the Securities Litigation. Accordingly, this matter is now resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The  following table sets forth the composition of the Company&#x2019;s marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company had no marketable securities as of December 31, 2021</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:RestrictedCashCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGV4dHJlZ2lvbjoyMzZlYTZmMTk1MTE0OGMzOTVkNjU2MjhhZTAwZjBhMF81NDk3NTU4MTY2NTc_5777559f-8c4b-4899-a161-0cacb4f3852d"
      unitRef="usd">21000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGV4dHJlZ2lvbjoyMzZlYTZmMTk1MTE0OGMzOTVkNjU2MjhhZTAwZjBhMF8yNzQ4Nzc5MDcyNzcy_6e9d1a9d-bd5b-4efc-85ba-c6d06e4af2be">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The  following table sets forth the composition of the Company&#x2019;s marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government securities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company had no marketable securities as of December 31, 2021</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i426ddaf2851e41c3b2b8a1b26933b3da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV81LTEtMS0xLTEwNjA4OQ_af8ea22e-e347-4ac2-b525-d2f2fb56ece5"
      unitRef="usd">49939000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i426ddaf2851e41c3b2b8a1b26933b3da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV81LTMtMS0xLTEwNjEwMg_9726dc6c-1375-4b70-b2b8-2c3d9bc4b374"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i426ddaf2851e41c3b2b8a1b26933b3da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV81LTUtMS0xLTEwNjExMg_865e2eda-f0c3-4547-83c8-60ca182a4c54"
      unitRef="usd">508000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i426ddaf2851e41c3b2b8a1b26933b3da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV81LTctMS0xLTEwNjEyMA_53375022-5f04-4a53-9950-07c941ee92c4"
      unitRef="usd">49431000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8260e3eaa13f41a3a609d11ef48a8540_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV82LTEtMS0xLTEwNjA4OQ_ca689fdf-6e12-4884-afcf-98ea779de6d2"
      unitRef="usd">4973000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8260e3eaa13f41a3a609d11ef48a8540_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV82LTMtMS0xLTEwNjEwMg_0510cfb8-a408-4f21-89ac-e66dd9117f84"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8260e3eaa13f41a3a609d11ef48a8540_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV82LTUtMS0xLTEwNjExMg_80d72a66-5272-4afa-a4d2-645dde09e201"
      unitRef="usd">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8260e3eaa13f41a3a609d11ef48a8540_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV82LTctMS0xLTEwNjEyMA_e4908a32-190a-4331-aaeb-d48c0f94ec01"
      unitRef="usd">4935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV84LTEtMS0xLTEwNjI5OQ_0d9667ab-b6e6-434f-8eb4-9814fb71c71a"
      unitRef="usd">54912000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV84LTMtMS0xLTEwNjI5OQ_490452d9-0b92-44a6-bfc5-2f5acb08af37"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV84LTUtMS0xLTEwNjI5OQ_67955ed9-08e2-4cbe-9960-d9d23f07a127"
      unitRef="usd">546000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEyL2ZyYWc6MjM2ZWE2ZjE5NTExNDhjMzk1ZDY1NjI4YWUwMGYwYTAvdGFibGU6ZjNlOWQ3YzI1OGJjNDI5ZGI3MjllNTQ0N2IwOTJlNWEvdGFibGVyYW5nZTpmM2U5ZDdjMjU4YmM0MjlkYjcyOWU1NDQ3YjA5MmU1YV84LTctMS0xLTEwNjI5OQ_106532fc-1f81-47f5-a73d-5296447237a4"
      unitRef="usd">54366000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMTIzNw_3218f56a-ef21-457d-9a9b-674feabb3ea1">RECEIVABLES &lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounts receivable balance as of December 31, 2021 was $21.0&#160;million, comprised primarily of a $20.0&#160;million milestone achieved in December 2021 due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $20.0&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. In January 2022 the payment of $20.0&#160;million was received. Additionally, i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". As such, the Company recorded $0.9&#160;million of revenue and accounts receivable for the additional purchase price resulting from Qilu's obligation to pay Sesen Bio an amount equal to its recovery of VAT. The Company received this payment in the second quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other receivable balance as of December&#160;31, 2022 was $0.8&#160;million, primarily consisting of German VAT recovery related to drug substance sent to Baxter. The Company expects to collect the remaining balance in 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other receivable balance as of December&#160;31, 2021 was $3.5&#160;million, primarily consisting of German VAT recovery related to drug substance sent to Baxter.&lt;/span&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMjc0ODc3OTA3MjA1Nw_4fde7bad-2fac-47da-87b6-6eae9e034f55"
      unitRef="usd">21000000</us-gaap:AccountsReceivableNetCurrent>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="if3cd4cc1171943f0abebe901bfe21fec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMTA5_9db33699-33c2-4c2b-ab48-df8c6d60e5f2"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="if3cd4cc1171943f0abebe901bfe21fec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMjI2_92e2e434-74ab-430d-8e5d-833f166a4279"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:AccountsReceivablePaymentTerms
      contextRef="i93938c1286d6418fb704e36349eb0d31_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMjUx_1dc5e99d-8575-48a5-9cc2-92a62f71cdff">P30D</sesn:AccountsReceivablePaymentTerms>
    <sesn:LicenseAgreementProceedsFromMilestoneAchieved
      contextRef="i9871161ad5a44399978150d031c7b8ce_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMzk1_26e0d5b8-09d6-4e0a-9d43-63b55e6262ba"
      unitRef="usd">20000000</sesn:LicenseAgreementProceedsFromMilestoneAchieved>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i71d9693f005d44b68ed0b5546044f4d8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfNTk1_fe9aed0f-5858-472e-b34c-c8c543155488"
      unitRef="usd">900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfODk5_7a9ac267-03f9-4fc7-ab91-5acde1213a64"
      unitRef="usd">800000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF85Ny9mcmFnOjExYzY0Zjk2N2Q5ZDQ5NzA5MWJlNGQ2NGE3NmRlNjhmL3RleHRyZWdpb246MTFjNjRmOTY3ZDlkNDk3MDkxYmU0ZDY0YTc2ZGU2OGZfMjc0ODc3OTA3MTQ5MQ_512e694e-f58e-4564-95ff-d3539418f80e"
      unitRef="usd">3500000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90ZXh0cmVnaW9uOjBkMTI3ODM2NWIyYzQyNzI5ZjFhNmY4NmJhYTg4NmI0XzI0MA_b216cfc1-3fd4-4a20-a18d-2010ef54ec36">PROPERTY AND EQUIPMENT&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of property and equipment, net as of December&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Property and Equipment, Net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation expense was de minimis, $0.1 million and $0.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90ZXh0cmVnaW9uOjBkMTI3ODM2NWIyYzQyNzI5ZjFhNmY4NmJhYTg4NmI0XzI0MQ_b3a6be3a-8ea6-4dc1-a5de-014e15f42b33">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of property and equipment, net as of December&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Property and Equipment, Net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if34f56efef5946f89e9010b83ecc7d97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzItMS0xLTEtOTIzNzU_1a862949-5121-4a62-9f55-4f95d9f884cf"
      unitRef="usd">94000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i611e9ad1d7694553bcda04f42fc4e80b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzItMy0xLTEtOTIzNzU_a9591f16-97c5-4cd2-89d6-96f0ca06f6b0"
      unitRef="usd">569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1df7ab1adf0148c78a21e7ce97a4d22f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzMtMS0xLTEtOTIzNzU_045e1553-667c-4629-87af-076fb6714dde"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id44669cb53d947d4ad326771aa7b9afe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzMtMy0xLTEtOTIzNzU_9b192067-941f-4c20-a281-27465a41514c"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib4f414a7418a405588fb22be6f30e0c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzQtMS0xLTEtOTIzNzU_6da1172c-f5ff-4000-b4fa-820ce0b52c91"
      unitRef="usd">7000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i655ddc8bcc5848c5b1d7a3ff27a40ba1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzQtMy0xLTEtOTIzNzU_543e3aee-8c83-4539-98fe-789bdcd2d35a"
      unitRef="usd">99000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4ab420bf8ef045078703d770aad32427_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzUtMS0xLTEtOTIzNzU_b3d16cdb-658d-4f04-aad0-2f3bce8205e2"
      unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic6e3f81d8d1b4f3f97c34c9b3d9b0f02_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzUtMy0xLTEtOTIzNzU_2293ac9b-ae90-4dc6-baea-f99631049e60"
      unitRef="usd">32000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ife751660f97f4281991e4b6aa712c73d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzYtMS0xLTEtOTIzNzU_465c7c66-541d-447e-8150-67410168006a"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i25d39b728d0147189730e15e9fd156c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzYtMy0xLTEtOTIzNzU_7a2871b4-f5c7-42c7-a588-43d210c5e3e6"
      unitRef="usd">293000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzctMS0xLTEtOTIzNzU_849efd66-c1de-47ac-8009-c1a755002f7b"
      unitRef="usd">105000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzctMy0xLTEtOTIzNzU_78dd8640-017b-4e93-b19b-926e6f84c4ed"
      unitRef="usd">1009000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzgtMS0xLTEtOTIzNzU_8815deb1-8d07-4db4-bd4c-28f5e3f8a79d"
      unitRef="usd">105000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzgtMy0xLTEtOTIzNzU_c35572d5-89b8-4eda-a72a-0b7592931369"
      unitRef="usd">966000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzktMS0xLTEtOTIzNzU_95ac216c-95d7-4987-bf9b-8a0e5c16304e"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90YWJsZToxNzc2NjY3OGZmYjE0YjRmYWU2MzI4MTRkZjJiYzk4OC90YWJsZXJhbmdlOjE3NzY2Njc4ZmZiMTRiNGZhZTYzMjgxNGRmMmJjOTg4XzktMy0xLTEtOTIzNzU_af9def2e-e461-4b4d-97e6-274738bbb0c6"
      unitRef="usd">43000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90ZXh0cmVnaW9uOjBkMTI3ODM2NWIyYzQyNzI5ZjFhNmY4NmJhYTg4NmI0XzE3Mg_e0c22616-51ab-439c-b234-fa305b1d9cbf"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDAvZnJhZzowZDEyNzgzNjViMmM0MjcyOWYxYTZmODZiYWE4ODZiNC90ZXh0cmVnaW9uOjBkMTI3ODM2NWIyYzQyNzI5ZjFhNmY4NmJhYTg4NmI0XzE3OQ_c04d9796-3a8b-461e-8e6c-2b276c3afef5"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzY5MjA_650998bd-3f07-42d3-a9b2-0de5fce70092">INTANGIBLES AND GOODWILL&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets on the Company's consolidated balance sheet were the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of December&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum United States rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the acquired intangible assets for the United States and E.U. rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in share price and a resulting decrease in its market capitalization. On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum following discussions with the FDA, which had implications on the size, timeline, and costs of an additional Phase 3 clinical trial for the treatment of NMIBC. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of its intangible asset of Vicineum E.U. rights. The Company concluded that the carrying value of its intangible asset of Vicineum E.U. rights of $14.7&#160;million was fully impaired as of June 30, 2022 and was reduced to zero in the second quarter of 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's MAA, an interim impairment analysis &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#x2019;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the United States market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill on the Company's consolidated balance sheet is the result of the Viventia Acquisition in September 2016. Goodwill had no carrying value as of December&#160;31, 2022 and had a carrying value of $13.1&#160;million as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022, the Company observed continued trends in its market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, size, length and cost of a clinical trial, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of its typical annual assessment date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. The Company updated its revenue forecast models based on further expected launch delays in both United States and OUS regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. The Company also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the annual testing and quarterly reviews performed, the Company concluded that there was no goodwill impairment during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzY5MjE_340f9234-fb16-421a-9b57-11db0075d65c">The following table sets forth the composition of intangible assets as of December&#160;31, 2022 and 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum United States rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i94c243529fbd4ad2a365269cda0a0347_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzMtMS0xLTEtOTIzNzU_ce8d9d09-29f6-47fc-ae4a-4c79c39beddc"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i1bf382fe4d8647e58e6ad3d32e4f377c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzMtMy0xLTEtOTIzNzU_89b5507b-1b69-4340-bbba-79be397ad399"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="id21ae50c8649402492cc8890f61aece0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzQtMS0xLTEtOTIzNzU_4a53836c-590d-409b-b31a-88f42a40c579"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ie6fca7ca9a1e4c2bb4c5439eaa2b6d6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzQtMy0xLTEtOTIzNzU_22061154-7740-4d27-bbad-fa67d368c8f8"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i50aaf5a9d1c54113a3349e45d1378020_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzUtMS0xLTEtOTIzNzU_b70ec735-a95e-455a-8d01-9122b3053fee"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ica22b69fbf7d46f5a9b967bc6cee46d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90YWJsZTo2ZGNlYjNhMjlmM2M0NmQ4OTVkMWFlM2IyN2EyM2VjMS90YWJsZXJhbmdlOjZkY2ViM2EyOWYzYzQ2ZDg5NWQxYWUzYjI3YTIzZWMxXzUtMy0xLTEtOTIzNzU_abd5ef05-e64b-4db9-9da2-64b14c226886"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="iff61ad1254204984b2cd73c3460b9b29_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzI3NDg3NzkwODgxNDE_709d340a-0f65-46b8-a424-ad5604a2f468"
      unitRef="usd">14700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ied811451007444bf9c9766b4e6b6f65e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzI3NDg3NzkwODgxNTU_a120e3e5-ea43-49b7-afcd-df12a07d6968"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0Xzc2OTY1ODE0MDUxNjA_3cde8d47-d81a-4b86-82e4-d805cd1dd95a"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzU0OTc1NTgzMjYzOA_8275c674-2104-49ee-9ee7-4f1718727e99"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzQyNDQ_27dcb272-5638-4868-bbba-4a0c0e78f8f6"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6fb401e67dfc467b98d93144d057b5fc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0XzU0OTc1NTgzMjY0Mw_07bd440e-6b78-4a20-bc2c-943eec910515"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDMvZnJhZzo5MDk0ODFiM2RkZDQ0MWNjYmE4MDExNGRjYzkxZWNjNC90ZXh0cmVnaW9uOjkwOTQ4MWIzZGRkNDQxY2NiYTgwMTE0ZGNjOTFlY2M0Xzc2OTY1ODE0MTA0MzU_9793a857-795e-463d-9858-6fded67a621d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90ZXh0cmVnaW9uOjMzMGZkY2ZkOTFiNDQ5MWZiMjZmMmUzZDA5YWMzZjA2XzEyNQ_3498c16d-c881-4033-b17a-75a2a7cdcdbe">ACCRUED EXPENSES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of December&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal expenses, including the preliminary securities litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,636&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90ZXh0cmVnaW9uOjMzMGZkY2ZkOTFiNDQ5MWZiMjZmMmUzZDA5YWMzZjA2XzEyNg_08dc5ef8-d0d5-4ea8-aa7a-113c75ecd6f1">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of December&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal expenses, including the preliminary securities litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,636&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzItMS0xLTEtOTIzNzU_740f0f9f-fd77-4b67-90d6-935c091c528e"
      unitRef="usd">40000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzItMy0xLTEtOTIzNzU_fb332504-1c94-4689-a798-d4b3315da829"
      unitRef="usd">1841000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzMtMS0xLTEtOTIzNzU_ba2f3eef-2819-4b4b-97a6-dcf8a88dd939"
      unitRef="usd">1404000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzMtMy0xLTEtOTIzNzU_acd11e0e-11a4-4407-ae78-9c3837fb088c"
      unitRef="usd">2967000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzQtMS0xLTEtOTIzNzU_6f905c40-04db-41f1-b5ba-e3d66cfd47d2"
      unitRef="usd">5733000</sesn:AccruedRestructuringChargesRelatedCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzQtMy0xLTEtOTIzNzU_85248e81-e4fc-405b-a286-2f5e6c2f59ef"
      unitRef="usd">1497000</sesn:AccruedRestructuringChargesRelatedCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzUtMS0xLTEtOTIzNzU_3c2888e0-dd3b-4eb3-81bf-ac34891c3d18"
      unitRef="usd">301000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzUtMy0xLTEtOTIzNzU_ea2ba64f-7e03-477f-9158-4bd3348bee37"
      unitRef="usd">597000</us-gaap:AccruedProfessionalFeesCurrent>
    <sesn:AccruedLegalFeesCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzYtMS0xLTEtOTQ4NjI_5cb5f849-2596-42b6-b866-2d8cd2ae67ea"
      unitRef="usd">21919000</sesn:AccruedLegalFeesCurrent>
    <sesn:AccruedLegalFeesCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzYtMy0xLTEtOTQ4NjI_bb8b2b45-f429-49d5-8f2e-917fffada3cd"
      unitRef="usd">1344000</sesn:AccruedLegalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzYtMS0xLTEtOTIzNzU_dfa2cefe-1818-4cf8-bff9-987a0a1912bc"
      unitRef="usd">239000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzYtMy0xLTEtOTIzNzU_f279858f-ed25-4e86-8fc4-73a6a920ca66"
      unitRef="usd">9000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzctMS0xLTEtOTIzNzU_92e38554-53a7-4fb1-8df3-139dfc73038d"
      unitRef="usd">29636000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDYvZnJhZzozMzBmZGNmZDkxYjQ0OTFmYjI2ZjJlM2QwOWFjM2YwNi90YWJsZTo4YzE0ZDMwZWQ1OTM0NTJmOTRlMWU5ZjJhZjQ5Zjg2MC90YWJsZXJhbmdlOjhjMTRkMzBlZDU5MzQ1MmY5NGUxZTlmMmFmNDlmODYwXzctMy0xLTEtOTIzNzU_2b205498-efa0-48cc-89ce-c573f0665b41"
      unitRef="usd">8255000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0NDg_fee58c28-47cf-4885-8cc5-d7bf4f0ce981">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#x2019;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bibb v. Sesen Bio, Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., Case No. 1:21-cv-07025, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cizek v. Sesen Bio, Inc., et. al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 1:21-cv-07309 and M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;arkman v. Sesen Bio, Inc. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the United States District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#x2019; fees. On October 29, 2021, the court consolidated the three cases under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Sesen Bio, Inc. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Master File No. 1:21-cv-07025-AKH (the &#x201c;Securities Litigation&#x201d;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (collectively, the &#x201c;Lead Plaintiffs&#x201d;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. On November 24, 2021, defendants filed a motion to transfer venue to the United States District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#x201c;Amended Complaint&#x201d;). The Amended Complaint alleged the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022, and that motion was fully briefed on May 6, 2022. On June 3, 2022, before the court ruled on the motion to dismiss, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. On June 30, 2022 and July 6, 2022, the Company and the plaintiffs engaged in mediation sessions in an attempt to resolve the Securities Litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which was filed with the court on August 17, 2022. The Stipulation and Agreement of Settlement related to the Securities Litigation provides for a settlement payment of $21.0&#160;million to the class and the dismissal of all claims against the Company and the other defendants. On September 1, 2022, the United States District Court for the Southern District of New York issued an order denying the motions to appoint a different lead plaintiff. On September 28, 2022, the court issued an order granting preliminary approval of the proposed settlement of the Securities Litigation. The settlement payment of $21.0&#160;million, including the insurance carriers coverage, was funded into an escrow account in the fourth quarter of 2022. Accordingly, $21.0&#160;million remained in restricted cash on the Company's balance sheet as of December 31, 2022. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 31, 2023, the court issued an order granting final approval of the settlement of the Securities Litigation. Accordingly, this matter is now resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Myers v. Sesen Bio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 1:21-cv-11538 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;D&#x2019;Arcy v. Sesen Bio, Inc., et. al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 1:21-cv-11577 were filed against the Company&#x2019;s board of directors and certain of its officers in the United States District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tang v. Sesen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bio, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was filed in Superior Court in Massachusetts against the Company&#x2019;s board of directors and certain of its officers (the &#x201c;State Derivative Litigation&#x201d;). The three derivative complaints alleged breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#x2019;Arcy complaint further alleged unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints sought unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#x2019; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Sesen Bio, Inc. Derivative Litigation, Lead&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Case No. 1:21-cv-11538 (the &#x201c;Federal Derivative Litigation&#x201d;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On July 6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in mediation in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2022, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims (collectively, the &#x201c;Derivative Litigation&#x201d;). Pursuant to that agreement, the individual defendants will cause the Company to adopt certain enhancements to its corporate governance policies and procedures. In exchange, plaintiffs will dismiss the Derivative Litigation and, on behalf of the Company, provide broad customary releases to the individual defendants. On August 22, 2022, the parties entered into a Stipulation of Settlement to settle the Derivative Litigation, which was filed with the court on August 30, 2022. The Stipulation of Settlement related to the Derivative Litigation confirms that the Company previously adopted certain corporate governance enhancements in response to, among other things, the filing of the Derivative Litigation, and that, subject to final court approval, the Company will adopt additional corporate governance enhancements. The Stipulation of Settlement also provides for a $630,000 payment for plaintiffs&#x2019; attorneys' fees due to the benefits the corporate governance enhancements are intended to provide to the Company. The payment of plaintiffs&#x2019; attorneys' fees is being funded by the Company. On September 2, 2022, the court issued &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an order granting preliminary approval of the Stipulation of Settlement related to the Derivative Litigation. On November 8, 2022, the court issued an order granting final approval of the Stipulation of Settlement related to the Derivative Litigation. Accordingly, this matter is now resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 28, 2022, a purported stockholder filed a complaint in the United States District Court for the Southern District of New York against the Company and its board of directors, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keller v. Sesen Bio, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 1:22-cv-10085 (S.D.N.Y.) (the &#x201c;Original Keller Complaint&#x201d;). The Original Keller Complaint asserted claims against the Company and its board of directors under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement on Form S-4 (File No. 333-267891) (the "Registration Statement") in connection with the Merger and under Section 20(a) of the Exchange Act for alleged &#x201c;control person&#x201d; liability with respect to such allegedly false and misleading statements and sought, among other relief, an order enjoining the Merger and an award for plaintiffs&#x2019; fees and costs. On December 20, 2022, the purported stockholder voluntarily dismissed the Original Keller Complaint and on December 21, 2022, filed a new complaint as a putative class action in the Court of Chancery for the State of Delaware, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keller v. Sesen Bio, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 2022-1186 (Del. Ch. Dec. 21, 2022) (the &#x201c;New Keller Complaint&#x201d;). Along with the complaint, the purported stockholder filed motions for expedited proceedings and for a preliminary injunction to enjoin the Special Meeting. The New Keller Complaint and associated filings contain substantially the same assertions as the Original Keller Complaint, and seek, among other relief, an order enjoining the Merger and an award for plaintiffs&#x2019; fees and costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2023, a purported stockholder filed a complaint in the United States District Court for the District of Delaware against the Company and its board of directors, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumley v. Sesen Bio, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 1:23-cv-00131 (D. Del.) (the &#x201c;Plumley Complaint&#x201d;). The Plumley Complaint asserts claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement in connection with the Merger and under Section 20(a) of the Exchange Act for alleged &#x201c;control person&#x201d; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the Merger and an award for plaintiffs&#x2019; fees and costs. On February 7, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against the Company and its board of directors, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Franchi v. Sesen Bio, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 1:23-cv-01041 (S.D.N.Y.) (the &#x201c;Franchi Complaint&#x201d;). The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. Additionally, on February 9, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against the Company and its board of directors, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Menzer v. Sesen Bio, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, et al., 23-cv-01119 (S.D.N.Y.) (the &#x201c;Menzer Complaint&#x201d;). The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint and the Franchi Complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 21, 2022, November 4, 2022, February 8, 2023, February 13, 2023 (as updated on February 15, 2023) and February 17, 2023, the Company received letters from purported stockholders (collectively, the &#x201c;Demand Letters&#x201d;) demanding that the Company amend the Registration Statement to provide additional disclosures that such stockholders allege were improperly omitted from the Registration Statement, including information regarding the financial projections for Carisma, the financial analyses performed by the Company&#x2019;s financial advisor in support of its fairness opinion, and the background and process leading to the execution of the Merger Agreement. In addition, the Company received a books and records demand, dated November 18, 2022 (the &#x201c;Section 220 Demand&#x201d;), on behalf of a purported stockholder of the Company seeking access to certain relevant books and records of the Company&#x2019;s pursuant to Section 220 of the Delaware General Corporation Law in connection with the Merger and the securities and derivative litigations arising out of the CRL that the Company received from the FDA. The Section 220 Demand states that the purpose of the demand is to, among other things, investigate purported questions of director independence and disinterestedness and the possibility of wrongdoing, mismanagement, and/or material non-disclosure related to the Company board&#x2019;s approval of the Merger and the other transactions contemplated thereby and to determine whether suit should be brought in connection therewith.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the claims asserted in the Demand Letters, the Section 220 Demand, the New Keller Complaint, the Plumley Complaint, the Franchi Complaint and the Menzer Complaint are without merit and intends to vigorously defend against them. At this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment agreements and offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sesn:NumberOfLawsuits
      contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0OTc1NTg1OTkyNg_7d41d685-47ed-4ed5-999e-0cb31aec84dc"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0OTc1NTg1OTk0MQ_584b8a10-fd1f-4162-b070-7bb4b05b0208"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0OTc1NTg1OTk0Ng_5503728a-312d-4b24-8f34-9b2455913c82"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0OTc1NTg1OTk1MQ_60a85571-2b90-4513-9fa7-1029d0034767"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <us-gaap:LitigationReserve
      contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzI3NDg3NzkwOTgzMTU_fe565eb7-aacc-4cd2-a906-aeb8f8b17007"
      unitRef="usd">21000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzEwOTk1MTE2NzMwMDk_1de92a3a-236f-442f-8ae1-10c1b5781f55"
      unitRef="usd">21000000</us-gaap:LitigationReserve>
    <us-gaap:RestrictedCashCurrent
      contextRef="ic6a7b597081d4512984c70d7af968aac_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzEwOTk1MTE2NzMxNDU_ab6174d9-bc56-459d-99ac-a6f63b4e84bf"
      unitRef="usd">21000000</us-gaap:RestrictedCashCurrent>
    <sesn:NumberOfLawsuits
      contextRef="ic2c8425e295a4831bc9d718ca118ecff_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzU0OTc1NTg1OTkxMg_7bbfe00d-9a95-41ef-ae8a-55aeb4249b92"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ia1c302f137734bc69da3529bc113e959_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMDkvZnJhZzo0NTU2M2IwNjc5MDE0MDVlYjI1ZDA0NzgxNzk3NmUxMi90ZXh0cmVnaW9uOjQ1NTYzYjA2NzkwMTQwNWViMjVkMDQ3ODE3OTc2ZTEyXzI3NDg3NzkwOTgzMzE_6f893a2e-088c-4b50-8976-35542a0a38da"
      unitRef="usd">630000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzIwMjM_a983d3f7-aae2-432f-ba6f-72b899793ba8">LEASES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for operating leases under ASC Topic 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio included an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consisted of manufacturing, laboratory, warehouse, and office space. During the third quarter of 2022, the Company entered into a Lease Termination Agreement (the &#x201c;Lease Termination Agreement&#x201d;) pursuant to which the Company terminated its operating lease agreement. As part of the execution of the Lease Termination Agreement, the Company paid the landlord the all-inclusive sum of CAD $1.2&#160;million (USD $0.9&#160;million). Operating lease cost under this lease were $0.2&#160;million for the year ended December&#160;31, 2022 and $0.3&#160;million for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right of use asset total was zero as of December 31, 2022 and $123,300 as of December 31, 2021. As of December 31, 2021, the asset component of the Company&#x2019;s operating leases was recorded as operating lease right-of-use assets and reported within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzU_722ba763-9575-481e-82ea-4900d469c804"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzU_e7bf87fd-276f-41e8-a126-4410ad3340e7"&gt;other assets&lt;/span&gt;&lt;/span&gt; on the Company's condensed consolidated balance sheets. The short-term lease liability was zero as of December 31, 2022 and $123,300 as of December 31, 2021. As of December 31, 2021, the short-term lease liability was recorded in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzODc_0f5642b4-7404-4c0d-8695-7cd3f0d7638d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzODc_e3383e46-0bd5-473a-9c94-1fb2c501553a"&gt;other current liabilities&lt;/span&gt;&lt;/span&gt; on the Company&#x2019;s condensed consolidated balance sheets. There was no long-term operating lease liability as of December 31, 2022 or December 31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The minimum monthly rent for these office spaces is $2,500 and $18,000, respectively. The Company terminated the Philadelphia lease on December 31, 2022 and plans to terminate the Cambridge lease in connection with the closing of the anticipated Merger with Carisma. The short-term lease in Cambridge ends in June 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended December&#160;31, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lease Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease (including related operating costs)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term property leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;458&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;589&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Supplemental Information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <sesn:OperatingLeasesAreaOfOfficeSpace
      contextRef="iebe3ee0020554764957e449756650c1d_D20220101-20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzE1Mw_77813780-9e09-4ba9-96d3-0c35e2dc29f1"
      unitRef="sqft">31100</sesn:OperatingLeasesAreaOfOfficeSpace>
    <sesn:OperatingLeaseLeaseTerminationPayment
      contextRef="i0673287f84aa4bb4988c54a1565f24ce_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzMzc_91493686-0b58-463d-b583-780564fe7339"
      unitRef="cad">1200000</sesn:OperatingLeaseLeaseTerminationPayment>
    <sesn:OperatingLeaseLeaseTerminationPayment
      contextRef="i0673287f84aa4bb4988c54a1565f24ce_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNTE_1df2c650-3894-46e1-b34b-94eab49f44b9"
      unitRef="usd">900000</sesn:OperatingLeaseLeaseTerminationPayment>
    <us-gaap:ShortTermLeaseCost
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzgwMg_98a73225-dcd5-4f1e-9491-78f99354ad51"
      unitRef="usd">200000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzg0NQ_f7e1563b-f9f7-45da-a952-1244b350f803"
      unitRef="usd">300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzU0OTc1NTgyNTI3OQ_c7240406-d398-44d0-8eba-4a792d6f965b"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNjY_4a45b3ac-40ba-408c-914e-e79cd329e56a"
      unitRef="usd">123300</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzU0OTc1NTgyNTI5MQ_a4df5fb3-cd9d-4faf-ac8f-4666488261e7"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzI3NDg3NzkwNzkzNzg_b891f302-de85-4d85-9f5d-05362c2307e8"
      unitRef="usd">123300</us-gaap:OperatingLeaseLiabilityCurrent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i973f2496cf69482fb40920ac6f30b991_D20220101-20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzcxNDY4MjU1OTEzOTk_e004d9a0-3de2-41d4-b649-4cdbd44809de"
      unitRef="usd">2500</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="ibaf5b39852dc407e946c46788b3a04b6_D20220101-20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzcxNDY4MjU1OTE0MDc_af860a68-15ab-4416-ac62-cd6dd0b1e0be"
      unitRef="usd">18000</sesn:OperatingLeaseMonthlyRent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90ZXh0cmVnaW9uOmVkNWQ5ZTQyZDhlMDRiZDhiNWUwNDQ4MDBlZDZlODNiXzIwMjY_f11fa54a-9a37-491b-8c85-4ac491ed6b5d">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended December&#160;31, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lease Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease (including related operating costs)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term property leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;458&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;589&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Supplemental Information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzItMS0xLTEtOTIzNzU_6ca8e04e-169c-4fb1-87db-fe66a43b8faf"
      unitRef="usd">245000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzItMy0xLTEtOTIzNzU_975beed2-e171-4b3b-b146-470e0977b0d7"
      unitRef="usd">327000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzMtMS0xLTEtOTIzNzU_de126b50-6ae3-4969-b116-4550f1cfa5a0"
      unitRef="usd">213000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzMtMy0xLTEtOTIzNzU_347b5b31-9544-4535-b512-c303c90eb258"
      unitRef="usd">262000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzQtMS0xLTEtOTIzNzU_d75207ad-83a1-486f-a2af-413d86a8d80c"
      unitRef="usd">458000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZToyNzJlYjcyNDNhYWQ0ZWIyYTJiNDcwMDNlMDIxNThmOC90YWJsZXJhbmdlOjI3MmViNzI0M2FhZDRlYjJhMmI0NzAwM2UwMjE1OGY4XzQtMy0xLTEtOTIzNzU_79504842-f105-4b2c-ad92-9a7053f3bd17"
      unitRef="usd">589000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZTpmZDdlMWU2MWFjZDM0N2NlOGI5M2JlODFmYjAxZjM1YS90YWJsZXJhbmdlOmZkN2UxZTYxYWNkMzQ3Y2U4YjkzYmU4MWZiMDFmMzVhXzEtMS0xLTEtOTIzNzU_368110ea-f46b-462c-84c7-da44aad80f46">P0Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZTpmZDdlMWU2MWFjZDM0N2NlOGI5M2JlODFmYjAxZjM1YS90YWJsZXJhbmdlOmZkN2UxZTYxYWNkMzQ3Y2U4YjkzYmU4MWZiMDFmMzVhXzEtMy0xLTEtOTIzNzU_493d58dd-5910-414d-b4fc-db9740ac7adf">P0Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZTpmZDdlMWU2MWFjZDM0N2NlOGI5M2JlODFmYjAxZjM1YS90YWJsZXJhbmdlOmZkN2UxZTYxYWNkMzQ3Y2U4YjkzYmU4MWZiMDFmMzVhXzItMS0xLTEtOTIzNzU_919def92-3c36-42cb-bfd0-e5e9ca709386"
      unitRef="number">0</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTIvZnJhZzplZDVkOWU0MmQ4ZTA0YmQ4YjVlMDQ0ODAwZWQ2ZTgzYi90YWJsZTpmZDdlMWU2MWFjZDM0N2NlOGI5M2JlODFmYjAxZjM1YS90YWJsZXJhbmdlOmZkN2UxZTYxYWNkMzQ3Y2U4YjkzYmU4MWZiMDFmMzVhXzItMy0xLTEtOTIzNzU_92042a4d-a7c6-4ac7-8379-da9db782f40b"
      unitRef="number">0.12</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzExMTYy_758def7b-0924-47b0-89ff-26132202f472">STOCKHOLDERS' EQUITY (DEFICIT)&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Financings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ATM Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company entered into an Open Market Sale Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time (the &#x201c;ATM Offering&#x201d;) for an aggregate sales price of up to&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $35.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through Jefferies. In October 2020 and February 2021, the Company entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively. Amendments No. 1 and No. 2 modified the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $50.0&#160;million and $34.5&#160;million, respectively. In June 2021, the Company entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200.0&#160;million of common stock pursuant to the Sale Agreement. Sales are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Capital Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#x2019;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the year ended December 31, 2022. The Company raised&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$175.0 million of net proceeds from the sale of 56.9 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of common stock at a weighted-average price of&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.17&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;per share during the year ended December&#160;31, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $5.4 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;June 2019 Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Company raised $27.8 million of net proceeds from the sale of 20.4 million shares of common stock and accompanying warrants to purchase an additional 20.4 million shares of common stock in an underwritten public offering (the "June 2019 Financing"). The combined purchase price for each share of common stock and accompanying warrant was $1.47. Subject to certain ownership limitations, the warrants issued in the June 2019 Financing were exercisable immediately upon issuance at an exercise price of $1.47 per share, subject to adjustments as provided under the terms of such warrants, and had a one-year term that expired on June 21, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to its Certificate of Incorporation, the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following approval by the Company&#x2019;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;203&#160;million and&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;199&#160;million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares were issued and outstanding as of December&#160;31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,759&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#x2019;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the dissolution of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASC 815-40")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company's warrant activity for the year ended December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Cancelled)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification described below and (ii) subject to further adjustment based on down round provision added by amendment described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Modifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company entered into transactions with holders of its outstanding 2018 Warrants and 2017 Warrants to purchase the Company's common stock. At such time, the 2018 Warrants and 2017 Warrants utilized the same form of warrant, which contained a prohibition on variable rate transactions (as defined therein). Warrant holders agreed to waive such prohibition in exchange for certain concessions from the Company. Management evaluated the warrants after modifications and determined that they continued to be equity-classified under the derivative scope exception of ASC 815-40. The warrants were revalued immediately before and immediately after the modifications to calculate the $1.1 million incremental value of the modified warrants. The Company considers this incremental value to be akin to an offering cost since the modifications were directly related to enabling the ATM Offering and would not have otherwise been incurred. Therefore, in the fourth quarter of 2019, management initially capitalized the $1.1 million to deferred financing cost asset, with an offsetting credit to additional paid-in capital, and then reclassified the deferred financing cost asset to reduce the ATM Offering proceeds within equity as proceeds were received from sales of common stock under the ATM Offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company entered into transactions with the holders of its outstanding 2018 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2018 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2018 Warrant Amendment Agreements"). As consideration for those holders executing the 2018 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $1.20 to $0.60 per share of the Company's common stock, resulting in proceeds of $2.0 million from the exercise of 3.4 million warrants. Pursuant to the 2018 Warrant Amendment Agreements, the prohibition on certain variable rate transactions included in the 2018 Warrants was amended to exclude ATM offerings and the exercise price of the warrants was reduced from $1.20 to the lesser of (a) $0.95 per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2018 Warrant Amendment Agreements. During the second quarter of 2020, the anti-dilution provision was triggered to lower the exercise price of the warrants to $0.55; as such, the Company recognized a deemed dividend of approximately $0.1&#160;million which reduced the income available to common stockholders. As the Company has an accumulated deficit balance, there is no overall impact to additional paid-in capital, as the deemed dividend is recorded as offsetting debit and credit entries to additional paid-in capital. Therefore, the amounts were not presented on the Statement of Stockholders' Equity (Deficit). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2018 Warrant Exercise Agreements and 2018 Warrant Amendment Agreements, the Company entered into an amendment to the Securities Purchase Agreement dated March 21, 2018 related to the March 2018 Financing, by and among the Company and each purchaser identified on the signature pages thereto, with certain holders representing greater than 50.1% of the securities issued based on initial subscription amounts, pursuant to which the prohibition on variable rate transactions, including ATM offerings, was deleted in its entirety.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company entered into transactions with the holders of its outstanding 2017 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2017 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2017 Warrant Amendment Agreements"). As consideration for those holders executing the 2017 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $0.80 to $0.55 per share of the Company's common stock. Pursuant to the 2017 Warrant Amendment Agreements, the prohibition on certain variable rate transactions, including ATM offerings, included in the 2017 Warrants was deleted in its entirety and the exercise price of the warrants was reduced from $0.80 to the lesser of (a) $0.55 per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2017 Warrant Amendment Agreements. As of December&#160;31, 2022, there has been no adjustment to the exercise price of these warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5f88572fbcae4d3b843b90b31979aadf_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI4Mw_87e2d109-084c-430c-98ca-892a0a84e0af"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction
      contextRef="i2761fdbe240c456bb83255f46df5df11_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzU0OTc1NTgyNTc2MQ_ca22101d-f8c4-4944-ab1a-80262975de27"
      unitRef="usd">35000000</sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction>
    <sesn:SaleOfStockAdditionalSharesAuthorizedForSale
      contextRef="i0f7e4670d4c7461595be03c9af5334ba_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzcxOQ_d2012f50-3e97-42f2-ab66-f0280afc494b"
      unitRef="usd">50000000</sesn:SaleOfStockAdditionalSharesAuthorizedForSale>
    <sesn:SaleOfStockAdditionalSharesAuthorizedForSale
      contextRef="i8cda9cd3a8574fc2a6b9461f91c4497c_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzcyNg_ca1590d8-dbdb-435c-97f5-3c926b8c8db8"
      unitRef="usd">34500000</sesn:SaleOfStockAdditionalSharesAuthorizedForSale>
    <sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction
      contextRef="i87f4d91941044efabca8fc31db5686f0_D20210601-20210731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzExMDc_692c14de-0d45-47e9-a15b-265e76c267a5"
      unitRef="usd">200000000</sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction>
    <sesn:SaleOfStockCommissionFixedRate
      contextRef="i2761fdbe240c456bb83255f46df5df11_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzIxMjk_f7b7d584-aae4-449a-b402-93a44e01610f"
      unitRef="number">0.030</sesn:SaleOfStockCommissionFixedRate>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6a4e17d327564862bc9c9d71d1aabc8f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzIzNzM_703e137b-8daa-4eca-900b-0ad2fbd59f68"
      unitRef="usd">175000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6a4e17d327564862bc9c9d71d1aabc8f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI0MDk_baf18886-bb34-4a61-a488-56bfe9f947a6"
      unitRef="shares">56900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="i6a4e17d327564862bc9c9d71d1aabc8f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI0NjY_c2ab01d0-fd11-4e1d-8fc5-e3d13bdf0ca4"
      unitRef="usdPerShare">3.17</sesn:SaleOfStockWeightedAveragePricePerShare>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="i6a4e17d327564862bc9c9d71d1aabc8f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI1OTk_fd1917e3-3f4e-449a-af6e-a881d7f61280"
      unitRef="usd">5400000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8cdc8306a15942548c12172f72054f94_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI3MTA_989dfeaf-2667-4eb0-b002-d20b91c84898"
      unitRef="usd">27800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8cdc8306a15942548c12172f72054f94_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI3NDY_66605fef-645a-4d40-baee-48f223e34913"
      unitRef="shares">20400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i84030fd2a4514267a4a2169a1b8e2e55_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzI4MjQ_350def16-f797-4a0b-9f3e-fd5f89854250"
      unitRef="shares">20400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <sesn:CommonStockAndWarrantOrRightsPricePerShare
      contextRef="i84030fd2a4514267a4a2169a1b8e2e55_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzMwMDI_48558d87-05ef-4d72-9391-1b70787047ab"
      unitRef="usdPerShare">1.47</sesn:CommonStockAndWarrantOrRightsPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i84030fd2a4514267a4a2169a1b8e2e55_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzMxNjI_1b7a7928-00e2-4117-94b6-db529186b8f8"
      unitRef="usdPerShare">1.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i84030fd2a4514267a4a2169a1b8e2e55_I20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzExMTY3_3d90cc7e-17c9-49b0-ba29-2a046d2547fb">P1Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM0NTU_bab101c1-fdf2-44a6-be70-1a9e8deda731"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM0OTk_7ce2a466-ff56-4a05-9905-4b57e6894e9a"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM5NDM_3168377f-803e-4394-b281-ca26ee9f42e5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM5NDM_55c731f8-cc9f-4e39-b217-153d05301eb7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM5NDM_572eda60-7669-4884-ad6b-d03e6136c9a6"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzM5NDM_714880f6-fe4b-43a1-b40a-650376389c13"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i653d509451834b36b0c7c25dd6f1e8ea_I20210502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyMTQ_bedff809-4c5f-4789-8d1d-ad02da68c547"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i26100f264698454388e652d4dcede710_I20210503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyMjA_ef0056ff-5e9a-49a0-b787-0893cec0f9f3"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyMzM_0488ff24-332a-4421-991b-14dde43702ff"
      unitRef="shares">203000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyMzM_170fed70-1f19-4c05-8675-ae1d164c8add"
      unitRef="shares">203000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyNDA_5099b3d5-5591-4dcc-80f6-7f471898768b"
      unitRef="shares">199000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQyNDA_c6ddb903-39ee-4235-bf7b-a99939a406d8"
      unitRef="shares">199000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzExMTY2_dae48cc5-b495-418b-8e68-51b1f3bbadec">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&#160;31, 2022 and 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,759&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzItMS0xLTEtOTIzNzU_d1b76ae5-993f-4b07-a395-ac05304bb604"
      unitRef="shares">202759000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzItMy0xLTEtOTIzNzU_165acb63-85cc-43e9-897e-5154e7ddec4d"
      unitRef="shares">199464000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i34e59a9de0bb4644baea5c1090868f0b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzQtMS0xLTEtOTIzNzU_77143b0f-3b17-4ab8-a35f-03bdaf3fecd5"
      unitRef="shares">187000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1bd6743eae8e4cfdbb03b06c8b121eee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzQtMy0xLTEtOTIzNzU_1b3973b7-d99b-48b4-bed6-a7288ee8d3ae"
      unitRef="shares">199000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2979721cc12044649222cc680229209d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzUtMS0xLTEtOTIzNzU_04d930cc-6238-4295-a86a-a867c4c622aa"
      unitRef="shares">15304000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2fff5776971a48a586881cd89287df3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzUtMy0xLTEtOTIzNzU_fa22671b-a27b-45c7-8a58-b3cf277bee18"
      unitRef="shares">15703000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i106b662daae24333b435aacc7c1a07b0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzYtMS0xLTEtOTIzNzU_ac7bca42-3fd1-43a9-8ea3-fb29204b7b83"
      unitRef="shares">4695000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i72d9266aa5eb429b9daf124e3bbc9a6f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzYtMy0xLTEtOTIzNzU_68bdfbe8-5c18-4304-a012-2e205d3179c3"
      unitRef="shares">3041000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8327d77c1755491d93d7990856f3cc52_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzctMS0xLTEtOTIzNzU_de4ca502-a834-4c6a-9832-913ef8a28a65"
      unitRef="shares">4532000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i019d2729b50e475f80b2f52267d77679_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzctMy0xLTEtOTIzNzU_8fdaa073-1f18-4c1a-a640-92c776ad8741"
      unitRef="shares">8933000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ica9046a3714e4afebe942291c8bb1be6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzgtMS0xLTEtOTIzNzU_0d3c42de-21bf-4f67-8b7b-ea1b59b89801"
      unitRef="shares">2300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id9f2bff1e4304c31873755098104fc76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzgtMy0xLTEtOTIzNzU_a334cce5-572c-4096-81c4-740237ac8435"
      unitRef="shares">2300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzktMS0xLTEtOTIzNzU_a0ea51f9-9b89-40ae-8e06-a5667b6d74ce"
      unitRef="shares">229777000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZTo0NmZjYzFjMWQ1MGM0NDY4OTlmYmZkZjQzY2M4OTQ1OS90YWJsZXJhbmdlOjQ2ZmNjMWMxZDUwYzQ0Njg5OWZiZmRmNDNjYzg5NDU5XzktMy0xLTEtOTIzNzU_4c63562d-892b-4df7-8ebd-f54f4a1a7b51"
      unitRef="shares">229640000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <sesn:NumberofVotesEntitledForEachShare
      contextRef="i822d046be15341d59a14431cd169a913_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzQ3MTg_2d051f16-89e0-4870-9f2f-4af22f1b989d"
      unitRef="vote">1</sesn:NumberofVotesEntitledForEachShare>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzExMTY1_baa883c0-11e0-4d21-bc37-6de8f52e1dd9">The following table sets forth the Company's warrant activity for the year ended December&#160;31, 2022 (in thousands):&lt;div style="margin-bottom:10pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Cancelled)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification described below and (ii) subject to further adjustment based on down round provision added by amendment described below.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i800abfbe2a3a4ff98ee18c6daa3452eb_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItMi0xLTEtOTIzNzU_750b2b8a-0f2c-4b1e-812b-dfe2ed3049d4"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7529f34d71c8489d8eddf8fd724fd5ad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItNi0xLTEtOTIzNzU_8d459ecb-5e8d-4b8c-871f-9f407878342d"
      unitRef="shares">132000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="idc78166d67464d8dbbf2a4acfe7206bd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItOC0xLTEtOTIzNzU_89dcf198-1da6-4a5c-b3a3-de5f28136fed"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="idc78166d67464d8dbbf2a4acfe7206bd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItMTAtMS0xLTkyMzc1_7bfaa053-04da-4e7b-8f9b-388d7b893119"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="idc78166d67464d8dbbf2a4acfe7206bd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItMTItMS0xLTkyMzc1_05316fd5-6798-497b-af12-d0cd58aeef90"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i800abfbe2a3a4ff98ee18c6daa3452eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzItMTQtMS0xLTkyMzc1_fa796eaa-1b82-4261-8632-53fa01b0253c"
      unitRef="shares">132000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8d3704f824a24ee3ab53e3e9b975ae7f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtMi0xLTEtOTIzNzU_d136a594-19fa-423b-8008-ef2fe4fdf0b1"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia6e4124d7d374ca0bc952081d6c500f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtNi0xLTEtOTIzNzU_97a02454-20d7-456d-9ff6-a6570e54681f"
      unitRef="shares">12000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i82a243d92e624ce19e709802a563543c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtOC0xLTEtOTIzNzU_ef50fffc-43a5-4a81-9704-f7bf9758cc7d"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i82a243d92e624ce19e709802a563543c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtMTAtMS0xLTkyMzc1_ab57c438-8caa-4c4e-a80a-ae15d5b2903b"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i82a243d92e624ce19e709802a563543c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtMTItMS0xLTkyMzc1_973b0f4e-7fce-4e3e-8715-5bcc9508a2fa"
      unitRef="shares">12000</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8d3704f824a24ee3ab53e3e9b975ae7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzMtMTQtMS0xLTkyMzc1_08df287c-d7f7-4faf-a96f-c578c12d5be8"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie68ccfa087a542998d3e397047b34a57_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtMi0xLTEtOTIzNzU_02ecfdc1-52c6-457c-9492-c15784ed8a53"
      unitRef="usdPerShare">11.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ifdcb7e9d6aeb45f3b64cf0988fbf00e8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtNi0xLTEtOTIzNzU_f960b86e-d8b7-4d8c-958f-6fcf8b1292c5"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i0ed2728c8f6640a5b89ab51323c10e96_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtOC0xLTEtOTIzNzU_856883e4-a6a3-409e-91a6-3ee948abcf2e"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i0ed2728c8f6640a5b89ab51323c10e96_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtMTAtMS0xLTkyMzc1_dee793c9-5eae-4f8c-80f2-e689fe2ddba8"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i0ed2728c8f6640a5b89ab51323c10e96_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtMTItMS0xLTkyMzc1_40b44ff8-db26-484e-b636-e5839541d84f"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie68ccfa087a542998d3e397047b34a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzQtMTQtMS0xLTkyMzc1_a639d771-4062-448a-a569-22f7ff4ba851"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib00557f6793a464ebb3158651e79e729_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtMi0xLTEtOTIzNzU_dca93f69-2e13-469d-afc9-c4e48f0089a2"
      unitRef="usdPerShare">11.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie3c6905ce21c40b18f3059d5f6e237f4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtNi0xLTEtOTIzNzU_0cc2263a-ae9e-4163-acc9-ef69b019e161"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="ieeddaa2b96474d13a379ff7566291039_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtOC0xLTEtOTIzNzU_8fdab103-1878-4b93-9187-4c81b15c18e3"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="ieeddaa2b96474d13a379ff7566291039_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtMTAtMS0xLTkyMzc1_8312f6cb-4b94-4da4-a111-062247bde882"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="ieeddaa2b96474d13a379ff7566291039_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtMTItMS0xLTkyMzc1_e86ab7bf-6fdd-4f15-8576-b5bbaa571cb7"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib00557f6793a464ebb3158651e79e729_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzUtMTQtMS0xLTkyMzc1_011593a1-7310-44e4-9ea6-b33b4cf60007"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzYtNi0xLTEtOTIzNzU_ce072475-f17b-45f0-bc62-409bebcde21a"
      unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzYtOC0xLTEtOTIzNzU_322c4b42-16b1-421c-bee5-a14a9be43466"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzYtMTAtMS0xLTkyMzc1_1334d25d-021f-426d-a46b-c305f3890615"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzYtMTItMS0xLTkyMzc1_db48c316-cc5b-4d7d-888c-873259b59126"
      unitRef="shares">12000</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90YWJsZToxY2I1ZjhhYTkzYjU0NjM5OTQzNWI4NTViOGFiNzExYS90YWJsZXJhbmdlOjFjYjVmOGFhOTNiNTQ2Mzk5NDM1Yjg1NWI4YWI3MTFhXzYtMTQtMS0xLTkyMzc1_f3d9887e-b495-4ad7-afd0-c9cfc7a2e2cd"
      unitRef="shares">187000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i23b7cb6c58024d5b9f676827326355bb_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzcyNzc_6a7263e8-3f77-457e-a91d-0d43a8e737eb"
      unitRef="usd">1100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="iaa5fc09e9b4244549466aede24ab208e_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzc1OTg_5e79336f-38cb-447d-9c77-1d9c86a1c591"
      unitRef="usd">1100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i48ca0d5ad9bd4085818dc426b3589eb2_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg0MDM_56172784-f275-4354-8ccc-f68cdb7d47fb"
      unitRef="usdPerShare">1.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib6e50ab15b3f4156bd82e204e7b093e6_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg0MDk_3855cb6a-36c7-4804-a860-7318a59676e9"
      unitRef="usdPerShare">0.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i7a1490314240433882cb0da9a6d1b2de_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg0Nzg_5910e082-6b60-42c8-b397-c12505823ebd"
      unitRef="usd">2000000</us-gaap:ProceedsFromWarrantExercises>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i7a1490314240433882cb0da9a6d1b2de_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg1MDI_7771c479-048d-4462-ac80-6e7c82fbfcc0"
      unitRef="shares">3400000</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7d82589e0dd040a795545a962a2cb1a0_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg3NDM_30dbe1d2-29f7-4710-8eb5-90310544924a"
      unitRef="usdPerShare">1.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i015d83f362d9409aaffa4d0d06f715d7_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzg3Njc_67647563-cb24-4f27-b25a-81c585aa336d"
      unitRef="usdPerShare">0.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id958531e2fb946e3920b1cee8b9b3c37_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzkwNjI_44ac15cc-69cc-4ce9-a657-77cd42626c2b"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sesn:OtherDividendAndAdjustments
      contextRef="i5725754243984358952852405d13672b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzkxMzM_8048c503-3cc3-4a67-819e-ce73ccd184f3"
      unitRef="usd">100000</sesn:OtherDividendAndAdjustments>
    <sesn:ClassofWarrantorRightMinimumPercentageofSecuritiesIssued
      contextRef="i56bec24a6f664962bb4939227b4c9cda_D20191001-20191031"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzk4NjY_9c7c0ba2-fa2e-4864-8952-b29a625c4be0"
      unitRef="number">0.501</sesn:ClassofWarrantorRightMinimumPercentageofSecuritiesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i05fdf323c4eb41f591b33f27de2e40b4_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzEwNTc5_3ddad621-1de1-42ba-8747-d4fdc7dac284"
      unitRef="usdPerShare">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3f9fd02125934e03bde7e6db929d631b_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzEwNTg1_0afea676-cbb6-49c0-89c8-c54b3fb535c2"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i05fdf323c4eb41f591b33f27de2e40b4_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzEwODc0_37656165-6d21-4f06-8113-3b8554adb533"
      unitRef="usdPerShare">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3f9fd02125934e03bde7e6db929d631b_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTUvZnJhZzozOWI5MDE3OGFiNDE0OWQ0YWNkOTE3NjhhN2VkZjVmMy90ZXh0cmVnaW9uOjM5YjkwMTc4YWI0MTQ5ZDRhY2Q5MTc2OGE3ZWRmNWYzXzEwODk4_dd018f33-bfff-42c7-a9bf-ce0aed1d3a01"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90ZXh0cmVnaW9uOjQ3NjVlOWZkMGZjYTQ2ZWE4MTFlZjk2Yzc5MWZlMmU4XzI4MDE_e4a91dd9-253c-4dbd-a40e-2fa9e5ffcb18">EARNINGS (LOSS) PER SHARE&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#x2019;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods with net income, diluted net earnings per share is calculated by either (i) adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii) the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The two-class method was not applied for the twelve months ended December&#160;31, 2022, 2021 and 2020 as the Company&#x2019;s participating securities do not have any obligation to absorb net losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of December&#160;31, 2022, 2021 and 2020 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,394&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90ZXh0cmVnaW9uOjQ3NjVlOWZkMGZjYTQ2ZWE4MTFlZjk2Yzc5MWZlMmU4XzI4MDA_56355aec-6cf6-492d-8663-99ad8e5bb822">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of December&#160;31, 2022, 2021 and 2020 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,394&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9dcf8ba7b1154c71807f93d29f6d1cc8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzItMS0xLTEtOTIzNzU_7c362cf5-6a50-4895-bcda-8d1ae9423ce0"
      unitRef="shares">187000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia76e658e62f94a39b6fa63c38baf1887_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzItMy0xLTEtOTIzNzU_d41acf13-e3de-4f85-bded-0095c4d3ccb5"
      unitRef="shares">199000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id51afed260f64269a2103be0fab8e386_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzItNS0xLTEtOTIzNzU_c12e9639-14d4-4260-95fd-4114a3ffab67"
      unitRef="shares">2247000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iacca46a3fbcd45eab8928c23a788895e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzMtMS0xLTEtOTIzNzU_ebf01158-51e7-42e9-88fa-72a50d0c9748"
      unitRef="shares">15304000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia69316b9d7f84c72bf9062ad8a344515_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzMtMy0xLTEtOTIzNzU_4d847871-fc92-4547-a469-56a917f35af1"
      unitRef="shares">15703000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic4cad1b5e12a475d81796c7dfd472fba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzMtNS0xLTEtOTIzNzU_6bcc62e8-1bae-412c-8cbd-d5a7e1d8ee72"
      unitRef="shares">10147000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iea92dc95dce94ad983cf2eaf1ef27507_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtMS0xLTEtOTUwMzQ_97639c5e-f7fe-46cd-96ee-65eed8aaa4c4"
      unitRef="shares">4695000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i645aef5340be4c348f095065f63145e6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtMy0xLTEtOTUwMzQ_6da8f71a-e51b-4f0e-a1da-8bddf624c715"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i33fae254eac8482dab713b9f73f69e41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtNS0xLTEtOTUwMzQ_35b31495-56e0-4aad-ba78-cd7a1d63f764"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtMS0xLTEtOTIzNzU_cddd2197-3e1b-4ef4-862c-f4a3b71147ca"
      unitRef="shares">20186000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtMy0xLTEtOTIzNzU_2a0ddb7b-af68-4f3e-b849-0cd0a9a612bf"
      unitRef="shares">15902000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMTgvZnJhZzo0NzY1ZTlmZDBmY2E0NmVhODExZWY5NmM3OTFmZTJlOC90YWJsZTpjYTVhY2I0M2ZkMTY0MmRmOWZmMjI3Y2RjOTRhYWUyYy90YWJsZXJhbmdlOmNhNWFjYjQzZmQxNjQyZGY5ZmYyMjdjZGM5NGFhZTJjXzQtNS0xLTEtOTIzNzU_e7f10e81-63b9-4e64-a161-7004d68c0a5b"
      unitRef="shares">12394000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyMzY_1a5f0f3f-0ec8-4262-93d8-36949f6019f9">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:277.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Share Based Compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,909&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#x201c;evergreen&#x201d; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#x2019;s stockholders in May 2021, the Company&#x2019;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 4.5&#160;million shares of common stock available for issuance under the 2014 Plan as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 12.2&#160;million stock options outstanding under the 2014 Plan as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#x201c;Retention Program&#x201d;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (&#x201c;RSU&#x201d;) award which vested in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#x2019;s common stock. The Company recorded an expense of $2.5&#160;million for retention-related RSUs for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#x201c;PSU&#x201d;) award equal to the value of approximately fifty percent of current base salary. Each PSU represents a contingent right to receive one share of the Company&#x2019;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of December 31, 2022, achievement was deemed probable for only the cash management milestone, representing $87,000 (or 20% of the PSU awards). Therefore, $55,000 was expensed during the year ended December 31, 2022, and $32,000 remains measured but unrecognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A summary of the status of restricted stock units is presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units     &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,695&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining contractual life of unvested RSUs and PSUs as of December&#160;31, 2022 is 2.67 years. The weighted average remaining contractual life of unvested RSUs and PSUs as of December&#160;31, 2021 is 9.75 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2009 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-of-Plan Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;here were approximately 2.9 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;br/&gt;Contractual&#160;&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DM&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation expense of $6.9&#160;million, $5.1&#160;million, and $1.8&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. The stock option related expenses were $4.3 million, $4.6 million and $1.8 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. The RSU related expense was $2.5&#160;million and $0.5 million for the years ended December&#160;31, 2022 and 2021, respectively. The Company did not record RSU related expenses for the year ended December&#160;31, 2020. As of December&#160;31, 2022, there was $5.5 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 1.88 years. The weighted-average grant-date fair value of stock options granted during the year ended December&#160;31, 2022, 2021 and 2020 were $0.46, $2.16 and $0.56, respectively. The total intrinsic value of stock options exercised for the years ended December&#160;31, 2022, 2021 and 2020 was de minimis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyNDE_80f1bea6-c33a-45f3-b3a0-28d9ae763fa0">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:277.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Share Based Compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,909&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i70ca9f2083e648768635ed14bf7c4dd2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzItMS0xLTEtOTIzNzU_4c99eb60-6821-4b30-b006-506a266b9756"
      unitRef="usd">1985000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1333cc72fc424e2a8f8774a8f0d872fb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzItMy0xLTEtOTIzNzU_abab92a0-c572-491a-bcd0-76fc3d44450e"
      unitRef="usd">973000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieaa2ee52082f4e3e8053f82bebfa0168_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzItNS0xLTEtOTIzNzU_c9a8373e-ba1b-4493-bfa0-0023b28520d2"
      unitRef="usd">350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iad3615d1132f4e6db8c87630585bb158_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzMtMS0xLTEtOTIzNzU_e26c2310-ee9a-4cee-94d7-39b5e1c5f112"
      unitRef="usd">4924000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f6527bbe7574825a65695e1c732589c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzMtMy0xLTEtOTIzNzU_ef04846c-1c19-484d-9d2f-c0ebd567b1f6"
      unitRef="usd">4170000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic025f71331f24e12b56e608440ce56ce_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzMtNS0xLTEtOTIzNzU_899a0a46-d4ef-44f3-b51f-254afaa23d6e"
      unitRef="usd">1407000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzQtMS0xLTEtOTIzNzU_d0aa7ef1-1735-4af2-84b0-42f84a6187cb"
      unitRef="usd">6909000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzQtMy0xLTEtOTIzNzU_bfc71032-fb2b-4d32-84e6-f77419363d3a"
      unitRef="usd">5143000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTpiYTgyM2JkYzY3ZTE0MDJjYTUxNThhMzExODlmMTQ5ZS90YWJsZXJhbmdlOmJhODIzYmRjNjdlMTQwMmNhNTE1OGEzMTE4OWYxNDllXzQtNS0xLTEtOTIzNzU_68778b6e-b324-4ef2-ac5a-c3c5f86548a5"
      unitRef="usd">1757000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="i486533c551a2452c99626829ee478c51_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzExMDA_6348f999-c17c-47cf-839d-4c3ebf064e94"
      unitRef="shares">7900000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="i236b00a74d3948dcae1d6b9ffcfa4fcf_D20210501-20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzE1Njk_dcb1c345-6fcd-48b9-951e-574eca38c119"
      unitRef="shares">12000000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i16c46bb406f14eaa81b7c198dcc44d8a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzE2Nzc_446a95cb-2e88-46e7-9502-9b72de559bb7"
      unitRef="shares">4500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic44a95cc271a49b0aa716f7ebe2e6879_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyMzM_410428cc-8008-465f-8bd6-c9792a70a170">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i7a361b7208b64753a71edeaa3c23d956_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzE4NTQ_a6756b61-a339-4b39-a8c3-59189dba653b"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i61d80b79fadf491ba762bf6b77e43e6a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzE5Mjg_18d1a4f5-dd3e-4c78-8806-a13829ccfe55"
      unitRef="number">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic44a95cc271a49b0aa716f7ebe2e6879_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzIwODc_c800390c-2fcb-4dc0-b307-498bf36d0618">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i16c46bb406f14eaa81b7c198dcc44d8a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzIxMzk_e5899bcc-3852-47d4-9973-5f518aa80558"
      unitRef="shares">12200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward
      contextRef="iaf581044871b4e4a95de21bdefb73475_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI4NjY_04623beb-b01e-47d5-870a-24e345f0e93c"
      unitRef="shares">1</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9a728dfe3c4454cbc533710495f8f5b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI5NDE_0c9ed2b3-c866-421d-b040-ee3873068b35"
      unitRef="usd">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary
      contextRef="ifadff6a5daba493cb2a7db4117d654bf_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzMzNjA_dea5e836-1fb6-4445-b590-d82e7157c489"
      unitRef="number">0.50</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward
      contextRef="ifadff6a5daba493cb2a7db4117d654bf_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzM0NDU_1f4797a3-4e0e-4ada-9d2b-f476d211589f"
      unitRef="shares">1</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ifbcb93bc03d34a29ba0472e96a5c17db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzkwMTg_1fb44cbd-ddda-41ff-94ec-529bd19c6abb"
      unitRef="usd">87000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent
      contextRef="ifbcb93bc03d34a29ba0472e96a5c17db_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzkwNDU_1ce93128-7edb-45ae-888a-dbcd5b68853c"
      unitRef="number">0.20</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee027c64b36746299c057f499c9540ad_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzkwMzY_df668af3-b77e-4201-99db-cefee060bfc6"
      unitRef="usd">55000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i7750d93e565f4062abf14eab356f22e7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzkwMjc_bb333915-1b92-4b35-9cbe-3379d70c4846"
      unitRef="usd">32000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyNDY_75971d2e-2f4a-4511-b1b2-80514a8d436c">A summary of the status of restricted stock units is presented below: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units     &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,695&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzEtMS0xLTEtOTIzNzU_25b50503-d8d9-4788-9a22-4f4469887815"
      unitRef="shares">3041000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idedbd5e4782a4a07988637e4ee0dffc0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzItMS0xLTEtOTIzNzU_be27ad42-e082-4aae-a34f-a2cd1f4b59f7"
      unitRef="shares">4160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i438fa29ca3bb484a8da013a3e14bb5aa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzMtMS0xLTEtOTIzNzU_0be733af-39bb-48f6-afad-070bd02a682b"
      unitRef="shares">1004000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzQtMS0xLTEtOTgyNjI_1acab563-1c99-4b43-806c-b4a87f9f05c4"
      unitRef="shares">3293000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzUtMS0xLTEtOTgyNjI_b887ca91-60d6-476e-b1d2-7c3e0a6ef075"
      unitRef="shares">217000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo2YjVmNzNlNGRkODg0YTI4YTdiNzczMGQyODQyY2M2My90YWJsZXJhbmdlOjZiNWY3M2U0ZGQ4ODRhMjhhN2I3NzMwZDI4NDJjYzYzXzQtMS0xLTEtOTIzNzU_52b27d89-3e13-494e-8b71-7a1cf956618f"
      unitRef="shares">4695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="idedbd5e4782a4a07988637e4ee0dffc0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzQyOTQ_98c15bcf-836e-45f1-8d5d-bd851f07c31c">P2Y8M1D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i438fa29ca3bb484a8da013a3e14bb5aa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzQyOTQ_d256f132-0b7b-4da7-9195-fed4b73ab7cd">P2Y8M1D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="iac240dff34d54c259fa7dcc1af037866_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzczMjY_4030b874-b525-4adb-90a5-41227742f351">P9Y9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ie548983137d0429b97bbb1a0cea18f7f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzI3NDg3NzkwNzczMjY_590b7400-2a97-4ee7-8d6d-47153163e95a">P9Y9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i3e7114012079469c8021b30d065673e7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzUzMzc_8b8d927b-fee8-445e-8704-081751dbae68">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i3e7114012079469c8021b30d065673e7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzUzODk_a011bb00-f85d-4810-bd1c-ea987095aade"
      unitRef="shares">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1f1e396274dc4a98b5466fd643278d94_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzU4OTc_b5669ab9-c2b8-4b12-9cf0-eb52a15b8eb3"
      unitRef="shares">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyMzQ_3da8d328-dcc4-4c93-8c6e-fc10f791703c">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;br/&gt;Contractual&#160;&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DM&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i73c47e791149483dac9b339dd293b4ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEtMS0xLTEtOTIzNzU_0de75d6d-3fa9-4ac2-8ffc-8f6b12af1900"
      unitRef="shares">6236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i73c47e791149483dac9b339dd293b4ca_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEtMy0xLTEtOTIzNzU_ae228450-31f1-4977-92cf-82b507cfa499"
      unitRef="usdPerShare">1.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0fe3f29a701248b9893e3e02d72f5095_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEtNS0xLTEtOTIzNzU_469fe7e2-279b-4089-a471-9a047df0f3e8">P8Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i73c47e791149483dac9b339dd293b4ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEtNy0xLTEtOTIzNzU_9af31670-0e49-46f5-93d8-7c58ebe0eb0c"
      unitRef="usd">358000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzItMS0xLTEtOTIzNzU_5a712cc8-279e-4cce-8154-01ecf7e526c7"
      unitRef="shares">4044000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzItMy0xLTEtOTIzNzU_d336e9e6-e6f3-44f6-a8b5-0ed2bb28b183"
      unitRef="usdPerShare">0.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzMtMS0xLTEtOTIzNzU_a5ad0421-4118-4482-b5f5-3229b2c758a6"
      unitRef="shares">12000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzMtMy0xLTEtOTIzNzU_a9fd7673-b81c-4f68-869a-210c9743bd4b"
      unitRef="usdPerShare">1.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzQtMS0xLTEtOTIzNzU_6db4a6ab-51f2-4b62-aafc-9aa6ed03692d"
      unitRef="shares">121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzQtMy0xLTEtOTIzNzU_38df78d5-8dc7-4443-b3ad-e13b4f0ad43a"
      unitRef="usdPerShare">1.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzUtMS0xLTEtOTIzNzU_d98597cc-915f-4233-adba-a337f2f76b6b"
      unitRef="shares">10147000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzUtMy0xLTEtOTIzNzU_9e0c6853-aef0-4a32-a833-858f7e13f8c7"
      unitRef="usdPerShare">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzUtNS0xLTEtOTIzNzU_b421b176-65a6-44ed-ac36-299171d1dc23">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzUtNy0xLTEtOTIzNzU_54a81688-b5ec-4d88-90f1-cfcc4bd62d72"
      unitRef="usd">3160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzYtMS0xLTEtOTIzNzU_0d604dc3-2083-4827-9b01-bfb61ce3c862"
      unitRef="shares">8273000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzYtMy0xLTEtOTIzNzU_e84078c3-3795-4c8c-8a66-aa38796153a8"
      unitRef="usdPerShare">3.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzctMS0xLTEtOTIzNzU_07b4c657-4bf2-4b1e-83bc-b83208baef10"
      unitRef="shares">34000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzctMy0xLTEtOTIzNzU_92067554-791a-4784-8400-4f1888432a96"
      unitRef="usdPerShare">1.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzgtMS0xLTEtOTIzNzU_b4eedbc6-c240-434c-9988-3ac330115b61"
      unitRef="shares">2683000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzgtMy0xLTEtOTIzNzU_ff89e461-72fb-4ddf-8f32-980afe28acbe"
      unitRef="usdPerShare">3.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzktMS0xLTEtOTIzNzU_d81607ec-4b1d-43f1-a372-4c9fdbc6a97a"
      unitRef="shares">15703000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzktMy0xLTEtOTIzNzU_a6b6980e-b9a2-4899-b20b-30fa23fada06"
      unitRef="usdPerShare">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzktNS0xLTEtOTIzNzU_8e79c000-b1e2-4da7-a168-cc905ef9e392">P8Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzktNy0xLTEtOTIzNzU_a0391c7f-3177-4e87-9fe8-a9074c0e5759"
      unitRef="usd">82000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEwLTEtMS0xLTkyMzc1_6e6aaef4-5f78-498e-bb5e-6eed177fb8fc"
      unitRef="shares">1510000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEwLTMtMS0xLTkyMzc1_b6a43f2b-83f9-4421-a94b-6514f4f7b60b"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzExLTEtMS0xLTkyMzc1_a8a4f092-8e92-4600-a2d6-c80d34aabb33"
      unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzExLTMtMS0xLTkyMzc1_92624da8-81a4-4b0e-a9cd-aedc5f2dc8dc"
      unitRef="usdPerShare">0.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEyLTEtMS0xLTkyMzc1_9a7b7ecb-a025-41f4-beb6-b847a36ce7ed"
      unitRef="shares">1907000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEyLTMtMS0xLTkyMzc1_0c008b54-b3e8-4394-a14c-59479abd3101"
      unitRef="usdPerShare">1.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEzLTEtMS0xLTkyMzc1_d99ce24a-3e55-477a-881b-93b960bd0c94"
      unitRef="shares">15304000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEzLTMtMS0xLTkyMzc1_8ca7518b-4748-451f-98a7-e103666ec324"
      unitRef="usdPerShare">1.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEzLTUtMS0xLTkyMzc1_9f117140-67a2-4e11-bc3e-db60ac121724">P7Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzEzLTctMS0xLTkyMzc1_b1e17cd1-4deb-4b23-adab-fb1e4fd16446"
      unitRef="usd">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzE0LTEtMS0xLTkyMzc1_28e069fd-7fe0-416b-bcb3-a45e88064afe"
      unitRef="shares">10427000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzE0LTMtMS0xLTkyMzc1_67509e38-fddb-41cc-b77c-16eb825745fd"
      unitRef="usdPerShare">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTo5YWZjODA1YWM2ZGI0YjgxOWZmNTg5ZWQwNzYzYmRlYy90YWJsZXJhbmdlOjlhZmM4MDVhYzZkYjRiODE5ZmY1ODllZDA3NjNiZGVjXzE0LTUtMS0xLTkyMzc1_7496b322-888a-48b5-8d2c-8b38b0d4de21">P6Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzU0OTc1NTgyMzU2Ng_5dc18189-3b02-4ecf-8e9a-201494c204ef"
      unitRef="usd">6900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzU0OTc1NTgyMzU1Mg_bbb5ce19-96bf-4d74-a85a-ffebcdff56f0"
      unitRef="usd">5100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzU0OTc1NTgyMzUzOA_45533e4e-f703-43e8-93bf-091a43218f81"
      unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY0MDE_102d96e6-a6a4-4804-959b-cfd99a8c6fdf"
      unitRef="usd">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY0MDU_7946db3a-e509-40d6-a4e9-d852c560f546"
      unitRef="usd">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY0MTI_9721c874-378e-4a78-8cd8-df5e9c8c1be5"
      unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9a728dfe3c4454cbc533710495f8f5b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY0OTM_0c9ed2b3-c866-421d-b040-ee3873068b35"
      unitRef="usd">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4cd59fe7a7ec49b7be31865888e57cd0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzEwOTk1MTE2MzUxODE_4d4ab101-adb9-46be-92b5-fff901996bda"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7e820c7440e2402791def7b12470f1f6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY1MzU_1df3e006-8ba1-459b-9b2f-a5fa3c16274b"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY2MzI_739ca913-2f8e-4750-9e5d-c877e9b10f24"
      unitRef="usd">5500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY3ODQ_def4ab2e-33c3-4f4a-ac93-abc0bfd830cf">P1Y10M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY5MDM_55e155b8-5554-416a-bd2c-cddb7325f35b"
      unitRef="usdPerShare">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY5MDc_d9b8164d-4af1-46a3-a59e-a7158276feee"
      unitRef="usdPerShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzY5MTQ_60f2f5fe-595e-4b32-9c3e-48af825c9674"
      unitRef="usdPerShare">0.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90ZXh0cmVnaW9uOjVhMDA2MjMxNjRkODQwOThhMzA1ZmJhZmFiMDI0OWMyXzcyMzg_c9c3e689-dc62-4550-acc7-78f086227ae3">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzItMS0xLTEtOTIzNzU_61685257-89d6-47c0-a57c-c0932f85f6c8"
      unitRef="usdPerShare">0.72</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzItMy0xLTEtOTIzNzU_a40dfc87-8f01-497b-9501-2b03705c04ba"
      unitRef="usdPerShare">3.32</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzItNS0xLTEtOTIzNzU_b6f963bc-83a0-4431-a806-24a8fef97c30"
      unitRef="usdPerShare">0.87</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i2979721cc12044649222cc680229209d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzMtMS0xLTEtOTIzNzU_267a8aaf-f7ac-48a8-ae58-c398b2c7f813"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i2fff5776971a48a586881cd89287df3c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzMtMy0xLTEtOTIzNzU_02b6b01b-898d-4bef-897b-a8e91bb33a6a"
      unitRef="usdPerShare">3.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ide0c3c6cf2a04d4383911137e51d3b5b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzMtNS0xLTEtOTIzNzU_cbe6ed12-69e6-4ffe-8290-3d21a15a3810"
      unitRef="usdPerShare">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzQtMS0xLTEtOTIzNzU_9c9a89fd-5713-4526-ada7-20ddcbc24416">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzQtMy0xLTEtOTIzNzU_4b0d26f6-46e9-4768-880f-bfeebfe1cdfe">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzQtNS0xLTEtOTIzNzU_acdd3808-bd96-45d2-aa2f-3f39e3ef141e">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzUtMS0xLTEtOTIzNzU_2a7e3483-3f20-4685-815b-488c866acafc"
      unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzUtMy0xLTEtOTIzNzU_00813a7c-2c6f-4b16-8bbf-0f5a24b981d9"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzUtNS0xLTEtOTIzNzU_a6235848-4c68-41d8-a826-b5a4df78bb54"
      unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzYtMS0xLTEtOTIzNzU_38b3d656-d32d-48e8-93e2-37eee285eca8"
      unitRef="number">0.718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzYtMy0xLTEtOTIzNzU_8a36c555-ab78-4da8-856c-c78f0337100e"
      unitRef="number">0.746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzYtNS0xLTEtOTIzNzU_372a94b7-f310-4156-9bf9-1e896cf570c7"
      unitRef="number">0.715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id1249ce1aca94aa89687426119ea9780_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzctMS0xLTEtOTIzNzU_a1a3a3b5-69e3-49f3-be24-b269dd8e8320"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6a75b37ecc1648f390b3fa848066bba5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzctMy0xLTEtOTIzNzU_e3fe721f-449c-4f69-bf13-d3ecd08024bb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie1d86644bfde4103969c02d969f6b925_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjEvZnJhZzo1YTAwNjIzMTY0ZDg0MDk4YTMwNWZiYWZhYjAyNDljMi90YWJsZTplZGJlNTVjMmJiMzI0MTY4YTA5ZDM0NTg3NDMyYWJjMC90YWJsZXJhbmdlOmVkYmU1NWMyYmIzMjQxNjhhMDlkMzQ1ODc0MzJhYmMwXzctNS0xLTEtOTIzNzU_4a2164d0-91e6-4a24-9331-f8d0c2788258"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzI2NTc_4a7ea0bc-bfc5-4e0a-8947-28cc2b4ecf5e">EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders' equity (deficit). As of December&#160;31, 2022, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company sold a de minimis number of shares under the ESPP for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States - 401(k) Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 401(k) defined contribution retirement plan which covers all of its United States employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canada - Defined Contribution Plan&lt;/span&gt;&lt;/div&gt;The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The Company contributed a de minimis amount for each of the three years ended December&#160;31, 2022, 2021 and 2020, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3f2e215c48c94cc88ad545b140478fd4_I20140228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzM4Ng_4103c136-80f9-4817-8428-8be8daee90d7"
      unitRef="shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i50afeb8b2fbe4a90bd225677491dd878_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzYxNg_7189337b-0d1a-4cde-9d7e-b850231c2f17"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="ic9ccb359bb07464c8b5a4bf7acd0ee69_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzk2Mw_0646332a-d7ac-4cd7-bed6-c1bff5db5b6d"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i81090f1cef414033a4de39f36d28f951_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzEzNzY_449f5735-3ac4-46c7-90a6-948997c126a2"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ieddcde47d6134b21a63f741b8434c23a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzE4NzE_68d717af-cf60-4958-9bdd-6c9c1ba7fd51"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee
      contextRef="ieddcde47d6134b21a63f741b8434c23a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzIwNzA_8260d052-bea4-48d8-8e4e-696fb453e5c5"
      unitRef="usd">4000</sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i284162f0c4ac4a84a203966f8ee455b8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjQvZnJhZzoxMzEwYTllNzI4Mjg0ZmU2OGQ1MDYwYjk4MjQ3NTYxYi90ZXh0cmVnaW9uOjEzMTBhOWU3MjgyODRmZTY4ZDUwNjBiOTgyNDc1NjFiXzI0NjI_1c9e97ad-424d-4cf8-b8d7-67a074b7843d"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzUzODU_486b41f1-c77e-4731-ac80-0d70704ca5b4">INCOME TAXES &lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the Company's loss before income taxes by country (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total Loss Before Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(23,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's tax benefit (provision) is comprised of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Tax Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Tax Benefit (Provision) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,875&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company&#x2019;s effective income tax rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option cancellations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill write-off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Income Tax Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IRC 174 Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accruals and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Capitalized start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net Deferred Tax Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of the Company's deferred tax assets, management considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL and R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company has generated NOLs since its inception, and management believes that it is more likely than not that the Company's deferred tax assets will not be realized. As a result, valuation allowances of $82.5 million, $71.8 million and $65.6 million have been established as of December&#160;31, 2022, 2021 and 2020, respectively. The $10.6 million increase in the valuation allowance was attributable to the NOL for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's NOL and R&amp;amp;D and other credit carryforwards in the United States and Canada as of December&#160;31, 2022 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration Beginning in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Through&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards - indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal non-capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal scientific research and experimental development&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expense carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal and provincial investment tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Tax Reform Act of 1986 (the "Act'), NOL and R&amp;amp;D credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service, and there are similar provisions in certain state and non-US tax laws. NOL and R&amp;amp;D credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interests of significant shareholders over a three-year period in excess of 50 percent, as defined in Sections 382 and 383 of the Internal Revenue Code, respectively. This could limit the amount of tax attributes that can be utilized to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Management completed a Section 382 study through March 31, 2016 and determined that it is more likely than not that the Company's NOL carryforwards are subject to a material limitation. Accordingly, the Company reduced its NOL carryforward by $0.8 million. The Company has continued to raise additional equity capital since March 2016 but has not done any additional analysis to determine whether or not ownership changes, as defined in the Act, have occurred, which would result in additional limitations. There could be additional ownership changes in the future that could further limit the amount of NOL carryforwards that the Company can utilize. The Company has not yet conducted a study of its R&amp;amp;D credit carryforwards. Such a study may result in an adjustment to the Company&#x2019;s R&amp;amp;D credit carryforwards; however, until a study is completed, and any adjustment is known, no amount is being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s R&amp;amp;D credit carryforwards, and, if an adjustment is required, it would be offset by an adjustment to the valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it has operations to determine the potential effect on its business and any assumptions it has made about its future taxable income. The Company cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, the Company has no assurance that the provision will be repealed or otherwise modified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's consolidated statements of operations. Due to NOL and R&amp;amp;D credit carryforwards that remain unutilized, income tax returns filed in the United States, certain states within the United States and Canadian tax jurisdictions from the Company's inception through 2021 remain subject to examination by the taxing jurisdictions. There are currently no audits in process in any of the Company's tax filing jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzUzODQ_b687bd4d-a7b7-4c3b-ab37-2629c6a3eac8">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the Company's loss before income taxes by country (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total Loss Before Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(23,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ice90a69ceeff49f0b8f1ce82d2bb4ded_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzMtMS0xLTEtOTIzNzU_aa67cae5-6b58-4b95-885a-443aa7a36b38"
      unitRef="usd">-37289000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i921a13a0674c431a99d0b747823d5a59_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzMtMy0xLTEtOTIzNzU_47c7b0e5-d951-4c45-a3bd-cb69cf7bb99c"
      unitRef="usd">-32757000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ib11ddd9e85084edeb9ff837ed2550dcc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzMtNS0xLTEtOTIzNzU_da912b3f-b567-414a-ba6e-37dd1774790a"
      unitRef="usd">-35529000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="iebe3ee0020554764957e449756650c1d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzQtMS0xLTEtOTIzNzU_fde55794-056c-430e-8365-7a3a49e79612"
      unitRef="usd">13530000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ic7b74c8246e3465ebe694e85ae1cf30f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzQtMy0xLTEtOTIzNzU_626e3376-b954-4512-bcb6-72289426f986"
      unitRef="usd">24148000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="idc1992bb56f84f4d954e523e989b4498_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzQtNS0xLTEtOTIzNzU_c918b6d0-aace-49c5-a443-8fc35761bc18"
      unitRef="usd">14577000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzUtMS0xLTEtOTIzNzU_ed474ffa-f16b-4637-b4da-4b8eca7478ce"
      unitRef="usd">-23759000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzUtMy0xLTEtOTIzNzU_8dcf175d-b518-4a36-b164-aba3d9a97294"
      unitRef="usd">-8609000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo2ZTQ5MDRjZmIwYmE0ZjE2ODJlMDliZWE1YzliNzJmNi90YWJsZXJhbmdlOjZlNDkwNGNmYjBiYTRmMTY4MmUwOWJlYTVjOWI3MmY2XzUtNS0xLTEtOTIzNzU_bcfdd293-3afc-4956-855e-69b31c8fe81d"
      unitRef="usd">-20952000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzU0MDM_800ad440-f7f2-4e55-bf4b-5c7ae8e17e5e">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's tax benefit (provision) is comprised of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Tax Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Tax Benefit (Provision) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,875&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzMtMS0xLTEtOTIzNzU_a005f7a1-5939-47b9-ae2c-ae3b0743f13f"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzMtMy0xLTEtOTIzNzU_9e629a6b-8feb-4bd4-9fed-1ee6ac57175d"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzMtNS0xLTEtOTIzNzU_4bfd5210-6e4e-44b2-a680-4d05db656d52"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzQtMS0xLTEtOTIzNzU_4c314fd1-6b42-4fbc-9ce6-bf755b71034f"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzQtMy0xLTEtOTIzNzU_776c09de-6bae-4e05-802a-e8c5d419ec4c"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzQtNS0xLTEtOTIzNzU_addbf942-2a16-4502-a912-f476ddb7a17e"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzUtMS0xLTEtOTIzNzU_7f1a2332-49e5-4393-85c4-4c7af660d2f5"
      unitRef="usd">94000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzUtMy0xLTEtOTIzNzU_0d52403c-7bfe-4727-b51b-2a59ba66b94e"
      unitRef="usd">286000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzUtNS0xLTEtOTIzNzU_a6ff4489-9882-4e56-877c-ccb01747267b"
      unitRef="usd">1445000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzYtMS0xLTEtOTIzNzU_0a84d69a-b1e7-44b1-a2a5-4da7cdd3f38a"
      unitRef="usd">94000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzYtMy0xLTEtOTIzNzU_284e6801-6603-4892-9642-cfd4103a812b"
      unitRef="usd">286000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzYtNS0xLTEtOTIzNzU_0b2ad2e9-8b81-4728-9514-aff2a150d747"
      unitRef="usd">1445000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzgtMS0xLTEtOTIzNzU_8ee02c53-6e1a-4150-8cd7-5820435fe504"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzgtMy0xLTEtOTIzNzU_5954d210-a630-4488-9342-90da81679664"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzgtNS0xLTEtOTIzNzU_9fbbfe26-2b46-4c26-bbe3-15cff76bc203"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzktMS0xLTEtOTIzNzU_76c2633d-f03a-4224-8673-2db9787e30e0"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzktMy0xLTEtOTIzNzU_664ec1db-ad59-484b-b5a8-dffa4549db14"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzktNS0xLTEtOTIzNzU_cef8859c-b96a-4cae-9fd1-29b775d59fdb"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEwLTEtMS0xLTkyMzc1_8174f4bf-bed6-4324-8043-d8c6e85a6b1b"
      unitRef="usd">-3969000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEwLTMtMS0xLTkyMzc1_c6d04c7c-ef25-4da6-bc92-0fb1932fab35"
      unitRef="usd">-8559000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEwLTUtMS0xLTkyMzc1_df86021f-d083-43ba-b9bb-a26e72250d84"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzExLTEtMS0xLTkyMzc1_6586e9fd-0342-4481-a690-e4069decb869"
      unitRef="usd">-3969000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzExLTMtMS0xLTkyMzc1_91469266-a200-497d-acf5-6449b657a422"
      unitRef="usd">-8559000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzExLTUtMS0xLTkyMzc1_90c417e9-9c21-4fc1-bc84-9088d7608208"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEzLTEtMS0xLTkyMzc1_561f4887-3875-4951-a56e-06fa8dd17984"
      unitRef="usd">-3875000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEzLTMtMS0xLTkyMzc1_9623d37c-8b8c-4318-8c7b-3281089f9fd2"
      unitRef="usd">-8273000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo0N2NmYmVjOGU1OWQ0ZDE4OTg3NTRmMmIxNWMyMWFiYS90YWJsZXJhbmdlOjQ3Y2ZiZWM4ZTU5ZDRkMTg5ODc1NGYyYjE1YzIxYWJhXzEzLTUtMS0xLTkyMzc1_a9615fcc-997c-490c-8bfd-863d2d3e8d4a"
      unitRef="usd">1445000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzUzODc_ba2138e9-230a-4f52-a022-df976a102d90">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company&#x2019;s effective income tax rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option cancellations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill write-off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Income Tax Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzItMS0xLTEtOTIzNzU_ed3c3b8e-8516-401c-a701-a46859eba651"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzItMy0xLTEtOTIzNzU_143f8f37-f8c4-4737-adc0-7640d85c307d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzItNS0xLTEtOTIzNzU_71a82499-7688-4822-8107-f1a98fa01cc8"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzMtMS0xLTEtOTIzNzU_09fb7739-1af0-4a6d-8292-9f11b7dc2c26"
      unitRef="number">-0.033</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzMtMy0xLTEtOTIzNzU_54bab78e-fe7f-4fc2-8fad-8efbc03d427d"
      unitRef="number">-0.159</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzMtNS0xLTEtOTIzNzU_d418e672-53df-45ba-8fbe-4c8c9f9d94ae"
      unitRef="number">-0.042</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzQtMS0xLTEtOTIzNzU_b5e27a3d-d54e-4432-947b-b97da95c940a"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzQtMy0xLTEtOTIzNzU_abd66f3f-2657-40e0-959f-39441b1cfef2"
      unitRef="number">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzQtNS0xLTEtOTIzNzU_d7ace37a-f1bd-4bc3-a962-e0bd54c80171"
      unitRef="number">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzUtMS0xLTEtOTIzNzU_734b5b05-592d-41fa-b892-9181347828d0"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzUtMy0xLTEtOTIzNzU_3796d697-3e74-4818-8e92-f3fb5d2fff7b"
      unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzUtNS0xLTEtOTIzNzU_44484bb6-c65c-4b62-a28e-b2bd16dc6d3e"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzYtMS0xLTEtOTIzNzU_fc209082-26e5-4bde-8216-ebc6f6bf8e74"
      unitRef="number">0.591</sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent>
    <sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzYtMy0xLTEtOTIzNzU_ff7c9be7-2d0b-4678-b89a-c1b4ce21dd20"
      unitRef="number">1.782</sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent>
    <sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzYtNS0xLTEtOTIzNzU_6a67549b-2232-4492-b1ef-5c78a3388d6d"
      unitRef="number">0.144</sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzctMS0xLTEtOTIzNzU_fe2f4720-1935-422b-a28b-be56ad961e45"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzctMy0xLTEtOTIzNzU_05d1e3ad-fb4b-49dc-98d9-a8ade0ce1d8b"
      unitRef="number">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzctNS0xLTEtOTIzNzU_40ca1653-b907-42fa-9024-16941d83b896"
      unitRef="number">-0.066</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <sesn:EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtMS0xLTEtMTA2Nzky_223b999f-c653-4074-834c-39cd25c7af76"
      unitRef="number">-0.148</sesn:EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent>
    <sesn:EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtMy0xLTEtMTA2Nzky_f337b7df-345d-4942-bad7-0e97f6f76007"
      unitRef="number">0</sesn:EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent>
    <sesn:EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtNS0xLTEtMTA2Nzky_20350efa-1e8f-453b-8918-6f2ad6222f2e"
      unitRef="number">0</sesn:EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent>
    <sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtMS0xLTEtOTIzNzU_a559331c-0603-4436-bbfc-ab2f98782091"
      unitRef="number">-0.019</sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtMy0xLTEtOTIzNzU_b5edc145-7386-40f1-b7f3-97f6ea9ee069"
      unitRef="number">-0.014</sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzgtNS0xLTEtOTIzNzU_0c4db07c-f66b-438b-b6cd-4872901e7f71"
      unitRef="number">0.002</sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzktMS0xLTEtOTIzNzU_c61378e8-be24-4b34-a529-73186daa133c"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzktMy0xLTEtOTIzNzU_a9b3686c-0378-4d3d-b7cf-d7510adc0451"
      unitRef="number">-0.138</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzktNS0xLTEtOTIzNzU_fa978264-a95e-4be1-a404-056249ca0c9c"
      unitRef="number">-0.021</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEwLTEtMS0xLTkyMzc1_8c53ec5e-f6b5-49a4-80e4-369ef484d90b"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEwLTMtMS0xLTkyMzc1_058b2078-8bf4-4f96-993b-93838562ad35"
      unitRef="number">-0.033</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEwLTUtMS0xLTkyMzc1_53ad6cf3-9eef-4a87-89e9-8305ee76707b"
      unitRef="number">-0.069</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzExLTEtMS0xLTkyMzc1_a7f47d2e-75b5-4eed-9dd4-6ee7652247c9"
      unitRef="number">-0.446</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzExLTMtMS0xLTkyMzc1_17e6a5df-f925-4e52-884c-737501e0dd19"
      unitRef="number">-0.723</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzExLTUtMS0xLTkyMzc1_2b888979-4ad7-4de8-a83b-70dd0100fd31"
      unitRef="number">-0.377</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEyLTEtMS0xLTkyMzc1_d7d938ce-edac-4fe4-91b5-f14f7f9465fa"
      unitRef="number">0.167</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5081748a7d70459fba89ea6fb523d62a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEyLTMtMS0xLTkyMzc1_98b19526-396f-4ad5-aae2-c6e61709b60b"
      unitRef="number">0.961</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib61f894ae1a64f4eaac1e56b5080f29c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4ZGQxNWY4YWVkMzA0YjcxYmVkZDY4NDZkNTAxMzQ4NC90YWJsZXJhbmdlOjhkZDE1ZjhhZWQzMDRiNzFiZWRkNjg0NmQ1MDEzNDg0XzEyLTUtMS0xLTkyMzc1_5e8215bf-1c06-4165-badd-dc5b2a5484b5"
      unitRef="number">-0.069</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzU0MDE_708b7f02-4db6-4b95-90f5-c5980f320151">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IRC 174 Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accruals and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Capitalized start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net Deferred Tax Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzMtMS0xLTEtOTIzNzU_7bb03b18-2750-4ac2-b86b-37b48539afe3"
      unitRef="usd">66374000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzMtMy0xLTEtOTIzNzU_1cb39a10-92e4-43dd-a7ec-34b7a3707c14"
      unitRef="usd">63381000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzMtNS0xLTEtOTIzNzU_d37c983d-ce51-4945-a0a5-263d57fadba4"
      unitRef="usd">57935000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzQtMS0xLTEtOTIzNzU_414424f8-ba26-4220-9a4f-768c97b1755d"
      unitRef="usd">4489000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzQtMy0xLTEtOTIzNzU_f52b4de5-9d33-4bdf-b319-e9fb1941f904"
      unitRef="usd">4316000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzQtNS0xLTEtOTIzNzU_a3e96f68-78fa-4fd2-97ef-733a546f7d49"
      unitRef="usd">3787000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <sesn:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtMS0xLTEtMTAyMTM2_d82f566a-3ada-4767-9448-ef99b34606ee"
      unitRef="usd">6214000</sesn:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <sesn:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtMy0xLTEtMTAyMTM2_10a790ee-340e-4787-b7fd-4b129c2cd019"
      unitRef="usd">0</sesn:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <sesn:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtNS0xLTEtMTAyMTM2_7a40a9ce-2049-4783-98d8-1ebe53dc7347"
      unitRef="usd">0</sesn:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtMS0xLTEtOTIzNzU_efaedec1-fe59-4565-961e-777f23799917"
      unitRef="usd">5326000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtMy0xLTEtOTIzNzU_620f8396-b598-4e41-a4b9-b522c31a0408"
      unitRef="usd">4058000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzUtNS0xLTEtOTIzNzU_e084e0ec-3635-4ad0-b48f-facf80dc8183"
      unitRef="usd">3811000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <sesn:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzYtMS0xLTEtOTIzNzU_420abaeb-2fd8-44c2-8bd4-4b3f0f17f317"
      unitRef="usd">34000</sesn:DeferredTaxAssetsCapitalizedStartUpCosts>
    <sesn:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzYtMy0xLTEtOTIzNzU_4702dd3f-1cd8-4d6b-a521-b6acc0049efd"
      unitRef="usd">53000</sesn:DeferredTaxAssetsCapitalizedStartUpCosts>
    <sesn:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzYtNS0xLTEtOTIzNzU_3bc06733-22bf-4f94-888c-60b10cb01322"
      unitRef="usd">70000</sesn:DeferredTaxAssetsCapitalizedStartUpCosts>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzctMS0xLTEtOTIzNzU_86af66e5-2e1f-4e2c-b111-900f5f0ae5d6"
      unitRef="usd">16000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzctMy0xLTEtOTIzNzU_7f395233-a963-4662-aac5-04aec5d2a230"
      unitRef="usd">41000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzctNS0xLTEtOTIzNzU_c294c2cc-8322-4e33-9fc9-a21d2c5cd9cc"
      unitRef="usd">28000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzgtMS0xLTEtOTIzNzU_e57da831-d420-42f5-a26f-6455f605d5fe"
      unitRef="usd">82453000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzgtMy0xLTEtOTIzNzU_ce1524ef-4432-43e5-8326-211afa3e4dc8"
      unitRef="usd">71849000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzgtNS0xLTEtOTIzNzU_cf6e3711-229f-4286-824e-ab347296530d"
      unitRef="usd">65631000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEwLTEtMS0xLTkyMzc1_67ff877f-73f8-4041-92bc-1ac7f378876a"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEwLTMtMS0xLTkyMzc1_2bd92b12-24cf-4d0a-99b2-42843d037f6a"
      unitRef="usd">3969000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEwLTUtMS0xLTkyMzc1_eea88bc2-88f1-4694-8394-c3920d02b395"
      unitRef="usd">12528000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEyLTEtMS0xLTkyMzc1_15af9949-767a-45d5-8919-1c0fbb39a132"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEyLTMtMS0xLTkyMzc1_ad4ce31e-9713-4140-93e7-2c67795597a3"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEyLTUtMS0xLTkyMzc1_3f08b739-36c2-4597-9150-886f97dc3eef"
      unitRef="usd">12528000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEzLTEtMS0xLTkyMzc1_ca7fe971-286f-4997-abdc-11b1a920e7e2"
      unitRef="usd">82453000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEzLTMtMS0xLTkyMzc1_f39dc0e0-6768-444c-a85f-8f2a1a43cfb6"
      unitRef="usd">71849000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzEzLTUtMS0xLTkyMzc1_57fbdb56-f482-4140-8e15-061c7be45913"
      unitRef="usd">65631000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzE0LTEtMS0xLTkyMzc1_9c023684-d543-4d51-a953-1abae81b5f1c"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzE0LTMtMS0xLTkyMzc1_c7bc00f5-8b1b-4d59-b335-34486ed016b5"
      unitRef="usd">3969000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZTo4YTFjMWE3OTZlYWM0MWIxYWVkMjQ4YTI3ZjhiMGJlZi90YWJsZXJhbmdlOjhhMWMxYTc5NmVhYzQxYjFhZWQyNDhhMjdmOGIwYmVmXzE0LTUtMS0xLTkyMzc1_54939ebc-8e0e-4500-82ce-c0e05c8434ed"
      unitRef="usd">12528000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzEzMjk_c0c799c1-7650-40bd-b5ad-db168da1014e"
      unitRef="usd">82500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzEzMzM_3d7f7e0f-af0e-459c-a33f-3ce6c086aaff"
      unitRef="usd">71800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i01d57c119960482d81011d8c04ff8399_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzEzNDA_e3c4a788-4b52-47c7-9b3f-fe091bf51187"
      unitRef="usd">65600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzE0MDQ_9aadae0e-5ff2-4331-bede-3304c5566dd8"
      unitRef="usd">10600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzUzOTU_58caf33d-2bc3-4762-a2a3-23c9eab9ec17">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's NOL and R&amp;amp;D and other credit carryforwards in the United States and Canada as of December&#160;31, 2022 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration Beginning in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Through&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards - indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;State R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal non-capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal scientific research and experimental development&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expense carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Federal and provincial investment tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2917e2d690494115aa405efdcd442035_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzItMS0xLTEtOTIzNzU_6749df4f-a281-4977-a121-cd2540c2dc69"
      unitRef="usd">101200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iaedc518daaca46d48e4045cf67580747_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzMtMS0xLTEtOTIzNzU_a1dfdc53-7688-4a21-9775-6007b9120b2b"
      unitRef="usd">117700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id942c56598a7425a8f604363c0ccee90_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzQtMS0xLTEtOTIzNzU_639d38fe-01ac-4137-91bf-a049014f09c6"
      unitRef="usd">138400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i2ce909ec953045fcb9590f2a8585912f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzUtMS0xLTEtOTIzNzU_27c99c9c-4e88-4adb-bdd3-1c057da0433c"
      unitRef="usd">2600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ib3541e5363f343a3a43242a6a366098b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzYtMS0xLTEtOTIzNzU_19c288ea-72fc-43b8-957f-408589d0729c"
      unitRef="usd">900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i2a7959f49c234c9eaa2618a72fb438f9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzgtMS0xLTEtOTIzNzU_031f5c22-ec47-463d-9a0f-e711e43315e7"
      unitRef="usd">43200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="idd3a316709d6476199e3824ccf11239c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzktMS0xLTEtOTIzNzU_08c08154-a36f-454c-a30f-fdbfee89e9d6"
      unitRef="usd">5100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="iea773b2e97a1449f9f95fa34f634aee4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90YWJsZToyYjc1MDk1ZDcwMDk0NmVjOTZlY2M5MjFjYmNmNjJmZS90YWJsZXJhbmdlOjJiNzUwOTVkNzAwOTQ2ZWM5NmVjYzkyMWNiY2Y2MmZlXzEwLTEtMS0xLTkyMzc1_30201fa4-0be0-426d-ac45-1b0684444918"
      unitRef="usd">1200000</us-gaap:TaxCreditCarryforwardAmount>
    <sesn:OperatingLossCarryforwardsDecrease
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMjcvZnJhZzpmZTMxMTJjN2ZlMWY0YjVmYWQ5YzFiYjE5Yzg3MmVmNy90ZXh0cmVnaW9uOmZlMzExMmM3ZmUxZjRiNWZhZDljMWJiMTljODcyZWY3XzMwOTg_807a6dc5-f849-4d69-a41f-b7defc8770d0"
      unitRef="usd">800000</sesn:OperatingLossCarryforwardsDecrease>
    <sesn:LicenseAgreementTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzIwOTQw_43827902-adef-4b94-9db0-761373a8c4db">LICENSE AGREEMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Zurich&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#x201c;Zurich License Agreement&#x201d;). These patents cover some key aspects of Vicineum. Upon the Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company became obligated to pay $0.5&#160;million in a milestone payment to Zurich. The Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded expenses of $0.3&#160;million and $0.5&#160;million related to meeting a development milestone, the submission of the Company&#x2019;s BLA with the FDA in December 2020, and a regulatory milestone, the Company&#x2019;s receipt of the CRL from the FDA in August 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Micromet&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#x201c;Micromet License Agreement&#x201d;). These patents (which are now expired) cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of December&#160;31, 2022, even though the patents have expired, the Company may be obligated to pay up to &#x20ac;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.6&#160;million at exchange rates in effect on December&#160;31, 2022). The Company is also required to pay up to a 3.5% royalty on the net sales for products covered by the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#x20ac;50,000, which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#x20ac;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ecember 2020. The Company recorded an expense of &#x20ac;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#x2122; in the first quarter of 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2022, the Company recorded an expense of &#x20ac;50,000 ($51,770) related to the annual license maintenance fee. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vysyneum is the proprietary brand name conditionally approved by the EMA for oportuzumab monatox in the E.U. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with XOMA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights (which are now expired) and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#x201c;XOMA License Agreement&#x201d;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, even though the patents have expired, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#x2019;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Roche License Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company entered into the license agreement with Roche (the &#x201c;Roche License Agreement&#x201d;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#x2019;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#x201c;Roche Licensed Product&#x201d;) and pursue ongoing patent prosecution, at its cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company entered into an asset purchase agreement with Roche (the &#x201c;Roche Asset Purchase Agreement&#x201d;) pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $70.0&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40.0&#160;million payment to the Company upon execution of the Roche Asset Purchase Agreement, which was recorded as license revenue in the third quarter of 2022. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30.0&#160;million payment to the Company upon Roche&#x2019;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026. Pursuant to ASC 606, the variable consideration of $30.0&#160;million is constrained. Therefore, the amount was not recorded as revenue during the year ended December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At or prior to the effective time of the Merger, the Company will enter into a Contingent Value Rights Agreement (the &#x201c;CVR Agreement&#x201d;) with a rights agent (&#x201c;Rights Agent&#x201d;) pursuant to which the Company intends to declare a dividend payable to the Company&#x2019;s stockholders of record as of a date agreed to by the Company and Carisma prior to the effective time of the Merger with respect to the receipt of one contingent value right (each, a &#x201c;CVR&#x201d;) for each outstanding share of the Company&#x2019;s common stock held by such stockholders on such date. Each CVR will represent the contractual right to receive (i) contingent cash payments upon the receipt by the Company of certain proceeds payable by Roche, if any, pursuant to the Roche Asset Purchase Agreement, upon the achievement by Roche of a specified milestone set forth in the Roche Asset Purchase Agreement, as well as (ii) proceeds from any sale of the Company's legacy assets, including Vicineum, subject to certain customary deductions, including for expenses and taxes, in the event any sale occurs prior to March 31, 2027. The contingent payments under the CVR Agreement, if they become due, will be payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement. There can be no assurance that any cash payment will be made or that any holders of CVRs will receive any amounts with respect thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Former OUS Business Development Partnership Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Qilu License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu (the &#x201c;Qilu License Agreement&#x201d;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to develop, manufacture and commercialize&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Vicineum (the &#x201c;Qilu Licensed Product&#x201d;) for the treatment of NMIBC and other types of cancer (the &#x201c;Field&#x201d;) in China, Hong Kong, Macau and Taiwan ("Greater China&#x201d;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#x201d;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#x201c;Royalty Terms&#x201d;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 23, 2022, the Company terminated the Qilu License Agreement. In connection with the termination of the Qilu License Agreement, the Company agreed to make an aggregate payment to Qilu of $1.4&#160;million, which consists of a $1.2&#160;million termination fee payable upon the termination of the Qilu License Agreement, which was paid in the fourth quarter of 2022, and a $200,000 payment payable upon our receipt of certain clinical data and chemistry, manufacturing, and controls data from Qilu, which such payment was not made as of December 31, 2022. Accordingly, $0.2&#160;million remained on the Company's balance sheet in accrued liabilities as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hikma License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region (the "Hikma License Agreement"). The Company retained development and commercialization rights in the rest of the world excluding Greater China, Turkey, and MENA. In consideration for the rights granted by the Company, the counterparty to the Hikma License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the Hikma License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2022, the Company provided notice of termination of the Hikma License Agreement as a result of the Company&#x2019;s strategic decision to voluntarily pause further development of Vicineum in the United States. In connection with such termination, the Company refunded to Hikma the $3.0&#160;million upfront payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;EIP License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 5, 2021, the Company entered into an exclusive license agreement with E&#x130;P Eczac&#x131;ba&#x15f;&#x131; &#x130;la&#xe7; Pazarlama A.&#x15e;., (&#x201c;EIP&#x201d;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#x201c;EIP License Agreement"). Under the terms of the License Agreement, the Company was entitled to receive an upfront payment of $1.5&#160;million. The Company and EIP have subsequently amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company would have been eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and also to receive a 30% royalty on net sales in Turkey and Northern Cyprus. &lt;/span&gt;&lt;/div&gt;On July 20, 2022, the Company provided notice of termination of the EIP License Agreement as a result of the Company&#x2019;s strategic decision to voluntarily pause further development of Vicineum in the United States. The EIP License Agreement was terminated on October 20, 2022.</sesn:LicenseAgreementTextBlock>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i5b7c86274f4d47eaa8553199408d4b91_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzY4Mw_1f4242c4-b763-4d76-b5e0-314c1fc3ed55"
      unitRef="usd">500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="i15671c3d0d094adaac0c1229062ca074_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2NQ_a1fd2f43-f81c-42c3-b85a-95edab06a000"
      unitRef="number">0.04</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="i15671c3d0d094adaac0c1229062ca074_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzEwMzY_c3948190-a6e3-451a-94ed-287e64537874"
      unitRef="number">0.10</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="i15671c3d0d094adaac0c1229062ca074_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzExMTM_35d5844f-2526-4736-8c10-5424a4420b8e"
      unitRef="number">0.02</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i22d0546a2e584012b01ef15556862322_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTYwOTI_10a5458a-58c0-4167-956d-46599227ec23"
      unitRef="usd">300000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="iced9f5bd4c3647f9a7e60cc7a6ea99ed_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTYxMDY_49f6143f-836f-4222-867c-0504f75e3161"
      unitRef="usd">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzIyODc_0a910ab1-b4a8-4c9c-9381-2f2879f49696"
      unitRef="eur">2400000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI0MzQ_f996ba31-7583-4a3f-8899-779078034b54"
      unitRef="usd">2600000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI1MTc_34399fc6-dc6c-4c01-95b9-b46b0d8bb6e8"
      unitRef="number">0.035</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent
      contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI2ODY_b0e4a670-aa1c-480a-bb56-1b0aacaea9fa"
      unitRef="number">0.015</sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent>
    <sesn:LicenseMaintenanceFees
      contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzMwNzk_9a6dea15-32be-41cd-8332-12c17c00460e"
      unitRef="eur">50000</sesn:LicenseMaintenanceFees>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i211e8012b6af40e08411ca15f526f29f_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzMyNTQ_f271b4b1-5e9e-4e00-8607-589854b1a406"
      unitRef="eur">700000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i211e8012b6af40e08411ca15f526f29f_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzMyNTg_ce86ddbc-6ad0-4f2e-84a0-e12fc652e91f"
      unitRef="usd">900000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i5589d69bf52247d28185c2f78a22516f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzM0Nzk_a59a29b3-993a-4587-bbda-c7daf4dd77ed"
      unitRef="eur">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i5589d69bf52247d28185c2f78a22516f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzM0ODM_866163ec-eb82-4123-8fe3-75e228c02bc9"
      unitRef="usd">600000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzcxNDY4MjU2MjgwODM_1c0fddf5-ae58-4d09-8b2b-aaa29217b065"
      unitRef="eur">50000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i9b934f9a49004429b714a139ec11cb7a_D20220101-20221231"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTczMzc_79ee66de-de94-4444-956e-3c44e8bb1730"
      unitRef="usd">51770</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i672eb9cc12ef4dfabefe71540f49d9d4_D20220101-20221231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzQxOTI_58c3b964-5cd7-4080-a30a-3695f5f4f012"
      unitRef="usd">250000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="i672eb9cc12ef4dfabefe71540f49d9d4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzQ1MjI_250cff7a-0fa0-4c91-a36a-a0b26868cb71"
      unitRef="number">0.025</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="i672eb9cc12ef4dfabefe71540f49d9d4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzQ4NDA_5a8a694a-5b00-482b-a5ae-e3596e4c825b"
      unitRef="number">0.0175</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="i672eb9cc12ef4dfabefe71540f49d9d4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzQ5MTM_4589a619-e23d-4fe1-97db-84883a070d0f"
      unitRef="number">0.50</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:OtherReceivableAssetPurchaseAgreement
      contextRef="i1eaf6421a30f4d65931441ab3517bbd0_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MTU3MDA_cf372f04-7d1e-436a-b581-2111233261d0"
      unitRef="usd">70000000</sesn:OtherReceivableAssetPurchaseAgreement>
    <sesn:ProceedsFromExecutionOfAssetPurchaseAgreement
      contextRef="icabd5c54fc0449559aeac9215c25207e_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MTU5NzE_43614cc5-6962-4dcb-bf93-2abba31270f9"
      unitRef="usd">40000000</sesn:ProceedsFromExecutionOfAssetPurchaseAgreement>
    <sesn:OtherReceivableAssetPurchaseAgreement
      contextRef="ie66655811a134f9b8b6e989ecb525174_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MTYyMDQ_8c3bcad9-0818-413d-b091-ae7631489a29"
      unitRef="usd">30000000</sesn:OtherReceivableAssetPurchaseAgreement>
    <sesn:AssetPurchaseAgreementVariableConsideration
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MTY0MTM_fc925abc-b1d8-473b-9c6e-9392c80f22b7"
      unitRef="usd">30000000</sesn:AssetPurchaseAgreementVariableConsideration>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ie9a4679b42de470d95370417666d7ba5_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzExNjQx_3e9603ba-a7c6-457d-ad27-7da3d6e0319c"
      unitRef="usd">12000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount
      contextRef="ie9a4679b42de470d95370417666d7ba5_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzExNjgz_6cecb178-ba44-4325-a590-8e4c2c5bddc9"
      unitRef="usd">23000000</sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount>
    <sesn:BusinessCombinationRoyaltyPaymentPercent
      contextRef="ie9a4679b42de470d95370417666d7ba5_D20200730-20200730"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzExOTg1_e96526e5-e6c9-403a-a14a-183b634102c6"
      unitRef="number">0.12</sesn:BusinessCombinationRoyaltyPaymentPercent>
    <sesn:CollaborativeArrangementRoyaltyPeriod
      contextRef="i4383d15b8e8f48599512b909df5f7d25_D20200730-20200730"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkwOTAzODM_5ec781c1-e801-4492-bbf2-3d16e2a1fc48">P12Y</sesn:CollaborativeArrangementRoyaltyPeriod>
    <sesn:LicenseAgreementTerminationExpense
      contextRef="ie9cd9290db5c494b8aac997b30e9f530_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTYxMjA_97ba5a87-ed56-4001-b59d-a2768847f367"
      unitRef="usd">1400000</sesn:LicenseAgreementTerminationExpense>
    <sesn:LicenseAgreementTerminationPayment
      contextRef="i068115fbd385473eaf14a517d80898f9_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTYxMzQ_1597fe3f-8e9c-4d79-9578-a524256bf4e6"
      unitRef="usd">1200000</sesn:LicenseAgreementTerminationPayment>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="icdcdf96fee1148569a372008cbcbc48f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzI3NDg3NzkxMTYxNDg_fc84dc20-ccdb-4672-ab65-15a7f262b493"
      unitRef="usd">200000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="icdcdf96fee1148569a372008cbcbc48f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzEwOTk1MTE2NzQ2ODE_5c7b876d-c541-4b60-81c3-7f1664ccabb6"
      unitRef="usd">200000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i40dde77c20a24756b6c9849cf8a19522_D20201130-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzEwOTk1MTE2NjMzMjI_1d23ca43-79da-4656-91ba-184978f067c3"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <sesn:PaymentsToRefundLicenseAgreementDeposits
      contextRef="i3078e30e83804e5189a02bd018d21ad5_D20220720-20220720"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzM4NDgyOTA3NDQyMDg_cde0ef46-bbb4-4005-a712-ffbee45fb2fe"
      unitRef="usd">3000000</sesn:PaymentsToRefundLicenseAgreementDeposits>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i4a1663e77ac1498184a0073f406681d3_I20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzE5NDI3_0efb2f9f-c88f-414e-b564-57acc8e23ea0"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="iaa658292b071478aa327ee12757b1aec_D20210805-20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MjQ3MzA_5fb66638-ecdd-4b4e-a8e7-f42853406477"
      unitRef="usd">2000000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RoyaltyRevenuePercentage
      contextRef="ic1294558bb964edc87c70925cf5cde03_I20210805"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzAvZnJhZzo0YTY5ZTYzNDdjYjI0ZmYwODVlZWZmYTExNTExYzk2Yi90ZXh0cmVnaW9uOjRhNjllNjM0N2NiMjRmZjA4NWVlZmZhMTE1MTFjOTZiXzc2OTY1ODE0MjQ3NTY_2e1913e8-cda1-4af8-a9e7-672e980b84aa"
      unitRef="number">0.30</sesn:RoyaltyRevenuePercentage>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90ZXh0cmVnaW9uOjZmNTMxMWVlNzkxOTRjYzRiMmI5MTRkYzdmYjQzNzZiXzEwNzI_87893932-ba47-48d8-97c6-c3437ec037c5">RESTRUCTURING AND RELATED ACTIVITIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to voluntarily pause further development of Vicineum in the United States (the &#x201c;2022 Restructuring Plan&#x201d;). Execution of the 2022 Restructuring Plan is expected to be substantially completed in connection with the closing of the Merger with Carisma, which is expected to occur in the first quarter of 2023. The 2022 Restructuring Plan includes an incremental reduction in the Company&#x2019;s workforce as well as additional cost-saving initiatives intended to preserve capital during the pendency of the Merger with Carisma and while the Company seeks a potential partner for the further development of Vicineum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also incurred one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan. The following is a summary of accrued restructuring costs related to the 2022 Restructuring Plan, (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 Restructuring Plan &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and benefits costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract termination and other associated costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructurings costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring costs related to the 2022 Restructuring Plan were recorded in operating expenses in the Company&#x2019;s Condensed Consolidated Statements of Operations and Comprehensive Loss in the year ended December 31, 2022. The Company expects that substantially all accrued restructuring costs as of December 31, 2022 will be paid in cash in connection with the closing of the Merger with Carisma, which is expected to be completed in the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#x201c;2021 Restructuring Plan&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2021 Restructuring Plan included a reduction in the Company&#x2019;s workforce by 18 positions (or approximately 35% of the Company&#x2019;s workforce as of the date of the 2021 Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continued development of Vicineum. The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Restructuring Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Restructuring costs related to the 2021 Restructuring Plan were recorded in operating expenses in the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Loss in the year ended December 31, 2021.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90ZXh0cmVnaW9uOjZmNTMxMWVlNzkxOTRjYzRiMmI5MTRkYzdmYjQzNzZiXzM4NDgyOTA3MDMxMzQ_8957a3cd-cfe3-47c4-aee8-8ddd7121d59f">The following is a summary of accrued restructuring costs related to the 2022 Restructuring Plan, (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 Restructuring Plan &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and benefits costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract termination and other associated costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructurings costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Restructuring Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="ia82aa374295f472f94fa22a817803cf0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTplOWYxNDBkNjA0OTI0MDBjYmM4YzMxNzZiYjVlZGEyMS90YWJsZXJhbmdlOmU5ZjE0MGQ2MDQ5MjQwMGNiYzhjMzE3NmJiNWVkYTIxXzEtMS0xLTEtOTUyNDM_107e6244-509c-4e82-a393-32e997f726c9"
      unitRef="usd">6976000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib391d9ecf3114b2c994998943181cc31_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTplOWYxNDBkNjA0OTI0MDBjYmM4YzMxNzZiYjVlZGEyMS90YWJsZXJhbmdlOmU5ZjE0MGQ2MDQ5MjQwMGNiYzhjMzE3NmJiNWVkYTIxXzItMS0xLTEtOTUyNDM_1f19992a-9296-4f9d-8928-3e9eb55d7569"
      unitRef="usd">4788000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i712c5f7e1c9a4489a1932903418a4389_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTplOWYxNDBkNjA0OTI0MDBjYmM4YzMxNzZiYjVlZGEyMS90YWJsZXJhbmdlOmU5ZjE0MGQ2MDQ5MjQwMGNiYzhjMzE3NmJiNWVkYTIxXzMtMS0xLTEtOTU1NzE_4efcb9d9-5f6c-4ed9-acb2-47c2507325a3"
      unitRef="usd">11764000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i712c5f7e1c9a4489a1932903418a4389_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTplOWYxNDBkNjA0OTI0MDBjYmM4YzMxNzZiYjVlZGEyMS90YWJsZXJhbmdlOmU5ZjE0MGQ2MDQ5MjQwMGNiYzhjMzE3NmJiNWVkYTIxXzQtMS0xLTEtOTUyNDM_99858c2f-8690-4775-95a6-df75c1699e58"
      unitRef="usd">6031000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="if2ad0b07f8ff40c5a4c7df314a525778_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTplOWYxNDBkNjA0OTI0MDBjYmM4YzMxNzZiYjVlZGEyMS90YWJsZXJhbmdlOmU5ZjE0MGQ2MDQ5MjQwMGNiYzhjMzE3NmJiNWVkYTIxXzUtMS0xLTEtOTU1NzU_3159ba9f-a7ce-4f42-83a5-0c911f3f0413"
      unitRef="usd">5733000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="i5532051f20ab4b50a0fedc0c29b03429_D20210830-20210830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90ZXh0cmVnaW9uOjZmNTMxMWVlNzkxOTRjYzRiMmI5MTRkYzdmYjQzNzZiXzcxNDY4MjU1ODk1MDI_f60aaf7e-e37b-408e-b135-9b1fec6ac6b7"
      unitRef="position">18</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i5532051f20ab4b50a0fedc0c29b03429_D20210830-20210830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90ZXh0cmVnaW9uOjZmNTMxMWVlNzkxOTRjYzRiMmI5MTRkYzdmYjQzNzZiXzcxNDY4MjU1ODk1MzQ_1c26456d-1aba-4a05-a509-823de5dc126e"
      unitRef="number">0.35</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringReserve
      contextRef="i6a787f6e1c15471ebea82677593dbf11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTo2NjBhYTMzMWE4Mzk0ZTQ3YjEyM2U5MjA4YmMzMzdmMy90YWJsZXJhbmdlOjY2MGFhMzMxYTgzOTRlNDdiMTIzZTkyMDhiYzMzN2YzXzEtMS0xLTEtOTkxMDY_884e0ea9-13cd-4eaf-923d-cf16f3fc2aa9"
      unitRef="usd">1497000</us-gaap:RestructuringReserve>
    <us-gaap:PaymentsForRestructuring
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTo2NjBhYTMzMWE4Mzk0ZTQ3YjEyM2U5MjA4YmMzMzdmMy90YWJsZXJhbmdlOjY2MGFhMzMxYTgzOTRlNDdiMTIzZTkyMDhiYzMzN2YzXzItMS0xLTEtOTkxMDY_850e1231-717a-402c-b088-68598148e7b6"
      unitRef="usd">1497000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzYvZnJhZzo2ZjUzMTFlZTc5MTk0Y2M0YjJiOTE0ZGM3ZmI0Mzc2Yi90YWJsZTo2NjBhYTMzMWE4Mzk0ZTQ3YjEyM2U5MjA4YmMzMzdmMy90YWJsZXJhbmdlOjY2MGFhMzMxYTgzOTRlNDdiMTIzZTkyMDhiYzMzN2YzXzMtMS0xLTEtOTkxMDY_753012a9-bd46-4da7-9d1b-a28fdf763e4b"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkNzU1YzIxM2Y3ODQ5OTRhOWQ5OGI5ZTRlYmRhOWUwL3NlYzo2ZDc1NWMyMTNmNzg0OTk0YTlkOThiOWU0ZWJkYTllMF8xMzkvZnJhZzphNzM3Y2QyMGU0ZDk0NGVmYmIzZjhhYjkxM2E4NTU1YS90ZXh0cmVnaW9uOmE3MzdjZDIwZTRkOTQ0ZWZiYjNmOGFiOTEzYTg1NTVhXzI5ODQ_0b71ee3f-cf93-4b81-a80e-636ca30c483d">SUBSEQUENT EVENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nasdaq Delisting Notice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger with Carisma, the Company is seeking the approval of its stockholders to, among other things, (a) issue the shares of its common stock issuable in connection with the Merger pursuant to the rules of Nasdaq, and (b) amend its amended and restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of its common stock at a ratio of 1-for-20 (clauses (a) and (b), collectively, the &#x201c;Sesen Bio Voting Proposals&#x201d;). The special meeting of stockholders in which the Company&#x2019;s stockholders will be asked to vote on the Sesen Bio Voting Proposals will be held on March 2, 2023 at 10:00 a.m. Eastern Time (the "Special Meeting").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2023, the Company was notified by the Listing Qualifications Department (the &#x201c;Staff&#x201d;) of Nasdaq that, based upon the Company&#x2019;s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#x201c;Bid Price Rule&#x201d;), the Company&#x2019;s common stock will be delisted from Nasdaq unless it timely requests a hearing before a Nasdaq Hearings Panel (the &#x201c;Panel&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company requested a hearing before the Panel, which stayed any delisting action by the Staff and ensured the Company&#x2019;s common stock remains listed and eligible for trading on Nasdaq pending a determination by the Panel. The hearing had been scheduled for March 16, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 24, 2023, the Company received a determination from the Nasdaq Office of General Counsel that the Panel granted the Company an exception from its non-compliance with the Bid Price Rule to complete the Merger by March 10, 2023. Pursuant to Nasdaq Listing Rule 5110(a), the Company must demonstrate compliance with all initial listing requirements of Nasdaq upon the closing of the Merger. The Company is seeking approval for the Merger and the implementation of a reverse stock split of its common stock at the Special Meeting. In the event the Company fails to establish compliance with the initial listing standards by March 10, 2023, the common stock will be delisted from Nasdaq, unless granted an additional exception by the Panel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, on January 24, 2022, the Company received written notice from the Staff indicating that, based upon the closing bid price for its common stock for the previous 30 consecutive business days, the Company no longer satisfied the Bid Price Rule and, in accordance with the Nasdaq Listing Rules, was afforded an initial grace period of 180 calendar days, through July 25, 2022, and a second 180-calendar day period, through January 23, 2023, to regain compliance with the Bid Price Rule. The Company did not regain compliance with the Bid Price Rule by January 23, 2023, which resulted in the Staff&#x2019;s January 25, 2023, determination.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #% 7%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  Q0%Q61\("F.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TE!EM#-1?&D(+B@> O)[&ZP:4(RTN[;V];=+J(/X#$S?[[Y
M!J:U2=F8\3G'A)D\EILQ='U1-FW9D2@I@&*/&$RIIT0_-?<Q!T/3,Q\@&?MA
M#@B2\UL(2,89,C #J[02F6Z=53:CH9C/>&=7?/K,W0)S%K##@#T5$+4 IN>)
MZ31V+5P!,XPPA_)=0+<2E^J?V*4#[)P<BU]3PS#40[/DIAT$O#T]OBSK5KXO
M9'J+TZ_B%9T2;MEE\FMS=[][8%IRV51<5G*S$XWB0HG-^^SZP^\J'*+S>_^/
MC2^"NH5?=Z&_ %!+ P04    "  Q0%Q6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #% 7%;NFPT7\P<  #XQ   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9MA<^*V%H;_BH;N='9G0K!E(.PV889 TLO=)J4A;6?;Z0=A"]"L;7%E.23_
M_A[98..,$'9'? D8?%Y;#Y)\7NGD>LO%]V1-J42O41@G-ZVUE)LOG4[BKVE$
MDDN^H3%\L^0B(A(.Q:J3; 0E0184A1WL./U.1%C<&EYGG\W$\)JG,F0QG0F4
MI%%$Q-LM#?GVIN6V]A\\L=5:J@\ZP^L-6=$YE;]O9@*..H5*P"(:)XS'2-#E
M36OD?IEX Q60G?$'H]ODX#U235EP_ET=3(.;EJ/NB(;4ETJ"P,L+'=,P5$IP
M'__;B;:*:ZK P_=[]?NL\="8!4GHF(=_LD"N;UJ#%@KHDJ2A?.+;_]!=@WI*
MS^=ADOU%V_S<;K>%_#21/-H%PQU$+,Y?R>L.Q$' P#D2@'<!^%V >^P*WB[
MJQO0W05T,S)Y4S(.$R+)\%KP+1+J;%!3;S*8630TG\7J=Y]+ =\RB)/#,7^A
M K71[_,)^OCA$_J 6(P>6!C"CY)<=R1<0IW8\7=RM[D</B+G8O3 8[E.T%T<
MT* JT(%[*VX0[V_P%AL5)]2_1)Y[@;"#L>:&QN;P>[JX1#@/]S3A$W/X?],8
MKN[HKEYIC5?@]C(]SXC[[]$BD0*Z_#\ZPKE"5Z^@YH$OR8;X]*8% SVAXH6V
MAC_^X/:=GW1T;(I-+(E5R'4+<EV3^G#"_13F&XF>WS94A\T<[CKMKSH^QJBF
M?"R)5?CT"CZ]>GQ&<9R2$#W1#1=2!\JL(T6JPSLV1C4%94FL JI?@.K7 S6C
M@O% 350(IDYMGSJAM)^:CLY-QOBFT"R)5:!=%="NC$T=IT(H9O<L\:%S?:-$
M&,&9U=IM%[<]5T?,&-B4F"6Q"K%!06Q0<[X2!+*D+,DY/B;-6DL2)MI!:0QK
M2LN26(76YX+69V,+[V+)Y!MTKY"BQS1:4*&C9-9P'+?M]?'GOHZ4,;0I*4MB
M%5*N4V9L3AU63W3%5!8!7>R11-I1>$)H#C<7HUO&+] T]B]UV,P*3;G94JN"
M.TAUW3K@H*U<P$ D:DQ>H+F$.0QQ@<8\C:5X@]= 3].L/KG3 C0&-09H2:T*
M$)< <1V S^0530.8V]B2^1E%PY@](8G[;7AX]OJN=M2:@QO3LZ16I5>F_JXQ
M/][3&P4!J"<7^S?H%S@/_1KK^YQ9$G=[,&>*1$(O%F !M0RM6@!;:E6&I0EP
MS6F\D>'SEFL9FB7G*8/Q[PX<1TO/JD&PI5:E5UH$UYS;OZ<W5D<P\SWS;:PE
M9Y8;DV@A6+#2IB;FV,;@SN$8W-(RN.9,_SVXXIDQ$_R%Q;Y^[)HU'T9:;%8M
M@RVU*K;2-+CF//\]MAE/)+B'O]CF^$/6K.A@MZMU6N:XQMS.X1S<TCJXYGP_
M&Y<C0<EQ3&:!OGNEA635+]A2JT(J'8-K3O=_X<J)SM8\-EF&$R+=;K<]Z/7T
M4[]5SV!+K;J(6IH&;,[UGYD$:\67R,4?%Y_0G/JI@%ZF0W9":<RC"#*^N>3^
M]POTP;D$WX4V1* 7$NJ7CLR"34':4JN"+$T$-J?Y8.<#%J_0_"U:\%#+SRPP
MOYL_:BE9=0JVU*J42J> S6G]OG^ANU=_3>(5/>I13P@]CN:3T6]:7E:]@2VU
M*J_2&^!:WN!/&H;M[S&D8S!"20)36X"F29+JY[83FH^Z;'AL#FJ,[1QV )=V
M ->R W_P$*P[$?D"DM#N6YU0.@++:O9O2ZT*J\S^<:WL?[^4FR]&9E,99+.I
M'II9\1O518W-48VIG2/UQV7JCVNE_M-84I%O4JM%;[+'J*5F5CQ&S6KF;TNM
M2JW,_'&MS#\;CF@,9FG%A3[9,.L\\KA-?)^"#(@$N:"6GM7\WY9:E5Z9_V-S
M^KZC-X](&*+;-(&O$_WX-.L<V\LSAS6&=0X?@$L?@&MM'=Q%5*S4;/8S*,@U
M.*=H0V)]GS,+'MUM,<<UQG8.0^"5AL SI_'3\?T3&J4!DUR@D904K'FVE'L?
MDI6V+,&L=Y2:.:YQ"<(YLG^OS/Z]6EL(\S4D:J8N=D+F."RK)L"66A56:0*\
M6ML%LW01,A_Z%2?:QZ59I7'!BU5;L%/K96JJANYEZ/;=R_YUYT6'YJ ,J%:^
M7_72\S6!6T*_IA+&8JQ<IA:7W?J@7*U_T$#L>-W/&#NX:.2.Q3ER?:_,]3US
MAK[?4$\.-O @(UBHG= EA5Q,OPI[0G6F<F >)VII1*XI$L6NZH\_#+![]5."
M)G3)8I9E?C/!7]_RU=]L;U_0D&0IM.19M"HRVQ?@/%":?07"V>^[YF$ W@1]
M;&5GO9-J?5++R21&8)/C(!//-%E2+>A!:H;F(D*JH E!?T'L'0VQIP'?@,2,
M0-!T.LT;:):[1,\5!&C+8)I;JDWYHG7O$?R+N]XR>#XKP=TJ 8-.#_V]7"M0
MPX(E66FI.I?%R,4."LA;]C--J$_5<E]1%:C=N3;_[HWG@7-8-Z^T;EX]ZP:
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ME)G\QIX_TR:@0/M+6":J3_#<8+T12$HA6=X8*P9Y6M3?Y*49B"T#Z \8H,8
M'6J &P-<!5HSJ\*Z))+,SCA[!ERCE3=]4(U-9:VB20L]C0O)U:^ILI.S^<W7
MQ<WUE\N+NZM+\.GB^N+K_ HL/E]=W2W $?B^N 2_?_@#? !I >Y6K!2D6(JS
MB51WUO:3I+G+I_HN:. NES0Y!AB. ?(0LIC/#S>'N^83%6\;-&J#1I4_/!1T
MR3DM)"!"4"E.;/'4#GR[ [VW3L2:)/1\I#:/H'Q#1[./O\'0.[5%]T[.=F+%
M;:S8Y7TV)V(%U*R!1!_0'V6Z(9D*WCJ+M:NH<J43P&8&(0H"?#;9;,=C@84H
MQ&$+VV'JMTQ])]/%BG$)).6Y6N#\B4IRGU$@:%+R5*;42KCV&&XQ"7P<ACV^
M)LJS4PU:JH&3ZC<J)$\32>MAM3$+C'LBZ'E>CYF)&F 6MLQ")[.+)&&EFEV5
M8A.JIEH-H77@0L>-:VHF0@4 H9U>U-*+G/1NY(KR?=PBX\Y3%/38F1CL3Y&=
MW+0E-W62N^5T3=(EH"]*) 45U;9A%>-D)V/82$\-0KXQVR8&3OUH8-O$+>O8
MR?J.29(=0#"VW#R&OM_C:,*0%X1>8"<)O4YG/&?._<J*HV1_WFV\O%/B?2]O
MNS%O:2O\U331>-A9R/UE8\&@@30!.PF$3M51BUV5@ER^5HM<R\):%6=R# HJ
MK3S1WH1A@?AX@&:G7M M7U\*28K'5"O!\-)N?#C)F1#H1][0,'::!=VB]1=C
MR^<TRZRT7+K3T#(A$'NA/T"KTR?H%JAK5CS64KKN)34K49<,-41-2 3C@80+
M.[6";KFJ]< QL_MUR@*!:&C==3H%W4)59]7"2%I6DA8Q,EA:, 'TAP:PDRSH
MUJR:Y\4P-YOFQ##JIWT+#OE>Y$<#!#MU@O%!M7:6DOLTJPHY>^)WJMQ/)_YW
M\K;;7G1BAYS"TE5A:_*JRQQKA^'9UFV_U+:@T#086-ZH4R;D5B9%D)?4G160
M17;B[2J_86C"5+DV4"^@K1;-K4\W.W77UNJQ4C6E!\)^R6@!^>&  *!.H)!;
MH';+KWT\317"7CSM;T8+3(433@>X=F*%_(-KL'W[$3EU[Z<[X'?RMAMX)X?(
M+8=S5LBT>-1Q)ZP0Z9)RHI\B60/?+X862("\H6("=6J(W&IX21^HFITED.2E
MG:!7*\G]NFB!X#B,!SAVPHC<PMARY'1#B]*>VDRQ,]B9$!@,CF GA^@0.2SL
MZ]Q*U=0]@ZH)"2)_<"0[942'-&[7>_B9_9@U8YBP,/;P@'KC3LBPNVM;2)8\
MK5BF-HSX^-L4P>@47*EF0;Y:DP9^U^[MO;SMQMYI)'9KY"U_6^I"C\(8?/".
M/0\J3>=@0[*2 M5  ;$BG)Z"8*SVO_ZO+PA 2KEB//U/F1,)+FE"\WO*:WIO
M3T*KWDL_TSQ52_;-,!5"*W/U[*&40K4_2Y6Z#G!BG1!3G/O+VPG9';I.O+%;
MO.<LSUEQR+CY]:C]PLBISW$4Q&//Q]55&,=C/\3CT ]^>4C'*LN)-:U>-636
M1(S-HD(9]H?84I[$ _D#;SW8=5<>%\MEJD5,)1'=X1VE!4C(.E5)Q4K4K"G\
MV ^C?I5DPTVC:*CXP%WQ@=V=LBHYR[S,B'X:LJ0/:9):'S1@LR,^PCB$/NP3
MM0%AB(*AI-=5"]A=+32E)\M56EGI-U8;"C(F[$_,S5+@*/#[-;(%-;3'NF(!
MNXN%6CZ&$[25K:57#J8P-G*"!1>IOR'27?6 #VFKMS2OVFH_&41DOGZPM;06
MG+6EG6R]/=.O+O\F_#$M!,CH@S+TCB,U>;Q^&UB?2+:N7JC=,RE97AVN*%'D
M-4#]_L"8?#O1[^C:=[*S_P%02P,$%     @ ,4!<5J0@A:)N P  71   !@
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M2$_Y=L4HE!DE@,^7G,O7"_4%S6\MT_\!4$L#!!0    ( #% 7%:>V.IMZ0(
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ME!9":1&4QH_M>?&.\2X+HD>RH!YW"FU1^T>[D>W(H;E9L/=]W]  "$H+J!H
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M9II/15T7J\W+^R1>)F6[0//Y;5'47]^T7W:S^PJHR_\!4$L#!!0    ( #%
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M</ 0Y)WOTVM8M>DPCBKM5.HMQ33:&#*O9+P$%YLXF QATU@QZ$\GSY_/?NG
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M,VOZ$UMFM,4!\/O"F,Y_P 7"/S[ST_\ 4$L#!!0    ( #% 7%:CQ"'FNP4
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MT? ">I]H[;8##K"[MX[^!5!+ P04    "  Q0%Q68??NU@T)  #S&0  &0
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MI0 V"YI77Y=G;\VDVD^VC<9Z1FT?Q(G1&1A*@T[ C?,=-2(A5I>&$F&10A6
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M[0[0_E+1'=I-G('F_\3P7U!+ P04    "  Q0%Q6['^[! <$  !7"0  &0
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MNPW;!,P<>G5>MBRZ;(20%I>=WJ3#[WI)"&##F35M@.=J$ .DS4*O-QQO'BL
M)09JR 1Z:4C$QIHJZOX&Z5PKN16QA2,+.%1:X0)J6DJ#6"2J$(GX<Q.JQY!L
MHYH=VUBP]XN[I^74G3S(2-<G"44;R#EX@C_ +(HI^(=TM@ &!O;+;U76WJIT
M>'ZZ5*>KA#!.NB@6OC^B<*$%7$_<+2OA TU#A6VV2 7:5XSGN*W(I7@ R:?J
M^*'&O'-A&Z,AS+ZHRW(8T"%:1QJ"07+RGZ0=&\9D^/9_EO9<;QT]&G85VVT<
MZ8YBP;5SKU_MOQH6[; \F;>?'!^%W4KM2/$&KNGPV[<)V7:,MR_>U'%TKHW'
M((Y_2WSYL T&V-\8X[N7$*#_EIK_!5!+ P04    "  Q0%Q6_82'[NX"  !M
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6R5E=MNVS@0AE]EH!9%
M @31P8X;N[:!'%QL@2;K3=)=+!9[04LCBRA%JN0H3M]^AY0MIX!C8&\D'O[Y
M^ \ICJ8;8[^["I'@I5;:S:**J)G$L<LKK(4[-PUJGBF-K05QUZYCUU@410BJ
M59PER2BNA=31?!K&EG8^-2TIJ7%IP;5U+>S/:U1F,XO2:#?P(-<5^8%X/FW$
M&A^1OC5+R[VXIQ2R1NVDT6"QG$57Z>1ZZ/5!\*?$C7O5!I_)RICOOO.EF$6)
M-X0*<_($P:]GO$&E/(AM_-@RHWY)'_BZO:-_#KES+BOA\,:HOV1!U2RZC*#
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M_P.T7L#SI3&TZ_@%^C_,_#]02P,$%     @ ,4!<5HF+9_@)"0  (!@  !D
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MNRU,Q,_/>%B* E14-[ ]]8_.-H+Y!0NN&SEW=R+JMCFEL<1 1K]6J%5_C@6
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M"AL6%8G^?C3L#U#TYGE,G8T=1>D&W4.X5%_FH1'A]J)W[G]P[;2AC%NUJ%(
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MZ'?"KE3)DWX)5?:XTPRJ[8LW5=@T%\9C;PV//!.D90'<\VZP?6$#NW\])O\
M4$L#!!0    ( #% 7%93#.FXA1   *TS   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;,5;;7/;QA'^*S>LVT@9BN*K*?EM1I'EB=,X=BVGF4ZG'X[
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M\;D^5B7\]G#;WGC: MK(9#E*>N4V*<![:=>2\G2)6R1DL DS/DZQ]/6^,]R
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MB[?'-+&0MML='D"!!<4PR.0%WG ;B5CM5N!FJM1P*3#4UY#_.CD=!_N5Y<G
MXFP8'2-K9K[3:8IN4T$!&WHZ2>)I]Y'-/AV/T(:Z)PMBTYE2M5"6B%GCU%?
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M)J;;S5O#7MO^MH'<*^&H]=>BGMH\8'PV[;B0-O K@@U=280L\%,3BJTG%'=
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M&EJ [^<-2#I\H WZ_T_Q\K]02P,$%     @ ,4!<5K+1MTRM$@  K3T  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULY5M9<QM'DOXK';!LDQ$@"("'
MO*:D")"F;>Z*,E?73LS&/A2Z"T"-NKO@/DA!OWZ_S#JZNM& H)EYF(AY(8$^
MLO+.+[,*+YYT\:E<25E%G[,T+U\.5E6U_OGTM(Q7,A/E2*]ECCL+762BPM=B
M>5JN"RD2?BE+3Z?C\>5I)E0^>/6"KST4KU[HNDI5+A^*J*RS3!2;:YGJIY>#
MR<!=>*N6JXHNG+YZL19+^4Y6']8/!;Z=>BJ)RF1>*IU'A5R\',PF/U^?T_/\
MP$<EG\K@<T22S+7^1%_NDI>#,3$D4QE71$'@WZ.\D6E*A,#&GY;FP"])+X:?
M'?5?67;(,A>EO-'I_ZBD6KT<_#2($KD0=5J]U4^_2RO/!=&+=5KRW^C)/CL>
M1'%=5CJS+X.#3.7FO_AL]7#("U/[PI3Y-@LQE[^(2KQZ4>BGJ*"G08T^L*C\
M-IA3.1GE757@KL)[U:O7=S>W;][=1K/?WM[>WM^^>?_NQ6D%NG3W-+8TK@V-
MZ0X:DVETK_-J54:W>2*3-H%3,.2YFCJNKJ=[*?XBXU%T-AE&T_%TNH?>F9?R
MC.F=[:#W1[$4N?HBR!&&T8W.2YVJ1!B_R)/HH9"ES"MS02^B7U4N\EB)-'J'
MBQ).6)71_\[F957 C?ZO3T6&@?-^!BBT?B[7(I8O!VM:JWB4@U<_?#>Y'%_M
M$>_<BW>^C_J!1MQ+HY_#;<+177[R6L6(2AG-EH6TNMFZ!#>N5M%?ZT+%J^C]
M2D+IV5KDFV@ERDA$J7U>M)^O\."''&%:E*K:D"4LA:.!^3 XCIY6=&%9"%JW
M"BC+SW%:EWC94R\H),MA0YLO1)5&#IK;AX;T-1.?\&$E\&XF$GRLB3<X!M)'
M&M7PZB**95$AR45K. 0MO2X4TIA*-U&B"N08F1"E@*$?P9XHEK)2^1*"XJ5A
MI'+PF/"%/+I=W\SNHWB%)%<(7JZ0J2!"*LOJ7,<Z_UN]Q(62;V:R6NFD)*TX
M]C*1UPMX9%U(NDR+ER*3T1%]^N&[GZ;3\975X):%^/;DZGA$YL$-)U>LH?ZH
MU"#S26XB4:XA'*_Z4<5PFCH;11_6B).VJ%"!5.O*L7'S]C4N+47!PM*5Z]>S
M"$7$4^$O=*-",:G8!_#N]<UO)W4.!\0*;,LW]W?7-\.6H><R)B$U3+@45N]K
ML8F>C4<7R)%I2E$,2PGZ(I%"<Y)NPTO@4:.04<LK%52<EGJ;9KVF3R(Z_SXJ
M]$:DY)5&]!P5<UWHI(XK*!WKL$#VBE4CZ,SQ0A$:*H'UV &L0<,G1?0HD)BB
M.!4J(Q%H(6M 8Q_KTZ/H+7.CL*Q^,NS:YYZ@ *@(V@<CY$O&()6ND,Z<# 6(
MF1>Q:JC;A@[Y%UW1N$V&4D4"'HJ*E349?T]B+<ETLAB2V(\J(3Y6HC*A%J[4
M4,V@TUQ7Q"!41@&,0)A^3Z8GA;(BC6FL*<B6UA:%%YF-2\RHN$X%8E/7>550
M"E@C%DM8S1J)+]BT#B%D@1+JLSP]D(K2^VR?HHU ;"*3;0)+FC0!NL0U$1'.
M_"P!8A*:RO77)7'L&U/Y]T)?Z++A/ ^K>T<"!PUW+NQ"CKR5$:RZ('-!/Y05
M.+P1/F<^?,CZK7ARJ8FRI;0Y#?#G$;!NS9'E8\T$*S)LILHR4+5=G/+.Y/E5
MR0G!9^9??YF1+E#X93:'OZ'PCX?&!RF/P,J5AH8ZBW1)]B2A1:&S<(59O02J
M(OJ %Y1G)./"=#/:5<3N50P:<,[M,O:U-V:_H7*Y;X/C(:SZQ'Y+',XRU(0A
M"FH\&K:KFJKP8-[4LU8=<W6H*6'^/B6@3UCB9(5E2'<NIXL4X)M,!GNG6C5
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M%HJI=!MIW#ND<>;%>]OFR>CY1;=SO@.7B<E+QJ>@3+G4I+N0<,FQ[! 1F+]
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M6V^C0R0Q]SE21/3L/%!,N%<0ZI$+D/QL_?10C1E_(=TT74O9[% 1.*R#?I'
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M?C$PQ<U]J?2:?Y [UU6E,_ZXDH!D!3V ^PL-4]@OM(#_A?:K_P=02P,$%
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MV1455]B#?5.UEE/.6K&FT3'MT\UOA";.7(>8#T "MMU-++F#VK_OD-]ORCC
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M=Y3.]G,?DMD+>[.S9NH5!6BEA ?_WW^&PP=<0#G$SR;K2!-_Q_WDH/T8/PX
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M$7HE[0)7#."HA_[-J^QMO^:V<NE.0"]44OQ1*CS,M&3Z?O?Q.K2O)%W97.=
M\SG#/7UE*P_8'YAYC+]*,O^J E-I/V7JT_JD?U_-U)^KU0J<H'+Z1BNYIV6_
M=O\7*A4>KAV@"_SB;BJP0(K[C;;6(&VC\G"C:[FD+=YPK*J]WTZ)!E1 -2ZV
MHPJQ0P4#:4T=)L9[7I&K5'!A3"+N]+B<_]]MP92L*#\4PGF3-!I6YFJHN"_*
M/%"=FOC!0[_[4CZYADN\=_Z*T3RDZY8CR_H?1GA2N*N:#&0K'A2F$!Z=/O+!
M']AT#H9\:'7098>Z@1RV^1-WSOZV@6P-15[!':5:/%+*G(MAA@JZ1$23.+L.
M!:NN6('PY-+7J HN6"<]PHIJ3WV?8NHR-JW9@H,X/U$7TN25Z:'L+1#[]P^>
MJL4)*.=>Q4)\&K"[C<6SW _#4AE5%+Z(X0\<'RW&4_!S,E<R7ZZ" (%>&H'O
M_HFZC*K-Y:)HFC;' OHRALH,:QP?@1K$)X@2#TV>\. $IW57*9;V'N TZ,B&
M92TDTH<GB<"-J(%BO*A.4R+ $%1#XTA)H P_89;D<_ Y5X%7+]-JVG>$\/<N
M7'TVD,?O9?U3$R/FK"$VWPR]P2 FFL$%FOXHNSBLM3242D4$2%@RJ8P7SO+#
M&_S0S>&SBL;W8"FKJ&A9Q)GV%TZ->SCX+1-)@;P[.OR_!M$FU>VHZ*EC=^(\
M"!<U',8=1Y!L\V78TW/>Q[Y*7H41]5$DY08XJ46)'R*RU(1?)C[P-E KA6)<
M5C]X5KXPVPT@1//:+^*<(LD0OV+/T@^:;K!GE#*K5/D\V!FTBR@N9A=O;7JQ
MZD\IS$+$-D3RN+BXFLWPOK[D(VP8O(@=I/ZUHFIAZCD8Y7L&K4?C(<RD6;!@
M> ! JXWX*^%41M:E^,$QR'"B$3=+*BW1[&-)@N0^',\IC?1I>-\QB'R!BT*,
M8UU97P7HV'QA&E2'#=*19'5Q^(F/: Q$KSW;Q_OM@T9D]EG&,=!QMW"!+A U
MKFDL"1'+)@Y&+L*8ZOGA =/GR8C?-^ M#]KFW[J(2K\B+]R+9/30>9APE*WM
M7\Z$['S?\3#TZ*1B+YVBOI@NC$ 6C\C-0$;-.C@$.X5C+!X>1<('0,'@.$5X
MJ8Q,=G_P_,(4Y/GA,<A7/*$J?I\8F,95)X4YPZ=Y>,DS,2-ITNMBD8XP.Y71
M8&?7SUV2\.SZ(X6[\=<I6I8OS))Y8/$4_V1&.J]*U#JN\)+5^CN)W1]?=\N6
MJ@P?/#Z=+DY/I.BCMK?2;DQ.D,EQ7+@L?2ZV%1WL2^S:#UFZ=W<EC6W&&=1^
MZ2?SA],'IR<_Q,C"^!9#UM(PG8MHLC\^,GF(/OB<(\2#X.#H1,U4]%GYS$+C
M:K2VA?E,R9I^P0@&@A T< _H36<(HDLMK@9?0<!3_->:RAUJ&I'6^&*5$ 9T
M0ZLQ;GU9U:EP%=V/X]AXT565=;[\[Z:SN7_93Q;AR_;PE?LC$T<E5,[+K0DZ
M38I.C%?'PP<0@U3.1'"YF4I%Y^K%J9%LZTKXX0A>OL<! 0[:OATMR3PWTL>%
MH>UJ*EM"3Y 3FKY<<WBOZ>%BZI'B:%;::CEX'R+T/,\ZS"X2[])UPW-HK D&
M4-68WN5+ Y1/?II>82&SES_2K3,7?W7M^A5=)Q%5%6 K/(]+RGE.1FW =/+Q
M4RHSZ(T.$!G08AN1/WU:[- B$1X2]U/F)X*)VJND="^PVBLS#93NXE6ND;#A
M=&447W1G#-]-F1(DHDPSHD(C*Q7&7.I=-(IQ1([-IZ</)M041R3V'A!]S23&
MM="+1Z<GB9R[)*2X9B*:&O\9!4QGFS5S1RKB'N+]<:&)K$,E+6D%BCSR\?S)
MR>2?*A8O$ UAAG]?2HH(2G<*/[BW*M*Y8/Z/[!>\C1\U/0]O??DKZ%1,/YXC
M;WGA[R0G8CV6G/@9"Z9K>;^%K]=O,*6#RH3G*2(9I;#K%/9-'V83P[R*86;Q
M,XW>5',G,&<4.'8PKV@5C6)\ OH=[>VV.5'2F(&-!&YH5/S2&^+=&)H8F'3?
M__)"9?M[),B_N'Q@JT2F?D9$M$UL*A$8/*D-@=V9-NPLN)S][E\>LRF9LM@+
M!"CZT['2J5A??HL<O;Y1LG2$>GOX/6N+\.*$Q>%W'+S"JI&?R>>/@E=#=N7A
MA8:SG$@RZ727\"8DBAGOO1*I3M^0-?$5B[Y>-W(KI)' O0+1-:11NC$J,QBN
M]!H?'1GY;"X?&8IKFM'.%_$1YM%<$%O'!=E<V3+SPG:D]6/8#$QRCNFK;*2+
M6]'[KJ;<:^X'5+#0HO8QV_K\D50YN=D.LO!^C_'0R(N]Q:1R:G^(!F($ ]";
M_J4#$S=8OO KNV@+352--0XGI\L;B2HW/RB>VS%7H/$$"'KU [W/AU_DP]T!
M%''.>DBV[M7>KG=^(NLMOK0>N  6=-GAU9X>!&1\%;D]#:CQTD_%\C/%U'70
M1P.>[D@OV !XA':JY,6?XR BXS2O20'W[I@-)@SO1>\+WYCZAMZ*WG#ZB%\=
M[K]5[LWK9_R^\7 YO[;]4M<W^.:BPJS@UM/9XX='W.KA/H!)0V\?!]>GK3;T
M)Q:6FQHO@-]7%6!7/N #_/OHG_TO4$L#!!0    ( #% 7%;MY<QD% 0  . *
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;,U676_J.!#]*Z/<U=U6
M8AL(](L+2"EMM4AM;[>4[L-J'TPR$*M.S+6=<OGW.W9""&V*[N.^@#]FSIP9
M>TX\6$OUJA-$ S]3D>FAEQBSZON^CA),F3Z1*\QH9R%5R@Q-U=+7*X4L=DZI
M\(-V^\Q/&<^\T<"M/:K10.9&\ P?%>@\39G:7*&0ZZ'7\;8+3WR9&+O@CP8K
MML0IFMGJ4=',KU!BGF*FN<Q X6+HA9W^U:FU=P8O'->Z-@:;R5S*5SN9Q$.O
M;0FAP,A8!$9_;SA&(2P0T?A18GI52.M8'V_1;UWNE,N<:1Q+\3>/33+T+CR(
M<<%R89[D^D\L\W$$(RFT^X5U87M^Z4&4:R/3TID8I#PK_MG/L@XUAXOV)PY!
MZ1 XWD4@Q_*:&38:*+D&9:T)S0Y<JLZ;R/','LK4*-KEY&=&M^'D"5["N]D-
MW-^$T]G3S?W-PS.$#]=P.WD('\:3\ XF#]/GIYG=F,+1,YL+U,<#WU!X"^)'
M9:BK(E3P2:A. /<R,XF&FRS&>!_ )]X5^6!+_BHXB'B-T0ET.RT(VD%P *];
M%:/K\+J?%8-Q!2],Y C77$="ZERAAG_"N3:*[L^_34D7D+UF2-M3?;UB$0X]
M:AJ-Z@V]T=<OG;/VMP.$>Q7AWB'TT91Z-,X%@ES F"FUX=D2PE3FF=' LAAV
M&6EK<\LSED6<"9ADE%).W46&]\ALHG%3=@?C-V?WG" LI*!VMVR,NRZ@25](
M0DP"AK:C+5=6X[JP7-\JKM9N+-,5RS:_:UA4S'F->5HR!V9J[F"[G10CRI6R
M0:AK.85PJ'1E,)VCJJZ-"TV##ASQC(+*7-.*/NXWF-;N1UDS2P.N2!5B&_3=
M$=3M_\JE(:-'Q2-*CR*%3HY@RI<97_"(D?EW2EG!][FMHZW:WN8LD[N-4%,]
M=9\"Z@3P1\XI;UN0ONTPW)! J%=;\)PR@=_@_*QU'EPT#KY^N0@ZP;?:Z-[Y
MNC#:EI ;C@0\F\)2OJ'*7,J['?+L7;9ZW4Y]L$/]L$0X1KGB;=ZAM"Z[I[7_
M&L:[E?<'T_G_'4SC,73.6MV+H''P\1CN.)MS419_3+I)]&U.D:0/8HR*N8_:
M'R"D;3)4*?F>!JUVNUT??,2M-@_(SVDE/Z>_+C\[BN,]BMM$-DWR<A#_E^7%
MJHLNY85MWQ=;#8D21K3 -3?NJ<1[C3'2D+Y$G]5:;!-I[72G66D,((L26E\1
M);N^0L5EW+(47<P-,@5HOX(?5>:$KJT@K4.+\_&J5^<WKO+:S^E3_O6[<E2
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M69HLWDQIE*-V&VA]J93=.2Y!^>?0^P=02P,$%     @ ,4!<5B5"7U7Z @
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M7LQI:Z-V#G0^5\JN%9>@^1](_@-02P,$%     @ ,4!<5N&RA]P/ P  ; 8
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M:4'_ M3.@?97BIY!:[@$W=]E\@=02P,$%     @ ,4!<5L383S/E!0  V X
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M@X=BBLY7ULC4!<'97:J,M/&RU&J%RDN4-]YOE89C^%JY^4WI-0W4)LX_W 5
MI$>3%6;W0KP<N!5T2R*7)XN%%@LL9W"-@"V:<(%X01 VPO0.P@'LL6X_@&%W
M6->084O)""D;P9[?'<98]X5.))6( Q8<D@P+7Z,F"YA;@5S>#0&+&_.QM,2T
M.A@@!JQ@B.%98@R]@*I;V V#IRC"R-D(7D41>(,AI@\*8KW[!0X&K._%?D@:
M1R'BH"8,@Q8$\_K,IU#$ST!0)'P"]EHDL'[&#N?HEQ@"PA!BS' U6HZ[C"IO
MN#'G,F2[F.]%@0LA@AMTXQ@NKG8D?=PF??SFI']!MR]%B=XX_DX,IFI9GY9X
MP)UE/+D_0F&%-[R&O]O*PV[C'W\CB3PGX3+VB$YUF'.I8<6SZC%GFUIA8,T-
MGJ56:#PBJ3 85X:>%:7UQFG>."T?G>;/G2;!YXXW-:G$<X)TY2H5V9M/_(\$
M'*O?/3Z<:OPU\^HDJ!/2,1.O/C47G:%MR^B^YDXJ<M7=0%Q(#Y$H?O-C<"O-
M_=%<"W(1U^&1 IH"&'39/OC=T3ZP;KC_J&NE,KPA9%AK(4:R[D,<=0?[U.[O
MPP46X11W#!ZDR%)P%3OXL/^RL8VCO2>OC5SHA7M3&;SNX1VP?GBTH^VS;5*_
M5AZ7UV^^*ZX7$K<G$W,4Q<#@?4'7[ZBZ8U7IWBXS9?$EY)I+?'H*30MP?JZ4
MW73(0/N8'?\'4$L#!!0    ( #% 7%:;NF&_ P<  -X2   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;+586V_;-A3^*X3G=C:@R+I+3I, B9-V =HT
M2-)NP[ '6J)CHI+HD70N^_4[AY3E2Q2W*+"'*)3,\YWK=WBDHT<AOZDY8YH\
M566MCGMSK1>'HY'*YZRBRA4+5L,O,R$KJN%6WH_40C):&*&J' 6>EXPJRNO>
MR9%Y=BU/CL12E[QFUY*H9551^7S&2O%XW/-[JP<W_'ZN\<'HY&A![]DMTU\6
MUQ+N1BU*P2M6*RYJ(MGLN'?J'YYEN-]L^,K9H]I8$_1D*L0WO+DLCGL>&L1*
MEFM$H/#O@4U862(0F/%/@]EK5:+@YGJ%_M[X#KY,J6(34?[."ST_[F4]4K 9
M79;Z1CS^QAI_8L3+1:G,E3S:O7':(_E2:5$UPF!!Q6O[GSXU<=@0R+Q7!()&
M(#!V6T7&RG.JZ<F1%(]$XFY PX5QU4B#<;S&I-QJ";]RD-,GEU>3SY\NR-WI
M'Q>W9'!'IR53PZ.1!FC<,,H;F#,+$[P"XP?DDZCU7)&+NF#%-L (;&H-"U:&
MG05[$<]9[I+0=TC@!<$>O+!U-#1XX6N.UKFH&+FC3^2<J[P4:BD9^>MTJK2$
MTOB[RV>+&'4C(ET.U8+F[+@'?%!,/K#>R=M?_,1[M\?>J+4WVH=^<@OT*Y8E
M(V)&)J):B)K56N'=M60'&MSX*)3JLGH_[MV<D9DH@8R\OB<:$TX4 V0@N)X3
M#3_G6^KP"1I Z^=?%8&X*3)EL)D1;D,*MC!X]@QRRUK+9S+@-4B)I:)UH8:'
MY$]&I:T+ EEEU93)-K-X\?'B@1(K_J7F&K;>:JH!MT\&8>H$V7AHEH&3QJE=
MQDX<P-,)K6E!B1\Z<>B1('+\*"-^Y,1I2NZ$IJ4)%#FS-J_+P&('(0!:[,Q)
M/+L*/&<<!\,]68S;+,8_F<6->CQC-9MQ30;74CQP;'>=#-ROZ6XK35@?TQ7L
MHH4E7)GL2JX@PDURU]6PD?B?S>%22I W;K7>D/>L8!(2T2=O?\D"/WC7N3()
M;^]V_T,/A@Y;D\$X&D*&L@2NOA-%\;#)<MZHWG2W;[?W&X%^*W+.9@RV%R90
MB__%T- 9)V.2.7$\;G^SEA8KY5T9ZC>"_4:TOR/\2L$8N2R-C5R0AFM?]U1Q
MTE9QLK>V;E@NZIR7G)J3%.KFXFD!QRJXL%'&^*Q6K*MT]\-_IR51./QW]6/=
M*DC#4HL7'6/6)''=GHC$A&FQV<M,5--WBK#9C)G18%>@*7KVW:+O5K\V;]>0
MP'<]\F;GWR58E6OT;=84D-E;<# /ZYH#Y"!T0RS[V(4^-8C<8-C4HFG!#JF9
M!6@L6)67YXY)X(;PY\%^D7\C8F$"F=,ZAWG(1%6U=3;P71_@/82?P*$.24%>
M00H41V C&H]=G_AIY@;0:]V(? !=1N=207:AW^90X!QR"/V#"(B[;)]X;@RF
M1"1Q$_)!B.*1ES#U2(CA@9C-0'WD9D.(R,J>S=4U@TD,.U0;F!Q"#A9C0'P7
MN YFD\]&G_5@X(<(-PC0J14W[9'5.FS#FB#(9$[!74@9>:#ETOI*L30Q5!#S
MR,7&DP9&(DQ=.(LNV@+:(,,-IL5/W!2,'B<0JS>-@C=[^)BV?$Q_[%39/E+:
MIH8&?.1T"HS1G'4."?L5_,"0@-5LJ6.G! :62!CKMQ*CYU23>PJAP1,'&:@@
M_'S&H?(T 0%;>2^FC&*S/5-E5&,AE6NG7IQ0^QAZ_A+OD%Q]_@@,D/(9G'JD
MLL!Y($F<,(UP$3IAYL,B3IUQ&).;M[1:O#MOBGA'+G*B; S7T$^@"Z=92BYO
M)L"."(:3!8>NS?\%W2N(Q G\Z,6Q<9KG<DG+3<+$3A@D .O%&39WW]^"@_XB
M]<%R <14$)XP(G%(4J\I?K D N<S\D'B]-,5T"QP(A3QG2P:DR1VDM#?CM1&
MN _)Y?7*@35O\*1"B@4PB@').G1M9NQ5N:]=5+/F(=F,@4A08^*07$&;ZZSU
MYZWC>J6FWRK:0[VLI5[VXP.=K87)9BUT<6T_8B?7S"LRI%GM$ -K%@MDE8K=
M[KI3F(8B;.> 0IEF:*9-W]AE#G*K@K:,[ 1JG58XFN,!SYOV?\;N>5VCP;#S
M;B[%\GZ^K>:P':9>\NP I*!*..Z']/B>#TW["AJ9O;PN"'M]Z+E@)([Z7I@U
MYU_GSC"#0Z;9"5Q8H>YE<A].I@1CD%HA"_\=$7.^MB(VM&OW:U$?Y):W]NUI
M5SP*7>Q5T&2V[%0YQV,?>B7!MTLJ\[E)'8,Q2^)W$3M*/K!2+/ .>Y6+_2X,
MMH%0R R8,$*9L>B!*6TDD*"O^.1;FRQ4%V]&&]\<*B;OS9<59=\![>>']FG[
M\>;4?K-8;[=??CY1"=4$[Y9L!J*>F\*;CK1?4^R-%@OS!6,JM!:56<X9!>]P
M _P^$T*O;E!!^TGKY#]02P,$%     @ ,4!<5@02?97_ @  L 8  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&ULA55M;]HP$/XKIVR:6@DU)%"@'2 !
M91O2-E60=A^F?3#)0:PY=F8[I?WW.SN0M15E7Q+[<L_+^>4RW"G]V^2(%AX+
M(<THR*TMK\/0I#D6S%RH$B5]V2A=,$M3O0U-J9%E'E2(,&ZW>V'!N S&0Q^[
MU>.AJJS@$F\UF*HHF'Z:HE"[41 %A\"2;W/K N%X6+(MKM#>E;>:9F'#DO$"
MI>%*@L;-*)A$U].NR_<)]QQWYMD87"5KI7Z[R2(;!6UG" 6FUC$P>CW@#(5P
M1&3CSYXS:"0=\/GXP/[)UTZUK)G!F1(_>&;S43 ((,,-JX1=JMT7W-=SZ?A2
M)8Q_PJ[.O6P'D%;&JF(/)@<%E_6;/>[7X1E@\!8@W@-B[[L6\BYOF&7CH58[
MT"Z;V-S E^K19(Y+MRDKJ^DK)YP=+^>K9'DW2^Z6B^^?8?+]!I;SKY-D?@.3
M6;*X7R2+^0K.$K86:,Z'H25)!PS3/?VTIH_?H(]B^*:DS0W,98;92X*0O#:&
MXX/A:7R2\0;3"^A$+8C;<7R"K],L0,?S==Y: #165ZFM-)=;8#*#)0IF,8.)
M.S#<<C3P<[*F+#I!OXXM02W0/2[@;M6U*5F*HX"NC4']@,'XP[NHU_YXPGZW
ML=\]Q3Y>T2W-*H&@-O"RE&6M!>LG2)Y*GS!3QAXKX*3$\0*2'&&C!-UII\4-
ML,.]=D(L375%2ZA?.$I)WE"L7EZKP!*)V\97SF\%DRTXXY(25&5H3\SY]5N)
ML,('U$RFZ#=OC1(WG&1JL??0:UWU>U2Y]/L'%C7=(E9W!,I7Y$$#,T:EW-NJ
M<=U6?S" 1%DF7A9Q((ZB5K_7A1DS.93LB=H4!<]ZK78G.H<I$[4A"W1<L5B3
MQ.'(DJ7+5K_3<9/H6#T-V+B5?(V/"!^UNE?]U](^^%_I#^\&<11_A&,G+WS6
M10K46]\K7;V5M'5#::)-.Y[47>A?>MW+OS&]Y=* P U!VQ?]RP!TW1_KB56E
M[TEK9:G#^6%.OQ34+H&^;Y2RAXD3:'Y2X[]02P,$%     @ ,4!<5JO:1255
M!@  Y2@  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULM9IM3^,X$,>_
MBM5;G78EH$GZ" >5H,GJ.!V[B"[<B].],*G;6"1QUW;H<KH/?^,D)$T;O%2:
MOJ%YFI^=^<?C\>#SM9!/*F),DQ])G*J+3J3UZJS;56'$$JI.Q(JE<&<A9$(U
MG,IE5ZTDH_/<*(F[GN,,NPGE:6=RGE^[E9-SD>F8I^Q6$I4E"94O5RP6ZXN.
MVWF]<,>7D387NI/S%5VR&=/WJUL)9]V*,N<)2Q47*9%L<=&Y=,\"KV\,\B<>
M.%NKC6-B7N51B"=S<CV_Z#BF1RQFH38("C_/;,KBV)"@']]+:*=JTQAN'K_2
M/^<O#R_S2!6;BO@O/M?116?<(7.VH%FL[\3Z=U:^T,#P0A&K_"]9E\\Z'1)F
M2HND-(8>)#PM?NF/TA$;!L!I-_!* V_;8/B&0:\TZ&T;]-\PZ)<&_?<:#$J#
M_-6[Q;OGCO.III-S*=9$FJ>!9@YR[^?6X"^>F@]EIB7<Y6"G)WXPF]Y=WWZ[
M_OJ%?/U,KNYGUU^"V8Q\])FF/%:?R#&YG_GDXX=/Y /A*?D6B4S1=*Z.B(JH
M9,I<O.%Q#+*K\ZZ&/AER-RS;ORK:]]YHWR4W(M61(D$Z9_,6^^E/[#T+H O.
MJ#SBO7KDRK,29VQU0GK.$?$<=]C6(;NYST(P=XVYY[68^^\W=UO,@_>;.Q9G
M]*K/HY?S>F_P'JCD]#%FY#K5#,36X&;-]0OY^T]XDEQKEJA_VE0OL/UVK(E^
M9VI%0W;1@?"FF'QFG<FOO[A#Y[<VCV/"?$Q8@ 1K:-.OM.G;Z),I5=$1">$O
M8=\S_DQCEFH8EC X(4+()QC 1CG%PDQRS5GKZ+0VL:].!6R4P\P,]3QQA\-3
M!S[$YTT%,-L,D& -!0:5 @.K I=AF"593#6;F\F)AURW^=@*V=?'!6RXX>->
M;^CVW2T?#W:DZ+E#;S!J/A8@=:WAO6'EO:'5>U_8DIHLH?B$%Y"R*+*0(B&0
M!4FXDRZ+-"+_=F&6@<]8MDX15]9V]G7P<,=SQUY_?#K8<O#N8\/Q>#3>\N_N
M4SUGW*M5:#AN5#EN9'7< S@-HC E5UQ 8 Y/VGQB1>SK$TR8CPD+D& -'<:5
M#N/#3(YC3&TP83XF+$""-;0YK;0YM8Z169&;B@4)19+ B@0RZ?")<*4R"-9:
M$!V9J1'25@@S>2(;B7C.I"(?(9\M,MM/;=J=[L3??G/,3ZT=VU<03%B !&L(
MXCKU2L.Q2G++9 AQ"Y:?1I9GD4=X7@X=!;$>DI@W GQ)-C^5VYT3]_1TR_7V
M'NSK>U1:@$5K>G]CG>?^S/M<0)H"N2"X?1WQ,"+?,RK!_?$+852FQR(S,DA&
M5O0ECVMT 7?)'/(;HUC*-%&09+:O\NRMNP/R FVTF4[MIGN+ADD+L&A-T;Q:
M-.\]HD%$*@0KQPB#.&9B6*98'MY@8'$:@XR242727#NV6 BI\\=H&'$&>5:Q
M*,CSJDQ'0O)_J7YSU6[OV,@BI]5R;SDQ:0$6K2EGO9AVK>O!W<2-_$<>8-60
M\BR!PZF(8_HH9)$57TI)TR5+P.*(W(%^:<;RFMB<P'0V6[&0+SB<W' 8DEJD
MK%5&U'4X*LU'I058M*:T]5K<[1\F%W115^"H-!^5%F#1F@K5:W77OEAOIA_5
M9&9.=N=!,P6:D:=>)\SZ1AZ2VV-FT0'7;60ICK>=I&#6 WQ46H!%:VI45P1<
M>TG@L $2"/<I-\6:F8:<IEU#U%H"*LU'I058M*;4=0W#'1TH8*)6-E!I/BHM
MP*(U%:JK&ZYU@3[YFK)CS1/(&ZL!5$9%DJU@A"VX5$40-3%T)<4\"UOKGV4[
MC;JP-]@N"T_MW=E;"M12!A:M*45=S'#MU8R#Q\4@DV+5GD%B5B"FJ#0?E19@
MT9K_=:S+(YYSF(#H898IIJ@T'Y468-&:"M4E%,]>Q$ +B&4[FT7$D;,3#^V]
MV5L)U+H(%JVI1%T7\>SEAX/'PS_HBJ:MTF'6(Z:H-!^5%F#1FA+7M1+O0#L/
M/-22!RK-1Z4%6+2F0G7)P[/O/\ +A[O[!GHMX1"UM(%*"[!HA1+=C>U<"9/+
M?!^=(J'(4EWL8ZJN5GOU+O,=:EO7I^Y94.RXJS'%!L ;*I<\521F"T Z)R-8
M]\MB3UUQHL4JWS3V*+0627X8,3IGTCP ]Q="Z-<3TT"ULW'R/U!+ P04
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M<C*5U@T-3U"SXE2.^F@9%^:XXUM*QY'RXRWU7DD]>(5Z,X 1P:X,#&2"R<\
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M#?-Z@TL'1#MP6D?QQK;@@BO=T-8L]8Q&80+T^9)SM7-,5^^G?O074$L#!!0
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MV^Y(G_U\.FZFFU*R2C>[TLW.\9QCNI7R7*!%1$I=:I7^N9?AZ$Y S/_M*K7
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MQ)P)[,>H""WD@<[>W<2POW< >T 9W.:\EH1E,G25WHHA=--VV4FS;+!C63^
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M"IE,>$8$K,;&C7T]\75\&? ]@:W<:Q/M9,GYH^Y\BL:&I8& 0:BT L7;!B;
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M9,'@P-9@>._>V#WK8Y-X.F&^)EA-R$XE9*>-[MT!%XP$ D(48!XU"5< SG*
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M0K9A/4SD10F8,I#?5Y2*W40%,%>O\"]02P,$%     @ ,4!<5J%N$#M%!@
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MZ]FG0JP]X9S$RJTC4FEY;:6"A)F0,&MZDE20)1U(F L$JTEU7DAUKI^\TJM
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M_ 4\/UC,%P_@5S#'6<8+9LGPZ@F\]A"#24I_F:B,#RT ZJH:YJ8<QN@81C?
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M&H/2.(JF2KLVW*R6OU/[ILIXW*)>G.M[TEF]4$\-2G.A- ]*8Q7-'"@?UN3
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MPL6%7A5#\4@#*@/$]SDA?%N1'13//O<_4$L#!!0    ( #% 7%:%0X= NPL
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M,)=XZ"1B4XAF@GJ.P9ZZ,J0<FI8\1?;S[JPGJ(T"I5$HC:%HNIY:&\6S;UP
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MC]HX%/TK5]EJU4IE\L4 ,PM(0&@[TDZ+AF[[L-H'3W(!BR1.;0/#OU_;R62
M)A&S15H>2.S<<^QSKIWX]G>,K\4*4<)3$J=B8*VDS&YM6X0K3(BX8AFFZLF"
M\81(U>1+6V0<261 26Q[CM.Q$T)3:]@W?3,^[+.-C&F*,PYBDR2$[\<8L]W
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MAN@2#.@*C.##.]NW/NM*=$ZQ\$QB.^7SFO)Y7>K!'<1 <:8K6$7L*Z)LDJM
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M3R6M-@[5"2>E&J6?"1>#N3I<B,T64 D0]Q-"^.9$/J#9O@7_ 5!+ P04
M"  Q0%Q6II=]1%\$   -$0  &0   'AL+W=O<FMS:&5E=',O<VAE970W,RYX
M;6RM6%%SXC80_BL:.NVD,W?&LHV!%)A)('?-0WJ9Y*[MJV*O01-;HI* W+^O
M)!L#/MG.P_$ EJSOD[[=U6K%[,#%J]P */16Y$S.!QNEMM?#H4PV4!#I\2TP
M_2;CHB!*-\5Z*+<"2&I!13X,?#\>%H2RP6)F^Q[%8L9W*J<,'@62NZ(@XOLM
MY/PP'^#!L>.)KC?*= P7LRU9PS.H;]M'H5O#FB6E!3!).4,"LOG@!E^O\,@
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M\-Q1E%,=Y#M!/!*@@V3V0;.&J-<036H8+@$7B(FS30URRH4QK2+=@_$ZZ)#
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M#O]>R ("!H=*!B.W5Z_DJ$P]LJ9>I'JAI$9.K6*;+]0*>V*]QB7I\?F$'7=
M%/K5(N[_O;1[C*?:^M!%]=K" PN!UNPWSW&2O9F#J#",)T1:ZFW/=&H=*^^
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M.]3AHCB:*#J*9_EQP!U7BB=Y<TVP_D=F'M#C*\[58\><,)0'1.'_4$L#!!0
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MJGV/]/VK1K&4FMM?]EK',\XZ>V%G+W3"_4OV7L%-I4;"BLPR@S)F?MZ;>+)
MR/6O<]2-^."\N*V7D2Y9"F-J"L(ITOC]N^#:__(&>K]#[[^E'B^K? N*R%UW
M'IJ X.8.,(3L'&VC=^WT;#$>X^ F\HYG& 8=P^ _&*Y("8K+S#8I%'B.J=$/
M@A,HO]<?_H/EG5Q@^Q9\9VK/S5X"=B;-[WT>4J*:^FH&*$MWI[<2386X[L$\
M2:!L@%G?28DO ULFW2,7_P502P,$%     @ ,4!<5F<_Q7 ^!   @A<  !D
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M[[A[!L0Z@>%>L N\QFG\I)/=TLENHY,JRI]\O^ZEOW7>-@I=&PQUBGF:Q"H
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M+_CF#4$W60ET286@2789 @F J0[R^8I2\=10 Y1E]^$/4$L#!!0    ( #%
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MWPCHN1#ZW4AB0$H7!K,N.IA+R ?M0 SI&3K%83@P*$\8S)Z0TYD??I%2W,H
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MW\"O_@!02P$"% ,4    "  Q0%Q6!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #% 7%9'P@*8[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( #% 7%:97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ,4!<5NZ;#1?S!P  /C$  !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( #% 7%;C)GG,.P(  +T%   8              " @380  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  Q0%Q6<=*:0X0&  "?
M'0  &               @(&G$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ ,4!<5J0@A:)N P  71   !@              ("!81D
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #% 7%;:?5VR
M,@8  '<9   8              " @04=  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    "  Q0%Q6GMCJ;>D"   ]"   &
M@(%M(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ,4!<
M5D3#4KL]"@  #FH  !@              ("!C"8  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( #% 7%:10S6/@ (  ,8%   8
M      " @?\P  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M"  Q0%Q6ET#_<#X)  !:+P  &               @(&U,P  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ,4!<5C2QCC7)$@  @C(  !D
M             ("!*3T  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    "  Q0%Q6ID6"!R$&   &#@  &0              @($I4   >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #% 7%88S;*3-"
M (AF   9              " @8%6  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ ,4!<5J/$(>:[!0  PPX  !D              ("!
M['8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  Q0%Q6
M8??NU@T)  #S&0  &0              @('>?   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( #% 7%;7=,1VX0,  %L(   9
M      " @2*&  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ ,4!<5NQ_NP0'!   5PD  !D              ("!.HH  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  Q0%Q6_82'[NX"  !M!@
M&0              @(%XC@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( #% 7%:)BV?X"0D  " 8   9              " @9V1  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ,4!<5F/US;;Z
M @  6@8  !D              ("!W9H  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    "  Q0%Q6;,GS4F 2  #Y/@  &0
M@($.G@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #%
M7%:+W^-\0 4  (8,   9              " @:6P  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ ,4!<5E,,Z;B%$   K3,  !D
M         ("!'+8  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    "  Q0%Q6MO?9 UP&  !?$   &0              @('8Q@  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #% 7%8R!/>3$PT  &\G
M   9              " @6O-  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ ,4!<5IN?G46O!0  H@T  !D              ("!M=H
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  Q0%Q6OT4H
M58T,  !;(0  &0              @(&;X   >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( #% 7%:RT;=,K1(  *T]   9
M  " @5_M  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M,4!<5IT%5(^%!0  ,P\  !D              ("!0P ! 'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    "  Q0%Q6\D,=EFT&   '$   &0
M            @('_!0$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( #% 7%;O^-L2RR4  )M^   9              " @:,, 0!X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ,4!<5NWES&04!
MX H  !D              ("!I3(! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    "  Q0%Q6((XTX>("   H!@  &0              @('P
M-@$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( #% 7%8E
M0E]5^@(  'H&   9              " @0DZ 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ ,4!<5IY$&O>\ @  $P8  !D
M     ("!.CT! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #% 7%;$V$\SY04  -@.   9              "
M@3U. 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ ,4!<
M5INZ8;\#!P  WA(  !D              ("!650! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    "  Q0%Q6!!)]E?\"  "P!@  &0
M        @(&36P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( #% 7%:KVD4E508  .4H   9              " @<E> 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ,4!<5@K1 LJT"P  &)<
M !D              ("!564! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    "  Q0%Q6E*J],$4'  !C/@  &0              @(% <0$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( #% 7%:EWV+/
M<@,  +0.   9              " @;QX 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ ,4!<5IOA;P8H P  N0@  !D
M ("!97P! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  Q
M0%Q60,55;ET"   !!@  &0              @('$?P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( #% 7%:L5!&I=0,  (8,   9
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M970U,BYX;6Q02P$"% ,4    "  Q0%Q69NB930L$  !=&   &0
M    @($@E $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M #% 7%;RI8.I*P,  !4)   9              " @6*8 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ ,4!<5BB=,NV. P  .1$  !D
M             ("!Q)L! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    "  Q0%Q63>!,& ,%  "R'@  &0              @(&)GP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( #% 7%;TP /R&0,
M (8)   9              " @<.D 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ ,4!<5J%N$#M%!@  ,C0  !D              ("!
M$Z@! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  Q0%Q6
M\??<$Y,"  !(!P  &0              @(&/K@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( #% 7%:?!C:YQ ,  )L5   9
M      " @5FQ 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ ,4!<5CA.0G$:!   E14  !D              ("!5+4! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    "  Q0%Q6: %.>?D%  "%+
M&0              @(&EN0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( #% 7%93%M8;  @   9<   9              " @=6_ 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ ,4!<5KD<8;;,
M P  KQ(  !D              ("!#,@! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    "  Q0%Q61A\\U%L#   "#@  &0
M@($/S $ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( #%
M7%:%0X= NPL  *J'   9              " @:'/ 0!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ ,4!<5MQ/G/X5 P   @H  !D
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M=#<Q+GAM;%!+ 0(4 Q0    ( #% 7%:B$/L!=P,  ,H-   9
M  " @>KP 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @
M,4!<5J:7?41?!   #1$  !D              ("!F/0! 'AL+W=O<FMS:&5E
M=',O<VAE970W,RYX;6Q02P$"% ,4    "  Q0%Q6B!8;QMP#   A#P  &0
M            @($N^0$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4
M Q0    ( #% 7%:1_8HLS@(  +0(   9              " @4'] 0!X;"]W
M;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ ,4!<5OZ,@>F5 P
M+!(  !D              ("!1@ " 'AL+W=O<FMS:&5E=',O<VAE970W-BYX
M;6Q02P$"% ,4    "  Q0%Q6E&!27M0/  #]^P  &0              @($2
M! ( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( #% 7%92
MMETH2@(  / $   9              " @1T4 @!X;"]W;W)K<VAE971S+W-H
M965T-S@N>&UL4$L! A0#%     @ ,4!<5F<_Q7 ^!   @A<  !D
M     ("!GA8" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #% 7%:TQ0JN: (  $<O   :
M          "  28H @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( #% 7%8L 6<[&P(   XN   3              "  <8J @!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !8 %@ 'Q@  !(M @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>241</ContextCount>
  <ElementCount>374</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/BASISOFPRESENTATION</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIES</Role>
      <ShortName>RESTRICTED CASH AND MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - RECEIVABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECEIVABLES</Role>
      <ShortName>RECEIVABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - INTANGIBLES AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL</Role>
      <ShortName>INTANGIBLES AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTS</Role>
      <ShortName>LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESTables</Role>
      <ShortName>RESTRICTED CASH AND MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - INTANGIBLES AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables</Role>
      <ShortName>INTANGIBLES AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/LEASES</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INCOMETAXES</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESDetails</Role>
      <ShortName>RESTRICTED CASH AND MARKETABLE SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES - Schedule of Cash, Cash Equivalents, Restricted Cash And Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails</Role>
      <ShortName>RESTRICTED CASH AND MARKETABLE SECURITIES - Schedule of Cash, Cash Equivalents, Restricted Cash And Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECEIVABLESDetails</Role>
      <ShortName>RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RECEIVABLES</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - INTANGIBLES AND GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails</Role>
      <ShortName>INTANGIBLES AND GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES - Components of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - LEASES - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASESLeaseCostsDetails</Role>
      <ShortName>LEASES - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails</Role>
      <ShortName>INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails</Role>
      <ShortName>INCOME TAXES - Components of Income Tax Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - INCOME TAXES - Schedule of Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - LICENSE AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails</Role>
      <ShortName>LICENSE AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/LICENSEAGREEMENTS</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Schedule of Restructuring Reserve by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES - Schedule of Restructuring Reserve by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="sesn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DepreciationAndAmortization, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  sesn-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="sesn-20221231.htm">sesn-20221231.htm</File>
    <File>exhibit211-subsidiariesofs.htm</File>
    <File>exhibit231eyfy2023consent_.htm</File>
    <File>sesn-12312022x10kex311.htm</File>
    <File>sesn-12312022x10kex312.htm</File>
    <File>sesn-12312022x10kex321.htm</File>
    <File>sesn-12312022x10kex322.htm</File>
    <File>sesn-20221231.xsd</File>
    <File>sesn-20221231_cal.xml</File>
    <File>sesn-20221231_def.xml</File>
    <File>sesn-20221231_lab.xml</File>
    <File>sesn-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="796">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sesn-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 29,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 796,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 241,
   "dts": {
    "calculationLink": {
     "local": [
      "sesn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sesn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sesn-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sesn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sesn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sesn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 609,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 9,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 13
   },
   "keyCustom": 69,
   "keyStandard": 305,
   "memberCustom": 30,
   "memberStandard": 45,
   "nsprefix": "sesn",
   "nsuri": "http://www.sesenbio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.sesenbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - DESCRIPTION OF BUSINESS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - BASIS OF PRESENTATION",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.sesenbio.com/role/BASISOFPRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIES",
     "shortName": "RESTRICTED CASH AND MARKETABLE SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - RECEIVABLES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.sesenbio.com/role/RECEIVABLES",
     "shortName": "RECEIVABLES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - PROPERTY AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - INTANGIBLES AND GOODWILL",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL",
     "shortName": "INTANGIBLES AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - ACCRUED EXPENSES",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.sesenbio.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.sesenbio.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - SHARE-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.sesenbio.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - LICENSE AGREEMENTS",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTS",
     "shortName": "LICENSE AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.sesenbio.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "30",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESTables",
     "shortName": "RESTRICTED CASH AND MARKETABLE SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - INTANGIBLES AND GOODWILL (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables",
     "shortName": "INTANGIBLES AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - ACCRUED EXPENSES (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.sesenbio.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.sesenbio.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i88aacf670d6d4b4d880e4b578f023b29_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementRoyaltyRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "icd6d796c44ea43198dc7c3fb8d6ae129_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESDetails",
     "shortName": "RESTRICTED CASH AND MARKETABLE SECURITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - RESTRICTED CASH AND MARKETABLE SECURITIES - Schedule of Cash, Cash Equivalents, Restricted Cash And Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails",
     "shortName": "RESTRICTED CASH AND MARKETABLE SECURITIES - Schedule of Cash, Cash Equivalents, Restricted Cash And Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i6a787f6e1c15471ebea82677593dbf11_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - RECEIVABLES (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.sesenbio.com/role/RECEIVABLESDetails",
     "shortName": "RECEIVABLES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "if3cd4cc1171943f0abebe901bfe21fec_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "sesn:LicenseAgreementMilestoneAchieved",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Property and Equipment and Related Accumulated Depreciation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i50aaf5a9d1c54113a3349e45d1378020_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
     "shortName": "INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i94c243529fbd4ad2a365269cda0a0347_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i3d35c30040aa4486b9b15a04bdee6aa2_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - INTANGIBLES AND GOODWILL - Narrative (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
     "shortName": "INTANGIBLES AND GOODWILL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails",
     "shortName": "ACCRUED EXPENSES - Components of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ic6a7b597081d4512984c70d7af968aac_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "sesn:NumberOfLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - LEASES - Narrative (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.sesenbio.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - LEASES - Lease Costs (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.sesenbio.com/role/LEASESLeaseCostsDetails",
     "shortName": "LEASES - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i6a787f6e1c15471ebea82677593dbf11_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Equity Financing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i87f4d91941044efabca8fc31db5686f0_D20210601-20210731",
      "decimals": "-6",
      "lang": "en-US",
      "name": "sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i822d046be15341d59a14431cd169a913_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "sesn:NumberofVotesEntitledForEachShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "sesn:CommonStockSharesIssuedAndReservedForFuture",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i84030fd2a4514267a4a2169a1b8e2e55_I20190630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i6a787f6e1c15471ebea82677593dbf11_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i23b7cb6c58024d5b9f676827326355bb_D20191001-20191031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails",
     "shortName": "STOCKHOLDERS' EQUITY DEFICIT - Warrants Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i23b7cb6c58024d5b9f676827326355bb_D20191001-20191031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE - Schedule of Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i70ca9f2083e648768635ed14bf7c4dd2_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i6a787f6e1c15471ebea82677593dbf11_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i6a787f6e1c15471ebea82677593dbf11_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i6a787f6e1c15471ebea82677593dbf11_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "id1249ce1aca94aa89687426119ea9780_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i9289325bda434664a6a39b85b67bfae9_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i73c47e791149483dac9b339dd293b4ca_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ieddcde47d6134b21a63f741b8434c23a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ieddcde47d6134b21a63f741b8434c23a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
     "shortName": "INCOME TAXES - Components of Pre-tax Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails",
     "shortName": "INCOME TAXES - Components of Income Tax Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails",
     "shortName": "INCOME TAXES - Reconciliation of Expected Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - INCOME TAXES - Narrative (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "iaedc518daaca46d48e4045cf67580747_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - INCOME TAXES - Schedule of Credit Carryforwards (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails",
     "shortName": "INCOME TAXES - Schedule of Credit Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "iaedc518daaca46d48e4045cf67580747_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5a59ba7057894da1ad383ca5f6d4bdc1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AssetPurchaseAgreementVariableConsideration",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - LICENSE AGREEMENTS (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
     "shortName": "LICENSE AGREEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i3078e30e83804e5189a02bd018d21ad5_D20220720-20220720",
      "decimals": "-5",
      "lang": "en-US",
      "name": "sesn:PaymentsToRefundLicenseAgreementDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5532051f20ab4b50a0fedc0c29b03429_D20210830-20210830",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i5532051f20ab4b50a0fedc0c29b03429_D20210830-20210830",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "i6a787f6e1c15471ebea82677593dbf11_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ib200f78d81c84f1caf083a586963ba04_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ib200f78d81c84f1caf083a586963ba04_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20221231.htm",
      "contextRef": "ibfaa55d9926c4671a8b114e3e3fc8326_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 81,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_TR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TURKEY",
        "terseLabel": "TURKEY"
       }
      }
     },
     "localname": "TR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "United States:"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sesn_A2014EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A2014 Employee Stock Purchase Plan [Member]",
        "label": "A2014 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2014EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Warrant Amendment, Amendment to Securities Purchase Agreement [Member]",
        "label": "2018 Warrant Amendment, Amendment to Securities Purchase Agreement [Member]",
        "terseLabel": "2018 Warrant Amendment, Amendment to Securities Purchase Agreement"
       }
      }
     },
     "localname": "A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_A2021RestructuringPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Restructuring Plan",
        "label": "2021 Restructuring Plan [Member]",
        "terseLabel": "2021 Restructuring Plan"
       }
      }
     },
     "localname": "A2021RestructuringPlanMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails",
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_A2022RestructuringPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Restructuring Plan",
        "label": "2022 Restructuring Plan [Member]",
        "terseLabel": "2022 Restructuring Plan"
       }
      }
     },
     "localname": "A2022RestructuringPlanMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ATMFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Facility [Member]",
        "label": "ATM Facility [Member]",
        "terseLabel": "ATM Facility"
       }
      }
     },
     "localname": "ATMFacilityMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_AccountsReceivablePaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Payment Terms",
        "label": "Accounts Receivable, Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "AccountsReceivablePaymentTerms",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_AccruedLegalFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Legal Fees, Current",
        "label": "Accrued Legal Fees, Current",
        "terseLabel": "Legal expenses, including the preliminary securities litigation settlement"
       }
      }
     },
     "localname": "AccruedLegalFeesCurrent",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AccruedRestructuringChargesRelatedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Restructuring Charges Related, Current",
        "label": "Accrued Restructuring Charges Related, Current",
        "terseLabel": "Restructuring charge related"
       }
      }
     },
     "localname": "AccruedRestructuringChargesRelatedCurrent",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AssetPurchaseAgreementVariableConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, Variable Consideration",
        "label": "Asset Purchase Agreement, Variable Consideration",
        "terseLabel": "Asset purchase agreement, variable consideration"
       }
      }
     },
     "localname": "AssetPurchaseAgreementVariableConsideration",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.sesenbio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "terseLabel": "Shares of common stock issued to the selling shareholders (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Change in fair value of contingent consideration - long term"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "label": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "terseLabel": "Total milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationRoyaltyPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Royalty Payment Percent",
        "label": "Business Combination, Royalty Payment Percent",
        "terseLabel": "Royalty payment, percentage"
       }
      }
     },
     "localname": "BusinessCombinationRoyaltyPaymentPercent",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ClassOfWarrantOrRightIssuedDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Issued During The Period",
        "label": "Class Of Warrant Or Right, Issued During The Period",
        "terseLabel": "Warrants Issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "label": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "negatedTerseLabel": "Warrants Cancelled (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_ClassofWarrantorRightMinimumPercentageofSecuritiesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Minimum Percentage of Securities Issued",
        "label": "Class of Warrant or Right, Minimum Percentage of Securities Issued",
        "terseLabel": "Minimum percentage of securities issued"
       }
      }
     },
     "localname": "ClassofWarrantorRightMinimumPercentageofSecuritiesIssued",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone",
        "label": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue based on Specified Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue based on Specified Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue based on Specified Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalty Period",
        "label": "Collaborative Arrangement, Royalty Period",
        "terseLabel": "Royalty period"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltyPeriod",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedforFutureIssuance",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_CommonStockAndWarrantOrRightsPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock And Warrant Or Rights, Price Per Share",
        "label": "Common Stock And Warrant Or Rights, Price Per Share",
        "terseLabel": "Stock and warrants price per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockAndWarrantOrRightsPricePerShare",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_CommonStockSharesIssuedAndReservedForFuture": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Shares Issued And Reserved For Future",
        "label": "Common Stock Shares Issued And Reserved For Future",
        "totalLabel": "Total shares of common stock issued and reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssuedAndReservedForFuture",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration [Policy Text Block]",
        "label": "Contingent Consideration [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sesn_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Capitalized Research and Development",
        "label": "Deferred Tax Assets, Capitalized Research and Development",
        "terseLabel": "IRC 174 Capitalized R&amp;D"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_DeferredTaxAssetsCapitalizedStartUpCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Capitalized Start Up Costs",
        "label": "Deferred Tax Assets Capitalized Start Up Costs",
        "terseLabel": "Capitalized start-up costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedStartUpCosts",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "label": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "terseLabel": "Discretionary match per participating employee, maximum"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_EBI031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EBI-031 [Member]",
        "label": "EBI-031 [Member]",
        "terseLabel": "EBI-031"
       }
      }
     },
     "localname": "EBI031Member",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_EczacibasiPharmaceuticalsMarketingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eczacibasi Pharmaceuticals Marketing Agreement",
        "label": "Eczacibasi Pharmaceuticals Marketing Agreement [Member]",
        "terseLabel": "Eczacibasi Pharmaceuticals Marketing Agreement"
       }
      }
     },
     "localname": "EczacibasiPharmaceuticalsMarketingAgreementMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Contingent Consideration, Percent",
        "label": "Effective Income Tax Rate Reconciliation Contingent Consideration, Percent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Goodwill Write-off, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Goodwill Write-off, Percent",
        "terseLabel": "Goodwill write-off"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGoodwillWriteOffPercent",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_FederalDerivativeLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Derivative Litigation",
        "label": "Federal Derivative Litigation [Member]",
        "terseLabel": "Federal Derivative Litigation"
       }
      }
     },
     "localname": "FederalDerivativeLitigationMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH",
        "label": "In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH [Member]",
        "terseLabel": "Securities Litigation"
       }
      }
     },
     "localname": "InReSesenBioIncSecuritiesLitigationMasterFileNo121Cv07025AKHMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) of Prepaid Expenses, Noncurrent",
        "label": "Increase (Decrease) of Prepaid Expenses, Noncurrent",
        "negatedTerseLabel": "Long term prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseOfPrepaidExpensesNoncurrent",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_IndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite [Member]",
        "label": "Indefinite [Member]",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "IndefiniteMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_IssuanceOfWarrantForCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Warrant For Common Stock",
        "label": "Issuance of Warrant For Common Stock",
        "terseLabel": "Deemed Dividend on adjustment of exercise price on certain warrants"
       }
      }
     },
     "localname": "IssuanceOfWarrantForCommonStock",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "label": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "terseLabel": "License agreement, amount payable upon achievement of specified milestone"
       }
      }
     },
     "localname": "LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Achieved",
        "label": "License Agreement, Milestone Achieved",
        "terseLabel": "Milestone achieved"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAchieved",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestoneAchievementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Achievement Expense",
        "label": "License Agreement, Milestone Achievement Expense",
        "terseLabel": "Expenses related to achievement of development milestone"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAchievementExpense",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Payment",
        "label": "License Agreement, Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePayment",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestonePaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Payment Term",
        "label": "License Agreement, Milestone Payment Term",
        "terseLabel": "Milestone payment term"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentTerm",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty On Net Product Sales",
        "label": "License Agreement, Percentage of Royalty On Net Product Sales",
        "terseLabel": "Royalty payment obligation, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSales",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "label": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "terseLabel": "Third party minimum ownership, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "label": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "terseLabel": "Third party maximum ownership, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementProceedsFromMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Proceeds From Milestone Achieved",
        "label": "License Agreement, Proceeds From Milestone Achieved",
        "terseLabel": "Proceeds from milestone achieved"
       }
      }
     },
     "localname": "LicenseAgreementProceedsFromMilestoneAchieved",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "label": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "terseLabel": "License agreement, royalty payment, reduction, conditions not met"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Rate",
        "label": "License Agreement, Royalty Rate",
        "terseLabel": "License agreement, royalty rate"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyRate",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementTerminationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Termination Expense",
        "label": "License Agreement, Termination Expense",
        "terseLabel": "License termination fee"
       }
      }
     },
     "localname": "LicenseAgreementTerminationExpense",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementTerminationPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Termination Payment",
        "label": "License Agreement, Termination Payment",
        "terseLabel": "License termination payment"
       }
      }
     },
     "localname": "LicenseAgreementTerminationPayment",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Text Block]",
        "label": "License Agreement [Text Block]",
        "terseLabel": "LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "LicenseAgreementTextBlock",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sesn_LicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Maintenance Fees",
        "label": "License Maintenance Fees",
        "terseLabel": "License maintenance fees"
       }
      }
     },
     "localname": "LicenseMaintenanceFees",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_MENALicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MENA License Agreement",
        "label": "MENA License Agreement [Member]",
        "terseLabel": "MENA License Agreement"
       }
      }
     },
     "localname": "MENALicenseAgreementMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_MicrometAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Micromet [Member]",
        "label": "Micromet AG [Member]",
        "terseLabel": "Micromet AG"
       }
      }
     },
     "localname": "MicrometAGMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_NetOperatingLossCarryforwardAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryforward [Axis]",
        "label": "Net Operating Loss Carryforward [Axis]",
        "terseLabel": "Net Operating Loss Carryforward [Axis]"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardAxis",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_NetOperatingLossCarryforwardDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Net Operating Loss Carryforward [Axis]",
        "label": "Net Operating Loss Carryforward [Domain]",
        "terseLabel": "Net Operating Loss Carryforward [Domain]"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardDomain",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_NonCapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Capital Loss Carryforward [Member]",
        "label": "Non-Capital Loss Carryforward [Member]",
        "terseLabel": "Non-capital loss carryforwards"
       }
      }
     },
     "localname": "NonCapitalLossCarryforwardMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_NumberOfLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Lawsuits",
        "label": "Number Of Lawsuits",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "NumberOfLawsuits",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_NumberofVotesEntitledForEachShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Votes Entitled For Each Share",
        "label": "Number of Votes Entitled For Each Share",
        "terseLabel": "Number of votes"
       }
      }
     },
     "localname": "NumberofVotesEntitledForEachShare",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_OperatingLeaseLeaseTerminationPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Lease Termination Payment",
        "label": "Operating Lease, Lease Termination Payment",
        "terseLabel": "Operating lease, termination expense"
       }
      }
     },
     "localname": "OperatingLeaseLeaseTerminationPayment",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Rent",
        "label": "Operating Lease, Monthly Rent",
        "terseLabel": "Monthly rent"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyRent",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeasesAreaOfOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Area Of Office Space",
        "label": "Operating Leases Area Of Office Space",
        "terseLabel": "Office space (in square feet)"
       }
      }
     },
     "localname": "OperatingLeasesAreaOfOfficeSpace",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "sesn_OperatingLossCarryforwardsDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Decrease",
        "label": "Operating Loss Carryforwards, Decrease",
        "terseLabel": "NOL carryforward reduced amount"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsDecrease",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Line Items]",
        "label": "Organization And Basis Of Presentation [Line Items]",
        "terseLabel": "Organization And Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationLineItems",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Table]",
        "label": "Organization And Basis Of Presentation [Table]",
        "terseLabel": "Organization And Basis Of Presentation [Table]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationTable",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OtherDividendAndAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Dividend And Adjustments",
        "label": "Other Dividend And Adjustments",
        "terseLabel": "Deemed dividend"
       }
      }
     },
     "localname": "OtherDividendAndAdjustments",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OtherReceivableAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Receivable, Asset Purchase Agreement",
        "label": "Other Receivable, Asset Purchase Agreement",
        "terseLabel": "Other receivable, asset purchase agreement"
       }
      }
     },
     "localname": "OtherReceivableAssetPurchaseAgreement",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_PaymentsToRefundLicenseAgreementDeposits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Refund License Agreement Deposits",
        "label": "Payments to Refund License Agreement Deposits",
        "terseLabel": "Payments to refund license agreement deposits"
       }
      }
     },
     "localname": "PaymentsToRefundLicenseAgreementDeposits",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_ProceedsFromExecutionOfAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Execution Of Asset Purchase Agreement",
        "label": "Proceeds From Execution Of Asset Purchase Agreement",
        "terseLabel": "Proceeds from execution of asset purchase agreement"
       }
      }
     },
     "localname": "ProceedsFromExecutionOfAssetPurchaseAgreement",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_QiluPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qilu Pharmaceutical Co., Ltd.",
        "label": "Qilu Pharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Qilu Pharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "QiluPharmaceuticalCoLtdMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RestrictedStockUnitsPerformanceBasedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units &amp; Performance Based Stock Units",
        "label": "Restricted Stock Units &amp; Performance Based Stock Units [Member]",
        "terseLabel": "RSUs and PSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsPerformanceBasedStockUnitsMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RetentionProgramCashManagementMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retention Program, Cash Management Milestone",
        "label": "Retention Program, Cash Management Milestone [Member]",
        "terseLabel": "Retention Program, cash management milestone"
       }
      }
     },
     "localname": "RetentionProgramCashManagementMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RetentionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retention Program [Member]",
        "label": "Retention Program [Member]",
        "terseLabel": "Retention Program"
       }
      }
     },
     "localname": "RetentionProgramMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "label": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodPotentialMilestonePayments",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-Use Asset Related To Adoption of Accounting Standard",
        "label": "Right-of-Use Asset Related To Adoption of Accounting Standard",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetRelatedToAdoptionOfAccountingStandard",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RoyaltyRevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Revenue, Percentage",
        "label": "Royalty Revenue, Percentage",
        "terseLabel": "Royalty revenue, percentage"
       }
      }
     },
     "localname": "RoyaltyRevenuePercentage",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "sesn_SaleOfStockAdditionalSharesAuthorizedForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Additional Shares Authorized For Sale",
        "label": "Sale Of Stock, Additional Shares Authorized For Sale",
        "terseLabel": "Additional shares to be issued"
       }
      }
     },
     "localname": "SaleOfStockAdditionalSharesAuthorizedForSale",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockCommissionFixedRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission Fixed Rate",
        "label": "Sale Of Stock, Commission Fixed Rate",
        "terseLabel": "Commission fixed rate"
       }
      }
     },
     "localname": "SaleOfStockCommissionFixedRate",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "label": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "terseLabel": "Aggregate sales price"
       }
      }
     },
     "localname": "SaleOfStockMaximumAggregateSalesPriceInTransaction",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Weighted-Average Price Per Share",
        "label": "Sale of Stock, Weighted-Average Price Per Share",
        "terseLabel": "Weighted-average stock price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent",
        "terseLabel": "Achievement deemed probable, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "terseLabel": "Fair market value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary",
        "terseLabel": "Percent of base salary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award",
        "terseLabel": "Shares received per award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "label": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "terseLabel": "One-time milestone payment upon first sale of product"
       }
      }
     },
     "localname": "SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "label": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "terseLabel": "Percentage of net sales of quarterly earn-out payments during earn-out periods"
       }
      }
     },
     "localname": "SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "label": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "terseLabel": "Period during which quarterly earn-outs are payable after date of net sales"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "label": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "terseLabel": "Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharesOfCommonStockReservedForIssuanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "label": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "terseLabel": "Shares of common stock reserved for issuance for:"
       }
      }
     },
     "localname": "SharesOfCommonStockReservedForIssuanceAbstract",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_StockIncentivePlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2009",
        "label": "Stock Incentive Plan 2009 [Member]",
        "terseLabel": "Stock Incentive Plan 2009"
       }
      }
     },
     "localname": "StockIncentivePlan2009Member",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIncentivePlanTwoThousandFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "label": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "verboseLabel": "2014 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanTwoThousandFourteenMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Exercise Of Warrants, Value",
        "label": "Stock Issued During Period, Exercise Of Warrants, Value",
        "terseLabel": "Exercises of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodExerciseOfWarrantsValue",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, New Issues, Issuance Costs",
        "label": "Stock Issued During Period, New Issues, Issuance Costs",
        "terseLabel": "Issuance of common stock, issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodNewIssuesIssuanceCosts",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Exercise Of Warrants",
        "label": "Stock Issued During Period Shares Exercise Of Warrants",
        "negatedTerseLabel": "Warrants Exercised (in shares)",
        "terseLabel": "Exercise of stock warrants (in shares)",
        "verboseLabel": "Exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_SupplementalLeaseInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Lease Information [Abstract]",
        "label": "Supplemental Lease Information [Abstract]",
        "terseLabel": "Supplemental Information:"
       }
      }
     },
     "localname": "SupplementalLeaseInformationAbstract",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_UniversityOfZurichMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Zurich",
        "label": "University of Zurich [Member]",
        "terseLabel": "University of Zurich"
       }
      }
     },
     "localname": "UniversityOfZurichMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViciniumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vicinium [Member]",
        "label": "Vicinium [Member]",
        "terseLabel": "Vicinium"
       }
      }
     },
     "localname": "ViciniumMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViventiaBioInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viventia Bio, Inc.",
        "label": "Viventia Bio, Inc. [Member]",
        "terseLabel": "Viventia Bio Inc."
       }
      }
     },
     "localname": "ViventiaBioInc.Member",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantOrRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Or Right Outstanding [Roll Forward]",
        "label": "Warrant Or Right Outstanding [Roll Forward]",
        "terseLabel": "Warrant Or Right Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "WarrantOrRightOutstandingRollForward",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_WarrantsExpiringMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring March 2023 [Member]",
        "label": "Warrants, Expiring March 2023 [Member]",
        "terseLabel": "Warrants, Expiring March 2023",
        "verboseLabel": "2018 Warrants"
       }
      }
     },
     "localname": "WarrantsExpiringMarch2023Member",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2022 [Member]",
        "label": "Warrants, Expiring November 2022 [Member]",
        "terseLabel": "Warrants, Expiring November 2022",
        "verboseLabel": "2017 Warrants"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2022Member",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedMay2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "label": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "terseLabel": "Warrants, Expiring November 2024, Issued May 2015"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedMay2015Member",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedNovember2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "label": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "terseLabel": "Warrants, Expiring November 2024, Issued November 2014"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedNovember2014Member",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WeightedAverageCostOfCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Cost of Capital",
        "label": "Weighted Average Cost of Capital",
        "terseLabel": "Weighted-average cost of capital"
       }
      }
     },
     "localname": "WeightedAverageCostOfCapital",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_XOMAIrelandLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XOMA Ireland Limited [Member]",
        "label": "XOMA Ireland Limited [Member]",
        "terseLabel": "XOMA Ireland Limited"
       }
      }
     },
     "localname": "XOMAIrelandLimitedMember",
     "nsuri": "http://www.sesenbio.com/20221231",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r202",
      "r203",
      "r326",
      "r331",
      "r636",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe",
        "verboseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r263",
      "r596",
      "r655",
      "r666",
      "r712",
      "r713",
      "r717",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r263",
      "r596",
      "r655",
      "r666",
      "r712",
      "r713",
      "r717",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r202",
      "r203",
      "r326",
      "r331",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r423",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r221",
      "r423",
      "r679",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r264",
      "r265",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r656",
      "r667",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r620",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r656",
      "r667",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r221",
      "r423",
      "r679",
      "r680",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_PA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PENNSYLVANIA",
        "terseLabel": "Pennsylvania"
       }
      }
     },
     "localname": "PA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r665"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r267",
      "r268"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Net amortization of discounts and premiums on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails",
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r73",
      "r173"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r180",
      "r608",
      "r616",
      "r619"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r25",
      "r28",
      "r136",
      "r558",
      "r612",
      "r613",
      "r684",
      "r685",
      "r686",
      "r694",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss Investments"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r11",
      "r665"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r462",
      "r463",
      "r464",
      "r694",
      "r695",
      "r696",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r115",
      "r116",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r86",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r81",
      "r86",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Increase in warrant value"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense",
        "verboseLabel": "Total Share Based Compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "netLabel": "Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r46",
      "r70"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Intangibles impairment charge"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r151",
      "r159",
      "r176",
      "r198",
      "r254",
      "r257",
      "r261",
      "r276",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r505",
      "r507",
      "r528",
      "r665",
      "r715",
      "r716",
      "r761"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r169",
      "r181",
      "r198",
      "r276",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r505",
      "r507",
      "r528",
      "r665",
      "r715",
      "r716",
      "r761"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r198",
      "r276",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r505",
      "r507",
      "r528",
      "r715",
      "r716",
      "r761"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r272",
      "r285"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r59",
      "r271",
      "r285",
      "r603"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r501",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r129",
      "r130",
      "r501",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r504",
      "r689"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r132",
      "r133",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Business combination, contingent consideration, liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r132",
      "r134"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Contingent consideration - long term"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r48",
      "r171",
      "r635"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "verboseLabel": "RESTRICTED CASH AND MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r49",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r683"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r42",
      "r48",
      "r50"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r42",
      "r148"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r95",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price per warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r95",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r312",
      "r313",
      "r622",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 1.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "netLabel": "Shares of common stock reserved for issuance (in shares)",
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "verboseLabel": "Shares of common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r694",
      "r695",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 2.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10",
      "r665"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 400,000,000 shares authorized at December\u00a031, 2022 and 2021; 202,759,043 and 199,463,645 shares issued and outstanding at December\u00a031, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r97",
      "r98",
      "r104",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r29",
      "r185",
      "r187",
      "r192",
      "r604",
      "r609"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r135",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractTerminationMember": {
     "auth_ref": [
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Contract Termination [Member]",
        "terseLabel": "Contract termination and other associated costs"
       }
      }
     },
     "localname": "ContractTerminationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r347",
      "r348",
      "r360"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current Tax Provision"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r693",
      "r751",
      "r753"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "negatedTerseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r693",
      "r751"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "negatedTerseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r482",
      "r493",
      "r693"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total current (provision)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r693",
      "r751",
      "r753"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "negatedTerseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r693",
      "r752",
      "r753"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r693",
      "r752"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r46",
      "r127",
      "r483",
      "r492",
      "r493",
      "r693"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total deferred benefit (provision)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r152",
      "r158",
      "r476"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r693",
      "r752",
      "r753"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedTerseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r125",
      "r750"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r125",
      "r750"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r123",
      "r125",
      "r750"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r125",
      "r750"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r119",
      "r749"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net Deferred Tax Liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r125",
      "r750"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "negatedLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees' eligible compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution retirement plan, maximum employee contribution deferred"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r46",
      "r71"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r427",
      "r458",
      "r459",
      "r461",
      "r466",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r224",
      "r227",
      "r234",
      "r235",
      "r236",
      "r240",
      "r513",
      "r514",
      "r605",
      "r610",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r227",
      "r234",
      "r235",
      "r236",
      "r240",
      "r513",
      "r514",
      "r605",
      "r610",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Income Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r200",
      "r472",
      "r495"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "United States federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r748",
      "r754"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r495",
      "r748"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r748",
      "r754"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Impact of foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r748",
      "r754"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock option cancellations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r748",
      "r754"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Foreign taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r748",
      "r754"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r748",
      "r754"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "negatedTerseLabel": "General business credits and other credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESReconciliationofExpectedIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll-related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period unvested stock to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r747"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance and benefits costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares available for sale under 2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r86",
      "r166",
      "r189",
      "r190",
      "r191",
      "r204",
      "r205",
      "r206",
      "r210",
      "r218",
      "r220",
      "r242",
      "r277",
      "r346",
      "r462",
      "r463",
      "r464",
      "r485",
      "r486",
      "r512",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r558",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r327",
      "r527",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r518",
      "r519",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r327",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r519",
      "r566",
      "r567",
      "r568",
      "r652",
      "r653",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r142",
      "r145",
      "r327",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r518",
      "r519",
      "r521",
      "r522",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r327",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r327",
      "r385",
      "r390",
      "r519",
      "r566",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r327",
      "r385",
      "r390",
      "r519",
      "r567",
      "r652",
      "r653",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r327",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r519",
      "r568",
      "r652",
      "r653",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r327",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r566",
      "r567",
      "r568",
      "r652",
      "r653",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r523",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Contingent Consideration Liability"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]",
        "terseLabel": "Fair Value, Option, Quantitative Disclosures [Line Items]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "auth_ref": [
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option.",
        "label": "Fair Value Option, Disclosures [Table]",
        "terseLabel": "Fair Value Option, Disclosures [Table]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r273",
      "r274",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r328",
      "r342",
      "r509",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r646",
      "r702",
      "r703",
      "r704",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r597",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r64",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r174",
      "r289",
      "r602",
      "r647",
      "r665",
      "r706",
      "r707"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLES AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r292",
      "r293",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r46",
      "r290",
      "r291",
      "r292",
      "r647"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r424",
      "r426",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r424",
      "r426",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r46",
      "r68"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangibles impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D intangible assets:"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r33",
      "r191"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss Before Taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r199",
      "r494"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Pre-tax income (loss) U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r30",
      "r149",
      "r154",
      "r164",
      "r254",
      "r256",
      "r260",
      "r262",
      "r606",
      "r645"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total Loss Before Income Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r199",
      "r494"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Pre-tax income (loss) Canada"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r298",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r200",
      "r473",
      "r474",
      "r481",
      "r490",
      "r496",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r201",
      "r219",
      "r220",
      "r253",
      "r471",
      "r491",
      "r497",
      "r611"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Benefit (provision) from income taxes",
        "negatedTotalLabel": "Benefit (provision) from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r188",
      "r467",
      "r468",
      "r474",
      "r475",
      "r480",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable (net)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r639"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r689"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "auth_ref": [
      "r0"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.",
        "label": "Intangible Assets, Current",
        "terseLabel": "Total Intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r63",
      "r65"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCreditMember": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment tax credit carryforwards arising from certain qualifying capital expenditures including, but not limited to, rehabilitation, energy, advanced coal project and gasification project.",
        "label": "Investment Tax Credit Carryforward [Member]",
        "terseLabel": "Investment tax credit carryforwards"
       }
      }
     },
     "localname": "InvestmentCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r35",
      "r252"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r555",
      "r664"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r18",
      "r198",
      "r276",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r506",
      "r507",
      "r508",
      "r528",
      "r644",
      "r715",
      "r761",
      "r762"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r15",
      "r153",
      "r161",
      "r665",
      "r692",
      "r705",
      "r759"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r170",
      "r198",
      "r276",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r506",
      "r507",
      "r508",
      "r528",
      "r665",
      "r715",
      "r761",
      "r762"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r198",
      "r276",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r506",
      "r507",
      "r508",
      "r528",
      "r715",
      "r761",
      "r762"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r21",
      "r709"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated litigation liability"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "RECEIVABLES"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r79",
      "r80",
      "r314",
      "r315",
      "r316",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r244",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r42",
      "r44",
      "r47"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Negative cash flows from operating activities incurred",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r47",
      "r155",
      "r163",
      "r168",
      "r184",
      "r186",
      "r191",
      "r198",
      "r209",
      "r213",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r232",
      "r254",
      "r256",
      "r260",
      "r262",
      "r276",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r514",
      "r528",
      "r645",
      "r715"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net loss",
        "totalLabel": "Net Loss After Taxes",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r224",
      "r225",
      "r233",
      "r236",
      "r254",
      "r256",
      "r260",
      "r262",
      "r645"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r236"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common stockholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r167",
      "r207",
      "r208",
      "r211",
      "r212",
      "r221",
      "r222",
      "r223",
      "r269",
      "r270",
      "r278",
      "r279",
      "r487",
      "r488",
      "r489",
      "r511",
      "r515",
      "r516",
      "r517",
      "r532",
      "r533",
      "r534",
      "r543",
      "r544",
      "r557",
      "r559",
      "r598",
      "r599",
      "r600",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r254",
      "r256",
      "r260",
      "r262",
      "r645"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r550",
      "r664"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease (including related operating costs)"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Short term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r554",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r553",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r182",
      "r183"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "negatedTerseLabel": "Unrealized loss on marketable securities",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r665"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payment of litigation fees"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r301",
      "r688"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r38",
      "r58",
      "r194"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r39",
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of machinery and equipment.",
        "label": "Payments to Acquire Machinery and Equipment",
        "negatedTerseLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-Based Awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r52",
      "r698"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedTerseLabel": "Deemed Dividend"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r9",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r9",
      "r665"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at December\u00a031, 2022 and 2021; no shares issued and outstanding at December\u00a031, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r683"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r682"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Long term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock under ATM Offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturity of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of machinery and equipment.",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Disposal of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r114"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from sale of common stock pursuant to ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r687"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercises of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r72",
      "r172"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r74",
      "r162",
      "r607",
      "r665"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Composition of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r118",
      "r165",
      "r763"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "R&amp;D credit carryforwards"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r48",
      "r50",
      "r621"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r681",
      "r690"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Short term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r621",
      "r682",
      "r690"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Long term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r299",
      "r301",
      "r304",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING AND RELATED ACTIVITIES"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of positions eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Number of positions eliminated, period percent"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r46",
      "r305",
      "r307",
      "r708"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charge"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails",
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails",
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails",
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r301",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r93",
      "r160",
      "r615",
      "r619",
      "r665"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r166",
      "r204",
      "r205",
      "r206",
      "r210",
      "r218",
      "r220",
      "r277",
      "r462",
      "r463",
      "r464",
      "r485",
      "r486",
      "r512",
      "r612",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r250",
      "r251",
      "r255",
      "r258",
      "r259",
      "r263",
      "r264",
      "r266",
      "r358",
      "r359",
      "r596"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "License and related revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r361",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r552",
      "r664"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of units issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Diluted Loss Calculation"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Benefit (Provision)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule Components of Deferred Tax Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Expected Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Carrying Amounts and Fair Values of Financial Instruments Measured"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r64",
      "r66",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Components of Pre-tax Loss"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Composition of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of the Status of Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r303",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails",
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r424",
      "r426",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r106",
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r82",
      "r84",
      "r85",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r177",
      "r178",
      "r179",
      "r243",
      "r329",
      "r330",
      "r331",
      "r333",
      "r337",
      "r342",
      "r344",
      "r654",
      "r678",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r83",
      "r84",
      "r85",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r95",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants Outstanding and Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r505",
      "r506",
      "r507",
      "r508",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Common stock purchase price, discount rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested, ending balance (in shares)",
        "periodStartLabel": "Unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Unvested weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Grant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Common stock available for sale (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares under Option (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting on the First Anniversary of Date of Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting at End of Each Successive Three-Month Period Thereafter"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r431",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r426",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of original number of shares subject to the option vesting"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Life (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-average Remaining Contractual Life (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested stock options outstanding (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r551",
      "r664"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short term property leases"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESLeaseCostsDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r51",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentandRelatedAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r86",
      "r166",
      "r189",
      "r190",
      "r191",
      "r204",
      "r205",
      "r206",
      "r210",
      "r218",
      "r220",
      "r242",
      "r277",
      "r346",
      "r462",
      "r463",
      "r464",
      "r485",
      "r486",
      "r512",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r558",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r242",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Shares available for grant under 2014 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r9",
      "r10",
      "r86",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Sales of common stock under 2014 ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r86",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock and common stock warrants, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r86",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock for RSU vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r86",
      "r93",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercises of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r9",
      "r10",
      "r86",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Sales of common stock under 2014 ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r86",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock and common stock warrants, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r9",
      "r10",
      "r86",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock for RSU vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r86",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercises of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r13",
      "r14",
      "r57",
      "r665",
      "r692",
      "r705",
      "r759"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r197",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r346",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY DEFICIT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r541",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of Credit Carryforwards"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of non-cash operating activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESScheduleofCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.",
        "label": "Time Deposits, at or Above FDIC Insurance Limit",
        "terseLabel": "Insurance coverage limit"
       }
      }
     },
     "localname": "TimeDepositsAtOrAboveFDICInsuranceLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r273",
      "r274",
      "r328",
      "r342",
      "r509",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r702",
      "r703",
      "r704",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r300",
      "r301",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r642",
      "r657",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US government securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r642",
      "r657",
      "r659",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/RESTRICTEDCASHANDMARKETABLESECURITIESScheduleofCashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r245",
      "r246",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance change"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYDEFICITEquityFinancingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r226",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding for diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r224",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14210-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14217-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r668": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r669": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r671": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r672": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r673": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r674": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r675": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r676": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r677": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>101
<FILENAME>0001485003-23-000090-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001485003-23-000090-xbrl.zip
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M;9G?W_"B[ \PI75WV=U>NS__/U!+ P04    "  Q0%Q6'0HD9&P(   6+@
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MRYKU9HM]4/I1#KDOM]+&<#9IY[3FGT]KKI/30(GQV:F00R;%VY)LU?</H74
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M??=P>R^OJ\_R*MU<Z@_^!E!+ P04    "  Q0%Q67_^^. 8%  #8&   &@
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M,C(Q,C,Q+FAT;>R]>5,;R=(O_/_S*70Y]S[/3(0;U[YX9GP#L_@PQQ(VR.;
M&S<<M4*#%DY+8OOT;U9+8C.VL2V06F@66U)OU96_7"LK\\__>]YNU4Y#T<N[
MG;^6\#):JOW?UW_^KRS[]YOM=[6UKANT0Z=?6RV"Z0=?.\O[A[5='WK'M5AT
MV[7=;G&<GYHL*Z]9[9Y<%/G!8;]&$*%W#A:OG.7:>Q,SZBC-F&,B4]KJ+$0D
M)5,88:=?'+R*7 AB$<],]"9CV*',"N4R%1&1E%M'#'KA7PDO.7<$TR@5TYH9
M[;6R.K!@O=$!I<<>]N'MX T[O5?Y>?^OI<-^_^35RY=G9V?+Y[9H+7>+@Y=Y
MIY5W0GK=E_W"='JQ6[1-'Z;C);P$RA#),%D:W<1U!YU^<7%UH_(FO>"6#[JG
M+T<'TV57%Z03?'[[_/10@I!X.3PX/K47>IU;(X0?0L?FW677;9<WQ83BJ[/[
M)\7]PTA';HUAT"_N?W,8A'X)1\<GPCP<?_5,^C(=MJ87KN[;RPZ,.;FZ(IJ>
M+<\>';@U"!_R^X<+!VZ=V"OZ7]X1?KQU4M[K,H+E-P8[.N.*#E^\VQDM3\9:
MZY?ET:M3>_E])\)=\<M_U]_MN,/0-EG>Z?5-QUU-!L K@U>Z0\#A*WX+89AG
M2&77=,W/O_92F-ZXT>CTK[]10OY-$.;?FJN;[_*J93H'?RV%3O9Q9PDX*!C_
M^L]VZ)M:NCX+_QGDIW\MK78[?9 +6?/B!"YSPV]_+?7#>?]E^>B7K__KO_[K
MSW[>;X77"=G9&,!_OAS^^.?+X:UMUU^\_M/GI[5>_Z(5_EKR>>^D92Y>=;J=
M  /(SU^E$T,Q_)A['SKE1SC> .%4Y&[X_//^=HA_+>4V&L.YUYH(D# 2&V4Q
M9H$&&IVB1'Q>2T-!(&VR:Z;JF'9Z=,A?K7=@?!>K\#J%:6UV?#C_5[A8JN4>
M;NWIIPN[UCU]1[9/]VA]X(_63_??ZJ.MH_WCQN5'O'>Y>5XG>W1K[0/?:FX?
M;NW"WV\W^7YSN[773M\_GKVCC=;>99?LKSG<V*U?U)N-=N/R &TUC]%>LW6\
MU3S,X3RTO_OW,7QOU3<4>D?V+_9VG=C:W6]O[=;IUML]VKC<NVBLM?(]LLZV
MUNJD<7F,ZTU_W-C=;^T=?3CU;S=R^_:CJ+<_L/JE/ZX?[9WM71ZCQMMU>/8Q
MW=MM'#7(!UXGVZW]M8^7^VOUT36?X%F\L]_L7NRO'5S".1>-HS='6\T/,+Y]
M&)\_W"-U"O>XW'_[Z;C1;!S7L<+OFNO]^@XZ?]<\OJA?.OS92Q*" ?$N'0L9
MB&>2*<M]I@C\*T5PRN"EUPC8BBD.,/SSY2VB/B:-QVIM(^\YT]H+IMB 7WH+
M*G^/RO0+*FMMO%5&98X0EC$D<:8,T-OZ$+CEQDBIEUXG(DR-ON_A_EV_H/"#
M*,R^H+!E#!.#1>8UTAE35&9:(I01&SDGT6FJV-+KC;TGI.\*$->7!&Z9@P5-
MOT=3_@5-C7)18ZPR(@A8XM3+S&HA,\.BC\9%(1%P;32M7O@1LG*D,!CR1GJ)
M&-?1&J6#$=%R0KT@IB0K'I,5WR3KR&9\M1U.0V<0-L"Y2#9&85Q_%WR.U4&O
MWX4GOB^Z?N#Z*QV_$XK3W(7U<[ \>KEMA7=YKS]=+)#&A6Z[]D9G"VBRUWQS
MN-?>;VV]!1JL?0!:_7U87]L_@ONW]XX:K7I[&X[MX7=T&\X[;VT='0/=#B[V
MX3F !=)8 VP<[1_N73J:<+1W]!'5CX!^37<^O@:>-=@G'P70_7AK[>]6G>P#
M%O90 ^[3:&\<-2X]C.,P;S0_7&PU-\\;EQNQL8K.1GC@]:,Z;7SXS*4DSEF;
M(6Y!4XNDJ8/SF:1.22XX-=0OO?Z6E?^/=T"*3B_40]N&XH<D@<!1@?,6L!$L
MLF",PX$+"U!"D6A70@:-(8,6D)D-R#CJM#?(9"+HF#&F768,N.P\:J*YX1A+
M\FB0^7GEL8#,]"#C;> $>9J!&0%V! X.= ZUF5"<(D&41S1, #(;B9C@6]<&
MG7P(F$'/+TT 03ZXO T:\:^EC-_%TUHX*>!PZ=0#:E;:W:*?7Y9?EVI#=Q\>
M>]Y_%?/SX+/+4'27:LDVA7N@Z<+IO'ZY@L=&3/WH(]\CC7QK;249$.W&VB;9
M?[O.@*1'C:,#O-_\.Z^3#8! ,F(^,?_/OUO[I'5JC[H7C6;K:(]LLOI:XWA_
M=P]@M _/.*#UW3K96OL$4-R\W-L%8V9#X088.8WF1U9OUGG]<O.SD41IZU6F
M-'(9\RADQH-@<0RL"2-T4A)+K_,VS"/0VK3&M!\3^]M6B>':&HFX!$7C#3:>
M*NH,C\(SZ\$:VOR:F-@Z"040L7/P+IA>V$Z1S:WXL1=6>KW0W^G#8)(1NA4W
M\H[I /E;[[N]/(UGEN3%>;VY>;K?^?MP__($K,E/Q^EXLCSWFRMH#_[>.P+B
MK'U 0/2S_=T/9+]Y<+F7:[3_[T/DVI\Z9E</MMI@3<)X]H'']]<.X?SM'/[.
M&S"F4H:LO8%[@QQ::^3_OMRD(!O "CX^@_\OX=T^2T* ! *8GTL.3@0.F2+!
M9$PCY,'B< JQ[S#_5O\P%.7,]QK=CAL4!<S]C^@-8:22403L,&<2!QN,(D)*
MKJFW$0]Q<*]1NL#!I' 0I(U !)\1*6)2 BHSF BP(# "OJ0,!?G8.)B4/'B7
M&YNW4K!P.(8%$!X(A*TU]QE%+ABQ+),,L8PYY#,E-,^D\S0B#Z)"?<_G*($P
M)D(>>JO3$PD+*/P"% (%_@M,9,AZT V2FDP[S3(<+7$<80X.Z$2A\*6)V!DD
MB_*.E:BM=(1KC; 23)*H0XB!81<P^#L2^])*I(@BDHT_W+02-QL;=T&ST^^Z
MX\-NRX>BM_Z? >"ET>V'\M>=$Q@Y^"*CI=CM9#OBV;$1P80?VX@ D\.M)I"U
MO7&\#^>#+7<&+@6OKX'K<0EN0?/-46-W'9ZY?L=&/#E.OR>W86\7W))=@%7S
M#;@4QV?U]OIEX^@#KK^MX_*9GV[;B' .V(@QDJ %N)Q2@@E! G@27F1:,>>!
M:YTC<>GU,N)?&H<O;Z\<%4!'@(<+O7L6O-)2X*M>N<@',*B52X.O^A<G0(5>
MWCYII56R\K?#(J'DUMK6\CFX&O"XV_<8/O_ZH:,Q]+J#HOQ6+L^]&D%O2.>?
M<5#&-PKE M;X6^[3]YB'HE8.*-R[0KFZ^:_;2S%W+WX]_NGVW4_*T/KX6Z]O
MBOX:2+XRWI_!X! >7W=][&J8_OI43#**KQ\Q/#+^/G[(RUL3=>^\B6@9PD%(
M'].\6:V\IL"N'I2]Y=$-53L2%,W = V77?NCR1(915<W&AUYV PD*5:^_J!$
MW_#'-JBE01%>C];!7WW<61M?/CXT_IZNOW<V2>#26$E\1(YY0A4&$4>-LYHH
M ?@L9Y,F_,W6;-*4M$'P+\YF[]  DWXQH2,XEP=_>$9_P/2<J1F]PZ$_-J.W
M.?3A%M=,S0#^E1FXR:'O0[&3P'/U>CX_A6'=/+4T5TR_6_PD,W]Q??IQ+72Z
M;;!%[[GM0R%]ZQ8O;X_^N\C_B:6AZ0/@ED;##]=H>&(:[6?61V9LWM##YPU-
M;-ZHI]Q1A!@RAC$EK+:8&\127H(PAHSP)D=X0WHF3(*[>),/QAO2-^R'7Y@W
M4.V:$FZ]890)P8PP5%O%+5A3T02=Y#/63P&ST5N'@^1'#[]Z>-@Y.$HN[P_7
M &H^;R=G.N6N7CM9(]][Z&&M=MLGW0Y\[:V<YZ#.QZ?![^UNI_2]QNL)]S[B
M:M:N1O)#B@/KB:E.I6,(CCH,N&9(2@UVK.!!1D.1Q!'/#6E6O"\C):;UWN1^
ML[-J3O*^:56$3"!*N++,(.L<,Y0J#IXKTQKSY+@:/S]D<F[0'K127G@9?TGG
M%>$PW>TT;'9<MQTJ0C*&.)(L!O :*2,"5*TQ&LQT3X)!+HBY(=EVZ)N\$_RZ
M*3IYYZ!7$?I(ZI@,4F/,-%/4&Z<MI=I[HJEESCP=?:8U UXH*A2R00?$2$#&
M12(I-38@KYVW4S #*P_5Z1NI6GHON9!!)8";J#UG&G0%#@*(:='\4?7)5/OT
MB:N4=(%:\'6#9DXAQ0)UA!B+:+0RF/DC[J.:U-,G*-91D>@)6 42[&^C)9@*
MSBO.E%3(Z2H1=&![N<]-<;%C6F$KEC0;$C,M:+Q::=8WC"M7-.>1DE8RY8+B
M1 D,]AZWCO%@P>(30=LXCW+WX:RYP- # TQ2:\XE58IJ9@G\)ST"_#!,E->\
M4AB:&"47YL)/XXEH[HRF8 9RQH2(*8K (U'<"6J)L.7"R&S#: :LA!LK-FAB
MSE?4@1LDA(T\@K?)#1'&46-@%@4*GLX-::80>)L@F:P6*M HE/0*]#DQBF(D
M-6)4TABYFQ\R33?P-D&2@8N$0]#8>$291M0BCW62>00\)HOUW)#L*0-O$Z0/
MPIX#B;#6 C%%?*K1@;URB,4(=L\3TF=:,^"I-]1@PC'13*%@25#!6A%3H(;8
M.(5UZ\I#=?JKZL)[YY0#<(,K#WZ\(A:@KH0 #:),H/-'U>E8TE,AKJ*(8R\I
M#E&P:(V5*&+KJ; @PP1S\T?<IPN\32<'!OSH*!5H'Z=8Q,Y$I*CA2FAPC0QB
M52+HS 1-ID-)11S#R:>-EOF4:R*"-^!,"0[FA;%5HN0B\#8=#$G-I)1@@ H<
M&);.".$8\U@P"Q]'@;>*8&@1>)L^GBQC@BA&C,:ZW(8H=90X2$%2  XL_"?+
M2)X94?1K[N<OI4K?)@T8;\93A"TX7XQ*RX7C'BOE"?><T;DAS30";Y,C4R38
M,RL8YXXSS:UB"FQP:@A56G*#YH=,4PZ\38YDQ+-H= 099SFS%%GB8R3>"8.-
M$M+.#<F>-/ V.?I@XBG\HR4+F$6EC0R.1B8Q)R0";TUA V#E"37][8D>6R6"
ME0A)SR0RJ4PQN+&<RYC6C?G\474Z=N14B*L(\8@)&S"G#'NN#0:;!3OP3#38
MEG/(LD\7=IH*03G!UB$P:KQ1##FM@^9$X<A3$#$E\L\=0:=BWTR?T)8:Z\')
M"*6;890QUBI',0J:!*K,T^W*K3+#/LIV888L)HRH"#8IBY8H[23U43C,O)=:
MS@UIIN$!3HY,)' NK.0.!7#+L5!2$>.X8L$@HBB9'S)-V0.<',FDPYIP8Y &
MIUT$82VVUI&H"3&22S<W)'M2#W!R]%$$21L"1EH;IADW+MA G*>!>69QN8J)
M!=*E]9$^//X&YI\EU)M!#PC0ZZTX(-2P"-:-(/<GX!QXA'F3=X&!EA_7P, B
M[91^D($Q/'4BFZI-T#1R@E@@E#$DC&%":"\C<)IQMHQC+DCXL#UU=ZCRDX4X
M1@6_QK_?KH1Q A_'-WAP:1=#(K<6G#[P[)GGR A%J, ,J>@)B:@"_-HK^M="
M]6WH'A3FY#!WIC4D]:B_T:N/.[^^#)7ZQFS%E:(PG8/R<3?0M-IMM8SMIO)Z
MI^'&*:.BS:D%D0<K]B2X])Z^GK="KP^2_U>7R-+KCRH_;Q6CPL^W0.[R3CYH
M3VHE[ME+1>2\0X(@:SEAVF/+.'4"5%X(G'@=*\ Q"SA_3VBDP^N#HGORR^^S
MX)OQ<EMP+$1GC+&&>25,(*F9!_<<8T>'<:D%W\PZWSP&G">EX?]^/U\<@SSW
M"!$E/;$,$:=P#%@%;*1 (1"\X)CGRC&5A#,F4GA*%5$*O$E)+5=62:0\)3H0
M5:65IO?),BCZ%^];X,2M='P*Y9RD>[RY2$B_'<FY.CB/BQ Q@#"*08 B1XPY
M8@URT4F@;J#"BFF4_'T2HFX,"G"IP<6&$S?R\_1I3M?^(S,L;5$4G 6%%2;I
M/YJVD-MHS;S2-X5E!_U0S#7S$NLUQ\'0(!2CA"GKC,+>$F.)Y$S-*W'+Y@>I
MH/UF^Z3HGI;6QEQR;\HV-QX3S@AB6C%+G)?442:0U9;H$8'9B,!/46'\1PD\
MK_& #1AV/[P#L\]O=OI@\Z;6&L/^,&\NZN:H6ZRV3._.HM!F!Z;"@1&Y'7K!
M%.X0D+X&9G*K^T0RBCT8PK<JP_\"A(-7&#..$9*,,1NUTU((RP)8%U'P\'2U
M\1?(K1)R)]^F #Y\L?)24C(=^>&%%V$ME8KP)(Q90$&+J(7@J7$&BLBRV4]E
MK@]?-5VUV0%CZ4L]>_>,M;Q7QFJV :T5R6A6DE*K(S>1)ODC%54JI"+&QFJ)
M1GLYR(S4X;Z-^9]?;[R=RT15-$0[0ZUEBAGE#<(4;$;,;.J47B$C<>7,%/Y+
MF+X/1=GLLN-"V>-@+DU!9H5VQ,.LQK1BI0R%Z74H(&TBCWQ461Z3&=Y_F%39
M:I(?H3B!*;MHF/9-A;K=A=%,5<F]*QN]YIV#E8,B/(E740JZI]YZZ /X$4("
M2(QD0DEC%3::1\QBC!A,LB&4T#.'TG?LO_4WFXCBQ\<'>OHR)>!<,D^P9@+^
M]E0;'T!QV! -C=:3.QH#M,D"'U/"QP^I(CAU,C4H53"$<B1!]3#*K?$D."8E
MIZF=LA:SG\.Y8?+BDVD- NB":QMWHPC_&82.N[@3*AZ??.-4<(-2"UA0%1-3
M6/<.Z8WIY7>SZ4U17,"#M\-)M^B'U/4;<'YU>;+16]UT?44R3IEF+G@;H_9@
MH+M4EP,[HA 1@D9'[ )-CXFF]5X_3^W-M^+5)=6%DE( GB@D\JFQ'?-*H< L
MERHB0E.XM$I0NOKX3[ACBKA<O$OQEJ^@J?3/>^49W],Y,XCK60$0MV #.X\<
M]9)1' WSR,<0E#644LF?!X#( D _"R GD91*:NL=8=Q;S2WB8$]3ZAT.V%<*
M0#.HS'X:T[0B !)66&2Q5EQ;1B0W('HP^&/&)$JK4 $ C3O/;\(L%(/K9+'Q
M"1]WWG9/0]$ICQP J/+06PNVOY-P4_91KY[\69CYWP4V#X*!5L5!:::UME$*
M@X,$>XU9A%@%@/VD-O6"WZJ :J45029J;:1D3GB#">#;TTBM$,Q58#OK;'D<
M"RQ/<6MV5)$'!-X/PRPE#8()XI#P FEG,*] T8/9<GX66)X>EBT(9L.YH4P+
MIKW0 &L1K8PTY<%Z50$L/T?X+%S">[#L4X]@%8DW(3(>L(K*"^DL=P*#H[@(
MD#^2=&X6Y0 NGHJAGH$32$($#&-*O4<,*V5(%)['Z"@"Y]!5-CPV?2?P>7#8
MK. X.A$5CLI&1)B(5(?@F="4<VL8156(TLV4V[= [Y.&XB)#+D1)4S\IP8C6
M46AIJ \Z$&&?2="B@JM<"_2F7?62*<)-0JU*B[4*6PPX)IP'0XRO5IAB9@#S
M!/[4 KV 7HVEP58924U@G&)EE4_-/R)FF@CO9W_;R&RCMPK^U.1VMSB#45!1
M8Q"#S#AO W5<2A88%LK*"FQ"JC*:9B!W;G)0$D91B00GP5 F*#%&I'W'SF%
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MI$O2.<A[Q)"1FG/&C1;$ +2P00M-]/- 6H&I4Z.C*W"U3Z.\^M#O7I=8>C\
MB*4*+P=%*-^E(KH*8>X5C500GQJ9&A.C81YY)**$0W*AJ^81/9/29EYSQ2D.
M)*8MM(%J@BQV(2BK+75TN#B 9K$3VNRC9SI9$VABV\VX)%QRL'.H5BQY19PH
M#E9/JF\I)+'#G?*@LH8[Y6=DY]V=[>F(/7A[^J0V*H*_$!RXWR(M!H :3X62
M@+&(M,RE(O(5LA K)2"G;\DA'GU,BSXL6(8CU]A2&HGT@02&+%M8<E59MG\4
M4XU&'3TBF'!-64#4^B"#\%83[07%=F&J51(>D[+%M'=162,MQIPYB16245-/
M=!0>.Z<JM-RQ G?P>6N0RF)>ZX#U<]<:^. WBFY[V,.LW/&P%==-T0&:]=Z'
M8N?0%.'-Q?TW>**MJM-?##%2!)$:?I"HF:':BF@$V., CXB5DA4J\S%'4)A*
MN1#/L8G!$X&B8$1H W2G-J!HK I4B9$5CL?UJA90> HHH(=# 4U.*CAGTGZK
M:)UG/   -%&.4".5 N_L;L?Y9P^%)]FQ/0/*0FB*A=4^%>9UX)A'C00Q7AG*
M&,=\H2RF#8NI* ['G/'8\H")89)[A:463OKH62HG:A:*8]JPF(H2"483[S3W
M+H!IZ;6B+I( 9F6(1'(D%TKDAE=Y7R4#N#QVB[;IN/#&]&X>F4?E(A@W(7+*
MD W,4:8BTAP)'@7%8(.(A7*95;A,1>E0&DT@G 63]L(2;ZS$U.HH:10Z,+Q0
M.K,*EZDH(XF<T9$@18-@2@HE* \>,QNE8]Z3"BFCS8[KML-5@/1=UY7 ^*(R
MSCU-M];/4_6/[W7DJZ3ZP)12!SY)=(RP0(R*2DH&?R&ODA5:(?4Q\P2>BL!/
MG3=#2!MZ262!!H4XC8K88*-!6*@*"?R9)_!T@DZ>"LP]QC016'BK' AJBKCB
MUF)>I56)!Q'X;>BDMEY WQ7?SCLYJ.BRN]<<"VD9!2?2VB"Y!*.-&\&%Y@$[
M25-BHILW(3U=$D\G&(0(CV"*4QQ!#V-BN0@"*<:0"UR,.G?-D9B>+HFG(JB9
M$AR,+<ZQ(8P3I[4@0A$= I/*<3R%NO(_[7I-J@+K@Y^8JNXU3/MF?\?R*0"V
M]#JG(9W0/.LV#[N#GNGXC>Z@Z(?PR!'"Z13:)ZFR/#*2>:J9\LX$[ 7X\-%%
MP^"/D3K@X]X<?'9EQ0)(UTJ'/[Q9"9^0\Y<:S%G+D(B8@:.@L)4.:X"48\PK
M,_N[Y9\S?AZGZSIC1G/G2*H.KBTR1F(19;"!!*%DE;9T/V=LS(#/8L MM9(@
M9063G *.@@<90QVA7O,J55SY%'K]O'-PIRYP&4-.$>";Q8&'F"M,!P:ZU?F>
M&;N <B6@++!7R$H=C8],8VND(#8**V5@- @S_U &0B^@/ ]0-I&G>M-,26Q3
M37#-?2#8^A"MI""F*VOQ_5Q+@U_!T';HI[?I=MX7J<]QNRH&GC:2*!\#=:D:
MB;..4RH!$YI'%;FMD#![1E"8ON1(RB\*P[VQX!A09XF1WC*,I1><V7$S%"#T
MK,+EUPGWJ\B\D3M0ZMQ'2!FX7>?KY@Z[7ZEW:9W5U#I$/66&:&L0DR1HD3K;
M 0IF7VL\@/:KIG=8-QUS,-S]F+= C'0?W81_6DA,L&)?0$0ZD;I<2B:(U@YQ
M"=:Q=IHS9*I4L?U9R(7I*Q I.?*:!BYX9"G_W99!1TNYB(2$"I0Y?A9 >9S>
M-\%;S],Z5VKK@*162E#PGD&*@%7A4(6DQ;1;JDV?D8TC+)&-,@_^ ^$Z@B7H
M'#814:E$I3*.9XF8TTD/XTQI13&5'I4]#J6UJ::5"P:K**O4KWY&E.MTTKJ#
MQ)@A3$"V,J&=@IM;FHI,<2'A8/4%[+0#A 0A/8_2'$<<J!9$,N^8T<IR)D3T
M@E$BE==L]LVRMVD[<2@3C@:]KT6VWYN+=-N5M/=XZ.&- 541$PK%0"/11@*3
M,V6UTJF3$B)>DLB1YJ/L(3S3980?BN\)EA'V,%W:!6R<T<P8I862C B,=3!:
MJCDP/9_)+FIA)+?@-("E*9B*5"-+HU%,(2&L-97:13TKA)R.R8D]> F,V>@#
M2VT"P%X!.09_16$UX15*=9T90DXGH=5Y</Z"-,"43%MI \5*<*54X-)Y5'V.
MG/NEI*D( !D404XRA@)AB$B-?8C2@J*6*.)8J8HYSQ0W4Y$W/B!'G7"1&,0\
MHXIJC#&8!!Q[:OEP&:J*<'D2?7&K!.VDO!)P20+!W#'E-'-.*>,YXQ8SQ*2*
M?EA0$WB<J%DER3V\E(JFLELT&1='32<_)F4PRQ#)B)H 93@R,5AE2;0ISP=9
M3P@74C*0MEY)5:%- C- HNGGZCOMG*5<6XM2DVRG+#=I&[X!0RL$4:7$[%FC
MYW1:8V.DP=IQ(3(0D)0:Y@/5D0I/5-0<SW[<;0;(^#BI#=X[\$RE%Y@R2[ 1
M-$J&K6*4I6)^%>(TL KSHHQVIOG?.>EV>MWB]H9,UQUT^L7%JX\[\\5?1#$L
M2$2.&?A/,4-2I$%$%0+CW%9I6_P/4'%U9;ZHZ()&1F@70HQ,1V15$IF*^%2T
MWX<JI!GUBOYU6>ZW(7EG)X>Y,ZWYYC\-@A-3@X1DCE%LM/;(RI0!0CTW7%<@
M.#1]RDTE/&,Q> A>!YA'Q8(/:6>Q B_;$\Z1=ZX"X9GI4VXJ 1(G@<.<(JE1
M$!,\6/ +&-#1!.PB155(YG@@Y1Y1STVGB+C#6H-.XV"@L,B\YBQP0H-6VC*F
MJU"E:?J4FPK/$8UE(%YHQ#3#F!O#$ \17 C&P.2<X1U5ORXDO_^(Y!0V0G\+
M)M2DC8?ONKW>JBF*B]@M4BSTAN^XV?$AYIV\/[&4^V$AFJ8Y7QGT#[L%S/GM
ML.L:'.WU<[<Z?-.*N*<F>,>Q\L:D8O.>J< 0XRX*R14" ^M9 VZ^2>\U(XX+
MKI61C'"CHD","NJ0 P])HP7I'T#Z<A@K'9\<Z-;?@R+O^=P]^I++Y$! DD^L
M@].< M]'9S77*!*CN.(:D[@  1 9R+]:!)_WOU0V=PM%+K3--YU!RAD.'(1,
MI(P::A@EC!AAJ!!(JQG>^O>\T59Y*9?:;.O(M".4.9VJV H,:H]$RZB*NO*X
M^X8?- G<#2WO;F?5G.1]T[IK=U<$!=Z#R,%"(NT%DP)\Y$ 58<[%%+S0;G91
M, 71,!4'_'%6X(R4U)*@I<&,Z0C_\F@HBX(R$\(,[TF8#>:_5A*G8'*DH0S/
MK C7<RN=2CM2(O-,IKJ$G%/@?8:49U;CBBSZE(9>*$Y,T;^XLT[^L9.?AJ('
M(]V*^Z"<)V<7I.2RK7ACF\N-IZYV6RUCN\-"NS=.V0ZGH3,8[I/9ZJRV\DY"
M[(WJZ0\MAE#)A2K,A<2.>N11ZK=D#'C3F)#4HLT9)-DS1%LEZ4B(1YP)0P)7
M:2>D13A$S#D7($LH&;8J23LD9SN$/DMT+*/D3[Z(%;R.W'KF*-A\41L9!').
M&A$,V']^M(BEQHF+:D''[]$1F%$]/&%132@!P&JPV+1A&B&6MI9+S RF.CB,
MG9552*/Z#AWKN2O ">^OO)T3>3KHY$/BA4%Q18MV,+U!$5[GO2XC6+Y:_[@]
MOGQ\:/P]77^_;,8XJ"23A8D,!:088,!@'CD1D>@XDLVHNK+YR;" ;E?U>AJ9
MS+D"#UQ;H!=ATA.%%7<D2F4(X5C<32Q =$&_B:07(#JAO;.2!*L=V+4!?*IH
M;(A!8LY09-IK/P<V[K^WZBN;16B9CG^7M_-^>(00U_1M7!Q,:C*/#07*><$U
MQ8SA5$,+2VO]: $0R<J1;[L+HYE$ .Q]T?4#U]\J=D)Q"K;DC6>LO]E$%#]R
M# 3)"95I-=9SQUET8#QISK4)QNFTU8IP(/"XE;P<<>R<DGP"3"H?S*2W2/<K
M^]N%$* P<<I_!0/8*BM2'E=PEH.RE#,>O7QZBCU."!D<#R&U921MY4!><RH1
MPQ)HX^6X6@0"MD'9^,.L46,<TGLSZ.6=T.NMN/\,<O :KY+^2Z)\R%N#]X>F
M:!L7!OT4N%OMONM_3_L]^.$;94;6.W!8_68'B'&0VU98Z?5"O_?FHFZ.NL5J
MR_3NE-UY!X(7[M,Y6#DH0AEB?(+FN/)&<Z5O6\6W3OV5^@=448^Y54%%(+O6
M'#P<C;2//(*17 6,?8?C?PY<E21FT,YKHI&WW#'-K#*@;[6T% 4=.475#SM-
MAYA3B3TA >J71^NIXDQ2L)HQ,Z![O4)*I^R!TGH:QQNJJ(NG0TSR\.##!/>
M>>>C%C$$G.97:$,E2%/E+/S+5*R^\SHM8D[!@V7(^R"E(\@0)KFPPFG%M(O*
M8,VO5FGP2&>F#Q4C9GV]L3(T@,*5^?/LK#&,'ZS ;YWZ*R50D50!M+6B"K'
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M""92S9&78NDU$8D:7."ONS^/(:&'NNO)S:X2Q+^58K/6+6K=_F$H:D<WNJF
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MUB!1HV:*8(!:/CQ*>LG#%A9KTTQM^>TQ$ZB3:(8)KJPX_OEE\088C-P:P90
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MD>?#FF3>./-]T3U)PPD+5ERP8@7P>LV*=-Y8\5TX,*V4:N%"6<%PP9$+CJP
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MP*YM FA.4C/'A?V\8.5*P/T&*\_=]KSW1=YQ^0GHXNN5\MI&&!46WPG%*7C
M"Y4[]WRZ"!$^88CPTS.($,[=CKWU\\/<YJ-<P'N2!&L[[C#X06LA+2LN+35(
MRV>2?E_#<[?#[;HN_ZAR[8(;J\R-G"R]YM^I(_F\;)>I8NX^TV9:F/O!L?P
MYOC2ZYW-MXV5YL?M]9UO8>][#7E&#7Z6?J2_WKB)#[F-B>FV"OW8::5NN</^
MNV4'O%HW)8.=Y;TP[CN> CVMUG7WL-ZP]_NW6UKUN[6EG= +G1=+Y=W37DB"
M_AAUFWY1?L5_C'\^"W=_&?2N?DEVV>C7[J 8_SIJ1%\K'U)[DW=?I#Z!R^79
MR9KK#6PO][DI4HF$VFX8CG_<CJTW  ?X-.74C%NDI8V7L=MJ=<_&'<_;H3B
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M/@-\W_+&*$I/0;2B,SF2#(!F,,BUP-FF\(M4HTM8S .C^]9K.N,RKG\"7L7
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M_T!1/B\"6J7^TPJ$'CCX46%JR-C>R'54A7H]3K$^WKUXW@-.2,+5TZ IK+5
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M>A*I,WWX_\;'CQYV:+9QOSM:DF[]__[\P\?@=5M*MUR*)X]N?A@\[=Z ]<,
M+[JG*4&*EW_['^,GA\_'HX#_:/_OKU] R?*@9N'=%<)P]/5N&S7=>D:  BI
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M7S0;%W:N_-<?!2]<>6+]NH$=IJ- 4+SY4,?*#K&]$="MRT!R>$MY)RT?L*!
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M<O+\:'12CT3%'5'LPFI])A)L@2=984O\K? UGQ?0H@0&QE4%C=D9FX-YKJ-
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M.A,YBE4SD ,9HQ&8/4?W0MP3A/W!!%0EQUN5QUM%4^>K^D2KR%>YM>A=G"(
M23)^MI_YJH8S$*SAP/+)(?*,6?_71:,WBP7, JU;(YZ(BF%24S19A_,TJ4I/
M5APDA )7[+A]+Q$/X]V24UJLJSVAZ8 MPT*H@UJ+>I'B:K*(2Q9#/\(/.Y\L
M>BMS-=2<%40;!IE@D0WM.&NA]<>%I4RJ.=R]7K_AH#_:+$J? !BEA:F[AM;:
ML-X$3\U<'U*R >!?!:[F@@WJ*I7;H6KID!C>WJA5DWA!5]6Y#*^YY&E3N@M^
M/T,0ZU2Q\4T=?6H/7_LJ1(V8<\-NJQ4)&[MBH)"+ZCH1;MW$!OVF/JA"(*I^
MJ11<GTIVUGE1/(K.YT^8*YV[LIH:(3LIUI2?QGAZ(/0WJI@2X&L49N-4A%/8
M[[K0+4OU]/X>V>0CFX[WR*9O.+T-*(D[B"QZ ?[V/ _EVBYQI+5H^3F1GI+1
MYG<Z:A'+>@J!S"VR"J_-!FN"1+;$K[A4VVU#6:0Q87,4KDY33;(K?9M&0;<M
M9D#FLA[=^ITUGP01J<(KDOI0PGY&+<Q!\^'?BSGGUQ\EB@,FRA0A"&1NZD'R
M:F$J]-!@ DM*-\0A'F141J"2RNAQB^_ONL&@%LMJH>!-J=::ZMR.](<$EVV]
M%KE6M-(8C:%$J1^>X3' L9J;UUT[Y =KJ=5#>_7LB7G1&,,<\17'X.::>7Z-
M6PSG?"1%T!@-]26$BSC[Q,=*"4P'TNXC98PO+];6VK@2]7*Y>ERW"U0PL1T7
M-B$,D"7#CL-C%TGU+"/?&HV;B2ZOD:B6'LX::X#OA=.6%44L^*(-A2TR,-OO
MUJ%1UF#YC;*R\*5UTS2P/#VW.A!QM!8,$9%QN,KJ]H@\O;&KV^:&VM+6@=C:
M]CHBQ8 >F:T"8PR&JB+RH1B.YH9(M79U<M;J%(,4_2)?FY%Z:T!?&\$Y ^L*
M<-C'175NP@-BL6%VP0:-0H\EJH127L5C.4_4]< M;@_&O1:Y$C /VSBH+W]7
M1:3^&7"IZ%O>.&_>7%@N&?[>-C*GB"@3<O)I'7,CZC45T_($H1 WSZBG/QN@
M)>^N5*[2?_1RIL-1=S1N9ML_W*0V[!^$&*6:9X2+:J)68Y?;[ZQN%]CHQH[]
M!CYFZ_(OVYYTD3R(X%-X-66DM:-]*P@(E/OCQ- I\_(8E%0=(?B=6)!OU'51
MX=N1X34A)O<X,7/DT<TEYD(Y2.@J(SE<8C'@SF5%:<#>E-(GIB(KA!W6/,H3
M9^H:@0^;/K;@;V4@<,0>YT"<C>L?I$I^7W&;KQJ(D-02ZHV:ZUJ[(E%8TQ(*
M#[*[W!4ENT_KB]=8K9[EZ>N1>=-38X0LRZ"8%2I::2!PY1DPC%3"$G%0V+EX
MD\L**9?*.K02C;V%,K73#$<GL \]]P.6F)>";+HTQ+R6Y?ER>"*OOQ&7>O *
M\SV_9Z/@^/AX>/3DZ;.S\>,:JTSWLZS2OQ$A=YN,FX(#@A[S=B+ZWZ"U*E3M
M]/I,SU,[?Y-$STPSQ07N#F) S^0PM*BR[O'[HM;-84Q[WE8_POW_TB()GM4X
M:%RF8/ K#$C 8*@WH[4=O&NBJ[C @&OJ %93:H^'!BIS@R_CU-;>X!-<1VA#
MF$!M"S!9Y3JL>>1,O6P>7O,'8W\76F2-CQ\#P%S %B_-*<(G!37ICF=9SDWO
M(CW5J=MBG$,ZMXN(. @C\-[V;"AA2H_EC(B&*Y";::LMR]'62]FRXQ/D"9.W
M]B312J$#SIW4&.DZF;#@8BN?1'C'F#PU/,.97U3)S,'W>1Q3/EA!(".8F*E*
M"F8I ,DW:^3XL\V)PCS;]O._F00^YB)D:FJ5N=V2+-RW51D*TI>VBEE18I=:
MF?I \ZG1*'X,0ZY$/H:9]%@J'.UJS9X0@ 0\"*5P6B7X1BP-W-6$%U"9 #PO
M["BP![$+@Y @F(#8S;2V(>7M/"W-H1HA/QE_I$H"<[J.!!X2K]2*VX^[OB<6
MVQRIU;#,AA$.L%9?61K:S_6XC'H9M37V=O4 _S*'LQ>@T+-]V<P)"31LL]"$
M7Z"4AK=*@H?BC(Q_P9H*KH+X5%DIJ@7AV3#@8"E27$L+A$QQLV^$7&&L![=8
M/$&L0$?P5@!S4O9+TJ$GM?X/TKK0<MM@WQ3F'\!WG5:X_:84U*9^D+O."]S3
MQ)A0(L:\:3&(MBE>/7K*P1ILFB@!\6$,6,/Y.>)FR:FXKGJOZ2L)4R%+A$=;
M8#V?:P,#(31<.J=;^48H18RLS_8CE@*O*[Z5B?CZ6EI3=KFOFUV#/QX(;:0!
M,M5B Y:5C6I3UVI@ZLH!*]]#<ENBPU/60D<&Y>A80OQB5\S:U_'%[A94-E%C
MRP95BQZMD07D&LOPQ!>\E&0F65=6"].MK- J#^="/VK9L\@[O'+NA\\:94 (
M=1YWV1Q;'3WGMI< \>?;K%OALIUA5I1"((]4UT-F!C589S:T:#-;XTN*ZSRO
M9\ID662EBS+B]%#IGE-+3!1HZ6J/<Y90&OC\!*OD8 ,B.4_:0J%F1I6:@!9#
M&>M'J*V"-H^V8(GVP.T LGPWJZ1MPL$:I;5EI/:I)D."T33SSGL8AP_C.-G#
M.+[A]#I_BBQ2UDQ8V]4@=N)M*0P'$>\6P^JDV!^Q.]/4&DB/5 Z9"S!5ZN$(
MR.;BW&C0LF*).7_8M('%>NB@XW)!:.;T=?$+'X6'L6CGH7-E&E/H)C&,*%*&
M05WP]$3>K9U*ZBKY10(PG,F">;[\- "/>A2\P/>J*2I'"RXS8;]EC\ X":9\
M3L@'7<].5LXR^-""R G,)\^P(']Q%SST."(V3%8HE.@F5C.2<BK$]J$#Q(N+
MP4L,#+S0K"W907 )1LLHY8.4P(I^"H(/;D>*C:-?$X:-!83=$",3G6=YP=:W
MM-P=.+^(/"_L]$"-@VE\?CVHQ ,]S(PU:,FD(PQ+0G#N8DY&-<FNK)ZX7*4.
MYRGLNAG]7((7Y-U71% &WCIQA8HML,RS6:X6IN$*->L-,7@:$5DH0V[A"M@]
MTNZX:)PX7E2CA@NL"F?T"N*]@9QNG246KK$]M93A=!)8@C3"0>M$N>\PQJD+
MDZ6J/+I0T[J'Q+Y*8P2D?SW1E$>#V=TFMMX#UQ6_H%8P@_.Q[CRT!VIQ?W60
M0^RXV$T-5V*N*7F6<$1!:L<O]&/O405_55',C;B'!,2[BC$_9(+#?)5M,P+_
M::<G6 ZI;U/@14(+-47?/I]DILD#WS6B@'PM]%H$1\^XT^O1L[$7A+7/_4WH
M9R^\SA)OU'4M\OKBMXLW+J/ 5+?"A4TV<X'RWN>F&',4SPR*Q9K(OQW"!4P>
M15$OR*W/P?$!9QNV6C&W[<$Y2D2Q.DRA8!R5#ZD5^5J&9%ABU/B1I>0EK6 J
M0=CQF(G)6:4+A<J+'1+L<=J^ SY>8@S"Y<X13X)4,ES)#(4/U"KECE=R)Q2M
M@0,$(4]SX??$&G#O7PNHQA@ &;D332%COA2W=(PQ>9 UZ=8.)Y6$RP*LJ>#R
M>%(8+SQ?Z0#N1$HP@:7A8M8XHXV ?LB O>^,L.[$BR_-X >FY=&:5>+](YBG
MQSN;CMY$<D5[GT+3@UI$<BH%F\[.,'%(% [_P.T,15Y+]!M%$]F8KV*WCUVH
M4[(! O<%;<Q,'+V#:#_;N-*LCS23'N#J7;,AP<):9_0FXZ4=J7&,,XTBY0;8
MOD>?4JX/)5C("/#6%A [L*F"^BS5?S-8Z^GW )@=%0,J*A.,H]?V,(M>Y'?
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M</RSU!1P\Z&GFB!J4JO%^P>WM51O*<>)B$RX<HH)6GD'S>..-JI!SB"MF*H
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M@B3!18:!]?*R9.#55!8@<YOH5P&B%$YT.1"'BK 9.N8RHF[F2*F*Y+BK(GG
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M2Q*IE>M4-0AA^6K&*V=PJJ&G4V>/J. ;0<V#03LZ^GG?;O6T<-:15WK,3PJ
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MTQ("E1^H0J;5;FIT/5O76WLEU%-2;FZ-FR#?E8L@B(;2-XA.]D0*YU%ZJ%$
M/.K$"Y-ROQY.(".)1D)$%9-AJ=5,+;'0-DENPNW:<HM&@A$H/#?%]!:*_''+
MPL@2;:N-7;REWW;E&W;YQEE7OO& QUL?1(BD_ZDG8)A,H&(B6!UH5E;,0,/1
M^)#ZY@_,&L0$/DI]UFRUL"[ 0DX[,P:N@Y2+U*WPAF?O<'*.I HO3^.[2\D
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M2W6N"FWN!N\/%[\L1(<U0+(V!(M!78GH*$58*V?L G^P3F$7J1A]:T@N(@?
MO$=#]RFI%0$S32P2)3&7:45O@L=""RR]X,HNK@C:9&4D62;C0UZ#!H%S"#JY
M]+UR":\*;,O38V</#K4/9XXV,1C&ZAZ+$@H7T"R<SJG'SS)_Y!OK:(ZI1*$5
M3ZE#>AGXI-?L"FE!B4/BL4R@$#R]2!<O,=]P3!?]+Z!7+($3\ 3KK>"HH=6;
MXZOQH8.#7PX.'*^/0#&4&8H</' D[ ]> DS.)MI(INU<RL,_\,-?B%RN.QQF
M6X,R!=NE[:"HP5A 5U]KT>7PH*NO?<#C+<;K=;J+C09B/TEY-4I[C@UA[>?C
M:+ =->W?!N.$DU,J-_4PEKUMT"N5N.L&_:=YOI@'=6F$EFE.L.A'5#)P,!@-
M0'NBWIR7#'JUF09#OO*Q\**>S=)9YH]HF8-42Q_/,-<RXD3+B$@B8UT,X'8B
MXRUB/ER%K1496E(,#@X'3;Z_VD2#J*A\K"S(,EJA2L,3\4L&ARA/(@**TAM^
MQB2O#(&*@ (;7_?=8EPNM@CYK"/D[RU'"*)_U3J-3YU!YP2ZHN+!X*R)BF4'
M#41<_O1I:%AC)E1X:C>[8_5T14[/(708XRK(<5CCD@K-+ K?G0#X&P?O$, [
MNN0)0K %OFZ,L0'#S><80X)WH5)F9T&9$>!6,YJ %^EF:8;IL)YM?JQ^5UX>
MMXBHE4FWCNXVH72-25';V81HI7IXK/-8UVYCDJE6?WI-STVYU89$GT8BE11X
M6IQ/B3<=Y^E\99K5U2\(EETW%1L+![B$L8U>.E?Q#2(FNCBJ"9N]!.LPL=!3
M3<!!1V,0X),PVU51EK2*22./.93@&P9=9-Z# E2BH6*P=7L I)E.-T9T2)X.
M1EQ;!WW-\G=>FM19AH,KM2K50,FY]5U)U%E/9$&TTG+7<<MY41]OU'P!V"MB
MF5\P9U[B1ENZP]LB2M4"%,X8(P3D<DCDIZEX+@"B,MVN, ?M-R_UO;_ 0V-P
MVP\D.MRJ1%-8C0$^++"&-=0^H$"NV[7-C>T17_S#A?<UP'EH-)92 V:26;.*
M<]UYN2+H&Q *9F32#DU!:PB(E,\_3!TY>:FZ;K@X0AD6&#GT8A%PU!;U_+/_
M2*WYFG7D8=? %,BF[#1:^H:A^K HAT;9S%>P)93;=#-NY5NR'?TQ^(B+?.&,
M0U\TUS*0:Y7&4OF"'9+^#YIL1&K3N*!2C558MMV=S-:MU DM0E!%V,#M!X+F
M')2!)K".*)VNRD-2LZN@=&1&RF_))KM)FJ:0<GBDW!?LR,>:4/!BN()+BJW>
M"VW]=PY+G\H, '!4 @Q_4)"C5,@WG>JV#712^-30\'&E<"Y?BL! ?/\Z:??3
MH']P8)&1=4<D.JJ$#P_\LH:C4BQGP9_2$%#U-;4S"B$='1UA9&:OE/EY!8OX
M1(O ;YGFEXIT59"(1;J1-^41#=BZ"50_/^XH2''6L8RNA)\2GWOJ)W^7D9;.
M)P^[9PKA-?R+=C%VD0#_"-0)D$]<.@-R7W"/RF8"XW1%)OA*CE?-:H/3%RHE
MNF/+"XVWP*_>$! 0.5UR/_1=.(M0S>G%H;E"2W('RG;TX+4VDH&\D];([H3:
M 0YM8].\D&CC;-J .XQ&Q4"8-!<P!^JI4>57EJ701ZJB10;[-8BH-.TBSL'@
MG+.+H9?'Y4K(=(2UCT;NLM@@W\2$1<IG["B%ZF"B@' 4LKD#M;E/>9+F7F3I
MJA*G#0;(:2QLL3[,#Q8TK]O+@HKQX]$ 9AZ_UF0$*29;BEXM(<?S2LG!*.#8
MJ<(M%6.QXIKXSQ W2V,)5"V71U/ T.YA@DIAI5FM\R@W4$J8TJA;_'L%L43/
MG:XU_LK[1U_-!P685D__EH+)59))48D7V0ASAEH*%+^+$N<\)3P0<3]E*#-B
MI,26+CRT0"$U)]XD:%]$I!<G%HXQ2QQ$4YPH<+:2BK-IT2@S)+?*)6E(0UFC
M,SJ@$F0:MH#NOIX.YZW83(EB@A9& XN,FU!*5DIL"Y1"N/D>E146Z:J&.>G9
MJ(800\YG@E#D!S0RT;! 0/6#4U@C3J3TL?V)UJ5&-_+X5(VQZ3&V<X#.+/ZL
M9_],GFC]6%V'3B.N]XV*.R8^]T-?)@=L^2LD\.I[6?NPWQWHF(XV<2@.4C6D
M"H)[)YGEM5:RFWS$YF"&A16G(0R#LIPEH,H-OTX\!%ZRI)($1XCCF&*XS(:'
M;R9Z;J@"!67_PHJ0N394H'DO/D6]EZ8 J['?Z",EV-Y1G3T*KU-C98L/8A^)
MP6?A_;XU2K+@V3KFK+UY&MO^-D>H]-1:"?_8;AWM6Q>4*U0F-4/$4;/J)P%7
M(JDO8*Y .C)HB+W:IV &8L,&TGK=1$HG)LCU/.+9[5T9CUW&,^C*>![P>$W$
MK-;%LJ(F*/E53 V_656WU)(A$W<D!5]C.2DX5^>O/+;"-A^_7#BO\CE!B3FO
M.,^FQPR)B[8,([ /K\#N2_LJ;6_A/[L\O0T?/T6E:D.7JM@:J7]$@IX0XJ7P
M?#%,\LN6VF6$/(@B-)KUYL$T^V54?[7\)XRD1-DOO<'I,GNBRZ8S.W[Y= G
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M=Y<?SO&&$F\9Y%DX23G2L_?BPDLP#/AB?Q<&N74CEA]QQ'(G:[NAS-L.9:[
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M,0GA:$)+\EM6445[4Z^5-K*4O+8RX+9A1[+52%8-2O5!I<<-U]*.HMA!\)J
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MLG+CO<)KI@'9#3^=](^+(W&EB3T)PL4X1\.A+"_5("TG7W)RB#S:G+)"/PV
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MMH,6$5FCH@IT[96IX<_L7H![ZS$HJ,*&6S0QJC=ER.V&7]14S13G!Y@:FB9
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MUNN_N8K)*3)>EXK%P0^D%1P;D(#I KPVL'A[&9IGY>>Q18.R!WZPD#,(HIY
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MX=[A#^8>[/O*?.SY?%JJ:WH9XP)" KO3CY8?6;A);85(NB7+@KN=);E"T+L
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MF:=9.%T]W*[HB;^$&;SN_[#WKEUM(]G"\%_1XO3,P'EMQY)\39[)6@1(ADR
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MC*.B<V[>*8$:\5".)/T>J !)+QZCWXV($]4:GTMC:A8G<7R0P)DJ+=D%?7P
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ML:-(A!KN+&TI;BH6K!$LOYEM;3#QG;5]DH&YKNB+6Z+/:6^?ZS%.LX9-;7/
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MMKP,JND-V< ,<+P1)0Q@]C"J?X[X(:,JK?N>KA;WM%9YJIX0T!OONNP,FO.
MV?,]8"LH,^V=Y^\V>ZY<:[ZF=2"""D+$?L;XJXN*U;.T@S+&:<PYUCI/-7>T
M\6/1Y9_H'\5":1 Y&H]S]*./TJ-3=():I DKZ2EG/QW=2(FP[X#63KU=39M5
MS>8NWZ-MFTU7_%3)XF0NQX">3&\-Z*AZ-GB!M4N B,Q**J^4W!Y3U$ X8'@I
MPHC3$,N7TW+RW,Z\.'5 5%1N OXS3H;H/?LE(YRI%-'RD:DR2S@?TTXBF??D
M_.C@7['6U!9/H1JXPFG)1:*?#3-2'2<9)L*!IA(,D\!S5#J!*'M3WG+=AX>?
M2#F)3L4;[B1D1H7]/LC*2**)E*.:V)2?5ZA+"68?B>2A29K%%&N-7U+H9XA8
M,_;38&8\ ?44M- @5'(<,_>IG Y3*V1G&?304?4N AF3?F0>D*@?UDO(J8Y?
MRL\*I==&3*2AR-*:-):0=@G.;X4P2@5!:\9[D?)3D5%O1#19=9=_:H@]<0"[
M9(T&[/D2J"]&#3P&.#LB+CZ.D"R+*7UB\=2/*O,WB%+5LKGFPT*AD!$]3[9M
MG=GZ!2N;QEGZ/CJAQ7YS;R'H\ZG\;MJ #FP%5PVL(DM30$)VL1&YZZIB&BM'
M(I; M7F8BC"I*%K(,K0R7QOF)**GEG+BXKGGR%I(P<VK9!:\WRQ[&AF?2JD;
M,DKGDKEB?9;XLL,P/4,ZAAM>!^*L%$-.HTQTTS$FS7&#1Q'P!6R] !85^XE8
MG";&89I0#F1X9>3)Q#PKP6K$Q8!D\5RJ=W3$5<>AX >QZ#\]P3&W?A*K?*;K
M,.WV,.+A2#"G?$HX>LTC(H;LWE1688JO &>)J?KM(OO 6CGAL,=F^=BFAL:8
MS2I?9>13$5&QG]SW!J%HJJ&2FJYX'KD5*(*P2(FDW8O=D2.9,JG%%@3M428Z
M0(@,7]>X##'Y0'!CQ+DL.2VM2Y(-GN,WLJ0'6))V*9@WW\,^3G@)S 6FA)%"
M[9[URMUT+95KX7(T0V06]<CWLF;D(E-.Z]:>R551DH%IMEX841@FEU9V>3NY
M$F5710L!I/CI&ZS,\A$@AFKMOV7U58J_1(^T.8'LN&O\"5EGCVM$B/Z(V]6'
M*1&LV,4R;)F,-G7?@IME#%HECU(T*^V]PO-5FE26/8W9I H,\!WHH$5<##A*
M:19-*KELFCF7M^%J[GP'DB[J,PQ5=3!Z\_T#@'L?]!HE]L\TL2\^RSP/9TKD
MJVPP47Z=HF8@DS/#)5%&Q-YYX*;9IB(<2TU0%;]<[%(RWA'3(F9%W\T0HW+7
M\Q73.9<\CBC)2,F4J5$ "O\UA!?E& ORYS>^,>!L"TLKKLHN*PT[2Z/+.$/.
MG$']BZHZW.P3SR8V[<1D#L0CU-'PMC'VR6.LY//B@?+B*8.,?E;R)\T@2'/[
M$$ 92\_*,G=WC@_>?]G9*QIK\PVF?LY@ZN]59O-F#3?SW1JQ+EXD"T\49<_:
MF.KA59CN,7,0!0%&Q=A'230*54/$&2,^:@:>.$M5)6ME-K/.$A^)[D.A"QT(
MR:$"=+O>7CH,A&I\0)"'$XY/2X-&C>0 TXX:!5![1Y(=V#E/ZD,<>(TCCB7"
MC&]@96UI2B#$N^:!DG#"5*3T"1WP(&B9Y].U#+@_TJS7E/=HR:-DIL^>"4(&
M"TAR@+,O-%LLXB'#2-BHM$78X\+;%Q:2]D*Q<((E**H0,6]+%L!%M12%T'PJ
M=#-;4153J"TOA3ES<$3,JMCUKFXY6QZS8];GEXG\A:J;SV KL9DJ),0X@-2\
M'<O6FU)H)8$&'JWROB(J7TEV**]N_D65A<VC\DVC9@&D2!R:'4L_#&/N7W&1
M%B-OZU^@D(8!%F'(8XO4WDR35->.QDT@FD5&>+=26>\CY05$?5KG&#+-,7,:
M.:/6ES//UGAPY45RGH(TA4 'I1:M0U!YQSRMR.R%<"_X0XI7H#;GC)>IQ3&>
M,%.%SM?-*1577BU=#UUH7EVNH5-0-8A1IE/>.)ZI^=!]8'FML$>4AX<*BA)2
M:=-QQU[\4Y8O+;9.4CMF23M%#0=:SEBAL,A<6^692^1<DZ"96BK=%TN=0%(5
M%5(N;;68]7<>4%8]5HUS-4PI'2)$VJ=6GI?">@4<U_8NC?%Q;DVTR"./^$.F
M6SR*OW;%$:!3.E^5U,!+<MX9[R,VY-=A]-/8M>JFO?>4OF:5.R09TH%^3>>H
MS E.>19=LD!V"DO1Y0+$C'L--$-/4=&E,DB4.9)=7J4H-V=8&82.6)NFF1$+
MC(3[Z7*/J\=M-BN9TV,HX[)3"!W>SXC9S)#\%9?^'Q#]FHB9*<WG&BE:Q:LJ
M=5TT[E9@/[T[:T4AA^GQQ7/?IKZ_VD[7DSXQ*U3\TC,"&MM6$W,W%%@N\Z%1
MW^HTSNZ[N<D%HM3V.(MD/L^$IM,P> DYF=V#N1>I959\256.]V!O86CG(\B#
M&)M:";L2N?UG:7T=IW,LXJ?4 5="NPV]O?LE#K](*=5<1]Y:P]Z"O+7'OY+9
MS.;S_I<+X_CX>/N9J5E?P$RE/Z R';82[JR#$(PM\II^0-V67,S/T\#*.^DW
M^PCSHZWOR)4SH*Z X8A2L(SK"-T(01J'4+U"U5GI(H\PC!!K'%JE:KD9#JBP
MA,BHT.(52Z=P5;0/9^1O91]JF=,J^RM,8^2^^$DFJ:BZ.:JU\@"N#$RL)'#D
M%.T+<J7<?G**]&+7XL!E5+KAIZ$5F<4F79=I=:B6TBW"/RJG6P5_THB"=AH9
M>Q%1D6E#$$![%7H$2CAL'^Y"N/3(DJ0&S;+[D/+\XSK2$RM@CWEI,I](3\S+
MGT%X0WQ0D'RC,)!;QHVD[WD_[<WMA*-)EJ'F4F\1D+1CY6'B,WD!=IK2HPW7
MO ?"F:MP P[OD!TLV%CPG*?3O@0ENWA!!+/7HID[?&OG[?7U=2W&#L0]+ZP!
M')]41Z1F^1C0<T5KD[$7]X7/<+J 0 Q=I#PE9/E&LU9OXF50WD*G^E_-,4<Y
M6:J_.OK[<,2<G+I#,WZNF7<EV[E61%WWE9<FAJ&+D>@,\:DW(=P@DBRFB$IL
MD9B W=PBU;,V;;"0Y:&R'N#2\S3&+JA6>&9#Z#0)5>65>'@WJH09)\=A0?U
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M TN77>R6?>V-!^D:V7[4^_;^^3]FJ_YF^L_<16P3DIT?_&=;D>R"W81!.)R
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M;%HJ$6M@1]^FE BSY;A-%Z#);5 =&DV35SN->KO::35Z5LOL-'F_5_H@MI^
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M+/UT>]UTKY\&YKAU:@:C5C^V1H=AF -<O8ID33IP6[';,SW737^4CMQ1J+I
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M2LJBP;R$WQ9"3/-PH_R,B2<Y^#*IN2B)TW#MN/-$!AZ(I0ZXR0,:D%1@(I/
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MB:9M*LJTKZ7!_*0.\T3 3Q?X^0G<BUXR':+/;R-:*^^PREVZ<<RS-PD%K;
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MBN8Y1T?GR5EW$?]<*>M_YK0'II!]HYC\#K7U431>AB/.@J/'&H%Z'",)*(!
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M#_K-^?/YP.+6+BCR2S1"Q*P\GRF"IPB *M5\)=-RP<LK"VSX>& 58+!8V&0
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M1?NO7W. U2YCW%>0!EI&ZH77<57K[QEY3&^,0=0UV"H@.Q1@$RGI:ZC#VE2
MU<6U,[ZDQ]K?)(,H15/HLR+CB]E<FI# ^N5TMOM(KV:D5E/OL+GWF1Q3V ,H
M 9;D:@L?=LRQ_[!MBV^#X-WC&+2;6LBL3U(PU'M5[W.^F%,_0DN%PJ]G< W8
MT)D\1PI'1:##+PLA6C9HRX$CA\D86F ]<.#0$L-?V@1K?=WLN+X9FD!7;<U%
M8@>_#_1.KAA<WAQRK<",'.O>NFW'-!=->&-?*A,,/7:EC)7G+V_V^Y5+!*QF
MC<&,G'/EP',,?5%*7[LT]5,?*X7<46/^75R0)6(-Q7\6A8K)/](WNY;V][N1
M%B?LZJ].S();1RA%K3<+$ 881VP\1R*Q>D_J?-. ?(E&TA>U.(=[+J:95&;=
MF%_6W/,&G92I(.E_2+%<N-<.G_*,6\^VS",P)EIK0R,0R2[32\"TK>:_HJMA
MCN1XC +QJ'5IV]P>("(Y2'>4Q*0K^#D7Q?R*7!VX%M9<RO,2Z7E.W #+&_,"
M[-GR,[PT< >%+2OK]3R[]PTP6M(\L%YXYPW7G-(UP9=N? (O4 D1C+X4$_"U
M^%2:@+ QE,B@::B?(K[C\2KE"UN(C*7U;?N8\G(VT?IJ^50Z+[6*X1K-NL8D
MP\8RK63QUU7WZ-MK8&=EUMH:1V5&],H<8]>.4BD=.TFXG_@!%S*5KL@\Z6=^
MZE"9HQ/:"=45X ^>W2ES##IECB^UH[9#3@J1S0ZH 73<Z9=C#)3FL@2VQ $-
M\ZM]XM%J7NW3XF'/][4AN <O.[^B+=4?OI$EO3L<,/WY=G,=PM^LR.%@=]\^
M.#V)@L06490R[N<9\WGDL#@.(R9=1P0\<2/?3K9>^-O++;062.HQ$LXU9J>V
MOE<1OLG'<*WG,;/3"!VTK=&/^%*@80 LN99:X3Q!K/>HE<O$RP/7]J7K^;X=
M<NZ'89)%.8^ <E,/YXDL$^E2;[<ATQ8K 7%A111X\8>YLCIKTM1$UP ,,O>W
MHZF1,QJ>^")RD\2)&<\2G_G2#EAJ^R 8/.E%<9*YH?2W7CC)]O*@C_\R8NQ"
M6?3GLTOEE79DMR*V"6B_0E''.2B0TE!;H6NHZ]"9(M#ME@K#I/S4XGE>C OM
MA;V6U;B0UNMM:Y=KXTX%E_M/1S3)L85IN1+\"8W]7NB,+I!5TK/^_M6KUMF4
ME[+DB9:7KJR[NK&.JE=W9:<\]1,I;9D*'T0MYXGCY=+!.=R)Z[A/INYJO\FZ
M#UIVWCK+;"EHI"'OE!5V#G[:-=JB#@,#N<^9,7G4QIXB PHUKN%*F:6+<^VV
M<G&&V003TJ3 1%[ (V$_0&;/IE)'CJGV@2Z;RCE%7LD!M"3< 6\N^QDZH,A)
MI<L0UF?BUF]&[5S^83TKP"@'1ULR4H+UTLS[X,K_SQU:4KB;!VF:<"?S(S\+
M;!X"@8:.;\=YYKJY?3=;C5[!O$'] H=3B<0T,FM]HY;Z'G:0$K)'L(.S_(TJ
M,-M88*NUY><O!\.3S,]S+Q8)$W[N(9RNQS@<&8N%&P>Q(T08X;A8=SM8;X(!
MH5!0M*9[%=7M)Q ZSH8YTLS2I]2X3JL*AOX$,KUG.K5%)NS0M=,T</TD<U(_
M\$0(3H:4 4)/;>CT<=#I\= >79X(5\9IX-A,.,)F?B@\%D>Q9)&?^FX:QE[D
M@*<07><IW$"F%!GH4R42(RH,I+-6^4,CR>LL(P%]EX4FU7NFU5P*7^:"<YYR
M/XM#+MT\<9P@"QQ'>#S;T.HCH=4]__#MB>W)*(9C83+,.<C4+&9)(ET&EE:<
MV''"[0P\$.]'T.J_.=@W?ZID2G'QW&36P#>0O)PR#"+79HJ$#\=H4-S-N[6S
M(+-M-XXR-_5M5\0.F(^Q='@4VA(<]QMHT;T%*39N[BP_D$1YU2Q_:]YE#U[E
M<#'7!%KM4CK1_!&LR5E6_<9>\/'H<O3V)'90AZ42%'D$-.A'(>.Q3, 5COV$
M"R=,\VSKA;O:!:Z-T/6TIG.XC2!LZ$N=P+9UA-[O,ME1G8PF;PHC@G=L2@*:
M!Z/<U3+URDHE>"%3"C,J;LBTV]SC#)3,^%!SG2IZR%H7PG+ SR:O&NW>NC+/
M<S#QYGDZW8KR^[H^IV^*1]Z&[&'G%#G_@^&I/L57>)7:NB$ZI;NP#0V'=&0R
MN%7B#SBDRUF957+ZVS'!>_=P>"(EV'5Y&")TJ,-\%XU;\)&9S0-;NH&=."DP
M05[ 7LJI=07$4?5;GRSR_CM$IZ(ZL..#ME>&E'5%?ID.*5.-@"F7+$JQF&"T
M'A.3A2[<K@H0][RL&V&*NMQ\HLH"M"6L*[J1831E;X-U?">/=Z *!TS(";Q+
M72ZN/5!X$21PE )8T(AWK(O0X>46U P]F2!:%[628&7^;$I+DCGZG'#'NEJ)
M&/*AV*>8$NN8&'P!MLS[2NZT%O^N7ON>6OI\-E2.NJK& .X;+K '05<%;QBK
MS5BG/ECCX"T)/XU1L;@I6#AHC3LN9YZ3\B01?F3+:.M%A8GT-6S5='#</HLT
M,P$5S1]4+-<Y*5-@B0H';P2'-,Y4RK%5=-3BIY[6&JCN!4,KIEIRI:FUY*,.
MK%=4>3"P_@(I0$RW/^=8Q')T#D)@8+[]O[".;#89*&-M8.V<@<10)>^4@]RF
M6AY==3@G((*5RA.66H!RNRBR!1:=8+5_S=\4HFY]2$F.5 K@(4M.SL>S*^1\
MN&1"^J_JA9G_>U69\[;U/[-+K 4:].K:%3B%4J%8)3_5WI):>WL9!+= M3W?
ML8I'6@1PQ_*&UP60=D99;SIYE;]]!X8N$%MK=.O]O:3KX__[@2'9X;54T8Z_
M8IL5QDP'*G**FN8"%.ITKOL1%'\3E8.X!<YM3[-]D!Z\.SKL 0^2E$=V$,6)
MGW&'9U[L(0)>" HN$PZF %? & ;]'"#. <;_[34[-)QF1R#RYL<@9%K%$!N/
M?*6^^KIG'WPZO3HX_G!U>+SO'%R>Y(*[?B <)N(D8[[-'<9EZH)GQ-.49ZD?
M<QRU&H8K$H2U?\ZO(<8?SF?8%#!%-)O%9$$CYX"$\D(4=PXK?3N55B!MX*<E
M.'*I\,?17\'2VF&SQEVUQ V9KB333^\=\%<2WXZ]%$@S]@+)?"$2EH!.9WX2
MYZGGVK;+Q=8+SPNWG;6DV6E: N7[D%(3)#<Z$"I)?"&5L,_![JM465)W(-Q#
MLI1"OP;^>5 E<Q?>_5[$W"55<R#GJ&G>J!:F[.45N$W9_K2>'C"L0<(W/+R:
MAS]\'9V>1)GGQC+D3&29SWS721GW[)AE&?PUS$&O2&?KA>M?IUV,)XVNDZ5J
M_5=;5=L/R3./3]!,Y2E_&H+F(3?K3A;"=V+?KC<5-N+F^\7-P>E)XJ1V#J*?
MA;;G,%^*D,69F[/4 :/!26R>>]G6BS"^UI@%@_).JN<[04<W1/$#B0*3Y5'H
M1SR.);-ERAFP;\X2VW>9EV:1&]M.CM!A+SQ[.[Z=#JIZ2DBG2UR'2 ?/>&"R
M.-2VM6T=47W]J@8K_.!<!?3 8<&NU1+N6F __)0:9"3VRI#4KE-0"F2$(F\Z
M0-!M]C>ME3K.U4C[\0SQ8WJ-[76<>H;5OI*B#+H="7MHY]1/J'!,X/JU?3[7
MZ=Y8!*&4/U+W/J0".>Y$<BK=3:S!8%H=71K'0N/#(&*0Z7^'OUS0)V,N%)+J
MJ@+N <+DJ#I\\X=.?;>9$6+JX B<"T\S+8OL5"J(UX&%L60\W$RF<RN=E27%
MG2N5$E$MTV/K?)&."P&K@.<AY3S;VG]SB#TP*E#-,"??_0K<0!&H:I148 Q;
M?,Z 7I@*8&W!;8;'B(K5NFC5R:U%\/UI!E0KYJVR5ZW&]=5K_EE+FRWFK,8V
M,KD>=>88!<&Q9]AMH[)?O$' .))UL=D!MFTZWK9JNFUU)(%$LE2+A_5,!RB>
MZT(TA(*879*P**9*U^"VE&!BEIG))/2%&XJRZ;S3PR/5[>MA2]6V->)3?JJJ
M0C7>1*M9L7]+,F6)P'N1TFN#\*UFQQQ?2T- Y(NN[/SO#K\28-"<1D*KM4Q!
MY5OS2SG&E L<U%G5M!,19\]O!Y-L76*3INK\^46Z$U\M5%W!.Y4E5:]YGZ_V
MX"+AN$,F6D'F^K7+]FL3K:F>79/ !J8%%JAK-*[#_;A7@GA,NT;0!$V! +=4
M.17N";PX6!@F_P\?*CR"'IYG8>3"&;] ]:6*"U1&7F&M-9J5]%-9+:Y!7.NT
M%*>+.74S4TLQW1(S-&CNZ,8H4I@&9DC5U[]!</1]:Q^XVG*&V]8[> OKE2X9
M,&AQP^ET08FL\UE)_=NO$.;1L=G_/E;.O_5Y$IW#'BY*@KN9<P64@C@7TTK7
M=2C GF+^QRU?UL.^&P73SW#$QA_>ZM=7?RJH*_X/YL0TW.,A-H348_CGPUD$
MW>UR?,1EW7H!?P-KGDX!C<GIZ8SL?S#N3HWB'IMNC\:@_W-S2C_UE":\F&*&
M2)EO!#DKYI4VQ.>2@#\6"K4(S!(PFU"(@ 5>S#8G]7-/"GRNA=#<!$=18>OW
M6*/U@0"L:G["(A\J>U'5EKJJ@YF/"27UMH<7;@[O7@X/--(8@QN#&F5$,QPA
M;E74T; :=@1U6!<WL UY\FB-][L;L@8PX3I#%FNXK%S9-^V6N8TH^JG4W/8G
M3.QO#F9K4R]XG7NQ41P/?%KU22$WG9MR_-(P8LM$*Z87L_%%+[:"7T4E9- 5
M-^?Y\\]309UW3].8<@:,6F*03*P+C*VV[FC\F+IQ)G--&BJ;O.+KC4TQYL6D
MHBZGC6'Q4XF!?"O5.*\!7B?\<ZN_<6"5LRNP)U11JPIJU+7+Y'D59<8PM'RE
M&Q 4?#)&%_#>ZF]$!76D][8VA^,^)J/C/>%T4*L(MH .T+"J:Z?;X@VAZT[E
M%(.PLA-6T*FPJ@<71J":M)DZ[:(*Z#$X/)4RJTO@%<:PP3<BK'D5B6ZE(B@C
MTD2F!RAK3V>PRJEJ4BT;G,SZV'0$<-LZ5HXTP=K/E^+75LD+],9;DQ&,R646
M2.ABNJ'1K*WLY'%H?4T!L-H)Q/ZFM 1)"<*^4:/DBVK>FQW0(#AF!8*39$WR
M4 $HU$7JS4,(LT_9>JB<L$B;&QQT3="4E)(-QB#/"" 3P;\59B9A?BK9MFYE
MV]9N9_.)0/@%+\:8CQSH5: ^[&0]%$IXO3HYK9IUX5:4A:JN%W"*4\J-48!O
MG5CF:3'&?4?61$;6[7S"4A%#3'$A!1.T,-;8$&<V)XKG@TO]W(8@HW 8?&51
MJMK^3(*\+M6L#LSJ3[$W<+^+:E,0AKIN:B#*:3\&20Z.\DQ.B<3Q&(LY[5#:
M;5/*0$%<#=0K#WK1^ T0SA(0CF,_422<)Z(#5B/VW(S HV(O-#Q,MQ-*U;[7
M&8:SVH%?8JT:MW0-[.FM<-E73CU !L2"FXRX5L<<M"RZ+U!397V:00-++/RM
M8Q>#)S9VT?WA8Q=?\JJH#O.AH Y3.* 'KIPZ.#*54Q_<@[\.BL/=SY<?W(]G
MHZ_OQA\G>\&'KT-GM/OOSQ]W][\>_O-W,?J4C?N54UA1]<'=]P^/7WZ":[X>
M_/7W!.[_:;3[_G(T>?=Y]&D4?/QG_^K _3N'G]W1\"00-FY8SO(@C9AO^Q%+
MXB1G#F)K>5R&=APM06IE/G<<5[B9RWT_]^&?*$M"/PW#)(C2I#]T\>7P:/\(
MQRV^>8<C4H^'.'[Q&T8NWOC<QT?=MYS-O+*&@)*@*39J@P$&MJ@JN,'KRHSL
M8!):W=%?RK"FV7<"R\X0V+&F<,R>PE/.L8;GV=9?P^&;K>?;UA!M5V/@Z3[/
M2M<241JW:1X]1=N0O@7"4'(S92.7E-+%&Z+EE&,VVC2,#H]VR 1M^ R7.LU
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M#M#;_L&KOD# H]-KKX;SPW*8PKIPL?6+D"MT.W0.^W<3$5_W/ )FC^.(PVZ
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M?2*@I5B4UR&@?_1JAVJQ.[#6PWQ'K71#08J"WE^.WIYX86XGDF<,.XV8'\N
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M7^DN_.'1CG4\.P>6BWUW< V6Z@\]A=7O8JEC:*H2'@L8N1H?@*53.<B262]
M:^G8K&LF$F(5V;D95J:N); !=+@ES[3Y3<F"'3Y)RR([E>#L#WLS=TWZH$(T
M 0P0ECA_LBZ7XOK6NI,!W?Q.'(G@LT!(JX@>KU2<E>M!DY8<:WPL4.'8PUY)
M;%;!;/UB3K5>ZN[UZ,1*Y=3Z?QVH:C;, X\I=(J/[W8<U9/*%#!4ZXYK4"Z6
M2+<_<;+W!17-8+.<+:H&^5L!8,"9Z6+">DJD_L(=T#G4\JF/AG7F9*O?-NV+
M=VU?]'ZE]L4;VQ%[6E5(R:,$Q&]LVWZ6A[%P4ELZF>_$6'_OKFM?O%$;/Q6=
MU102MV1!A\>;B:ZZI:[M<S2E2:V_=H?5#WK<W:!]7,/CP_5IMU[J("L4[H="
M%T#GO%"3)I6\>I)1HG=K9&A?UG9.0I^9'G*9MGN,ENJ^M1(U<8MZY&5K-H]I
MRB/$2:$TG4*]7"YRQRILH;+/?&REL[)4Z3G289V5M.JKFWG2:E)H[SE(=T;M
MMOH7KWN/@5;.*N-7-!5OI9PORJF!,:KQ-.N\CU&D2DEO6X>WT6E8G) AG1C\
MHBE*<FJ;-#BE3Y+X^B^O8H0]\J),;7=\JBK?74%* ZI9I]@;,29M.]J^:/6J
M7 /VL&J##0ZW5+!6#;6K)=3(?2OJVE^WE]J^&Y\H,[P5FFO9#BMEQ,_J@S+^
M\3L]#V8XS7:;Y.J>PB_\;6'Y1L<?3AQ/!K$72L9M&3$_<UU,\GDL=ST[MI,D
M"43VR_B][]IC@5J$8&'EVI/TA]^M&W2$X:J+1FUIJ,X:/K.NU5;\CD/LUTU,
M,B"?NGD!A3VA#I@.$U48\$7_HN5#K[$)'2847J(UF:E>X* I_%CW!EBO)L69
M^I*>X=3)J9CD*U^-(:T7MW8LE'FW\[*8J-(;[-P"IW4VG4K]4NWNF@I,J9*6
M7E>54'$[UC\PI8W1UH.-T_A\.1?&BE "<5 OAAFYB7(='>9!%]NYG2G"?%*W
M2$8OK8,GW3(9C<)%+%A97H Q#E\V2>M<=LS+[AD^2<6ZW^ 3=2"SNO9LT:6=
M">)1&/">=F7+A9QFB/" I@<V A,JE]E&W;:#O<$$(:AATTU_EDI?X94+-4)E
M+>TU=$[(8YC76[7XI07VHP3G-/,]:QNS-=<3Z![=13WL2E=$P5\;E"-8:_T]
M];ID\-.WUIA;/S?*?83L19W].RWF.J0P$,'N:NL0IX]6OZ]6__KVQ UEEN>I
MS[(L=9EOYQ%H=3MF+JAU&4OPX-U?!SR7R((IQ(<V83Q% ;8&2I-8LN1P-?EM
MW2:PMM;AE[P$QJ7O*K'0UD/XNY8)MW O2$96Q5P:F=?K?(;OGH+V*ZG)%"^X
MT  ;VK@P8QEQ2>#2SLCG[$KB,SU(C48=U*N_)) -<S<LF5RDV$.MA+5"NIM-
M5;$%",U7U%"AD>'PO\O/,/L!7Z!.XB]2+,B/_&_8@IGX#(Z0VA^S #T<@#0)
M63M:3*((-EL]K76J_HM9L2@+:DK<MMXT5ZUHG(67;,^76!W *<]GY&.?SL#I
M:ML@M:);93S-:,.TI]RIF)@"H?:A]7HF1M,FW-QFVSI:8]S4%-4W^I:WK+]!
M2A/7'F\SM0I<63E&UY2ZOV&5Z:(-HESDQHBM=[<FB!Y>K>IW'*OYAJW^1NQD
MKCM2Z^TVK:LJ M-CLQ:A$'YU4Y6E SE$@PAG7%(K=_TV+\=<?&9'XFQ&O6**
MU!!^FO 0$:>@ 1-8[CS67>"JDKCIM"4[@5=K4 U:*0E:]P!IOA1%C7NMOZ<6
M,VB5X% TH2RJSRS'X>-DY<.;4J"G];VFJU89- 7&>^ 'ZB)YNHVV*P!1U6G"
M;^;H>_@OU74 ,*YJ8Z ]@A_LU4VYJH3:5-PK(E\Z\3]NN:<>)E:P%FUZRL8R
MG__AK=YE]2=LQIG._V!.?#Y_ (V^^B2HJ#?\\S&E:[M;ZOC; >[7GF&'8SC0
M;>NOA\SDUB-^SL><0"VFX)MP,*')$^GP>Z,0TZNVVAGHZN:6+$!!MY)>MRJ*
M 2.\ZI8FV8%V0Q -)%6^T-'>#G:DY#E5!BK4>^OE8HR#G'&PS]'PY=9SZV"V
M;3EVI'['GW#8#UD!>GT- &*1$R XZ$*E*$"3G,'3$55/=TSJ-S6ZAE[B66.H
M7.>C^%Z<<S<1W$M3/_9YG'';\;@G'3]- \Z_V4<9-KGLEU?-5]XH7VZ(5@?]
M\[=:]!LRH)SE(BX0/;]K$==>@$A>@9_9W/=]EH0A.#:9SUD:@'WAB<CC<$9I
M*J*M%SB_0,GFOH?ZO![X,"L+$)H4[5 A$@41A\3R,T@DO9E$TCZ)O +E]#?J
MIF&C%8P$0@&T(9@NP<!Z3A+/2;+("9GO)4 P3IZPU,D$RQSI26EG81PD6R]P
MAL4:>ND92G/^6</K-)"@R@R>(/;(^;@E>>! Q5F[P&>CN1^-YGZ'%NXKM'#W
MC86+;5_;#[7RU:&-!R\-:QP!<D+;L%4U#JWQ#C TJ5RM:0]Q^+BDWNDK;%0$
MXYG"X C1HZ82K/2>J,S*1!)4RT"E,]AP)^H=-ZEELI%EUK5;;AN^WO#< UC+
M?S>03!M^ZP(]K?"OVTQW5H [7U+LIOZ&!G+B#12A&E-P6LX6YY3(6J3P^ABD
M*SEZJFDQ.^]T.^IF9DIH=>&LFW+!V>6TM:@.3/H=V'*5BZ!,_KODFQX;P_X:
M[+EK8C@?NC&<A^*%;DP)V>!N'>+W/Y7IFYV[ZRQWL^V_>]?YOCO:'9W$09QF
M4>2P$/YE?IJ$+'6]E,5IDD2>]#//S;=>K((1266#*=C)+\@+PE008QJ$0^ /
MA08UK)$79B@X)5DO9K[<3*K<A))?JLB [J%N 2*0-R0ZFVHLOLD$F] QY/J@
MJ=+]*2Q%'O,OFVZ@@]W]DSB73L01O"N*$^8GN0""LCT$@0MCQPX<3RX/'W4<
MQTZ$S)TH]T/I)X$3N4X>A-(302)_G6X@12L6$,O3[ G2ZY_C^E7-J#!PT%1_
MT8SCI(8,:F:H2[)5Y!(QC'-)E8]PFW8)Q37UOPUL"PD,O! C O(_"TECVDSB
M2@T0G;4&DE:=B:1-N@VGR:OT5#VHPQ178C;B2Z$'&*Q9GHIL%66K-IQ6E:JN
M$O@8$0M;%<ZS"J?!'!R^WGJN&TC6U4?A%,PY?/?=_^63\S]W]1_@,EHH[ 0E
M3F^_C36VLPHHRZFJ4<*K2G(9VSWAB#]V1?E+_D4#(].)ZUH;E81IP8XJ[(\)
M)D[+J\ZV\V7843S0"ZDU ZQW/C8C+9NA>=DMWDK-+"-D7%I8_2;='">6^C<3
M +O5>,K--4U5%/?&?6G5A0];",8<\T64^]1/*+,FRZNG:BJ4'QK4BBAPE*<'
M!J4AGOBP"K>1,+*QD4HU-NF UZIWIFHGO%@-325LWR=9)_9^VCD2(S^::K[:
ME6I_:GJ/*HP"(HK,M/VIJH#7=6%4.:5V2E5/M<Y_#<_W!C'UJC_TRC1XUHI%
MJ:FE.(AW_9EO.K?NVKGE_TJ=6[?HQ'H:[+MFWMU-!MN+9Z<:+H0X(K#_Z[E5
MC\;J\)(IZZS@-16&SN)\IH2Z_,(-;LI QV6 G)'-=$RT*51&OFK:/ML/V+8.
ML>3VLJCD (%0#'=W=(62!SVQ5 N2CA;M!&4)BJZ:US?5 HD&,O?>7TF(XFRF
MRK5222U%6K*K=\:L!F'M*]W85,>LFO@L1+D@(:?#PFJ,YE1/K&A5(M73 'J"
ME5=MV68JBPKC7;6ZV1JYJ6HSC$Z]OK'-%&(X-W2XK5G?]@HAV>&^']W&0@,#
ML>!M1V<M_RGF9SM I;!EY<;7&WW]<&)GGI0BR9F=A!A!\!/&4QXP;O/03KF7
M1"+X97PW31'6.\6$OTK9*YFR]7A,K._4"),MX#Z+&X0J98P?OC]JY@VWG1<-
MLUF=%>>M:_J1;OV I9M;S_!3#3WX;B;@ER6(K!J$D(+?K[:M_YGE.6S*E+WF
MEKYFKBI&ES^A43RKD0[I"_7-\7*-7XHKQ?=MO1H(OO?DZ5+1FM(YG4WJ2KRZ
M(I8:4-%;+O%F5S3-X#IXP^[\!P1"Z]4;&EQ%TXE#VJ)[7*:R=G'.X'"IW[GI
M2!ETNR/(+5T>1-'J2"4(?EUANNKS>NR$_HX:H715?^-)>C!KH#/,%'DJ6;@W
M7M&S?*Q*@)Y%VL+6TM .ZTIP.*=L=JXKSA%%D(-ZA.,BK>O$AC3KRU8T'E._
MTWE9T&0$"GJHMF(E QI?W9@_58><\\4X!YM-3<-I89TWT9\>+[3&T>@RXJI7
MAEG-Y?F]%UT^$+4XSRW+VM?ST$4'],^4/X&82?P_?XW7=>%U=V4/X;#-&D!J
MDP)EP7);%Z% MPK+V\34:(S6S:[HDC7_EU'(3M1 G=HB_)4WWX/-;V'EU^X/
M*)Q*Y^VH!+VO@&EL00EJ@4)N=8MZI\CJ5]HG'_9I",*FRXY+VV0B>FMH4NT(
M"O5[SI\_T*X$L"LM8[:M Z@Y$8.47=&/2=@J1_^2+)_5^_18=?P=S?W=GF7T
MKK&,1MTY6Q1?L'0.^DFF=88K@+YZL&#=@'G;CEEE![94OE1A])[!M/(&K<E]
MRQU%=< $['1EWW=&$VH[1ADOA0' U:I@F=.;XOH)3OW1T5M]$Y.HVC<1WGH=
MM N\,Z'0L S^MP3;5X\7Q!#'3(A%.3#Y,-.PM7KO5"-,4=V\]NT.G,+R[NM%
MEBHHWAIDV<$CFY>SL:6S:MIRE<TG@[KG:05X,MKY^N[7GE4]90Y[$<8Z653?
MQ*3X5*^S]4IE^M4;G"_*:L'5<:JI7RM'LUZU**XMINK<26W$UJ=DEH+QQE3E
M#]5@,954ZCM4Z@@KM;P6.^CY'#.:P$-#']=J#;6T'HTW/1)<J24LWH*EE5)G
MWYI367-?JNYZYCS7<5"TJ>$-NB,D^KNDHX)U)Z3J)NT^#:][!D:=7A<U2:T;
MBWNKA=9-@IUAG))Z7S$'QEMZV;1 #NH*DQ6-@S7;M]^WOS0BLR_T/:7"L,$_
MXV/<&C.UM].=IU_BADJ2IR'.]]MXX12 Y7>"X_;3,!%NYOAQGOJ!%W,O#FQA
M2SOA>9 '+H5/'7@6A4^7)D"Q\-K)'[7VU!IS@\"]!DKYR\'7T8GT,ID&D<T"
M_,=/HH0E3IRQT,US+_2YXWL)>&'+55I=U.U&,-"4,2.9-9R^BHX5: <:S'HU
M*&A_O]? W,U'%-.+68'0[^H&&QI[<C1V=?!5G-C2#5-;>"Q(L-,K"FS&O2QE
MF2UE'*=9['KY+6A,=:+K:1FU2KJVP^M;B. .QXZ=6BL;M3+^^\&5B*^CW?T3
MF8@P3,.8!;:3,]_C-DO\-&>YB 2/O"AS0V?KA6?W59\%6U:U0G8*.J SQ%A%
M%DJLB$*$@+;EH' 8!AW##K^^)LC?&;YM'(ALR1Q>M".=NI"J;I_]%LO=V(UD
M]:$!KNO-5-%0U1[/H>IZ:*1Z:P"(O"AFB\I\_YH9'77FY2XR$S2!*\((&(%'
M?AA'/(T=G@2YX^=Y[@12LXN]3F8N33NX(<FY;X)&0YI<)[-C_F4C25>.:3Q^
M&^#[X#"BT?$'_R3.<S?Q_(SE(4A3/\L<ED2Q9![W4L=QPM#._%N(5!PGI)G#
M4*N99J5Q(-%_0@*O"]RP(1?D<'<2CT-X5R95T,#.&FD-W[K3O!8[3?S,=1(_
MA/]F7L(S&?L\E3GW\C1S>_EUV[F3\GZ#<W1D5B%9UA)]J$V6#?W=3'_OG1/;
MCX. )PZ+'.F V1AZ+)&^ %GO.8'OYC(,^&U4.F_!OSY9I)&E\IF[B=WO;&Y9
M'E.T$;OW9]1XA\=O3T ;^J[KQ<R1.5"[L#F+PU@P&3MA*L"ZC$*0MKZ]8B;N
MTG"BOKSM83JIPG:P8P0Y2$WM EF_RI[IH=;T0&NL3H'470@QL&,G\F,>99'M
M!TF>\CB1/,S3P/6RT%6 "(XAQ&7]OR'$'TB( 8["P0GUB>>">P[Z'SPI[K X
MB\'$CD&C!3BCRDE![(;;P7<3(I&:'K!'U2[%YPE?-J67,)364*/3%^\_MKP.
M17(ISV"MH%I45XDJJ?O="^OJ 5I?1Y\^7QY<GCAQP,%!#ID,O00L22$9C]*$
MA;;C@!S(XMSY=?JC.F1AO9Y5MTVG.>YC,CJZKT&]/W7J#/N"Z"]MY.#^UU7"
MX28%,EA[?9-%4FTRY!TLIG6YL2[\5<-F*II8H] >R5=NH".ZZ[@6?JT%O+9B
M/6A($I84#0726W!#L'W3)+'<)!&L;Y+ !9.P#+,H"(3K>'D$VBCQ>9(E<0KF
MOTPSGDC[)'&VGD1GQ:.18M?*+'_[VACG/2A+6&@#Z0;>\72VT+-%JN$TVU$<
MOC]M?P<8' &2JD>B2(/1D5:DG\[.#G;W+S],WE\=?!HYX+C"L][[!\<C[^"?
M=Y,/DQ$HU],O'X\_7/45Z>%?>_;HT\OBX_&^.X*U'NP*N.[4&7T5SL>_/A:H
MG ]W7XT//OT[/SP>@1-L!SSC(6=1;MO,#YV0I:$4#'@C%6$2I,)Q^JW(GIO'
MF1?&<>0+/W!Y*D,@GSQ(<S\*HFBIG/W=WL[>P;$UW-DY?']PO'_PE_7FW>$!
M_+RS-X(/CI:E6L_(6FZNN7$)/]HXNX;>'J&1]A"TY9U(. _IHZ7O.1[S@PR$
M9QZX3 8BD&X:9]+[=5H?AKKB&(P(I)FG& ?:GUK#Q2DL@4P4%?U\-3QZ:?"P
MAT?O"1L3/V58-_V80&2P&BU5%1#NG_BCBC: SXZ9"S.'6]6A'6K8T6='BW1.
MXSC]R 96?ZXGL93%!5=HU>0UR@Q.[%3?V@0!R%S< _:?-_#8AY?PI_\LL)&_
MN76,. _V\S_:D*/8JZ]6-B_0FMS'6M-%4Q#?>0B_[CD/B8KS; LI0E/#UO-K
MEA*+()3R!R[E.N"N^WCX76>I/N2QM [%JE%Q*YUZA%_E%X+)[L_$050#I,WW
M1]9?P^$;HE'3==CTAQ<M2J7KP'FBB2XEEI:+JI['TV!:4!TB4>NV-9J5W=HJ
M7?H'-\S43?.96-3C04\7A9H@1HMI,4S18YBLYEG=%2*_F#I-?6F'GV27GQ!,
MS*P0@^&X@S13C-:EMBXKT/^!-^$E-HE0 E/-.K">;>V].=IZ7J^V7TJN8=15
MSG]F&52@(F?ZE;!32$')U^-<5[_KMM4^7 1])U (?&V\4B&K-?!I],>\P("C
M<DY5]Q'UPQ83DX)MZA^Q^+#[]52"Z*.F&')X&O_:"0:F;HHF#5%!9TJUB^/"
MC(O+%V,JH)S,,D)F1E""<E:#@=" AVZUC.G;@055S>G3S:Z[26L?.KT^.H!<
MS/LMM3@QD"LTC6[99T/IQO>ET4B+<;^QMW7&\#>F*$'#HPSPI06OSJQ\/+M\
MFAU=8 R,^%6K.7F-)> PVW]LDZSW#(^^ 4H]4CRJQFZ[H?U\8+4LA1%1E=!G
MBL2R]P55]**HSI1XZ1H) 5[?AEO3]SFB<0SM#\PC(R=^/OBAAL4^'DI9?[EO
M9V@9WGU3^&#OBPE\ 6$C]BS5?^)EZE%L!V=**Y[[IRSFB$J\@\+)F$^/PO9
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M/,C<.Y]QCV-W$>X"QHYX9GQ9XK8&J,T#J,4J_H%+EPG,D U4()X)@[2S-/X
M(LGRH!XQNGCSZHILB!M@M6_L35N;=J<NV5\_8_-*]F]>5/2O?.4OY1U]"5?
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M;CF9_J_O?C0AL<BG[R;CC*SZ\B%>\.S78UT"!P]K'<5LB&/:.K*G(@<%4:B
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MB*,$9X+18!$)DB">!X%TSAP25&6<YY3EFB<+ ,N6H?3Y":9KF@C,50*[K:G
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ME? >6-F@XK$-G<VM>%R-_4'%#$#^^/I2!I,W1I//]Z]GN@2;JQ%Q12@"_N7
M\ .,!\9W=';3A"<>[IY*F@N;Y1S!P<1!N?,>P?\YXH'D1.8T]S$\O;="M5LX
MHN\L1Q")0:\XV!]RPGYEF<1[4DA]9E9D\O8:OC^EN;.&YA2)C$G$92:+U 6N
ML<4^ET&&Z*9D*RI3S1N)"MI8Y;A<&VCXPSP>JPB6/)&/-8WH>5I%OM9S-*FC
M$@T?/3>\U6/22*H%/&$P=;ZMMF]'&WXGGE^7L0@=?!M!9=:C!Q);[ZRP0)06
M@:A"C+N7A5FC%&F6':LFN@>BG['P9<9'ET--_J#MTIW1\;VST?G$EY%<&0MN
MB\+3$?T><2I37T'YN(X>]^SYO'F_[>(UH5TX,89^,@N8T/0!,W)IN^>BNZ4_
M*'RH("9&O$OV*=@>N'R4[ ,K[0_)-O,YR03EHHZN+]/P=0\TUTYCQB,418AX
MU:$=]:,<0.;'77F/2N<+<+L?=-*FS:[Y>%CL:FF02:\L7<"5BS5>5VF-5;VE
M7G&CCIM^UHNV*)UF?CF.0^Y/C6$K=C2V4HR6HMG!5FZBV=?#JGD0?4>%BVC&
M15:YW"9R<K%M,\(_,.OY"E_[X8?WI:-YP863W(^%M:MS3P_KAKI65^D34U?Y
MI=>?YEAGSNRV8DUFO&UI:+"5-E'VE!,+9_S4$Q?WN7(VAADWJNX 2?02Z0]G
M9S%#'%/BWFGL+AOZ5ACN8&='\R!W;V_<V41$?Z X% S'Q&>Y"[$NF%'2*48X
M=R!"&Q'L&K](+0Y]B]2,FU>G.#>.<^Q19G*0C#3%R%AJD>+,>ZL(%D3<2S*Z
MG_OLOEKT9D4F_3D;GE.>&9%)$NY/!81./!\^M_W5<'H^W<5'@Z+L\8^SS1VT
M7JUCFJF1[LU].L[_>CKGC 'N:!<W8^^+7#$M18[R%,J>,8>4%!)E 38YRW5&
MB5NM=$Z0<@9X9P \UK^]K?PMV;F/5^6^!6ZS9U;@EN#O7F9RUZ:PFN'?^CH&
M6\8RT-8.0+Q_TY[8,S>QU.UQQ1,WS9L_NT"_W9.]3U^.+]["?:^ZQQ<'].3B
MKTZ3OKTZ_/CJ L9PU6HO\D3SIODZQ@6?P#M>M8$G1//C2;MY<=)M=C_<G.SM
MBN./S9N3BUWZWYO]Z];;4\:5M"0#U5=*@CAFL:]IKE$N--6Y==89OUAI,N<*
M=')-C'$YQT&:C'F=>VLR^(\&O5AI<O?ERW<?]O<:^__]>[_U?O_]5U2XO?.5
M+WY8[=)E8MJPDJ5/0$=GIU@Z*WR0R&$G$/=:(JV!C@AA-A?>NBR01;K8.,BZ
M);KY0852=4$B4T_(5]9)O9_ M:80ZH\M:*KX#A'TJPJ:YCLXRQ^_1BC?X?3K
M'GO[=R+_#@5-8;!L_==U0=/G5&BR+FA:%S2M"YI^&S2\\T-0H\H8]YGHN'5I
M7\\U._6!Y>:>78[I-Q>'^=;^HB!]]?XH1?:*J$ CW)N2U'XAI$WBL#<FK_3K
MY/@RKY0?W^SCD[WFU<G'M^3PJ(E;1W]U87R=YL</ NX[/[EX"_^>T>92@[KS
MB]C #M[9.=G[()HW;TFS>RQ:KS]\.3GJ@/S_JMO:ZW0/]XZO_GMSL%0B(*IG
M.*B @LMSQ$V6(X5=AA03%BMB!94 *ORAQ6">)L_^KG3Z&G9^4MCYUEZ8#X>=
MYY'K_DPP:2'7/1C&J, <$:LXXIE42.=*(CA"&"/"P=ZJK1=D6_)UOI*G@J4?
M7:?J*=CR;WT]Z'<Z*&4*S%A-OJKDY7U+##]K='JLINO[W<M._]K[=\7*SY@T
M:UAZ=%A:+A-N- T,R!51253LY6N0RG6&G U22^F<8@F6..8;5)3WD2H2U=S\
MV'VW:V[^L=R\6%#'.D(\]H@0#4(&QSG2/I=(60#G/!@LI=UZ0;=5MBZ?^1F7
MV-YH 0,$\-%@;$>%C[[(DVF4TD9=5_L'65ZF._"R2%0J8:K&ID?'IN5:VUE0
M6%B.$>;.($X"0488C3QS66:#X[FC6R_$=L[8!A7IK2MM;YBD4;/T$[+T8D\/
M0;GTDB#/@T4<"X,TE1FB0?C,PD_E0U(>U#>+&\^X[O:3V#,&_>!3$:I8%\K7
MAHSO;\@H,6EVY5_Y&;VGQIH'8,URV6=FJ9328^0< _'!&X8D,0%IR[A4Q#)'
MY-8+AA]J/:W-%,^(5Q_+3%'SZN/RZH)<X#4U.N,!Y1XSQ/,\($6$1("G#+C5
M>,]R$/6_72JHC1 /XK0W_@S$@<JWL7U+QMC06Q"J4]6-:+X[*\*@AWXTZOA5
M,3"U?O,]3!9IO^: J=9F'@NUCF<DC+>\=7%P*JP107*%J% 9XM1DR,@,M!DG
MK:/:9[G76R\HV5:QXM;&J#.UA6+#A(R:@W\8!U_/<[ QTE##!0J<*L25$T@&
MZD'XR(%LM=/,NFB/8/R;G9FU/>)!['<8DU5K&\3WMD&D95Y.#JOUFF^5$ J]
MQ@5-K0\>$4E F[%!(A."0DKF&FNB"#71O<J^63RH;1";RZN/98.H>?4[R0)E
MO"7-8RY]0-[1F P:BUL&RU'.=*85Q59GV=:+3>+4'VV!6-</E,@G[@=:,D5C
M?S$(\WY-0<MEJ=O)_;@%VA1P__:FH(_K#*KCW[XGZ-LE 4U1SZ00' FF8^U.
M0Y!T@2'"E LV9YA)4 "IVLY8]IP;RCTZ!S^Q\:G&\AK+'QW+']E96&/Y=\;R
M!0&>&HH%5Q+YH#'BTEHDE?7(BIP%G&7"<++U0FY3(6HH?_3>H).R8',UDKZI
M3)BZ7YFP#>@PNJ9L&/GN9<->]KO==M$#=+?G7J:E/O,]NZ'5PCY5P *@\($V
MZ<%5Z\**9FHQ\4\'@(6<[.UB>,Z7ULTGUNI^^-)<JO+TEK2.CF^.+W9I[+75
M/'I[U?KX3[MY\<^GYMY;&/,^.SRR].1H_SK6GVSMG9T&[X6T5"*>VP# ( 4"
M<!#(Y2;P@*U7DBR6"Y-:,XESQR6U',<FPUG.J,Z,%A0;YQ?+0KT\;#8/CIK[
MK:/WC=W67N/E8>OHH/5ZO_7RX*MJA]W]_OGQ6D$XIID4F<.<&"&#\X:&/.?"
M:!\CG3:G<-4#>T@400A_#_K6^PA:BQV>-F9>M[==2BW-RJ+5\=_%GJ77#1-;
MA,6&O":6^HW7==+4+Z=3WV[8CFYWAT4-[)E("SUH#\N"P:FL<&R8%N,R;'\\
M&*9ZN54![IW&QW,_U]&B?/&PH:]B.>&RY#:\IA&["D_*8Z>/8D^ULL:O+UI=
M=-J??*=]WN^[HN_H=0-09QAO]5\N$_ZD7FO:6AA4JHJ=*BOK<>R16M71/ANW
MTW=+7>%B,\'B@786W*IJYP%FV8N]6&)[F)$OFB'W>YWK5!091*V13X6.R]+7
M\4%QGJG_;.P4TRE:T%J@!^-3N>U^#SZ]GC9I2<L%U^O&()8,CW,LAK/^EF*"
MO=@_9CB:?%QM37K,ZGFFWJGM7KL[[LX\K5/*D=>PCD41Y32 ]C!UI9O,HVR#
MI[NIWW)_YDH8:KQRS6CGA^**4Z/<VYY.S6O*ATU:UA7$T0ZK]G^&8*IASKP5
M"&(86S%M3[J]E>-M]S[W.[%>=SN6L(\UHG5GJ45KQ+O^> C/F:/ F3=62U5E
M2E7%[A<;8%WZ7@ICFN6@7FJ<W4[M]4;3-CU#H!T_UTVWW2O$^'C7A'4^ZW8G
M[L-"X?EBD\J"XW'@J:7M=>K-E]B^F.HJ3B^*=8_.=2K?[^"\&;1-;#CC._VK
M3>T/="L&'DXZ0!*U778R*S^HZLP6A%&5P\^K#]=J<1U]-1RW1PN:G 55S@B5
M8TD<%X0JR6V.7:Z#RN!DM:NM<C.UBE-(!AS7,(C#\*9XQ_#V=J<;4Z;XQPM9
M99%OT/8^Q;*:(+40!Z((R%O>(>Z=0$HIC[ UC&AO)7=VZ\7H?.#]<J'BF8K[
MG:IQ0RRS/Q-@"/ #P%)20DD $>52.P1@D.^LS*T57]94\VX;T_B\TW@?.X,V
M_FSWM^$XM#O;#0\':>>)%,^B8<IVXV7L"][J[S3('Y0@^QGA'%.QO6%+^!+N
M_K1F#7=@$7>><A57+B+#*@%9<[,64@\^P5-7K&1!C!NWCI)A6?0K">U.+/%_
MIMN]X6A.8DGR6]F)IFP+T0\@I92"WW*#/5",1Z"%C> )X\%HTC_X?7\<#]S>
M]/O81QCF=MP??"I.]?H4>B:G$&Z^/162&ZD)1L$1T/I)1I$!=$.Y,=Q@83#%
M<NTI%&LC=V*W8SAG.B"; ?5\;O<[TYXH[\NF.@V"?S._USV'[^HY3/'/U'/X
M3FO+@G7&9T[DUE!F8ROXC)K,9CQP;KDW2NMLDZPSMQ\@J>SW;_KW2B=\/Q7+
M]K\47;4:NP5V$L7X=FKVW2TZ2_P6;]B:O6SK]T+>?S<&!99@@T14@;KCSEFA
MO$7-.S6]FC:.FM'SN]KYAKE>:GD"(%ZEJ-RO6_R?+U^C<6_@AY>Q5=)G7[2
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M_U']\A_7'@(W7__1[J7YIIO^,_^&&!3\.58< 5 NWY)>6'P]C1?>P47,\&@
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MZ*\[D6WY7KHULO<+\>59+I/?P/U.ASU_".0V_<3_[8,L/C[NYFWH^J^;K1>
M9$-_V!K .U=KN^S.PT&[ ^\?RL5](-3B;,AK/*LNV6B=';;AEIDN+>Q':-E,
MXH=MURZ< _]]L[UVQKD6J/=Q]L6?VC[0?"K?R\P3VR?/-D=/'^^(_=*+^8(N
M/+3]+5;O,/V0]DDK?H?7/_E2UM?R@+RPF+PH'_O]\JC4ZQY/;\YF:]N>V"^Q
M\%W\9CO 4_5[GHWW(\&)S2!!M4<APN^/ZU7;0?[2>:OFS&JA+K;B?X?MP3GR
M67&![\/O@?WA=OD)\'?[&]PPOXSOGL:\_'A:;5AJO?CPLJ4)R&"\V=J;7L\9
M[! @5%YLIJ/CXQC:L.K..3P/WCN6Q4W_NGJ!_,39EX 5@F#RPTXY$?CXPE*M
M.96.,J>\DUYH3'D0SB2II*9@2T@FA'/9*"0&Q',V"O,/<[J=F-?M7HP1L[_7
M?0%2+:_ =M[:=GAS\M*>9ARI::)RBUTRYZ;6!.4#U00__^<0^^._3NPG,]P%
M[6__Z.O9]I[/VAL&K4U\WGI_N$_?"?@=W?WS%?O\Z?WQSJ?]'__YX<]W?O@#
M:16<1-2()96G1H!*9PT)" ?.K(Z*J>A D=LD"XI<"R"Q4S&4[Q7.L)U6H;9,
MEA,R N(;T61%H2.( SKIMPO/#@[;_26WJ5C#?@7FA!]M)O<4L[4/7^T#.L$W
MXA)Z+80?VCT0M4#5O=BI>+4+F K(DK^>O_-B;[NU.[I?9H6S[K 36B==@!(+
MK-;-$'.6I;Z+L;SDL > 7%ZA5QAH(T-)OE7J9FG>^N_0]C('P=M7>'X\P8PV
M<$C;=F ]OB+1,4Y>AYDLF$(>FV@<IYP+;KB4-H9(N744ZSC/3/.&4L-,=\9,
M9'?ORX'(+5.83(CIG*#,54#& UN18+R6EGAAR"7,!&0*,BYF4FN!J+,G?DSO
M(!IB%J%9_E?, /\>E(_AZG;1*^WX#%NG<(@HR[7J&#<*D0/%@6X9I^1,)6$N
M>&*^+7PVK'EMAF] KH*-%"JE) O6(L;@>U.?5&+(1Y!?H1*L?2"2HKI,*QQ3
M F_Z$9NM-57MKFE#S.A.:_I*=Z:MYDNOK+&"<MH?9HTNJW!%72PJW.C[L5T,
MIVQ^Q=HN*T3<[DU4G^E;V+&&.#;C7F05L<#RT[RR)]//7W)5_\FS5K=7F7#%
M^KKJ U^,3;4+G[CD,G@D*.#]L8BL#,NLK0X.N_W)9L(.^.%@)-(N>X_9,ZMX
MN@* .&OAUO)[_'J%:V]2H,^UMS@(&XP+'&NAB0Z>4^F8T"8ZFAUZQ&##<%.@
M?XO2Z O>WMH^$)(HJC1'B2JP#YC@2'OO49+:!Z<"5ZFH=A0OBB.@XQLU9)!1
M8.N(<"QQ(J0+FD:*\Y1X..0HJ_.>5_*;\[Z%\_YZP+008&I9Q*0'55YCCJR6
M..=A:RL,V%W1Y.&3<LEYGP*D%I?\B/>7>P4V #7ZPTY!'!#W8R$/7[J.'JLL
MX0:( +18S!G3FGJ'@S56!N)H6-!C+S4*W]8+>0U 51/&B%SZC<JZBFA@30>@
MD>*(-472 :EPZC5RS"CD"158:,JB"Z"];"ZAF9'*.G:6C*4(D,/U C^W1A _
MGQ/3$,B80,CVUIL#I13Q7!F$N0Y@TTB*K-<8R:B\ILDE[_&3YVQSL4G+F$ F
MYO_;*3UI06-9I@=5*LN<CW#DL;O 5PCF>F<8BD:ZQ'5Y!@;*6)/K9G]:OKC8
M'2,70W]D+EVF&^5[C52I&^M)"N1DUHAP")ACJXP07%@CJ05&(!8W>M+=4#C;
M 3V)X> B"111DZ>\*(*1CDZ@#$A8<&XHMQ?H29D:P)[M5YZ?I_;9C2@ $Q$T
M2TS28#@VUJ9D>< !RZ3@(]5H3G=% 4?^ %0CKH1DR#O*$0=]&3DJ+-+$"RVL
M94R&K#F9Q;'=LYK3C$.CQ/W<LV4@4B(9X[! )4#!6"_DE/\^G<-)^+&-0KLS
M+.0TC@KVE\';4AS=;%62L K-1""],.NOI'CCHB<5F!OTVE^^%#L?EM7IGM7N
MFDL \H:F1#"P]8Q$$#&&R\@,Q8Z DJ>=<<RSJA$EQK*!Q%MEB*]G.T=O#CBW
MG@BP%:6!/[B/IHR11DKY .8[E9ZZ%7/L_Y&).WMLYKT-OOOEI'B]+9P74&5H
MA?:W=@!:S21C3X'6OL,IEE#4=8P)H:A0 C1'9C3/?@5!M0 ]4@3"I*(EP@2$
MPJNTPP6*F=,==[-W::M>V OX;^(A;_3$%23S??O']@&8F]H+S!#SGB%NI0+X
M-!'YJ. W@6B>6":91=]WE94S5A:+RV_:.06Z7!<PT7ZS[4Y1]W) <@IH:V=8
M<9A-D]QAUO).6M;[X?&P"@+E\+%OYUR+CCWQ55@;D+O=;YUT6]UOL6<[G58;
MONXO]Z;W:]?Y+"FW^X74>UFUM/UI)WV(H,$6H5"[ZX&F>NW8O_A!,_&F M#'
MW>$XO)NC5:=@U&3_:\D=R5=\&,"[%OP'OOHPM4/_VWI5^>>?;E7[\&QMO>N7
MN:(! 4YB!0UC#_-E[L]1QL)5+(ZECNU,3.-OU)+Y0_0@6 ?Y'-^.LBHFWMY0
MJ&[;P@<M2C:JIT]%)/,=ZD_S)Z]'X9>-DND#RX73KH7V:$7YM]'FG(;Z<;U6
MIKQ!%<VI2: /AV0'0Z"04_LE]BLR'W3KX-'(?AIYD7NQIJ%,IK!V6^4!P.NN
MA.&3DH@]C\3210_*LLQMXL%X<8X;D-M4.>Z-#_82*WY)_G=W))N[E6C>;I^T
MCX?'H#+D-IOP:MTT.8!1A+(&8D0?'Q+SG:/] ^.5Q\Y28#X:$=>2HRP40:4U
M5E+AN8M@L8ME4/RWD?;6GY!UNVSK)#VM#F7G;+:<?U8EHM2HM+$D>K/$@%]M
MN&_4EGNFQ!ES?*-HH"%VXJ"RZG,0*9,LT/7Y=5+?:B3A=%.5Q,ANORSKC\*5
M[6_Q'V?M,#@<I2]/?;%&0CSYBG7]+BC*J[^RT!;VG@#S-:)B;HNF_CSLC=:3
MP0(Y ("OJ"0#_6$[9_:\_^3OLY(!Q,+<+J[:@*MF%3[_OZ[W]^?+ECAWE!5'
M [(8Z@U+6&LNB#52.:$]D2H&I@A=NH@'$R=6UXT3$[IFTOD. \7JG@/%ZI<'
MBM6=!(HO?(]?'RC&(H64Y\GPZ#A)PA#'6*(J1!KS>)+& 7HG"L.KLYT]+PY8
M"#9(2A ),9?E.XNTX@H%GH)7P7JJ>;;=].U%BEDR*6!*J#",1\Q<B"K* +AN
M@F3$-?[..SOP+^0 VQ3!0I?(.R<1-QZ#BN@U\H([EIQ@PM,5_IVKAHJ7!GLN
MQK(;!GLNT!F7A('4;!AHA4;Y2Z,_#?C=$R_L;GE\P)04DDB!9  $Y E+I EA
MB#DM!+<!N(%= 'ZW$_YIX/#>2. K/P@!YUD-#+F4<N\&KY U+B$?L8V!!&8Q
MN1(<WF/\YV)H+4HB+' K^I@]-Y7/E167%*4C/VCVF)9L]Y/N=&5:O8BE4-B?
M@.&5K/!"8#(H 1*&L*0T-X9;$XQV)@+^!6LB/B!$/UE7G^3RJC3"-T?>LIWA
M,=S#WT)SA%GF?F5[)UFLC2!D#V[^SPY0VKVS[9<1V^*='_OD\U[G^//6/X_W
MZ2N\<_S7X>[6J^^?/^V+G>-MMKOW^OCSWK\ZNR_GV?8=L/5?G=U/G[]N__GY
M:'_O'?W\Z17?WGO=^7STE>[_\&+[T^?.]O%'_I\?;SA PT'DN5(E&$0%\X@'
MESNNX(AH AH2*7D'5#2IM'J1 S<^4"TY%]0;S(.U&E ^6*>)]RY)#-=' ,/3
M[+OI#>.3YZ]>O-]YL_/GA];3?^]^^/"L]?;5^]:'__?B_:L1$-2'/>>[6.JU
MN/39ZT?KRRW\%ZV3.&AUNGW0^.Q)CD&X7'"376&S]3%GN=I@VI0L93Y@^(Z_
M/_*E;63_(O!,*9BK[E1? / Z0M6"LOG_H_K"S=:;-.L<]X?M^"V6\H/4'EC7
M[K0'YQMUI.:D"WAK!]TBJ>WX.;'FJ\5GC<K>ZBJGK$H"0'9K1T6U1Q&H+@>.
MOL16Y13/-Z^2W&9\%R.%<G+1C+#(E1/?0 H7-;B=1H&OSK!?U_D5W\:JK]3%
M2Z-C:'^#K=FJ?UK]I=/N(.N[I2RI?KTQF&_4UW=/)Y6,0.X(-C?O&;S= ,@^
M_U@+._ABJ"[+ZDZ_!0NOO0V#7K3]8>^\OO(X#@Z[8:-E.SFT,7;[1-#:_:"\
M.YSD1B44IS<0&*H4R6<;8.*>KDK*CNU1MY<C6[,F2>FVI/XQ>Q#3B0GC0MB9
M/2KU7Z<V%^2W3ZO3+W7S5:@.R&P4[>M7%9W']KQL?2ZKZ4V,C30L$9@2QJF(
MMN*+L;-F7/TY]2Q8X/3+O5WQ2;7&R;[E%Z^.'BXK%+K(3S-T7A%XJ))"3DM^
M9.5R*\'6<;K(U">9'3>R9E#X$C@9Z*;KIR-9JUYCJE)OY(\JRS_I%G3.JM30
M=EI=!]A6;3?<L%I@O97YD57)T'11[D.,74Z*[#KGN22K6)Q N(60ZC!<?]E1
MP9^=SB2-HFS$3+7EA!!RG')%&D]&WY,EU<8)%,4QA]158' D[1-@\V%=P5B=
M<2&("U.%VE.90ID]X<7JM57OX"I(&%01\L5LD,(P^8-B6(_JG*^8!9#769'^
MXAY66+$D8E\W5[# ^W#7JSZI2#=[>MHYOQ#IBC=V-0\^2"I^#:\T@H:"X%F@
M5_NV,7[7_+LEA-SN3\K)2T>+*4=]972,MG-!P"X1JY6K>R+WIMA@I=Q;]OV:
MKF<-LTMDV-C97ZXXZU8,-?IPA/*5[%HEZDO@ E267MZ7XVYO6H+O+;MMNR2U
MC/>U!N':ZY_S7.HN YG#,A,M!>52H@D8G'\U$6WCFY8[3 J@*^6B0':Q#B_/
MQ'F(-+UTM[-_+RNXF<T+3M;D,CB+G6^Y\/QD<)B]AAD_5MG6N9EZG7M"\2AO
M:%Y#62D[0W=2DYYUCUDIF4/0/3?6I^,#W?N")\,>6 ,3*3\-(V-38$$OWUC-
MYOG*.K4_3(I49G3Z5,?G:M 8:]%3HNW;/$+?K9'_ = @##MQ-[V -8R6,$ER
M>56_4*YTRC0T')17V4V-=V#:._#B0.3^(C9Z)'W*(0X:D):2(6-LT%$XIRF=
MM_97Y&[</RZE+L#\65'(IVRVL<R;@HL9D_-"E]\L+$W0?9%EYBSG:>:<8\QY
MJ3MCOTTQWM.B37:'L"^A_^R/Z^0Y3*64S.<]C'-L2J>T2=Y.Z<X&Q]6QI_WX
MQ^B'?X1V_[1CS_]HGY1-+U_ZQ^P3<V[+7&>V\KSJXSKMQ=!-HVG.?*E'R-0/
MKI-B-DM2S%RSN>HSP3:Y,"L_QIMDY6<7W9:P34'IC6Y[\6="RV:Q5%SIMI?,
M%+JTFR@1"]>NV[3QY2T_1WC3 JB9:;5XQ1U9\I:YC^%:S2Y;WDAR63?9:[2&
M7/-SS5+CMM[X*@.B?JN=(\W.W7#G\'4PY-+FS5<$E^-V")UX3^"RD/UY\T;3
M#["/]&T,BS3!)^VL NM+<*^(QBH9%JA),A#O]94[T8_[I/V<+?:B9,>O4=?I
MFYED5=?I4S"__CK<IV_P-@5S;&\?;Q^_/P;3['C[Z W;I^^/\EKW/WT\WS^?
MZSI]O'.X\REWGG[WX_/QN^\[1^_./_^Y+SX?[Y]O'X6CSW]NBYT_7Q_"\X[
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M_K'SHZPJ'0GTF:SDGDP_."-O:2Q4ZP"C-P<U$5XPG@[*"^96ZI-UCU^WWEM
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MQ/+T/RP(9?^L>+ZR%._%4S1<],! C9A26:RWT>IT8FB!O047/NFW<K727E$
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MR]8G\%FKWRB:J, WCN"Q-N"V$WB.7R(_Y/IU#B:\]5E^33AE=)(?X8[+;R&
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M?=+(@8F!I+)8<:= 5P8@UL76Q(6!.R5FLX*,BJ(]5PS3L?#,6-M58.=YGEK
MU[?-=%%KE6/YFY-'U*,GC[SO@J3$/?LC&TOMWF#4KU ?43\&X F IOFCN??'
M\0X]:#>_[./]X[\[^W"?_?/?6OO'V_#O(6MV_N[LG,T L /?/]_^T>PT&8#V
MQ\'QQ];.EX.C@YQ%]^6/5G.O?;R[Y<\.ONRS?\X_G^]N??[*M72<)(*\4A%Q
ME8OT>XT1#@HKS+T5CL_F8 B6%]I<B(P'3ETT%/B1>0[(]2)P,ILL\G[GW6YS
MN['W]I_M3XU[Y(C\_'[3SR<-C<#KRG@M> P4P!$%P]X3HB63^.9R8DOM<%M*
MW*\1^")>2A_\ TCS;[MY(1TPT*U82]OG$,4/7YW4R@50 U8Y!;J .60=4XA*
M:KRT#/A6KVA+V[VIOK+CMJUQ6/BEXV6YK,-ZW<D"P/3:.E#5H.$*(<K+Y2 ^
M<(T?\'@N:RK01V Z_;M8;NR-X#'#X#_W[31+%V5QKU2G6;-!]2/T0R4;DIA5
M:=ZZ:@]+Z3([S:["GL;2*KQV_T;=$_=%3.-+[:1:=^^MN_=6NGOO'3FDTPJA
M'9^)0]Z5!MP3"L:R9>BY;[FD6F.-XE]3<7&96OR=%9J[O#%NK(*&_3\/>L6K
MK];/5ZW4N_W[#HN)/N8$'E.\(S<).YV3LS0-U#D.YM9/PM8HPP%>&'Y;'!3[
M$US,G";YKHRDP CNGL1^&8J?"5_$P22 <;M%0[:B\8QRTRG<:^^#:&Y]/#[H
MO#_=[VSC@^-MNKOU1[NYU6X=?-F&YVZW=L[_Z.RT9C:='A^T=[:^G>[\OM/9
M/_ZUM;_WL9,WK#8[GT]WO_S1WM_[^WCWRWNXWSY=U/_.6JF\C0)))S3BS@BD
MM;"YDZ:URC+IF%[;9&J=ZOFZJ'.];^Y#AG? SS)+0]4L]E)9S.3>5<QBJ;CG
MC%AC G:**TU9$%:8GQ2_J%EL!5ALMD&*\LIA8+%@!$$P[0)9YD#>'6BSI)PS
MQ@.+T74EYCN9U2Q6):37+#9>(2(DA&"B%ECS&*(S*6FF8J!"X.#]3TJ#U"Q6
M?1:;+0 2K"'4L82<D IQPBUR5D;$5 A$@08#ZQQ83*P+6A%;;$F5 5?#*2[S
MP:X-H="[O?9"-JX>9=TE%=5%%B,&,A*"*\F-4)%SHX24 GMR&^_QP40U7NJN
M>6IY/#7?_C&%*(0R'.%<VY<S')%F4B!P%RTW41E)Z-HF8>N"S6>J+E[-N ]A
M/);)==O:9:\>\&!S@XNE*9>1<2D _])P,%AL)#XQG&[A:-6 KR3@9]PK26&&
MF9+(&<$1%X0B!ZX54I1JPZE,1LNU3<K7"9^OLE\#_L4 /GAB#'5@GB;-$P=G
MFT=!633:.-#T^A8^20WX*@)^KB^\(=K)@)&U/B)NO$"6<X9T\DPH29PG&C0\
M7Q=J/I[R?(!?YAH=HQNB,@[)X@7K<J"O^[G7&]IV(V.K48*H4:*H4<#HKM[B
M>,%TG&#'8)!";Y33]2:O>>M$@*J%H1:/[9W#4$L<H*KHB\4C<Z<@UGW2G!\K
MB+7]8]BW, FMO'GQ_3!V!CN];K$'H]>&USR<]'BK5<OR5,M\/]08N.(I692(
M=(A+II#CP2+N=/0V+]-XX%/*UI580I!K>:BL>*"_YN>:G^_.SP)KHKBV*BC,
MA4G.:A.M3 ZL^B"I?=*ETIJ?GX6?9UMX!9^($@$Y033BEH'73R1'UED6C#6*
M&KZVJ=<EKNFYIN>:GA_5?)8D:<-M)%;RQ"-XXR0*Z8"V<:+F:=> :WI^#GJ>
MC<PXGT*@AB%FD\^U<2320N0B(8X1KU/4).14]G4CYBO]KB _UXTL[M/(@N&9
MTB17?E:Z)<7"K=D_W6H]LS4[8">2U\KG?BH.R-,IX:U-0*$.8^N><&OVNXL-
MMY-MVL"EVV51T'$[B=>^+1LWMYI?-<Q+X!RCI!)%/ J!',P6$E[9J"-14<RU
MAZA\_Y+;-"O()<I<*0B-?Q<5E0<@]__)=9_S9NU^*Y<5&>_5OMS<?64?]VVW
M9"]\_WK']8IM8EZIAWV6'=?/FB)6[[A^#=/X4G>_UCNNZQW7E=YQ?=L%_ 7&
M7J7XY=VHW\\EX< 7:/PUL?GNU6=UVD]_N&S=->Y9/^1R<N#-) F^^L)[<];)
M;Q&&S[8?DOU3M0CW0_<I+7K%JL2H'YP2N(0,CYFN<"4WCN5H+EKRT_;#*QY8
MQCMTI[/?^?MX]_?/!)X)'VQM\]W<=3@'BCOO?Q3/\07._S0;6/[ ]NE!Z^!+
MDQ_L?18'6Q^_-?<.Q6Y^]M_WS^!^Q3O#.4<+-X)C+)*R! G##.+*&60C]?"#
MY0Y++!&6KN\^O/))OC5!O5""6D**0TU0ST)0,XD))DIJK'1(I^@0=X$CDV!P
M28S2>J%RTD)-4#5!5>+=GG:1OR:HYR"HV:5Y[E(0H$J0S%T[.'<46:DQX@&+
MX*20<+2*!+64H,N+<6"+FF?WVN1]VY(;J\U6C^3O%</^MAO^[/F:LQZ+L^:W
M<G//"$^!(.DX13PYCXR/$KFDA'"*8,:7Y_55KWQ.C>O'=I-J7#\-KF><):6D
MQR9$P+4%6R1B@32F%D5=-+,PT7-?X_H5X/JQO(L:UT^"ZUD? V35)0.JFEHB
M$1<8? Q#*$I<23BD+%&QBKBN%\FF%LG*&@:OK)34$V\<7AP4F;1"FB.LFICN
M0$SSVWI5(I8R!CZ$B0)Q9AC2(K>%]\HF*7&@2:QMFODF>[??DU"]F&P-V,=?
M9JD!NR3 SG@(. C*,?-(N91[\E&5=WPZ,"R$<59*9WC>AZ]EC=B7B=A'6W>X
M%K&O8%_@D\%YSC&0*7&N#3):%QMH)-)*>>2]PT#,N8VS6]LDZYR+:@!Z&:L.
M3+T4C^ V/\N"3GZ<.WIEL] ]=W7.YSB^Z$7DN[W\"^+Y1W*EKMG.6#/YG9A\
M?\Z3PE;S((U%CD25EY$)LF"4(1ZL\B&PQ+1]H"=U)RBL1F6-FLQ>!9D]EIM9
MD]F2R&S&RZ2:1ZEA-J3$#(%]2I&1G"*? B>864VH>ZB76;-9S6;5>>LJN.#7
MLEGM@2^/ZF8]<.RH#30:I)TF.:"FD1&$(YL2M43@ %[XPSWP)R&[);5UJ;I+
MOA53!+R$H@C'R8/V88X'X.?3<J^]B;<-:K[&)ZRS5Q^R_;)N$U=!$^(Y@SL3
M3AP+TJTLB3J_YYY&Q.%<\$?'B*D7#$FP"1$'LP%I'Q02FF+.1(H"\RKF]]3M
M+&N>>M*X3<U33\M3,W$=800/>:^3E0PCSC4X.XQ39'"PFDAEI*QYJN:I:KS;
M<T9D:IYZ4IZ:#<J IG$I4HFHXQ)Q#[\Y%QDBPJ>DI/,4LRKR5)TOO9P]F:N;
MRE4%)W!JDT=-78])7=_F,ZHEL!5C 27,P!6DE",M%4,T.*.TB@Q'7,7MY'6F
MYJKX3C6\GQ+>LSUU)8^>!(=L$ 9QS1URPFH44K)<<!,<69X'5<.[NO!^-)>C
MAO<3PGNN@VY,6@OCD3,2M+>W$9E<9X$:IY0 R*?@J@CO>CEM61LU7\?V\D=K
M\'H1."FGH$YI>702VS[-!%:Z(=_.FN>>?,V&9^(N(1>#1)QE'P1SAH+V,FIA
MI2/ 8FS=R/EF@"L?Y*U1_OAM0FN4/P?*F],H]S)@[I5',=%BGX%$SAN*<'+$
M,)JL8R*W_!0+.C+7*'\Q*'^\M8\[@+MV01Z Z\_3N Y)2Z#CA +6#+2WL^"-
M.(<LE5%1*G#0E5RD7<;BQVO<&AHF^:P+&LK=U9=\G1L1[O;R+X?Y']V+JPV[
MQU< /^;<-RFTC"8%A'-N#N>:("L-1I%C:6"4G99F2>[;G9!3\5+J-?>](NY[
M?-^VYKXGX;X9I]80+D&?2;!V,4;<J("L3P))SHV30EE.Z9*<VIK[:NZKSEM7
MP>.O7?W'9KL95]]@SXF*!AE/">+)$^2\YLA@K8.26%.LE[W<^"1[4"=/,1%Q
M5;!9E1I#5K]UY:H^X2O9AEP&;W(OV%\G<9N+IK#_:=P3E268WC 8YM ;N78L
MQWDUU?OB[L'W5>\/&YJJ*/_%8U*)H$_M\#R^"7 ^%^P18,QQK15B6@EP> 1!
M5LB(L$Q6AT"4R=%^M@Y'YPR "9*>+_K]'%A>#5>L9O*:R9\KA%4S^9,P^6SH
M2L*\,>5S)2&/.",:::\<8E03K$TR*12A*ZI8S>0UDU>)M6HFKUA%N)K!GX3!
M9\)QUD@BDO?(&*!Q;G#F\A20EBS0P*(.W"ZM&OMS$F@1HOGOT,+MX-_0^KXY
M>9^=40?@XC?_%SZ<O,)\(&8,R<W_=?W_7NBN\CI3EUF"ZSJ-BT_^*(91.^ZF
M[90BC/SW> &5CW88/T:XHV^U6S9/REY^P3VX_Z_MGO^VHJ@X^.<(^\[?7?O%
MC'8[\/WS[1_-3I,==#[_.#C^V-KY<G!TL-4^;G[YH]7<:Q^#M)\=?-EG_YQ_
M/H??OSI+"=/1(,JP13P)BBR,+@K)*&D)IL'@M48$[CC)<]T?Y8#:E=GOV/YA
MJSN14[DP,/?T(3A:A.".(A!BN]T[!4 T"G%N#.)PD%ER>-2PC?Z4.#1ZJ3&$
M4P9#.QP->_VSQF>@]!@:Q98K.*LL]M!H%1)5E!?LPX'&L%><]J[7@7<\*Z+Q
MZI=!(TXD</:$-].(F!_+C&HQ/9 ^ E#Z.49>OL68/$H6@/%LVY-!?#/YY9?0
M&IRT[=F;5K<8E>*D7Z9G*M]@A@2*^Y6'?SEMA>%15G4;N'1<QA';\9W'AS>*
M0S.45AZ3=(.)ZP_C#7+ML9LN2_"&,.)>E[WYF&#UPTI\N\O^)(1_0Z3^KJ:M
M]D+&^.3>S<5+$7&;MRK162GS=#_:?B-V0PSE&VY%'SLN]LN_&%F?>N77,Z%7
M_,'K3*@%5E3%)SN;0\MZX]NL!+ZHD2/UR-USY/ C<LBSKMTNMOLN[<(9@^XV
M&XEO._&KO@&I.\I:9KF+DN]W?IMU]&[CWKT=CLNS?9I,W-27+^(AB*ZHZS<.
MB/"#WS_\V/FRS_>__/VM>?X6SO$_]CM_?SO8VN<[6_#L>V]_-,\_\)UWLP&1
M(_C.-CDX/CHZ^/+AO+D%[B+<Y^#+QV\[QX=XI_.!-+>VSW>V#O$_Y^_G:AG%
MP#QS.B(M<MMJ3#RR"N;0<JF%B<Y*08 HP.B\8V[2'5CRKO&-YP#+OVZA8>ZR
MD?%5<\D#E\5J+JD(E\P43B*<)9V80DGG_M(*?K/!8Z0DQT$+S[ *-9?47+)<
MN^1AZS(UEU2#2V:K-&4#DW)C@#RT1EQ3BC3!0"W$&ITLV"E>UUPRRR5+J1%5
M<<?N?><$)CH'^E-9O:",X(<6P#:WV&K--UEYX94DKE_&?@Q/[OJ<I-L0YVS%
MB?R-K2M35S/GW9BS.=^E%NQII9A!Q":,N)4!:9J[.R9"G J>>BK7-MG&?(;2
MG7N=U<5B*@KQ!SI8-<0K!O'9'A_<6:=T1"FJE/>4@7&4+. \)N<Q"YQF1XN(
MC?D-M#7&7PK&'^CXU!BO%L9G':# B8Y24218 (P+9P'C+B+NM3?)A#SS:YM\
M@U8#XH^P([!RGD>QEI17C.)@O=&-I0\R7E@:%W:J6V$\JN-Q=Z):7&H[#FJ"
MNAM!?9CS,YR(5%D64! <:(DS<#&X<L@9%:P1WG!LUS;Q AND+I'_DE#]<%^C
M1O4SHGK&M; N2)E80E0*A3B.&!F85,0,Y\01GV*B:YMT0?2@1O5+0O7#O8L:
MU<^'ZCEG0ED?F;(H$1<0=YXA:R1%$3O0WEYCHG*6QYT74RK?[Z+R'D7/?VOT
M3@I >MOUL=TNH#!X94L8U7<D=GHY$7L$7W/M.-ZR]^G(]N.O=A!#WC@"GQ3?
M?-<;_+R>5DUEMZ*RS_/-]QAWPF&!A*% 9219Y'1>WB":,*XTU6%YS??J&&BU
M8Z#/NLYQ5T:HD7]'Y,^X)DP9&:11B$7%$=>Y^$($Y(.WXD2@8'<HM[9)-D@U
M(J(UX%_:HD<-^,<%_*S7PGENONDD\E)X\%K 8;%41^2H"T0&+P.+.<)8+X$\
M&5S?P3?@66-WF'$Y:.7%CSSB];K'$[@K@SCHWHJH+F?IW=5)^BOV\R:TFICN
M1DS[<SY(\A0;K"FB,@H@IA 1N!L21>=EDBYI,%#6-H598(K44=*7A.QEK7W4
MR'XN9,_X&.!#>..B0C1@AX"L=8XN6.2)XSY2$@+%X&,HO<#HJ*']DJ"]K 60
M&MK/!.U9;T):J00W#E'*<LLE0Y$C,2'AE;:,:1UD3IKD&[Q"R'X-BR"_QVZ9
M0C4:P+'!H.'[,;2&@X;MAD9O>!3[DT_J19&J;NN #]^5<[2;)ZQFJ[NQE9]W
M,2)-7%&,B&'@8E":FX-JAQSH(!N,))&+'/N8KU)8+W&\)%0_ZPI'C>J'HGK&
MO< BD,AL0,EQ<"],\,CH8)#5-D3L(PG:Y3R,!YL@-:HKC>IG7<:H4?U 5,^M
M4V!OB10,.8,5Z.IDD<&4(R(-!T0SIXU<VY0;LD*H?J+%BF?%Y.^]7CAMM=N-
MTWYK&%$OI5>V3/'<&\-O'?N8S-27/%&[*=5!CWM1T^&%&]'<>TMWSK^=?:64
M.6-,RFNH#'&L.-*,>\2,#U1X99.21=1#/[S<^<J7SZCCJ%5T8);%)75&YI(X
MYFR&8Q)CRJF0$.,B@%?#*7(V*(2C44D"P6"LEMWBM.::FFN>?\VFYII'YIJ=
M.7L&,X$C>%@DZKPMGCFD#=%()FI!G5"::*RYYA66!0/HP35R8MJD$IB/KVW!
M:&7\O8O)VKJ<JYH<[^OL7>S=%<(P1CS"$K.\(U\BYY)'UM%DM-(4&Y(3Y.NJ
M0"\7TTM?+ZHQ_2S.U94J&\$3+I!B.M=G3P0YE1C*GE6T)D8L3<;T_(I1C>G*
M8KKB7DV-Y&6Z+A=KOYX'AY5'24J'.,O)'-('Q+6B!I.H4MZ#OV@WRXM?)7I6
MQZ%8!*T7ABJ;6O;NR'8/X0M;$;BH'P-\Z>T@MX#\V[9'93'VW!XR%T^H2>IN
M)/5MSH7PDC"EHT8N4HZX8QQ900U8'T3+8"UAS#]TRUV=^%YMM#]KREF-]L=$
M^VRQ+^.8U-(C#*!'/+  SH5/*"A!<&[=PG/S)\(JL#A<P_U%;JFOX?Z(<)_U
M0)(U2E,)*MV(",H]YC9OF",L).7&6^R-S]FG#RF@4>]]N1-6QW6TRZ+"KVRU
MHOHUOPK7\&TX'@V&G=@=#NIUW>50T_9IL:9;T-.WL^:Y)U^U%RQZH*4$F@=Q
M8SG2.'+$I(F):QX,=G59KU6%^BIY(/.@K\%]5W WI\&-A784@XNA7>*()R.1
M,<PAPS338'S8P$3=DNAE8_I9W8P:TP_'].=I3 MF@_1Y)1($&'&K%0*2-D@S
M+&)44N%<C4]6)=G@-:QDE,YTH]5M?)]XSPT[<9_K%8[*KW!L=^%9BQA(W4/V
M'ASU8\ZIL"IQ%6A$2F2G(H*[9D+@2&:"$I1RY<W:)N<+=N;5\<V7 NU*+&?4
MT'XHM&=<"J*BM"(DE S-T!84:<T]4DP)3"(.@0"TU:)&)36T7PJT*[%T44/[
MH=">\2RHTUH;9<"I" KQ$#6RFCFD -0PES@%F,9-IC94-:"]I'6*XMY,5<;'
M4 L1>H&,1@F-!LA](PO^0Q8O7*\?8A^5P_J&P5B$WLBU8V/R/N,O#'LG;_)(
M#7KM5K@X6&F>6SR*55SZ*.L/CF D=T_&M0?K.,E=V>QLS@<)*ABF?40Q6(]X
MBAP9 MY((CRI9+@4R:YM$KF S2:0>@Y-?+\5E>4!N7+[[!8#^7Y[>I<8.*ZI
MLP+-*6OJ7 YUSOAX!O2<$50B9F0.,0>!K(T4>1DE4=@XF=>$C5R0L%)39TV=
M-76NE'==D^AR2'1VG2YJ2H1+B'@L$2=2Y.(L 04O'+4B=]@12UJG>^445L0!
M_CNT\,;P;VA]WYP,Z<ZH S?PY=^^E'-;ZBGXVN2IQY?F=$,)N/U);]#*WWG3
MC[DGZ/?XRVDK#(\F9M"5$\<#CB]/L0[&=C2\_I0KPYH+E@#VGUQ7TB+_$3%R
M,8CED%WY>=2?/,^)/8S(]:/]AFR"QWUCVZ?V;+#VWZFWZK2Z:&84KQN CNT?
MPK>S*,IIWLY) JUT-AZ0S?]U_?]N+GK$F:D<TQ-V IQRY2F1.<'6.B6\M0GX
MTV%L74FQ<$X,;W,:H9) JP9;Z;#G6DL=B#8):!<;24)T%_;N6(26$!B8YN)/
M_BB&43ONIKD4[-R)N65=JPTR%0=[6:[WX-:_MGO^VXJR\<$_1]AW_N[:+V:T
MVX'OGV__:'::[*#S^<?!,3#KEX.C@ZWV<?/+'ZWF7OMX=\N?'7S99_^<?\;
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MC6"(Y,*(FCB1B+]^P6V"G.>+,ST?=I]Y-:!F\9K%;S<RU<FLK1V#Y7+Y3(
MK'^?*ULA[8C+7&Z08TP@QKF6,6 BG5CVJFE-I#61UD3ZU-G*-9$NETAG(RS<
M,!.=1SKFIHD"8Z2ICRA'7X77G/$8EK[\_(Q,6H1@_CNT<%/X-[2^;T[>:F?4
M :SXS?^%#R<OTK']PU9W\KP2H#/^I'A .DUOQZ/!L)7.9A![[5@\@?- B\[/
MW:+.T6  0]<8'L5&/^9L_W'$I-%+Q8?O>AUXZ+/_65@A:;T!3V$/8]X-D+$_
M:,$D#?+"-5RL';];^/BD-P"\?H]%@[=N/+3%'_$[?+7K8Z/5A0L/8[_3ZN;G
M.#V*N6!9HS5LM :-3J\?&^W6M]@^@X>!L>OVAOF7+ "=")?N%QS4ZQ>W'#_Q
M@N=LG+;@>#[935XSAHW&WN5+E]=)"T]NY7<_B=V0WQ*^-H@@2;;=2"#MO3X,
M0JOKVZ,P&<;#V(7#DPL.1BFU?"N?"I?,XI6_7CQ]OP4//NP5)\4?)ZW+D_(G
M.[M_%D,VW@#;\$43^X:_VL7^F7S/0GS*X1N+1^/(#B8O#H,'SSYH@%SE^<T#
M"+^<Y'=;+][HBLRXV&[!: [*2?W9I/]4'J^9Y[<@DO#G8-0>KC>^S^=7#/*8
M_Y_'C_2(1UM(D"NJY@[^.<*^\W?7?C&CW0Y\_WS[1[/39 >=SS\.CC^V=KX<
M'!ULM4$%_M%J[K6/=[?\V<&7?987!9K'W[YZ[)4QGB E!48<NX"<L $%1Z2&
MB<&$%_6J-L2<CFH )MJ%3-YEYN_I'-8SO]29/V]^94$E%7%"-A7VB?'(,I80
M\U%ZK*6U*>65X(UYZV0R\P49W67R[VG0UI._S,G?V7K[-3+/ 8@:<2<HXLHK
M9!Q,?HK8$)<$(5KEY;^-^;+6%Y-_9,$,<3%V&W&0S;[6X ATB2UTP5;TL>-B
MOXRO,K+>R'Q>_"2%U.1Y7L\JY23Z;,^TSTIU>!=I<LE:(8(Q5'HN%;':$: K
M%EGRN>S6UZU\4PPRAFZG3>:E:%;0WH$Z/8SONV\[8'<.:QF[1L9P<^O#5V-M
ML-GW$2GE8FB,(!=#1(QA[H60,@0-#A"^2<; \ $K9%!8N=EX66![-$Y!Y.QP
MV&^Y4>%]3"S";/^E;"#"[V?1]AO9  W7B.;&A<-5>"Y3CLL2I&Y:SCZ-.N#M
MG.VFW9/"T.T>_MD;#-Y=-4SWX'Z_MGO^VZL3GL_GNWN?OPKM;6(L(.H\ X+*
M);VI98@R;Z)U)GJBUH!XO#V!@1WV1WDQ_D;_\J?^Y%/9_9GF4B^+;^'P%"([
M*"0"+C*8L=%GG9B+)M\+W9D)3#X#:8*H?QJ",U$V!G\'+D.P-[)SX]]P]AAX
M@_^\F0;$;5WWF=P)#SY*[,- CU]S[+F7L0@8\+8]&<0WDU]^F>P$;G6+82M.
M^F7Z?OD&,W&(XG[EX5].6V%XE$-M&[A<?1XGA8SO/#Z\41R:B:V4QX39H/KZ
MPWB#7'OLILL2LB&)N==E;SXF6/VPDM);7?8G64)W*%9V0WF[4N0K%7,NK95;
M5+-[L2.P?1D=^C4"FQ2ALE;W-0_)WE&_-SH\FAJ"6P)D%8HZ3JG 6U5R7%(M
MQ+N4/%R%6RYSW]EJ;SO[#;R7'+;.-MFTV86 2T),K2QS#RD94[7%W<6C=/O%
MW46O6)7EV0<7":&&J$B#-)@;3HBPEF,14_"!<XJ9N&T,^WHG<.5#".-%V+/]
M8T^:6]\(W/,4_L4[G;^/BP59VA3-X]^.]SOP#,=_= X^S2["_M&"]SK=W?L;
MWN\M_/N!'GQIY@79X_WS;V?-+SNM?0I7 0_SG_/W<]T8I.(F))[ =]0$<:,4
MLH02Y ,5''L:O#0Y!$$VZ NN]7AWLJZ,Z;(8I#N];FS<JSCSJQZRNYAZ=]HQ
M\4+5^D.:3KTT3;[H%5^,)K<Q>$%TL-9;+@/7D6,N?))*:*RXJC7Y$VORYIPF
MMR2 92484C*O6EE0XJ#-!9(8*V<(Q8XZT.1$;:@*M9![AFKYJZ66P$[&#^FR
M\"I'3#],D;]8_[R(]3Q C=<.^6JK\6 X]4(*HZWB5%B=).9,,H_S:QM<J_$G
M5N,?YAUR9@+3*2),K$><L%R3RX%_CKG!A"=L?&ZFSO0&KQWRE5)*]U/CKWC$
M<CORVA^_P1^_3=YV[9J_<-><>E#<)GHC&+CDR3LC#$[4:J$%N'WIMCI]S_YX
M5\C157T^R>*KE?H=E/KG.:5.E3?&&]#GL?#-@T,N!);K;>=NR&"#L=S;?4&>
M7^V95UA!455[YD^KTE^X9[X4A5X[Z:NMT!T3G$0!;GEBG%EF.:.<6FF9E-AH
M5ROTIU;H^W,*G1A/M8X6*9I JS.GD1$J(8[![#(!*VI H>.-9?4PKWWT*BOT
M5SQBC^.C5UJ1EQL%'M3ZNBJ-HRM]C=HXG(WW@!Y!OFR9V&CGIF:U@?@:#41J
ME1$F<;!!&,^;O2R51%LP11QG.IG:0'QJ _%PSD#$C"3A*471<X6X9 $9BQ.*
MBI"8=WJ*J-8V.:O3*E?+WF&BMA"K8"&6^DJ^"+4^*&KWM%++Y^W^11?D8D=J
M_'$"M\U%;.!+X;(I\O^Z_G\?5.(ZEMV7ZP6C5[E@% *SC$B%39!<26),9)IR
M[U,N*F-\;3X\M?GP;=Y\T!YK(CBR+#<C$KD)"0/S(0678M0FPMRM;8J-^<X#
M]8)1A74AHU6)&JS*B-4+1C\Q'K*A<-+O?6]U?0O^;'6_Q\&P,ZX%6"\DO>8X
M0;1*,4>C499P;A+\7R3+>)*,VQAYK>B?6M%OG\YUAF"YG%NR'&$7,>)4!F0]
M%X@X+#6'_QF2:T#5<8+5TEOWU/2O>,06:?J;BR7GOS/AM;IEQ;.I&DSCJW.Z
MH7)!I+)$< _$.[:+\L"7=9#^-5T7:UQ%"5^>8MV@UQX-KS]E43FG)Q[$HF[6
M;^B*V)5#=N7G4?^R&L9A1*X?[3=D$SSN&]L^M6>#M?].5[%J==',*%XW %?*
M6]U82&RS"%TL>L29J2R5B9+16H.M=-ASK:4.1)N4M,%&DA#=SPJ:W;E@]E--
MU.<N&&]%';+<0@RT=:_?:;SUPUQZC!@M&__.Q];@D__YS_JMRC0W;#_72'/'
M$:XR[#7Z\7L+GK6P#GN#02O7%K,AOW59%/FLN/O[+*S=G$D<O\?N*#8^Q?[W
MEH]E$>5<1"V6%V[!(-A^:6@.<O6S7$?- W_85AZ\G+M4U-[N=='G3X7EV;:G
M@XW;/7K'GC5<+ I67WD#FXNG@CBT&VVX^W L%F7UMORTQ6!-'L&/.J,2UPU?
M%*"\*/36.^W&_N"H=0(?P,N"<5P4>!N $.2(6RX?/CB"=SSJM8O"XCU@Q8:%
M4_LQHJ(H8@["]4*^7OSAXZ X7>#\<0;[>JX85U0VB<5W/L5".P\:3-/BU9EF
MDWK;<\/]KA?B?(W/U@"(?M0.Y8L79]K"VBJNDRM1CVLY3HI:PUOD:M2C8:NH
M1IU'KY?2( X;:30<P?S-E 7/)1_S%%UV.BA+BUZY2_YK?O0'%X74X2[.#N!G
M[[+L9)PIZ-YH=3HPW2 <[;/I4N27DU+.UD;CT\@-XO\;%=,Z<[ 4D#3J%T7]
M;$J%@!S%&;D8OVJ>,GB=YM6B\9V3=LRECNQD=HK)&0Q'(<.@*/($)^2P:UGI
MC\ABYJZ\ZSUJA\_7P)F!J(7W@ANTIL9X VC ]_I9<[?/UJ=&$Z S\EG(AO,7
MSX!^RNKB@SCHWK +;"N614GK\J^+*W@VP4\X_*JQLC)X@9+F!O$@#;*<).04
M\(G72N& <Q+9]>6EYPODCY5H20)]VQIDV@^%'0-R!@C+?1<F.01E^?Q2\@NI
M!TXIKI)%.N02(OFR5\X'4+7/!@ "N/@%.BX:*@"^\XES^)VER"S4H-K6R_K(
M/>]'N8#P.ERG!0]R6E!?64H_?_O*[2]A4A(6X*DD2C?UEO,$,K[IA T+SBQ.
MG+#*(J:=!_ LR@OB';/N_%3DL3B+1=,* &[)/R7GP,4SB&]2BID1\S+0^(S,
M@%>&I'M5EX\Y=7SKHH>@^N7FJ__2..J=YA83ZT 2\/P7]RE4SY@N2R.@E("+
MF\$7OG5A@-?A]29C!9^YF,L%GN3EJ^ZPK'&=AZ8[T<]9W4SL:: X&/=V>V&I
MXCQP1<7LPM3(U8CM(5Q@,+SS.Q:/O]YHI9GA@J?M9QP4(@<GG4XD:*PR@4D7
MCN^"IYTIB;PZQ74G8EHV9QF7U&W!9Z4)^MV"LAX-BEGKE\8I3 ?,'VB!LKU&
M+Q3&4VGIP #%'ZW!L"S6^Z,Q!.[/1D4AJC#/QZ-^:Q!:8[OHM,!MJR2:WLFX
MC\D,I>3G.>D-\[)HIJU2YV<]#[!Q(^"M;(==B.=@,.J<E%<97[=C T#9]4;#
MXI2%9M T8@'*&; G69+@7A-.RX>R=5:LSEX.0M$$!&0F=JTOH)(?.#]\81T6
M)V7X7IX W'B:V:-\E;%8@H*?^5HIC"4OSKQMJ["MSAJG>?A@L"[OOC%5L7-<
M1W[B7+P;#<N1^J/G!A,? \A>-6(FO:X=CJ>_8.'N$*P:^]V"M9\'JE>,:CDU
MF<.FUZ>O+$D7:]5=P" ,<WF[,<8*(3JQ9]FT'A:,T1^"L.8[=DI;.V6C?6RU
MY0GYO/%I V:E>]@OWGIPT?0GOUX;7G30+F%8L'$Y8$6?E@E]YQN4WQ@_PP3%
M8RDH[7G@APL.',XQ=R%3_8*1+DC_POFYF/U^/(E@P80\NT7)Z=.L;TMPP+3<
MDAVJY9J^O;$[P?1(A6*DO.^/"L5>NE=Y,$ 6;+N@@"+<4EHCB[7!8.PXCI7)
MX$K3A#[XA."EG5]:#9?6=1:*7)FSN'CA@.99+I[]DE,V&ENC BNW<D.+B09I
MR4\XZDZ<J?6)TU22(4@0/')JM2\?:JJ.ZOJT5YR98GAT<\WQEBU'9)HF4[_7
MF7GGBQY'%TY+T2QB_,A7/(OXPQ;(SE\=>_IP@XR?J7M,;*CLEURB/T_%*)0]
ME;+,%RYO870L:-B5GQL&8_[2,S&>A9&ZPNB700GA*6%)@15LN#7!:&<BCRY8
M$_%7PO!:537L7-W@ D)$;S0>J3]"X7?]V?(Y?><M,&0A]97IA'#^=NQ']> [
M^W"]_?.=K7"\?_P>'W3V3W>W_FX??('?]K9_[,!_^^??Z'YKQH\Z_GBT<]QN
M[QPW\0[=:36//W8.CM_RG2]P;N?@J+FW39I[O^6UF=8_Y^_S>LOI5P[NO#*8
M(M#Z"7%G.#+!8:0D88I9[7EP:Y>NT=OLCP*O)1AU%ZA,N1BI)=X[;I*.RBD9
MQ&SKA#_?O]O>^;3=>/O[Q^WMYO;.WJ?Y>/15D5\8T/SY3:<?4H2<Z\$L%E0#
M()3#$6N'14A<$!I(E3HZ%%=\D_W*EK\%2-YWT5B.&Q>"/*BH/7WMJRU6H7/O
M52B!Q@$0I#^JZ"O>VF7(]I$%?[E\13O]BF,M!T;58-S?L7SIQK_7RE_6_C/V
M\@_!N!I.M?+(T=4V&+O?X\75BZ5(4*D7URX^R!H.E-WX2^OYSX[]%L?AA&SY
M@U<[* /2@PB6VJB(MD_T\HD=%I;"2;^5&XJ Q@M@(_JQD3*KWOJ'L?!K[&$1
MZ[ULPPBSL'WR[FVSX8]@J/MV;/26UDZKTQEU>X#EX]'AA;+O@$<!=F<>E<GC
MP<R,<HO';):.=>L >+X,_V<OE^)?QB,X)U3%8?++?PHM#@<F[^4+J[IH7ODM
M9N<HQY:+N_[=\C"UH\Y&X_-);]:@@B&(K9.+X.^[CW_"1X>V?]%S\M<_WQ;-
M@B97N>@<5+A[G7% _M=WOZ-1-T>TL]4.\['3?/_KNVG#T46?7[('4W@X,0[!
M1;A; -,IKR55//' 5;16"\$(V ]8!U  Y-:=K19JU#*YX2][EKV@/%AO89;!
M5\C'>NE3Z0_&T 0S<##L=5<ESOGD^GF?-T^_$E!UG'J.0,4QQ(.2R(F($2/<
MD^19#$+D,.=\_\32^[CL=)5#YI,ASQ(S<>Q*B$S[\ZW<(W;0FY>RT4D9?+]6
MV&#ZP/.9D3<BP%#S+." P4;-=5"Q)Y0:+*FW6/&?R-O[G=]N%+B_RL4D8)G=
M]+%W!L[3V6YW)P[_ZO>RW_T)Y.>RM!JBKTZ0/-WY\-62%&CB#"5-/ *18LAI
M89$1,5B'I04MN+8Y7Q;M7XU^.:23Q:INS(&>8F2!;V%H"RX;?S)FT%BLJ<#'
M5S@Z-$9%)V,[YO*KW[0Y0-B"C]JVU9FXAF/N+JEYK,XV&N4$9^^X=UK*Y?A[
MEW&%\4I/R<7#7@[63]XAM[\M3QR[=A.)O[S.)#!6ML$"_[,?X!GZPP(5%97[
MC_!:'XMX#8SPQR+:!$_WO@N8+MEX @P8MUUX^]>,ANW3YOG^5\\,U\1@9&4$
M7A4$D,!C0%2K*+E@2BN>2_<OP .(]6'6VCGX=1%HOPAT34G:I53E-8AQW^-V
MC@D4BY\5E:;K6;39ZK8ZH\ZK%I\?S;WF5R:"T)PG1 65B"LFD?8$(P':VN;^
M'$Z#VSN?=OBO;.9E!BV8\_]O[UN;VN:UMO]*AN?4SL1L2Y9LZ>X\G:&%=G._
M#?20=F_ZA9%E&0(Y\,1)"_SZ=RW)=NS$"4E+6V@S]^Q=(+$MR4M+ZW"M:[E#
M-S]D\U@QGK+C4L?98QNU3T]/$4.B<3./;UP[<OA\6MBBU?[DXY;+!-3:E?=5
M5MJG39JU2.Q]L<'F<U-5W<XE@/OBJ&V,OM#W112L9^.^=\ZD&+[3S>5U5>4_
M/XSBJ,$>\L7) 2.8C:XPL:LCJJ3]$0]@7#G8,-N\DSBEB<]9J*B!]^T3&OO$
MI(1S'H(!'5!J-QW\W6VZ%;V%&_=<:0-73.0#-]*M5;PD:A4<[9\%1[>7L _A
M_MW#4^(KSKA0'A?:]Q@)(S!JPL1C(9>2TLAH&J")'-QA(F_:;1J,#)GR.&$Z
M"%F42@4GAZ]U!">*DM(D5C2(+YQHP ];T?B)HG'=V3\Y93(-"0M23]A*,$JI
M)\)(>S[W61IQ$Y"0K.,]51(Q Y/'-&H9O-*S<LYZ-HT'O2RKJ-_YY#L&!,K(
MS*O]/=2/1=XH[UYM#5&,(R X;P1:<^XA\[=L"$*4>9#\"7O3LRD< RB.<\BY
M!QI9NY_@8:>G82',Y(%.<L/PX1V3;.V];CW9*7[;>8I@DZ_6AD#)V!N<F6&[
M=3C4N^UZ-+$W003J+(Y8BQ^6>;DR=%A^CMX?HEJ\\U$.F<UC::KH00QG;W]4
M@ TKN%-T!_L6<VHS9)->/$IN9IYD-8Y73F[M2-X3-SE,S^'\G<&4/%TOPE<B
MC$M4 OZR?!#M._K2(V(5;F'3CM96R0=I@Z[YT.IA/@?K71: @4G#F?-LZ6%E
MIO/.@XQEP.",8M+WP3Z5<428(@$VNB8ZCM1F(;\<@OO>Y9CQV>5QU;$FVML"
M?E+^_:V+.&7;PVO)X75SO*]/?27!G(F)%S,E/(:LMS(0\$Y2<$R1M2:4(7+=
M+J.OKX3[%H)]61ET3GOC;!;$T;!I+1; V=[*V1NP?Z^N8*];*$OE$+*) 71>
M/ =A;CP%8?O!U>/1=6_@ ,R;V%5;47WHHNIW;M^=IE*&L0J(%W$1>$RAE26D
M]*)(^I'P Q9SMHJ6N32[$?_DL*8V:&)=Q1EHK5FE/FV.5Q?8Q.\+5W^G &[#
MU=\I7O"S/@U8(&6J0R_1H09-"(LM>2Q!,8:QGX@X#HW8>1XTF.Z-$>O5D6K\
MUCJ@FS^[/"[XG<KC[D2'S*%)E(G 692,I$PQ94 K"#^ETL1P8(./&3XD-,G*
M%ZEF1JLSD5U:'AXP,X"[\X'L(M=2FL#+ I/S61BXYD$IWUSAYD=\F2IY.1JZ
M"HCL:#0!NR#7T7^T&J;'^R>GL"V8"B/?4PK3AL)77ASS$"OLL9VE43)56&'?
MI(;+**]SPJIAWES[SL5N7>;/U9>@--UC?!SC-^/"D:L$RZW=6PV15V/1C6/,
MBSM;:#5BMM A=M2X!'@ZZUJ/!@,0(D3@%U'SN9E:]'HYTU>](3C,<U5KE7*+
M8N[535BM\G0>*8)986 6>YT:^]2?[RL&33NP,QO9*V/6M*W]/V[7=;X>W5Z>
M2A4F1A'N!30V'B,Z\4004(]032(-;R7TS<YS[K?AJ%C8>(5>SPM;'5S;"E!>
M23F\*95[B0.I"!WH^JPJ9DLR*FI8)%6^3<HH(49@1B54*</#EX%TP9Q33D,X
M6-,\L^)O,RL_2_1NCKK@UM&(Q"PF'C<21,_XOB="/_*XD(+#WQ7S0PR9+^N#
M6[AU3S;*LFUEX>')PMFI-B),DEA[H4I\CZ74>((IWS.$@F?&J9$D7=6H(9>%
MI]7\B9J] Y=);@P@%1@@RR30&H"LG&<M,T2]4V9)\EB WVXEKE!E9>;E?[)%
M$.9" J;P'JIV^5(VN)]EL%>S0C](%W/LNQ'*&/8;95%"!1%<TS02BE).PC1/
M99(BE1EL]]\/WG\^F@&*2P7F5^!)&2B/<1&!\9TH3T<)Z,DDB2*3K).^W$@7
M;V7AP<G"\7[G5(0A"0.C/1,+"B8A#3R1FL"+N*%4:)_&6J(LW!%NK>GB9H79
MV=LK/CSHY!KS)KM!C0F:A0GZK*0$L)[._TW!_W+.%0K$;JM)B_ZT,%6>XK#D
M,\T'!IUG!KDG)?I#W*;[VSA_GB^EKX_V3UCGXB/M7)Q]Q4U$M)\F2<H]9;CP
M6.)+3\0T]I0"/4M)%/LA7^I7;:9&OU<:5E<M;J7AN]!!^K9SJT\C:4P(CC8L
MCF0>TD4B<,QX@6;,B#@F$5;/<M*.HD5I6%"DJR,QS5KQE]N6A6+'2%,>GKH:
M]\P$PUGQV!:78[61+L*C&*)JV=3NEUGFI#@E1E>C\61Z.QVH&$UV-1E=%R?%
MP>['W=8#A=_<#\;HW\>=O0<ZP?LI3\0)M@Y1Z$$JWB#E#TC DQW\\WQAHH,2
M>?-8(MPI!?;'WJT.0%Z&V,'GE0"CRJ8K;@5?1+8+&Q\V^GP("W=V4ZTVO.JK
M;-!#THK*5[/)&*EQVL6GL&&OLH(0.L\*M+*;;&(&=2B2'?G:,*1J86,YB>_
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MVH_^,4D6/XO8+A-LZ<?^+EGZV:K;PDD5D'"MV_[##MD-&U8&W^__[@0[=^(
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M)3^#@GO)'A,RO'F7C\$%A9DJB@5HXGF"!"G*F5!H809' Z4D\KEZ)S,)<;S
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MA343O"J!M=XVO&!P)9XS_P1)R).+XP0X;W[KWA$6$'N7@W+42NV1Q4HU(GL
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MVEPOJ:L7U;4/J*S"%=31XH[2 @;]+@LO:DAYXX]B^(3HKR/!"OV1,0T4+%T
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M7"%_:^*(^/P6LY9DA3__\']02P,$%     @ ,4!<5B ^V'D_(0  LT4! !4
M  !S97-N+3(P,C(Q,C,Q7V-A;"YX;6SM?5M76TF2[GO_"I^:UQ/EO%]J=?<L
M#+B+-2[C8ZBNGB>MR)NM*2%Y).'+_/H3*>X@0$BYQ;;7]*K&((3VEQE?QB4S
M(O*O__[U9/3B<Y[.AI/QWW[B/[.?7N1QG*3A^,/??OK]^#6XG_[][W_YRU__
M#\"_7KU_\V)O$D]/\GC^8G>:<9[3BR_#^<<7?Z0\^_-%F4Y.7OPQF?XY_(P
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M.M5(7=+LX02@9@)L9N-NS,4 1;+:DL[TRB_:1 4::3)@%,]91-+=JM,%U:?
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M.\:O>;;_=3Y%6@3#,=GF ^+NHLD&_26-B1[SX6 \S\2@^8![M)Q+=1Y*N\0
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M7%G4T7L!WOI<[YY--%)K(-=:00JF4LZMDQ:7(^G3\7$#+MR7T+K!]+<Q<7>
MG#<5J=>U',UQ.O_]TZ+EVR"ZHK5W#(+,]9;$X,&G>ENARKFDC-$QMI(]6_6)
M?3J8;<B [F:]>?[[);K+W;I=G$Z_E<GT"T[3[**-\R @.A.5@%A$+2X6"*$(
M 4D:J0O&R'U7Y44K0NS36>HVM$E#@77'JJO.?33^&T '2:) *S4A2IJ"3)$
M&7>0E8[9.>M9Z-S,W@^O3X>;6[%-;035J7ZZ>.W\4/6\<U*]>G?19!9'YQ;6
M2E]"\>8\B*3_@2^D6G5,QDGAO;S=N:T37;4BW#X=8&Y);W4AR.Y=I>57&@PT
MQ939&(2D RT/3M%LL)JTK4Y.%%]4;N T+7]VG_H\;]-]:B")+A35M;!U0,97
M:A\*2*SMZ#5+X%G)8+067GGF%795/W@327-%?"97X6+*Q3@0MI![8;4%IS0-
MMT2I@G(1;U^ILY4@^=$@LMO3]P9D>%1_/GW^NRN:O3Y(EY(*UG 27.3U_$I
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MOI 5[3]GN]6RF3ZT_GB*=F7I]U 7<1^L2^__\EBX"\">BFD>!;>=6IHFJNQ
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M:KV<S.OZ^D]FG^M<[QG%A;6*^N/7;:)<]#88U,Q8HJ2.AB*R.@2(*Z=C$L)
M:%TF^#BJM7/>Y/P\PX_CZ9#"X=G)Y""./^'S9R39T?1B4KN5O1B>#V<#!SP(
M1V^5Y64^ZKQ0.!HR*U@<F4MZLT3KZ4\=H6T^A="8*W>2X3VHI(?3DJ52>#?%
M<G'V8DAO,"BEDM.9*6D#0>2&!5D,RRIJL-$J85MWI^@ :^\8TUH5/>2\C\\_
MPG RO_1<CD<S&+T?UKM[TRG.ID=_IK.+^6S#\3C_,3P[&_"@T$I#?D =4D!N
M0!U<7>@KIVB3P&QHPVC,FY4 [AV#^E-/#RWD;P,\O)C4QK(#"KVE-LJPE-6\
M W)D8# RG;B(W'DK>>MVA4N@[!\_&HB\AR/:5Q=5*B?E#6V7DWKYY!W)N8YK
MS*Z I@C"UUK![#R+.0$3/#F%*IOBL#$1[D>R=SQH(/"&6>HK5%\,D[#T0\3$
M0#O)- ^Z3C?A+"F#/$9EO>Z4E5Q!\7N[)3Q)J#W<-K["<;U%U?''M>9("A$B
MX_-1!K713J00DD& P*-(@F-K8W\_DKU5_!H";WAI>'Z6^F*8<'3C:OV;\6<X
MFWU^ S,<*!512Y%8$.!HJ44Q2!&93SD94 (C/)I%>>PA>Z/CIM)L>.5WCNL?
M.'S_88;YX!-.X/V\3?I)N6RC/@C*2V(?UJI0(/\"+8/L'?/HK0G6"IFZ%2P\
M])3]TG,S>?9P-_?^SG_5HZ"U?]4#\,40XF4C5)A>3.:,/1Y]O)@-H%23Q#4#
M2)HV)B%H"?17(S YKJS,03;> AK WAN.;4N5=]D8ML#& 1?!J"(42SH7$IDD
MFXF@F4MU#$\(R<C6.8HGP/S!MA55=4_N:_U9&[4_T*^UX*M.>*2]%Q8J^%(3
M]NOGZU^Y[+1V\ =,\OR/WW%:E[=H)R0&6EM:CE7,\&"9-H+<\1@#\Y =I[ ;
MI6X]);,E_KTCY-:4>P]3U^_I7Y'&QQ<3;R_F.84*O\/91<T/79Q_G%=0'OWY
M$1/Y'[7]D!@([IPS8!<5,EJ:S'S0GBDMZ16D'WC;.C;O;S7[R>+M*_X>3J\_
M<?2I+^A#2WLVK-UO1GD>-$5$HT5!)NV\STV@_05HIPG1TO(4H$W-&\CTO:C]
M9/C.T. >HJ_7!_5V4'^[J?# AE(T)SC<2,ZTUYJ%% P3.NF0//<25:< ^K$G
M[0USVLOU'JVOUVST,735 @\2%!Y<T$S)FIWG&EE0V;&</=<ZI: 0FFB^/NW[
MTO[*\KV' 6MGR"]OE#PGR=10: )I]H_A[,/A!2$]Q\GQZ/+\MA[=T?_R6_AS
MH TH#5$R[;)@NFC)(IDGYI41/"9;@FS=,.\),/>&3)M2U3WT:IMY)_DDQ#RM
M*_CR,ERVJ\T#[5$:GSCC.F:F,UK: 95G4A=GX[S.KUN2=J7'[@U+>I;X/>18
MNT?G]<VHI3)97(VJE0+$6(*'M$-JJ1W)@SPD4"X[K7*Q(;;VD3MBVU27Q;X=
MW#Y4L2N=%I<NZ=?/]1[PXB*.-\)+$*Q +8B42C+(SC#'<T@Z0HK=;B>VJ#:\
MAK7].XLMZ="U\O"):NFA\G#YZND#KJ[:=8#84^N&#O"VTZZAN6J[4F=-O6R)
M0LI(X,8[AMI@K7\SS#LO&%I4(6(LP;=N$[,UZCS2F&$7F+.*.GI@S!=(ES?*
MBA8:H'IH/M>\O@W,6R,)'?EM1A0)W7I\K<".6Q!VR$E^JIK&[63<PWV(YQ<3
MDNC%!&FISX=_UJ^N>DAH:85&ATPA;:X$$VM1C6;6^1RC209+ZV![.9K](T(C
MR?=@!FJF^6*&D]M434&94,^BI<?"M(J<0GIIF57%1ZT$E-OCI=8?BW(_E/UC
M0PN9]W!IX07"%#^,S_+Q^<?)^-.B <TE-(ZY7MK*3+CH:M^[5%/(FI!*!TK8
MI'/K0J8'X.P?)5K)ON7LNF5],(7CDHR39SRCJ*,6>!T@:AGPJ!0O 3)VXL(W
MV0BXATBUB: WU@FX"ZCOJ!/P2CKJU!3V*0+>6"=@J4TTT1*KO:QW-)U@H6 B
M6^0R%$=^;>ET77:WM+YJ)^#V2E]%KCUW D:94U:TT^0@"(JUDGDI%).VH%#<
MY5BZG9#L9B?@E23]0"?@5<34LI-.A7+TZS%7XA)(]"F!UYG!_(*CJX,EHJ2_
M@BE:!RNE[79V?O-3OWEM/5E$K?N3+6W*E8R2X#"SY&K@IVLRP#O)L'!G?/"U
M<T(#4[K#G0I[\J7:B+RQ)[V\HU 74-];J\*5%-6I8=U3I+RQ5H4VQF0R.@:8
MR#Z)E)DGL\1 :Q&4*AQMI^S;;JG^2:T*VVM^%>$VUOA7+=M,LCR':)GGCK:R
M4B<4.I59CA:309=5:J'D76QYMY(*EK6\6T5^?23/J^SPQ?!3'27Z=:N)7S^_
MA/\:3P[/8#J=DY@;(F_PR&3VJMX54PRLY[4RBN?BD\+FPQ57@+>7&W_?:NJA
M)\0#4*^!OH+SJ_QB%[@]E0"L"'4[Y0"]J;X[Q9KIK8>3GE5A0Y;*"R]9X87L
M+5E9"L*,H?")FURTX2JF?:39(Z4#N\JR5=351_>TT;P*=#I]@U.D3_Y 9OT9
M?L*S\<T3+AVEES$4%DT-Q+54+%@5&11NM:% 7$#[_E<=@&W^0*E7]=YIC=5:
M-SWX5XNBXEI8?E56?'7^%41T 9QGSJ%DVB P#X*S)(HTB:"EW-H0+06SWT1I
MHX,^YA'56VY?*K,@&?(''3)3(-(2?6)>6,>,I+7I3.&B;-WI]2L >^U /UW4
M/736>O1&Y/3!J^OS98QRE=+--Z3#FGKRH_M8SW:<[35HLNJMUTWIN >[U<O:
MT J5N-2L1&UK*6%A@7-D-A27N<A!IM;9A6^'MX]X[SM.VU54VT<5.4[*>')>
M&WC/H7^I0(K<(,^1!2G)DQ HR#4DL5F18@HQ"Q5;5W\M@;)Y_VO[>KY=6]Y
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MH(61*+3LKZ!T%YI#?P'S"F?/<#+\-'>TY\ANIXEN8IJ#>#<:QRE./E57?&X
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MR%RH/8MBBBRZH!F7*I*]-U&D3GG^%92_Q_;@26+MH;K]"L>U?:I3*@?"UO/
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M@O.KX79=UM13[KB/]6PG];P&3>Z,^=D1'7\K_%4 P*UQS*7:PR[GR+P \O)
M\.@<!G#AN^7M(WGR':?M*JKM@:Z7>\E566NP)2H>&44/!$8CR0DCIVBB"+09
MK-&M4V)? =A\8F#[.KW_<MD3%-)#,=_1^<>S\6?$>71Q\O'F3%<$K632#+-/
MM2M,85X*8#YR5(7^H'>I]=';,C _6--(43W8%XI!9Y-AFF&>0WM'FIF^.7WW
M93(PN:<."C-19UIR22Q8,"Q"%*B1.].\V].#@'XPJ:'">D@@7/4X^R*HNO!+
M:"$:GTN,S'"@1:O &0BI&&(6"2"!;E]HMAS.#R8U4U8/!8M?F<M+2$(F24$R
M$+5]K&WR(HM<DF?H'/<E.@6\]66W>V#\X,W:RNFA"=W!:#;,P[.+.C3]NNO,
MT9_I[")C?DXRK;*[F,U%=U*.8#(:CMY/KQJ0_/KY_@]85.J0'V>"S<SI9)F&
M%,BD*B 7KTYIBMY&;'TQHL?E[%MJ;$<4W\->>C^R&^]P%WP])<T>P[:E!-BN
MD*$32=?49 ^QP*,X==$2(!N63:XW5J1E@6P]DU&8'$34_'8S\&^4:8^EK+Y5
MHJVBP#ZJA)=&P2DEZ4OAS!5-JQ;T52#7A)DZM5>@Y=RT+H':H71%6[UU3CVL
M(O0MEY%>M73JHSST]F?W6?;YX#INE7/JZ(0()1F5N):E!!&T]T$[#HZL 2PO
MY[S]E%[+-$$%43)DEI1R3&ORW$ EXF9 G51)H.Q&*@->-"O3?%*SN2#JB3]W
M3*@ -1.L6$30% M1\*-UD5E]W^T 6_"G35_ 5535N@#T:Z@WK@._&9^=/1]/
M:L@^\,F:B"4SA%2OBP:*SE71#+U,Q06?I.QV][;+T_:"$/W(MH\2S_O6?O-6
M>) $R07!2@BUJ(CB8H*<&7T[)<*8[?4L^C[MR%9NXO>DQBY6XZDZ:%ZE>1^X
MFTV\WW[ 11_O00F6?+\DF=6$4(>L63#>,H4 0B@P49E.9J+[,_>%"GV*NOD4
MGOO;N"^*2:\VN^M];N"UU#Y;8";5@2#UDB&8H.NE=C!<2>Y%MV;5*SYXK[C1
MI] ;'I@LY_%5$_:C/S\.%^-CIK=)G;+1I'(*_5 $IIV.+$"1]:JZ!PPE<MEM
MK,(3 >P583:AA!Y.3A[?"VT),G%DM3D&X;.)03"<.96*X$$G ZWO<*_FCS0M
M<Z^[.TD],A'IY=7)9>;!DG*R53;'XFSN:0+H[I:Y-P_05A?UKI2YW[N<>=I6
MA&!E,I855QO&:%>G?.?(8BH*7<XNF-;U5DO![. 9WTK*[L*AE86^J5CNJI=I
M!VA]]6=>#FM+;9K;*+ ++=:0_H8)@N1D&$$;?<RE)M]%C2C0L8B^:&G0.+N1
MG6:;+9PWSHM5A-XZL+\*%>:^('DQ+^FC/Y".U.5I#")W.22@-6=R_X+.C"QF
MJG8R .?*A=PMFG_D03N2[WN*1NY)]C419T])WB_87HT_S4%575W"\T+I*$Q@
M(JGJ[*<Z]#D[^JMU"(Z@V_@D;=]]UIXJ?$VA]OUZWX"G%WF$E_!9<F$NL2K4
M)2@0#,"3B5,$V$,D?NJ<2E8@9<>18BL^>/_9L+:X6R?P'L=Z_1VAKP"[&"SG
MA?$4 M.1A *0(C,"I?;1!HS=6G\\Y>G?#4G6%/S23-YFJR)>U?_6XI$^RR/N
M/&03=1(/K^Q6P01W$H1-DCLM-882L%[/Y]IC5$9P^7C!Q)W']5HYP8U%;[EF
M'!4Q34-AD&Q@,I%)(FLE4]S(4=^+5I43!_F_+J:S>4WZV_%!SG-&P-EK&.;C
MT66'E,M'7_9BLI E!RY9X8BT8^?,HHZU/4H!2SMV@=#Z@M'*('?$&#Z--W=*
M!'M541_S"IXV^M%)BPH3RPD2(W- .SV)ATD#**)U2NGF+=7VHAIG'6[UKZH>
M<C2O)^.$F*>U:O<2W!7DZ2":Y)!+RY(7-6V9$P.G@257L* !GG3K%J8/X=DK
MMC03_+;/VY/RV@E!!E)K$H)/R*(HR R L5DHP3WOY*GO['E[CVSH7>*M#]M/
M9A]P\FSX:9C)]3R@_UUOJ /MM2_>9P86Z\#AH%BL04214F59I ;1+:GSP$/V
M1^NM)-GP5/SZ)']\M=[Q8KTO2<SG%^=$S$0 X3V.;XRWO_24'"83Z\"Z8#$R
M[:1A467%."CII0=NRPKU%$] L#_<V(@.[A+']-E!3^HZU0Z8M20!+5$SGY1F
MP151E)<RJ^8#MG:]M*"YM[FZJ'>_M" +DZ*IP^N3%+2:)%@HM-LI:91T,1JN
M-I(FV-'2@I64W;FT8!6A;_CDN NT'Z4%*REPA2/DITA_PP31Z(CW2'M@T+6+
MK*&(N@3)C'!9"A%,@M9)M6^GM* O7JPB]$V7%@2KLT8/+*1:O8[D2 >1$A/)
MTVYK!+JPTGVB;Z.T8"6-K%):L(HXMU!:$%"KC'7L=>+SWBZ&>:GJP9GW);F(
MPCY-V[M>6M!,X6L*M?7K?2"Y\)<8#\@"YGF'GZLO9N/K(.CU!3$5IGCP?H)S
M]_02O39"6IDU4Z6>H'(G6>0QLQR"*C8"&M.-$FM#V1/&;%8EO71J>V@Z62PN
M6YLLP^P(7(# 8@R<$2BR=BYS$5K'JCLYWK&GL*.=\'M@QOT#S+J ^MZG.ZZD
MN$XS_9XB]8U-=]0E:V="84H[\J2S)Y\Z>,&2B=(4680MW^MTQ_9,6$78&YGN
M"-X%ZZQBSI MU;I.LL&HF HV9/*57';-I[/MZG3'E93SZ'3'522[F;8\1P=O
M7AV_^NWTQ<GIZ>NC-Z=_.WAS=#7Y>%SN[UZT1BG:.H]K4)36;+6WRM."M1B#
M\. YU]'F&*T!DRP4DTP1<;#.@[?:/_,ZH0]62>^%J$>Q]4JKT[678V82R!HZ
M+PU/K?>$5MBWW(/TX'Q\,9H-ZKFV,K1I&&DU19>TAP2TCC:2+.N,,!)NZVY*
M38#O2M.TGCG;N/_H$Y3>0XG=]1#[-9>SB(QL%B9@;:\4E6?:\]K1/G&692D
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MDSP#4SR+CO:<>G>% M5.:8/&P+X;FFY=JW<9:C=4NI5DUM);8$DEPW2Q@D$
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M>DC?W^7_>SV?_FB[F@T>EH)*PAF@T:MC)L&$1!15UAJCI$CMTJK[5ABW5\-
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MP]H-U#XMU!_(*XX$>A>YUK8L+GY[307[T9S26TUY($;I5$9_6C2G2ID.WG_
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M[_(9F/E^5FA1"RVM%3LKJKUA4:L.3YG@.,4<049P"E&<4L@R&D.&<<(4E;'
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MN),#5W6H;7NCR45[2Y</I:R_HI_RJ6:462';+^R$1)QG@4@@"BDSM6T#R(*
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M1:TCF&HE/47.;"!]9NA,-_S>,G;F C0Z@YMC>/J+FME%J.^PF0V)XXB;V87
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MO?Q:F;7JJJ7S)==.4]VWWE3ER8N%_EG[RUFQ6>%!J)2F%&9*KRB1I@VH:4-
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ML;H*U%CTGN_<\QSVFS+=E_)CR+KN>6(L$[?[UL)KV]:V9.IFR\$)C2/&:9S
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MB&@9_"$YSI^CG_J>*7EI.MBP_6*]K?.Z+N:F_?JRU2/38-"FC>V]]0*L@+@
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MH_CR)XZ>2X?)LO1N>L)^( ]HJ?TFP1D#P+8%%_4O&B,N0&W%A<D]Y5YW+\_
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M-KD(]_-7_TBV!TSGP#8.1,/'N:V=C9X3J"T%OUG4_C),D'L9EW@Q;T];8X?
ME]T^$1$[W!1SG;#)_W^L%M_:\Y6&IV9(L%R7/(6I+@5$"G/(1&[B7,,:3!8\
M+1,\VRPW;'[-NN"IIKVH9&O "ZQ+Q5CV.XG]-:M]UR(ZF46^D5;T^O :="'O
M9,,36+_K \1MV:[W"8$S^\<?/]CJZ4Z?/P&^TRM!"2]3IDJH1&X%,/,4\BQ-
M(>-4L*(LBRSWJH7HT_C4XJ#/XKN2C_/Z1/2)!2W/&,FK&QRGRP.!._24MS';
MPMJG#M%6V1JFHF((=+&FG3Y-CSMU# #E:/H7\HP X8G/;*[N=!WFU3IVZ[6A
MRG?5+R4MC<YR0ZY2B@+F$JM6)H*:B*R@:<:4T)SE3O4%'-J:&FWM3 3:V@A6
MSO&6"[+]U!09KZ&9R!AJB_NUPKQ[R-76>D2J+LAY: O$0W D)8"KD/0[K>^&
M3>_9^@N/&.\DO)LO!^?6'6\)*8%E@$KK*?2CV#RN#'7?FSYN%W%*6=)"F7!0
ME32SV;4($BD4-&%BJ3%3*&/NNCM]+4V-3JVIX,!68(WU*>C4AZL#G<9":V R
M/0/4Y24Q3\1\"F!%0FXD$O5]U3QK7CF T5_QJN\!(]:[<O#CL-J5RPUA<^OW
MYIU8?*O,-*4N4[A^W:F4::494P1*F280$5U"1E+#FWG&BSPS<VGIE1)SIIVI
M<>47NZ0(=L9Z3I'/H>DV&XZ T< ,N;,0-"::0"GVR>$+*$2:PYYK9=3IZ@57
MG\],+UT>Q@!?UR8:>[O>5#],]+6>Y5DI6(XH+"DF$.E,VN-("=0<E265N7 4
M"3G]^*E][\8ZNXJSM<_O<W\&G=M7'@[(P!_W<RQNP/UR7HDG\$?[YR#K6*?A
MB/25/WOXJ!_W:<>>?]-GK@H4%F%K>[K7_F%S$7Z:B=9BLSXAK3P3JA1%R3 4
MF980I=CFL)4)%)CAG-!4YB7URV%S;MOGC1\G">WWY4(]@1]L]0^U ?IQX;LP
M[@Z[&T,, N7 Y&&-;8JKV!_VS+X!)S77(RJ-^*(52VO$N=UQU49\X3C2&_%^
M0.C,0ZP46ZLWJOGS_:(KZGO/GNR^R4QH5"B*%!14&))BN(2<FRE)GC&>%$3H
M1"._.<B%%J<6G6RK23\T]OE.1BX![#HMB0C;X!.4QD;P6V?M7VI]U@[(^PM
M!LQ6',&)-F^YU-[(,QA']X_G,JXW!N8,M%O?=_IO;%79!YK9DS*OVJ86<ZO4
MNMZ;G<E,E'E&&"R9SB"B6$$FK" I1SDORPP7S$FUQ+/=J3'-?J9 9SCH+ >=
MZ>V&MF\U;\>N<&.C 0 >>H\N#K;^&0)^2,5*#G!L==R\ #\HCE("/&^_L@!6
MDRW^_SPR^W!F,ZSVB^+4WPHVT[="9F;61I" B&,$.58F2$(8B:1,\B+QDHKQ
M:'MJU+4WO6B,OWE6VBF LGRZPHVV!@)X8.JZ$MOPBEGN*,6NG^70\LM4TW*'
MY&QM+8]'A&9J\K7ZGT<K*_?3SAJW!681*P7B90I)FDG+5X:YE.*0)HE2I.1"
MY5[E^\XU-#5RVMD)&D.#"_J>A=8Q;(H V-!Q4@A6 7F3_4!$RY$\T\S(^9#]
MSA[G/EZX?N2CV8W<]IV^E;*RM[!Y?=WZ]G'S?;FJ_J7DC$B4EBAC4-L2$BA+
MB"TK8?Z:9I01CBB53L4D1K!U:N346&RG)6QK<WL*&["MU2]P-MNAVQU9;QJ=
M.31Q7G\">_<J[#QNKE^#G<\3.'#MWC$O?<;:P=(_Q[%J=\BCG:3V:#)X\Z$Y
MLK0+@'=G5Y@MP5@P6Y\HTQ 1:L)6A C,5"Y309(T2S//?8>SC4UM3'C_\?7=
M[V_!E]O_]ZUG&>E>2)UW&J( -?PF0W=X<6?H0#6D72")M[5POJFQ=Q4N.GUB
M0^'R/=<IOGXV<V9UNY ?3*_-S^F0I@41&2D1Q"1-(1),&!I1%)H)+LT412@1
MX@K=5Q<;G#Z5\245:]/#M%^=D'?CF.A CJP#6]M=9UK4EH^L!^N#6F156*>F
M7T0;U@>4<PJQ7L\(S ZK3P"_8Z*N'/-F^8-5BQF7.BT8+J HD)D^%ZB 1!(,
MB2C*@B5(4^ZE$W.JD:G%..U1Z,Y(\$=CIN>"W$DXW3CH6I &YAIO?/QSMGH
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ME6SU##\:'[N81],L9]($.0A+JS]HJ4T@F**"ZTP*0HB7_N"YAJ9&7A^6BV_
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M?!CC?5 U0_R97@;'79HI=N\HJZA7G9AKQ9'VW >U_V!C -B=I]MB8'ZL49C
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MLP/@W%K@\K_XKN3C7-WIVY^LFML'OUNN/K.Y^JS$XZHN&+%;0" 2*<P3:N(
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MSFV&1N<)V+EB D_K"VBOK[VY :T_,0NO7XMIM.+LP8:,7,#]6L".B[Q?_<0
MQ9&[U3>V:*O"&<ZN]]KNM&&#=:>GL%MFR4R(*C*L#7L*,PG)= %Y9J:7."]P
M6<B<EZ6[MJI'PU/CRGW3@;&]W?F^TV#?_(#U+N\>Z2?,(7$>F!ZG [&'ILE
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ME9)JY[P>O[:G1AJ-]4<+VJO6 V"XNA8PK]6?S5\<2TR%],J%R=VP6 ^]CMW
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MI<Q4KBC*G5;7'-N;'"DUZM4'-M\TB?0&9M!:#JSIOL+?_;CWT]D : Y-<A&
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MC&*-L3)3@4PQ!I%($"2))!#E2:Y+G*J,ESY3@?[FIA;W-VS2%FSZK4U\_4O
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M K/Y#-9*-EO5_,7\UC&VUM_"VQU41[&<?>][W71V%;]4LY*5@J83YW)EKBG
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MQ"%*: Q)BK2GG&0)+F*6H=BJ]W>O4H[.-JXU,L[R3)_-ET8I\X]_MFH!J56
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MY A;33FH)^P"PKXK[/2L.^]Z4T/^%B?LJ5SI;SZ2/-?6AL)8%!(B4P5&>91
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MWJJ;+"1P&J4$0:4,2SW*!:0J*2 6*D8JS61$8A>#>3C%Z QA)2%H172Z$.P
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MM'W83SVV#6&OR^O+?%9E[.I_M=V%FE8UCEN"PV+8&?E^(.[9;&^CV^*Y)?=
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MP-1BSK&9A^U+S;6@X*L1U='?L '<SFP$AK%G"^*%H+,)<< DD#6QF7%0P^(
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MC;D:V_W]\4/S/^H?G:;AXX?_ 5!+ P04    "  Q0%Q6ZTFQD%Z[  "$1@@
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M>HXQ@T21X%>6$4J-E#YS[L5+Q9_;P&<E(?T$5=T!9W=I-P"9O1A+'[C9*41
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MD$Q&PW0S8NK3/?I/\G5,48;N7INL>Y6:/C"G*26@H"3_F"%E[!3!73(8!=:
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M9G]&K%76R.88<TN,C>&BO+,*RM!I*<L'H\MOPP3IW0\T\>EP?-ONX>Y:]4"
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ML'ESS>(F^>U8,,X;2XP!7H9Q>&(]HR2RS%5$5F*J;?V>):;?;/);@JR./AH
MUF*P_6T)BX\*/1 #1&4?4"0V$LMT*4A'6<B$(1&O/;KS 0&M='OIT'';7N -
MH&5QX^M=Z;-9CG=Q!5SKYJX!Z+L?=[]S?6EWP?$=V^-4I'IO'8)F(E(N20Y2
MEVJ53!RE0+3+)E&6'(^U8XDN^.BY[G9[6#TNM>U;QPW@_!-,\V1ZZ<=QV6_F
M]J0Y4 4T!>(XQXV" 4.O <6L60S1A<1$J'WB_PPI/9??]HZ1Q_63%136<QIN
MO]3-PQ05,/]1I+)8R,8&YB6-)&B*,F$,%W+(&;T),.BK>!-%C9DLJ][=[Z7E
MSK/\.XN[9[B<PM?'-Z\?LW23RZ248O2>2-3,8Z@3*6X&Z)%"XBGBVDC1K]4Q
M_Q4,K4U0?_G>W74^Z5H!?1\NGTYPX=T.M/+2RA1)6K2B" KICC83DQG^Q'C&
M'M?=/G.V?.^A_2F_(WU-*@BO 8_G(_@R][U(Y7#\]6I^ZTHJ6I:'=B0F4790
M)DGPUN :X9"M2LE4G[?Q'"W]-B)XD^BPBAH:A=--%:CT/HI2H\DC)Q*T(-9G
M02 8+H5-"<WN&P"JA:"MCK;7@- 6HF\01.^'L\7ETE,_O[&R-FB74#0$:&G?
M+'SQ[P7&O0 1(&7)1>UJ_M>I:@]4V^C_%5CMJ(P&X/6L&3^Z;;U@@M5.@21*
M,U4V<8VFW$1"A9$A,J:\>[.KMT<;M<3NK$=*OS=OMU-- V K33K?P]?);#B?
M[<U/IGMA\@T^O#_</QSCLBIYBZ/AY7 ^,)Z68B-!-"V72(%E$KA+I%QP<-1+
M9UGM#/R:I#5Z>W)+1#P>I=>!>AI W;-2^SR#?#4Z&F88>($[@I&)"*Y+82U5
MN#UD19((TNN@!=.U>_ZO05:CURSKH*VV6AI VN'E5S^<+CH2Y\>GKP??X^@J
M#<<7OTTFZ8_A:#2@3H#F&!)#%(E(#X($G?$K(S*WD!25M??5C0AL]&IF'?1U
MIZH6</B(H?VK:1'YPAN1"H.IN"C\%RH0KR"46X@L4&,U$E.]+F<E*8W>TZR$
MK0KB;P!%QU<EH#G)I^@23$LSH\]C= P&"9+)7F)L8SG2GHPE)1E(&(U&@$@J
M&Z@,HM64]%LGT3&&*@B_ 0C=&E"F\8<8 1,O#0;=U$EBE:$D"@4T!*&MK)VB
MV&@;Z^P(KV.8;"7@AH!QMPT?36:S,D.>,^8"08,8EA-#@O.9>.<=#2PR"K4W
MJ-64])ME?R/0["#\OD_HEJ6'=X=8IY,??C3_4?)P R$"2,XB<<P;%$T6I4<+
M$!M35%XP"/[5!I>OO:3?]%-'^*@JV;X1\CL,+[[,(>U]@ZF_@/W)##W]??]U
M./>C@1.6(]*!>.L]^E^@B4_E: &L5DYKQN-ZE\-?>DN_#76[Q$@UV3:P$ZT>
MV58\KL79^+WA;4=#'X:CX?S'XU. @<_%=%))O(^R7!AAR#)^JQA$0X7FR=6N
MB*M ]GJY3/J3 ;0OO?Z<4!Y0YI3(3)!8VE']7_:^K+NM)$?S%V$F]N51:<O9
M/NVTW98S>_I))Q:$S6F9])"4*]V_?A 4M5@KE[B\(57UJ<YRVBY=+!\0  (!
MJ"C(N6-08%/2F7F?M&A=A-J!S,V@^ESK[D/KK0-H/MDK^VBK[%^X6 U37BU5
MX:=*&>+>2-#,UZ&.G'*=&#VXD"U+C*-0H3%F6]*_&9B?:UE_-$WW@O+X-._Q
M-N]O* _[*YR=UX+A^;?OJTT_QW]_QT1!5EW"PD\YL];J8&I'@0,E= ;GE0.I
M!%D[_8$SK0LHPW&SF04\UZN%3E#0BSWLX@L>D\3K2=WB,<VKC#0B:L4+@C"K
M?1V>CL%0WTQ$0]*0 4UJ';X,SM1FUO%<+T?ZPL3858K;U9;;*VQ/C2^KJ0/
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M'2#SX30OI21<*0QL420E3K_R=(Z!5JAKF8$QW7KKX'ZY^8&QN*O.-\ZSMU%
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MGJ),B* #EZ!XY. R9Q1;.,Q>"6*N=8V[I_:/W37Y "1V$.O8-XE'@G'U2Q/
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M;UO8/2Z_TY!LRID7R-83;TDC1&5R;<!3%.T@A1>M\_*-"!NWTWXL"#945G=
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M\P),>R]"8,Q9>;0:O+OBX(,N3Z[\#N;W&%7>YBBD%(/B(8*M;7R5R8)T=F+
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M_$SGC<SD:VKVL*G#T1BZ3\$((7.H<.?-.#VTX_1^/MNF"!\:]MO-."ZB52*
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M&[N31XA<6>6S!<;KR<42("HR.%.AP\5)T=O0^BW&GB0.J_MZ@TIW2!XMMQ'
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MMU;'':/DXN]?Z]],>%9*!++!HR#S6W'.(6CB*(:062Q1&7?8-?W,HJ-.'?6
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M&0_AUJ>8^G]&LOU%_1+#$O_OO_PO4$L! A0#%     @ ,4!<5INP2>+[ @
M\@\  !X              ( !     &5X:&EB:70R,3$M<W5B<VED:6%R:65S
M;V9S+FAT;5!+ 0(4 Q0    ( #% 7%:0SEIZ] 0  )DG   >
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M,&ME>#,R,BYH=&U02P$"% ,4    "  Q0%Q6?XKS7_9F P E*A\ $0
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64$L%!@     ,  P 0@,  +P6!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
